{"fetched":"2026-10-01","source":"https://api.openalex.org/works","license":"CC0","papers":{"paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016":{"doi":"10.1089/thy.2015.0020","openalexId":"W2145150141","cited":16739,"byYear":{"2012":197,"2013":236,"2014":281,"2015":244,"2016":752,"2017":1142,"2018":1230,"2019":1262,"2020":1666,"2021":1713,"2022":1728,"2023":1756,"2024":1698,"2025":1410,"2026":854},"year":2015,"title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer"},"paper-fearon-cell":{"doi":"10.1016/0092-8674(90)90186-i","openalexId":"W2001258296","cited":12233,"byYear":{"2012":368,"2013":390,"2014":407,"2015":389,"2016":371,"2017":391,"2018":363,"2019":349,"2020":337,"2021":396,"2022":376,"2023":337,"2024":314,"2025":251,"2026":180},"year":1990,"title":"A genetic model for colorectal tumorigenesis"},"paper-lapidot-nature":{"doi":"10.1038/367645a0","openalexId":"W2090982381","cited":4804,"byYear":{"2012":309,"2013":282,"2014":270,"2015":274,"2016":228,"2017":235,"2018":183,"2019":243,"2020":230,"2021":272,"2022":201,"2023":220,"2024":159,"2025":137,"2026":52},"year":1994,"title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice"},"paper-sahai-nat-rev-cancer":{"doi":"10.1038/s41568-019-0238-1","openalexId":"W3003058300","cited":3998,"byYear":{"2014":1,"2015":1,"2018":1,"2020":204,"2021":518,"2022":697,"2023":689,"2024":765,"2025":629,"2026":489},"year":2020,"title":"A framework for advancing our understanding of cancer-associated fibroblasts"},"paper-kralovics-n-engl-j-med":{"doi":"10.1056/nejmoa051113","openalexId":"W1980568348","cited":3496,"byYear":{"2012":211,"2013":193,"2014":196,"2015":184,"2016":171,"2017":158,"2018":124,"2019":138,"2020":138,"2021":143,"2022":144,"2023":125,"2024":103,"2025":74,"2026":61},"year":2005,"title":"A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders"},"paper-lyon-eur-heart-j":{"doi":"10.1093/eurheartj/ehac244","openalexId":"W4293217929","cited":3074,"byYear":{"2021":2,"2022":69,"2023":586,"2024":772,"2025":885,"2026":758},"year":2022,"title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)"},"paper-sharma-cell":{"doi":"10.1016/j.cell.2010.02.027","openalexId":"W2106391833","cited":2871,"byYear":{"2012":143,"2013":127,"2014":138,"2015":131,"2016":151,"2017":158,"2018":154,"2019":187,"2020":217,"2021":239,"2022":214,"2023":204,"2024":234,"2025":200,"2026":212},"year":2010,"title":"A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations"},"paper-cardoso-n-engl-j-med":{"doi":"10.1056/nejmoa1602253","openalexId":"W2517421365","cited":2104,"byYear":{"2013":1,"2014":2,"2015":1,"2016":45,"2017":199,"2018":188,"2019":205,"2020":262,"2021":275,"2022":277,"2023":201,"2024":165,"2025":158,"2026":115},"year":2016,"title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer"},"paper-devita-cancer-res":{"doi":"10.1158/0008-5472.can-07-6611","openalexId":"W2147328441","cited":1983,"byYear":{"2012":24,"2013":47,"2014":77,"2015":99,"2016":103,"2017":98,"2018":99,"2019":154,"2020":193,"2021":226,"2022":197,"2023":184,"2024":169,"2025":152,"2026":86},"year":2008,"title":"A History of Cancer Chemotherapy"},"paper-pan-n-engl-j-med":{"doi":"10.1056/nejmoa1701830","openalexId":"W2767600184","cited":1893,"byYear":{"2013":1,"2016":1,"2017":4,"2018":104,"2019":144,"2020":195,"2021":242,"2022":220,"2023":250,"2024":285,"2025":264,"2026":174},"year":2017,"title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years"},"paper-kratochwil-j-nucl-med":{"doi":"10.2967/jnumed.119.227967","openalexId":"W2930582547","cited":1509,"byYear":{"2018":1,"2019":18,"2020":103,"2021":230,"2022":244,"2023":251,"2024":257,"2025":226,"2026":175},"year":2019,"title":"68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer"},"paper-depil-nat-rev-drug-discov":{"doi":"10.1038/s41573-019-0051-2","openalexId":"W2998345757","cited":1252,"byYear":{"2013":1,"2020":69,"2021":148,"2022":219,"2023":203,"2024":241,"2025":194,"2026":176},"year":2020,"title":"‘Off-the-shelf’ allogeneic CAR T cells: development and challenges"},"paper-rindi-common-classification-framework-mod-pathol-2018":{"doi":"10.1038/s41379-018-0110-y","openalexId":"W2888018398","cited":1164,"byYear":{"2012":2,"2013":1,"2015":2,"2017":1,"2018":11,"2019":69,"2020":170,"2021":206,"2022":187,"2023":162,"2024":127,"2025":133,"2026":84},"year":2018,"title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal"},"paper-therap-lancet-2021":{"doi":"10.1016/s0140-6736(21)00237-3","openalexId":"W3130934287","cited":1160,"byYear":{"2021":128,"2022":195,"2023":213,"2024":210,"2025":228,"2026":185},"year":2021,"title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial"},"paper-sottoriva-nat-genet":{"doi":"10.1038/ng.3214","openalexId":"W2010873488","cited":1089,"byYear":{"2015":32,"2016":106,"2017":123,"2018":112,"2019":116,"2020":125,"2021":125,"2022":89,"2023":73,"2024":67,"2025":74,"2026":47},"year":2015,"title":"A Big Bang model of human colorectal tumor growth"},"paper-hera-b31-n9831-lancet-2017-update":{"doi":"10.1016/s0140-6736(16)32616-2","openalexId":"W2588881638","cited":1058,"byYear":{"2016":2,"2017":38,"2018":95,"2019":100,"2020":147,"2021":158,"2022":126,"2023":143,"2024":111,"2025":81,"2026":53},"year":2017,"title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial"},"paper-bertotti-xenopatients-her2-cetuximab-resistant-colorectal-cancer-discov-2011":{"doi":"10.1158/2159-8290.cd-11-0109","openalexId":"W1987443121","cited":963,"byYear":{"2012":23,"2013":49,"2014":60,"2015":62,"2016":71,"2017":90,"2018":87,"2019":90,"2020":72,"2021":74,"2022":77,"2023":87,"2024":49,"2025":44,"2026":23},"year":2011,"title":"A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer"},"paper-neosphere-lancet-oncol-2016-update":{"doi":"10.1016/s1470-2045(16)00163-7","openalexId":"W2379981061","cited":900,"byYear":{"2016":15,"2017":63,"2018":72,"2019":89,"2020":85,"2021":117,"2022":121,"2023":88,"2024":103,"2025":80,"2026":64},"year":2016,"title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial"},"paper-rxponder-n-engl-j-med-2021":{"doi":"10.1056/nejmoa2108873","openalexId":"W3215275071","cited":891,"byYear":{"2021":3,"2022":140,"2023":203,"2024":197,"2025":200,"2026":144},"year":2021,"title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer"},"paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018":{"doi":"10.1245/s10434-017-6025-x","openalexId":"W2741375122","cited":856,"byYear":{"2013":1,"2017":2,"2018":19,"2019":64,"2020":105,"2021":123,"2022":129,"2023":159,"2024":109,"2025":80,"2026":63},"year":2017,"title":"8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers"},"paper-heuser-blood":{"doi":"10.1182/blood.2021013626","openalexId":"W3209416216","cited":778,"byYear":{"2021":1,"2022":110,"2023":188,"2024":184,"2025":170,"2026":125},"year":2021,"title":"2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party"},"paper-bensch-nat-med":{"doi":"10.1038/s41591-018-0255-8","openalexId":"W2901272595","cited":757,"byYear":{"2018":1,"2019":51,"2020":112,"2021":118,"2022":119,"2023":110,"2024":109,"2025":80,"2026":57},"year":2018,"title":"89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer"},"paper-ata-anaplastic-thyroid-guideline-bible-thyroid-2021":{"doi":"10.1089/thy.2020.0944","openalexId":"W3137149901","cited":744,"byYear":{"2019":2,"2020":3,"2021":42,"2022":108,"2023":168,"2024":133,"2025":175,"2026":109},"year":2021,"title":"2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer"},"paper-hugosson-eur-urol":{"doi":"10.1016/j.eururo.2019.02.009","openalexId":"W2916798133","cited":718,"byYear":{"2019":18,"2020":59,"2021":95,"2022":111,"2023":135,"2024":120,"2025":111,"2026":66},"year":2019,"title":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer"},"paper-errani-wwtr1-camta1-ehe-gcc-2011":{"doi":"10.1002/gcc.20886","openalexId":"W2021542512","cited":557,"byYear":{"2012":17,"2013":25,"2014":42,"2015":45,"2016":39,"2017":28,"2018":43,"2019":36,"2020":46,"2021":46,"2022":37,"2023":37,"2024":31,"2025":45,"2026":21},"year":2011,"title":"A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites"},"paper-wang-nature":{"doi":"10.1038/s41586-024-07894-z","openalexId":"W4402220065","cited":555,"byYear":{"2024":20,"2025":264,"2026":271},"year":2024,"title":"A pathology foundation model for cancer diagnosis and prognosis prediction"},"paper-zhao-j-hematol-oncol":{"doi":"10.1186/s13045-018-0681-6","openalexId":"W2906581363","cited":539,"byYear":{"2019":46,"2020":111,"2021":97,"2022":96,"2023":71,"2024":67,"2025":39,"2026":12},"year":2018,"title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma"},"paper-vorontsov-nat-med":{"doi":"10.1038/s41591-024-03141-0","openalexId":"W4400889241","cited":535,"byYear":{"2023":1,"2024":28,"2025":222,"2026":284},"year":2024,"title":"A foundation model for clinical-grade computational pathology and rare cancers detection"},"paper-stock-blood":{"doi":"10.1182/blood-2018-10-881961","openalexId":"W2908746540","cited":490,"byYear":{"2019":33,"2020":68,"2021":69,"2022":67,"2023":60,"2024":68,"2025":78,"2026":45},"year":2019,"title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403"},"paper-springer-pancreatic-cyst-molecular-classification-gastroenterology-2015":{"doi":"10.1053/j.gastro.2015.07.041","openalexId":"W1945428417","cited":478,"byYear":{"2015":2,"2016":40,"2017":64,"2018":55,"2019":55,"2020":47,"2021":50,"2022":35,"2023":35,"2024":32,"2025":33,"2026":29},"year":2015,"title":"A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts"},"paper-eclipse-shield-n-engl-j-med-2024":{"doi":"10.1056/nejmoa2304714","openalexId":"W4392744338","cited":430,"byYear":{"2024":89,"2025":203,"2026":138},"year":2024,"title":"A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening"},"paper-piccart-lancet-oncol":{"doi":"10.1016/s1470-2045(21)00007-3","openalexId":"W3135974134","cited":375,"byYear":{"2021":28,"2022":83,"2023":83,"2024":74,"2025":61,"2026":44},"year":2021,"title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age"},"paper-psmafore-lancet-2024":{"doi":"10.1016/s0140-6736(24)01653-2","openalexId":"W4402552580","cited":338,"byYear":{"2024":8,"2025":154,"2026":176},"year":2024,"title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial"},"paper-cd19-multiple-myeloma-lancet-haematol-2019":{"doi":"10.1016/s2352-3026(19)30115-2","openalexId":"W2965223724","cited":326,"byYear":{"2019":11,"2020":60,"2021":63,"2022":45,"2023":40,"2024":50,"2025":39,"2026":17},"year":2019,"title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial"},"paper-persephone-lancet-2019":{"doi":"10.1016/s0140-6736(19)30650-6","openalexId":"W2948726637","cited":288,"byYear":{"2019":16,"2020":74,"2021":51,"2022":38,"2023":43,"2024":29,"2025":23,"2026":13},"year":2019,"title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial"},"paper-peter-thuss-patience-ann-oncol-2019":{"doi":"10.1093/annonc/mdz199","openalexId":"W2955746156","cited":252,"byYear":{"2018":1,"2020":20,"2021":28,"2022":31,"2023":47,"2024":52,"2025":48,"2026":25},"year":2019,"title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study"},"paper-carboplatin-glioblastoma-eur-j-cancer-2017":{"doi":"10.1016/j.ejca.2017.04.019","openalexId":"W2652551831","cited":156,"byYear":{"2017":4,"2018":5,"2019":12,"2020":16,"2021":14,"2022":37,"2023":20,"2024":24,"2025":13,"2026":11},"year":2017,"title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma – A final report"},"paper-shuch-lancet-oncol":{"doi":"10.1016/s1470-2045(24)00402-9","openalexId":"W4402388619","cited":154,"byYear":{"2023":1,"2024":7,"2025":72,"2026":74},"year":2024,"title":"[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial"},"paper-makvandi-j-clin-invest":{"doi":"10.1172/jci97992","openalexId":"W2791912178","cited":135,"byYear":{"2018":5,"2019":18,"2020":20,"2021":21,"2022":24,"2023":12,"2024":16,"2025":16,"2026":3},"year":2018,"title":"A PET imaging agent for evaluating PARP-1 expression in ovarian cancer"},"paper-capivasertib-breast-hr-positive-breast-2022":{"doi":"10.1016/j.breast.2022.03.018","openalexId":"W4221066482","cited":104,"byYear":{"2022":3,"2023":16,"2024":32,"2025":31,"2026":22},"year":2022,"title":"“The emerging role of capivasertib in breast cancer”"},"paper-phergain-lancet-2024-update":{"doi":"10.1016/s0140-6736(24)00054-0","openalexId":"W4393858340","cited":103,"byYear":{"2022":1,"2024":19,"2025":43,"2026":40},"year":2024,"title":"3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial"},"paper-empower-cscc-1-j-am-acad-dermatol-2025-update":{"doi":"10.1016/j.jaad.2024.06.108","openalexId":"W4402333617","cited":68,"byYear":{"2024":1,"2025":35,"2026":32},"year":2024,"title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6"},"paper-donenberg-bahamas-brca1-founder-bcrt-2011":{"doi":"10.1007/s10549-010-1156-9","openalexId":"W2021833052","cited":74,"byYear":{"2013":7,"2014":9,"2015":8,"2016":7,"2017":8,"2018":2,"2019":3,"2020":5,"2021":6,"2022":4,"2023":4,"2024":3,"2025":1,"2026":2},"year":2010,"title":"A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas"},"paper-pramesh-ncg-pooled-procurement-2023":{"doi":"10.2471/blt.23.289714","openalexId":"W4386209307","cited":22,"byYear":{"2023":1,"2024":6,"2025":10,"2026":5},"year":2023,"title":"A National Cancer Grid pooled procurement initiative, India"},"paper-psmaddition-lancet-2026":{"doi":"10.1016/s0140-6736(26)01092-5","openalexId":"W7196929723","cited":4,"byYear":{"2026":4},"year":2026,"title":"[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial"},"paper-cd47-neuroblastoma-curr-oncol-2024":{"doi":"10.3390/curroncol31060243","openalexId":"W4399282195","cited":5,"byYear":{"2024":1,"2025":1,"2026":3},"year":2024,"title":"A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma"},"paper-nct05751798-eur-j-cancer-2026":{"doi":"10.1016/j.ejca.2026.116729","openalexId":"W7152601764","cited":1,"byYear":{"2026":1},"year":2026,"title":"A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours"},"paper-nct05933265-invest-new-drugs-2026":{"doi":"10.1007/s10637-026-01626-y","openalexId":"W7167487687","cited":1,"byYear":{"2026":1},"year":2026,"title":"A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors"},"paper-yeh-ca19-9-lewis-negative-fut3-cutoff-ccr-2026":{"doi":"10.1158/1078-0432.ccr-25-4564","openalexId":"W7161817239","cited":0,"byYear":{},"year":2026,"title":"A New CA19-9 Cutoff Value Identifies Lewis Antigen Status and Refines Prognostic Stratification in PDAC"},"paper-nct05195632-lung-cancer-2026":{"doi":"10.1016/j.lungcan.2026.109580","openalexId":"W7171616114","cited":0,"byYear":{},"year":2026,"title":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study"},"paper-aaronson-eortc-qlq-c30-jnci-1993":{"doi":"10.1093/jnci/85.5.365","openalexId":"W2167571044","cited":16265,"byYear":{"2012":493,"2013":531,"2014":571,"2015":631,"2016":638,"2017":670,"2018":718,"2019":749,"2020":920,"2021":1177,"2022":1030,"2023":1098,"2024":1176,"2025":955,"2026":730},"year":1993,"title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology"},"paper-abc-02-gemcitabine-cisplatin-nejm-2010":{"doi":"10.1056/nejmoa0908721","openalexId":"W2115261608","cited":4500,"byYear":{"2012":136,"2013":139,"2014":177,"2015":192,"2016":195,"2017":225,"2018":233,"2019":284,"2020":376,"2021":466,"2022":480,"2023":425,"2024":438,"2025":364,"2026":233},"year":2010,"title":"Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer"},"paper-vasan-nature":{"doi":"10.1038/s41586-019-1730-1","openalexId":"W2988773550","cited":2836,"byYear":{"2019":5,"2020":157,"2021":370,"2022":410,"2023":488,"2024":562,"2025":542,"2026":301},"year":2019,"title":"A view on drug resistance in cancer"},"paper-abiraterone-acetate-prostate-n-engl-j-med-2013":{"doi":"10.1056/nejmoa1209096","openalexId":"W2137467802","cited":2825,"byYear":{"2012":4,"2013":168,"2014":310,"2015":243,"2016":271,"2017":239,"2018":254,"2019":237,"2020":201,"2021":213,"2022":189,"2023":165,"2024":131,"2025":110,"2026":79},"year":2012,"title":"Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy"},"paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004":{"doi":"10.1056/nejmoa032295","openalexId":"W2047318784","cited":2728,"byYear":{"2012":130,"2013":128,"2014":116,"2015":147,"2016":158,"2017":163,"2018":134,"2019":139,"2020":145,"2021":142,"2022":125,"2023":97,"2024":94,"2025":83,"2026":40},"year":2004,"title":"A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer"},"paper-abiraterone-acetate-prostate-lancet-oncol-2012":{"doi":"10.1016/s1470-2045(12)70379-0","openalexId":"W2168108459","cited":1403,"byYear":{"2012":12,"2013":105,"2014":144,"2015":131,"2016":128,"2017":127,"2018":108,"2019":100,"2020":104,"2021":109,"2022":76,"2023":97,"2024":78,"2025":48,"2026":32},"year":2012,"title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study"},"paper-braun-n-engl-j-med":{"doi":"10.1056/nejmoa050434","openalexId":"W2068503417","cited":1395,"byYear":{"2012":81,"2013":69,"2014":79,"2015":64,"2016":70,"2017":61,"2018":71,"2019":68,"2020":55,"2021":55,"2022":58,"2023":58,"2024":37,"2025":37,"2026":20},"year":2005,"title":"A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer"},"paper-abiraterone-acetate-prostate-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71205-7","openalexId":"W2055346449","cited":1378,"byYear":{"2014":2,"2015":79,"2016":135,"2017":136,"2018":137,"2019":126,"2020":153,"2021":155,"2022":90,"2023":96,"2024":114,"2025":98,"2026":54},"year":2015,"title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study"},"paper-den-boer-bcr-abl1-like-all-lancet-oncol-2009":{"doi":"10.1016/s1470-2045(08)70339-5","openalexId":"W2069709802","cited":938,"byYear":{"2012":48,"2013":55,"2014":57,"2015":54,"2016":71,"2017":86,"2018":62,"2019":54,"2020":83,"2021":75,"2022":45,"2023":51,"2024":51,"2025":31,"2026":18},"year":2009,"title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study"},"paper-lu-nat-med":{"doi":"10.1038/s41591-024-02856-4","openalexId":"W4392947532","cited":927,"byYear":{"2023":1,"2024":90,"2025":397,"2026":439},"year":2024,"title":"A visual-language foundation model for computational pathology"},"paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015":{"doi":"10.1097/pas.0000000000000533","openalexId":"W2431396139","cited":876,"byYear":{"2015":1,"2016":28,"2017":61,"2018":79,"2019":80,"2020":101,"2021":100,"2022":98,"2023":100,"2024":80,"2025":84,"2026":57},"year":2015,"title":"A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas"},"paper-xu-nature":{"doi":"10.1038/s41586-024-07441-w","openalexId":"W4398201291","cited":872,"byYear":{"2023":14,"2024":77,"2025":367,"2026":414},"year":2024,"title":"A whole-slide foundation model for digital pathology from real-world data"},"paper-latitude-lancet-oncol-2019-update":{"doi":"10.1016/s1470-2045(19)30082-8","openalexId":"W2938589827","cited":843,"byYear":{"2014":1,"2019":32,"2020":87,"2021":91,"2022":137,"2023":142,"2024":157,"2025":121,"2026":71},"year":2019,"title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial"},"paper-peace-1-lancet-2022":{"doi":"10.1016/s0140-6736(22)00367-1","openalexId":"W4223443163","cited":830,"byYear":{"2022":76,"2023":184,"2024":209,"2025":215,"2026":146},"year":2022,"title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design"},"paper-rimm-pd-l1-assay-comparison-jama-oncol-2017":{"doi":"10.1001/jamaoncol.2017.0013","openalexId":"W2594102731","cited":774,"byYear":{"2017":71,"2018":130,"2019":120,"2020":105,"2021":103,"2022":67,"2023":73,"2024":47,"2025":29,"2026":26},"year":2017,"title":"A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer"},"paper-aall0031-imatinib-ph-positive-all-schultz-jco-2009":{"doi":"10.1200/jco.2008.21.2514","openalexId":"W2096336184","cited":711,"byYear":{"2012":70,"2013":72,"2014":66,"2015":50,"2016":40,"2017":55,"2018":40,"2019":37,"2020":27,"2021":32,"2022":29,"2023":28,"2024":28,"2025":14,"2026":11},"year":2009,"title":"Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study"},"paper-kuhl-j-clin-oncol":{"doi":"10.1200/jco.2013.52.5386","openalexId":"W2141798739","cited":686,"byYear":{"2014":6,"2015":20,"2016":48,"2017":62,"2018":53,"2019":60,"2020":73,"2021":63,"2022":72,"2023":78,"2024":58,"2025":66,"2026":26},"year":2014,"title":"Abbreviated Breast Magnetic Resonance Imaging (MRI): First Postcontrast Subtracted Images and Maximum-Intensity Projection—A Novel Approach to Breast Cancer Screening With MRI"},"paper-monarche-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(22)00694-5","openalexId":"W4311018441","cited":603,"byYear":{"2023":114,"2024":181,"2025":196,"2026":112},"year":2022,"title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial"},"paper-adusumilli-cancer-discov":{"doi":"10.1158/2159-8290.cd-21-0407","openalexId":"W3179214161","cited":602,"byYear":{"2021":15,"2022":91,"2023":130,"2024":134,"2025":119,"2026":112},"year":2021,"title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab"},"paper-overgaard-radiother-oncol":{"doi":"10.1016/s0167-8140(97)00220-x","openalexId":"W2022342238","cited":574,"byYear":{"2012":22,"2013":19,"2014":23,"2015":34,"2016":28,"2017":25,"2018":21,"2019":20,"2020":25,"2021":36,"2022":24,"2023":24,"2024":13,"2025":19,"2026":12},"year":1998,"title":"A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85"},"paper-notta-punctuated-evolution-pancreatic-nature-2016":{"doi":"10.1038/nature19823","openalexId":"W2531887049","cited":565,"byYear":{"2015":1,"2016":5,"2017":60,"2018":83,"2019":64,"2020":80,"2021":68,"2022":43,"2023":48,"2024":44,"2025":43,"2026":25},"year":2016,"title":"A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns"},"paper-aaml0531-gemtuzumab-gamis-jco-2014":{"doi":"10.1200/jco.2014.55.3628","openalexId":"W2169923083","cited":490,"byYear":{"2014":5,"2015":27,"2016":40,"2017":39,"2018":38,"2019":28,"2020":46,"2021":59,"2022":42,"2023":46,"2024":45,"2025":41,"2026":31},"year":2014,"title":"Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531"},"paper-swanson-cell-prolif":{"doi":"10.1046/j.1365-2184.2000.00177.x","openalexId":"W2157358125","cited":471,"byYear":{"2012":21,"2013":22,"2014":25,"2015":15,"2016":15,"2017":23,"2018":19,"2019":30,"2020":32,"2021":29,"2022":23,"2023":18,"2024":26,"2025":25,"2026":23},"year":2000,"title":"A quantitative model for differential motility of gliomas in grey and white matter"},"paper-tam-blood":{"doi":"10.1182/blood.2020006844","openalexId":"W3046825703","cited":466,"byYear":{"2020":9,"2021":73,"2022":102,"2023":98,"2024":75,"2025":69,"2026":40},"year":2020,"title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study"},"paper-clarke-nejm-evid":{"doi":"10.1056/evidoa2200043","openalexId":"W4281770555","cited":425,"byYear":{"2022":20,"2023":111,"2024":114,"2025":110,"2026":70},"year":2022,"title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer"},"paper-johnson-sleep-med-rev":{"doi":"10.1016/j.smrv.2015.07.001","openalexId":"W1696447131","cited":386,"byYear":{"2013":1,"2016":17,"2017":23,"2018":29,"2019":36,"2020":36,"2021":54,"2022":46,"2023":42,"2024":37,"2025":38,"2026":26},"year":2015,"title":"A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors"},"paper-aall0232-larsen-jco-2016":{"doi":"10.1200/jco.2015.62.4544","openalexId":"W2342769258","cited":385,"byYear":{"2012":2,"2014":1,"2015":1,"2016":8,"2017":35,"2018":28,"2019":51,"2020":46,"2021":44,"2022":50,"2023":43,"2024":34,"2025":34,"2026":7},"year":2016,"title":"Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232"},"paper-aall1331-brown-jama-2021":{"doi":"10.1001/jama.2021.0669","openalexId":"W3135688349","cited":384,"byYear":{"2021":30,"2022":71,"2023":76,"2024":80,"2025":74,"2026":53},"year":2021,"title":"Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia"},"paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010":{"doi":"10.1056/nejmoa1001527","openalexId":"W1967139222","cited":304,"byYear":{"2012":22,"2013":14,"2014":18,"2015":15,"2016":21,"2017":18,"2018":28,"2019":19,"2020":18,"2021":28,"2022":22,"2023":19,"2024":17,"2025":9,"2026":13},"year":2010,"title":"Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma"},"paper-montgomery-j-natl-cancer-inst":{"doi":"10.1093/jnci/djm106","openalexId":"W2127020060","cited":296,"byYear":{"2012":18,"2013":15,"2014":22,"2015":10,"2016":19,"2017":24,"2018":12,"2019":17,"2020":13,"2021":17,"2022":21,"2023":12,"2024":9,"2025":13,"2026":8},"year":2007,"title":"A Randomized Clinical Trial of a Brief Hypnosis Intervention to Control Side Effects in Breast Surgery Patients"},"paper-castroviejo-bermejo-embo-mol-med":{"doi":"10.15252/emmm.201809172","openalexId":"W2898861270","cited":279,"byYear":{"2018":1,"2019":18,"2020":36,"2021":36,"2022":43,"2023":40,"2024":43,"2025":43,"2026":19},"year":2018,"title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation"},"paper-aall0434-nelarabine-t-all-dunsmore-jco-2020":{"doi":"10.1200/jco.20.00256","openalexId":"W3063038225","cited":267,"byYear":{"2018":1,"2019":3,"2020":11,"2021":35,"2022":47,"2023":55,"2024":43,"2025":45,"2026":26},"year":2020,"title":"Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia"},"paper-xiang-nature":{"doi":"10.1038/s41586-024-08378-w","openalexId":"W4406168947","cited":238,"byYear":{"2025":85,"2026":153},"year":2025,"title":"A vision–language foundation model for precision oncology"},"paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020":{"doi":"10.1038/s43018-019-0010-1","openalexId":"W2999646041","cited":213,"byYear":{"2020":26,"2021":39,"2022":28,"2023":35,"2024":35,"2025":26,"2026":24},"year":2020,"title":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma"},"paper-al-hallaq-med-phys":{"doi":"10.1002/mp.15532","openalexId":"W4212859994","cited":211,"byYear":{"2022":21,"2023":52,"2024":47,"2025":53,"2026":38},"year":2022,"title":"AAPM task group report 302: Surface‐guided radiotherapy"},"paper-msb-gvhd001-bbmt-2020":{"doi":"10.1016/j.bbmt.2020.01.018","openalexId":"W3004044398","cited":208,"byYear":{"2019":1,"2020":17,"2021":46,"2022":22,"2023":24,"2024":17,"2025":43,"2026":38},"year":2020,"title":"A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease"},"paper-carboplatin-glioblastoma-neuro-oncol-2003":{"doi":"10.1093/neuonc/5.2.96","openalexId":"W2100968876","cited":205,"byYear":{"2012":9,"2013":5,"2014":10,"2015":8,"2016":14,"2017":5,"2018":5,"2019":4,"2020":20,"2021":19,"2022":10,"2023":17,"2024":7,"2025":7,"2026":3},"year":2003,"title":"A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma"},"paper-aaml1031-bortezomib-aplenc-haematologica-2020":{"doi":"10.3324/haematol.2019.220962","openalexId":"W3004873674","cited":179,"byYear":{"2020":5,"2021":31,"2022":26,"2023":43,"2024":32,"2025":29,"2026":12},"year":2020,"title":"Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group"},"paper-wattel-blood":{"doi":"10.1182/blood.v88.7.2480.bloodjournal8872480","openalexId":"W1541537086","cited":158,"byYear":{"2012":5,"2013":15,"2014":8,"2015":10,"2016":12,"2017":9,"2018":6,"2019":6,"2020":4,"2021":14,"2022":5,"2023":4,"2024":4,"2025":2,"2026":1},"year":1996,"title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group"},"paper-aall1231-bortezomib-t-all-teachey-jco-2022":{"doi":"10.1200/jco.21.02678","openalexId":"W4221105120","cited":158,"byYear":{"2022":12,"2023":27,"2024":51,"2025":39,"2026":29},"year":2022,"title":"Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma"},"paper-attard-lancet-oncol":{"doi":"10.1016/s1470-2045(23)00148-1","openalexId":"W4367693912","cited":117,"byYear":{"2023":9,"2024":33,"2025":39,"2026":36},"year":2023,"title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol"},"paper-aall1331-low-risk-hogan-jco-2023":{"doi":"10.1200/jco.22.02200","openalexId":"W4378802651","cited":111,"byYear":{"2023":7,"2024":28,"2025":40,"2026":36},"year":2023,"title":"Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse"},"paper-aaml1031-sorafenib-flt3-pollard-jco-2022":{"doi":"10.1200/jco.21.01612","openalexId":"W4220664559","cited":110,"byYear":{"2020":2,"2021":2,"2022":11,"2023":22,"2024":33,"2025":25,"2026":15},"year":2022,"title":"Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3 /ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031"},"paper-yurkovetskiy-cancer-res":{"doi":"10.1158/0008-5472.can-15-0129","openalexId":"W2118964148","cited":106,"byYear":{"2016":4,"2017":13,"2018":12,"2019":11,"2020":8,"2021":17,"2022":11,"2023":13,"2024":5,"2025":6,"2026":6},"year":2015,"title":"A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy"},"paper-nct04454437-int-j-cancer-2023":{"doi":"10.1002/ijc.34424","openalexId":"W4313826298","cited":41,"byYear":{"2023":2,"2024":18,"2025":11,"2026":10},"year":2023,"title":"A Phase IIb , single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments"},"paper-duvic-j-am-acad-dermatol":{"doi":"10.1016/s0190-9622(96)90500-9","openalexId":"W2171285233","cited":173,"byYear":{"2012":4,"2013":11,"2014":8,"2015":4,"2016":4,"2017":7,"2018":8,"2019":5,"2020":13,"2021":8,"2022":8,"2023":5,"2024":10,"2025":12,"2026":7},"year":1996,"title":"A randomized trial of minoxidil in chemotherapy-induced alopecia"},"paper-nct02152631-front-oncol-2020":{"doi":"10.3389/fonc.2020.578756","openalexId":"W3097340813","cited":52,"byYear":{"2020":1,"2021":11,"2022":15,"2023":8,"2024":7,"2025":8,"2026":2},"year":2020,"title":"A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER"},"paper-polcagb-protocol-bmj-open-2019":{"doi":"10.1136/bmjopen-2018-028147","openalexId":"W2955524650","cited":37,"byYear":{"2020":1,"2021":4,"2022":5,"2023":6,"2024":6,"2025":11,"2026":4},"year":2019,"title":"A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB): study protocol"},"paper-mansoori-mebendazole-gi-cancer-phase-2a-sci-rep-2021":{"doi":"10.1038/s41598-021-88433-y","openalexId":"W3157961088","cited":33,"byYear":{"2022":7,"2023":9,"2024":6,"2025":7,"2026":4},"year":2021,"title":"A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer"},"paper-nct03706365-lancet-oncol-2025":{"doi":"10.1016/s1470-2045(25)00475-9","openalexId":"W4415602001","cited":5,"byYear":{"2025":2,"2026":3},"year":2025,"title":"Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-abramson-nature":{"doi":"10.1038/s41586-024-07487-w","openalexId":"W4396721167","cited":16106,"byYear":{"2014":1,"2020":1,"2021":1,"2022":4,"2023":18,"2024":1918,"2025":7522,"2026":6639},"year":2024,"title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3"},"paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004":{"doi":"10.1056/nejmoa040938","openalexId":"W2043696829","cited":11591,"byYear":{"2012":681,"2013":693,"2014":681,"2015":673,"2016":623,"2017":563,"2018":492,"2019":389,"2020":437,"2021":389,"2022":337,"2023":409,"2024":249,"2025":213,"2026":167},"year":2004,"title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib"},"paper-hanahan-cancer-cell":{"doi":"10.1016/j.ccr.2012.02.022","openalexId":"W2168631000","cited":4786,"byYear":{"2012":40,"2013":182,"2014":211,"2015":251,"2016":266,"2017":283,"2018":306,"2019":362,"2020":589,"2021":564,"2022":456,"2023":470,"2024":373,"2025":283,"2026":147},"year":2012,"title":"Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment"},"paper-pao-egfr-t790m-acquired-resistance-plos-med-2005":{"doi":"10.1371/journal.pmed.0020073","openalexId":"W2002937040","cited":3555,"byYear":{"2012":223,"2013":271,"2014":248,"2015":255,"2016":236,"2017":221,"2018":206,"2019":157,"2020":143,"2021":119,"2022":118,"2023":143,"2024":60,"2025":57,"2026":35},"year":2005,"title":"Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain"},"paper-dohner-n-engl-j-med":{"doi":"10.1056/nejmra1406184","openalexId":"W4231346141","cited":3464,"byYear":{"2015":5,"2016":136,"2017":220,"2018":236,"2019":316,"2020":386,"2021":476,"2022":462,"2023":373,"2024":381,"2025":306,"2026":164},"year":2015,"title":"Acute Myeloid Leukemia"},"paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971":{"doi":"10.1056/nejm197104222841604","openalexId":"W2902914441","cited":2523,"byYear":{"2012":72,"2013":61,"2014":56,"2015":61,"2016":58,"2017":52,"2018":42,"2019":51,"2020":50,"2021":42,"2022":36,"2023":41,"2024":35,"2025":35,"2026":28},"year":1971,"title":"Adenocarcinoma of the Vagina"},"paper-conko-001-adjuvant-gemcitabine-observation-jama-2007":{"doi":"10.1001/jama.297.3.267","openalexId":"W2129197203","cited":2432,"byYear":{"2012":170,"2013":151,"2014":155,"2015":147,"2016":141,"2017":177,"2018":150,"2019":135,"2020":154,"2021":139,"2022":96,"2023":89,"2024":65,"2025":66,"2026":19},"year":2007,"title":"Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer"},"paper-hunger-mullighan-all-children-nejm-2015":{"doi":"10.1056/nejmra1400972","openalexId":"W1801876107","cited":2277,"byYear":{"2012":10,"2013":4,"2014":9,"2015":6,"2016":73,"2017":103,"2018":138,"2019":182,"2020":255,"2021":297,"2022":279,"2023":252,"2024":226,"2025":199,"2026":147},"year":2015,"title":"Acute Lymphoblastic Leukemia in Children"},"paper-cheng-science":{"doi":"10.1126/science.adg7492","openalexId":"W4386861232","cited":2250,"byYear":{"2012":1,"2022":3,"2023":87,"2024":659,"2025":854,"2026":646},"year":2023,"title":"Accurate proteome-wide missense variant effect prediction with AlphaMissense"},"paper-stampede-lancet-2016":{"doi":"10.1016/s0140-6736(15)01037-5","openalexId":"W2214621962","cited":1986,"byYear":{"2015":3,"2016":130,"2017":197,"2018":255,"2019":227,"2020":253,"2021":227,"2022":208,"2023":150,"2024":138,"2025":122,"2026":72},"year":2015,"title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial"},"paper-create-x-adjuvant-capecitabine-nejm-2017":{"doi":"10.1056/nejmoa1612645","openalexId":"W2618058692","cited":1953,"byYear":{"2016":4,"2017":32,"2018":65,"2019":116,"2020":214,"2021":292,"2022":331,"2023":278,"2024":262,"2025":215,"2026":138},"year":2017,"title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy"},"paper-adaura-nejm-2020":{"doi":"10.1056/nejmoa2027071","openalexId":"W3087210493","cited":1817,"byYear":{"2016":1,"2020":23,"2021":262,"2022":389,"2023":393,"2024":286,"2025":290,"2026":171},"year":2020,"title":"Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer"},"paper-thress-nat-med":{"doi":"10.1038/nm.3854","openalexId":"W1546552389","cited":1583,"byYear":{"2015":44,"2016":149,"2017":178,"2018":184,"2019":168,"2020":195,"2021":161,"2022":137,"2023":96,"2024":92,"2025":102,"2026":76},"year":2015,"title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M"},"paper-felip-impower010-adjuvant-atezolizumab-lancet-2021":{"doi":"10.1016/s0140-6736(21)02098-5","openalexId":"W3199241644","cited":1530,"byYear":{"2021":20,"2022":254,"2023":415,"2024":398,"2025":295,"2026":146},"year":2021,"title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial"},"paper-quasar-adjuvant-chemotherapy-vs-observation-lancet-2007":{"doi":"10.1016/s0140-6736(07)61866-2","openalexId":"W2109740395","cited":1449,"byYear":{"2012":87,"2013":74,"2014":103,"2015":100,"2016":85,"2017":78,"2018":79,"2019":79,"2020":108,"2021":84,"2022":84,"2023":67,"2024":73,"2025":37,"2026":22},"year":2007,"title":"Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study"},"paper-nct03785249-n-engl-j-med-2022":{"doi":"10.1056/nejmoa2204619","openalexId":"W4281650778","cited":1059,"byYear":{"2022":57,"2023":214,"2024":308,"2025":270,"2026":210},"year":2022,"title":"Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation"},"paper-gatenby-cancer-res":{"doi":"10.1158/0008-5472.can-08-3658","openalexId":"W4251104453","cited":907,"byYear":{"2012":18,"2013":23,"2014":29,"2015":50,"2016":51,"2017":54,"2018":54,"2019":54,"2020":100,"2021":77,"2022":61,"2023":78,"2024":79,"2025":79,"2026":70},"year":2009,"title":"Adaptive Therapy"},"paper-acalabrutinib-cll-n-engl-j-med-2016":{"doi":"10.1056/nejmoa1509981","openalexId":"W2316021978","cited":904,"byYear":{"2014":1,"2015":2,"2016":85,"2017":99,"2018":91,"2019":109,"2020":110,"2021":152,"2022":82,"2023":52,"2024":50,"2025":44,"2026":24},"year":2015,"title":"Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia"},"paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014":{"doi":"10.1089/thy.2013.0367","openalexId":"W2068973781","cited":830,"byYear":{"2013":3,"2014":28,"2015":46,"2016":60,"2017":70,"2018":77,"2019":86,"2020":81,"2021":79,"2022":80,"2023":86,"2024":63,"2025":41,"2026":28},"year":2013,"title":"Patient Age Is Significantly Related to the Progression of Papillary Microcarcinoma of the Thyroid Under Observation"},"paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.0096","openalexId":"W7212039067","cited":6,"byYear":{"2024":1,"2026":5},"year":2019,"title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial"},"paper-brightness-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30111-6","openalexId":"W2788106879","cited":787,"byYear":{"2017":1,"2018":31,"2019":78,"2020":99,"2021":132,"2022":124,"2023":103,"2024":96,"2025":74,"2026":48},"year":2018,"title":"Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial"},"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet":{"doi":"10.1016/s0140-6736(15)60908-4","openalexId":"W2138691465","cited":754,"byYear":{"2014":1,"2015":23,"2016":75,"2017":87,"2018":83,"2019":81,"2020":71,"2021":76,"2022":52,"2023":58,"2024":59,"2025":42,"2026":42},"year":2015,"title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials"},"paper-act-ii-anal-cancer-chemoradiation-lancet-oncol-2013":{"doi":"10.1016/s1470-2045(13)70086-x","openalexId":"W2164644812","cited":739,"byYear":{"2012":1,"2013":13,"2014":42,"2015":44,"2016":38,"2017":68,"2018":66,"2019":56,"2020":71,"2021":80,"2022":68,"2023":54,"2024":58,"2025":48,"2026":28},"year":2013,"title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial"},"paper-soft-text-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1412379","openalexId":"W2169649287","cited":737,"byYear":{"2013":1,"2014":1,"2015":97,"2016":90,"2017":99,"2018":73,"2019":67,"2020":56,"2021":76,"2022":44,"2023":38,"2024":35,"2025":37,"2026":19},"year":2014,"title":"Adjuvant Ovarian Suppression in Premenopausal Breast Cancer"},"paper-acalabrutinib-cll-j-clin-oncol-2021":{"doi":"10.1200/jco.21.01210","openalexId":"W3185756680","cited":673,"byYear":{"2021":41,"2022":99,"2023":146,"2024":144,"2025":143,"2026":99},"year":2021,"title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial"},"paper-checkmate-238-lancet-oncol-2020-update":{"doi":"10.1016/s1470-2045(20)30494-0","openalexId":"W3087697977","cited":538,"byYear":{"2020":7,"2021":103,"2022":121,"2023":106,"2024":97,"2025":67,"2026":36},"year":2020,"title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial"},"paper-wilson-lancet":{"doi":"10.1016/s0140-6736(18)30458-6","openalexId":"W2792433889","cited":471,"byYear":{"2018":21,"2019":34,"2020":48,"2021":46,"2022":73,"2023":87,"2024":65,"2025":55,"2026":41},"year":2018,"title":"Access to pathology and laboratory medicine services: a crucial gap"},"paper-capstone-1-lancet-oncol-2022":{"doi":"10.1016/s1470-2045(22)00224-8","openalexId":"W4280546819","cited":435,"byYear":{"2022":21,"2023":77,"2024":130,"2025":121,"2026":84},"year":2022,"title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-nct02362594-lancet-oncol-2021-update":{"doi":"10.1016/s1470-2045(21)00065-6","openalexId":"W7212054421","cited":1,"byYear":{"2026":1},"year":2021,"title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial"},"paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019":{"doi":"10.1200/jco.18.01765","openalexId":"W2918069808","cited":239,"byYear":{"2019":14,"2020":27,"2021":41,"2022":35,"2023":43,"2024":29,"2025":29,"2026":20},"year":2019,"title":"Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma"},"paper-durham-nat-med":{"doi":"10.1038/s41591-019-0653-6","openalexId":"W2989688132","cited":234,"byYear":{"2013":1,"2019":1,"2020":24,"2021":32,"2022":34,"2023":30,"2024":49,"2025":46,"2026":17},"year":2019,"title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms"},"paper-alexander-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-17-0764","openalexId":"W2748703947","cited":231,"byYear":{"2012":1,"2018":11,"2019":21,"2020":29,"2021":35,"2022":33,"2023":36,"2024":26,"2025":19,"2026":19},"year":2017,"title":"Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE"},"paper-acns0331-michalski-jco-2021":{"doi":"10.1200/jco.20.02730","openalexId":"W3170859953","cited":216,"byYear":{"2021":10,"2022":27,"2023":55,"2024":27,"2025":61,"2026":36},"year":2021,"title":"Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma"},"paper-acns0333-atrt-high-dose-chemotherapy-reddy-jco-2020":{"doi":"10.1200/jco.19.01776","openalexId":"W3008366344","cited":203,"byYear":{"2020":14,"2021":23,"2022":28,"2023":33,"2024":37,"2025":41,"2026":26},"year":2020,"title":"Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333"},"paper-zammarchi-blood":{"doi":"10.1182/blood-2017-10-813493","openalexId":"W2781864644","cited":185,"byYear":{"2018":6,"2019":11,"2020":18,"2021":24,"2022":28,"2023":32,"2024":26,"2025":28,"2026":11},"year":2018,"title":"ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies"},"paper-apt-trial-lancet-oncol-2023-update":{"doi":"10.1016/s1470-2045(23)00051-7","openalexId":"W4322490942","cited":178,"byYear":{"2023":24,"2024":62,"2025":60,"2026":32},"year":2023,"title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial"},"paper-acns0332-leary-jama-oncol-2021":{"doi":"10.1001/jamaoncol.2021.2224","openalexId":"W3184618654","cited":167,"byYear":{"2021":11,"2022":17,"2023":35,"2024":31,"2025":52,"2026":21},"year":2021,"title":"Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma"},"paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019":{"doi":"10.1200/jco.19.00701","openalexId":"W2977021423","cited":131,"byYear":{"2019":1,"2020":6,"2021":19,"2022":32,"2023":19,"2024":22,"2025":20,"2026":12},"year":2019,"title":"Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study"},"paper-parsons-j-clin-oncol":{"doi":"10.1200/jco.21.02838","openalexId":"W4220724408","cited":122,"byYear":{"2022":7,"2023":32,"2024":41,"2025":22,"2026":20},"year":2022,"title":"Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial"},"paper-actg-a5263-kaposi-sarcoma-resource-limited-krown-lancet-2020":{"doi":"10.1016/s0140-6736(19)33222-2","openalexId":"W3010235078","cited":91,"byYear":{"2020":5,"2021":15,"2022":19,"2023":20,"2024":14,"2025":14,"2026":4},"year":2020,"title":"Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial"},"paper-comet-dcis-jama-2025":{"doi":"10.1001/jama.2024.26698","openalexId":"W4405320341","cited":85,"byYear":{"2024":1,"2025":46,"2026":38},"year":2024,"title":"Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ"},"paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023":{"doi":"10.1016/s2213-8587(23)00193-6","openalexId":"W4386024295","cited":84,"byYear":{"2023":3,"2024":30,"2025":30,"2026":21},"year":2023,"title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study"},"paper-acns1123-germinoma-neuro-oncology-2022":{"doi":"10.1093/neuonc/noab270","openalexId":"W3214977940","cited":77,"byYear":{"2022":9,"2023":20,"2024":17,"2025":18,"2026":13},"year":2021,"title":"Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children’s Oncology Group study"},"paper-soft-text-j-clin-oncol-2023-update":{"doi":"10.1200/jco.22.01065","openalexId":"W4311018682","cited":64,"byYear":{"2023":12,"2024":13,"2025":25,"2026":14},"year":2022,"title":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT"},"paper-halder-lancet-reg-health-southeast-asia":{"doi":"10.1016/j.lansea.2024.100514","openalexId":"W4405563632","cited":23,"byYear":{"2024":1,"2025":13,"2026":9},"year":2024,"title":"Access to timely cancer treatment initiation in India: extent, determinants and trends"},"paper-relativity-098-nat-med-2025":{"doi":"10.1038/s41591-025-04032-8","openalexId":"W4415310197","cited":16,"byYear":{"2026":16},"year":2025,"title":"Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial"},"paper-sirolimus-ehe-stacchiotti-cancer-2021":{"doi":"10.1002/cncr.33247","openalexId":"W3093617452","cited":53,"byYear":{"2020":1,"2021":10,"2022":7,"2023":5,"2024":14,"2025":10,"2026":6},"year":2020,"title":"Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network"},"paper-timbergen-eur-j-cancer":{"doi":"10.1016/j.ejca.2020.06.022","openalexId":"W3045572131","cited":50,"byYear":{"2021":10,"2022":8,"2023":8,"2024":9,"2025":10,"2026":5},"year":2020,"title":"Active surveillance in desmoid-type fibromatosis: A systematic literature review"},"paper-alphafold2-jumper-nature-2021":{"doi":"10.1038/s41586-021-03819-2","openalexId":"W3177828909","cited":47741,"byYear":{"2012":7,"2013":4,"2014":1,"2017":2,"2019":2,"2020":19,"2021":1123,"2022":6534,"2023":10016,"2024":11950,"2025":11045,"2026":7007},"year":2021,"title":"Highly accurate protein structure prediction with AlphaFold"},"paper-al-hajj-breast-cancer-stem-cells-pnas-2003":{"doi":"10.1073/pnas.0530291100","openalexId":"W2023427658","cited":10464,"byYear":{"2012":766,"2013":741,"2014":672,"2015":657,"2016":624,"2017":586,"2018":492,"2019":497,"2020":510,"2021":463,"2022":386,"2023":394,"2024":287,"2025":201,"2026":111},"year":2003,"title":"Prospective identification of tumorigenic breast cancer cells"},"paper-allemani-concord-3-lancet-2018":{"doi":"10.1016/s0140-6736(17)33326-3","openalexId":"W2787553551","cited":6329,"byYear":{"2013":2,"2017":2,"2018":242,"2019":445,"2020":1075,"2021":764,"2022":819,"2023":1002,"2024":862,"2025":644,"2026":465},"year":2018,"title":"Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries"},"paper-scher-affirm-enzalutamide-nejm-2012":{"doi":"10.1056/nejmoa1207506","openalexId":"W2148643283","cited":4643,"byYear":{"2012":51,"2013":326,"2014":424,"2015":372,"2016":403,"2017":353,"2018":363,"2019":372,"2020":370,"2021":385,"2022":342,"2023":295,"2024":244,"2025":198,"2026":125},"year":2012,"title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy"},"paper-asco-cap-er-pr-testing-guideline-jco-2010":{"doi":"10.1200/jco.2009.25.6529","openalexId":"W2137853125","cited":4301,"byYear":{"2012":230,"2013":272,"2014":323,"2015":333,"2016":338,"2017":350,"2018":309,"2019":308,"2020":388,"2021":344,"2022":216,"2023":214,"2024":178,"2025":159,"2026":106},"year":2010,"title":"American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer"},"paper-alsympca-radium-223-nejm-2013":{"doi":"10.1056/nejmoa1213755","openalexId":"W2141454098","cited":3417,"byYear":{"2012":4,"2013":50,"2014":250,"2015":253,"2016":287,"2017":278,"2018":322,"2019":268,"2020":278,"2021":312,"2022":258,"2023":258,"2024":229,"2025":213,"2026":146},"year":2013,"title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer"},"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011":{"doi":"10.1056/nejmoa0910383","openalexId":"W2098775844","cited":2805,"byYear":{"2012":125,"2013":205,"2014":215,"2015":229,"2016":204,"2017":205,"2018":187,"2019":202,"2020":219,"2021":253,"2022":241,"2023":180,"2024":144,"2025":110,"2026":66},"year":2011,"title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer"},"paper-peters-alex-alectinib-crizotinib-nejm-2017":{"doi":"10.1056/nejmoa1704795","openalexId":"W2624310346","cited":2586,"byYear":{"2016":1,"2017":82,"2018":280,"2019":275,"2020":332,"2021":343,"2022":312,"2023":281,"2024":295,"2025":220,"2026":157},"year":2017,"title":"Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer"},"paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013":{"doi":"10.1158/1078-0432.ccr-12-2246","openalexId":"W2154149901","cited":2519,"byYear":{"2012":1,"2013":32,"2014":90,"2015":137,"2016":186,"2017":278,"2018":259,"2019":231,"2020":291,"2021":250,"2022":228,"2023":177,"2024":148,"2025":121,"2026":85},"year":2013,"title":"Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers"},"paper-alliance-n0574-brown-jama-2016":{"doi":"10.1001/jama.2016.9839","openalexId":"W2492450141","cited":1693,"byYear":{"2015":2,"2016":18,"2017":126,"2018":166,"2019":168,"2020":197,"2021":185,"2022":204,"2023":185,"2024":162,"2025":174,"2026":100},"year":2016,"title":"Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases"},"paper-sanai-j-neurosurg":{"doi":"10.3171/2011.2.jns10998","openalexId":"W1887747927","cited":1677,"byYear":{"2012":56,"2013":60,"2014":93,"2015":93,"2016":108,"2017":133,"2018":102,"2019":140,"2020":152,"2021":157,"2022":135,"2023":146,"2024":119,"2025":109,"2026":56},"year":2011,"title":"An extent of resection threshold for newly diagnosed glioblastomas"},"paper-knaul-lancet":{"doi":"10.1016/s0140-6736(17)32513-8","openalexId":"W2761242421","cited":1494,"byYear":{"2016":1,"2017":5,"2018":99,"2019":101,"2020":183,"2021":184,"2022":164,"2023":168,"2024":223,"2025":175,"2026":190},"year":2017,"title":"Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report"},"paper-admiral-gilteritinib-flt3-nejm-2019":{"doi":"10.1056/nejmoa1902688","openalexId":"W2982353618","cited":1296,"byYear":{"2019":8,"2020":160,"2021":215,"2022":235,"2023":192,"2024":197,"2025":161,"2026":127},"year":2019,"title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML"},"paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.0528","openalexId":"W2944044607","cited":1056,"byYear":{"2019":20,"2020":94,"2021":159,"2022":141,"2023":187,"2024":154,"2025":161,"2026":137},"year":2019,"title":"Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer"},"paper-fraass-med-phys":{"doi":"10.1118/1.598373","openalexId":"W2116272759","cited":915,"byYear":{"2012":42,"2013":29,"2014":44,"2015":50,"2016":38,"2017":37,"2018":36,"2019":46,"2020":31,"2021":44,"2022":43,"2023":37,"2024":26,"2025":34,"2026":12},"year":1998,"title":"American Association of Physicists in Medicine Radiation Therapy Committee Task Group 53: Quality assurance for clinical radiotherapy treatment planning"},"paper-chan-n-engl-j-med":{"doi":"10.1056/nejmoa1701717","openalexId":"W2742681205","cited":808,"byYear":{"2017":11,"2018":64,"2019":83,"2020":100,"2021":99,"2022":118,"2023":89,"2024":108,"2025":86,"2026":48},"year":2017,"title":"Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer"},"paper-rock-ca-cancer-j-clin":{"doi":"10.3322/caac.21591","openalexId":"W3033699454","cited":803,"byYear":{"2020":20,"2021":97,"2022":138,"2023":158,"2024":171,"2025":150,"2026":67},"year":2020,"title":"American Cancer Society guideline for diet and physical activity for cancer prevention"},"paper-aews0031-interval-compressed-chemotherapy-ewing-womer-jco-2012":{"doi":"10.1200/jco.2011.41.5703","openalexId":"W2128628566","cited":776,"byYear":{"2012":5,"2013":25,"2014":35,"2015":55,"2016":53,"2017":52,"2018":51,"2019":52,"2020":69,"2021":70,"2022":73,"2023":78,"2024":55,"2025":54,"2026":43},"year":2012,"title":"Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group"},"paper-aethera-brentuximab-consolidation-after-asct-hodgkin-lancet-2015":{"doi":"10.1016/s0140-6736(15)60165-9","openalexId":"W2062486240","cited":741,"byYear":{"2014":4,"2015":34,"2016":57,"2017":102,"2018":100,"2019":68,"2020":85,"2021":65,"2022":76,"2023":62,"2024":41,"2025":25,"2026":16},"year":2015,"title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-alcohol-cancer-burden-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00279-5","openalexId":"W3183035192","cited":709,"byYear":{"2021":28,"2022":86,"2023":140,"2024":206,"2025":144,"2026":105},"year":2021,"title":"Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study"},"paper-park-j-clin-oncol":{"doi":"10.1200/jco.21.00662","openalexId":"W3191219220","cited":659,"byYear":{"2021":16,"2022":141,"2023":158,"2024":144,"2025":124,"2026":74},"year":2021,"title":"Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study"},"paper-solar-1-ann-oncol-2021-update":{"doi":"10.1016/j.annonc.2020.11.011","openalexId":"W3109453522","cited":621,"byYear":{"2020":1,"2021":70,"2022":111,"2023":128,"2024":127,"2025":113,"2026":71},"year":2020,"title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1"},"paper-alcanza-brentuximab-vedotin-lancet-2017":{"doi":"10.1016/s0140-6736(17)31266-7","openalexId":"W7212050288","cited":3,"byYear":{"2026":3},"year":2017,"title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial"},"paper-hillmen-j-clin-oncol":{"doi":"10.1200/jco.2007.12.9098","openalexId":"W2099145932","cited":562,"byYear":{"2012":57,"2013":50,"2014":54,"2015":40,"2016":31,"2017":23,"2018":16,"2019":9,"2020":14,"2021":10,"2022":8,"2023":1,"2024":5,"2025":4},"year":2007,"title":"Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia"},"paper-zahalka-science":{"doi":"10.1126/science.aah5072","openalexId":"W2765161542","cited":545,"byYear":{"2017":7,"2018":24,"2019":39,"2020":57,"2021":58,"2022":74,"2023":63,"2024":72,"2025":70,"2026":81},"year":2017,"title":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer"},"paper-agile-ivosidenib-azacitidine-nejm-2022":{"doi":"10.1056/nejmoa2117344","openalexId":"W4224290890","cited":517,"byYear":{"2019":1,"2022":58,"2023":122,"2024":127,"2025":131,"2026":78},"year":2022,"title":"Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia"},"paper-wu-alina-adjuvant-alectinib-nejm-2024":{"doi":"10.1056/nejmoa2310532","openalexId":"W4394675771","cited":426,"byYear":{"2023":1,"2024":91,"2025":209,"2026":125},"year":2024,"title":"Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer"},"paper-cardenas-semin-radiat-oncol":{"doi":"10.1016/j.semradonc.2019.02.001","openalexId":"W2941434555","cited":418,"byYear":{"2019":9,"2020":41,"2021":57,"2022":82,"2023":71,"2024":74,"2025":56,"2026":26},"year":2019,"title":"Advances in Auto-Segmentation"},"paper-hu-j-natl-cancer-inst":{"doi":"10.1093/jnci/djy225","openalexId":"W2908716024","cited":401,"byYear":{"2018":1,"2019":26,"2020":60,"2021":59,"2022":62,"2023":66,"2024":65,"2025":42,"2026":20},"year":2018,"title":"An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening"},"paper-besser-til-melanoma-intent-to-treat-ccr-2013":{"doi":"10.1158/1078-0432.ccr-13-0380","openalexId":"W2149209349","cited":391,"byYear":{"2013":5,"2014":23,"2015":33,"2016":22,"2017":25,"2018":32,"2019":37,"2020":38,"2021":38,"2022":39,"2023":30,"2024":35,"2025":23,"2026":10},"year":2013,"title":"Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies"},"paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019":{"doi":"10.1200/jco.18.02236","openalexId":"W2923683745","cited":386,"byYear":{"2018":1,"2019":21,"2020":57,"2021":80,"2022":68,"2023":58,"2024":45,"2025":33,"2026":23},"year":2019,"title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer"},"paper-nct04538664-n-engl-j-med-2023":{"doi":"10.1056/nejmoa2306441","openalexId":"W4387844767","cited":379,"byYear":{"2023":8,"2024":102,"2025":170,"2026":98},"year":2023,"title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions"},"paper-adriatic-nejm-2024":{"doi":"10.1056/nejmoa2404873","openalexId":"W4402519167","cited":349,"byYear":{"2022":1,"2024":27,"2025":164,"2026":157},"year":2024,"title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer"},"paper-all-r3-mitoxantrone-relapsed-childhood-all-parker-lancet-2010":{"doi":"10.1016/s0140-6736(10)62002-8","openalexId":"W2101272773","cited":337,"byYear":{"2012":19,"2013":20,"2014":16,"2015":18,"2016":17,"2017":28,"2018":25,"2019":24,"2020":28,"2021":28,"2022":42,"2023":20,"2024":22,"2025":14,"2026":8},"year":2010,"title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial"},"paper-alliance-a021501-mfolfirinox-radiotherapy-borderline-resectable-jama-oncol-2022":{"doi":"10.1001/jamaoncol.2022.2319","openalexId":"W4285390129","cited":308,"byYear":{"2022":18,"2023":75,"2024":78,"2025":81,"2026":56},"year":2022,"title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas"},"paper-aeneas-j-clin-oncol-2022":{"doi":"10.1200/jco.21.02641","openalexId":"W4280558216","cited":302,"byYear":{"2022":16,"2023":52,"2024":83,"2025":93,"2026":58},"year":2022,"title":"AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations"},"paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017":{"doi":"10.1158/2159-8290.cd-17-0146","openalexId":"W2608211931","cited":277,"byYear":{"2017":12,"2018":38,"2019":32,"2020":43,"2021":35,"2022":42,"2023":23,"2024":20,"2025":17,"2026":15},"year":2017,"title":"Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors"},"paper-trigos-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.1617743114","openalexId":"W2612580399","cited":234,"byYear":{"2017":3,"2018":15,"2019":22,"2020":29,"2021":31,"2022":33,"2023":32,"2024":34,"2025":23,"2026":11},"year":2017,"title":"Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors"},"paper-lian-adjuvant-temozolomide-cisplatin-mucosal-melanoma-ccr-2013":{"doi":"10.1158/1078-0432.ccr-13-0739","openalexId":"W2097691839","cited":204,"byYear":{"2013":2,"2014":8,"2015":10,"2016":15,"2017":12,"2018":14,"2019":14,"2020":22,"2021":20,"2022":25,"2023":15,"2024":22,"2025":16,"2026":8},"year":2013,"title":"Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma"},"paper-ampect-nab-sirolimus-pecoma-wagner-jco-2021":{"doi":"10.1200/jco.21.01728","openalexId":"W3207811858","cited":185,"byYear":{"2022":22,"2023":48,"2024":37,"2025":43,"2026":34},"year":2021,"title":"nab -Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors"},"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022":{"doi":"10.1056/nejmoa2206660","openalexId":"W4308146252","cited":171,"byYear":{"2022":3,"2023":39,"2024":50,"2025":51,"2026":27},"year":2022,"title":"Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma"},"paper-fruhwald-neuro-oncol":{"doi":"10.1093/neuonc/noz244","openalexId":"W2997655299","cited":145,"byYear":{"2020":13,"2021":17,"2022":17,"2023":24,"2024":26,"2025":28,"2026":18},"year":2019,"title":"Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors"},"paper-martini-african-ancestry-tnbc-cancer-discov-2022":{"doi":"10.1158/2159-8290.cd-22-0138","openalexId":"W4296322703","cited":139,"byYear":{"2022":3,"2023":38,"2024":46,"2025":39,"2026":13},"year":2022,"title":"African Ancestry–Associated Gene Expression Profiles in Triple-Negative Breast Cancer Underlie Altered Tumor Biology and Clinical Outcome in Women of African Descent"},"paper-amplify-acalabrutinib-venetoclax-nejm-2025":{"doi":"10.1056/nejmoa2409804","openalexId":"W4407162998","cited":122,"byYear":{"2025":51,"2026":71},"year":2025,"title":"Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia"},"paper-a071401-brastianos-jco-2023":{"doi":"10.1200/jco.21.02371","openalexId":"W4307431542","cited":114,"byYear":{"2021":1,"2022":8,"2023":22,"2024":29,"2025":32,"2026":22},"year":2022,"title":"Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations"},"paper-chrysalis-nat-med-2023":{"doi":"10.1038/s41591-023-02554-7","openalexId":"W4386741480","cited":110,"byYear":{"2023":5,"2024":35,"2025":49,"2026":21},"year":2023,"title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial"},"paper-aphinity-j-clin-oncol-2024-update":{"doi":"10.1200/jco.23.02505","openalexId":"W4402447549","cited":37,"byYear":{"2024":2,"2025":14,"2026":21},"year":2024,"title":"Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update"},"paper-nct05379595-j-clin-oncol-2026":{"doi":"10.1200/jco-25-02187","openalexId":"W7155083975","cited":5,"byYear":{"2026":5},"year":2026,"title":"Amivantamab Monotherapy in Chemorefractory RAS / BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study"},"paper-nct01436968-lancet-oncol-2026":{"doi":"10.1016/s1470-2045(26)00071-9","openalexId":"W7163030033","cited":5,"byYear":{"2026":5},"year":2026,"title":"Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial"},"paper-kwak-crizotinib-alk-nsclc-nejm-2010":{"doi":"10.1056/nejmoa1006448","openalexId":"W2104830962","cited":4508,"byYear":{"2012":538,"2013":547,"2014":504,"2015":458,"2016":403,"2017":338,"2018":240,"2019":219,"2020":241,"2021":186,"2022":139,"2023":119,"2024":111,"2025":82,"2026":35},"year":2010,"title":"Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer"},"paper-llovet-tace-lancet-2002":{"doi":"10.1016/s0140-6736(02)08649-x","openalexId":"W2125763116","cited":3532,"byYear":{"2012":196,"2013":221,"2014":224,"2015":196,"2016":180,"2017":199,"2018":151,"2019":175,"2020":202,"2021":154,"2022":135,"2023":130,"2024":137,"2025":94,"2026":58},"year":2002,"title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial"},"paper-antonarakis-ar-v7-resistance-nejm-2014":{"doi":"10.1056/nejmoa1315815","openalexId":"W2156923287","cited":2748,"byYear":{"2013":2,"2014":33,"2015":231,"2016":326,"2017":303,"2018":254,"2019":249,"2020":254,"2021":249,"2022":218,"2023":203,"2024":182,"2025":131,"2026":108},"year":2014,"title":"AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer"},"paper-asco-irae-guideline-jco-2021":{"doi":"10.1200/jco.21.01440","openalexId":"W3210474759","cited":2233,"byYear":{"2021":3,"2022":191,"2023":368,"2024":458,"2025":589,"2026":622},"year":2021,"title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update"},"paper-yu-anti-gd2-neuroblastoma-nejm-2010":{"doi":"10.1056/nejmoa0911123","openalexId":"W2130465135","cited":1849,"byYear":{"2012":91,"2013":103,"2014":95,"2015":115,"2016":105,"2017":135,"2018":107,"2019":107,"2020":166,"2021":154,"2022":148,"2023":136,"2024":127,"2025":99,"2026":85},"year":2010,"title":"Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma"},"paper-androgen-receptor-prostate-endocr-rev-2004":{"doi":"10.1210/er.2002-0032","openalexId":"W2064293531","cited":1803,"byYear":{"2012":88,"2013":93,"2014":104,"2015":93,"2016":86,"2017":94,"2018":70,"2019":82,"2020":87,"2021":103,"2022":85,"2023":115,"2024":73,"2025":65,"2026":32},"year":2004,"title":"Androgen Receptor in Prostate Cancer"},"paper-wiegand-arid1a-clear-cell-nejm-2010":{"doi":"10.1056/nejmoa1008433","openalexId":"W2034852369","cited":1731,"byYear":{"2012":130,"2013":143,"2014":121,"2015":137,"2016":105,"2017":111,"2018":107,"2019":109,"2020":122,"2021":111,"2022":80,"2023":116,"2024":86,"2025":74,"2026":65},"year":2010,"title":"ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas"},"paper-ascent-nejm-2021":{"doi":"10.1056/nejmoa2028485","openalexId":"W3156985612","cited":1679,"byYear":{"2021":68,"2022":224,"2023":306,"2024":356,"2025":395,"2026":329},"year":2021,"title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer"},"paper-apl0406-lo-coco-nejm-2013":{"doi":"10.1056/nejmoa1300874","openalexId":"W2129338773","cited":1643,"byYear":{"2012":1,"2013":32,"2014":119,"2015":144,"2016":118,"2017":107,"2018":124,"2019":127,"2020":142,"2021":149,"2022":118,"2023":157,"2024":137,"2025":91,"2026":72},"year":2013,"title":"Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia"},"paper-jain-cancer-cell":{"doi":"10.1016/j.ccell.2014.10.006","openalexId":"W2022540958","cited":1595,"byYear":{"2014":3,"2015":69,"2016":103,"2017":126,"2018":118,"2019":139,"2020":179,"2021":155,"2022":147,"2023":171,"2024":146,"2025":112,"2026":125},"year":2014,"title":"Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia"},"paper-nct02489318-n-engl-j-med-2019":{"doi":"10.1056/nejmoa1903307","openalexId":"W2947014957","cited":1578,"byYear":{"2014":1,"2017":1,"2019":49,"2020":199,"2021":236,"2022":242,"2023":206,"2024":248,"2025":221,"2026":166},"year":2019,"title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer"},"paper-aphinity-nejm-2017":{"doi":"10.1056/nejmoa1703643","openalexId":"W2624590002","cited":1430,"byYear":{"2016":3,"2017":55,"2018":143,"2019":167,"2020":200,"2021":212,"2022":159,"2023":169,"2024":126,"2025":118,"2026":72},"year":2017,"title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer"},"paper-arches-j-clin-oncol-2019":{"doi":"10.1200/jco.19.00799","openalexId":"W2963794755","cited":1242,"byYear":{"2014":1,"2017":1,"2019":17,"2020":124,"2021":165,"2022":217,"2023":176,"2024":193,"2025":195,"2026":149},"year":2019,"title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer"},"paper-nagendran-bmj":{"doi":"10.1136/bmj.m689","openalexId":"W3013681994","cited":1160,"byYear":{"2012":1,"2019":1,"2020":79,"2021":196,"2022":182,"2023":182,"2024":159,"2025":172,"2026":187},"year":2020,"title":"Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies"},"paper-dillekas-cancer-med":{"doi":"10.1002/cam4.2474","openalexId":"W2967213355","cited":1000,"byYear":{"2019":4,"2020":69,"2021":152,"2022":183,"2023":167,"2024":191,"2025":139,"2026":94},"year":2019,"title":"Are 90% of deaths from cancer caused by metastases?"},"paper-young-angiosarcoma-review-lancet-oncol-2010":{"doi":"10.1016/s1470-2045(10)70023-1","openalexId":"W4241497580","cited":978,"byYear":{"2012":32,"2013":43,"2014":38,"2015":36,"2016":38,"2017":60,"2018":53,"2019":52,"2020":98,"2021":95,"2022":90,"2023":78,"2024":92,"2025":92,"2026":57},"year":2010,"title":"Angiosarcoma"},"paper-arasens-nejm-2022":{"doi":"10.1056/nejmoa2119115","openalexId":"W4213140514","cited":976,"byYear":{"2022":117,"2023":198,"2024":240,"2025":236,"2026":185},"year":2022,"title":"Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer"},"paper-androgen-receptor-prostate-acta-pharmacol-sin-2015":{"doi":"10.1038/aps.2014.18","openalexId":"W1968786809","cited":975,"byYear":{"2015":18,"2016":42,"2017":44,"2018":51,"2019":66,"2020":99,"2021":109,"2022":121,"2023":115,"2024":124,"2025":105,"2026":79},"year":2014,"title":"Androgen receptor: structure, role in prostate cancer and drug discovery"},"paper-aramis-nejm-2019":{"doi":"10.1056/nejmoa1815671","openalexId":"W2913767564","cited":946,"byYear":{"2014":1,"2017":1,"2019":71,"2020":156,"2021":179,"2022":141,"2023":113,"2024":116,"2025":96,"2026":67},"year":2019,"title":"Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer"},"paper-murray-nat-rev-cancer":{"doi":"10.1038/nrc3846","openalexId":"W1996613294","cited":922,"byYear":{"2014":3,"2015":34,"2016":60,"2017":57,"2018":83,"2019":72,"2020":120,"2021":90,"2022":99,"2023":93,"2024":99,"2025":66,"2026":45},"year":2014,"title":"Aryl hydrocarbon receptor ligands in cancer: friend and foe"},"paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017":{"doi":"10.1016/j.ccell.2017.09.003","openalexId":"W2762381618","cited":793,"byYear":{"2017":2,"2018":53,"2019":79,"2020":88,"2021":103,"2022":87,"2023":112,"2024":105,"2025":101,"2026":63},"year":2017,"title":"Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling"},"paper-apt-tolaney-nejm-2015":{"doi":"10.1056/nejmoa1406281","openalexId":"W2095633632","cited":760,"byYear":{"2013":1,"2014":2,"2015":61,"2016":66,"2017":73,"2018":66,"2019":72,"2020":76,"2021":74,"2022":74,"2023":60,"2024":54,"2025":48,"2026":30},"year":2015,"title":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer"},"paper-weaver-cancer-cell":{"doi":"10.1016/j.ccr.2006.12.003","openalexId":"W2102922697","cited":752,"byYear":{"2012":58,"2013":42,"2014":37,"2015":56,"2016":42,"2017":44,"2018":33,"2019":36,"2020":48,"2021":23,"2022":21,"2023":30,"2024":23,"2025":10,"2026":7},"year":2006,"title":"Aneuploidy Acts Both Oncogenically and as a Tumor Suppressor"},"paper-oxnard-osimertinib-resistance-mechanisms-jama-oncol-2018":{"doi":"10.1001/jamaoncol.2018.2969","openalexId":"W2885289995","cited":709,"byYear":{"2018":9,"2019":89,"2020":103,"2021":136,"2022":112,"2023":84,"2024":90,"2025":50,"2026":36},"year":2018,"title":"Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib"},"paper-angiotax-paclitaxel-angiosarcoma-penel-jco-2008":{"doi":"10.1200/jco.2008.17.3146","openalexId":"W2170973522","cited":696,"byYear":{"2012":41,"2013":41,"2014":39,"2015":35,"2016":34,"2017":52,"2018":44,"2019":31,"2020":63,"2021":41,"2022":46,"2023":35,"2024":44,"2025":40,"2026":22},"year":2008,"title":"Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study"},"paper-romana-1-2-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(15)00558-6","openalexId":"W2278001291","cited":649,"byYear":{"2015":1,"2016":27,"2017":69,"2018":73,"2019":59,"2020":64,"2021":59,"2022":50,"2023":70,"2024":65,"2025":60,"2026":51},"year":2016,"title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials"},"paper-anchor-anal-hsil-treatment-nejm-2022":{"doi":"10.1056/nejmoa2201048","openalexId":"W4282974371","cited":510,"byYear":{"2022":41,"2023":121,"2024":134,"2025":129,"2026":84},"year":2022,"title":"Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer"},"paper-arrow-pralsetinib-gainor-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00247-3","openalexId":"W3172213464","cited":456,"byYear":{"2021":14,"2022":103,"2023":112,"2024":123,"2025":68,"2026":35},"year":2021,"title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study"},"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.1838","openalexId":"W2964980115","cited":438,"byYear":{"2019":7,"2020":44,"2021":59,"2022":71,"2023":71,"2024":84,"2025":56,"2026":45},"year":2019,"title":"Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer"},"paper-aspen-armstrong-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(15)00515-x","openalexId":"W2233483325","cited":424,"byYear":{"2014":2,"2016":29,"2017":48,"2018":36,"2019":43,"2020":50,"2021":49,"2022":45,"2023":39,"2024":44,"2025":31,"2026":8},"year":2016,"title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial"},"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2020":{"doi":"10.1200/jco.20.01342","openalexId":"W3044350523","cited":388,"byYear":{"2020":15,"2021":56,"2022":74,"2023":91,"2024":69,"2025":55,"2026":27},"year":2020,"title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma"},"paper-anbl0532-tandem-transplant-park-jama-2019":{"doi":"10.1001/jama.2019.11642","openalexId":"W2971319283","cited":369,"byYear":{"2019":4,"2020":34,"2021":54,"2022":56,"2023":71,"2024":64,"2025":48,"2026":38},"year":2019,"title":"Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma"},"paper-screentrustcad-dembrower-lancet-digit-health-2023":{"doi":"10.1016/s2589-7500(23)00153-x","openalexId":"W4386533578","cited":358,"byYear":{"2023":11,"2024":105,"2025":136,"2026":106},"year":2023,"title":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study"},"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015":{"doi":"10.1038/modpathol.2015.98","openalexId":"W2342934617","cited":322,"byYear":{"2015":2,"2016":16,"2017":18,"2018":26,"2019":28,"2020":28,"2021":24,"2022":43,"2023":45,"2024":44,"2025":27,"2026":21},"year":2015,"title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study"},"paper-yamazaki-nat-commun":{"doi":"10.1038/s41467-021-23793-7","openalexId":"W3167756601","cited":309,"byYear":{"2021":12,"2022":27,"2023":72,"2024":59,"2025":81,"2026":58},"year":2021,"title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance"},"paper-gyawali-jama-intern-med":{"doi":"10.1001/jamainternmed.2019.0462","openalexId":"W2947583588","cited":302,"byYear":{"2019":18,"2020":46,"2021":51,"2022":46,"2023":31,"2024":47,"2025":35,"2026":28},"year":2019,"title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval"},"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30355-8","openalexId":"W2618869560","cited":282,"byYear":{"2017":9,"2018":21,"2019":25,"2020":46,"2021":31,"2022":36,"2023":38,"2024":25,"2025":34,"2026":17},"year":2017,"title":"Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial"},"paper-golfier-mol-cancer-ther":{"doi":"10.1158/1535-7163.mct-13-0926","openalexId":"W2138654358","cited":257,"byYear":{"2012":1,"2014":5,"2015":12,"2016":22,"2017":21,"2018":21,"2019":23,"2020":24,"2021":22,"2022":22,"2023":20,"2024":23,"2025":30,"2026":11},"year":2014,"title":"Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect"},"paper-anbl00p2-expectant-observation-nuchtern-ann-surg-2012":{"doi":"10.1097/sla.0b013e31826cbbbd","openalexId":"W2323539794","cited":200,"byYear":{"2012":1,"2013":4,"2014":13,"2015":10,"2016":13,"2017":16,"2018":17,"2019":15,"2020":12,"2021":16,"2022":20,"2023":14,"2024":19,"2025":16,"2026":8},"year":2012,"title":"A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants"},"paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020":{"doi":"10.1200/jco.20.00203","openalexId":"W3018670999","cited":200,"byYear":{"2020":7,"2021":23,"2022":35,"2023":32,"2024":39,"2025":36,"2026":28},"year":2020,"title":"Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children’s Oncology Group"},"paper-nakamura-anti-pd1-acral-melanoma-ann-oncol-2020":{"doi":"10.1016/j.annonc.2020.05.031","openalexId":"W3033948992","cited":144,"byYear":{"2020":8,"2021":17,"2022":38,"2023":28,"2024":20,"2025":20,"2026":13},"year":2020,"title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients"},"paper-anbl0531-twist-jco-2019":{"doi":"10.1200/jco.19.00919","openalexId":"W2206018086","cited":130,"byYear":{"2014":1,"2016":1,"2017":1,"2019":3,"2020":8,"2021":16,"2022":16,"2023":26,"2024":23,"2025":22,"2026":13},"year":2019,"title":"Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531"},"paper-aquila-daratumumab-smouldering-nejm-2025":{"doi":"10.1056/nejmoa2409029","openalexId":"W4405179775","cited":120,"byYear":{"2024":1,"2025":56,"2026":63},"year":2024,"title":"Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma"},"paper-nct02257736-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00402-2","openalexId":"W3201981182","cited":109,"byYear":{"2021":8,"2022":21,"2023":30,"2024":21,"2025":21,"2026":8},"year":2021,"title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study"},"paper-kindler-lancet-oncol":{"doi":"10.1016/s1470-2045(22)00061-4","openalexId":"W4221061521","cited":70,"byYear":{"2022":4,"2023":22,"2024":16,"2025":18,"2026":10},"year":2022,"title":"Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial"},"paper-chen-jama-oncol":{"doi":"10.1001/jamaoncol.2018.5526","openalexId":"W2902112970","cited":48,"byYear":{"2019":1,"2020":8,"2021":8,"2022":19,"2023":4,"2024":3,"2025":3,"2026":2},"year":2018,"title":"Anlotinib for Refractory Advanced Non–Small Cell Lung Cancer in China"},"paper-bussey-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.1706990114","openalexId":"W2622658491","cited":78,"byYear":{"2018":7,"2019":5,"2020":16,"2021":15,"2022":3,"2023":10,"2024":13,"2025":7,"2026":2},"year":2017,"title":"Ancestral gene regulatory networks drive cancer"},"paper-trastuzumab-deruxtecan-tnbc-expert-opin-biol-ther-2021":{"doi":"10.1080/14712598.2021.1840547","openalexId":"W3094175163","cited":52,"byYear":{"2021":11,"2022":12,"2023":7,"2024":7,"2025":7,"2026":8},"year":2020,"title":"Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan"},"paper-arches-eur-urol-2026-update":{"doi":"10.1016/j.eururo.2025.12.021","openalexId":"W7127337907","cited":7,"byYear":{"2026":7},"year":2026,"title":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients"},"paper-nct06015503-j-thorac-oncol-2026":{"doi":"10.1016/j.jtho.2025.11.008","openalexId":"W4416356168","cited":3,"byYear":{"2026":3},"year":2025,"title":"Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study"},"paper-balkwill-mantovani-inflammation-virchow-lancet-2001":{"doi":"10.1016/s0140-6736(00)04046-0","openalexId":"W2116554142","cited":7771,"byYear":{"2012":305,"2013":370,"2014":413,"2015":390,"2016":384,"2017":453,"2018":386,"2019":447,"2020":483,"2021":465,"2022":453,"2023":444,"2024":376,"2025":278,"2026":162},"year":2001,"title":"Inflammation and cancer: back to Virchow?"},"paper-bao-glioma-stem-cells-radioresistance-nature-2006":{"doi":"10.1038/nature05236","openalexId":"W2060551076","cited":6482,"byYear":{"2012":414,"2013":424,"2014":403,"2015":346,"2016":379,"2017":370,"2018":313,"2019":316,"2020":388,"2021":398,"2022":367,"2023":340,"2024":251,"2025":226,"2026":134},"year":2006,"title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response"},"paper-keunchil-park-lancet-2017":{"doi":"10.1016/s0140-6736(16)32517-x","openalexId":"W2567564314","cited":4824,"byYear":{"2012":1,"2013":2,"2014":1,"2015":1,"2016":3,"2017":305,"2018":573,"2019":603,"2020":718,"2021":700,"2022":516,"2023":498,"2024":482,"2025":273,"2026":140},"year":2016,"title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial"},"paper-impassion130-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1809615","openalexId":"W2897422388","cited":4481,"byYear":{"2013":1,"2016":2,"2017":1,"2018":17,"2019":399,"2020":739,"2021":870,"2022":670,"2023":592,"2024":489,"2025":412,"2026":283},"year":2018,"title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer"},"paper-bclc-2022-reig-j-hepatol-2022":{"doi":"10.1016/j.jhep.2021.11.018","openalexId":"W3213277274","cited":4367,"byYear":{"2013":1,"2015":1,"2021":2,"2022":434,"2023":1000,"2024":1231,"2025":1077,"2026":613},"year":2021,"title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update"},"paper-lee-biol-blood-marrow-transplant":{"doi":"10.1016/j.bbmt.2018.12.758","openalexId":"W2905654445","cited":3680,"byYear":{"2013":2,"2018":1,"2019":112,"2020":320,"2021":417,"2022":420,"2023":524,"2024":595,"2025":676,"2026":604},"year":2018,"title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells"},"paper-keunchil-park-lancet-2016":{"doi":"10.1016/s0140-6736(16)00587-0","openalexId":"W2293531514","cited":2827,"byYear":{"2014":1,"2016":122,"2017":362,"2018":370,"2019":327,"2020":380,"2021":311,"2022":284,"2023":237,"2024":219,"2025":147,"2026":61},"year":2016,"title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial"},"paper-aza-001-fenaux-lancet-oncol-2009":{"doi":"10.1016/s1470-2045(09)70003-8","openalexId":"W2118771330","cited":2682,"byYear":{"2012":179,"2013":182,"2014":199,"2015":171,"2016":177,"2017":166,"2018":132,"2019":149,"2020":148,"2021":183,"2022":152,"2023":165,"2024":113,"2025":100,"2026":63},"year":2009,"title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study"},"paper-basch-epro-survival-jama-2017":{"doi":"10.1001/jama.2017.7156","openalexId":"W2620925856","cited":2382,"byYear":{"2014":1,"2017":52,"2018":171,"2019":249,"2020":298,"2021":287,"2022":300,"2023":291,"2024":318,"2025":220,"2026":192},"year":2017,"title":"Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment"},"paper-antoine-italiano-nature-2020":{"doi":"10.1038/s41586-019-1906-8","openalexId":"W3000282923","cited":2027,"byYear":{"2020":210,"2021":351,"2022":347,"2023":332,"2024":326,"2025":265,"2026":192},"year":2020,"title":"B cells are associated with survival and immunotherapy response in sarcoma"},"paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020":{"doi":"10.1056/nejmoa1917346","openalexId":"W3091399767","cited":1737,"byYear":{"2013":1,"2016":1,"2020":9,"2021":271,"2022":359,"2023":365,"2024":346,"2025":252,"2026":132},"year":2020,"title":"Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC"},"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014":{"doi":"10.1200/jco.2013.51.4489","openalexId":"W2170928115","cited":1652,"byYear":{"2012":3,"2013":8,"2014":45,"2015":119,"2016":148,"2017":139,"2018":134,"2019":128,"2020":144,"2021":168,"2022":146,"2023":150,"2024":128,"2025":122,"2026":64},"year":2014,"title":"Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial"},"paper-yamamoto-nature":{"doi":"10.1038/s41586-020-2229-5","openalexId":"W3020766569","cited":1284,"byYear":{"2020":56,"2021":193,"2022":187,"2023":221,"2024":253,"2025":212,"2026":162},"year":2020,"title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I"},"paper-javelin-merkel-200-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(16)30364-3","openalexId":"W2510686645","cited":1241,"byYear":{"2014":1,"2016":10,"2017":125,"2018":211,"2019":199,"2020":180,"2021":160,"2022":103,"2023":91,"2024":70,"2025":58,"2026":30},"year":2016,"title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial"},"paper-impassion130-lancet-oncol-2020-update":{"doi":"10.1016/s1470-2045(19)30689-8","openalexId":"W2990398119","cited":1231,"byYear":{"2019":1,"2020":141,"2021":257,"2022":267,"2023":200,"2024":166,"2025":117,"2026":81},"year":2019,"title":"Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-aza-aml-001-dombret-blood-2015":{"doi":"10.1182/blood-2015-01-621664","openalexId":"W1600365609","cited":1176,"byYear":{"2014":1,"2015":29,"2016":80,"2017":104,"2018":99,"2019":112,"2020":137,"2021":155,"2022":139,"2023":138,"2024":82,"2025":60,"2026":40},"year":2015,"title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts"},"paper-brown-jama-oncol":{"doi":"10.1001/jamaoncol.2016.1373","openalexId":"W2436534309","cited":1114,"byYear":{"2016":5,"2017":34,"2018":59,"2019":104,"2020":114,"2021":141,"2022":129,"2023":127,"2024":163,"2025":137,"2026":100},"year":2016,"title":"Association of the Extent of Resection With Survival in Glioblastoma"},"paper-azacitidine-aml-j-clin-oncol-2010":{"doi":"10.1200/jco.2009.23.8329","openalexId":"W2157287007","cited":975,"byYear":{"2012":79,"2013":78,"2014":88,"2015":79,"2016":70,"2017":76,"2018":63,"2019":71,"2020":76,"2021":56,"2022":39,"2023":42,"2024":25,"2025":19,"2026":11},"year":2009,"title":"Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia"},"paper-epstein-nat-rev-cancer":{"doi":"10.1038/nrc2503","openalexId":"W1990453562","cited":843,"byYear":{"2012":62,"2013":49,"2014":62,"2015":55,"2016":45,"2017":46,"2018":51,"2019":51,"2020":65,"2021":59,"2022":35,"2023":41,"2024":30,"2025":27,"2026":22},"year":2008,"title":"Basal cell carcinomas: attack of the hedgehog"},"paper-belzutifan-vhl-jonasch-nejm-2021":{"doi":"10.1056/nejmoa2103425","openalexId":"W3215189579","cited":701,"byYear":{"2021":4,"2022":126,"2023":138,"2024":140,"2025":169,"2026":123},"year":2021,"title":"Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease"},"paper-imspire150-lancet-2020":{"doi":"10.1016/s0140-6736(20)30934-x","openalexId":"W3034459487","cited":674,"byYear":{"2020":36,"2021":148,"2022":153,"2023":117,"2024":109,"2025":59,"2026":50},"year":2020,"title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-molinaro-jama-oncol":{"doi":"10.1001/jamaoncol.2019.6143","openalexId":"W3005337228","cited":668,"byYear":{"2020":42,"2021":71,"2022":108,"2023":119,"2024":161,"2025":105,"2026":61},"year":2020,"title":"Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma"},"paper-davis-bmj":{"doi":"10.1136/bmj.j4530","openalexId":"W2761792472","cited":614,"byYear":{"2016":2,"2017":17,"2018":83,"2019":93,"2020":94,"2021":90,"2022":59,"2023":66,"2024":55,"2025":28,"2026":26},"year":2017,"title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13"},"paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018":{"doi":"10.1001/jama.2018.6228","openalexId":"W2809494794","cited":595,"byYear":{"2017":1,"2018":14,"2019":59,"2020":63,"2021":98,"2022":89,"2023":87,"2024":73,"2025":67,"2026":43},"year":2018,"title":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer"},"paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(19)30027-0","openalexId":"W2938645074","cited":580,"byYear":{"2019":25,"2020":69,"2021":98,"2022":85,"2023":97,"2024":100,"2025":59,"2026":46},"year":2019,"title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial"},"paper-bcma-multiple-myeloma-leukemia-2020":{"doi":"10.1038/s41375-020-0734-z","openalexId":"W3006655689","cited":508,"byYear":{"2019":1,"2020":45,"2021":72,"2022":88,"2023":81,"2024":98,"2025":75,"2026":48},"year":2020,"title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches"},"paper-augment-101-revumenib-menin-nature-2023":{"doi":"10.1038/s41586-023-05812-3","openalexId":"W4324330071","cited":508,"byYear":{"2023":67,"2024":165,"2025":166,"2026":110},"year":2023,"title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia"},"paper-augment-lenalidomide-rituximab-leonard-jco-2019":{"doi":"10.1200/jco.19.00010","openalexId":"W2925270992","cited":433,"byYear":{"2019":25,"2020":53,"2021":75,"2022":70,"2023":57,"2024":54,"2025":60,"2026":37},"year":2019,"title":"AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma"},"paper-dess-black-race-prostate-mortality-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.0826","openalexId":"W2944891078","cited":415,"byYear":{"2017":1,"2019":15,"2020":60,"2021":71,"2022":73,"2023":62,"2024":62,"2025":44,"2026":25},"year":2019,"title":"Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality"},"paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022":{"doi":"10.1001/jamaoncol.2022.1981","openalexId":"W4283030292","cited":397,"byYear":{"2021":1,"2022":19,"2023":98,"2024":135,"2025":92,"2026":52},"year":2022,"title":"Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels"},"paper-rockstar-blood-2021":{"doi":"10.1182/blood.2021012021","openalexId":"W3095621154","cited":354,"byYear":{"2021":23,"2022":38,"2023":62,"2024":64,"2025":94,"2026":73},"year":2021,"title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study"},"paper-aminian-jama":{"doi":"10.1001/jama.2022.9009","openalexId":"W4281721185","cited":350,"byYear":{"2022":26,"2023":84,"2024":97,"2025":79,"2026":64},"year":2022,"title":"Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity"},"paper-radovich-ctdna-ctc-bre12-158-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2020.2295","openalexId":"W3041271367","cited":313,"byYear":{"2020":11,"2021":41,"2022":59,"2023":56,"2024":60,"2025":57,"2026":28},"year":2020,"title":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer"},"paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017":{"doi":"10.1001/jamaoncol.2016.3916","openalexId":"W2536154437","cited":306,"byYear":{"2016":1,"2017":25,"2018":31,"2019":21,"2020":52,"2021":47,"2022":43,"2023":38,"2024":23,"2025":13,"2026":11},"year":2016,"title":"Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma"},"paper-qian-driver-genes-outcomes-resected-pancreatic-jama-oncol-2018":{"doi":"10.1001/jamaoncol.2017.3420","openalexId":"W2767007332","cited":277,"byYear":{"2018":7,"2019":20,"2020":26,"2021":29,"2022":58,"2023":49,"2024":42,"2025":32,"2026":14},"year":2017,"title":"Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma"},"paper-jensen-clonal-haematopoiesis-cfdna-interference-prostate-jama-oncol-2021":{"doi":"10.1001/jamaoncol.2020.5161","openalexId":"W3097906791","cited":167,"byYear":{"2020":1,"2021":30,"2022":36,"2023":25,"2024":29,"2025":31,"2026":15},"year":2020,"title":"Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference"},"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023":{"doi":"10.1056/nejmoa2303383","openalexId":"W4386471099","cited":167,"byYear":{"2021":1,"2023":4,"2024":46,"2025":65,"2026":51},"year":2023,"title":"Atezolizumab for Advanced Alveolar Soft Part Sarcoma"},"paper-nct03178552-nat-med-2022":{"doi":"10.1038/s41591-022-01933-w","openalexId":"W4292641407","cited":117,"byYear":{"2022":8,"2023":39,"2024":24,"2025":30,"2026":16},"year":2022,"title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial"},"paper-beamion-lung-1-zongertinib-nejm-2025":{"doi":"10.1056/nejmoa2503704","openalexId":"W4409870405","cited":111,"byYear":{"2025":34,"2026":77},"year":2025,"title":"Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer"},"paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017":{"doi":"10.1001/jamasurg.2016.3642","openalexId":"W2545357035","cited":108,"byYear":{"2016":1,"2017":4,"2018":6,"2019":13,"2020":14,"2021":10,"2022":13,"2023":15,"2024":11,"2025":6,"2026":15},"year":2016,"title":"Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival"},"paper-friedman-cancer-discov":{"doi":"10.1158/2159-8290.cd-21-0450","openalexId":"W4200388746","cited":104,"byYear":{"2022":15,"2023":35,"2024":23,"2025":21,"2026":10},"year":2021,"title":"Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study"},"paper-dix-j-clin-oncol":{"doi":"10.1200/jco.18.01972","openalexId":"W2971112654","cited":87,"byYear":{"2018":1,"2019":1,"2020":6,"2021":20,"2022":10,"2023":14,"2024":8,"2025":13,"2026":13},"year":2019,"title":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children’s Oncology Group AREN0532 and AREN0533 Study Report"},"paper-raghav-atezolizumab-bevacizumab-peritoneal-mesothelioma-cancer-discov-2021":{"doi":"10.1158/2159-8290.cd-21-0331","openalexId":"W3178464379","cited":76,"byYear":{"2021":5,"2022":15,"2023":22,"2024":15,"2025":15,"2026":4},"year":2021,"title":"Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma"},"paper-keynote-042-tmb-mutations-ann-oncol-2023":{"doi":"10.1016/j.annonc.2023.01.011","openalexId":"W4318041056","cited":76,"byYear":{"2023":12,"2024":25,"2025":24,"2026":15},"year":2023,"title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC"},"paper-b7-h3-glioblastoma-int-j-biol-sci-2023":{"doi":"10.7150/ijbs.85813","openalexId":"W4385617285","cited":49,"byYear":{"2023":1,"2024":16,"2025":19,"2026":13},"year":2023,"title":"B7-H3 in Brain Malignancies: Immunology and Immunotherapy"},"paper-keynote-189-407-tmb-jtocrr-2023":{"doi":"10.1016/j.jtocrr.2022.100431","openalexId":"W4308522396","cited":44,"byYear":{"2022":1,"2023":14,"2024":16,"2025":10,"2026":3},"year":2022,"title":"Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC"},"paper-atomic-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2507874","openalexId":"W7140292121","cited":21,"byYear":{"2026":21},"year":2026,"title":"Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer"},"paper-nct04687241-lancet-oncol-2026":{"doi":"10.1016/s1470-2045(25)00643-6","openalexId":"W7123360585","cited":9,"byYear":{"2026":9},"year":2026,"title":"Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial"},"paper-roman-anderson-eclinicalmedicine-2025":{"doi":"10.1016/j.eclinm.2025.103539","openalexId":"W4415507443","cited":3,"byYear":{"2026":3},"year":2025,"title":"Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)"},"paper-nct04923906-lancet-oncol-2026":{"doi":"10.1016/s1470-2045(26)00090-2","openalexId":"W7164816574","cited":2,"byYear":{"2026":2},"year":2026,"title":"Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial"},"paper-bray-globocan-2018-cacancer-2018":{"doi":"10.3322/caac.21492","openalexId":"W2889646458","cited":88289,"byYear":{"2012":3,"2013":6,"2014":3,"2015":4,"2016":3,"2017":6,"2018":297,"2019":7608,"2020":19462,"2021":21959,"2022":14532,"2023":10348,"2024":7987,"2025":4927,"2026":1031},"year":2018,"title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"},"paper-bray-globocan-2022-cacancer-2024":{"doi":"10.3322/caac.21834","openalexId":"W4393935425","cited":26176,"byYear":{"2012":2,"2017":2,"2018":3,"2019":13,"2020":29,"2021":70,"2022":66,"2023":40,"2024":3792,"2025":14361,"2026":7796},"year":2024,"title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"},"paper-chapman-vemurafenib-nejm-2011":{"doi":"10.1056/nejmoa1103782","openalexId":"W2128542677","cited":7811,"byYear":{"2012":697,"2013":863,"2014":844,"2015":828,"2016":653,"2017":618,"2018":502,"2019":477,"2020":447,"2021":388,"2022":415,"2023":294,"2024":277,"2025":187,"2026":131},"year":2011,"title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation"},"paper-binnewies-tumor-immune-microenvironment-natmed-2018":{"doi":"10.1038/s41591-018-0014-x","openalexId":"W2801309958","cited":6357,"byYear":{"2012":1,"2018":49,"2019":267,"2020":613,"2021":807,"2022":983,"2023":907,"2024":987,"2025":924,"2026":809},"year":2018,"title":"Understanding the tumor immune microenvironment (TIME) for effective therapy"},"paper-harbeck-nat-rev-dis-primers":{"doi":"10.1038/s41572-019-0111-2","openalexId":"W4211005384","cited":3078,"byYear":{"2019":8,"2020":210,"2021":436,"2022":519,"2023":534,"2024":570,"2025":503,"2026":294},"year":2019,"title":"Breast cancer"},"paper-olivier-chinot-n-engl-j-med-2014":{"doi":"10.1056/nejmoa1308345","openalexId":"W2156330848","cited":2574,"byYear":{"2013":1,"2014":153,"2015":228,"2016":239,"2017":243,"2018":237,"2019":228,"2020":248,"2021":215,"2022":199,"2023":176,"2024":162,"2025":140,"2026":98},"year":2014,"title":"Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma"},"paper-blinatumomab-all-leukemia-n-engl-j-med-2017":{"doi":"10.1056/nejmoa1609783","openalexId":"W2591709377","cited":2168,"byYear":{"2016":1,"2017":95,"2018":155,"2019":211,"2020":235,"2021":271,"2022":282,"2023":222,"2024":263,"2025":259,"2026":168},"year":2017,"title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia"},"paper-bischoff-onyx-015-science-1996":{"doi":"10.1126/science.274.5286.373","openalexId":"W2016080258","cited":1768,"byYear":{"2012":56,"2013":43,"2014":43,"2015":41,"2016":31,"2017":24,"2018":18,"2019":17,"2020":32,"2021":32,"2022":31,"2023":29,"2024":20,"2025":28,"2026":17},"year":1996,"title":"An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells"},"paper-rummel-lancet":{"doi":"10.1016/s0140-6736(12)61763-2","openalexId":"W2169209759","cited":1514,"byYear":{"2012":3,"2013":58,"2014":117,"2015":136,"2016":113,"2017":135,"2018":134,"2019":108,"2020":121,"2021":109,"2022":114,"2023":109,"2024":97,"2025":93,"2026":56},"year":2013,"title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial"},"paper-braf-thyroid-endocr-relat-cancer-2005":{"doi":"10.1677/erc.1.0978","openalexId":"W2118986295","cited":1321,"byYear":{"2012":80,"2013":80,"2014":87,"2015":95,"2016":75,"2017":74,"2018":69,"2019":65,"2020":56,"2021":64,"2022":58,"2023":50,"2024":48,"2025":36,"2026":28},"year":2005,"title":"BRAF mutation in thyroid cancer"},"paper-bilcap-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(18)30915-x","openalexId":"W2923282967","cited":1282,"byYear":{"2012":2,"2019":47,"2020":164,"2021":188,"2022":196,"2023":196,"2024":179,"2025":179,"2026":123},"year":2019,"title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study"},"paper-gandara-blood-tmb-atezolizumab-nat-med-2018":{"doi":"10.1038/s41591-018-0134-3","openalexId":"W2886963239","cited":1211,"byYear":{"2018":23,"2019":153,"2020":219,"2021":230,"2022":189,"2023":189,"2024":105,"2025":67,"2026":34},"year":2018,"title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab"},"paper-olivier-chinot-cancer-treat-rev-2020":{"doi":"10.1016/j.ctrv.2020.102017","openalexId":"W3013347515","cited":1186,"byYear":{"2020":30,"2021":135,"2022":191,"2023":213,"2024":258,"2025":237,"2026":121},"year":2020,"title":"Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook"},"paper-achrol-nat-rev-dis-primers":{"doi":"10.1038/s41572-018-0055-y","openalexId":"W4211260961","cited":1073,"byYear":{"2019":27,"2020":89,"2021":132,"2022":168,"2023":172,"2024":197,"2025":190,"2026":98},"year":2019,"title":"Brain metastases"},"paper-tiacci-n-engl-j-med":{"doi":"10.1056/nejmoa1014209","openalexId":"W2099780734","cited":1028,"byYear":{"2012":89,"2013":101,"2014":118,"2015":91,"2016":74,"2017":73,"2018":68,"2019":50,"2020":79,"2021":55,"2022":59,"2023":39,"2024":37,"2025":33,"2026":27},"year":2011,"title":"BRAF Mutations in Hairy-Cell Leukemia"},"paper-braf-thyroid-endocr-rev-2007":{"doi":"10.1210/er.2007-0007","openalexId":"W2101888941","cited":1002,"byYear":{"2012":73,"2013":90,"2014":87,"2015":64,"2016":67,"2017":51,"2018":53,"2019":49,"2020":50,"2021":39,"2022":28,"2023":47,"2024":39,"2025":26,"2026":18},"year":2007,"title":"BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications"},"paper-alta-1l-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1810171","openalexId":"W2894476389","cited":996,"byYear":{"2017":1,"2018":14,"2019":107,"2020":150,"2021":165,"2022":140,"2023":124,"2024":120,"2025":107,"2026":65},"year":2018,"title":"Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer"},"paper-horwitz-lancet":{"doi":"10.1016/s0140-6736(18)32984-2","openalexId":"W2903308035","cited":740,"byYear":{"2018":1,"2019":67,"2020":95,"2021":143,"2022":113,"2023":110,"2024":79,"2025":85,"2026":44},"year":2018,"title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial"},"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023":{"doi":"10.1016/j.annonc.2022.10.506","openalexId":"W4308904392","cited":721,"byYear":{"2023":99,"2024":187,"2025":243,"2026":190},"year":2022,"title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-mainprize-sci-rep":{"doi":"10.1038/s41598-018-36340-0","openalexId":"W2921121152","cited":626,"byYear":{"2019":38,"2020":88,"2021":91,"2022":96,"2023":88,"2024":85,"2025":87,"2026":51},"year":2019,"title":"Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study"},"paper-alta-jco-2017":{"doi":"10.1200/jco.2016.71.5904","openalexId":"W2610816290","cited":586,"byYear":{"2016":1,"2017":43,"2018":119,"2019":91,"2020":82,"2021":69,"2022":69,"2023":55,"2024":28,"2025":16,"2026":12},"year":2017,"title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial"},"paper-villani-lancet-oncol":{"doi":"10.1016/s1470-2045(16)30249-2","openalexId":"W2480841917","cited":547,"byYear":{"2016":9,"2017":53,"2018":52,"2019":52,"2020":78,"2021":58,"2022":44,"2023":41,"2024":65,"2025":48,"2026":46},"year":2016,"title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study"},"paper-levin-cell":{"doi":"10.1016/j.cell.2021.02.034","openalexId":"W3145858057","cited":527,"byYear":{"2021":19,"2022":70,"2023":108,"2024":132,"2025":117,"2026":81},"year":2021,"title":"Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer"},"paper-kim-j-clin-oncol":{"doi":"10.1200/jco.2017.73.7916","openalexId":"W2763133656","cited":499,"byYear":{"2017":2,"2018":46,"2019":48,"2020":67,"2021":90,"2022":58,"2023":48,"2024":48,"2025":53,"2026":38},"year":2017,"title":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement"},"paper-esmo-bone-sarcoma-guideline-strauss-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.08.1995","openalexId":"W3197355167","cited":490,"byYear":{"2021":4,"2022":58,"2023":90,"2024":117,"2025":117,"2026":103},"year":2021,"title":"Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-bolt-sonidegib-migden-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(15)70100-2","openalexId":"W2122406360","cited":439,"byYear":{"2015":12,"2016":42,"2017":50,"2018":40,"2019":43,"2020":35,"2021":46,"2022":40,"2023":40,"2024":28,"2025":39,"2026":22},"year":2015,"title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial"},"paper-javle-biliary-ngs-cancer-2016":{"doi":"10.1002/cncr.30254","openalexId":"W2520639290","cited":419,"byYear":{"2012":1,"2017":13,"2018":21,"2019":27,"2020":44,"2021":74,"2022":64,"2023":60,"2024":50,"2025":35,"2026":29},"year":2016,"title":"Biliary cancer: Utility of next‐generation sequencing for clinical management"},"paper-kunkler-n-engl-j-med":{"doi":"10.1056/nejmoa2207586","openalexId":"W4320892490","cited":416,"byYear":{"2023":81,"2024":156,"2025":120,"2026":58},"year":2023,"title":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer"},"paper-camidge-j-thorac-oncol":{"doi":"10.1016/j.jtho.2021.07.035","openalexId":"W3200994971","cited":393,"byYear":{"2021":1,"2022":56,"2023":99,"2024":94,"2025":84,"2026":57},"year":2021,"title":"Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial"},"paper-andre-j-clin-oncol":{"doi":"10.1200/jco.22.00069","openalexId":"W4224213278","cited":377,"byYear":{"2022":43,"2023":77,"2024":99,"2025":87,"2026":71},"year":2022,"title":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update"},"paper-bardia-ascent-trop2-biomarker-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.06.002","openalexId":"W3169973594","cited":323,"byYear":{"2021":17,"2022":58,"2023":72,"2024":56,"2025":62,"2026":58},"year":2021,"title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer"},"paper-bourgeois-daigneault-neoadjuvant-ovt-tnbc-scitranslmed-2018":{"doi":"10.1126/scitranslmed.aao1641","openalexId":"W2781905683","cited":301,"byYear":{"2018":43,"2019":33,"2020":56,"2021":43,"2022":41,"2023":32,"2024":22,"2025":17,"2026":14},"year":2018,"title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy"},"paper-hirose-radiother-oncol":{"doi":"10.1016/j.radonc.2020.11.001","openalexId":"W3098575676","cited":262,"byYear":{"2021":20,"2022":41,"2023":37,"2024":56,"2025":62,"2026":46},"year":2020,"title":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial"},"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023":{"doi":"10.1056/nejmoa2214171","openalexId":"W4367041068","cited":222,"byYear":{"2023":31,"2024":59,"2025":80,"2026":52},"year":2023,"title":"Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia"},"paper-rossi-richter-syndrome-blood-2018":{"doi":"10.1182/blood-2018-01-791376","openalexId":"W2799716396","cited":192,"byYear":{"2018":7,"2019":16,"2020":26,"2021":34,"2022":30,"2023":24,"2024":29,"2025":17,"2026":9},"year":2018,"title":"Biology and treatment of Richter syndrome"},"paper-bmt-ctn-1102-transplant-older-mds-nakamura-jco-2021":{"doi":"10.1200/jco.20.03380","openalexId":"W3165899249","cited":148,"byYear":{"2021":2,"2022":30,"2023":32,"2024":31,"2025":34,"2026":19},"year":2021,"title":"Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome"},"paper-asco-biomarkers-metastatic-breast-cancer-guideline-jco-2022":{"doi":"10.1200/jco.22.01063","openalexId":"W4283574464","cited":147,"byYear":{"2022":10,"2023":27,"2024":40,"2025":33,"2026":37},"year":2022,"title":"Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update"},"paper-breakwater-nejm-2025":{"doi":"10.1056/nejmoa2501912","openalexId":"W4410875702","cited":144,"byYear":{"2025":41,"2026":103},"year":2025,"title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer"},"paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024":{"doi":"10.1038/s41591-024-03083-7","openalexId":"W4399640828","cited":140,"byYear":{"2021":1,"2024":14,"2025":57,"2026":68},"year":2024,"title":"Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial"},"paper-pandit-taskar-j-nucl-med":{"doi":"10.2967/jnumed.117.193169","openalexId":"W2735652803","cited":135,"byYear":{"2017":1,"2018":10,"2019":13,"2020":16,"2021":13,"2022":22,"2023":18,"2024":9,"2025":19,"2026":14},"year":2017,"title":"Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies"},"paper-nct03334617-nat-med-2024":{"doi":"10.1038/s41591-024-02808-y","openalexId":"W4391779877","cited":134,"byYear":{"2024":28,"2025":64,"2026":42},"year":2024,"title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial"},"paper-redman-lancet-oncol":{"doi":"10.1016/s1470-2045(20)30475-7","openalexId":"W3096044474","cited":127,"byYear":{"2020":1,"2021":22,"2022":22,"2023":27,"2024":26,"2025":14,"2026":15},"year":2020,"title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol"},"paper-sun-bmc-cancer":{"doi":"10.1186/1471-2407-12-526","openalexId":"W2002499576","cited":103,"byYear":{"2013":7,"2014":5,"2015":6,"2016":12,"2017":8,"2018":7,"2019":15,"2020":7,"2021":9,"2022":11,"2023":6,"2024":4,"2025":4,"2026":2},"year":2012,"title":"Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials"},"paper-bmt-ctn-0803-autologous-transplant-hiv-lymphoma-alvarnas-blood-2016":{"doi":"10.1182/blood-2015-08-664706","openalexId":"W2430909787","cited":100,"byYear":{"2016":3,"2017":9,"2018":16,"2019":16,"2020":11,"2021":10,"2022":6,"2023":5,"2024":12,"2025":4,"2026":7},"year":2016,"title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial"},"paper-bsg-cholangiocarcinoma-guideline-gut-2023":{"doi":"10.1136/gutjnl-2023-330029","openalexId":"W4387141633","cited":87,"byYear":{"2023":2,"2024":19,"2025":38,"2026":28},"year":2023,"title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma"},"paper-nccn-biliary-tract-cancers-v2-2025-jnccn-2025":{"doi":"10.6004/jnccn.2025.0042","openalexId":"W4414093883","cited":54,"byYear":{"2025":2,"2026":52},"year":2025,"title":"Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology"},"paper-bien-pancreatoblastoma-expert-european-cooperative-ejc-2011":{"doi":"10.1016/j.ejca.2011.05.022","openalexId":"W2080579280","cited":119,"byYear":{"2012":8,"2013":8,"2014":2,"2015":7,"2016":9,"2017":10,"2018":5,"2019":5,"2020":9,"2021":13,"2022":14,"2023":5,"2024":9,"2025":7,"2026":5},"year":2011,"title":"Pancreatoblastoma: A report from the European cooperative study group for paediatric rare tumours (EXPeRT)"},"paper-nct05077449-nat-commun-2025":{"doi":"10.1038/s41467-025-58647-z","openalexId":"W4409308301","cited":5,"byYear":{"2025":1,"2026":4},"year":2025,"title":"Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis"},"paper-litespark-011-motzer-lancet-2026":{"doi":"10.1016/s0140-6736(26)01089-5","openalexId":"W7202281633","cited":3,"byYear":{"2026":3},"year":2026,"title":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial"},"paper-nccn-breast-cancer-v4-2026-jnccn-2026":{"doi":"10.6004/jnccn.2026.0033","openalexId":"W7167804549","cited":2,"byYear":{"2026":2},"year":2026,"title":"Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology"},"paper-vogelstein-cancer-genome-landscapes-science-2013":{"doi":"10.1126/science.1235122","openalexId":"W2044433401","cited":8224,"byYear":{"2012":2,"2013":198,"2014":539,"2015":679,"2016":719,"2017":777,"2018":770,"2019":730,"2020":696,"2021":680,"2022":686,"2023":522,"2024":514,"2025":406,"2026":288},"year":2013,"title":"Cancer Genome Landscapes"},"paper-calle-obesity-cancer-mortality-nejm-2003":{"doi":"10.1056/nejmoa021423","openalexId":"W2141662760","cited":7772,"byYear":{"2012":450,"2013":478,"2014":481,"2015":465,"2016":379,"2017":369,"2018":344,"2019":320,"2020":386,"2021":389,"2022":337,"2023":306,"2024":230,"2025":198,"2026":76},"year":2003,"title":"Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults"},"paper-burris-gemcitabine-pancreatic-jco-1997":{"doi":"10.1200/jco.1997.15.6.2403","openalexId":"W1931508686","cited":5939,"byYear":{"2012":296,"2013":273,"2014":315,"2015":353,"2016":292,"2017":304,"2018":270,"2019":247,"2020":257,"2021":288,"2022":209,"2023":177,"2024":135,"2025":115,"2026":65},"year":1997,"title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial."},"paper-dunn-nat-immunol":{"doi":"10.1038/ni1102-991","openalexId":"W2046972425","cited":5458,"byYear":{"2012":197,"2013":230,"2014":217,"2015":226,"2016":262,"2017":299,"2018":306,"2019":313,"2020":377,"2021":375,"2022":385,"2023":368,"2024":317,"2025":212,"2026":146},"year":2002,"title":"Cancer immunoediting: from immunosurveillance to tumor escape"},"paper-batlle-nat-med":{"doi":"10.1038/nm.4409","openalexId":"W2763367287","cited":2914,"byYear":{"2017":6,"2018":140,"2019":293,"2020":374,"2021":434,"2022":419,"2023":435,"2024":357,"2025":277,"2026":178},"year":2017,"title":"Cancer stem cells revisited"},"paper-han-j-natl-cancer-cent":{"doi":"10.1016/j.jncc.2024.01.006","openalexId":"W4391671392","cited":2250,"byYear":{"2012":1,"2021":2,"2023":1,"2024":383,"2025":1192,"2026":671},"year":2024,"title":"Cancer incidence and mortality in China, 2022"},"paper-tomasetti-science":{"doi":"10.1126/science.1260825","openalexId":"W2019078072","cited":2007,"byYear":{"2015":225,"2016":239,"2017":240,"2018":204,"2019":207,"2020":172,"2021":148,"2022":148,"2023":144,"2024":129,"2025":91,"2026":57},"year":2015,"title":"Variation in cancer risk among tissues can be explained by the number of stem cell divisions"},"paper-friedl-cell":{"doi":"10.1016/j.cell.2011.11.016","openalexId":"W2143468862","cited":1988,"byYear":{"2012":76,"2013":119,"2014":131,"2015":150,"2016":139,"2017":182,"2018":154,"2019":164,"2020":171,"2021":167,"2022":143,"2023":128,"2024":116,"2025":90,"2026":57},"year":2011,"title":"Cancer Invasion and the Microenvironment: Plasticity and Reciprocity"},"paper-merlo-nat-rev-cancer":{"doi":"10.1038/nrc2013","openalexId":"W2123558100","cited":1764,"byYear":{"2012":100,"2013":104,"2014":107,"2015":118,"2016":116,"2017":126,"2018":144,"2019":95,"2020":100,"2021":100,"2022":85,"2023":67,"2024":75,"2025":58,"2026":42},"year":2006,"title":"Cancer as an evolutionary and ecological process"},"paper-kinzler-nature":{"doi":"10.1038/386761a0","openalexId":"W2013743651","cited":1230,"byYear":{"2012":36,"2013":34,"2014":43,"2015":26,"2016":36,"2017":29,"2018":20,"2019":26,"2020":28,"2021":25,"2022":17,"2023":12,"2024":9,"2025":9,"2026":10},"year":1997,"title":"Gatekeepers and caretakers"},"paper-mathur-ncrp-cancer-statistics-2020":{"doi":"10.1200/go.20.00122","openalexId":"W3042980549","cited":1202,"byYear":{"2020":19,"2021":139,"2022":245,"2023":258,"2024":258,"2025":180,"2026":100},"year":2020,"title":"Cancer Statistics, 2020: Report From National Cancer Registry Programme, India"},"paper-mitsunaga-nat-med":{"doi":"10.1038/nm.2554","openalexId":"W1983692618","cited":1068,"byYear":{"2012":26,"2013":24,"2014":51,"2015":52,"2016":68,"2017":75,"2018":81,"2019":72,"2020":97,"2021":106,"2022":126,"2023":74,"2024":79,"2025":83,"2026":50},"year":2011,"title":"Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules"},"paper-wolf-geometry-mono-1-capmatinib-nejm-2020":{"doi":"10.1056/nejmoa2002787","openalexId":"W3082015854","cited":1039,"byYear":{"2020":23,"2021":162,"2022":204,"2023":169,"2024":233,"2025":147,"2026":96},"year":2020,"title":"Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer"},"paper-gupta-nat-med":{"doi":"10.1038/nm0909-1010","openalexId":"W2015831734","cited":1004,"byYear":{"2012":109,"2013":90,"2014":92,"2015":75,"2016":80,"2017":75,"2018":43,"2019":42,"2020":39,"2021":48,"2022":58,"2023":21,"2024":17,"2025":10,"2026":3},"year":2009,"title":"Cancer stem cells: mirage or reality?"},"paper-schafer-nat-rev-mol-cell-biol":{"doi":"10.1038/nrm2455","openalexId":"W1965038309","cited":972,"byYear":{"2012":56,"2013":56,"2014":56,"2015":62,"2016":59,"2017":70,"2018":62,"2019":64,"2020":63,"2021":51,"2022":63,"2023":58,"2024":49,"2025":33,"2026":31},"year":2008,"title":"Cancer as an overhealing wound: an old hypothesis revisited"},"paper-burnet-br-med-j":{"doi":"10.1136/bmj.1.5022.779","openalexId":"W1967229707","cited":813,"byYear":{"2012":47,"2013":40,"2014":52,"2015":29,"2016":35,"2017":56,"2018":47,"2019":49,"2020":41,"2021":38,"2022":23,"2023":32,"2024":25,"2025":26,"2026":8},"year":1957,"title":"Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation"},"paper-peccatori-ann-oncol":{"doi":"10.1093/annonc/mdt199","openalexId":"W2120335312","cited":795,"byYear":{"2012":2,"2013":2,"2014":13,"2015":51,"2016":53,"2017":73,"2018":76,"2019":86,"2020":93,"2021":69,"2022":73,"2023":74,"2024":40,"2025":51,"2026":35},"year":2013,"title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-capitello-291-nejm-2023":{"doi":"10.1056/nejmoa2214131","openalexId":"W4378801565","cited":784,"byYear":{"2023":47,"2024":226,"2025":285,"2026":226},"year":2023,"title":"Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer"},"paper-bolton-nat-genet":{"doi":"10.1038/s41588-020-00710-0","openalexId":"W3093490071","cited":771,"byYear":{"2020":11,"2021":77,"2022":145,"2023":158,"2024":142,"2025":147,"2026":91},"year":2020,"title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis"},"paper-ogitani-cancer-sci":{"doi":"10.1111/cas.12966","openalexId":"W2387397851","cited":753,"byYear":{"2016":1,"2017":9,"2018":10,"2019":32,"2020":53,"2021":70,"2022":87,"2023":127,"2024":133,"2025":126,"2026":105},"year":2016,"title":"Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity"},"paper-qin-lancet":{"doi":"10.1016/s0140-6736(23)00961-3","openalexId":"W4385211938","cited":735,"byYear":{"2023":33,"2024":252,"2025":273,"2026":176},"year":2023,"title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study"},"paper-seyfried-nutr-metab-lond":{"doi":"10.1186/1743-7075-7-7","openalexId":"W2103953491","cited":654,"byYear":{"2012":39,"2013":40,"2014":52,"2015":41,"2016":32,"2017":42,"2018":53,"2019":36,"2020":35,"2021":52,"2022":40,"2023":47,"2024":49,"2025":29,"2026":18},"year":2010,"title":"Cancer as a metabolic disease"},"paper-camel-lancet-respir-med-2021":{"doi":"10.1016/s2213-2600(20)30365-9","openalexId":"W3111665711","cited":515,"byYear":{"2020":1,"2021":51,"2022":107,"2023":134,"2024":119,"2025":67,"2026":35},"year":2020,"title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial"},"paper-stacchiotti-lancet-oncol":{"doi":"10.1016/s1470-2045(14)71190-8","openalexId":"W2082064668","cited":505,"byYear":{"2014":1,"2015":6,"2016":26,"2017":43,"2018":33,"2019":37,"2020":65,"2021":70,"2022":58,"2023":38,"2024":62,"2025":39,"2026":25},"year":2015,"title":"Building a global consensus approach to chordoma: a position paper from the medical and patient community"},"paper-aktipis-philos-trans-r-soc-lond-b-biol-sci":{"doi":"10.1098/rstb.2014.0219","openalexId":"W2098443490","cited":493,"byYear":{"2015":12,"2016":24,"2017":34,"2018":30,"2019":44,"2020":57,"2021":49,"2022":58,"2023":50,"2024":60,"2025":53,"2026":22},"year":2015,"title":"Cancer across the tree of life: cooperation and cheating in multicellularity"},"paper-c-144-01-lifileucel-melanoma-jco-2021":{"doi":"10.1200/jco.21.00612","openalexId":"W3162968491","cited":449,"byYear":{"2021":17,"2022":65,"2023":61,"2024":99,"2025":118,"2026":89},"year":2021,"title":"Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma"},"paper-capp2-aspirin-lynch-lancet-2020":{"doi":"10.1016/s0140-6736(20)30366-4","openalexId":"W3034846243","cited":433,"byYear":{"2020":20,"2021":57,"2022":63,"2023":89,"2024":63,"2025":79,"2026":61},"year":2020,"title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial"},"paper-schmid-pakt-capivasertib-tnbc-jco-2020":{"doi":"10.1200/jco.19.00368","openalexId":"W2996625978","cited":399,"byYear":{"2019":6,"2020":43,"2021":76,"2022":64,"2023":64,"2024":68,"2025":49,"2026":28},"year":2019,"title":"Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial"},"paper-laconi-br-j-cancer":{"doi":"10.1038/s41416-019-0721-1","openalexId":"W3005392003","cited":357,"byYear":{"2019":1,"2020":15,"2021":30,"2022":61,"2023":61,"2024":84,"2025":67,"2026":38},"year":2020,"title":"Cancer as a disease of old age: changing mutational and microenvironmental landscapes"},"paper-florence-duffaud-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(19)30825-3","openalexId":"W3006180429","cited":335,"byYear":{"2020":22,"2021":63,"2022":58,"2023":56,"2024":49,"2025":52,"2026":35},"year":2020,"title":"Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial"},"paper-davies-phys-biol":{"doi":"10.1088/1478-3975/8/1/015001","openalexId":"W2075033127","cited":262,"byYear":{"2012":6,"2013":13,"2014":16,"2015":13,"2016":13,"2017":16,"2018":25,"2019":15,"2020":25,"2021":23,"2022":18,"2023":20,"2024":28,"2025":16,"2026":10},"year":2011,"title":"Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors"},"paper-hess-ca19-9-response-chemotherapy-lancet-oncol-2008":{"doi":"10.1016/s1470-2045(08)70001-9","openalexId":"W2153704693","cited":240,"byYear":{"2012":21,"2013":14,"2014":11,"2015":16,"2016":12,"2017":7,"2018":15,"2019":10,"2020":15,"2021":17,"2022":10,"2023":13,"2024":9,"2025":3,"2026":4},"year":2008,"title":"CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial"},"paper-johnson-j-natl-cancer-inst":{"doi":"10.1093/jnci/djab141","openalexId":"W3186653455","cited":230,"byYear":{"2021":4,"2022":29,"2023":40,"2024":64,"2025":61,"2026":32},"year":2021,"title":"Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report"},"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023":{"doi":"10.1016/j.annonc.2022.11.013","openalexId":"W4312085177","cited":218,"byYear":{"2023":30,"2024":60,"2025":75,"2026":52},"year":2022,"title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-ux023t-cl201-jan-de-beur-jbmr-2021":{"doi":"10.1002/jbmr.4233","openalexId":"W3114617368","cited":190,"byYear":{"2020":5,"2021":15,"2022":46,"2023":32,"2024":30,"2025":31,"2026":30},"year":2020,"title":"Burosumab for the Treatment of Tumor-Induced Osteomalacia"},"paper-solheim-bmj-support-palliat-care":{"doi":"10.1136/bmjspcare-2017-001440","openalexId":"W2788888327","cited":177,"byYear":{"2018":11,"2019":24,"2020":22,"2021":29,"2022":33,"2023":23,"2024":10,"2025":14,"2026":11},"year":2018,"title":"Cancer cachexia: rationale for the MENAC (Multimodal—Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial"},"paper-cabinet-cabozantinib-nejm-2024":{"doi":"10.1056/nejmoa2403991","openalexId":"W4402581225","cited":160,"byYear":{"2024":4,"2025":91,"2026":65},"year":2024,"title":"Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors"},"paper-taha-oncologist":{"doi":"10.1634/theoncologist.2018-0383","openalexId":"W2913738642","cited":155,"byYear":{"2018":1,"2019":5,"2020":21,"2021":21,"2022":32,"2023":22,"2024":26,"2025":14,"2026":12},"year":2019,"title":"Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies"},"paper-nct04214288-lancet-oncol-2024":{"doi":"10.1016/s1470-2045(24)00387-5","openalexId":"W4403855243","cited":102,"byYear":{"2024":3,"2025":47,"2026":52},"year":2024,"title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial"},"paper-braun-j-clin-oncol":{"doi":"10.1200/jco.23.02596","openalexId":"W4392745023","cited":98,"byYear":{"2024":13,"2025":42,"2026":43},"year":2024,"title":"Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline"},"paper-c-post-adjuvant-cemiplimab-nejm-2025":{"doi":"10.1056/nejmoa2502449","openalexId":"W4410919601","cited":83,"byYear":{"2025":32,"2026":51},"year":2025,"title":"Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma"},"paper-geometry-mono-1-lancet-oncol-2024-update":{"doi":"10.1016/s1470-2045(24)00441-8","openalexId":"W4403012562","cited":82,"byYear":{"2024":2,"2025":35,"2026":45},"year":2024,"title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial"},"paper-camel-j-thorac-oncol-2023-update":{"doi":"10.1016/j.jtho.2022.12.017","openalexId":"W4315884147","cited":73,"byYear":{"2023":4,"2024":28,"2025":30,"2026":11},"year":2023,"title":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial"},"paper-capivasertib-breast-hr-positive-drugs-2024":{"doi":"10.1007/s40265-024-01998-6","openalexId":"W4392773703","cited":49,"byYear":{"2024":8,"2025":23,"2026":18},"year":2024,"title":"Capivasertib: First Approval"},"paper-capitello-281-ann-oncol-2026":{"doi":"10.1016/j.annonc.2025.10.004","openalexId":"W4415331967","cited":45,"byYear":{"2025":6,"2026":39},"year":2025,"title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study"},"paper-nct04446117-lancet-oncol-2025":{"doi":"10.1016/s1470-2045(25)00209-8","openalexId":"W4411260753","cited":26,"byYear":{"2025":6,"2026":20},"year":2025,"title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial"},"paper-vincent-bioessays":{"doi":"10.1002/bies.201100049","openalexId":"W2111850731","cited":115,"byYear":{"2012":5,"2013":2,"2014":11,"2015":4,"2016":10,"2017":7,"2018":9,"2019":8,"2020":10,"2021":10,"2022":7,"2023":9,"2024":12,"2025":8,"2026":1},"year":2011,"title":"Cancer: A de‐repression of a default survival program common to all cells?"},"paper-adams-j-clin-oncol":{"doi":"10.1200/jco.21.01436","openalexId":"W3200192401","cited":38,"byYear":{"2021":1,"2022":16,"2023":4,"2024":7,"2025":9,"2026":1},"year":2021,"title":"Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial"},"paper-capitello-290-capivasertib-paclitaxel-ann-oncol-2026":{"doi":"10.1016/j.annonc.2025.12.012","openalexId":"W4417505519","cited":6,"byYear":{"2026":6},"year":2025,"title":"Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial"},"paper-ctrak-tn-tissue-free-mrd-jamaoncol-2026":{"doi":"10.1001/jamaoncol.2026.2833","openalexId":"W7202378250","cited":0,"byYear":{},"year":2026,"title":"Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer"},"paper-checkmate-057-nejm-2015":{"doi":"10.1056/nejmoa1507643","openalexId":"W2104347254","cited":9570,"byYear":{"2012":1,"2013":3,"2014":3,"2015":41,"2016":688,"2017":1033,"2018":1177,"2019":1142,"2020":1292,"2021":1132,"2022":921,"2023":750,"2024":688,"2025":436,"2026":236},"year":2015,"title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer"},"paper-checkmate-017-nejm-2015":{"doi":"10.1056/nejmoa1504627","openalexId":"W2156353875","cited":8642,"byYear":{"2013":2,"2014":6,"2015":183,"2016":804,"2017":1001,"2018":1071,"2019":982,"2020":1088,"2021":969,"2022":745,"2023":662,"2024":582,"2025":335,"2026":185},"year":2015,"title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer"},"paper-cella-fact-g-jco-1993":{"doi":"10.1200/jco.1993.11.3.570","openalexId":"W2105258029","cited":6100,"byYear":{"2012":222,"2013":235,"2014":253,"2015":239,"2016":245,"2017":236,"2018":285,"2019":273,"2020":269,"2021":308,"2022":325,"2023":297,"2024":306,"2025":250,"2026":193},"year":1993,"title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure."},"paper-checkmate-141-ferris-nejm-2016":{"doi":"10.1056/nejmoa1602252","openalexId":"W2529484692","cited":5208,"byYear":{"2013":1,"2014":2,"2015":4,"2016":18,"2017":359,"2018":489,"2019":548,"2020":642,"2021":736,"2022":588,"2023":507,"2024":528,"2025":467,"2026":308},"year":2016,"title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck"},"paper-checkmate-214-nejm-2018":{"doi":"10.1056/nejmoa1712126","openalexId":"W2792937256","cited":4773,"byYear":{"2015":2,"2017":2,"2018":211,"2019":564,"2020":696,"2021":738,"2022":666,"2023":642,"2024":552,"2025":418,"2026":277},"year":2018,"title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma"},"paper-malumbres-nat-rev-cancer":{"doi":"10.1038/nrc2602","openalexId":"W2046024621","cited":4030,"byYear":{"2012":186,"2013":200,"2014":219,"2015":228,"2016":192,"2017":260,"2018":237,"2019":227,"2020":287,"2021":342,"2022":325,"2023":296,"2024":281,"2025":237,"2026":169},"year":2009,"title":"Cell cycle, CDKs and cancer: a changing paradigm"},"paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009":{"doi":"10.1056/nejmoa0805019","openalexId":"W2095201384","cited":3902,"byYear":{"2012":330,"2013":326,"2014":337,"2015":306,"2016":275,"2017":219,"2018":171,"2019":203,"2020":200,"2021":176,"2022":173,"2023":144,"2024":112,"2025":88,"2026":73},"year":2009,"title":"Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer"},"paper-chaarted-nejm-2015":{"doi":"10.1056/nejmoa1503747","openalexId":"W2150865892","cited":2924,"byYear":{"2015":50,"2016":204,"2017":244,"2018":277,"2019":288,"2020":286,"2021":318,"2022":303,"2023":241,"2024":257,"2025":257,"2026":188},"year":2015,"title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer"},"paper-checkmate-026-first-line-nivolumab-nejm-2017":{"doi":"10.1056/nejmoa1613493","openalexId":"W2635951006","cited":2606,"byYear":{"2016":1,"2017":61,"2018":337,"2019":376,"2020":450,"2021":411,"2022":338,"2023":236,"2024":222,"2025":121,"2026":49},"year":2017,"title":"First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer"},"paper-checkmate-238-nejm-2017":{"doi":"10.1056/nejmoa1709030","openalexId":"W2752227448","cited":2251,"byYear":{"2015":1,"2017":24,"2018":243,"2019":314,"2020":348,"2021":341,"2022":265,"2023":233,"2024":225,"2025":157,"2026":93},"year":2017,"title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma"},"paper-cd19-all-leukemia-j-clin-invest-2016":{"doi":"10.1172/jci85309","openalexId":"W2342423058","cited":2153,"byYear":{"2012":1,"2013":1,"2014":1,"2016":42,"2017":167,"2018":209,"2019":226,"2020":298,"2021":258,"2022":255,"2023":229,"2024":209,"2025":149,"2026":106},"year":2016,"title":"CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients"},"paper-bouvard-lancet-oncol":{"doi":"10.1016/s1470-2045(15)00444-1","openalexId":"W1941284977","cited":1901,"byYear":{"2015":12,"2016":129,"2017":160,"2018":170,"2019":185,"2020":172,"2021":192,"2022":201,"2023":190,"2024":211,"2025":188,"2026":88},"year":2015,"title":"Carcinogenicity of consumption of red and processed meat"},"paper-kras-colorectal-j-clin-oncol-2011":{"doi":"10.1200/jco.2010.33.5091","openalexId":"W2134142320","cited":1898,"byYear":{"2012":158,"2013":207,"2014":227,"2015":203,"2016":172,"2017":138,"2018":117,"2019":109,"2020":109,"2021":94,"2022":84,"2023":90,"2024":68,"2025":42,"2026":21},"year":2011,"title":"Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status"},"paper-calvert-j-clin-oncol":{"doi":"10.1200/jco.1989.7.11.1748","openalexId":"W2116996913","cited":1885,"byYear":{"2012":54,"2013":41,"2014":52,"2015":54,"2016":42,"2017":37,"2018":33,"2019":33,"2020":37,"2021":31,"2022":30,"2023":23,"2024":32,"2025":40,"2026":19},"year":1989,"title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function."},"paper-cartitude-1-cilta-cel-lancet-2021":{"doi":"10.1016/s0140-6736(21)00933-8","openalexId":"W3176532045","cited":1762,"byYear":{"2021":42,"2022":283,"2023":366,"2024":436,"2025":373,"2026":259},"year":2021,"title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study"},"paper-cercek-dostarlimab-rectal-nejm-2022":{"doi":"10.1056/nejmoa2201445","openalexId":"W4281732693","cited":1660,"byYear":{"2014":1,"2017":1,"2021":1,"2022":162,"2023":419,"2024":416,"2025":385,"2026":269},"year":2022,"title":"PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer"},"paper-demaria-cancer-discov":{"doi":"10.1158/2159-8290.cd-16-0241","openalexId":"W2561396377","cited":1369,"byYear":{"2013":1,"2017":38,"2018":81,"2019":107,"2020":164,"2021":155,"2022":207,"2023":183,"2024":182,"2025":156,"2026":95},"year":2016,"title":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse"},"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1411321","openalexId":"W1985864219","cited":1344,"byYear":{"2012":2,"2013":1,"2014":2,"2015":77,"2016":149,"2017":168,"2018":165,"2019":132,"2020":150,"2021":139,"2022":116,"2023":79,"2024":67,"2025":64,"2026":31},"year":2014,"title":"Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma"},"paper-guckenberger-lancet-oncol":{"doi":"10.1016/s1470-2045(19)30718-1","openalexId":"W2997721110","cited":1118,"byYear":{"2014":1,"2020":80,"2021":146,"2022":190,"2023":191,"2024":180,"2025":187,"2026":140},"year":2020,"title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation"},"paper-chen-nature-2016":{"doi":"10.1038/nature18268","openalexId":"W2395943362","cited":984,"byYear":{"2015":1,"2016":24,"2017":54,"2018":60,"2019":89,"2020":94,"2021":119,"2022":105,"2023":114,"2024":134,"2025":115,"2026":75},"year":2016,"title":"Carcinoma–astrocyte gap junctions promote brain metastasis by cGAMP transfer"},"paper-cassiopeia-lancet-2019":{"doi":"10.1016/s0140-6736(19)31240-1","openalexId":"W2948728876","cited":977,"byYear":{"2018":1,"2019":28,"2020":178,"2021":190,"2022":142,"2023":144,"2024":126,"2025":102,"2026":61},"year":2019,"title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study"},"paper-stylianopoulos-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.1213353109","openalexId":"W1998266575","cited":971,"byYear":{"2012":2,"2013":22,"2014":30,"2015":47,"2016":51,"2017":66,"2018":66,"2019":85,"2020":83,"2021":84,"2022":75,"2023":90,"2024":82,"2025":85,"2026":100},"year":2012,"title":"Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors"},"paper-tutt-nat-med":{"doi":"10.1038/s41591-018-0009-7","openalexId":"W2801956643","cited":924,"byYear":{"2018":40,"2019":103,"2020":131,"2021":162,"2022":160,"2023":118,"2024":86,"2025":70,"2026":51},"year":2018,"title":"Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial"},"paper-cartitude-4-cilta-cel-nejm-2023":{"doi":"10.1056/nejmoa2303379","openalexId":"W4379375986","cited":824,"byYear":{"2023":61,"2024":238,"2025":283,"2026":240},"year":2023,"title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma"},"paper-empower-lung-1-lancet-2021":{"doi":"10.1016/s0140-6736(21)00228-2","openalexId":"W3129022890","cited":816,"byYear":{"2013":1,"2021":74,"2022":170,"2023":203,"2024":184,"2025":133,"2026":50},"year":2021,"title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial"},"paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018":{"doi":"10.1200/jco.2017.76.0793","openalexId":"W2794872274","cited":768,"byYear":{"2017":1,"2018":46,"2019":83,"2020":137,"2021":119,"2022":99,"2023":122,"2024":87,"2025":38,"2026":34},"year":2018,"title":"Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial"},"paper-cd19-all-leukemia-blood-2015":{"doi":"10.1182/blood-2014-12-580068","openalexId":"W1555553634","cited":730,"byYear":{"2015":17,"2016":79,"2017":97,"2018":71,"2019":79,"2020":80,"2021":72,"2022":63,"2023":77,"2024":42,"2025":34,"2026":16},"year":2015,"title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia"},"paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020":{"doi":"10.1016/j.ccell.2020.08.004","openalexId":"W3087232085","cited":707,"byYear":{"2020":2,"2021":60,"2022":109,"2023":144,"2024":148,"2025":156,"2026":88},"year":2020,"title":"Challenges and Opportunities for Pancreatic Cancer Immunotherapy"},"paper-checkmate-067-10-year-nejm-2025":{"doi":"10.1056/nejmoa2407417","openalexId":"W7211992165","cited":30,"byYear":{"2026":30},"year":2025,"title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma"},"paper-fader-trastuzumab-uterine-serous-jco-2018":{"doi":"10.1200/jco.2017.76.5966","openalexId":"W2794839527","cited":536,"byYear":{"2018":11,"2019":28,"2020":61,"2021":78,"2022":84,"2023":88,"2024":78,"2025":75,"2026":32},"year":2018,"title":"Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu"},"paper-empower-cscc-1-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(19)30728-4","openalexId":"W2998989384","cited":501,"byYear":{"2013":1,"2020":40,"2021":88,"2022":96,"2023":70,"2024":79,"2025":71,"2026":51},"year":2020,"title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial"},"paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00302-8","openalexId":"W3177205810","cited":476,"byYear":{"2021":13,"2022":69,"2023":98,"2024":125,"2025":111,"2026":60},"year":2021,"title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial"},"paper-cardoso-ann-oncol":{"doi":"10.1093/annonc/mdx651","openalexId":"W2766828098","cited":412,"byYear":{"2016":2,"2017":1,"2018":22,"2019":28,"2020":53,"2021":62,"2022":48,"2023":50,"2024":65,"2025":49,"2026":30},"year":2017,"title":"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program"},"paper-catnon-lancet-2017":{"doi":"10.1016/s0140-6736(17)31442-3","openalexId":"W2744160381","cited":403,"byYear":{"2016":1,"2017":10,"2018":50,"2019":73,"2020":60,"2021":55,"2022":43,"2023":28,"2024":42,"2025":27,"2026":10},"year":2017,"title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study"},"paper-heetfeld-grade-3-net-erc-2015":{"doi":"10.1530/erc-15-0119","openalexId":"W1840972930","cited":396,"byYear":{"2015":2,"2016":20,"2017":33,"2018":37,"2019":46,"2020":49,"2021":70,"2022":47,"2023":33,"2024":25,"2025":18,"2026":10},"year":2015,"title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms"},"paper-iarc-monographs-vol-124-group-lancet-oncol":{"doi":"10.1016/s1470-2045(19)30455-3","openalexId":"W2955982493","cited":392,"byYear":{"2013":1,"2019":11,"2020":71,"2021":52,"2022":52,"2023":79,"2024":43,"2025":57,"2026":25},"year":2019,"title":"Carcinogenicity of night shift work"},"paper-challenge-exercise-nejm-2025":{"doi":"10.1056/nejmoa2502760","openalexId":"W4410927245","cited":350,"byYear":{"2024":1,"2025":101,"2026":248},"year":2025,"title":"Structured Exercise after Adjuvant Chemotherapy for Colon Cancer"},"paper-fernandez-cuesta-cd74-nrg1-fusion-lung-cancer-discov-2014":{"doi":"10.1158/2159-8290.cd-13-0633","openalexId":"W2154678665","cited":302,"byYear":{"2014":13,"2015":23,"2016":22,"2017":30,"2018":18,"2019":16,"2020":29,"2021":41,"2022":23,"2023":25,"2024":23,"2025":25,"2026":12},"year":2014,"title":"CD74–NRG1 Fusions in Lung Adenocarcinoma"},"paper-cemiplimab-bcc-stratigos-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00126-1","openalexId":"W3160231856","cited":285,"byYear":{"2021":20,"2022":69,"2023":73,"2024":53,"2025":43,"2026":26},"year":2021,"title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial"},"paper-malouff-front-oncol":{"doi":"10.3389/fonc.2020.00082","openalexId":"W3004203069","cited":249,"byYear":{"2019":2,"2020":15,"2021":48,"2022":41,"2023":44,"2024":46,"2025":36,"2026":17},"year":2020,"title":"Carbon Ion Therapy: A Modern Review of an Emerging Technology"},"paper-loomis-lancet-oncol":{"doi":"10.1016/s1470-2045(16)30239-x","openalexId":"W2429324456","cited":231,"byYear":{"2015":1,"2016":9,"2017":29,"2018":38,"2019":30,"2020":29,"2021":10,"2022":22,"2023":18,"2024":16,"2025":19,"2026":9},"year":2016,"title":"Carcinogenicity of drinking coffee, mate, and very hot beverages"},"paper-upadhaya-nat-rev-drug-discov":{"doi":"10.1038/d41573-022-00030-4","openalexId":"W4211168024","cited":218,"byYear":{"2022":37,"2023":48,"2024":62,"2025":52,"2026":18},"year":2022,"title":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape"},"paper-cepheus-dara-vrd-natmed-2025":{"doi":"10.1038/s41591-024-03485-7","openalexId":"W4407150890","cited":146,"byYear":{"2025":62,"2026":84},"year":2025,"title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial"},"paper-farwell-j-nucl-med":{"doi":"10.2967/jnumed.121.262485","openalexId":"W3194142396","cited":129,"byYear":{"2021":3,"2022":25,"2023":33,"2024":28,"2025":23,"2026":17},"year":2021,"title":"CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody"},"paper-nevin-gallbladder-carcinoma-staging-cancer-1976":{"doi":"10.1002/1097-0142(197601)37:1<141::aid-cncr2820370121>3.0.co;2-y","openalexId":"W1994148959","cited":322,"byYear":{"2012":5,"2013":7,"2014":8,"2015":10,"2016":5,"2017":5,"2018":5,"2019":2,"2020":4,"2021":9,"2022":1,"2023":6,"2024":2,"2025":2,"2026":1},"year":1976,"title":"Carcinoma of the gallbladder. Staging, treatment, and prognosis"},"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006":{"doi":"10.1016/s0020-7292(06)60029-5","openalexId":"W2430440116","cited":74,"byYear":{"2012":7,"2013":2,"2014":5,"2015":5,"2016":5,"2017":7,"2018":4,"2019":4,"2020":7,"2021":2,"2022":3,"2023":2,"2024":1},"year":2006,"title":"Carcinoma of the Vagina"},"paper-nct03381274-j-thorac-oncol-2023":{"doi":"10.1016/j.jtho.2022.12.021","openalexId":"W4316340189","cited":32,"byYear":{"2023":9,"2024":6,"2025":9,"2026":8},"year":2023,"title":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report"},"paper-hoang-ivermectin-toxicity-clin-toxicol-2022":{"doi":"10.1080/15563650.2022.2134788","openalexId":"W4308958497","cited":24,"byYear":{"2023":7,"2024":5,"2025":8,"2026":4},"year":2022,"title":"Characteristics of ivermectin toxicity in patients taking veterinary and human formulations for the prevention and treatment of COVID-19"},"paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019":{"doi":"10.4067/s0034-98872019000700860","openalexId":"W2979598987","cited":8,"byYear":{"2021":1,"2024":4,"2025":2,"2026":1},"year":2019,"title":"Mortalidad por cáncer de vesícula y egresos hospitalarios por patología biliar en Chile 2002-2014, en relación a la garantía GES colecistectomía preventiva"},"paper-chen-cancer-statistics-china-2015-cacancer-2016":{"doi":"10.3322/caac.21338","openalexId":"W2272984102","cited":18014,"byYear":{"2015":3,"2016":486,"2017":1649,"2018":2300,"2019":2662,"2020":2968,"2021":2734,"2022":2054,"2023":1386,"2024":1154,"2025":466,"2026":134},"year":2016,"title":"Cancer statistics in China, 2015"},"paper-chen-mellman-cancer-immunity-cycle-immunity-2013":{"doi":"10.1016/j.immuni.2013.07.012","openalexId":"W1994993231","cited":7160,"byYear":{"2013":10,"2014":63,"2015":139,"2016":204,"2017":338,"2018":430,"2019":493,"2020":718,"2021":829,"2022":912,"2023":998,"2024":926,"2025":649,"2026":444},"year":2013,"title":"Oncology Meets Immunology: The Cancer-Immunity Cycle"},"paper-cristofanilli-n-engl-j-med":{"doi":"10.1056/nejmoa040766","openalexId":"W2111976640","cited":4641,"byYear":{"2012":273,"2013":279,"2014":317,"2015":296,"2016":309,"2017":316,"2018":285,"2019":303,"2020":290,"2021":273,"2022":222,"2023":193,"2024":190,"2025":122,"2026":91},"year":2004,"title":"Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer"},"paper-oeffinger-n-engl-j-med":{"doi":"10.1056/nejmsa060185","openalexId":"W2015758016","cited":3646,"byYear":{"2012":165,"2013":194,"2014":190,"2015":232,"2016":236,"2017":207,"2018":215,"2019":198,"2020":267,"2021":240,"2022":239,"2023":217,"2024":182,"2025":149,"2026":106},"year":2006,"title":"Chronic Health Conditions in Adult Survivors of Childhood Cancer"},"paper-macdonald-n-engl-j-med":{"doi":"10.1056/nejmoa010187","openalexId":"W2026986976","cited":3519,"byYear":{"2012":232,"2013":228,"2014":211,"2015":227,"2016":147,"2017":183,"2018":157,"2019":162,"2020":164,"2021":150,"2022":115,"2023":89,"2024":81,"2025":72,"2026":38},"year":2001,"title":"Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction"},"paper-checkmate-649-lancet-2021":{"doi":"10.1016/s0140-6736(21)00797-2","openalexId":"W3171517418","cited":3126,"byYear":{"2014":1,"2019":1,"2021":84,"2022":487,"2023":618,"2024":787,"2025":660,"2026":487},"year":2021,"title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial"},"paper-checkmate-816-nejm-2022":{"doi":"10.1056/nejmoa2202170","openalexId":"W4223502512","cited":2748,"byYear":{"2022":207,"2023":616,"2024":722,"2025":680,"2026":523},"year":2022,"title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer"},"paper-aceto-cell":{"doi":"10.1016/j.cell.2014.07.013","openalexId":"W1993913242","cited":2541,"byYear":{"2012":2,"2014":10,"2015":129,"2016":163,"2017":197,"2018":203,"2019":263,"2020":276,"2021":291,"2022":260,"2023":251,"2024":201,"2025":194,"2026":100},"year":2014,"title":"Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis"},"paper-clarinet-lanreotide-nejm-2014":{"doi":"10.1056/nejmoa1316158","openalexId":"W2135049144","cited":1957,"byYear":{"2013":1,"2014":35,"2015":119,"2016":151,"2017":186,"2018":163,"2019":166,"2020":169,"2021":199,"2022":175,"2023":160,"2024":193,"2025":144,"2026":84},"year":2014,"title":"Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors"},"paper-checkmate-577-nejm-2021":{"doi":"10.1056/nejmoa2032125","openalexId":"W3148827278","cited":1875,"byYear":{"2012":1,"2013":1,"2021":143,"2022":335,"2023":383,"2024":395,"2025":356,"2026":259},"year":2021,"title":"Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer"},"paper-clear-nejm-2021":{"doi":"10.1056/nejmoa2035716","openalexId":"W3131063362","cited":1813,"byYear":{"2020":1,"2021":206,"2022":382,"2023":411,"2024":342,"2025":283,"2026":186},"year":2021,"title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma"},"paper-classic-adjuvant-capox-gastric-bang-lancet-2012":{"doi":"10.1016/s0140-6736(11)61873-4","openalexId":"W2113947048","cited":1751,"byYear":{"2012":48,"2013":99,"2014":115,"2015":137,"2016":97,"2017":102,"2018":106,"2019":159,"2020":157,"2021":161,"2022":127,"2023":138,"2024":126,"2025":103,"2026":71},"year":2012,"title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial"},"paper-bakhoum-nature":{"doi":"10.1038/nature25432","openalexId":"W2783667606","cited":1630,"byYear":{"2012":1,"2017":1,"2018":80,"2019":109,"2020":171,"2021":216,"2022":208,"2023":233,"2024":229,"2025":216,"2026":165},"year":2018,"title":"Chromosomal instability drives metastasis through a cytosolic DNA response"},"paper-tie-ctdna-minimal-residual-disease-stage-ii-colon-sci-transl-med-2016":{"doi":"10.1126/scitranslmed.aaf6219","openalexId":"W2460179076","cited":1519,"byYear":{"2015":1,"2016":14,"2017":91,"2018":135,"2019":146,"2020":176,"2021":215,"2022":183,"2023":183,"2024":137,"2025":132,"2026":102},"year":2016,"title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer"},"paper-chhip-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(16)30102-4","openalexId":"W2465092116","cited":1354,"byYear":{"2016":30,"2017":80,"2018":106,"2019":144,"2020":165,"2021":155,"2022":147,"2023":151,"2024":134,"2025":149,"2026":91},"year":2016,"title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial"},"paper-checkmate-648-nejm-2022":{"doi":"10.1056/nejmoa2111380","openalexId":"W4210696432","cited":1306,"byYear":{"2022":151,"2023":281,"2024":389,"2025":288,"2026":196},"year":2022,"title":"Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma"},"paper-checkmate-743-lancet-2021":{"doi":"10.1016/s0140-6736(20)32714-8","openalexId":"W3122627530","cited":1231,"byYear":{"2021":161,"2022":281,"2023":234,"2024":235,"2025":206,"2026":113},"year":2021,"title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial"},"paper-classic-5-year-follow-up-noh-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70473-5","openalexId":"W2165982376","cited":1091,"byYear":{"2013":2,"2014":1,"2015":36,"2016":53,"2017":71,"2018":87,"2019":105,"2020":149,"2021":130,"2022":112,"2023":122,"2024":95,"2025":76,"2026":48},"year":2014,"title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial"},"paper-glunde-nat-rev-cancer":{"doi":"10.1038/nrc3162","openalexId":"W2083166156","cited":859,"byYear":{"2012":14,"2013":48,"2014":52,"2015":56,"2016":72,"2017":64,"2018":58,"2019":51,"2020":48,"2021":68,"2022":91,"2023":62,"2024":86,"2025":51,"2026":35},"year":2011,"title":"Choline metabolism in malignant transformation"},"paper-aggarwal-t-sccpc-jco-2018":{"doi":"10.1200/jco.2017.77.6880","openalexId":"W2841858285","cited":854,"byYear":{"2018":17,"2019":68,"2020":88,"2021":117,"2022":102,"2023":136,"2024":133,"2025":105,"2026":85},"year":2018,"title":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study"},"paper-griffith-nat-genet":{"doi":"10.1038/ng.3774","openalexId":"W2583911935","cited":692,"byYear":{"2017":40,"2018":66,"2019":76,"2020":93,"2021":86,"2022":89,"2023":64,"2024":71,"2025":52,"2026":55},"year":2017,"title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer"},"paper-atchley-brca-status-triple-negative-jco-2008":{"doi":"10.1200/jco.2008.16.6231","openalexId":"W2166702788","cited":608,"byYear":{"2012":25,"2013":30,"2014":37,"2015":36,"2016":33,"2017":40,"2018":32,"2019":29,"2020":43,"2021":39,"2022":81,"2023":32,"2024":26,"2025":24,"2026":9},"year":2008,"title":"Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer"},"paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00301-6","openalexId":"W3179156059","cited":583,"byYear":{"2021":11,"2022":80,"2023":162,"2024":158,"2025":107,"2026":64},"year":2021,"title":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials"},"paper-annala-ctdna-resistance-abiraterone-enzalutamide-cancer-discov-2018":{"doi":"10.1158/2159-8290.cd-17-0937","openalexId":"W2789730857","cited":531,"byYear":{"2018":29,"2019":70,"2020":70,"2021":80,"2022":75,"2023":77,"2024":62,"2025":45,"2026":23},"year":2018,"title":"Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer"},"paper-kurtz-j-clin-oncol":{"doi":"10.1200/jco.2018.78.5246","openalexId":"W2888203943","cited":509,"byYear":{"2012":1,"2018":4,"2019":45,"2020":54,"2021":71,"2022":93,"2023":80,"2024":53,"2025":77,"2026":30},"year":2018,"title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma"},"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2018.4305","openalexId":"W2896105045","cited":502,"byYear":{"2012":1,"2013":1,"2018":2,"2019":43,"2020":64,"2021":86,"2022":85,"2023":77,"2024":71,"2025":51,"2026":20},"year":2018,"title":"Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer"},"paper-sausen-ctdna-pancreatic-resection-nat-commun-2015":{"doi":"10.1038/ncomms8686","openalexId":"W838548246","cited":498,"byYear":{"2015":2,"2016":51,"2017":52,"2018":51,"2019":55,"2020":52,"2021":56,"2022":48,"2023":42,"2024":34,"2025":40,"2026":15},"year":2015,"title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients"},"paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021":{"doi":"10.1016/j.annonc.2020.11.007","openalexId":"W3109124091","cited":465,"byYear":{"2020":4,"2021":34,"2022":67,"2023":103,"2024":96,"2025":92,"2026":68},"year":2020,"title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival"},"paper-wagner-sirolimus-pecoma-jco-2010":{"doi":"10.1200/jco.2009.25.2981","openalexId":"W2109038438","cited":398,"byYear":{"2012":29,"2013":30,"2014":31,"2015":27,"2016":23,"2017":24,"2018":33,"2019":29,"2020":27,"2021":25,"2022":27,"2023":21,"2024":17,"2025":13,"2026":12},"year":2010,"title":"Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors"},"paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019":{"doi":"10.1053/j.gastro.2018.09.022","openalexId":"W2890106882","cited":381,"byYear":{"2013":1,"2018":2,"2019":42,"2020":63,"2021":70,"2022":67,"2023":54,"2024":42,"2025":18,"2026":22},"year":2018,"title":"Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer"},"paper-plasmamatch-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30444-7","openalexId":"W3084269232","cited":370,"byYear":{"2020":7,"2021":67,"2022":61,"2023":77,"2024":61,"2025":60,"2026":35},"year":2020,"title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial"},"paper-loree-tumour-location-continuum-colorectal-ccr-2018":{"doi":"10.1158/1078-0432.ccr-17-2484","openalexId":"W2770347143","cited":330,"byYear":{"2017":1,"2018":23,"2019":36,"2020":37,"2021":59,"2022":46,"2023":56,"2024":24,"2025":26,"2026":20},"year":2017,"title":"Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes"},"paper-mackensen-nat-med":{"doi":"10.1038/s41591-023-02612-0","openalexId":"W4387880124","cited":296,"byYear":{"2023":3,"2024":87,"2025":112,"2026":93},"year":2023,"title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial"},"paper-henriksen-ctdna-stage-iii-colorectal-improve-it-ccr-2022":{"doi":"10.1158/1078-0432.ccr-21-2404","openalexId":"W3203274060","cited":262,"byYear":{"2021":3,"2022":37,"2023":59,"2024":57,"2025":56,"2026":50},"year":2021,"title":"Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences"},"paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021":{"doi":"10.1038/s41591-021-01553-w","openalexId":"W3212458558","cited":244,"byYear":{"2021":1,"2022":39,"2023":59,"2024":68,"2025":49,"2026":28},"year":2021,"title":"Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial"},"paper-checkmate-76k-nat-med-2023":{"doi":"10.1038/s41591-023-02583-2","openalexId":"W4387666867","cited":239,"byYear":{"2023":4,"2024":63,"2025":101,"2026":71},"year":2023,"title":"Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial"},"paper-checkmate-8hw-lancet-2025":{"doi":"10.1016/s0140-6736(24)02848-4","openalexId":"W4406818361","cited":238,"byYear":{"2025":101,"2026":137},"year":2025,"title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial"},"paper-aall1731-blinatumomab-children-nejm-2025":{"doi":"10.1056/nejmoa2411680","openalexId":"W4405130232","cited":224,"byYear":{"2024":1,"2025":113,"2026":110},"year":2024,"title":"Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children"},"paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019":{"doi":"10.1093/annonc/mdz200","openalexId":"W2962976163","cited":221,"byYear":{"2013":1,"2019":8,"2020":24,"2021":36,"2022":38,"2023":36,"2024":35,"2025":28,"2026":15},"year":2019,"title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer"},"paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019":{"doi":"10.1158/1078-0432.ccr-19-0197","openalexId":"W2947818769","cited":209,"byYear":{"2013":1,"2019":5,"2020":20,"2021":29,"2022":31,"2023":42,"2024":31,"2025":24,"2026":26},"year":2019,"title":"Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer"},"paper-chmielecki-acinar-cell-carcinoma-raf-fusions-dna-repair-cancer-discov-2014":{"doi":"10.1158/2159-8290.cd-14-0617","openalexId":"W2118189115","cited":189,"byYear":{"2012":1,"2013":1,"2014":2,"2015":11,"2016":12,"2017":15,"2018":13,"2019":21,"2020":22,"2021":14,"2022":22,"2023":16,"2024":18,"2025":11,"2026":10},"year":2014,"title":"Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes"},"paper-phergain-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00122-4","openalexId":"W3161369373","cited":166,"byYear":{"2021":4,"2022":21,"2023":33,"2024":51,"2025":38,"2026":18},"year":2021,"title":"Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial"},"paper-ct041-st-01-lancet-2025":{"doi":"10.1016/s0140-6736(25)00860-8","openalexId":"W4410914881","cited":152,"byYear":{"2025":42,"2026":110},"year":2025,"title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial"},"paper-taixiang-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd004540.pub2","openalexId":"W2100162670","cited":141,"byYear":{"2012":8,"2013":17,"2014":2,"2015":8,"2016":7,"2017":4,"2018":9,"2019":12,"2020":10,"2021":4,"2022":4,"2023":5,"2024":3,"2025":2},"year":2005,"title":"Chinese medical herbs for chemotherapy side effects in colorectal cancer patients"},"paper-durvalumab-endometrial-j-immunother-cancer-2021":{"doi":"10.1136/jitc-2020-002255","openalexId":"W3167167915","cited":133,"byYear":{"2021":3,"2022":24,"2023":47,"2024":23,"2025":21,"2026":15},"year":2021,"title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial"},"paper-dynamic-nat-med-2025-update":{"doi":"10.1038/s41591-025-03579-w","openalexId":"W4408234715","cited":129,"byYear":{"2025":36,"2026":93},"year":2025,"title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial"},"paper-ciltacabtagene-autoleucel-multiple-myeloma-front-immunol-2022":{"doi":"10.3389/fimmu.2022.991092","openalexId":"W4294219068","cited":103,"byYear":{"2013":1,"2023":14,"2024":25,"2025":47,"2026":15},"year":2022,"title":"Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma"},"paper-mody-biliary-ctdna-profiling-jco-po-2019":{"doi":"10.1200/po.18.00324","openalexId":"W2921077663","cited":88,"byYear":{"2019":4,"2020":9,"2021":12,"2022":15,"2023":13,"2024":13,"2025":13,"2026":9},"year":2019,"title":"Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers"},"paper-lu-j-natl-cancer-inst":{"doi":"10.1093/jnci/djq179","openalexId":"W2116609279","cited":72,"byYear":{"2012":5,"2013":9,"2014":9,"2015":6,"2016":1,"2017":5,"2018":2,"2019":5,"2020":5,"2021":3,"2022":1,"2023":3,"2024":3,"2025":5,"2026":1},"year":2010,"title":"Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial"},"paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024":{"doi":"10.1200/go.24.00090","openalexId":"W4403292610","cited":5,"byYear":{"2024":1,"2025":2,"2026":2},"year":2024,"title":"Clinical and Genomic Characterization of ERBB2 -Altered Gallbladder Cancer: Exploring Differences Between an American and a Chilean Cohort"},"paper-nivolumab-melanoma-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1504030","openalexId":"W2166662937","cited":8281,"byYear":{"2013":2,"2014":7,"2015":191,"2016":835,"2017":1045,"2018":926,"2019":877,"2020":953,"2021":859,"2022":721,"2023":654,"2024":549,"2025":395,"2026":254},"year":2015,"title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma"},"paper-dekker-lancet":{"doi":"10.1016/s0140-6736(19)32319-0","openalexId":"W4211168195","cited":5162,"byYear":{"2019":3,"2020":488,"2021":635,"2022":706,"2023":859,"2024":1041,"2025":920,"2026":509},"year":2019,"title":"Colorectal cancer"},"paper-siegel-colorectal-cancer-statistics-ca-2023":{"doi":"10.3322/caac.21772","openalexId":"W4322719806","cited":3920,"byYear":{"2014":4,"2015":29,"2016":20,"2017":40,"2018":109,"2019":93,"2020":144,"2021":160,"2022":123,"2023":403,"2024":1286,"2025":1152,"2026":355},"year":2023,"title":"Colorectal cancer statistics, 2023"},"paper-greaves-nature":{"doi":"10.1038/nature10762","openalexId":"W2023560061","cited":3298,"byYear":{"2012":101,"2013":163,"2014":225,"2015":241,"2016":251,"2017":304,"2018":256,"2019":228,"2020":258,"2021":268,"2022":225,"2023":250,"2024":195,"2025":162,"2026":166},"year":2012,"title":"Clonal evolution in cancer"},"paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012":{"doi":"10.1056/nejmoa1100370","openalexId":"W2140876736","cited":3220,"byYear":{"2012":99,"2013":189,"2014":212,"2015":233,"2016":204,"2017":225,"2018":203,"2019":243,"2020":276,"2021":264,"2022":239,"2023":245,"2024":195,"2025":220,"2026":153},"year":2012,"title":"Colonoscopic Polypectomy and Long-Term Prevention of Colorectal-Cancer Deaths"},"paper-mcgranahan-cell":{"doi":"10.1016/j.cell.2017.01.018","openalexId":"W2586629973","cited":3016,"byYear":{"2016":1,"2017":81,"2018":236,"2019":295,"2020":352,"2021":369,"2022":422,"2023":355,"2024":332,"2025":286,"2026":287},"year":2017,"title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future"},"paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012":{"doi":"10.1056/nejmoa1110557","openalexId":"W2121743767","cited":2109,"byYear":{"2012":76,"2013":167,"2014":147,"2015":167,"2016":174,"2017":146,"2018":142,"2019":122,"2020":161,"2021":169,"2022":142,"2023":140,"2024":140,"2025":105,"2026":105},"year":2012,"title":"A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis"},"paper-cobrim-n-engl-j-med-2014":{"doi":"10.1056/nejmoa1408868","openalexId":"W2121545342","cited":2085,"byYear":{"2012":1,"2013":3,"2014":22,"2015":202,"2016":242,"2017":263,"2018":204,"2019":193,"2020":191,"2021":195,"2022":157,"2023":135,"2024":126,"2025":90,"2026":57},"year":2014,"title":"Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma"},"paper-combi-d-n-engl-j-med-2014":{"doi":"10.1056/nejmoa1406037","openalexId":"W2096387850","cited":1920,"byYear":{"2012":1,"2013":2,"2014":26,"2015":209,"2016":207,"2017":216,"2018":163,"2019":172,"2020":177,"2021":149,"2022":148,"2023":133,"2024":126,"2025":100,"2026":88},"year":2014,"title":"Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma"},"paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012":{"doi":"10.1056/nejmoa1110556","openalexId":"W2115351357","cited":1834,"byYear":{"2012":70,"2013":159,"2014":130,"2015":160,"2016":164,"2017":133,"2018":124,"2019":116,"2020":129,"2021":150,"2022":127,"2023":116,"2024":98,"2025":81,"2026":72},"year":2012,"title":"JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis"},"paper-combi-ad-nejm-2017":{"doi":"10.1056/nejmoa1708539","openalexId":"W2752210999","cited":1507,"byYear":{"2012":1,"2015":1,"2017":18,"2018":187,"2019":220,"2020":209,"2021":234,"2022":175,"2023":152,"2024":153,"2025":99,"2026":56},"year":2017,"title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma"},"paper-thakker-j-clin-endocrinol-metab":{"doi":"10.1210/jc.2012-1230","openalexId":"W2086923046","cited":1487,"byYear":{"2012":17,"2013":55,"2014":74,"2015":87,"2016":95,"2017":131,"2018":101,"2019":105,"2020":127,"2021":138,"2022":138,"2023":106,"2024":125,"2025":115,"2026":61},"year":2012,"title":"Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)"},"paper-combi-d-long-lancet-2015":{"doi":"10.1016/s0140-6736(15)60898-4","openalexId":"W2160766792","cited":1422,"byYear":{"2012":2,"2013":1,"2014":2,"2015":38,"2016":154,"2017":197,"2018":153,"2019":170,"2020":160,"2021":137,"2022":109,"2023":88,"2024":101,"2025":62,"2026":44},"year":2015,"title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial"},"paper-checkmate-204-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1805453","openalexId":"W2888298425","cited":1347,"byYear":{"2017":3,"2018":25,"2019":184,"2020":232,"2021":222,"2022":191,"2023":174,"2024":141,"2025":106,"2026":66},"year":2018,"title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain"},"paper-siegel-colorectal-incidence-birth-cohort-jnci-2017":{"doi":"10.1093/jnci/djw322","openalexId":"W2592701528","cited":1240,"byYear":{"2016":1,"2017":43,"2018":116,"2019":139,"2020":160,"2021":199,"2022":154,"2023":131,"2024":127,"2025":102,"2026":63},"year":2016,"title":"Colorectal Cancer Incidence Patterns in the United States, 1974–2013"},"paper-jaiswal-science":{"doi":"10.1126/science.aan4673","openalexId":"W2982291252","cited":1191,"byYear":{"2019":4,"2020":91,"2021":147,"2022":170,"2023":178,"2024":215,"2025":221,"2026":165},"year":2019,"title":"Clonal hematopoiesis in human aging and disease"},"paper-columbus-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30142-6","openalexId":"W2793817570","cited":1047,"byYear":{"2017":2,"2018":64,"2019":119,"2020":140,"2021":153,"2022":166,"2023":136,"2024":131,"2025":90,"2026":42},"year":2018,"title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial"},"paper-cobrim-lancet-oncol-2016-update":{"doi":"10.1016/s1470-2045(16)30122-x","openalexId":"W2491982852","cited":1032,"byYear":{"2016":14,"2017":76,"2018":105,"2019":147,"2020":161,"2021":139,"2022":127,"2023":104,"2024":79,"2025":52,"2026":27},"year":2016,"title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial"},"paper-klein-ccga3-mced-validation-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.05.806","openalexId":"W3174187171","cited":1031,"byYear":{"2021":14,"2022":146,"2023":216,"2024":249,"2025":217,"2026":188},"year":2021,"title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set"},"paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019":{"doi":"10.1186/s13046-019-1259-z","openalexId":"W2952065098","cited":1010,"byYear":{"2018":1,"2019":14,"2020":97,"2021":170,"2022":171,"2023":165,"2024":219,"2025":114,"2026":57},"year":2019,"title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer"},"paper-skoulidis-kras-co-mutation-subsets-cancer-discov-2015":{"doi":"10.1158/2159-8290.cd-14-1236","openalexId":"W2145411470","cited":948,"byYear":{"2014":1,"2015":11,"2016":53,"2017":56,"2018":71,"2019":73,"2020":95,"2021":126,"2022":118,"2023":87,"2024":89,"2025":91,"2026":70},"year":2015,"title":"Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities"},"paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018":{"doi":"10.1016/j.ccell.2017.12.004","openalexId":"W2783494975","cited":889,"byYear":{"2018":32,"2019":69,"2020":118,"2021":118,"2022":144,"2023":114,"2024":106,"2025":104,"2026":78},"year":2018,"title":"Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer"},"paper-cll14-venetoclax-obinutuzumab-nejm-2019":{"doi":"10.1056/nejmoa1815281","openalexId":"W2948436219","cited":877,"byYear":{"2013":2,"2019":45,"2020":144,"2021":183,"2022":135,"2023":114,"2024":101,"2025":84,"2026":67},"year":2019,"title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions"},"paper-poole-bmj":{"doi":"10.1136/bmj.j5024","openalexId":"W2771044916","cited":829,"byYear":{"2015":1,"2017":2,"2018":59,"2019":68,"2020":108,"2021":112,"2022":111,"2023":90,"2024":119,"2025":99,"2026":60},"year":2017,"title":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes"},"paper-greenlee-ca-cancer-j-clin":{"doi":"10.3322/caac.21397","openalexId":"W2607992798","cited":791,"byYear":{"2016":1,"2017":14,"2018":59,"2019":73,"2020":107,"2021":107,"2022":106,"2023":108,"2024":100,"2025":65,"2026":48},"year":2017,"title":"Clinical practice guidelines on the evidence‐based use of integrative therapies during and after breast cancer treatment"},"paper-coffey-reovirus-ras-science-1998":{"doi":"10.1126/science.282.5392.1332","openalexId":"W2090599158","cited":754,"byYear":{"2012":30,"2013":30,"2014":24,"2015":33,"2016":18,"2017":20,"2018":18,"2019":19,"2020":27,"2021":25,"2022":23,"2023":23,"2024":13,"2025":11,"2026":6},"year":1998,"title":"Reovirus Therapy of Tumors with Activated Ras Pathway"},"paper-schettini-her2-low-features-npj-breast-cancer-2021":{"doi":"10.1038/s41523-020-00208-2","openalexId":"W3119128530","cited":716,"byYear":{"2017":1,"2021":30,"2022":111,"2023":179,"2024":198,"2025":130,"2026":66},"year":2021,"title":"Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer"},"paper-palmer-cell":{"doi":"10.1016/j.cell.2017.11.009","openalexId":"W2774112395","cited":682,"byYear":{"2017":4,"2018":38,"2019":59,"2020":92,"2021":105,"2022":87,"2023":84,"2024":81,"2025":85,"2026":46},"year":2017,"title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy"},"paper-codebreak-200-lancet-2023":{"doi":"10.1016/s0140-6736(23)00221-0","openalexId":"W4319337483","cited":611,"byYear":{"2023":84,"2024":203,"2025":199,"2026":124},"year":2023,"title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial"},"paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017":{"doi":"10.1073/pnas.1704961114","openalexId":"W2751788109","cited":592,"byYear":{"2013":1,"2017":5,"2018":60,"2019":86,"2020":78,"2021":92,"2022":65,"2023":67,"2024":49,"2025":57,"2026":30},"year":2017,"title":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers"},"paper-lee-clonal-history-small-cell-transformation-jco-2017":{"doi":"10.1200/jco.2016.71.9096","openalexId":"W2612786119","cited":523,"byYear":{"2017":16,"2018":51,"2019":36,"2020":86,"2021":62,"2022":70,"2023":51,"2024":51,"2025":69,"2026":31},"year":2017,"title":"Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas"},"paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023":{"doi":"10.1056/nejmoa2208470","openalexId":"W4312094134","cited":520,"byYear":{"2023":81,"2024":147,"2025":175,"2026":117},"year":2022,"title":"Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer"},"paper-comstock-jama":{"doi":"10.1001/jama.2020.0572","openalexId":"W3006788346","cited":463,"byYear":{"2020":48,"2021":67,"2022":85,"2023":91,"2024":81,"2025":60,"2026":30},"year":2020,"title":"Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening"},"paper-codebreak-300-nejm-2023":{"doi":"10.1056/nejmoa2308795","openalexId":"W4387859726","cited":382,"byYear":{"2023":7,"2024":126,"2025":144,"2026":105},"year":2023,"title":"Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C"},"paper-menden-nat-commun":{"doi":"10.1038/s41467-019-09799-2","openalexId":"W2951449549","cited":379,"byYear":{"2019":18,"2020":59,"2021":64,"2022":56,"2023":62,"2024":53,"2025":37,"2026":29},"year":2019,"title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen"},"paper-herbst-j-clin-oncol":{"doi":"10.1200/jco.22.00227","openalexId":"W4224283600","cited":304,"byYear":{"2022":30,"2023":82,"2024":77,"2025":69,"2026":46},"year":2022,"title":"COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer"},"paper-aparicio-aggressive-variant-prostate-tumour-suppressors-ccr-2016":{"doi":"10.1158/1078-0432.ccr-15-1259","openalexId":"W2137974207","cited":302,"byYear":{"2016":7,"2017":13,"2018":32,"2019":27,"2020":27,"2021":37,"2022":31,"2023":42,"2024":29,"2025":35,"2026":22},"year":2015,"title":"Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers"},"paper-kakiuchi-nat-rev-cancer":{"doi":"10.1038/s41568-021-00335-3","openalexId":"W3132294763","cited":265,"byYear":{"2021":28,"2022":58,"2023":49,"2024":45,"2025":51,"2026":34},"year":2021,"title":"Clonal expansion in non-cancer tissues"},"paper-jshbps-biliary-tract-cancer-guidelines-2019-jhbps-2021":{"doi":"10.1002/jhbp.870","openalexId":"W4211007077","cited":245,"byYear":{"2020":1,"2021":14,"2022":48,"2023":57,"2024":43,"2025":59,"2026":22},"year":2020,"title":"Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition"},"paper-p9641-low-risk-neuroblastoma-strother-jco-2012":{"doi":"10.1200/jco.2011.37.9990","openalexId":"W2122250312","cited":241,"byYear":{"2012":4,"2013":8,"2014":8,"2015":9,"2016":15,"2017":11,"2018":24,"2019":15,"2020":19,"2021":23,"2022":28,"2023":20,"2024":32,"2025":11,"2026":9},"year":2012,"title":"Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641"},"paper-fushimi-androgen-deprivation-salivary-duct-ann-oncol-2018":{"doi":"10.1093/annonc/mdx771","openalexId":"W2775239209","cited":230,"byYear":{"2018":12,"2019":14,"2020":33,"2021":25,"2022":31,"2023":33,"2024":26,"2025":34,"2026":22},"year":2017,"title":"A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma"},"paper-commands-luspatercept-mds-lancet-2023":{"doi":"10.1016/s0140-6736(23)00874-7","openalexId":"W4380154556","cited":176,"byYear":{"2023":21,"2024":67,"2025":58,"2026":29},"year":2023,"title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial"},"paper-larson-jco-precis-oncol":{"doi":"10.1200/po.20.00495","openalexId":"W3182939006","cited":126,"byYear":{"2021":5,"2022":19,"2023":24,"2024":37,"2025":23,"2026":18},"year":2021,"title":"Clinical Outcomes of Molecular Tumor Boards: A Systematic Review"},"paper-atlantis-lancet-respir-med-2023":{"doi":"10.1016/s2213-2600(22)00309-5","openalexId":"W4306247391","cited":126,"byYear":{"2022":3,"2023":24,"2024":33,"2025":46,"2026":20},"year":2022,"title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial"},"paper-preempt-crc-shaukat-jama-2025":{"doi":"10.1001/jama.2025.7515","openalexId":"W4410952687","cited":63,"byYear":{"2025":25,"2026":38},"year":2025,"title":"Clinical Validation of a Circulating Tumor DNA–Based Blood Test to Screen for Colorectal Cancer"},"paper-nct04068610-br-j-cancer-2024":{"doi":"10.1038/s41416-024-02796-3","openalexId":"W4400933413","cited":18,"byYear":{"2025":7,"2026":11},"year":2024,"title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer"},"paper-cll12-ibrutinib-early-stage-langerbeins-jco-2025":{"doi":"10.1200/jco.24.00975","openalexId":"W4404785526","cited":16,"byYear":{"2025":6,"2026":10},"year":2024,"title":"Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial"},"paper-neyaz-pdl1-gallbladder-histopathology-2018":{"doi":"10.1111/his.13669","openalexId":"W2806413170","cited":48,"byYear":{"2019":4,"2020":4,"2021":6,"2022":8,"2023":11,"2024":8,"2025":4,"2026":3},"year":2018,"title":"Clinical relevance of PD ‐L1 expression in gallbladder cancer: a potential target for therapy"},"paper-barchuk-registry-validity-acta-oncol-2021":{"doi":"10.1080/0284186x.2021.1967443","openalexId":"W3195218839","cited":13,"byYear":{"2023":9,"2024":3,"2025":1},"year":2021,"title":"Comparability and validity of cancer registry data in the northwest of Russia"},"paper-bar-j-pers-med":{"doi":"10.3390/jpm16060298","openalexId":"W7163039599","cited":0,"byYear":{},"year":2026,"title":"Clinical Utility of an Ex Vivo Functional Test in Personalized Cancer Treatment"},"paper-coussens-werb-inflammation-cancer-nature-2002":{"doi":"10.1038/nature01322","openalexId":"W1965037168","cited":15260,"byYear":{"2012":685,"2013":749,"2014":773,"2015":774,"2016":757,"2017":774,"2018":749,"2019":832,"2020":880,"2021":951,"2022":904,"2023":883,"2024":759,"2025":591,"2026":296},"year":2002,"title":"Inflammation and cancer"},"paper-tcga-breast-molecular-portraits-nature-2012":{"doi":"10.1038/nature11412","openalexId":"W4301159569","cited":12653,"byYear":{"2012":39,"2013":588,"2014":887,"2015":920,"2016":988,"2017":991,"2018":985,"2019":1011,"2020":1086,"2021":1272,"2022":960,"2023":865,"2024":865,"2025":704,"2026":486},"year":2012,"title":"Comprehensive molecular portraits of human breast tumours"},"paper-tcga-colorectal-comprehensive-characterization-nature-2012":{"doi":"10.1038/nature11252","openalexId":"W2262414037","cited":8844,"byYear":{"2012":86,"2013":422,"2014":580,"2015":619,"2016":651,"2017":684,"2018":699,"2019":722,"2020":793,"2021":830,"2022":715,"2023":643,"2024":576,"2025":471,"2026":342},"year":2012,"title":"Comprehensive molecular characterization of human colon and rectal cancer"},"paper-conroy-folfirinox-pancreatic-nejm-2011":{"doi":"10.1056/nejmoa1011923","openalexId":"W2151253787","cited":7945,"byYear":{"2012":221,"2013":280,"2014":381,"2015":473,"2016":454,"2017":555,"2018":580,"2019":571,"2020":733,"2021":804,"2022":639,"2023":636,"2024":604,"2025":534,"2026":384},"year":2011,"title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer"},"paper-tcga-gastric-nature-2014":{"doi":"10.1038/nature13480","openalexId":"W2126547130","cited":6691,"byYear":{"2013":1,"2014":41,"2015":299,"2016":401,"2017":492,"2018":565,"2019":568,"2020":678,"2021":802,"2022":632,"2023":696,"2024":627,"2025":489,"2026":392},"year":2014,"title":"Comprehensive molecular characterization of gastric adenocarcinoma"},"paper-tcga-lung-adenocarcinoma-nature-2014":{"doi":"10.1038/nature13385","openalexId":"W2180481128","cited":5981,"byYear":{"2013":1,"2014":47,"2015":314,"2016":434,"2017":527,"2018":491,"2019":517,"2020":655,"2021":653,"2022":597,"2023":560,"2024":478,"2025":426,"2026":275},"year":2014,"title":"Comprehensive molecular profiling of lung adenocarcinoma"},"paper-cross-nejm-2012":{"doi":"10.1056/nejmoa1112088","openalexId":"W2154444715","cited":5591,"byYear":{"2012":57,"2013":202,"2014":296,"2015":347,"2016":325,"2017":437,"2018":413,"2019":388,"2020":501,"2021":494,"2022":501,"2023":455,"2024":489,"2025":401,"2026":275},"year":2012,"title":"Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer"},"paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002":{"doi":"10.1056/nejmoa011954","openalexId":"W2037139573","cited":5008,"byYear":{"2012":277,"2013":286,"2014":283,"2015":266,"2016":239,"2017":229,"2018":208,"2019":192,"2020":173,"2021":153,"2022":150,"2023":148,"2024":87,"2025":64,"2026":70},"year":2002,"title":"Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer"},"paper-cou-aa-301-abiraterone-de-bono-nejm-2011":{"doi":"10.1056/nejmoa1014618","openalexId":"W2110534364","cited":4445,"byYear":{"2012":348,"2013":401,"2014":387,"2015":353,"2016":341,"2017":321,"2018":333,"2019":303,"2020":295,"2021":297,"2022":251,"2023":215,"2024":192,"2025":185,"2026":96},"year":2011,"title":"Abiraterone and Increased Survival in Metastatic Prostate Cancer"},"paper-tcga-lung-squamous-nature-2012":{"doi":"10.1038/nature11404","openalexId":"W2275877493","cited":4083,"byYear":{"2012":24,"2013":303,"2014":334,"2015":374,"2016":350,"2017":364,"2018":334,"2019":299,"2020":380,"2021":315,"2022":278,"2023":215,"2024":191,"2025":186,"2026":130},"year":2012,"title":"Comprehensive genomic characterization of squamous cell lung cancers"},"paper-jones-pancreatic-core-pathways-science-2008":{"doi":"10.1126/science.1164368","openalexId":"W2138155367","cited":4071,"byYear":{"2012":315,"2013":271,"2014":315,"2015":307,"2016":253,"2017":251,"2018":218,"2019":216,"2020":236,"2021":233,"2022":149,"2023":205,"2024":174,"2025":93,"2026":44},"year":2008,"title":"Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses"},"paper-alk-nsclc-n-engl-j-med-2013":{"doi":"10.1056/nejmoa1214886","openalexId":"W2050249255","cited":3431,"byYear":{"2012":3,"2013":91,"2014":375,"2015":493,"2016":439,"2017":397,"2018":306,"2019":262,"2020":257,"2021":209,"2022":181,"2023":137,"2024":116,"2025":100,"2026":53},"year":2013,"title":"Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer"},"paper-george-sclc-genomic-profiles-nature-2015":{"doi":"10.1038/nature14664","openalexId":"W1903523058","cited":2448,"byYear":{"2013":1,"2015":16,"2016":109,"2017":141,"2018":162,"2019":203,"2020":269,"2021":249,"2022":320,"2023":299,"2024":270,"2025":251,"2026":152},"year":2015,"title":"Comprehensive genomic profiles of small cell lung cancer"},"paper-swain-cancer":{"doi":"10.1002/cncr.11407","openalexId":"W1492360552","cited":2333,"byYear":{"2012":75,"2013":87,"2014":87,"2015":121,"2016":146,"2017":133,"2018":129,"2019":160,"2020":162,"2021":150,"2022":165,"2023":171,"2024":150,"2025":145,"2026":108},"year":2003,"title":"Congestive heart failure in patients treated with doxorubicin"},"paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019":{"doi":"10.1158/2159-8290.cd-19-0094","openalexId":"W2951222857","cited":2304,"byYear":{"2019":16,"2020":165,"2021":280,"2022":343,"2023":349,"2024":453,"2025":383,"2026":313},"year":2019,"title":"Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts"},"paper-ebctcg-polychemotherapy-regimens-meta-analysis-lancet-2012":{"doi":"10.1016/s0140-6736(11)61625-5","openalexId":"W1701849548","cited":2129,"byYear":{"2012":80,"2013":138,"2014":118,"2015":156,"2016":165,"2017":168,"2018":166,"2019":158,"2020":176,"2021":209,"2022":145,"2023":146,"2024":130,"2025":101,"2026":57},"year":2012,"title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials"},"paper-shaw-crizotinib-ros1-nejm-2014":{"doi":"10.1056/nejmoa1406766","openalexId":"W1990626198","cited":2015,"byYear":{"2013":1,"2014":9,"2015":153,"2016":199,"2017":199,"2018":239,"2019":199,"2020":214,"2021":204,"2022":154,"2023":131,"2024":158,"2025":104,"2026":46},"year":2014,"title":"Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer"},"paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006":{"doi":"10.1038/ng1834","openalexId":"W2169903102","cited":2003,"byYear":{"2012":125,"2013":124,"2014":148,"2015":107,"2016":118,"2017":116,"2018":84,"2019":85,"2020":90,"2021":96,"2022":70,"2023":91,"2024":94,"2025":50,"2026":39},"year":2006,"title":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer"},"paper-conko-001-adjuvant-gemcitabine-long-term-oettle-jama-2013":{"doi":"10.1001/jama.2013.279201","openalexId":"W2138582833","cited":1820,"byYear":{"2013":4,"2014":55,"2015":98,"2016":144,"2017":143,"2018":138,"2019":182,"2020":187,"2021":200,"2022":180,"2023":152,"2024":149,"2025":132,"2026":52},"year":2013,"title":"Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer"},"paper-burstein-tnbc-genomic-subtypes-ccr-2015":{"doi":"10.1158/1078-0432.ccr-14-0432","openalexId":"W2114505219","cited":1441,"byYear":{"2013":1,"2014":3,"2015":25,"2016":57,"2017":74,"2018":98,"2019":119,"2020":161,"2021":198,"2022":186,"2023":172,"2024":127,"2025":139,"2026":81},"year":2014,"title":"Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer"},"paper-tcga-papillary-rcc-nejm-2016":{"doi":"10.1056/nejmoa1505917","openalexId":"W2111867681","cited":1397,"byYear":{"2014":2,"2015":1,"2016":97,"2017":126,"2018":130,"2019":153,"2020":161,"2021":176,"2022":151,"2023":146,"2024":100,"2025":101,"2026":51},"year":2015,"title":"Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma"},"paper-fiolet-bmj":{"doi":"10.1136/bmj.k322","openalexId":"W2792720753","cited":1039,"byYear":{"2018":41,"2019":89,"2020":128,"2021":156,"2022":162,"2023":192,"2024":126,"2025":84,"2026":59},"year":2018,"title":"Consumption of ultra-processed foods and cancer risk: results from NutriNet-Santé prospective cohort"},"paper-cpx-351-study-301-lancet-je-jco-2018":{"doi":"10.1200/jco.2017.77.6112","openalexId":"W2883399820","cited":1029,"byYear":{"2012":2,"2016":1,"2017":2,"2018":22,"2019":109,"2020":147,"2021":160,"2022":140,"2023":140,"2024":115,"2025":117,"2026":72},"year":2018,"title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia"},"paper-promise-talhouk-cancer-2017":{"doi":"10.1002/cncr.30496","openalexId":"W2570729870","cited":1002,"byYear":{"2016":3,"2017":17,"2018":34,"2019":59,"2020":84,"2021":106,"2022":130,"2023":163,"2024":160,"2025":142,"2026":101},"year":2017,"title":"Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer"},"paper-kahles-cancer-cell":{"doi":"10.1016/j.ccell.2018.07.001","openalexId":"W2885227878","cited":994,"byYear":{"2018":14,"2019":81,"2020":132,"2021":149,"2022":157,"2023":123,"2024":143,"2025":124,"2026":71},"year":2018,"title":"Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients"},"paper-van-der-zee-lancet":{"doi":"10.1016/s0140-6736(00)02059-6","openalexId":"W2154935750","cited":945,"byYear":{"2012":44,"2013":52,"2014":30,"2015":42,"2016":49,"2017":44,"2018":28,"2019":38,"2020":45,"2021":36,"2022":45,"2023":28,"2024":30,"2025":30,"2026":9},"year":2000,"title":"Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial"},"paper-cortes-ciriano-nat-genet":{"doi":"10.1038/s41588-019-0576-7","openalexId":"W3005469082","cited":792,"byYear":{"2018":1,"2019":6,"2020":68,"2021":128,"2022":115,"2023":167,"2024":139,"2025":102,"2026":66},"year":2020,"title":"Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing"},"paper-ben-david-nat-rev-genet":{"doi":"10.1038/s41576-019-0171-x","openalexId":"W2973350525","cited":760,"byYear":{"2018":1,"2019":1,"2020":68,"2021":124,"2022":127,"2023":130,"2024":144,"2025":103,"2026":62},"year":2019,"title":"Context is everything: aneuploidy in cancer"},"paper-rosai-dorfman-destombes-consensus-recommendations-blood-2018":{"doi":"10.1182/blood-2018-03-839753","openalexId":"W2802582740","cited":646,"byYear":{"2018":10,"2019":44,"2020":56,"2021":70,"2022":99,"2023":92,"2024":117,"2025":92,"2026":65},"year":2018,"title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease"},"paper-convert-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30318-2","openalexId":"W2699278758","cited":595,"byYear":{"2017":22,"2018":50,"2019":47,"2020":66,"2021":77,"2022":82,"2023":71,"2024":56,"2025":70,"2026":53},"year":2017,"title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial"},"paper-boveri-j-cell-sci":{"doi":"10.1242/jcs.025742","openalexId":"W2089031587","cited":591,"byYear":{"2012":34,"2013":33,"2014":39,"2015":54,"2016":41,"2017":32,"2018":37,"2019":31,"2020":35,"2021":49,"2022":35,"2023":40,"2024":30,"2025":28,"2026":14},"year":2007,"title":"Concerning the Origin of Malignant Tumours by Theodor Boveri. Translated and annotated by Henry Harris"},"paper-marina-lancet-oncol":{"doi":"10.1016/s1470-2045(16)30214-5","openalexId":"W2513951655","cited":561,"byYear":{"2015":1,"2016":8,"2017":30,"2018":26,"2019":44,"2020":72,"2021":70,"2022":74,"2023":51,"2024":76,"2025":60,"2026":48},"year":2016,"title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial"},"paper-offin-rb1-tp53-transformation-risk-jto-2019":{"doi":"10.1016/j.jtho.2019.06.002","openalexId":"W2952506496","cited":471,"byYear":{"2019":4,"2020":55,"2021":58,"2022":82,"2023":70,"2024":62,"2025":82,"2026":58},"year":2019,"title":"Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes"},"paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017":{"doi":"10.1093/jnci/djx118","openalexId":"W2725414935","cited":425,"byYear":{"2017":6,"2018":29,"2019":47,"2020":60,"2021":65,"2022":65,"2023":58,"2024":33,"2025":38,"2026":23},"year":2017,"title":"Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer"},"paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021":{"doi":"10.1200/jco.20.03237","openalexId":"W3118937854","cited":416,"byYear":{"2021":27,"2022":66,"2023":93,"2024":94,"2025":86,"2026":49},"year":2021,"title":"Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline"},"paper-roumenina-nat-rev-cancer":{"doi":"10.1038/s41568-019-0210-0","openalexId":"W2982426375","cited":406,"byYear":{"2019":3,"2020":32,"2021":52,"2022":84,"2023":80,"2024":48,"2025":65,"2026":42},"year":2019,"title":"Context-dependent roles of complement in cancer"},"paper-anderson-n-engl-j-med":{"doi":"10.1056/nejmsa1409364","openalexId":"W1963526469","cited":388,"byYear":{"2014":1,"2015":37,"2016":50,"2017":39,"2018":53,"2019":29,"2020":38,"2021":33,"2022":38,"2023":19,"2024":18,"2025":14,"2026":19},"year":2015,"title":"Compliance with Results Reporting at ClinicalTrials.gov"},"paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024":{"doi":"10.1038/s41586-024-07205-6","openalexId":"W4394580100","cited":361,"byYear":{"2023":1,"2024":68,"2025":171,"2026":121},"year":2024,"title":"Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy"},"paper-jochelson-radiology":{"doi":"10.1148/radiol.2021201948","openalexId":"W3134701770","cited":353,"byYear":{"2021":17,"2022":46,"2023":68,"2024":85,"2025":84,"2026":50},"year":2021,"title":"Contrast-enhanced Mammography: State of the Art"},"paper-huo-tcga-ancestry-breast-jama-oncol-2017":{"doi":"10.1001/jamaoncol.2017.0595","openalexId":"W2611684441","cited":290,"byYear":{"2017":10,"2018":18,"2019":31,"2020":47,"2021":39,"2022":38,"2023":43,"2024":31,"2025":20,"2026":13},"year":2017,"title":"Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas"},"paper-pritchard-complex-msh2-msh6-hypermutated-prostate-nat-commun-2014":{"doi":"10.1038/ncomms5988","openalexId":"W1994987687","cited":272,"byYear":{"2015":7,"2016":24,"2017":24,"2018":40,"2019":33,"2020":41,"2021":19,"2022":26,"2023":29,"2024":13,"2025":9,"2026":7},"year":2014,"title":"Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer"},"paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021":{"doi":"10.1136/gutjnl-2020-320726","openalexId":"W3022265443","cited":258,"byYear":{"2020":10,"2021":44,"2022":49,"2023":43,"2024":36,"2025":40,"2026":36},"year":2020,"title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications"},"paper-continuum-sintilimab-nasopharyngeal-liu-lancet-2024":{"doi":"10.1016/s0140-6736(24)00594-4","openalexId":"W4399163381","cited":196,"byYear":{"2024":25,"2025":96,"2026":75},"year":2024,"title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial"},"paper-schoffski-lancet-respir-med":{"doi":"10.1016/s2213-2600(18)30116-4","openalexId":"W2797695262","cited":183,"byYear":{"2018":11,"2019":13,"2020":30,"2021":36,"2022":28,"2023":19,"2024":24,"2025":13,"2026":8},"year":2018,"title":"Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial"},"paper-giraldo-gallbladder-msk-impact-ccr-2022":{"doi":"10.1158/1078-0432.ccr-22-1954","openalexId":"W4306147264","cited":53,"byYear":{"2023":2,"2024":14,"2025":22,"2026":15},"year":2022,"title":"Comprehensive Molecular Characterization of Gallbladder Carcinoma and Potential Targets for Intervention"},"paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023":{"doi":"10.1186/s13058-023-01724-2","openalexId":"W4387503536","cited":36,"byYear":{"2024":9,"2025":13,"2026":14},"year":2023,"title":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms"},"paper-nct04765059-esmo-open-2025":{"doi":"10.1016/j.esmoop.2025.105807","openalexId":"W4414063624","cited":32,"byYear":{"2025":3,"2026":29},"year":2025,"title":"COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib"},"paper-barchuk-registry-completeness-bmc-cancer-2023":{"doi":"10.1186/s12885-023-11492-z","openalexId":"W4387734339","cited":7,"byYear":{"2024":2,"2025":3,"2026":2},"year":2023,"title":"Completeness of regional cancer registry data in Northwest Russia 2008-2017"},"paper-perez-jco-precis-oncol":{"doi":"10.1200/po.23.00615","openalexId":"W4393596023","cited":2,"byYear":{"2024":1,"2026":1},"year":2024,"title":"Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study"},"paper-almogy-biorxiv":{"doi":"10.1101/2022.05.29.493900","openalexId":"W4281715053","cited":79,"byYear":{"2022":13,"2023":21,"2024":17,"2025":21,"2026":7},"year":2022,"title":"Cost-efficient whole genome-sequencing using novel mostly natural sequencing-by-synthesis chemistry and open fluidics platform"},"paper-darnell-jak-stat-science-1994":{"doi":"10.1126/science.8197455","openalexId":"W2029275361","cited":6158,"byYear":{"2012":185,"2013":208,"2014":159,"2015":151,"2016":145,"2017":166,"2018":121,"2019":156,"2020":169,"2021":185,"2022":188,"2023":178,"2024":189,"2025":141,"2026":76},"year":1994,"title":"Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins"},"paper-fearon-lancet-oncol":{"doi":"10.1016/s1470-2045(10)70218-7","openalexId":"W2145280166","cited":5842,"byYear":{"2012":123,"2013":152,"2014":188,"2015":229,"2016":248,"2017":278,"2018":366,"2019":410,"2020":494,"2021":588,"2022":544,"2023":585,"2024":599,"2025":516,"2026":468},"year":2011,"title":"Definition and classification of cancer cachexia: an international consensus"},"paper-damico-risk-groups-jama-1998":{"doi":"10.1001/jama.280.11.969","openalexId":"W2117792530","cited":4558,"byYear":{"2012":226,"2013":206,"2014":299,"2015":259,"2016":248,"2017":249,"2018":239,"2019":229,"2020":244,"2021":240,"2022":234,"2023":177,"2024":153,"2025":131,"2026":84},"year":1998,"title":"Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer"},"paper-depmap-tsherniak-cell-2017":{"doi":"10.1016/j.cell.2017.06.010","openalexId":"W2741508285","cited":3636,"byYear":{"2017":26,"2018":109,"2019":197,"2020":296,"2021":385,"2022":406,"2023":470,"2024":629,"2025":712,"2026":406},"year":2017,"title":"Defining a Cancer Dependency Map"},"paper-va-larynx-induction-chemotherapy-nejm-1991":{"doi":"10.1056/nejm199106133242402","openalexId":"W2562414697","cited":2752,"byYear":{"2012":95,"2013":112,"2014":109,"2015":111,"2016":106,"2017":122,"2018":98,"2019":124,"2020":106,"2021":99,"2022":95,"2023":99,"2024":102,"2025":87,"2026":34},"year":1991,"title":"Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer"},"paper-ozdemir-caf-depletion-accelerates-pancreatic-cancer-cancer-cell-2014":{"doi":"10.1016/j.ccr.2014.04.005","openalexId":"W2088110734","cited":2720,"byYear":{"2014":41,"2015":143,"2016":167,"2017":167,"2018":190,"2019":192,"2020":262,"2021":288,"2022":333,"2023":253,"2024":253,"2025":220,"2026":211},"year":2014,"title":"Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival"},"paper-pd-1-nsclc-am-j-clin-oncol-2016":{"doi":"10.1097/coc.0000000000000239","openalexId":"W2263759961","cited":2388,"byYear":{"2012":1,"2014":1,"2016":25,"2017":99,"2018":170,"2019":198,"2020":272,"2021":292,"2022":314,"2023":270,"2024":313,"2025":261,"2026":169},"year":2015,"title":"CTLA-4 and PD-1 Pathways"},"paper-watson-nature":{"doi":"10.1038/s41586-023-06415-8","openalexId":"W4383957026","cited":2275,"byYear":{"2022":1,"2023":104,"2024":507,"2025":836,"2026":827},"year":2023,"title":"De novo design of protein structure and function with RFdiffusion"},"paper-bauer-triple-negative-california-registry-cancer-2007":{"doi":"10.1002/cncr.22618","openalexId":"W1995224853","cited":2106,"byYear":{"2012":123,"2013":112,"2014":143,"2015":142,"2016":158,"2017":138,"2018":127,"2019":128,"2020":138,"2021":134,"2022":115,"2023":93,"2024":83,"2025":66,"2026":43},"year":2007,"title":"Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype"},"paper-viswanathan-nature":{"doi":"10.1038/nature23007","openalexId":"W2727828415","cited":2096,"byYear":{"2014":1,"2015":1,"2016":3,"2017":19,"2018":67,"2019":123,"2020":168,"2021":241,"2022":275,"2023":318,"2024":396,"2025":289,"2026":192},"year":2017,"title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway"},"paper-falini-npm1-nejm-2005":{"doi":"10.1056/nejmoa041974","openalexId":"W2170515966","cited":1925,"byYear":{"2012":99,"2013":107,"2014":105,"2015":94,"2016":84,"2017":77,"2018":67,"2019":89,"2020":85,"2021":124,"2022":91,"2023":89,"2024":73,"2025":65,"2026":48},"year":2005,"title":"Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype"},"paper-decision-sorafenib-lancet-2014":{"doi":"10.1016/s0140-6736(14)60421-9","openalexId":"W2168076926","cited":1666,"byYear":{"2014":41,"2015":138,"2016":117,"2017":147,"2018":138,"2019":138,"2020":122,"2021":163,"2022":195,"2023":130,"2024":131,"2025":127,"2026":69},"year":2014,"title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial"},"paper-mullighan-ikzf1-nejm-2009":{"doi":"10.1056/nejmoa0808253","openalexId":"W2040329520","cited":1457,"byYear":{"2012":101,"2013":90,"2014":85,"2015":100,"2016":97,"2017":105,"2018":75,"2019":70,"2020":97,"2021":104,"2022":69,"2023":101,"2024":71,"2025":50,"2026":29},"year":2009,"title":"Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia"},"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016":{"doi":"10.1056/nejmoa1607751","openalexId":"W2528329272","cited":1457,"byYear":{"2015":1,"2016":15,"2017":148,"2018":193,"2019":177,"2020":239,"2021":226,"2022":142,"2023":110,"2024":78,"2025":78,"2026":45},"year":2016,"title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma"},"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30679-4","openalexId":"W2409383155","cited":1391,"byYear":{"2014":1,"2015":2,"2016":13,"2017":80,"2018":148,"2019":140,"2020":188,"2021":192,"2022":181,"2023":142,"2024":162,"2025":85,"2026":52},"year":2017,"title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial"},"paper-archer-1050-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30608-3","openalexId":"W2760639821","cited":1234,"byYear":{"2016":1,"2017":10,"2018":96,"2019":134,"2020":167,"2021":175,"2022":187,"2023":154,"2024":131,"2025":119,"2026":57},"year":2017,"title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial"},"paper-de-escalate-lancet-2019":{"doi":"10.1016/s0140-6736(18)32752-1","openalexId":"W2901385432","cited":1058,"byYear":{"2018":3,"2019":110,"2020":173,"2021":187,"2022":153,"2023":125,"2024":116,"2025":115,"2026":72},"year":2018,"title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial"},"paper-subbiah-dabrafenib-trametinib-atc-jco-2018":{"doi":"10.1200/jco.2017.73.6785","openalexId":"W2766581537","cited":903,"byYear":{"2015":1,"2016":1,"2017":2,"2018":35,"2019":75,"2020":129,"2021":125,"2022":143,"2023":136,"2024":98,"2025":91,"2026":65},"year":2017,"title":"Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer"},"paper-planchard-dabrafenib-trametinib-braf-nsclc-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(16)30146-2","openalexId":"W3164126191","cited":898,"byYear":{"2014":1,"2015":1,"2016":14,"2017":91,"2018":122,"2019":85,"2020":116,"2021":118,"2022":103,"2023":88,"2024":76,"2025":57,"2026":23},"year":2016,"title":"Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial"},"paper-quenet-prodige-7-hipec-peritoneal-colorectal-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(20)30599-4","openalexId":"W3126104714","cited":830,"byYear":{"2021":96,"2022":144,"2023":160,"2024":182,"2025":140,"2026":107},"year":2021,"title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial"},"paper-yan-peritoneal-mesothelioma-crs-hipec-jco-2009":{"doi":"10.1200/jco.2009.23.9640","openalexId":"W2150737595","cited":696,"byYear":{"2012":41,"2013":46,"2014":34,"2015":46,"2016":56,"2017":58,"2018":47,"2019":53,"2020":48,"2021":53,"2022":42,"2023":39,"2024":39,"2025":31,"2026":19},"year":2009,"title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience"},"paper-lievens-radiother-oncol":{"doi":"10.1016/j.radonc.2020.04.003","openalexId":"W3019546741","cited":680,"byYear":{"2014":1,"2020":14,"2021":86,"2022":128,"2023":127,"2024":124,"2025":120,"2026":77},"year":2020,"title":"Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document"},"paper-jak2-polycythaemia-vera-lancet-2005":{"doi":"10.1016/s0140-6736(05)67785-9","openalexId":"W2169405856","cited":653,"byYear":{"2012":32,"2013":34,"2014":31,"2015":38,"2016":26,"2017":19,"2018":21,"2019":22,"2020":20,"2021":20,"2022":16,"2023":13,"2024":4,"2025":4,"2026":6},"year":2005,"title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study"},"paper-dellphi-301-nejm-2023":{"doi":"10.1056/nejmoa2307980","openalexId":"W4387799038","cited":584,"byYear":{"2023":6,"2024":125,"2025":240,"2026":213},"year":2023,"title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer"},"paper-roar-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30321-1","openalexId":"W3049104202","cited":538,"byYear":{"2020":17,"2021":74,"2022":101,"2023":108,"2024":89,"2025":88,"2026":59},"year":2020,"title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial"},"paper-simon-col1a1-pdgfb-dfsp-nat-genet-1997":{"doi":"10.1038/ng0197-95","openalexId":"W2046841776","cited":536,"byYear":{"2012":23,"2013":23,"2014":21,"2015":21,"2016":18,"2017":23,"2018":23,"2019":15,"2020":17,"2021":15,"2022":15,"2023":13,"2024":10,"2025":15,"2026":6},"year":1997,"title":"Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma"},"paper-koopman-deficient-mismatch-repair-advanced-colorectal-bjc-2009":{"doi":"10.1038/sj.bjc.6604867","openalexId":"W2052228812","cited":529,"byYear":{"2012":13,"2013":6,"2014":11,"2015":20,"2016":25,"2017":29,"2018":36,"2019":37,"2020":46,"2021":58,"2022":62,"2023":53,"2024":53,"2025":31,"2026":18},"year":2009,"title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer"},"paper-shindo-germline-sporadic-pancreatic-jco-2017":{"doi":"10.1200/jco.2017.72.3502","openalexId":"W2741937391","cited":489,"byYear":{"2017":9,"2018":41,"2019":49,"2020":45,"2021":80,"2022":61,"2023":97,"2024":65,"2025":27,"2026":15},"year":2017,"title":"Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma"},"paper-roar-ann-oncol-2022-update":{"doi":"10.1016/j.annonc.2021.12.014","openalexId":"W4205515761","cited":367,"byYear":{"2022":33,"2023":83,"2024":76,"2025":104,"2026":71},"year":2022,"title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study"},"paper-dart-nivolumab-ipilimumab-nec-patel-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-3356","openalexId":"W3002973089","cited":344,"byYear":{"2017":1,"2020":34,"2021":69,"2022":70,"2023":54,"2024":47,"2025":43,"2026":25},"year":2020,"title":"A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors"},"paper-desktop-iii-nejm-2021":{"doi":"10.1056/nejmoa2103294","openalexId":"W3214984954","cited":331,"byYear":{"2021":4,"2022":62,"2023":68,"2024":71,"2025":75,"2026":51},"year":2021,"title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer"},"paper-salama-j-clin-oncol":{"doi":"10.1200/jco.20.00762","openalexId":"W3047024115","cited":307,"byYear":{"2020":4,"2021":16,"2022":39,"2023":85,"2024":62,"2025":59,"2026":41},"year":2020,"title":"Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H"},"paper-bouffet-n-engl-j-med":{"doi":"10.1056/nejmoa2303815","openalexId":"W4386881349","cited":300,"byYear":{"2023":8,"2024":95,"2025":103,"2026":94},"year":2023,"title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations"},"paper-fitzgerald-lancet":{"doi":"10.1016/s0140-6736(20)31099-0","openalexId":"W3046326116","cited":267,"byYear":{"2020":11,"2021":45,"2022":39,"2023":50,"2024":47,"2025":43,"2026":31},"year":2020,"title":"Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial"},"paper-pramesh-lancet-oncol":{"doi":"10.1016/s1470-2045(14)70117-2","openalexId":"W1990579800","cited":252,"byYear":{"2014":14,"2015":12,"2016":15,"2017":10,"2018":21,"2019":20,"2020":22,"2021":23,"2022":32,"2023":21,"2024":22,"2025":21,"2026":19},"year":2014,"title":"Delivery of affordable and equitable cancer care in India"},"paper-dasatinib-vs-imatinib-ph-positive-all-shen-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2019.5868","openalexId":"W3000081737","cited":247,"byYear":{"2019":1,"2020":23,"2021":42,"2022":48,"2023":43,"2024":35,"2025":31,"2026":23},"year":2020,"title":"Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia"},"paper-gilligan-am-j-med":{"doi":"10.1016/j.amjmed.2018.05.020","openalexId":"W2807821904","cited":236,"byYear":{"2018":2,"2019":19,"2020":26,"2021":29,"2022":55,"2023":25,"2024":29,"2025":36,"2026":14},"year":2018,"title":"Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer"},"paper-bradt-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd007103.pub3","openalexId":"W2108276209","cited":185,"byYear":{"2012":9,"2013":4,"2014":9,"2015":16,"2016":10,"2017":13,"2018":13,"2019":13,"2020":16,"2021":11,"2022":11,"2023":17,"2024":14,"2025":15,"2026":12},"year":2015,"title":"Dance/movement therapy for improving psychological and physical outcomes in cancer patients"},"paper-dawna-1-nat-med-2021":{"doi":"10.1038/s41591-021-01562-9","openalexId":"W3211241105","cited":185,"byYear":{"2021":4,"2022":22,"2023":30,"2024":47,"2025":43,"2026":39},"year":2021,"title":"Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial"},"paper-tropion-lung05-j-clin-oncol-2025":{"doi":"10.1200/jco-24-01349","openalexId":"W4406090459","cited":123,"byYear":{"2025":53,"2026":70},"year":2025,"title":"Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study"},"paper-daraxonrasib-pancreatic-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2605555","openalexId":"W7162952636","cited":93,"byYear":{"2026":93},"year":2026,"title":"Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer"},"paper-li-j-thorac-oncol":{"doi":"10.1016/j.jtho.2023.03.015","openalexId":"W4328104940","cited":89,"byYear":{"2023":7,"2024":26,"2025":38,"2026":18},"year":2023,"title":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results"},"paper-cupisco-molecularly-guided-therapy-cup-lancet-2024":{"doi":"10.1016/s0140-6736(24)00814-6","openalexId":"W7212023784","cited":3,"byYear":{"2026":3},"year":2024,"title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study"},"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023":{"doi":"10.1200/jco.23.00558","openalexId":"W4386244466","cited":75,"byYear":{"2023":4,"2024":22,"2025":30,"2026":19},"year":2023,"title":"Phase II Trial of Dabrafenib Plus Trametinib in Relapsed/Refractory BRAF V600–Mutant Pediatric High-Grade Glioma"},"paper-nct05379985-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2505783","openalexId":"W7160408317","cited":67,"byYear":{"2025":1,"2026":66},"year":2026,"title":"Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer"},"paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023":{"doi":"10.1038/s41523-023-00512-7","openalexId":"W4323309432","cited":46,"byYear":{"2023":7,"2024":13,"2025":18,"2026":8},"year":2023,"title":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease"},"paper-tropion-breast02-ann-oncol-2026":{"doi":"10.1016/j.annonc.2026.03.008","openalexId":"W7149012512","cited":17,"byYear":{"2026":17},"year":2026,"title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial"},"paper-nct03742102-ann-oncol-2026":{"doi":"10.1016/j.annonc.2026.05.693","openalexId":"W7212262747","cited":3,"byYear":{"2026":3},"year":2026,"title":"Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study"},"paper-alizadeh-nature":{"doi":"10.1038/35000501","openalexId":"W2147246240","cited":10014,"byYear":{"2012":419,"2013":376,"2014":382,"2015":368,"2016":351,"2017":326,"2018":310,"2019":344,"2020":359,"2021":350,"2022":307,"2023":326,"2024":212,"2025":217,"2026":124},"year":2000,"title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling"},"paper-begley-nature":{"doi":"10.1038/483531a","openalexId":"W1987777080","cited":2976,"byYear":{"2012":62,"2013":133,"2014":227,"2015":263,"2016":286,"2017":280,"2018":268,"2019":265,"2020":253,"2021":222,"2022":187,"2023":174,"2024":131,"2025":119,"2026":101},"year":2012,"title":"Raise standards for preclinical cancer research"},"paper-cohen-cancerseek-multi-analyte-blood-test-science-2018":{"doi":"10.1126/science.aar3247","openalexId":"W2783674487","cited":2879,"byYear":{"2017":2,"2018":236,"2019":324,"2020":341,"2021":403,"2022":316,"2023":363,"2024":324,"2025":348,"2026":219},"year":2018,"title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test"},"paper-curtin-melanoma-genetic-alterations-nejm-2005":{"doi":"10.1056/nejmoa050092","openalexId":"W1989121777","cited":2732,"byYear":{"2012":202,"2013":214,"2014":194,"2015":168,"2016":153,"2017":163,"2018":127,"2019":135,"2020":162,"2021":124,"2022":86,"2023":87,"2024":96,"2025":68,"2026":51},"year":2005,"title":"Distinct Sets of Genetic Alterations in Melanoma"},"paper-destiny-breast04-nejm-2022":{"doi":"10.1056/nejmoa2203690","openalexId":"W4281640394","cited":2718,"byYear":{"2017":1,"2022":183,"2023":642,"2024":725,"2025":693,"2026":472},"year":2022,"title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer"},"paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017":{"doi":"10.1084/jem.20162024","openalexId":"W2590390825","cited":2645,"byYear":{"2016":1,"2017":38,"2018":89,"2019":151,"2020":275,"2021":362,"2022":354,"2023":366,"2024":374,"2025":343,"2026":291},"year":2017,"title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer"},"paper-yachida-metastasis-late-genetic-evolution-pancreatic-nature-2010":{"doi":"10.1038/nature09515","openalexId":"W2169895148","cited":2564,"byYear":{"2012":197,"2013":181,"2014":223,"2015":234,"2016":211,"2017":222,"2018":181,"2019":152,"2020":176,"2021":169,"2022":131,"2023":118,"2024":87,"2025":81,"2026":67},"year":2010,"title":"Distant metastasis occurs late during the genetic evolution of pancreatic cancer"},"paper-khorana-blood":{"doi":"10.1182/blood-2007-10-116327","openalexId":"W1996600303","cited":2244,"byYear":{"2012":99,"2013":79,"2014":85,"2015":90,"2016":115,"2017":116,"2018":109,"2019":152,"2020":214,"2021":180,"2022":188,"2023":198,"2024":188,"2025":147,"2026":131},"year":2008,"title":"Development and validation of a predictive model for chemotherapy-associated thrombosis"},"paper-bell-annu-rev-biochem":{"doi":"10.1146/annurev.biochem.71.110601.135425","openalexId":"W2106130068","cited":2065,"byYear":{"2012":98,"2013":79,"2014":91,"2015":57,"2016":52,"2017":53,"2018":30,"2019":48,"2020":42,"2021":44,"2022":24,"2023":36,"2024":35,"2025":33,"2026":17},"year":2002,"title":"DNA Replication in Eukaryotic Cells"},"paper-doll-hill-smoking-lung-cancer-bmj-1950":{"doi":"10.1136/bmj.2.4682.739","openalexId":"W1998637589","cited":2001,"byYear":{"2012":66,"2013":74,"2014":65,"2015":70,"2016":69,"2017":73,"2018":69,"2019":69,"2020":81,"2021":52,"2022":87,"2023":44,"2024":51,"2025":69,"2026":38},"year":1950,"title":"Smoking and Carcinoma of the Lung"},"paper-beltran-nepc-divergent-evolution-nat-med-2016":{"doi":"10.1038/nm.4045","openalexId":"W2262087934","cited":1796,"byYear":{"2015":1,"2016":47,"2017":120,"2018":181,"2019":155,"2020":194,"2021":183,"2022":174,"2023":221,"2024":223,"2025":185,"2026":110},"year":2016,"title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer"},"paper-destiny-gastric01-nejm-2020":{"doi":"10.1056/nejmoa2004413","openalexId":"W3147820834","cited":1353,"byYear":{"2018":1,"2020":27,"2021":168,"2022":218,"2023":278,"2024":243,"2025":249,"2026":167},"year":2020,"title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer"},"paper-campbell-pan-lung-somatic-alterations-nat-genet-2016":{"doi":"10.1038/ng.3564","openalexId":"W2346025119","cited":1265,"byYear":{"2016":21,"2017":91,"2018":121,"2019":137,"2020":143,"2021":177,"2022":153,"2023":144,"2024":139,"2025":91,"2026":46},"year":2016,"title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas"},"paper-doronina-nat-biotechnol":{"doi":"10.1038/nbt832","openalexId":"W2090057677","cited":1216,"byYear":{"2012":59,"2013":59,"2014":69,"2015":86,"2016":71,"2017":83,"2018":74,"2019":83,"2020":70,"2021":70,"2022":51,"2023":90,"2024":64,"2025":76,"2026":51},"year":2003,"title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy"},"paper-destiny-breast03-nejm-2022":{"doi":"10.1056/nejmoa2115022","openalexId":"W4220964921","cited":1201,"byYear":{"2022":144,"2023":306,"2024":293,"2025":266,"2026":192},"year":2022,"title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer"},"paper-iacobuzio-donahue-dpc4-failure-pattern-autopsy-jco-2009":{"doi":"10.1200/jco.2008.17.7188","openalexId":"W2118797060","cited":1094,"byYear":{"2012":59,"2013":71,"2014":90,"2015":88,"2016":81,"2017":103,"2018":74,"2019":69,"2020":72,"2021":87,"2022":61,"2023":62,"2024":51,"2025":35,"2026":25},"year":2009,"title":"DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer"},"paper-destiny-pantumor02-jco-2024":{"doi":"10.1200/jco.23.02005","openalexId":"W4387865238","cited":1064,"byYear":{"2021":1,"2023":12,"2024":228,"2025":463,"2026":359},"year":2023,"title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial"},"paper-destiny-lung01-nejm-2022":{"doi":"10.1056/nejmoa2112431","openalexId":"W3201219318","cited":1036,"byYear":{"2021":13,"2022":149,"2023":227,"2024":241,"2025":231,"2026":174},"year":2021,"title":"Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer"},"paper-spencer-science":{"doi":"10.1126/science.aaz7015","openalexId":"W4200001874","cited":966,"byYear":{"2022":142,"2023":219,"2024":177,"2025":221,"2026":207},"year":2021,"title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response"},"paper-sahm-meningioma-methylation-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30155-9","openalexId":"W2598133926","cited":879,"byYear":{"2013":2,"2017":18,"2018":63,"2019":66,"2020":111,"2021":102,"2022":105,"2023":121,"2024":132,"2025":86,"2026":71},"year":2017,"title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis"},"paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014":{"doi":"10.1093/annonc/mdu275","openalexId":"W2113029107","cited":680,"byYear":{"2014":1,"2015":19,"2016":31,"2017":61,"2018":59,"2019":88,"2020":97,"2021":71,"2022":71,"2023":52,"2024":55,"2025":44,"2026":30},"year":2014,"title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features"},"paper-detect-a-science-2020":{"doi":"10.1126/science.abb9601","openalexId":"W3020301997","cited":680,"byYear":{"2020":45,"2021":114,"2022":126,"2023":107,"2024":104,"2025":115,"2026":68},"year":2020,"title":"Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention"},"paper-goodnow-nat-rev-drug-discov":{"doi":"10.1038/nrd.2016.213","openalexId":"W2560677837","cited":633,"byYear":{"2017":36,"2018":51,"2019":73,"2020":97,"2021":91,"2022":75,"2023":54,"2024":55,"2025":57,"2026":44},"year":2016,"title":"DNA-encoded chemistry: enabling the deeper sampling of chemical space"},"paper-loree-jama-oncol":{"doi":"10.1001/jamaoncol.2019.1870","openalexId":"W2969031691","cited":581,"byYear":{"2020":31,"2021":104,"2022":123,"2023":109,"2024":91,"2025":67,"2026":55},"year":2019,"title":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018"},"paper-dunleavy-da-epoch-r-pmbcl-nejm-2013":{"doi":"10.1056/nejmoa1214561","openalexId":"W2001196047","cited":569,"byYear":{"2012":4,"2013":16,"2014":42,"2015":50,"2016":56,"2017":49,"2018":43,"2019":53,"2020":52,"2021":57,"2022":28,"2023":40,"2024":24,"2025":35,"2026":18},"year":2013,"title":"Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma"},"paper-dreamseq-jco-2023":{"doi":"10.1200/jco.22.01763","openalexId":"W4297339120","cited":474,"byYear":{"2022":6,"2023":101,"2024":153,"2025":126,"2026":88},"year":2022,"title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134"},"paper-destiny-breast06-nejm-2024":{"doi":"10.1056/nejmoa2407086","openalexId":"W4402548585","cited":469,"byYear":{"2022":1,"2024":17,"2025":241,"2026":210},"year":2024,"title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer"},"paper-henricks-lancet-oncol":{"doi":"10.1016/s1470-2045(18)30686-7","openalexId":"W2896913847","cited":446,"byYear":{"2013":1,"2018":6,"2019":39,"2020":46,"2021":58,"2022":46,"2023":60,"2024":84,"2025":61,"2026":42},"year":2018,"title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis"},"paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022":{"doi":"10.1016/j.jtho.2021.10.013","openalexId":"W3136351248","cited":398,"byYear":{"2021":4,"2022":58,"2023":89,"2024":98,"2025":85,"2026":64},"year":2021,"title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status"},"paper-petersenn-nat-rev-endocrinol":{"doi":"10.1038/s41574-023-00886-5","openalexId":"W4386449135","cited":390,"byYear":{"2023":7,"2024":123,"2025":138,"2026":120},"year":2023,"title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement"},"paper-schultz-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-17-3089","openalexId":"W2792841925","cited":379,"byYear":{"2018":8,"2019":34,"2020":44,"2021":68,"2022":60,"2023":44,"2024":42,"2025":53,"2026":25},"year":2018,"title":"DICER1 and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies"},"paper-psma-prerp-hope-jama-oncol-2021":{"doi":"10.1001/jamaoncol.2021.3771","openalexId":"W3200874340","cited":361,"byYear":{"2021":8,"2022":54,"2023":68,"2024":108,"2025":80,"2026":43},"year":2021,"title":"Diagnostic Accuracy of 68 Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection"},"paper-destiny-lung02-goto-jco-2023":{"doi":"10.1200/jco.23.01361","openalexId":"W4386592635","cited":327,"byYear":{"2023":9,"2024":89,"2025":130,"2026":97},"year":2023,"title":"Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial"},"paper-johnson-mpmri-individual-foci-eur-urol-2019":{"doi":"10.1016/j.eururo.2018.11.031","openalexId":"W2902806174","cited":308,"byYear":{"2018":1,"2019":25,"2020":37,"2021":40,"2022":40,"2023":52,"2024":49,"2025":49,"2026":15},"year":2018,"title":"Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging"},"paper-dudley-cancer-discov":{"doi":"10.1158/2159-8290.cd-18-0825","openalexId":"W2906216049","cited":256,"byYear":{"2019":18,"2020":26,"2021":41,"2022":29,"2023":49,"2024":29,"2025":28,"2026":34},"year":2018,"title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA"},"paper-ambrosone-j-clin-oncol":{"doi":"10.1200/jco.19.01203","openalexId":"W2995817903","cited":251,"byYear":{"2020":19,"2021":48,"2022":35,"2023":49,"2024":35,"2025":34,"2026":29},"year":2019,"title":"Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)"},"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019":{"doi":"10.1158/1078-0432.ccr-19-0160","openalexId":"W2940163088","cited":236,"byYear":{"2019":4,"2020":31,"2021":49,"2022":32,"2023":44,"2024":33,"2025":28,"2026":14},"year":2019,"title":"Detection of NRG1 Gene Fusions in Solid Tumors"},"paper-kellogg-bioconjug-chem":{"doi":"10.1021/bc100480a","openalexId":"W1995431674","cited":221,"byYear":{"2012":18,"2013":14,"2014":16,"2015":26,"2016":17,"2017":11,"2018":23,"2019":19,"2020":12,"2021":14,"2022":7,"2023":12,"2024":11,"2025":9,"2026":8},"year":2011,"title":"Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage"},"paper-stoeck-notch-rearrangements-tnbc-cancer-discov-2014":{"doi":"10.1158/2159-8290.cd-13-0830","openalexId":"W2099835784","cited":155,"byYear":{"2014":3,"2015":8,"2016":20,"2017":14,"2018":19,"2019":12,"2020":12,"2021":16,"2022":17,"2023":12,"2024":14,"2025":5,"2026":3},"year":2014,"title":"Discovery of Biomarkers Predictive of GSI Response in Triple-Negative Breast Cancer and Adenoid Cystic Carcinoma"},"paper-berchuck-cfdna-methylation-nepc-detection-ccr-2022":{"doi":"10.1158/1078-0432.ccr-21-3762","openalexId":"W4200169768","cited":67,"byYear":{"2022":14,"2023":12,"2024":16,"2025":16,"2026":9},"year":2021,"title":"Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis"},"paper-stopsack-prostate-genomes-by-race-ccr-2022":{"doi":"10.1158/1078-0432.ccr-21-2577","openalexId":"W3207297220","cited":58,"byYear":{"2022":12,"2023":16,"2024":11,"2025":11,"2026":8},"year":2021,"title":"Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors"},"paper-hiraoka-her2-status-biliary-hum-pathol-2020":{"doi":"10.1016/j.humpath.2020.08.006","openalexId":"W3083261511","cited":49,"byYear":{"2020":1,"2021":2,"2022":3,"2023":8,"2024":11,"2025":14,"2026":10},"year":2020,"title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer"},"paper-philip-j-clin-oncol":{"doi":"10.1200/jco.23.02659","openalexId":"W4401209010","cited":46,"byYear":{"2024":3,"2025":22,"2026":21},"year":2024,"title":"Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study"},"paper-yu-ctdna-early-recurrence-biliary-tract-cancer-jco-po-2025":{"doi":"10.1200/po-24-00443","openalexId":"W4406119935","cited":16,"byYear":{"2025":6,"2026":10},"year":2025,"title":"Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection"},"paper-laktionov-prolgolimab-domajor-ejc-2025":{"doi":"10.1016/j.ejca.2025.115255","openalexId":"W4406642307","cited":9,"byYear":{"2026":9},"year":2025,"title":"Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer"},"paper-santosh-kesari-nat-commun-2026":{"doi":"10.1038/s41467-025-67783-5","openalexId":"W7119184058","cited":9,"byYear":{"2026":9},"year":2026,"title":"Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populations"},"paper-dhebri-pancreatoblastoma-diagnosis-treatment-outcome-pancreatology-2004":{"doi":"10.1159/000079823","openalexId":"W2112508808","cited":121,"byYear":{"2012":9,"2013":7,"2014":1,"2015":4,"2016":6,"2017":10,"2018":3,"2019":2,"2020":6,"2021":7,"2022":13,"2023":3,"2024":7,"2025":6,"2026":2},"year":2004,"title":"Diagnosis, treatment and outcome of pancreatoblastoma"},"paper-nxc-201-hbi0101-asherie-haematologica-2023":{"doi":"10.3324/haematol.2022.281628","openalexId":"W4302287875","cited":32,"byYear":{"2023":6,"2024":14,"2025":6,"2026":6},"year":2022,"title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial"},"paper-nct03851640-signal-transduct-target-ther-2026":{"doi":"10.1038/s41392-026-02618-3","openalexId":"W7153779193","cited":1,"byYear":{"2026":1},"year":2026,"title":"Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial"},"paper-nct05955391-j-thorac-oncol-2026":{"doi":"10.1016/j.jtho.2026.103737","openalexId":"W7155201259","cited":0,"byYear":{},"year":2026,"title":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial"},"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019":{"doi":"10.1016/s0140-6736(19)32222-6","openalexId":"W2977392388","cited":2318,"byYear":{"2019":4,"2020":213,"2021":348,"2022":340,"2023":367,"2024":383,"2025":380,"2026":277},"year":2019,"title":"Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial"},"paper-olivier-chinot-nat-rev-clin-oncol-2021":{"doi":"10.1038/s41571-020-00447-z","openalexId":"W3110787789","cited":2078,"byYear":{"2021":137,"2022":317,"2023":401,"2024":470,"2025":386,"2026":359},"year":2020,"title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood"},"paper-hangauer-nature":{"doi":"10.1038/nature24297","openalexId":"W2767055857","cited":1845,"byYear":{"2012":1,"2014":1,"2015":1,"2016":3,"2017":6,"2018":57,"2019":102,"2020":170,"2021":196,"2022":234,"2023":276,"2024":290,"2025":294,"2026":212},"year":2017,"title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition"},"paper-mccollough-radiology":{"doi":"10.1148/radiol.2015142631","openalexId":"W1926920987","cited":1607,"byYear":{"2012":1,"2015":3,"2016":34,"2017":91,"2018":148,"2019":149,"2020":160,"2021":178,"2022":174,"2023":181,"2024":171,"2025":187,"2026":126},"year":2015,"title":"Dual- and Multi-Energy CT: Principles, Technical Approaches, and Clinical Applications"},"paper-reardon-jama-oncol":{"doi":"10.1001/jamaoncol.2020.1024","openalexId":"W3026551532","cited":1562,"byYear":{"2012":1,"2020":57,"2021":224,"2022":250,"2023":285,"2024":316,"2025":233,"2026":195},"year":2020,"title":"Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma"},"paper-rothwell-lancet":{"doi":"10.1016/s0140-6736(10)62110-1","openalexId":"W2151036184","cited":1509,"byYear":{"2012":162,"2013":144,"2014":127,"2015":124,"2016":119,"2017":108,"2018":101,"2019":101,"2020":83,"2021":85,"2022":58,"2023":61,"2024":45,"2025":39,"2026":31},"year":2010,"title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials"},"paper-ivosidenib-idh1-dinardo-nejm-2018":{"doi":"10.1056/nejmoa1716984","openalexId":"W2806682325","cited":1471,"byYear":{"2016":1,"2017":1,"2018":50,"2019":178,"2020":237,"2021":252,"2022":211,"2023":156,"2024":141,"2025":140,"2026":103},"year":2018,"title":"Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML"},"paper-ridker-lancet":{"doi":"10.1016/s0140-6736(17)32247-x","openalexId":"W2750254726","cited":1363,"byYear":{"2017":30,"2018":146,"2019":158,"2020":170,"2021":141,"2022":144,"2023":153,"2024":178,"2025":125,"2026":117},"year":2017,"title":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial"},"paper-crosby-science":{"doi":"10.1126/science.aay9040","openalexId":"W4220903131","cited":1355,"byYear":{"2022":44,"2023":207,"2024":360,"2025":470,"2026":274},"year":2022,"title":"Early detection of cancer"},"paper-ogitani-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-15-2822","openalexId":"W2314772071","cited":1193,"byYear":{"2016":2,"2017":21,"2018":18,"2019":50,"2020":75,"2021":126,"2022":130,"2023":184,"2024":218,"2025":192,"2026":175},"year":2016,"title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1"},"paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018":{"doi":"10.1056/nejmoa1713709","openalexId":"W2795004907","cited":1157,"byYear":{"2018":31,"2019":105,"2020":193,"2021":214,"2022":134,"2023":133,"2024":150,"2025":103,"2026":87},"year":2018,"title":"Duration of Adjuvant Chemotherapy for Stage III Colon Cancer"},"paper-dynamic-nejm-2022":{"doi":"10.1056/nejmoa2200075","openalexId":"W4281738617","cited":1089,"byYear":{"2021":1,"2022":94,"2023":234,"2024":268,"2025":249,"2026":243},"year":2022,"title":"Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer"},"paper-chua-j-clin-oncol":{"doi":"10.1200/jco.2011.39.7166","openalexId":"W2097198751","cited":1076,"byYear":{"2012":9,"2013":56,"2014":57,"2015":76,"2016":85,"2017":90,"2018":75,"2019":97,"2020":80,"2021":89,"2022":79,"2023":80,"2024":79,"2025":65,"2026":53},"year":2012,"title":"Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy"},"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(16)00150-9","openalexId":"W2336815607","cited":1032,"byYear":{"2013":1,"2016":28,"2017":76,"2018":100,"2019":110,"2020":119,"2021":106,"2022":127,"2023":116,"2024":109,"2025":79,"2026":59},"year":2016,"title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial"},"paper-esmo-early-breast-cancer-guideline-ann-oncol-2024":{"doi":"10.1016/j.annonc.2023.11.016","openalexId":"W4389681263","cited":1003,"byYear":{"2022":2,"2023":3,"2024":173,"2025":436,"2026":389},"year":2023,"title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-dang-nat-rev-cancer":{"doi":"10.1038/nrc.2017.36","openalexId":"W2692768525","cited":947,"byYear":{"2017":10,"2018":58,"2019":67,"2020":118,"2021":125,"2022":139,"2023":114,"2024":125,"2025":113,"2026":78},"year":2017,"title":"Drugging the 'undruggable' cancer targets"},"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017":{"doi":"10.1001/jama.2017.7105","openalexId":"W2712978371","cited":918,"byYear":{"2016":1,"2017":16,"2018":83,"2019":106,"2020":123,"2021":120,"2022":118,"2023":109,"2024":98,"2025":77,"2026":64},"year":2017,"title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer"},"paper-e3a06-lenalidomide-smouldering-lonial-jco-2020":{"doi":"10.1200/jco.19.01740","openalexId":"W2981617674","cited":912,"byYear":{"2012":10,"2013":5,"2014":12,"2015":3,"2016":18,"2017":79,"2018":63,"2019":157,"2020":47,"2021":45,"2022":60,"2023":38,"2024":52,"2025":44,"2026":39},"year":2019,"title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma"},"paper-laird-br-j-cancer":{"doi":"10.1038/bjc.1964.55","openalexId":"W2081084899","cited":876,"byYear":{"2012":27,"2013":33,"2014":43,"2015":34,"2016":39,"2017":40,"2018":34,"2019":35,"2020":66,"2021":28,"2022":39,"2023":26,"2024":30,"2025":30,"2026":20},"year":1964,"title":"Dynamics of Tumor Growth"},"paper-michor-nature":{"doi":"10.1038/nature03669","openalexId":"W2154856176","cited":856,"byYear":{"2012":51,"2013":52,"2014":48,"2015":47,"2016":34,"2017":33,"2018":33,"2019":34,"2020":39,"2021":18,"2022":18,"2023":25,"2024":17,"2025":15,"2026":6},"year":2005,"title":"Dynamics of chronic myeloid leukaemia"},"paper-mcneil-n-engl-j-med":{"doi":"10.1056/nejmoa1803955","openalexId":"W2889884522","cited":828,"byYear":{"2018":29,"2019":126,"2020":134,"2021":146,"2022":97,"2023":99,"2024":77,"2025":80,"2026":39},"year":2018,"title":"Effect of Aspirin on All-Cause Mortality in the Healthy Elderly"},"paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.1588","openalexId":"W2959096163","cited":803,"byYear":{"2019":3,"2020":62,"2021":124,"2022":120,"2023":110,"2024":179,"2025":113,"2026":92},"year":2019,"title":"Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma"},"paper-echelon-1-brentuximab-avd-nejm-2018":{"doi":"10.1056/nejmoa1708984","openalexId":"W2775803967","cited":792,"byYear":{"2016":1,"2017":4,"2018":84,"2019":96,"2020":127,"2021":95,"2022":83,"2023":83,"2024":85,"2025":66,"2026":65},"year":2017,"title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma"},"paper-eano-meningioma-goldbrunner-neuro-oncology-2021":{"doi":"10.1093/neuonc/noab150","openalexId":"W3174532670","cited":769,"byYear":{"2021":10,"2022":110,"2023":146,"2024":196,"2025":170,"2026":134},"year":2021,"title":"EANO guideline on the diagnosis and management of meningiomas"},"paper-i-spy-2-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2019.6650","openalexId":"W3005738019","cited":724,"byYear":{"2020":52,"2021":135,"2022":111,"2023":139,"2024":121,"2025":103,"2026":63},"year":2020,"title":"Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer"},"paper-caspian-lancet-oncol-2021-update":{"doi":"10.1016/s1470-2045(20)30539-8","openalexId":"W3110002524","cited":709,"byYear":{"2020":2,"2021":66,"2022":135,"2023":149,"2024":170,"2025":131,"2026":54},"year":2020,"title":"Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial"},"paper-van-waart-j-clin-oncol":{"doi":"10.1200/jco.2014.59.1081","openalexId":"W2156420703","cited":670,"byYear":{"2014":1,"2015":8,"2016":34,"2017":56,"2018":49,"2019":59,"2020":67,"2021":83,"2022":69,"2023":83,"2024":92,"2025":44,"2026":25},"year":2015,"title":"Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial"},"paper-nct02453282-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2020.0237","openalexId":"W3016210953","cited":641,"byYear":{"2013":1,"2019":1,"2020":47,"2021":129,"2022":131,"2023":140,"2024":95,"2025":69,"2026":28},"year":2020,"title":"Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer"},"paper-alter-0303-jama-oncol-2018":{"doi":"10.1001/jamaoncol.2018.3039","openalexId":"W2885503610","cited":634,"byYear":{"2018":2,"2019":33,"2020":62,"2021":101,"2022":121,"2023":92,"2024":95,"2025":80,"2026":48},"year":2018,"title":"Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer"},"paper-rustin-lancet":{"doi":"10.1016/s0140-6736(10)61268-8","openalexId":"W2125498283","cited":603,"byYear":{"2012":54,"2013":40,"2014":40,"2015":38,"2016":46,"2017":46,"2018":25,"2019":36,"2020":50,"2021":34,"2022":30,"2023":22,"2024":28,"2025":41,"2026":19},"year":2010,"title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial"},"paper-neoptolemos-jama":{"doi":"10.1001/jama.2012.7352","openalexId":"W2000085538","cited":600,"byYear":{"2012":5,"2013":25,"2014":31,"2015":39,"2016":41,"2017":45,"2018":53,"2019":51,"2020":57,"2021":56,"2022":48,"2023":47,"2024":42,"2025":32,"2026":26},"year":2012,"title":"Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma"},"paper-molenaar-jama-surg":{"doi":"10.1001/jamasurg.2023.0198","openalexId":"W4361293588","cited":504,"byYear":{"2023":35,"2024":143,"2025":179,"2026":147},"year":2023,"title":"Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery"},"paper-astrum-005-jama-2022":{"doi":"10.1001/jama.2022.16464","openalexId":"W4297251744","cited":500,"byYear":{"2022":6,"2023":83,"2024":155,"2025":156,"2026":98},"year":2022,"title":"Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer"},"paper-primrose-jama":{"doi":"10.1001/jama.2013.285718","openalexId":"W2099998407","cited":482,"byYear":{"2014":25,"2015":51,"2016":39,"2017":39,"2018":26,"2019":41,"2020":58,"2021":40,"2022":44,"2023":60,"2024":18,"2025":23,"2026":14},"year":2014,"title":"Effect of 3 to 5 Years of Scheduled CEA and CT Follow-up to Detect Recurrence of Colorectal Cancer"},"paper-e3311-transoral-surgery-ferris-jco-2022":{"doi":"10.1200/jco.21.01752","openalexId":"W3210105851","cited":469,"byYear":{"2017":1,"2019":1,"2020":3,"2021":9,"2022":72,"2023":76,"2024":101,"2025":126,"2026":80},"year":2021,"title":"Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)"},"paper-basch-jama":{"doi":"10.1001/jama.2022.9265","openalexId":"W4281790169","cited":429,"byYear":{"2022":11,"2023":80,"2024":112,"2025":116,"2026":110},"year":2022,"title":"Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer"},"paper-duo-e-jco-2023":{"doi":"10.1200/jco.23.02132","openalexId":"W4387840851","cited":376,"byYear":{"2023":2,"2024":77,"2025":177,"2026":120},"year":2023,"title":"Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial"},"paper-topaz-1-lancet-gastroenterol-hepatol-2024-update":{"doi":"10.1016/s2468-1253(24)00095-5","openalexId":"W4399119041","cited":301,"byYear":{"2024":22,"2025":146,"2026":133},"year":2024,"title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study"},"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024":{"doi":"10.1056/nejmoa2312948","openalexId":"W4400940914","cited":272,"byYear":{"2024":24,"2025":132,"2026":116},"year":2024,"title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults"},"paper-goodwin-jama":{"doi":"10.1001/jama.2022.6147","openalexId":"W4282916913","cited":245,"byYear":{"2022":24,"2023":52,"2024":60,"2025":65,"2026":44},"year":2022,"title":"Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer"},"paper-qian-lancet-oncol":{"doi":"10.1016/s1470-2045(21)00546-5","openalexId":"W3214061521","cited":215,"byYear":{"2021":1,"2022":25,"2023":40,"2024":55,"2025":45,"2026":49},"year":2021,"title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study"},"paper-eau-asco-penile-cancer-guideline-eur-urol-2023":{"doi":"10.1016/j.eururo.2023.02.027","openalexId":"W4323655145","cited":189,"byYear":{"2023":20,"2024":54,"2025":70,"2026":45},"year":2023,"title":"European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update"},"paper-ng-jama":{"doi":"10.1001/jama.2019.2402","openalexId":"W2937486128","cited":188,"byYear":{"2018":1,"2019":21,"2020":35,"2021":34,"2022":23,"2023":25,"2024":22,"2025":14,"2026":13},"year":2019,"title":"Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer"},"paper-mcneil-j-natl-cancer-inst":{"doi":"10.1093/jnci/djaa114","openalexId":"W3048728071","cited":153,"byYear":{"2020":6,"2021":26,"2022":33,"2023":23,"2024":18,"2025":24,"2026":23},"year":2020,"title":"Effect of Aspirin on Cancer Incidence and Mortality in Older Adults"},"paper-topaz-1-three-year-survival-j-hepatol-2025":{"doi":"10.1016/j.jhep.2025.05.003","openalexId":"W4410384052","cited":89,"byYear":{"2025":23,"2026":66},"year":2025,"title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study"},"paper-nct03157128-j-clin-oncol-2024-update":{"doi":"10.1200/jco.23.02503","openalexId":"W4401244655","cited":56,"byYear":{"2023":1,"2024":4,"2025":20,"2026":31},"year":2024,"title":"Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001"},"paper-nct05724563-nat-commun-2025":{"doi":"10.1038/s41467-025-60757-7","openalexId":"W4411846824","cited":12,"byYear":{"2025":2,"2026":10},"year":2025,"title":"Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial"},"paper-nct03003962-j-thorac-oncol-2025":{"doi":"10.1016/j.jtho.2024.10.024","openalexId":"W4404135209","cited":11,"byYear":{"2025":4,"2026":7},"year":2024,"title":"Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study"},"paper-nct03775486-j-thorac-oncol-2023":{"doi":"10.1016/j.jtho.2023.06.013","openalexId":"W4382364398","cited":11,"byYear":{"2023":1,"2024":4,"2025":5,"2026":1},"year":2023,"title":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study"},"paper-powderly-fenbendazole-ivermectin-liver-injury-2026":{"doi":"10.7759/cureus.108896","openalexId":"W7161245064","cited":0,"byYear":{},"year":2026,"title":"Drug-Induced Liver Injury Following Co-ingestion of Veterinary Fenbendazole and Ivermectin for Prostate Cancer: A Case Report"},"paper-paez-egfr-mutations-gefitinib-science-2004":{"doi":"10.1126/science.1099314","openalexId":"W2161821474","cited":9462,"byYear":{"2012":549,"2013":576,"2014":570,"2015":565,"2016":513,"2017":492,"2018":435,"2019":335,"2020":332,"2021":308,"2022":301,"2023":237,"2024":188,"2025":161,"2026":100},"year":2004,"title":"EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy"},"paper-demetri-imatinib-gist-nejm-2002":{"doi":"10.1056/nejmoa020461","openalexId":"W2015015957","cited":4419,"byYear":{"2012":256,"2013":211,"2014":190,"2015":181,"2016":161,"2017":136,"2018":131,"2019":120,"2020":137,"2021":130,"2022":122,"2023":118,"2024":120,"2025":90,"2026":67},"year":2002,"title":"Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors"},"paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005":{"doi":"10.1056/nejmoa044238","openalexId":"W2003984225","cited":3987,"byYear":{"2012":212,"2013":241,"2014":230,"2015":258,"2016":248,"2017":247,"2018":244,"2019":196,"2020":201,"2021":197,"2022":162,"2023":155,"2024":105,"2025":87,"2026":83},"year":2005,"title":"EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib"},"paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996":{"doi":"10.1056/nejm199605023341802","openalexId":"W2317242858","cited":3664,"byYear":{"2012":143,"2013":123,"2014":133,"2015":109,"2016":84,"2017":90,"2018":74,"2019":70,"2020":88,"2021":65,"2022":79,"2023":62,"2024":54,"2025":53,"2026":48},"year":1996,"title":"Effects of a Combination of Beta Carotene and Vitamin A on Lung Cancer and Cardiovascular Disease"},"paper-stupp-jama":{"doi":"10.1001/jama.2017.18718","openalexId":"W2778283729","cited":2711,"byYear":{"2016":1,"2018":91,"2019":171,"2020":260,"2021":334,"2022":377,"2023":391,"2024":430,"2025":371,"2026":277},"year":2017,"title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma"},"paper-neosphere-lancet-oncol-2012":{"doi":"10.1016/s1470-2045(11)70336-9","openalexId":"W2123591186","cited":2404,"byYear":{"2012":92,"2013":167,"2014":172,"2015":170,"2016":158,"2017":170,"2018":142,"2019":141,"2020":153,"2021":184,"2022":183,"2023":199,"2024":190,"2025":159,"2026":114},"year":2011,"title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial"},"paper-egfr-gastric-eur-j-cancer-2001":{"doi":"10.1016/s0959-8049(01)00231-3","openalexId":"W2051120695","cited":2166,"byYear":{"2012":109,"2013":106,"2014":103,"2015":99,"2016":85,"2017":89,"2018":92,"2019":60,"2020":83,"2021":92,"2022":128,"2023":98,"2024":67,"2025":56,"2026":34},"year":2001,"title":"EGFR and cancer prognosis"},"paper-quintana-nature":{"doi":"10.1038/nature07567","openalexId":"W2104666893","cited":1799,"byYear":{"2012":203,"2013":175,"2014":146,"2015":82,"2016":99,"2017":97,"2018":67,"2019":69,"2020":58,"2021":56,"2022":44,"2023":49,"2024":30,"2025":33,"2026":6},"year":2008,"title":"Efficient tumour formation by single human melanoma cells"},"paper-patricia-paavonen-lancet-2009":{"doi":"10.1016/s0140-6736(09)61248-4","openalexId":"W2136236728","cited":1668,"byYear":{"2012":186,"2013":151,"2014":158,"2015":132,"2016":96,"2017":100,"2018":58,"2019":73,"2020":72,"2021":57,"2022":66,"2023":46,"2024":38,"2025":42,"2026":26},"year":2009,"title":"Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women"},"paper-avsec-z-nat-methods":{"doi":"10.1038/s41592-021-01252-x","openalexId":"W3203588026","cited":1427,"byYear":{"2018":1,"2020":1,"2021":24,"2022":117,"2023":247,"2024":324,"2025":353,"2026":359},"year":2021,"title":"Effective gene expression prediction from sequence by integrating long-range interactions"},"paper-nivolumab-hcc-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2020.4564","openalexId":"W3090413519","cited":1280,"byYear":{"2013":1,"2020":8,"2021":215,"2022":274,"2023":230,"2024":269,"2025":191,"2026":91},"year":2020,"title":"Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib"},"paper-keynote-158-j-clin-oncol-2019":{"doi":"10.1200/jco.18.01265","openalexId":"W2925815206","cited":1088,"byYear":{"2019":32,"2020":138,"2021":163,"2022":182,"2023":178,"2024":166,"2025":133,"2026":94},"year":2019,"title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study"},"paper-sankaranarayanan-oral-screening-lancet-2005":{"doi":"10.1016/s0140-6736(05)66658-5","openalexId":"W2109042771","cited":853,"byYear":{"2012":32,"2013":32,"2014":40,"2015":42,"2016":52,"2017":26,"2018":54,"2019":55,"2020":62,"2021":56,"2022":50,"2023":59,"2024":53,"2025":54,"2026":40},"year":2005,"title":"Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial"},"paper-sjostrom-lancet-oncol":{"doi":"10.1016/s1470-2045(09)70159-7","openalexId":"W2088828925","cited":769,"byYear":{"2012":41,"2013":78,"2014":52,"2015":59,"2016":54,"2017":57,"2018":54,"2019":44,"2020":46,"2021":33,"2022":53,"2023":44,"2024":27,"2025":23,"2026":17},"year":2009,"title":"Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial"},"paper-boeve-eur-urol":{"doi":"10.1016/j.eururo.2018.09.008","openalexId":"W2894350218","cited":580,"byYear":{"2017":1,"2018":12,"2019":60,"2020":80,"2021":87,"2022":88,"2023":74,"2024":82,"2025":65,"2026":29},"year":2018,"title":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial"},"paper-jun-gastroenterology":{"doi":"10.1053/j.gastro.2017.01.029","openalexId":"W2582922499","cited":579,"byYear":{"2017":11,"2018":26,"2019":34,"2020":63,"2021":69,"2022":84,"2023":65,"2024":99,"2025":72,"2026":55},"year":2017,"title":"Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality"},"paper-sankaranarayanan-lancet":{"doi":"10.1016/s0140-6736(07)61195-7","openalexId":"W2150236424","cited":545,"byYear":{"2012":41,"2013":34,"2014":46,"2015":55,"2016":35,"2017":24,"2018":21,"2019":33,"2020":20,"2021":17,"2022":23,"2023":18,"2024":24,"2025":8,"2026":7},"year":2007,"title":"Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial"},"paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016":{"doi":"10.1056/nejmoa1513098","openalexId":"W2472403803","cited":489,"byYear":{"2014":1,"2015":1,"2016":9,"2017":55,"2018":47,"2019":65,"2020":49,"2021":52,"2022":59,"2023":58,"2024":33,"2025":33,"2026":22},"year":2016,"title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis"},"paper-arbour-kras-co-mutation-outcomes-ccr-2018":{"doi":"10.1158/1078-0432.ccr-17-1841","openalexId":"W2767162493","cited":478,"byYear":{"2016":1,"2017":2,"2018":13,"2019":27,"2020":57,"2021":75,"2022":64,"2023":88,"2024":53,"2025":59,"2026":39},"year":2017,"title":"Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer"},"paper-mathijssen-j-natl-cancer-inst":{"doi":"10.1093/jnci/94.16.1247","openalexId":"W2138020718","cited":454,"byYear":{"2012":25,"2013":27,"2014":15,"2015":9,"2016":13,"2017":13,"2018":6,"2019":13,"2020":14,"2021":13,"2022":8,"2023":11,"2024":5,"2025":7,"2026":8},"year":2002,"title":"Effects of St. John's Wort on Irinotecan Metabolism"},"paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017":{"doi":"10.1200/jco.2016.70.8297","openalexId":"W2595349270","cited":421,"byYear":{"2017":17,"2018":28,"2019":43,"2020":32,"2021":49,"2022":66,"2023":52,"2024":64,"2025":34,"2026":36},"year":2017,"title":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer"},"paper-orient-11-j-thorac-oncol-2020":{"doi":"10.1016/j.jtho.2020.07.014","openalexId":"W3047859155","cited":403,"byYear":{"2020":5,"2021":60,"2022":92,"2023":89,"2024":66,"2025":59,"2026":32},"year":2020,"title":"Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)"},"paper-diamond-nature":{"doi":"10.1038/s41586-019-1012-y","openalexId":"W2921153272","cited":396,"byYear":{"2019":22,"2020":53,"2021":44,"2022":58,"2023":51,"2024":69,"2025":67,"2026":30},"year":2019,"title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms"},"paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023":{"doi":"10.1200/jco.22.01900","openalexId":"W4318580181","cited":395,"byYear":{"2021":1,"2022":3,"2023":72,"2024":116,"2025":119,"2026":84},"year":2023,"title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study"},"paper-florence-duffaud-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(18)30742-3","openalexId":"W2901259053","cited":330,"byYear":{"2018":1,"2019":24,"2020":52,"2021":62,"2022":41,"2023":56,"2024":38,"2025":34,"2026":22},"year":2018,"title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study"},"paper-dll3-sclc-clin-cancer-res-2019":{"doi":"10.1158/1078-0432.ccr-19-1133","openalexId":"W2973098277","cited":330,"byYear":{"2018":3,"2019":10,"2020":57,"2021":61,"2022":49,"2023":51,"2024":38,"2025":38,"2026":23},"year":2019,"title":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study"},"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019":{"doi":"10.2967/jnumed.118.217463","openalexId":"W2895476867","cited":298,"byYear":{"2018":1,"2019":16,"2020":35,"2021":44,"2022":53,"2023":36,"2024":47,"2025":38,"2026":27},"year":2018,"title":"Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma"},"paper-shastri-j-natl-cancer-inst":{"doi":"10.1093/jnci/dju009","openalexId":"W2155931571","cited":245,"byYear":{"2013":1,"2014":18,"2015":24,"2016":23,"2017":19,"2018":17,"2019":28,"2020":11,"2021":27,"2022":22,"2023":17,"2024":14,"2025":16,"2026":8},"year":2014,"title":"Effect of VIA Screening by Primary Health Workers: Randomized Controlled Study in Mumbai, India"},"paper-crown-lancet-respir-med-2023-update":{"doi":"10.1016/s2213-2600(22)00437-4","openalexId":"W4311691578","cited":236,"byYear":{"2022":1,"2023":37,"2024":93,"2025":68,"2026":36},"year":2022,"title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study"},"paper-barnabas-nejm-evid":{"doi":"10.1056/evidoa2100056","openalexId":"W4223574449","cited":222,"byYear":{"2021":1,"2022":18,"2023":52,"2024":57,"2025":50,"2026":44},"year":2022,"title":"Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women"},"paper-cd19-dlbcl-am-j-hematol-2021":{"doi":"10.1002/ajh.26301","openalexId":"W3185183014","cited":205,"byYear":{"2021":3,"2022":42,"2023":58,"2024":49,"2025":33,"2026":20},"year":2021,"title":"Efficacy and safety of CD19 ‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET , ZUMA ‐1, and TRANSCEND trials"},"paper-hanai-j-natl-cancer-inst":{"doi":"10.1093/jnci/djx178","openalexId":"W2761996700","cited":138,"byYear":{"2013":1,"2017":2,"2018":3,"2019":16,"2020":24,"2021":17,"2022":25,"2023":16,"2024":10,"2025":17,"2026":7},"year":2017,"title":"Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial"},"paper-hoskin-jama":{"doi":"10.1001/jama.2019.17913","openalexId":"W2993942484","cited":121,"byYear":{"2020":24,"2021":15,"2022":14,"2023":19,"2024":23,"2025":16,"2026":10},"year":2019,"title":"Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer"},"paper-badwe-j-clin-oncol":{"doi":"10.1200/jco.22.01966","openalexId":"W4362677546","cited":111,"byYear":{"2023":18,"2024":38,"2025":33,"2026":22},"year":2023,"title":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer"},"paper-imforte-lancet-2025":{"doi":"10.1016/s0140-6736(25)01011-6","openalexId":"W4410947809","cited":100,"byYear":{"2025":29,"2026":71},"year":2025,"title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial"},"paper-xm22-03-bondarenko-bmc-cancer-2013":{"doi":"10.1186/1471-2407-13-386","openalexId":"W1995429954","cited":93,"byYear":{"2013":1,"2014":7,"2015":15,"2016":12,"2017":8,"2018":9,"2019":7,"2020":4,"2021":7,"2022":6,"2023":6,"2024":3,"2025":5,"2026":3},"year":2013,"title":"Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy"},"paper-pellacani-jama-dermatol":{"doi":"10.1001/jamadermatol.2022.1570","openalexId":"W4281854311","cited":90,"byYear":{"2022":8,"2023":19,"2024":18,"2025":24,"2026":21},"year":2022,"title":"Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma"},"paper-garcia-jama-netw-open":{"doi":"10.1001/jamanetworkopen.2019.16910","openalexId":"W2993843714","cited":80,"byYear":{"2019":1,"2020":8,"2021":11,"2022":12,"2023":13,"2024":13,"2025":13,"2026":9},"year":2019,"title":"Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer"},"paper-durvalumab-endometrial-gynecol-oncol-2022":{"doi":"10.1016/j.ygyno.2022.02.025","openalexId":"W4220686962","cited":54,"byYear":{"2022":4,"2023":14,"2024":11,"2025":14,"2026":11},"year":2022,"title":"Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)"},"paper-zhou-j-thorac-oncol":{"doi":"10.1016/j.jtho.2024.08.005","openalexId":"W4401475898","cited":54,"byYear":{"2024":8,"2025":19,"2026":27},"year":2024,"title":"Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study"},"paper-ck-301-101-jitc-2023":{"doi":"10.1136/jitc-2023-007637","openalexId":"W4387693232","cited":50,"byYear":{"2023":2,"2024":6,"2025":24,"2026":18},"year":2023,"title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma"},"paper-zager-ann-surg-oncol":{"doi":"10.1245/s10434-024-15293-x","openalexId":"W4396634566","cited":48,"byYear":{"2024":6,"2025":27,"2026":15},"year":2024,"title":"Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study"},"paper-nct04395677-j-clin-oncol-2024":{"doi":"10.1200/jco.24.00731","openalexId":"W4399260107","cited":37,"byYear":{"2024":3,"2025":23,"2026":11},"year":2024,"title":"Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study"},"paper-pembrolizumab-glioblastoma-med-2025":{"doi":"10.1016/j.medj.2025.100708","openalexId":"W4411043588","cited":31,"byYear":{"2025":8,"2026":23},"year":2025,"title":"Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study"},"paper-nct04143607-lancet-respir-med-2025":{"doi":"10.1016/s2213-2600(25)00121-3","openalexId":"W4411477030","cited":15,"byYear":{"2025":5,"2026":10},"year":2025,"title":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial"},"paper-nct06198751-j-clin-oncol-2026":{"doi":"10.1200/jco-25-01153","openalexId":"W4416660084","cited":9,"byYear":{"2026":9},"year":2025,"title":"Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial"},"paper-oba-cancer-immunol-immunother":{"doi":"10.1007/s00262-006-0248-1","openalexId":"W2125067714","cited":115,"byYear":{"2012":10,"2013":11,"2014":3,"2015":7,"2016":7,"2017":9,"2018":2,"2019":6,"2020":5,"2021":4,"2022":4,"2023":4,"2024":3,"2025":6,"2026":5},"year":2006,"title":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer"},"paper-sakamoto-cancer-immunol-immunother":{"doi":"10.1007/s00262-005-0054-1","openalexId":"W2065072311","cited":102,"byYear":{"2012":4,"2013":9,"2014":4,"2015":2,"2016":3,"2017":7,"2019":5,"2020":5,"2021":2,"2022":7,"2023":1,"2024":5,"2025":10,"2026":6},"year":2005,"title":"Efficacy of adjuvant Immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials"},"paper-nct05300269-cancer-lett-2026":{"doi":"10.1016/j.canlet.2025.218006","openalexId":"W4413971663","cited":3,"byYear":{"2026":3},"year":2025,"title":"Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer"},"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026":{"doi":"10.1016/j.esmoop.2026.108344","openalexId":"W7171817858","cited":0,"byYear":{},"year":2026,"title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02"},"paper-el-deiry-waf1-p21-cell-1993":{"doi":"10.1016/0092-8674(93)90500-p","openalexId":"W2015519364","cited":8415,"byYear":{"2012":214,"2013":179,"2014":183,"2015":178,"2016":164,"2017":141,"2018":122,"2019":134,"2020":131,"2021":142,"2022":109,"2023":145,"2024":95,"2025":90,"2026":44},"year":1993,"title":"WAF1, a potential mediator of p53 tumor suppression"},"paper-eliana-tisagenlecleucel-nejm-2018":{"doi":"10.1056/nejmoa1709866","openalexId":"W2787301955","cited":5834,"byYear":{"2012":1,"2013":1,"2018":243,"2019":497,"2020":722,"2021":812,"2022":811,"2023":762,"2024":786,"2025":676,"2026":512},"year":2018,"title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia"},"paper-chen-nature":{"doi":"10.1038/nature21349","openalexId":"W2578528809","cited":5551,"byYear":{"2015":1,"2016":1,"2017":134,"2018":338,"2019":401,"2020":617,"2021":719,"2022":914,"2023":757,"2024":679,"2025":533,"2026":454},"year":2017,"title":"Elements of cancer immunity and the cancer–immune set point"},"paper-eln-2022-aml-dohner-blood-2022":{"doi":"10.1182/blood.2022016867","openalexId":"W4284884567","cited":3317,"byYear":{"2012":1,"2019":1,"2022":108,"2023":634,"2024":910,"2025":953,"2026":707},"year":2022,"title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN"},"paper-bernier-eortc-22931-nejm-2004":{"doi":"10.1056/nejmoa032641","openalexId":"W2120068217","cited":3211,"byYear":{"2012":146,"2013":140,"2014":152,"2015":164,"2016":149,"2017":193,"2018":154,"2019":182,"2020":191,"2021":191,"2022":173,"2023":147,"2024":145,"2025":179,"2026":106},"year":2004,"title":"Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer"},"paper-sylvester-eortc-risk-tables-eur-urol-2006":{"doi":"10.1016/j.eururo.2005.12.031","openalexId":"W2002045993","cited":3036,"byYear":{"2012":143,"2013":153,"2014":144,"2015":172,"2016":133,"2017":164,"2018":199,"2019":198,"2020":203,"2021":231,"2022":174,"2023":182,"2024":174,"2025":148,"2026":138},"year":2006,"title":"Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials"},"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012":{"doi":"10.1038/nature11156","openalexId":"W2062109911","cited":1929,"byYear":{"2012":27,"2013":134,"2014":146,"2015":162,"2016":177,"2017":176,"2018":166,"2019":164,"2020":139,"2021":157,"2022":129,"2023":121,"2024":88,"2025":76,"2026":61},"year":2012,"title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer"},"paper-doebele-entrectinib-ntrk-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(19)30691-6","openalexId":"W2996574710","cited":1805,"byYear":{"2014":1,"2018":1,"2019":2,"2020":152,"2021":259,"2022":354,"2023":322,"2024":306,"2025":241,"2026":163},"year":2019,"title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials"},"paper-enzamet-n-engl-j-med-2019":{"doi":"10.1056/nejmoa1903835","openalexId":"W2947893479","cited":1653,"byYear":{"2017":1,"2018":1,"2019":51,"2020":200,"2021":256,"2022":280,"2023":256,"2024":236,"2025":216,"2026":149},"year":2019,"title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer"},"paper-androgen-receptor-prostate-nat-rev-cancer-2015":{"doi":"10.1038/nrc4016","openalexId":"W2181283187","cited":1603,"byYear":{"2015":3,"2016":63,"2017":101,"2018":107,"2019":133,"2020":137,"2021":183,"2022":197,"2023":189,"2024":178,"2025":190,"2026":120},"year":2015,"title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer"},"paper-bolla-eortc-22863-nejm-1997":{"doi":"10.1056/nejm199707313370502","openalexId":"W2316095838","cited":1564,"byYear":{"2012":64,"2013":46,"2014":45,"2015":36,"2016":30,"2017":28,"2018":31,"2019":41,"2020":24,"2021":15,"2022":26,"2023":15,"2024":7,"2025":18,"2026":5},"year":1997,"title":"Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin"},"paper-enasidenib-idh2-stein-blood-2017":{"doi":"10.1182/blood-2017-04-779405","openalexId":"W2623089849","cited":1522,"byYear":{"2016":3,"2017":50,"2018":156,"2019":216,"2020":218,"2021":228,"2022":182,"2023":148,"2024":131,"2025":102,"2026":84},"year":2017,"title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia"},"paper-egfr-glioblastoma-mol-oncol-2018":{"doi":"10.1002/1878-0261.12155","openalexId":"W2767336741","cited":1519,"byYear":{"2017":1,"2018":22,"2019":76,"2020":154,"2021":240,"2022":212,"2023":259,"2024":251,"2025":186,"2026":117},"year":2017,"title":"Emerging functions of the EGFR in cancer"},"paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019":{"doi":"10.1056/nejmoa1908075","openalexId":"W2977895282","cited":1508,"byYear":{"2019":17,"2020":207,"2021":282,"2022":234,"2023":190,"2024":257,"2025":184,"2026":132},"year":2019,"title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer"},"paper-venkatesh-nature":{"doi":"10.1038/s41586-019-1563-y","openalexId":"W2974724557","cited":1420,"byYear":{"2019":22,"2020":153,"2021":168,"2022":171,"2023":230,"2024":236,"2025":246,"2026":193},"year":2019,"title":"Electrical and synaptic integration of glioma into neural circuits"},"paper-crosbie-lancet":{"doi":"10.1016/s0140-6736(22)00323-3","openalexId":"W4223523934","cited":1386,"byYear":{"2021":1,"2022":55,"2023":231,"2024":426,"2025":398,"2026":275},"year":2022,"title":"Endometrial cancer"},"paper-eortc-24891-larynx-preservation-lefebvre-jnci-1996":{"doi":"10.1093/jnci/88.13.890","openalexId":"W2022395184","cited":1337,"byYear":{"2012":59,"2013":50,"2014":49,"2015":49,"2016":52,"2017":50,"2018":29,"2019":40,"2020":38,"2021":36,"2022":37,"2023":15,"2024":32,"2025":29,"2026":12},"year":1996,"title":"Larynx Preservation in Pyriform Sinus Cancer: Preliminary Results of a European Organization for Research and Treatment of Cancer Phase III Trial"},"paper-eortc-26951-van-den-bent-jco-2013":{"doi":"10.1200/jco.2012.43.2229","openalexId":"W2133865472","cited":1239,"byYear":{"2012":10,"2013":61,"2014":91,"2015":110,"2016":102,"2017":112,"2018":110,"2019":120,"2020":106,"2021":80,"2022":93,"2023":92,"2024":66,"2025":52,"2026":28},"year":2012,"title":"Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951"},"paper-dcruz-elective-neck-dissection-nejm-2015":{"doi":"10.1056/nejmoa1506007","openalexId":"W2283809829","cited":1226,"byYear":{"2014":3,"2015":23,"2016":76,"2017":71,"2018":89,"2019":128,"2020":132,"2021":144,"2022":105,"2023":137,"2024":113,"2025":102,"2026":101},"year":2015,"title":"Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer"},"paper-eortc-62012-doxorubicin-ifosfamide-judson-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70063-4","openalexId":"W2136344041","cited":1193,"byYear":{"2013":1,"2014":18,"2015":44,"2016":88,"2017":97,"2018":92,"2019":97,"2020":106,"2021":118,"2022":123,"2023":114,"2024":94,"2025":126,"2026":75},"year":2014,"title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial"},"paper-hpv-vaccine-england-lancet-2021":{"doi":"10.1016/s0140-6736(21)02178-4","openalexId":"W3209481766","cited":793,"byYear":{"2021":12,"2022":153,"2023":156,"2024":183,"2025":168,"2026":120},"year":2021,"title":"The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study"},"paper-emerald-elacestrant-jco-2022":{"doi":"10.1200/jco.22.00338","openalexId":"W4280490473","cited":758,"byYear":{"2020":1,"2022":24,"2023":157,"2024":212,"2025":202,"2026":162},"year":2022,"title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial"},"paper-enets-lung-net-consensus-caplin-ann-oncol-2015":{"doi":"10.1093/annonc/mdv041","openalexId":"W2164252602","cited":716,"byYear":{"2012":1,"2013":1,"2015":19,"2016":46,"2017":75,"2018":58,"2019":69,"2020":65,"2021":87,"2022":74,"2023":57,"2024":73,"2025":60,"2026":29},"year":2015,"title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids"},"paper-elevate-tn-acalabrutinib-lancet-2020":{"doi":"10.1016/s0140-6736(20)30262-2","openalexId":"W3016538158","cited":633,"byYear":{"2013":1,"2020":42,"2021":126,"2022":109,"2023":118,"2024":98,"2025":75,"2026":63},"year":2020,"title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial"},"paper-tabernero-j-clin-oncol":{"doi":"10.1200/jco.20.02088","openalexId":"W3123642801","cited":582,"byYear":{"2021":29,"2022":108,"2023":116,"2024":153,"2025":100,"2026":74},"year":2021,"title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study"},"paper-epcore-nhl-1-epcoritamab-jco-2023":{"doi":"10.1200/jco.22.01725","openalexId":"W4312115076","cited":578,"byYear":{"2023":94,"2024":180,"2025":189,"2026":115},"year":2022,"title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial"},"paper-drilon-entrectinib-ros1-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(19)30690-4","openalexId":"W2995220921","cited":552,"byYear":{"2019":2,"2020":59,"2021":88,"2022":101,"2023":86,"2024":106,"2025":63,"2026":45},"year":2019,"title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials"},"paper-traina-enzalutamide-ar-tnbc-jco-2018":{"doi":"10.1200/jco.2016.71.3495","openalexId":"W2784775153","cited":537,"byYear":{"2016":2,"2018":35,"2019":49,"2020":65,"2021":84,"2022":103,"2023":71,"2024":40,"2025":50,"2026":36},"year":2018,"title":"Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer"},"paper-doronina-bioconjug-chem":{"doi":"10.1021/bc0502917","openalexId":"W2136101268","cited":523,"byYear":{"2012":27,"2013":31,"2014":26,"2015":40,"2016":38,"2017":40,"2018":31,"2019":31,"2020":40,"2021":27,"2022":20,"2023":28,"2024":32,"2025":17,"2026":14},"year":2005,"title":"Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity"},"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019":{"doi":"10.1200/jco.18.01585","openalexId":"W2905529840","cited":505,"byYear":{"2019":31,"2020":52,"2021":61,"2022":73,"2023":67,"2024":78,"2025":81,"2026":59},"year":2018,"title":"EGFR -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes"},"paper-empower-cervical-1-cemiplimab-nejm-2022":{"doi":"10.1056/nejmoa2112187","openalexId":"W4210971182","cited":460,"byYear":{"2022":57,"2023":100,"2024":121,"2025":104,"2026":78},"year":2022,"title":"Survival with Cemiplimab in Recurrent Cervical Cancer"},"paper-kurtz-nat-biotechnol":{"doi":"10.1038/s41587-021-00981-w","openalexId":"W3184558555","cited":389,"byYear":{"2021":9,"2022":71,"2023":79,"2024":76,"2025":89,"2026":65},"year":2021,"title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA"},"paper-embark-nejm-2023":{"doi":"10.1056/nejmoa2303974","openalexId":"W4387735431","cited":318,"byYear":{"2023":8,"2024":100,"2025":121,"2026":88},"year":2023,"title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer"},"paper-bower-ema-co-high-risk-gtn-charing-cross-jco-1997":{"doi":"10.1200/jco.1997.15.7.2636","openalexId":"W1929177538","cited":314,"byYear":{"2012":21,"2013":11,"2014":17,"2015":14,"2016":14,"2017":11,"2018":11,"2019":10,"2020":17,"2021":16,"2022":9,"2023":6,"2024":11,"2025":7,"2026":6},"year":1997,"title":"EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients."},"paper-emerald-1-lancet-2025":{"doi":"10.1016/s0140-6736(24)02551-0","openalexId":"W4406160687","cited":297,"byYear":{"2025":131,"2026":166},"year":2025,"title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study"},"paper-dewey-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd004597.pub2","openalexId":"W1908242390","cited":259,"byYear":{"2012":26,"2013":22,"2014":15,"2015":14,"2016":8,"2017":11,"2018":11,"2019":8,"2020":7,"2021":17,"2022":10,"2023":12,"2024":12,"2025":5,"2026":1},"year":2007,"title":"Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia"},"paper-nct02767804-jama-oncol-2021":{"doi":"10.1001/jamaoncol.2021.3523","openalexId":"W3196750844","cited":259,"byYear":{"2021":5,"2022":50,"2023":45,"2024":67,"2025":52,"2026":40},"year":2021,"title":"Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer"},"paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025":{"doi":"10.1056/nejmoa2405008","openalexId":"W4407162975","cited":136,"byYear":{"2025":67,"2026":69},"year":2025,"title":"Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer"},"paper-mao-j-clin-oncol-2015":{"doi":"10.1200/jco.2015.60.9412","openalexId":"W2145582161","cited":130,"byYear":{"2015":2,"2016":11,"2017":20,"2018":7,"2019":12,"2020":17,"2021":15,"2022":10,"2023":9,"2024":11,"2025":8,"2026":8},"year":2015,"title":"Electroacupuncture Versus Gabapentin for Hot Flashes Among Breast Cancer Survivors: A Randomized Placebo-Controlled Trial"},"paper-vistogard-cancer-2017":{"doi":"10.1002/cncr.30321","openalexId":"W2523060386","cited":125,"byYear":{"2016":2,"2017":3,"2018":16,"2019":7,"2020":21,"2021":10,"2022":16,"2023":14,"2024":11,"2025":18,"2026":7},"year":2016,"title":"Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity"},"paper-clover-eur-j-cancer":{"doi":"10.1016/j.ejca.2020.06.020","openalexId":"W3080759371","cited":123,"byYear":{"2020":5,"2021":15,"2022":23,"2023":23,"2024":17,"2025":27,"2026":13},"year":2020,"title":"Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019)"},"paper-breakwater-nat-med-2025":{"doi":"10.1038/s41591-024-03443-3","openalexId":"W4406820204","cited":120,"byYear":{"2025":58,"2026":62},"year":2025,"title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial"},"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019":{"doi":"10.1016/j.pan.2018.10.010","openalexId":"W2898561267","cited":116,"byYear":{"2019":7,"2020":15,"2021":20,"2022":14,"2023":26,"2024":12,"2025":15,"2026":7},"year":2018,"title":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study"},"paper-freites-martinez-jama-dermatol":{"doi":"10.1001/jamadermatol.2018.0454","openalexId":"W2797884904","cited":113,"byYear":{"2018":10,"2019":8,"2020":17,"2021":17,"2022":6,"2023":15,"2024":13,"2025":19,"2026":7},"year":2018,"title":"Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer"},"paper-epcoritamab-dlbcl-blood-2025":{"doi":"10.1182/blood.2024026830","openalexId":"W4406260228","cited":62,"byYear":{"2025":31,"2026":31},"year":2025,"title":"Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial"},"paper-nct05587296-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2415566","openalexId":"W4410961404","cited":53,"byYear":{"2025":14,"2026":39},"year":2025,"title":"Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer"},"paper-epcoritamab-dlbcl-drugs-2023":{"doi":"10.1007/s40265-023-01930-4","openalexId":"W4386001353","cited":43,"byYear":{"2023":1,"2024":13,"2025":17,"2026":12},"year":2023,"title":"Epcoritamab: First Approval"},"paper-nct06120140-j-thorac-oncol-2025":{"doi":"10.1016/j.jtho.2025.07.117","openalexId":"W4414082877","cited":38,"byYear":{"2025":5,"2026":33},"year":2025,"title":"Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial"},"paper-ezh2-sarcoma-bmc-med-2011":{"doi":"10.1186/1741-7015-9-63","openalexId":"W2145163779","cited":36,"byYear":{"2012":6,"2013":4,"2014":1,"2015":3,"2016":5,"2017":2,"2019":1,"2020":3,"2021":3,"2022":1,"2023":1,"2024":3,"2025":2,"2026":1},"year":2011,"title":"Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications"},"paper-mahalingam-nat-med":{"doi":"10.1038/s41591-026-04327-4","openalexId":"W7154248023","cited":3,"byYear":{"2026":3},"year":2026,"title":"Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial"},"paper-esteva-skin-cancer-deep-learning-nature-2017":{"doi":"10.1038/nature21056","openalexId":"W2581082771","cited":14468,"byYear":{"2012":1,"2014":3,"2015":2,"2016":2,"2017":276,"2018":889,"2019":1364,"2020":1719,"2021":1794,"2022":1532,"2023":1598,"2024":1738,"2025":2081,"2026":1455},"year":2017,"title":"Dermatologist-level classification of skin cancer with deep neural networks"},"paper-egfr-nsclc-lancet-oncol-2012":{"doi":"10.1016/s1470-2045(11)70393-x","openalexId":"W2111662961","cited":5559,"byYear":{"2012":138,"2013":404,"2014":449,"2015":535,"2016":512,"2017":531,"2018":498,"2019":443,"2020":479,"2021":431,"2022":371,"2023":278,"2024":229,"2025":170,"2026":77},"year":2012,"title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial"},"paper-schroder-erspc-screening-mortality-nejm-2009":{"doi":"10.1056/nejmoa0810084","openalexId":"W2095761465","cited":4038,"byYear":{"2012":475,"2013":340,"2014":278,"2015":264,"2016":207,"2017":206,"2018":181,"2019":147,"2020":145,"2021":123,"2022":124,"2023":100,"2024":87,"2025":79,"2026":63},"year":2009,"title":"Screening and Prostate-Cancer Mortality in a Randomized European Study"},"paper-arends-clin-nutr":{"doi":"10.1016/j.clnu.2016.07.015","openalexId":"W2505149831","cited":3127,"byYear":{"2016":7,"2017":93,"2018":187,"2019":252,"2020":375,"2021":455,"2022":404,"2023":329,"2024":363,"2025":339,"2026":316},"year":2016,"title":"ESPEN guidelines on nutrition in cancer patients"},"paper-bolero-2-n-engl-j-med-2012":{"doi":"10.1056/nejmoa1109653","openalexId":"W2167188058","cited":2874,"byYear":{"2012":139,"2013":304,"2014":274,"2015":266,"2016":243,"2017":254,"2018":206,"2019":175,"2020":190,"2021":180,"2022":153,"2023":157,"2024":138,"2025":114,"2026":68},"year":2011,"title":"Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer"},"paper-esgo-estro-esp-endometrial-concin-ijgc-2021":{"doi":"10.1136/ijgc-2020-002230","openalexId":"W3114074286","cited":2017,"byYear":{"2012":1,"2020":1,"2021":156,"2022":322,"2023":440,"2024":454,"2025":402,"2026":236},"year":2020,"title":"ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma"},"paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017":{"doi":"10.1016/s0140-6736(16)32409-6","openalexId":"W2581973599","cited":1958,"byYear":{"2013":1,"2016":4,"2017":97,"2018":168,"2019":265,"2020":273,"2021":285,"2022":235,"2023":218,"2024":170,"2025":161,"2026":76},"year":2017,"title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial"},"paper-eau-nmibc-guideline-eur-urol-2022":{"doi":"10.1016/j.eururo.2021.08.010","openalexId":"W3198719997","cited":1715,"byYear":{"2013":1,"2017":2,"2018":1,"2019":1,"2020":2,"2021":12,"2022":184,"2023":379,"2024":510,"2025":366,"2026":254},"year":2021,"title":"European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)"},"paper-wong-biostatistics":{"doi":"10.1093/biostatistics/kxx069","openalexId":"W2789816271","cited":1612,"byYear":{"2017":1,"2018":26,"2019":79,"2020":205,"2021":216,"2022":229,"2023":225,"2024":245,"2025":201,"2026":185},"year":2017,"title":"Estimation of clinical trial success rates and related parameters"},"paper-wouters-jama":{"doi":"10.1001/jama.2020.1166","openalexId":"W3009999522","cited":1571,"byYear":{"2012":1,"2020":67,"2021":185,"2022":218,"2023":320,"2024":313,"2025":261,"2026":206},"year":2020,"title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018"},"paper-eln-2020-cml-hochhaus-leukemia-2020":{"doi":"10.1038/s41375-020-0776-2","openalexId":"W3009751715","cited":1562,"byYear":{"2013":1,"2017":2,"2019":1,"2020":101,"2021":280,"2022":245,"2023":314,"2024":271,"2025":210,"2026":133},"year":2020,"title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia"},"paper-muscaritoli-clin-nutr":{"doi":"10.1016/j.clnu.2021.02.005","openalexId":"W4211216570","cited":1545,"byYear":{"2021":37,"2022":175,"2023":263,"2024":323,"2025":361,"2026":383},"year":2021,"title":"ESPEN practical guideline: Clinical Nutrition in cancer"},"paper-erivance-vismodegib-sekulic-nejm-2012":{"doi":"10.1056/nejmoa1113713","openalexId":"W2101616608","cited":1468,"byYear":{"2012":33,"2013":98,"2014":114,"2015":138,"2016":113,"2017":120,"2018":115,"2019":118,"2020":113,"2021":94,"2022":88,"2023":90,"2024":89,"2025":85,"2026":50},"year":2012,"title":"Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma"},"paper-haslam-jama-netw-open":{"doi":"10.1001/jamanetworkopen.2019.2535","openalexId":"W2943781197","cited":1464,"byYear":{"2019":31,"2020":145,"2021":205,"2022":238,"2023":247,"2024":292,"2025":196,"2026":110},"year":2019,"title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs"},"paper-esmo-metastatic-breast-cancer-guideline-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.09.019","openalexId":"W3207557929","cited":1448,"byYear":{"2021":4,"2022":168,"2023":289,"2024":363,"2025":370,"2026":253},"year":2021,"title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer"},"paper-european-evidence-based-guidelines-pancreatic-cystic-neoplasms-gut-2018":{"doi":"10.1136/gutjnl-2018-316027","openalexId":"W2798191310","cited":1415,"byYear":{"2015":1,"2018":47,"2019":131,"2020":156,"2021":186,"2022":186,"2023":196,"2024":193,"2025":173,"2026":133},"year":2018,"title":"European evidence-based guidelines on pancreatic cystic neoplasms"},"paper-flavahan-science":{"doi":"10.1126/science.aal2380","openalexId":"W2737272162","cited":1407,"byYear":{"2017":18,"2018":84,"2019":134,"2020":189,"2021":203,"2022":169,"2023":184,"2024":169,"2025":132,"2026":122},"year":2017,"title":"Epigenetic plasticity and the hallmarks of cancer"},"paper-espac-3-fluorouracil-vs-gemcitabine-adjuvant-neoptolemos-jama-2010":{"doi":"10.1001/jama.2010.1275","openalexId":"W2157590016","cited":1403,"byYear":{"2012":86,"2013":74,"2014":91,"2015":110,"2016":120,"2017":108,"2018":119,"2019":108,"2020":102,"2021":126,"2022":74,"2023":72,"2024":57,"2025":56,"2026":31},"year":2010,"title":"Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection"},"paper-rahib-projection-us-cancer-2040-jama-netw-open-2021":{"doi":"10.1001/jamanetworkopen.2021.4708","openalexId":"W3146983201","cited":1400,"byYear":{"2021":56,"2022":222,"2023":302,"2024":327,"2025":310,"2026":183},"year":2021,"title":"Estimated Projection of US Cancer Incidence and Death to 2040"},"paper-cortes-lancet":{"doi":"10.1016/s0140-6736(11)60070-6","openalexId":"W2127152525","cited":1110,"byYear":{"2012":65,"2013":43,"2014":68,"2015":82,"2016":76,"2017":92,"2018":100,"2019":80,"2020":86,"2021":97,"2022":64,"2023":71,"2024":60,"2025":50,"2026":31},"year":2011,"title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study"},"paper-ev-302-nejm-2024":{"doi":"10.1056/nejmoa2312117","openalexId":"W4392498919","cited":1081,"byYear":{"2021":1,"2024":230,"2025":474,"2026":375},"year":2024,"title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer"},"paper-ese-ensat-adrenocortical-carcinoma-guideline-eur-j-endocrinol-2018":{"doi":"10.1530/eje-18-0608","openalexId":"W2883682970","cited":974,"byYear":{"2018":11,"2019":66,"2020":110,"2021":145,"2022":160,"2023":111,"2024":155,"2025":127,"2026":85},"year":2018,"title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors"},"paper-feinberg-nat-rev-genet":{"doi":"10.1038/nrg.2016.13","openalexId":"W2297701691","cited":911,"byYear":{"2016":27,"2017":94,"2018":96,"2019":109,"2020":110,"2021":103,"2022":106,"2023":76,"2024":78,"2025":60,"2026":52},"year":2016,"title":"Epigenetic modulators, modifiers and mediators in cancer aetiology and progression"},"paper-eribulin-liposarcoma-schoffski-lancet-2016":{"doi":"10.1016/s0140-6736(15)01283-0","openalexId":"W2259955047","cited":782,"byYear":{"2016":48,"2017":94,"2018":86,"2019":80,"2020":87,"2021":75,"2022":91,"2023":82,"2024":57,"2025":49,"2026":31},"year":2016,"title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial"},"paper-eln-apl-sanz-blood-2019":{"doi":"10.1182/blood-2019-01-894980","openalexId":"W2918095490","cited":682,"byYear":{"2019":22,"2020":102,"2021":109,"2022":105,"2023":113,"2024":95,"2025":74,"2026":58},"year":2019,"title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet"},"paper-dulguerov-esthesioneuroblastoma-meta-analysis-lancet-oncol-2001":{"doi":"10.1016/s1470-2045(01)00558-7","openalexId":"W2148737695","cited":636,"byYear":{"2012":35,"2013":23,"2014":38,"2015":43,"2016":33,"2017":36,"2018":30,"2019":27,"2020":47,"2021":33,"2022":26,"2023":33,"2024":30,"2025":25,"2026":11},"year":2001,"title":"Esthesioneuroblastoma: a meta-analysis and review"},"paper-mack-nature":{"doi":"10.1038/nature13108","openalexId":"W2113432767","cited":626,"byYear":{"2014":40,"2015":58,"2016":74,"2017":66,"2018":68,"2019":57,"2020":61,"2021":55,"2022":38,"2023":32,"2024":33,"2025":28,"2026":13},"year":2014,"title":"Epigenomic alterations define lethal CIMP-positive ependymomas of infancy"},"paper-raverot-eur-j-endocrinol":{"doi":"10.1530/eje-17-0796","openalexId":"W2766825024","cited":603,"byYear":{"2017":3,"2018":34,"2019":60,"2020":73,"2021":95,"2022":81,"2023":74,"2024":81,"2025":66,"2026":31},"year":2017,"title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas"},"paper-bolero-2-ann-oncol-2014-update":{"doi":"10.1093/annonc/mdu456","openalexId":"W2151082560","cited":579,"byYear":{"2014":6,"2015":57,"2016":73,"2017":61,"2018":61,"2019":41,"2020":53,"2021":56,"2022":31,"2023":34,"2024":52,"2025":31,"2026":22},"year":2014,"title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2"},"paper-barton-radiother-oncol":{"doi":"10.1016/j.radonc.2014.03.024","openalexId":"W2002968221","cited":547,"byYear":{"2014":13,"2015":21,"2016":25,"2017":26,"2018":32,"2019":50,"2020":46,"2021":65,"2022":74,"2023":66,"2024":53,"2025":46,"2026":29},"year":2014,"title":"Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012"},"paper-merino-j-immunother-cancer":{"doi":"10.1136/jitc-2019-000147","openalexId":"W3013239365","cited":518,"byYear":{"2019":3,"2020":33,"2021":78,"2022":120,"2023":112,"2024":92,"2025":45,"2026":33},"year":2020,"title":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project"},"paper-erdheim-chester-disease-consensus-recommendations-blood-2020":{"doi":"10.1182/blood.2019003507","openalexId":"W3011169548","cited":422,"byYear":{"2019":1,"2020":23,"2021":55,"2022":54,"2023":64,"2024":86,"2025":81,"2026":58},"year":2020,"title":"Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era"},"paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023":{"doi":"10.1016/s2468-1253(22)00348-x","openalexId":"W4311425047","cited":347,"byYear":{"2020":1,"2021":1,"2022":3,"2023":66,"2024":117,"2025":95,"2026":64},"year":2022,"title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial"},"paper-esphall-imatinib-biondi-lancet-oncol-2012":{"doi":"10.1016/s1470-2045(12)70377-7","openalexId":"W2127226843","cited":336,"byYear":{"2012":2,"2013":21,"2014":28,"2015":23,"2016":28,"2017":32,"2018":30,"2019":20,"2020":31,"2021":30,"2022":22,"2023":21,"2024":26,"2025":10,"2026":8},"year":2012,"title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study"},"paper-esmo-anal-cancer-guideline-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.06.015","openalexId":"W3173506613","cited":268,"byYear":{"2021":6,"2022":33,"2023":50,"2024":69,"2025":65,"2026":42},"year":2021,"title":"Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆"},"paper-estimabl2-leboulleux-nejm-2022":{"doi":"10.1056/nejmoa2111953","openalexId":"W4220712737","cited":240,"byYear":{"2022":43,"2023":52,"2024":61,"2025":49,"2026":35},"year":2022,"title":"Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer"},"paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019":{"doi":"10.21037/cco.2019.08.03","openalexId":"W2970838954","cited":231,"byYear":{"2020":8,"2021":34,"2022":30,"2023":30,"2024":51,"2025":45,"2026":33},"year":2019,"title":"Epidemiology of gallbladder cancer in India"},"paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.1402","openalexId":"W2955567484","cited":230,"byYear":{"2018":1,"2019":3,"2020":28,"2021":35,"2022":42,"2023":49,"2024":33,"2025":25,"2026":14},"year":2019,"title":"Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers"},"paper-pik3ca-colorectal-j-clin-oncol-2013":{"doi":"10.1200/jco.2013.50.0322","openalexId":"W1973076801","cited":216,"byYear":{"2013":5,"2014":37,"2015":25,"2016":28,"2017":29,"2018":12,"2019":12,"2020":14,"2021":12,"2022":10,"2023":4,"2024":7,"2025":11,"2026":9},"year":2013,"title":"Evaluation of PIK3CA Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer"},"paper-ehe-consensus-stacchiotti-esmo-open-2021":{"doi":"10.1016/j.esmoop.2021.100170","openalexId":"W3170831652","cited":192,"byYear":{"2021":5,"2022":24,"2023":31,"2024":55,"2025":50,"2026":26},"year":2021,"title":"Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts"},"paper-esphall2010-continuous-imatinib-biondi-lancet-haematol-2018":{"doi":"10.1016/s2352-3026(18)30173-x","openalexId":"W2902050434","cited":115,"byYear":{"2018":1,"2019":8,"2020":19,"2021":17,"2022":15,"2023":18,"2024":19,"2025":10,"2026":7},"year":2018,"title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial"},"paper-danchev-jama-netw-open":{"doi":"10.1001/jamanetworkopen.2020.33972","openalexId":"W3124092284","cited":103,"byYear":{"2021":12,"2022":20,"2023":24,"2024":25,"2025":14,"2026":8},"year":2021,"title":"Evaluation of Data Sharing After Implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement"},"paper-voss-int-j-radiat-oncol-biol-phys":{"doi":"10.1016/j.ijrobp.2020.06.021","openalexId":"W3038366207","cited":98,"byYear":{"2020":3,"2021":10,"2022":19,"2023":15,"2024":16,"2025":20,"2026":15},"year":2020,"title":"ERGO2: A Prospective, Randomized Trial of Calorie-Restricted Ketogenic Diet and Fasting in Addition to Reirradiation for Malignant Glioma"},"paper-rodolakis-int-j-gynecol-cancer":{"doi":"10.1136/ijgc-2022-004047","openalexId":"W4319315876","cited":58,"byYear":{"2023":8,"2024":13,"2025":24,"2026":13},"year":2023,"title":"ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma"},"paper-li-jama-oncol":{"doi":"10.1001/jamaoncol.2024.4879","openalexId":"W4404124061","cited":25,"byYear":{"2025":16,"2026":9},"year":2024,"title":"Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma"},"paper-wen-j-clin-oncol":{"doi":"10.1200/jco-25-01137","openalexId":"W7154408116","cited":11,"byYear":{"2026":11},"year":2026,"title":"Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial"},"paper-copson-posh-ethnicity-young-breast-cancer-uk-bjc-2014":{"doi":"10.1038/bjc.2013.650","openalexId":"W2030546863","cited":83,"byYear":{"2014":8,"2015":2,"2016":5,"2017":6,"2018":9,"2019":3,"2020":7,"2021":8,"2022":9,"2023":6,"2024":4,"2025":10,"2026":6},"year":2013,"title":"Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study"},"paper-keam-mol-diagn-ther":{"doi":"10.1007/s40291-023-00673-y","openalexId":"W4386351752","cited":19,"byYear":{"2024":9,"2025":8,"2026":2},"year":2023,"title":"Equecabtagene Autoleucel: First Approval"},"paper-xm01-22-tjulandin-arch-drug-inf-2011":{"doi":"10.1111/j.1753-5174.2011.00035.x","openalexId":"W2111832780","cited":14,"byYear":{"2012":3,"2013":1,"2014":3,"2015":1,"2016":2,"2017":2,"2018":1,"2022":1},"year":2011,"title":"Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial"},"paper-baylin-cold-spring-harb-perspect-biol":{"doi":"10.1101/cshperspect.a019505","openalexId":"W2403874820","cited":1408,"byYear":{"2014":2,"2015":1,"2016":16,"2017":46,"2018":57,"2019":94,"2020":134,"2021":190,"2022":187,"2023":228,"2024":194,"2025":148,"2026":109},"year":2016,"title":"Epigenetic Determinants of Cancer"},"paper-ferlay-globocan-2012-methods-ijc-2015":{"doi":"10.1002/ijc.29210","openalexId":"W1757407923","cited":29253,"byYear":{"2012":18,"2013":145,"2014":220,"2015":1199,"2016":2445,"2017":3776,"2018":4638,"2019":4397,"2020":3694,"2021":3007,"2022":2123,"2023":1489,"2024":1145,"2025":638,"2026":263},"year":2014,"title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012"},"paper-ferlay-globocan-2018-methods-ijc-2019":{"doi":"10.1002/ijc.31937","openalexId":"W2895926103","cited":7847,"byYear":{"2012":1,"2014":1,"2015":1,"2016":1,"2018":13,"2019":430,"2020":1471,"2021":1867,"2022":1400,"2023":1013,"2024":894,"2025":516,"2026":227},"year":2018,"title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods"},"paper-ferlay-cancer-statistics-2020-overview-ijc-2021":{"doi":"10.1002/ijc.33588","openalexId":"W3147142721","cited":5855,"byYear":{"2020":1,"2021":247,"2022":1043,"2023":1393,"2024":1503,"2025":1098,"2026":563},"year":2021,"title":"Cancer statistics for the year 2020: An overview"},"paper-druker-imatinib-phase1-nejm-2001":{"doi":"10.1056/nejm200104053441401","openalexId":"W2329648702","cited":5300,"byYear":{"2012":251,"2013":237,"2014":184,"2015":181,"2016":163,"2017":163,"2018":138,"2019":142,"2020":136,"2021":132,"2022":149,"2023":128,"2024":106,"2025":107,"2026":90},"year":2001,"title":"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia"},"paper-extreme-vermorken-nejm-2008":{"doi":"10.1056/nejmoa0802656","openalexId":"W2112845420","cited":3771,"byYear":{"2012":181,"2013":181,"2014":215,"2015":196,"2016":242,"2017":227,"2018":233,"2019":258,"2020":321,"2021":302,"2022":233,"2023":233,"2024":209,"2025":204,"2026":111},"year":2008,"title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer"},"paper-impower133-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1809064","openalexId":"W2893960509","cited":3653,"byYear":{"2013":1,"2017":2,"2018":18,"2019":231,"2020":488,"2021":562,"2022":530,"2023":486,"2024":506,"2025":483,"2026":338},"year":2018,"title":"First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer"},"paper-stockwell-cell":{"doi":"10.1016/j.cell.2022.06.003","openalexId":"W4284889683","cited":3149,"byYear":{"2022":76,"2023":546,"2024":930,"2025":934,"2026":662},"year":2022,"title":"Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications"},"paper-campbell-med-sci-sports-exerc":{"doi":"10.1249/mss.0000000000002116","openalexId":"W2981263606","cited":3072,"byYear":{"2014":1,"2019":10,"2020":231,"2021":395,"2022":439,"2023":465,"2024":590,"2025":503,"2026":431},"year":2019,"title":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable"},"paper-doll-peto-50-year-doctors-bmj-2004":{"doi":"10.1136/bmj.38142.554479.ae","openalexId":"W4292672078","cited":2960,"byYear":{"2012":161,"2013":181,"2014":147,"2015":167,"2016":151,"2017":134,"2018":159,"2019":138,"2020":164,"2021":136,"2022":132,"2023":140,"2024":138,"2025":81,"2026":74},"year":2004,"title":"Mortality in relation to smoking: 50 years' observations on male British doctors"},"paper-davar-science":{"doi":"10.1126/science.abf3363","openalexId":"W3126208996","cited":1758,"byYear":{"2014":1,"2020":1,"2021":153,"2022":286,"2023":320,"2024":327,"2025":332,"2026":337},"year":2021,"title":"Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients"},"paper-baruch-science":{"doi":"10.1126/science.abb5920","openalexId":"W3111836013","cited":1736,"byYear":{"2014":1,"2021":182,"2022":308,"2023":328,"2024":275,"2025":331,"2026":311},"year":2020,"title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients"},"paper-fight-202-pemigatinib-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30109-1","openalexId":"W3010944770","cited":1640,"byYear":{"2019":1,"2020":105,"2021":268,"2022":296,"2023":282,"2024":300,"2025":216,"2026":163},"year":2020,"title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study"},"paper-barbieri-spop-foxa1-med12-prostate-nat-genet-2012":{"doi":"10.1038/ng.2279","openalexId":"W1580150455","cited":127,"byYear":{"2012":1,"2013":1,"2014":4,"2015":4,"2016":2,"2017":3,"2018":7,"2019":18,"2020":21,"2021":20,"2022":12,"2023":17,"2024":7,"2025":6},"year":2012,"title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer"},"paper-gross-eshhar-chimeric-receptor-pnas-1989":{"doi":"10.1073/pnas.86.24.10024","openalexId":"W2047205338","cited":1600,"byYear":{"2012":28,"2013":34,"2014":35,"2015":51,"2016":65,"2017":95,"2018":96,"2019":122,"2020":147,"2021":158,"2022":113,"2023":134,"2024":151,"2025":132,"2026":83},"year":1989,"title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity."},"paper-oktay-j-clin-oncol":{"doi":"10.1200/jco.2018.78.1914","openalexId":"W2795588819","cited":1510,"byYear":{"2017":4,"2018":54,"2019":162,"2020":196,"2021":223,"2022":204,"2023":192,"2024":203,"2025":176,"2026":91},"year":2018,"title":"Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update"},"paper-exam-cabozantinib-mtc-elisei-jco-2013":{"doi":"10.1200/jco.2012.48.4659","openalexId":"W2122956665","cited":1228,"byYear":{"2012":2,"2013":8,"2014":82,"2015":124,"2016":118,"2017":110,"2018":82,"2019":78,"2020":93,"2021":110,"2022":122,"2023":103,"2024":75,"2025":68,"2026":44},"year":2013,"title":"Cabozantinib in Progressive Medullary Thyroid Cancer"},"paper-atun-lancet-oncol":{"doi":"10.1016/s1470-2045(15)00222-3","openalexId":"W2164437838","cited":1124,"byYear":{"2015":11,"2016":50,"2017":59,"2018":71,"2019":85,"2020":96,"2021":122,"2022":127,"2023":124,"2024":140,"2025":151,"2026":88},"year":2015,"title":"Expanding global access to radiotherapy"},"paper-turner-nature":{"doi":"10.1038/nature21356","openalexId":"W2587686129","cited":937,"byYear":{"2016":1,"2017":19,"2018":51,"2019":65,"2020":72,"2021":99,"2022":118,"2023":144,"2024":152,"2025":126,"2026":90},"year":2017,"title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity"},"paper-ramsey-j-clin-oncol":{"doi":"10.1200/jco.2015.64.6620","openalexId":"W2266198524","cited":923,"byYear":{"2015":3,"2016":27,"2017":50,"2018":57,"2019":90,"2020":74,"2021":125,"2022":123,"2023":112,"2024":105,"2025":95,"2026":61},"year":2016,"title":"Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer"},"paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012":{"doi":"10.1056/nejmoa1200966","openalexId":"W1967352082","cited":883,"byYear":{"2012":22,"2013":51,"2014":67,"2015":67,"2016":52,"2017":45,"2018":65,"2019":63,"2020":71,"2021":76,"2022":77,"2023":65,"2024":68,"2025":55,"2026":36},"year":2012,"title":"Combination Chemotherapy in Advanced Adrenocortical Carcinoma"},"paper-badawi-j-nucl-med":{"doi":"10.2967/jnumed.119.226498","openalexId":"W2914020168","cited":761,"byYear":{"2017":1,"2019":33,"2020":103,"2021":136,"2022":113,"2023":136,"2024":113,"2025":72,"2026":53},"year":2019,"title":"First Human Imaging Studies with the EXPLORER Total-Body PET Scanner*"},"paper-bozic-elife":{"doi":"10.7554/elife.00747","openalexId":"W2123431502","cited":653,"byYear":{"2013":11,"2014":34,"2015":71,"2016":70,"2017":68,"2018":65,"2019":65,"2020":59,"2021":49,"2022":44,"2023":42,"2024":37,"2025":23,"2026":14},"year":2013,"title":"Evolutionary dynamics of cancer in response to targeted combination therapy"},"paper-brastianos-nat-genet":{"doi":"10.1038/ng.2868","openalexId":"W2145756448","cited":527,"byYear":{"2014":18,"2015":32,"2016":35,"2017":51,"2018":47,"2019":43,"2020":55,"2021":56,"2022":41,"2023":38,"2024":43,"2025":41,"2026":22},"year":2014,"title":"Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas"},"paper-mimic-01-nat-med-2023":{"doi":"10.1038/s41591-023-02453-x","openalexId":"W4383341159","cited":505,"byYear":{"2023":22,"2024":132,"2025":200,"2026":150},"year":2023,"title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial"},"paper-figo-2000-staging-gestational-trophoblastic-neoplasia-ijgo-2002":{"doi":"10.1016/s0020-7292(02)00063-2","openalexId":"W4206066015","cited":412,"byYear":{"2012":12,"2013":11,"2014":9,"2015":14,"2016":39,"2017":27,"2018":14,"2019":16,"2020":22,"2021":18,"2022":32,"2023":42,"2024":28,"2025":21,"2026":19},"year":2002,"title":"FIGO staging for gestational trophoblastic neoplasia 2000"},"paper-fernandez-jama-oncol":{"doi":"10.1001/jamaoncol.2021.7239","openalexId":"W4210684267","cited":357,"byYear":{"2022":45,"2023":111,"2024":85,"2025":85,"2026":31},"year":2022,"title":"Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue"},"paper-de-groot-nat-commun":{"doi":"10.1038/s41467-020-16138-3","openalexId":"W3036980661","cited":349,"byYear":{"2020":15,"2021":51,"2022":62,"2023":79,"2024":59,"2025":49,"2026":33},"year":2020,"title":"Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial"},"paper-figo-cancer-report-gestational-trophoblastic-disease-ijgo-2021":{"doi":"10.1002/ijgo.13877","openalexId":"W3205128316","cited":304,"byYear":{"2021":1,"2022":32,"2023":67,"2024":75,"2025":81,"2026":47},"year":2021,"title":"Diagnosis and management of gestational trophoblastic disease: 2021 update"},"paper-drug-dosing-conundrum-nejm-2021":{"doi":"10.1056/nejmp2109826","openalexId":"W3204811815","cited":293,"byYear":{"2021":3,"2022":46,"2023":75,"2024":75,"2025":55,"2026":39},"year":2021,"title":"The Drug-Dosing Conundrum in Oncology — When Less Is More"},"paper-hassan-j-clin-oncol":{"doi":"10.1200/jco.19.02085","openalexId":"W3013332534","cited":177,"byYear":{"2016":1,"2017":2,"2018":2,"2019":2,"2020":14,"2021":30,"2022":26,"2023":36,"2024":25,"2025":25,"2026":14},"year":2020,"title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors"},"paper-explorer-avapritinib-advanced-systemic-mastocytosis-nat-med-2021":{"doi":"10.1038/s41591-021-01538-9","openalexId":"W4200317891","cited":152,"byYear":{"2021":3,"2022":30,"2023":44,"2024":27,"2025":31,"2026":17},"year":2021,"title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial"},"paper-ezh2-colorectal-br-j-cancer-2009":{"doi":"10.1038/sj.bjc.6605333","openalexId":"W2062586342","cited":149,"byYear":{"2012":14,"2013":12,"2014":14,"2015":17,"2016":10,"2017":13,"2018":8,"2019":7,"2020":11,"2021":4,"2022":6,"2023":3,"2024":11,"2025":7},"year":2009,"title":"Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis"},"paper-lynch-frameshift-vaccine-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-3517","openalexId":"W3035696000","cited":147,"byYear":{"2020":3,"2021":20,"2022":18,"2023":38,"2024":24,"2025":22,"2026":22},"year":2020,"title":"A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial"},"paper-chawla-jama-oncol":{"doi":"10.1001/jamaoncol.2015.3101","openalexId":"W1906474388","cited":109,"byYear":{"2014":1,"2015":1,"2016":11,"2017":14,"2018":14,"2019":20,"2020":8,"2021":9,"2022":8,"2023":5,"2024":7,"2025":8,"2026":3},"year":2015,"title":"First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma"},"paper-figo-cancer-report-cancer-of-the-vagina-ijgo-2018":{"doi":"10.1002/ijgo.12610","openalexId":"W3142968022","cited":101,"byYear":{"2019":1,"2020":18,"2021":22,"2022":23,"2023":23,"2024":8,"2025":5},"year":2018,"title":"Cancer of the vagina"},"paper-orient-11-lung-cancer-2022-update":{"doi":"10.1016/j.lungcan.2022.07.013","openalexId":"W4285809093","cited":79,"byYear":{"2022":3,"2023":12,"2024":20,"2025":29,"2026":15},"year":2022,"title":"Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study"},"paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023":{"doi":"10.1146/annurev-med-042921-024707","openalexId":"W4297518691","cited":61,"byYear":{"2022":1,"2023":9,"2024":19,"2025":23,"2026":9},"year":2022,"title":"FGFR2 Inhibition in Cholangiocarcinoma"},"paper-ciltacabtagene-autoleucel-multiple-myeloma-clin-cancer-res-2024":{"doi":"10.1158/1078-0432.ccr-24-0378","openalexId":"W4396690836","cited":50,"byYear":{"2024":7,"2025":26,"2026":17},"year":2024,"title":"FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma"},"paper-destiny-lung02-j-thorac-oncol-2025":{"doi":"10.1016/j.jtho.2025.07.129","openalexId":"W4412749678","cited":28,"byYear":{"2025":2,"2026":26},"year":2025,"title":"Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC"},"paper-nct04561362-j-clin-oncol-2025":{"doi":"10.1200/jco-25-00559","openalexId":"W4415973365","cited":15,"byYear":{"2026":15},"year":2025,"title":"First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation"},"paper-brown-clin-trials":{"doi":"10.1177/17407745211069879","openalexId":"W4210472985","cited":26,"byYear":{"2022":5,"2023":12,"2024":3,"2025":2,"2026":4},"year":2022,"title":"Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer"},"paper-nct03476681-j-exp-clin-cancer-res-2023":{"doi":"10.1186/s13046-023-02649-6","openalexId":"W4361295263","cited":23,"byYear":{"2023":4,"2024":10,"2025":5,"2026":4},"year":2023,"title":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors"},"paper-nct05413850-j-nucl-med-2024":{"doi":"10.2967/jnumed.123.266741","openalexId":"W4390047899","cited":14,"byYear":{"2024":5,"2025":7,"2026":2},"year":2023,"title":"First Safety and Efficacy Data with the Radiohybrid177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer"},"paper-nct05199272-cancer-res-commun-2025":{"doi":"10.1158/2767-9764.crc-24-0568","openalexId":"W4405189264","cited":7,"byYear":{"2025":2,"2026":5},"year":2024,"title":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies"},"paper-fgfr2-cholangiocarcinoma-int-j-mol-sci-2025":{"doi":"10.3390/ijms262110755","openalexId":"W4415924713","cited":7,"byYear":{"2026":7},"year":2025,"title":"Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1"},"paper-fgfr2-cholangiocarcinoma-cancers-basel-2026":{"doi":"10.3390/cancers18030531","openalexId":"W7127941824","cited":6,"byYear":{"2026":6},"year":2026,"title":"FGFR2-Rearranged Biliary Tract Cancer: Biology, Resistance Mechanisms, and Emerging Therapeutic Strategies"},"paper-cd47-colorectal-cancers-basel-2025":{"doi":"10.3390/cancers18010054","openalexId":"W7117111748","cited":4,"byYear":{"2026":4},"year":2025,"title":"Expression and Clinical Significance of CD47 in Colorectal Cancer: A Review"},"paper-ghai-california-poison-control-ivermectin-2024":{"doi":"10.1177/00333549231201679","openalexId":"W4388457838","cited":7,"byYear":{"2024":3,"2025":3,"2026":1},"year":2023,"title":"Exposures to Bleach, Peroxide, Disinfectants, Antimalarials, and Ivermectin Reported to the California Poison Control System Before and During the COVID-19 Pandemic, 2015-2021"},"paper-boissiere-michot-her2-ultralow-tnbc-virchows-arch-2026":{"doi":"10.1007/s00428-026-04425-1","openalexId":"W7127655929","cited":1,"byYear":{"2026":1},"year":2026,"title":"Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status"},"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017":{"doi":"10.1001/jamaoncol.2016.5688","openalexId":"W2560322684","cited":6334,"byYear":{"2013":3,"2014":1,"2015":2,"2016":1,"2017":208,"2018":602,"2019":902,"2020":1138,"2021":1125,"2022":839,"2023":651,"2024":507,"2025":281,"2026":68},"year":2016,"title":"Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015"},"paper-flaura-nejm-2018":{"doi":"10.1056/nejmoa1713137","openalexId":"W2770828094","cited":5485,"byYear":{"2016":2,"2017":8,"2018":278,"2019":541,"2020":671,"2021":704,"2022":710,"2023":629,"2024":727,"2025":696,"2026":508},"year":2017,"title":"Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer"},"paper-hirota-kit-gist-science-1998":{"doi":"10.1126/science.279.5350.577","openalexId":"W2171620774","cited":4510,"byYear":{"2012":204,"2013":218,"2014":188,"2015":179,"2016":167,"2017":160,"2018":147,"2019":163,"2020":142,"2021":154,"2022":120,"2023":112,"2024":102,"2025":93,"2026":68},"year":1998,"title":"Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors"},"paper-stummer-lancet-oncol":{"doi":"10.1016/s1470-2045(06)70665-9","openalexId":"W2125372543","cited":3422,"byYear":{"2012":174,"2013":173,"2014":195,"2015":223,"2016":197,"2017":215,"2018":183,"2019":227,"2020":238,"2021":250,"2022":212,"2023":197,"2024":200,"2025":174,"2026":117},"year":2006,"title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial"},"paper-solomon-n-engl-j-med":{"doi":"10.1056/nejmoa1408440","openalexId":"W2099530756","cited":3250,"byYear":{"2012":1,"2013":1,"2014":10,"2015":233,"2016":349,"2017":375,"2018":366,"2019":363,"2020":318,"2021":304,"2022":261,"2023":227,"2024":201,"2025":142,"2026":85},"year":2014,"title":"First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer"},"paper-flot4-lancet-2019":{"doi":"10.1016/s0140-6736(18)32557-1","openalexId":"W2938774982","cited":2710,"byYear":{"2018":1,"2019":85,"2020":250,"2021":352,"2022":372,"2023":425,"2024":506,"2025":394,"2026":320},"year":2019,"title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial"},"paper-altman-nat-rev-cancer":{"doi":"10.1038/nrc.2016.71","openalexId":"W2503851771","cited":2194,"byYear":{"2014":1,"2015":1,"2016":12,"2017":128,"2018":139,"2019":182,"2020":252,"2021":289,"2022":308,"2023":286,"2024":248,"2025":228,"2026":119},"year":2016,"title":"From Krebs to clinic: glutamine metabolism to cancer therapy"},"paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70330-4","openalexId":"W2005348280","cited":1757,"byYear":{"2013":1,"2014":30,"2015":206,"2016":201,"2017":175,"2018":171,"2019":162,"2020":156,"2021":147,"2022":138,"2023":117,"2024":113,"2025":83,"2026":51},"year":2014,"title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial"},"paper-spigel-pacific-five-year-survival-jco-2022":{"doi":"10.1200/jco.21.01308","openalexId":"W4210772672","cited":1410,"byYear":{"2021":1,"2022":116,"2023":285,"2024":376,"2025":349,"2026":283},"year":2022,"title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer"},"paper-pembrolizumab-urothelial-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30616-2","openalexId":"W2760661635","cited":1364,"byYear":{"2015":1,"2017":14,"2018":129,"2019":152,"2020":222,"2021":213,"2022":184,"2023":163,"2024":138,"2025":104,"2026":42},"year":2017,"title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study"},"paper-jaffray-int-j-radiat-oncol-biol-phys":{"doi":"10.1016/s0360-3016(02)02884-5","openalexId":"W2112095335","cited":1335,"byYear":{"2012":71,"2013":67,"2014":69,"2015":74,"2016":64,"2017":60,"2018":51,"2019":53,"2020":45,"2021":32,"2022":39,"2023":42,"2024":35,"2025":34,"2026":18},"year":2002,"title":"Flat-panel cone-beam computed tomography for image-guided radiation therapy"},"paper-jones-arid1a-clear-cell-science-2010":{"doi":"10.1126/science.1196333","openalexId":"W1975141727","cited":1236,"byYear":{"2012":110,"2013":107,"2014":97,"2015":102,"2016":90,"2017":74,"2018":82,"2019":68,"2020":74,"2021":75,"2022":56,"2023":75,"2024":71,"2025":39,"2026":19},"year":2010,"title":"Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma"},"paper-keynote-024-189-j-clin-oncol-2021-update":{"doi":"10.1200/jco.21.00174","openalexId":"W3154805493","cited":1187,"byYear":{"2021":55,"2022":160,"2023":267,"2024":258,"2025":245,"2026":201},"year":2021,"title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%"},"paper-ascend-4-lancet-2017":{"doi":"10.1016/s0140-6736(17)30123-x","openalexId":"W2581996620","cited":1169,"byYear":{"2015":2,"2017":94,"2018":169,"2019":146,"2020":141,"2021":131,"2022":143,"2023":124,"2024":106,"2025":74,"2026":36},"year":2017,"title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study"},"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020":{"doi":"10.1056/nejmoa2027187","openalexId":"W3101089668","cited":1119,"byYear":{"2019":1,"2020":5,"2021":147,"2022":221,"2023":211,"2024":216,"2025":189,"2026":126},"year":2020,"title":"First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer"},"paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(15)00122-9","openalexId":"W2129998117","cited":1112,"byYear":{"2015":9,"2016":52,"2017":90,"2018":99,"2019":109,"2020":132,"2021":135,"2022":127,"2023":107,"2024":131,"2025":71,"2026":48},"year":2015,"title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study"},"paper-bcl-2-cll-nat-rev-drug-discov-2017":{"doi":"10.1038/nrd.2016.253","openalexId":"W2589060305","cited":928,"byYear":{"2016":1,"2017":52,"2018":100,"2019":94,"2020":128,"2021":124,"2022":99,"2023":95,"2024":99,"2025":88,"2026":45},"year":2017,"title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors"},"paper-shain-nat-rev-cancer":{"doi":"10.1038/nrc.2016.37","openalexId":"W2342564029","cited":912,"byYear":{"2016":7,"2017":61,"2018":76,"2019":99,"2020":101,"2021":126,"2022":112,"2023":86,"2024":120,"2025":77,"2026":45},"year":2016,"title":"From melanocytes to melanomas"},"paper-weiss-fgfr1-amplification-squamous-lung-sci-transl-med-2010":{"doi":"10.1126/scitranslmed.3001451","openalexId":"W7212017692","cited":2,"byYear":{"2021":1,"2026":1},"year":2010,"title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer"},"paper-galaxy-signatera-nat-med-2023":{"doi":"10.1038/s41591-022-02115-4","openalexId":"W4316507345","cited":518,"byYear":{"2021":1,"2022":1,"2023":69,"2024":171,"2025":161,"2026":115},"year":2023,"title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer"},"paper-landa-j-clin-endocrinol-metab":{"doi":"10.1210/jc.2013-2383","openalexId":"W2031978342","cited":471,"byYear":{"2012":1,"2013":5,"2014":35,"2015":37,"2016":48,"2017":41,"2018":45,"2019":37,"2020":39,"2021":42,"2022":28,"2023":45,"2024":22,"2025":27,"2026":18},"year":2013,"title":"Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease"},"paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022":{"doi":"10.1038/s41572-022-00398-y","openalexId":"W4307359779","cited":430,"byYear":{"2022":1,"2023":46,"2024":161,"2025":138,"2026":84},"year":2022,"title":"Gallbladder cancer"},"paper-combi-ad-n-engl-j-med-2020-update":{"doi":"10.1056/nejmoa2005493","openalexId":"W3082456432","cited":417,"byYear":{"2012":1,"2020":8,"2021":71,"2022":85,"2023":87,"2024":93,"2025":47,"2026":23},"year":2020,"title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma"},"paper-dasari-fresco-2-fruquintinib-lancet-2023":{"doi":"10.1016/s0140-6736(23)00772-9","openalexId":"W4380887702","cited":352,"byYear":{"2023":14,"2024":109,"2025":134,"2026":95},"year":2023,"title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study"},"paper-prodige-24-five-year-outcomes-jama-oncol-2022":{"doi":"10.1001/jamaoncol.2022.3829","openalexId":"W4294001741","cited":349,"byYear":{"2022":4,"2023":74,"2024":95,"2025":100,"2026":76},"year":2022,"title":"Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer"},"paper-keynote-042-j-clin-oncol-2023-update":{"doi":"10.1200/jco.21.02885","openalexId":"W4307585126","cited":345,"byYear":{"2022":2,"2023":46,"2024":102,"2025":116,"2026":79},"year":2022,"title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study"},"paper-mailankody-jama-oncol":{"doi":"10.1001/jamaoncol.2015.0373","openalexId":"W2060918723","cited":300,"byYear":{"2015":16,"2016":35,"2017":29,"2018":43,"2019":33,"2020":25,"2021":36,"2022":28,"2023":18,"2024":13,"2025":9,"2026":13},"year":2015,"title":"Five Years of Cancer Drug Approvals"},"paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70036-1","openalexId":"W1987270559","cited":249,"byYear":{"2014":7,"2015":18,"2016":16,"2017":14,"2018":15,"2019":30,"2020":28,"2021":29,"2022":21,"2023":15,"2024":28,"2025":16,"2026":10},"year":2014,"title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial"},"paper-furlong-lancet-respir-med-2022":{"doi":"10.1016/s2213-2600(22)00168-0","openalexId":"W4281984185","cited":240,"byYear":{"2022":9,"2023":39,"2024":75,"2025":78,"2026":39},"year":2022,"title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study"},"paper-kornauth-cancer-discov":{"doi":"10.1158/2159-8290.cd-21-0538","openalexId":"W3205761999","cited":215,"byYear":{"2021":4,"2022":33,"2023":55,"2024":47,"2025":47,"2026":29},"year":2021,"title":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders"},"paper-kroep-mpnst-first-line-chemotherapy-ann-oncol-2011":{"doi":"10.1093/annonc/mdq338","openalexId":"W2105567069","cited":214,"byYear":{"2012":8,"2013":5,"2014":11,"2015":4,"2016":18,"2017":21,"2018":11,"2019":18,"2020":25,"2021":11,"2022":14,"2023":15,"2024":23,"2025":16,"2026":7},"year":2010,"title":"First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC Soft Tissue and Bone Sarcoma Group study"},"paper-serena-6-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2502929","openalexId":"W4410927250","cited":168,"byYear":{"2025":49,"2026":119},"year":2025,"title":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer"},"paper-capivasertib-breast-hr-positive-lancet-oncol-2022":{"doi":"10.1016/s1470-2045(22)00284-4","openalexId":"W4281809721","cited":149,"byYear":{"2022":8,"2023":37,"2024":51,"2025":38,"2026":15},"year":2022,"title":"Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial"},"paper-kraljevic-lancet-digit-health":{"doi":"10.1016/s2589-7500(24)00025-6","openalexId":"W4393021028","cited":116,"byYear":{"2023":4,"2024":21,"2025":48,"2026":43},"year":2024,"title":"Foresight—a generative pretrained transformer for modelling of patient timelines using electronic health records: a retrospective modelling study"},"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(20)30686-0","openalexId":"W3128117091","cited":112,"byYear":{"2021":6,"2022":29,"2023":19,"2024":22,"2025":22,"2026":13},"year":2021,"title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial"},"paper-empower-lung-1-lancet-oncol-2023-update":{"doi":"10.1016/s1470-2045(23)00329-7","openalexId":"W4385803968","cited":106,"byYear":{"2023":3,"2024":19,"2025":54,"2026":30},"year":2023,"title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial"},"paper-firstmappp-sunitinib-metastatic-ppgl-baudin-lancet-2024":{"doi":"10.1016/s0140-6736(23)02554-0","openalexId":"W4392029110","cited":70,"byYear":{"2024":23,"2025":32,"2026":15},"year":2024,"title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial"},"paper-nct04129502-j-clin-oncol-2025":{"doi":"10.1200/jco-24-01269","openalexId":"W4406923629","cited":30,"byYear":{"2025":15,"2026":15},"year":2025,"title":"First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial"},"paper-nct05351788-nat-med-2025":{"doi":"10.1038/s41591-025-03883-5","openalexId":"W4413306670","cited":22,"byYear":{"2025":3,"2026":19},"year":2025,"title":"First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial"},"paper-nct05668988-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2604461","openalexId":"W7162799555","cited":10,"byYear":{"2026":10},"year":2026,"title":"First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations"},"paper-nct05186974-j-thorac-oncol-2026":{"doi":"10.1016/j.jtho.2025.10.016","openalexId":"W4415680764","cited":9,"byYear":{"2026":9},"year":2025,"title":"First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study"},"paper-gorski-brca1-founder-mutations-poland-ajhg-2000":{"doi":"10.1086/302922","openalexId":"W1979368669","cited":258,"byYear":{"2012":11,"2013":9,"2014":12,"2015":9,"2016":7,"2017":8,"2018":9,"2019":13,"2020":3,"2021":8,"2022":5,"2023":5,"2024":2,"2025":3,"2026":4},"year":2000,"title":"Founder Mutations in the BRCA1 Gene in Polish Families with Breast-Ovarian Cancer"},"paper-shah-br-j-haematol":{"doi":"10.1111/bjh.17421","openalexId":"W3156837343","cited":29,"byYear":{"2022":7,"2023":6,"2024":8,"2025":2,"2026":6},"year":2021,"title":"Front‐line management of post‐transplantation lymphoproliferative disorder in adult solid organ recipient patients — A British Society for Haematology Guideline"},"paper-nct04547166-med-2024":{"doi":"10.1016/j.medj.2024.05.009","openalexId":"W4399566583","cited":18,"byYear":{"2024":3,"2025":7,"2026":8},"year":2024,"title":"First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial"},"paper-checkmate-227-int-j-clin-oncol-2023-update":{"doi":"10.1007/s10147-023-02390-2","openalexId":"W4385616716","cited":13,"byYear":{"2023":1,"2024":7,"2025":2,"2026":3},"year":2023,"title":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1"},"paper-cid-chile-programme-gallbladder-cancer-mortality-am-j-epidemiol-2024":{"doi":"10.1093/aje/kwae027","openalexId":"W4393988000","cited":9,"byYear":{"2024":3,"2025":3,"2026":3},"year":2024,"title":"Gallbladder cancer mortality in Chile: has the government program targeting young gallstone patients had an impact?"},"paper-nct04657991-eur-j-cancer-2024":{"doi":"10.1016/j.ejca.2024.115070","openalexId":"W4403329913","cited":8,"byYear":{"2025":5,"2026":3},"year":2024,"title":"First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study"},"paper-nct05227664-nat-med-2026":{"doi":"10.1038/s41591-026-04564-7","openalexId":"W7202250977","cited":0,"byYear":{},"year":2026,"title":"First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial"},"paper-keynote-671-ann-oncol-2026-update":{"doi":"10.1016/j.annonc.2026.08.005","openalexId":"W7203953659","cited":0,"byYear":{},"year":2026,"title":"Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study"},"paper-sorlie-breast-carcinoma-subclasses-pnas-2001":{"doi":"10.1073/pnas.191367098","openalexId":"W2131994307","cited":11083,"byYear":{"2012":666,"2013":650,"2014":591,"2015":622,"2016":542,"2017":534,"2018":512,"2019":524,"2020":537,"2021":506,"2022":414,"2023":390,"2024":359,"2025":245,"2026":137},"year":2001,"title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications"},"paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009":{"doi":"10.1056/nejmoa0810699","openalexId":"W2166084034","cited":8322,"byYear":{"2012":625,"2013":657,"2014":675,"2015":689,"2016":602,"2017":619,"2018":547,"2019":533,"2020":495,"2021":421,"2022":380,"2023":326,"2024":245,"2025":270,"2026":167},"year":2009,"title":"Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma"},"paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988":{"doi":"10.1056/nejm198809013190901","openalexId":"W2091723114","cited":6784,"byYear":{"2012":255,"2013":212,"2014":225,"2015":178,"2016":179,"2017":171,"2018":144,"2019":173,"2020":150,"2021":170,"2022":176,"2023":121,"2024":119,"2025":80,"2026":51},"year":1988,"title":"Genetic Alterations during Colorectal-Tumor Development"},"paper-galon-immune-contexture-colorectal-science-2006":{"doi":"10.1126/science.1129139","openalexId":"W2142300779","cited":6652,"byYear":{"2012":237,"2013":278,"2014":266,"2015":374,"2016":394,"2017":411,"2018":454,"2019":439,"2020":562,"2021":610,"2022":476,"2023":459,"2024":367,"2025":279,"2026":208},"year":2006,"title":"Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome"},"paper-egfr-nsclc-n-engl-j-med-2010":{"doi":"10.1056/nejmoa0909530","openalexId":"W2132157071","cited":5598,"byYear":{"2012":377,"2013":418,"2014":437,"2015":454,"2016":428,"2017":457,"2018":420,"2019":390,"2020":376,"2021":379,"2022":314,"2023":265,"2024":218,"2025":175,"2026":84},"year":2010,"title":"Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR"},"paper-smyth-lancet":{"doi":"10.1016/s0140-6736(20)31288-5","openalexId":"W4210990885","cited":5034,"byYear":{"2020":19,"2021":362,"2022":747,"2023":937,"2024":1348,"2025":1073,"2026":546},"year":2020,"title":"Gastric cancer"},"paper-bailey-molecular-subtypes-pancreatic-nature-2016":{"doi":"10.1038/nature16965","openalexId":"W2285093314","cited":3805,"byYear":{"2014":1,"2016":118,"2017":262,"2018":307,"2019":326,"2020":428,"2021":538,"2022":479,"2023":438,"2024":331,"2025":352,"2026":218},"year":2016,"title":"Genomic analyses identify molecular subtypes of pancreatic cancer"},"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011":{"doi":"10.1126/scitranslmed.3002003","openalexId":"W1980497534","cited":3602,"byYear":{"2012":154,"2013":255,"2014":233,"2015":269,"2016":279,"2017":332,"2018":300,"2019":261,"2020":318,"2021":274,"2022":275,"2023":187,"2024":181,"2025":144,"2026":82},"year":2011,"title":"Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors"},"paper-minn-nature":{"doi":"10.1038/nature03799","openalexId":"W2082833890","cited":2984,"byYear":{"2012":184,"2013":158,"2014":163,"2015":173,"2016":175,"2017":151,"2018":125,"2019":156,"2020":139,"2021":164,"2022":94,"2023":190,"2024":118,"2025":83,"2026":30},"year":2005,"title":"Genes that mediate breast cancer metastasis to lung"},"paper-lengauer-genetic-instability-colorectal-nature-1997":{"doi":"10.1038/386623a0","openalexId":"W2080308138","cited":2007,"byYear":{"2012":75,"2013":88,"2014":56,"2015":70,"2016":53,"2017":62,"2018":54,"2019":51,"2020":55,"2021":44,"2022":37,"2023":48,"2024":40,"2025":21,"2026":15},"year":1997,"title":"Genetic instability in colorectal cancers"},"paper-delattre-nature":{"doi":"10.1038/359162a0","openalexId":"W2069351898","cited":1928,"byYear":{"2012":45,"2013":62,"2014":60,"2015":61,"2016":69,"2017":58,"2018":57,"2019":71,"2020":87,"2021":90,"2022":82,"2023":68,"2024":74,"2025":73,"2026":45},"year":1992,"title":"Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours"},"paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019":{"doi":"10.1073/pnas.1902651116","openalexId":"W2944403040","cited":1468,"byYear":{"2018":1,"2019":41,"2020":154,"2021":234,"2022":202,"2023":262,"2024":232,"2025":203,"2026":139},"year":2019,"title":"Genomic correlates of clinical outcome in advanced prostate cancer"},"paper-nakamura-biliary-genomic-spectra-nat-genet-2015":{"doi":"10.1038/ng.3375","openalexId":"W1903979702","cited":1324,"byYear":{"2015":2,"2016":39,"2017":66,"2018":83,"2019":116,"2020":138,"2021":175,"2022":186,"2023":146,"2024":144,"2025":133,"2026":92},"year":2015,"title":"Genomic spectra of biliary tract cancer"},"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019":{"doi":"10.1016/j.ccell.2019.02.001","openalexId":"W2921768356","cited":1141,"byYear":{"2019":17,"2020":100,"2021":138,"2022":209,"2023":196,"2024":172,"2025":189,"2026":119},"year":2019,"title":"Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies"},"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019":{"doi":"10.1056/nejmoa1905287","openalexId":"W2947165726","cited":970,"byYear":{"2018":1,"2019":19,"2020":134,"2021":177,"2022":157,"2023":132,"2024":128,"2025":133,"2026":87},"year":2019,"title":"Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma"},"paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016":{"doi":"10.1016/j.celrep.2016.03.075","openalexId":"W2339723519","cited":948,"byYear":{"2015":1,"2016":14,"2017":84,"2018":105,"2019":114,"2020":119,"2021":132,"2022":116,"2023":108,"2024":59,"2025":60,"2026":36},"year":2016,"title":"Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma"},"paper-majzner-nature":{"doi":"10.1038/s41586-022-04489-4","openalexId":"W4210924686","cited":833,"byYear":{"2022":94,"2023":229,"2024":215,"2025":175,"2026":120},"year":2022,"title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas"},"paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017":{"doi":"10.1056/nejmoa1614598","openalexId":"W2761878534","cited":812,"byYear":{"2016":2,"2017":9,"2018":78,"2019":86,"2020":95,"2021":111,"2022":106,"2023":77,"2024":111,"2025":86,"2026":49},"year":2017,"title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma"},"paper-quigley-structural-variation-mcrpc-cell-2018":{"doi":"10.1016/j.cell.2018.06.039","openalexId":"W2884001931","cited":761,"byYear":{"2018":15,"2019":81,"2020":106,"2021":116,"2022":96,"2023":117,"2024":108,"2025":76,"2026":45},"year":2018,"title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer"},"paper-bertucci-metastatic-breast-genomics-nature-2019":{"doi":"10.1038/s41586-019-1056-z","openalexId":"W2946317931","cited":758,"byYear":{"2019":31,"2020":121,"2021":145,"2022":139,"2023":111,"2024":106,"2025":69,"2026":35},"year":2019,"title":"Genomic characterization of metastatic breast cancers"},"paper-bielski-nat-genet":{"doi":"10.1038/s41588-018-0165-1","openalexId":"W2884903585","cited":726,"byYear":{"2016":1,"2018":10,"2019":34,"2020":83,"2021":108,"2022":99,"2023":110,"2024":105,"2025":101,"2026":75},"year":2018,"title":"Genome doubling shapes the evolution and prognosis of advanced cancers"},"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002":{"doi":"10.1200/jco.2002.11.050","openalexId":"W2161170571","cited":689,"byYear":{"2012":45,"2013":40,"2014":30,"2015":45,"2016":29,"2017":45,"2018":31,"2019":19,"2020":20,"2021":15,"2022":23,"2023":22,"2024":12,"2025":10,"2026":7},"year":2002,"title":"Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial"},"paper-aung-compass-early-results-ccr-2018":{"doi":"10.1158/1078-0432.ccr-17-2994","openalexId":"W2780727948","cited":651,"byYear":{"2016":1,"2017":1,"2018":17,"2019":58,"2020":79,"2021":122,"2022":78,"2023":93,"2024":79,"2025":75,"2026":46},"year":2017,"title":"Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial"},"paper-rodon-nat-med":{"doi":"10.1038/s41591-019-0424-4","openalexId":"W2938634307","cited":614,"byYear":{"2019":30,"2020":82,"2021":107,"2022":91,"2023":80,"2024":102,"2025":78,"2026":44},"year":2019,"title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial"},"paper-casali-ann-oncol":{"doi":"10.1016/j.annonc.2021.09.005","openalexId":"W4200569669","cited":610,"byYear":{"2021":5,"2022":62,"2023":140,"2024":139,"2025":141,"2026":120},"year":2021,"title":"Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-gap70-geriatric-assessment-lancet-2021":{"doi":"10.1016/s0140-6736(21)01789-x","openalexId":"W3209480926","cited":604,"byYear":{"2021":4,"2022":110,"2023":132,"2024":150,"2025":103,"2026":104},"year":2021,"title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study"},"paper-grasso-immune-evasion-colorectal-cancer-discov-2018":{"doi":"10.1158/2159-8290.cd-17-1327","openalexId":"W2793126529","cited":567,"byYear":{"2012":1,"2018":27,"2019":60,"2020":78,"2021":99,"2022":91,"2023":77,"2024":49,"2025":42,"2026":42},"year":2018,"title":"Genetic Mechanisms of Immune Evasion in Colorectal Cancer"},"paper-chen-east-asian-lung-adenocarcinoma-nat-genet-2020":{"doi":"10.1038/s41588-019-0569-6","openalexId":"W3004318979","cited":561,"byYear":{"2020":28,"2021":85,"2022":104,"2023":125,"2024":101,"2025":73,"2026":45},"year":2020,"title":"Genomic landscape of lung adenocarcinoma in East Asians"},"paper-seddon-lancet-oncol":{"doi":"10.1016/s1470-2045(17)30622-8","openalexId":"W2752560124","cited":537,"byYear":{"2016":2,"2017":12,"2018":41,"2019":43,"2020":73,"2021":58,"2022":78,"2023":67,"2024":68,"2025":58,"2026":37},"year":2017,"title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial"},"paper-zhang-gemcitabine-cisplatin-vs-fluorouracil-cisplatin-rm-npc-lancet-2016":{"doi":"10.1016/s0140-6736(16)31388-5","openalexId":"W2512237822","cited":536,"byYear":{"2016":5,"2017":22,"2018":33,"2019":54,"2020":58,"2021":89,"2022":69,"2023":69,"2024":62,"2025":47,"2026":24},"year":2016,"title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial"},"paper-bonilla-nat-genet":{"doi":"10.1038/ng.3525","openalexId":"W2293178613","cited":508,"byYear":{"2014":1,"2016":21,"2017":37,"2018":38,"2019":50,"2020":52,"2021":70,"2022":50,"2023":58,"2024":60,"2025":50,"2026":21},"year":2016,"title":"Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma"},"paper-gap-phase2-mdacc-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2019.0270","openalexId":"W2937317161","cited":481,"byYear":{"2018":1,"2019":14,"2020":46,"2021":91,"2022":94,"2023":86,"2024":70,"2025":53,"2026":26},"year":2019,"title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers"},"paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004":{"doi":"10.1038/nrc1429","openalexId":"W2069828527","cited":462,"byYear":{"2012":13,"2013":26,"2014":32,"2015":32,"2016":22,"2017":24,"2018":18,"2019":27,"2020":24,"2021":31,"2022":35,"2023":26,"2024":13,"2025":17,"2026":12},"year":2004,"title":"Gallbladder cancer: lessons from a rare tumour"},"paper-noronha-j-clin-oncol":{"doi":"10.1200/jco.19.01154","openalexId":"W2967398721","cited":430,"byYear":{"2019":12,"2020":63,"2021":79,"2022":86,"2023":64,"2024":69,"2025":43,"2026":14},"year":2019,"title":"Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer"},"paper-duesberg-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.95.23.13692","openalexId":"W2163894688","cited":385,"byYear":{"2012":18,"2013":16,"2014":5,"2015":22,"2016":10,"2017":7,"2018":8,"2019":4,"2020":7,"2021":15,"2022":3,"2023":4,"2024":16,"2025":3,"2026":3},"year":1998,"title":"Genetic instability of cancer cells is proportional to their degree of aneuploidy"},"paper-wardell-biliary-drivers-germline-j-hepatol-2018":{"doi":"10.1016/j.jhep.2018.01.009","openalexId":"W2786714651","cited":384,"byYear":{"2018":8,"2019":30,"2020":35,"2021":67,"2022":66,"2023":63,"2024":49,"2025":33,"2026":33},"year":2018,"title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations"},"paper-garnet-dostarlimab-oaknin-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2020.4515","openalexId":"W3090741377","cited":368,"byYear":{"2020":2,"2021":40,"2022":87,"2023":106,"2024":60,"2025":47,"2026":26},"year":2020,"title":"Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer"},"paper-okane-gata6-basal-like-compass-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-3724","openalexId":"W3011562658","cited":365,"byYear":{"2019":1,"2020":17,"2021":60,"2022":51,"2023":63,"2024":62,"2025":60,"2026":50},"year":2020,"title":"GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer"},"paper-mateo-genomics-lethal-prostate-diagnosis-castration-resistance-jci-2020":{"doi":"10.1172/jci132031","openalexId":"W2997243361","cited":317,"byYear":{"2020":25,"2021":57,"2022":58,"2023":44,"2024":52,"2025":54,"2026":27},"year":2019,"title":"Genomics of lethal prostate cancer at diagnosis and castration resistance"},"paper-zhang-lung-cancer-never-smokers-nat-genet-2021":{"doi":"10.1038/s41588-021-00920-0","openalexId":"W3196488607","cited":255,"byYear":{"2021":3,"2022":28,"2023":66,"2024":55,"2025":64,"2026":38},"year":2021,"title":"Genomic and evolutionary classification of lung cancer in never smokers"},"paper-park-hrd-pancreatic-platinum-ccr-2020":{"doi":"10.1158/1078-0432.ccr-20-0418","openalexId":"W3028410510","cited":239,"byYear":{"2020":13,"2021":42,"2022":36,"2023":48,"2024":35,"2025":36,"2026":29},"year":2020,"title":"Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection"},"paper-tukachinsky-ctdna-3334-advanced-prostate-ccr-2021":{"doi":"10.1158/1078-0432.ccr-20-4805","openalexId":"W3127113113","cited":204,"byYear":{"2021":17,"2022":39,"2023":54,"2024":37,"2025":38,"2026":19},"year":2021,"title":"Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms"},"paper-jin-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd007731.pub3","openalexId":"W2116867946","cited":169,"byYear":{"2013":7,"2014":7,"2015":6,"2016":10,"2017":10,"2018":15,"2019":18,"2020":28,"2021":12,"2022":12,"2023":17,"2024":10,"2025":10,"2026":5},"year":2016,"title":"Ganoderma lucidum (Reishi mushroom) for cancer treatment"},"paper-diaz-gay-colibactin-geographic-age-mutational-processes-nature-2025":{"doi":"10.1038/s41586-025-09025-8","openalexId":"W4409729414","cited":165,"byYear":{"2025":49,"2026":116},"year":2025,"title":"Geographic and age variations in mutational processes in colorectal cancer"},"paper-noe-cyst-malignant-progression-genomics-nat-commun-2020":{"doi":"10.1038/s41467-020-17917-8","openalexId":"W3049139822","cited":147,"byYear":{"2020":2,"2021":22,"2022":25,"2023":30,"2024":21,"2025":28,"2026":19},"year":2020,"title":"Genomic characterization of malignant progression in neoplastic pancreatic cysts"},"paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019":{"doi":"10.1038/s41598-019-49860-0","openalexId":"W2972688118","cited":116,"byYear":{"2019":1,"2020":12,"2021":22,"2022":23,"2023":13,"2024":18,"2025":15,"2026":12},"year":2019,"title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information"},"paper-nct04585035-signal-transduct-target-ther-2025":{"doi":"10.1038/s41392-025-02274-z","openalexId":"W4411331277","cited":22,"byYear":{"2025":6,"2026":16},"year":2025,"title":"Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation"},"paper-lin-gallbladder-neoplasia-carcinoma-evolution-nat-commun-2021":{"doi":"10.1038/s41467-021-25012-9","openalexId":"W3191669928","cited":44,"byYear":{"2022":9,"2023":6,"2024":11,"2025":11,"2026":7},"year":2021,"title":"Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer"},"paper-suryavanshi-indian-gallbladder-genomics-jco-go-2025":{"doi":"10.1200/go-25-00332","openalexId":"W4417535666","cited":2,"byYear":{"2026":2},"year":2025,"title":"Genomic Profiling of Indian Gallbladder Carcinoma: Mutational Insights in a High-Incidence Population"},"paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024":{"doi":"10.4067/s0034-98872024001001028","openalexId":"W4408246568","cited":1,"byYear":{"2025":1},"year":2024,"title":"Cáncer de vesícula: ¿Es momento de modificar el GES?"},"paper-grivennikov-immunity-inflammation-cancer-cell-2010":{"doi":"10.1016/j.cell.2010.01.025","openalexId":"W2118278569","cited":10905,"byYear":{"2012":405,"2013":510,"2014":519,"2015":600,"2016":717,"2017":813,"2018":787,"2019":799,"2020":888,"2021":971,"2022":939,"2023":784,"2024":749,"2025":627,"2026":409},"year":2010,"title":"Immunity, Inflammation, and Cancer"},"paper-hallmarks-new-dimensions-cancer-discov-2022":{"doi":"10.1158/2159-8290.cd-21-1059","openalexId":"W4206662285","cited":9903,"byYear":{"2019":1,"2021":4,"2022":1031,"2023":2075,"2024":2713,"2025":2346,"2026":1731},"year":2022,"title":"Hallmarks of Cancer: New Dimensions"},"paper-gerlinger-intratumour-heterogeneity-nejm-2012":{"doi":"10.1056/nejmoa1113205","openalexId":"W2150575159","cited":7936,"byYear":{"2012":326,"2013":626,"2014":682,"2015":691,"2016":740,"2017":676,"2018":653,"2019":558,"2020":569,"2021":603,"2022":541,"2023":372,"2024":318,"2025":299,"2026":259},"year":2012,"title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing"},"paper-llovet-nat-rev-dis-primers":{"doi":"10.1038/s41572-020-00240-3","openalexId":"W4210774372","cited":6753,"byYear":{"2014":1,"2016":1,"2020":2,"2021":290,"2022":1140,"2023":1518,"2024":1658,"2025":1329,"2026":813},"year":2021,"title":"Hepatocellular carcinoma"},"paper-rose-cisplatin-chemoradiation-cervical-nejm-1999":{"doi":"10.1056/nejm199904153401502","openalexId":"W2314753133","cited":2696,"byYear":{"2012":121,"2013":101,"2014":102,"2015":112,"2016":106,"2017":99,"2018":107,"2019":90,"2020":116,"2021":109,"2022":106,"2023":90,"2024":82,"2025":79,"2026":68},"year":1999,"title":"Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer"},"paper-gog-240-bevacizumab-cervical-nejm-2014":{"doi":"10.1056/nejmoa1309748","openalexId":"W2100756525","cited":1535,"byYear":{"2014":65,"2015":121,"2016":121,"2017":128,"2018":118,"2019":113,"2020":158,"2021":136,"2022":145,"2023":123,"2024":120,"2025":108,"2026":75},"year":2014,"title":"Improved Survival with Bevacizumab in Advanced Cervical Cancer"},"paper-grid-regorafenib-gist-lancet-2013":{"doi":"10.1016/s0140-6736(12)61857-1","openalexId":"W2116922255","cited":1428,"byYear":{"2012":5,"2013":58,"2014":102,"2015":117,"2016":110,"2017":120,"2018":104,"2019":113,"2020":118,"2021":113,"2022":116,"2023":124,"2024":79,"2025":91,"2026":51},"year":2012,"title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial"},"paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002":{"doi":"10.1056/nejmoa020152","openalexId":"W1972618930","cited":1372,"byYear":{"2012":83,"2013":59,"2014":79,"2015":60,"2016":44,"2017":49,"2018":52,"2019":47,"2020":54,"2021":47,"2022":29,"2023":24,"2024":26,"2025":25,"2026":17},"year":2002,"title":"Germ-Line Mutations in Nonsyndromic Pheochromocytoma"},"paper-venkataramani-nature":{"doi":"10.1038/s41586-019-1564-x","openalexId":"W2973686658","cited":1242,"byYear":{"2019":18,"2020":142,"2021":144,"2022":147,"2023":195,"2024":196,"2025":221,"2026":178},"year":2019,"title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression"},"paper-andrew-lassman-neuro-oncol-2020":{"doi":"10.1093/neuonc/noaa106","openalexId":"W3020099303","cited":1188,"byYear":{"2020":29,"2021":124,"2022":199,"2023":222,"2024":250,"2025":217,"2026":143},"year":2020,"title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions"},"paper-weller-nat-rev-dis-primers":{"doi":"10.1038/nrdp.2015.17","openalexId":"W4211105004","cited":1174,"byYear":{"2015":1,"2016":15,"2017":14,"2018":22,"2019":49,"2020":121,"2021":144,"2022":184,"2023":196,"2024":220,"2025":147,"2026":60},"year":2015,"title":"Glioma"},"paper-palles-germline-pole-pold1-proofreading-nat-genet-2013":{"doi":"10.1038/ng.2503","openalexId":"W2145606954","cited":1023,"byYear":{"2012":2,"2013":40,"2014":80,"2015":95,"2016":86,"2017":92,"2018":89,"2019":91,"2020":81,"2021":87,"2022":68,"2023":81,"2024":48,"2025":39,"2026":41},"year":2012,"title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas"},"paper-foulkes-brca1-basal-phenotype-jnci-2003":{"doi":"10.1093/jnci/djg050","openalexId":"W4256127173","cited":976,"byYear":{"2012":52,"2013":42,"2014":40,"2015":48,"2016":45,"2017":52,"2018":27,"2019":32,"2020":25,"2021":25,"2022":34,"2023":17,"2024":22,"2025":12,"2026":8},"year":2003,"title":"Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer"},"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010":{"doi":"10.1056/nejmoa1000067","openalexId":"W2140801657","cited":932,"byYear":{"2012":78,"2013":67,"2014":68,"2015":89,"2016":67,"2017":77,"2018":63,"2019":42,"2020":62,"2021":59,"2022":48,"2023":38,"2024":42,"2025":32,"2026":24},"year":2010,"title":"Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma"},"paper-castro-germline-brca-prostate-outcomes-jco-2013":{"doi":"10.1200/jco.2012.43.1882","openalexId":"W2116284235","cited":861,"byYear":{"2013":14,"2014":44,"2015":29,"2016":42,"2017":63,"2018":64,"2019":66,"2020":89,"2021":96,"2022":91,"2023":83,"2024":79,"2025":61,"2026":39},"year":2013,"title":"Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer"},"paper-groinss-v-sentinel-node-vulvar-cancer-jco-2008":{"doi":"10.1200/jco.2007.14.0566","openalexId":"W2147322486","cited":820,"byYear":{"2012":51,"2013":43,"2014":50,"2015":57,"2016":45,"2017":54,"2018":47,"2019":47,"2020":49,"2021":57,"2022":51,"2023":37,"2024":42,"2025":36,"2026":35},"year":2008,"title":"Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer"},"paper-glofitamab-dlbcl-n-engl-j-med-2022":{"doi":"10.1056/nejmoa2206913","openalexId":"W4311537867","cited":754,"byYear":{"2022":3,"2023":124,"2024":203,"2025":249,"2026":174},"year":2022,"title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma"},"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013":{"doi":"10.1016/s1470-2045(12)70560-0","openalexId":"W2142466432","cited":748,"byYear":{"2013":15,"2014":20,"2015":67,"2016":72,"2017":67,"2018":64,"2019":70,"2020":61,"2021":71,"2022":70,"2023":57,"2024":49,"2025":40,"2026":24},"year":2013,"title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial"},"paper-sullivan-lancet-oncol":{"doi":"10.1016/s1470-2045(15)00223-5","openalexId":"W1935362880","cited":711,"byYear":{"2015":11,"2016":30,"2017":47,"2018":39,"2019":65,"2020":48,"2021":80,"2022":79,"2023":74,"2024":74,"2025":91,"2026":71},"year":2015,"title":"Global cancer surgery: delivering safe, affordable, and timely cancer surgery"},"paper-glow-zolbetuximab-nat-med-2023":{"doi":"10.1038/s41591-023-02465-7","openalexId":"W4385429828","cited":660,"byYear":{"2023":24,"2024":168,"2025":225,"2026":243},"year":2023,"title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial"},"paper-plotkin-bevacizumab-nf2-nejm-2009":{"doi":"10.1056/nejmoa0902579","openalexId":"W2170249858","cited":534,"byYear":{"2012":34,"2013":29,"2014":29,"2015":41,"2016":37,"2017":27,"2018":21,"2019":26,"2020":38,"2021":51,"2022":20,"2023":38,"2024":25,"2025":31,"2026":21},"year":2009,"title":"Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2"},"paper-saxena-mol-cell":{"doi":"10.1016/j.molcel.2022.05.004","openalexId":"W4283012954","cited":467,"byYear":{"2021":1,"2022":11,"2023":83,"2024":109,"2025":149,"2026":114},"year":2022,"title":"Hallmarks of DNA replication stress"},"paper-huang-bone-marrow-transplant":{"doi":"10.1038/sj.bmt.1705445","openalexId":"W2079110478","cited":441,"byYear":{"2012":22,"2013":13,"2014":22,"2015":27,"2016":26,"2017":35,"2018":34,"2019":28,"2020":27,"2021":31,"2022":29,"2023":18,"2024":26,"2025":15,"2026":14},"year":2006,"title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies"},"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017":{"doi":"10.1001/jamaoncol.2017.1007","openalexId":"W2734897937","cited":409,"byYear":{"2016":1,"2017":5,"2018":39,"2019":54,"2020":75,"2021":50,"2022":63,"2023":31,"2024":51,"2025":23,"2026":14},"year":2017,"title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer"},"paper-global-retinoblastoma-study-jama-oncol":{"doi":"10.1001/jamaoncol.2019.6716","openalexId":"W3008735477","cited":385,"byYear":{"2019":1,"2020":18,"2021":43,"2022":86,"2023":65,"2024":75,"2025":61,"2026":35},"year":2020,"title":"Global Retinoblastoma Presentation and Analysis by National Income Level"},"paper-filippini-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd005004.pub3","openalexId":"W1485232676","cited":326,"byYear":{"2012":21,"2013":26,"2014":17,"2015":16,"2016":12,"2017":12,"2018":11,"2019":4,"2020":24,"2021":20,"2022":27,"2023":30,"2024":35,"2025":24,"2026":4},"year":2020,"title":"Green tea (Camellia sinensis) for the prevention of cancer"},"paper-ryan-support-care-cancer":{"doi":"10.1007/s00520-011-1236-3","openalexId":"W2107176806","cited":267,"byYear":{"2012":6,"2013":17,"2014":14,"2015":28,"2016":18,"2017":23,"2018":18,"2019":23,"2020":21,"2021":26,"2022":20,"2023":19,"2024":12,"2025":12,"2026":6},"year":2011,"title":"Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients"},"paper-heining-nrg1-fusions-kras-wild-type-pancreatic-cancer-discov-2018":{"doi":"10.1158/2159-8290.cd-18-0036","openalexId":"W2804827327","cited":244,"byYear":{"2018":4,"2019":22,"2020":24,"2021":52,"2022":43,"2023":41,"2024":24,"2025":22,"2026":10},"year":2018,"title":"NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer"},"paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016":{"doi":"10.1002/path.4679","openalexId":"W2212171768","cited":242,"byYear":{"2016":6,"2017":15,"2018":18,"2019":25,"2020":26,"2021":24,"2022":37,"2023":27,"2024":30,"2025":23,"2026":11},"year":2015,"title":"HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR , FOCUS and PICCOLO colorectal cancer trials"},"paper-gog-281-trametinib-lgsoc-gershenson-lancet-2022":{"doi":"10.1016/s0140-6736(21)02175-9","openalexId":"W4210288145","cited":237,"byYear":{"2022":24,"2023":44,"2024":63,"2025":61,"2026":45},"year":2022,"title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial"},"paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017":{"doi":"10.1038/ncomms13671","openalexId":"W2570660231","cited":235,"byYear":{"2016":1,"2017":17,"2018":29,"2019":31,"2020":28,"2021":35,"2022":21,"2023":25,"2024":23,"2025":15,"2026":8},"year":2017,"title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories"},"paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019":{"doi":"10.1038/s41436-018-0009-5","openalexId":"W2810883871","cited":224,"byYear":{"2017":1,"2018":5,"2019":19,"2020":33,"2021":50,"2022":36,"2023":28,"2024":20,"2025":21,"2026":11},"year":2018,"title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer"},"paper-sharma-tnbc-registry-germline-brca-bcrt-2014":{"doi":"10.1007/s10549-014-2980-0","openalexId":"W1991808212","cited":217,"byYear":{"2014":3,"2015":9,"2016":12,"2017":17,"2018":18,"2019":22,"2020":23,"2021":24,"2022":14,"2023":18,"2024":38,"2025":12,"2026":7},"year":2014,"title":"Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing"},"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024":{"doi":"10.1200/jco.23.02225","openalexId":"W4390575634","cited":211,"byYear":{"2023":1,"2024":50,"2025":83,"2026":77},"year":2024,"title":"Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline"},"paper-getug-13-marker-guided-dose-dense-chemotherapy-fizazi-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70490-5","openalexId":"W2073794968","cited":206,"byYear":{"2014":2,"2015":25,"2016":26,"2017":11,"2018":21,"2019":15,"2020":19,"2021":14,"2022":21,"2023":16,"2024":15,"2025":14,"2026":6},"year":2014,"title":"Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial"},"paper-gog-174-methotrexate-vs-dactinomycin-low-risk-gtn-jco-2011":{"doi":"10.1200/jco.2010.30.4386","openalexId":"W2160168356","cited":199,"byYear":{"2012":13,"2013":11,"2014":14,"2015":11,"2016":11,"2017":10,"2018":6,"2019":9,"2020":18,"2021":29,"2022":15,"2023":14,"2024":10,"2025":10,"2026":10},"year":2011,"title":"Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study"},"paper-glofitamab-dlbcl-lancet-2024":{"doi":"10.1016/s0140-6736(24)01774-4","openalexId":"W4404353984","cited":176,"byYear":{"2024":4,"2025":98,"2026":74},"year":2024,"title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial"},"paper-harmoni-2-lancet-2025":{"doi":"10.1016/s0140-6736(24)02722-3","openalexId":"W4408177149","cited":167,"byYear":{"2025":77,"2026":90},"year":2025,"title":"Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China"},"paper-graall-2005-huguet-jco-2018":{"doi":"10.1200/jco.2017.76.8192","openalexId":"W2806642795","cited":161,"byYear":{"2018":4,"2019":11,"2020":24,"2021":15,"2022":24,"2023":23,"2024":23,"2025":24,"2026":12},"year":2018,"title":"Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial"},"paper-kamath-neurosurgery":{"doi":"10.1093/neuros/nyy375","openalexId":"W2888317767","cited":146,"byYear":{"2019":8,"2020":26,"2021":25,"2022":21,"2023":18,"2024":25,"2025":13,"2026":8},"year":2018,"title":"Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes"},"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024":{"doi":"10.1016/s0140-6736(24)01315-1","openalexId":"W4400268343","cited":141,"byYear":{"2024":18,"2025":60,"2026":63},"year":2024,"title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial"},"paper-groinss-v-ii-radiotherapy-vulvar-micrometastases-jco-2021":{"doi":"10.1200/jco.21.00006","openalexId":"W3195589874","cited":135,"byYear":{"2021":7,"2022":25,"2023":33,"2024":24,"2025":26,"2026":20},"year":2021,"title":"Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II"},"paper-freites-martinez-j-am-acad-dermatol":{"doi":"10.1016/j.jaad.2018.03.056","openalexId":"W2796969854","cited":103,"byYear":{"2018":2,"2019":8,"2020":14,"2021":16,"2022":13,"2023":19,"2024":10,"2025":8,"2026":12},"year":2018,"title":"Hair disorders in cancer survivors"},"paper-gog-0261-carcinosarcoma-powell-jco-2022":{"doi":"10.1200/jco.21.02050","openalexId":"W4206020407","cited":99,"byYear":{"2015":1,"2020":2,"2021":6,"2022":19,"2023":19,"2024":21,"2025":20,"2026":10},"year":2022,"title":"Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial"},"paper-nct04576455-j-clin-oncol-2024":{"doi":"10.1200/jco.23.01500","openalexId":"W4393216842","cited":77,"byYear":{"2024":12,"2025":35,"2026":30},"year":2024,"title":"Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study"},"paper-nct04270591-eclinicalmedicine-2023":{"doi":"10.1016/j.eclinm.2023.101952","openalexId":"W4362675504","cited":58,"byYear":{"2023":2,"2024":22,"2025":24,"2026":10},"year":2023,"title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial"},"paper-nct05009329-nat-med-2025":{"doi":"10.1038/s41591-024-03401-z","openalexId":"W4406104531","cited":35,"byYear":{"2025":19,"2026":16},"year":2025,"title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial"},"paper-nct05288205-lancet-respir-med-2026":{"doi":"10.1016/s2213-2600(25)00258-9","openalexId":"W4416807145","cited":12,"byYear":{"2025":1,"2026":11},"year":2025,"title":"Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial"},"paper-nct05671510-nat-med-2026":{"doi":"10.1038/s41591-026-04323-8","openalexId":"W7141500883","cited":1,"byYear":{"2026":1},"year":2026,"title":"Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial"},"paper-garate-calderon-gallbladder-cancer-worldwide-exome-ebiomedicine-2026":{"doi":"10.1016/j.ebiom.2026.106305","openalexId":"W7161983502","cited":1,"byYear":{"2026":1},"year":2026,"title":"Geographic and genetic diversity in gallbladder cancer mutation profiles: insights from a worldwide exome analysis"},"paper-hodi-ipilimumab-melanoma-nejm-2010":{"doi":"10.1056/nejmoa1003466","openalexId":"W2097995306","cited":15363,"byYear":{"2012":693,"2013":895,"2014":1024,"2015":1263,"2016":1261,"2017":1289,"2018":1225,"2019":1121,"2020":1204,"2021":1184,"2022":909,"2023":924,"2024":798,"2025":590,"2026":371},"year":2010,"title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma"},"paper-hurwitz-bevacizumab-crc-nejm-2004":{"doi":"10.1056/nejmoa032691","openalexId":"W2157769714","cited":11029,"byYear":{"2012":713,"2013":664,"2014":605,"2015":519,"2016":461,"2017":424,"2018":325,"2019":294,"2020":297,"2021":271,"2022":273,"2023":286,"2024":266,"2025":164,"2026":115},"year":2004,"title":"Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer"},"paper-hollstein-p53-mutations-science-1991":{"doi":"10.1126/science.1905840","openalexId":"W2042316019","cited":8129,"byYear":{"2012":214,"2013":209,"2014":221,"2015":172,"2016":149,"2017":146,"2018":126,"2019":127,"2020":127,"2021":128,"2022":123,"2023":100,"2024":75,"2025":52,"2026":19},"year":1991,"title":"p53 Mutations in Human Cancers"},"paper-bonnet-nat-med":{"doi":"10.1038/nm0797-730","openalexId":"W2009886857","cited":7040,"byYear":{"2012":477,"2013":426,"2014":428,"2015":433,"2016":366,"2017":329,"2018":303,"2019":290,"2020":317,"2021":295,"2022":267,"2023":290,"2024":189,"2025":192,"2026":94},"year":1997,"title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell"},"paper-ang-hpv-oropharyngeal-nejm-2010":{"doi":"10.1056/nejmoa0912217","openalexId":"W2110664940","cited":6628,"byYear":{"2012":295,"2013":349,"2014":425,"2015":454,"2016":468,"2017":466,"2018":509,"2019":476,"2020":555,"2021":497,"2022":472,"2023":433,"2024":356,"2025":336,"2026":263},"year":2010,"title":"Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer"},"paper-lehmann-tnbc-subtypes-jci-2011":{"doi":"10.1172/jci45014","openalexId":"W2134539328","cited":5688,"byYear":{"2012":69,"2013":186,"2014":259,"2015":342,"2016":377,"2017":380,"2018":434,"2019":423,"2020":504,"2021":614,"2022":524,"2023":524,"2024":386,"2025":377,"2026":262},"year":2011,"title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies"},"paper-birkmeyer-n-engl-j-med":{"doi":"10.1056/nejmsa012337","openalexId":"W2046133119","cited":5019,"byYear":{"2012":227,"2013":228,"2014":254,"2015":260,"2016":244,"2017":253,"2018":265,"2019":242,"2020":255,"2021":204,"2022":190,"2023":173,"2024":141,"2025":115,"2026":103},"year":2002,"title":"Hospital Volume and Surgical Mortality in the United States"},"paper-body-fatness-iarc-nejm-2016":{"doi":"10.1056/nejmsr1606602","openalexId":"W2510411424","cited":3670,"byYear":{"2015":1,"2016":26,"2017":143,"2018":227,"2019":298,"2020":381,"2021":465,"2022":449,"2023":474,"2024":491,"2025":404,"2026":304},"year":2016,"title":"Body Fatness and Cancer — Viewpoint of the IARC Working Group"},"paper-wolff-j-clin-oncol-2018":{"doi":"10.1200/jco.2018.77.8738","openalexId":"W2806209829","cited":2545,"byYear":{"2012":1,"2017":1,"2018":34,"2019":115,"2020":209,"2021":302,"2022":364,"2023":450,"2024":482,"2025":336,"2026":246},"year":2018,"title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update"},"paper-feinberg-nature":{"doi":"10.1038/301089a0","openalexId":"W1974747095","cited":2464,"byYear":{"2012":133,"2013":114,"2014":128,"2015":111,"2016":102,"2017":104,"2018":92,"2019":92,"2020":91,"2021":107,"2022":80,"2023":85,"2024":70,"2025":48,"2026":27},"year":1983,"title":"Hypomethylation distinguishes genes of some human cancers from their normal counterparts"},"paper-jan-burger-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1509388","openalexId":"W2233614027","cited":1606,"byYear":{"2013":2,"2014":2,"2015":2,"2016":108,"2017":181,"2018":164,"2019":173,"2020":169,"2021":193,"2022":141,"2023":146,"2024":137,"2025":106,"2026":80},"year":2015,"title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia"},"paper-himalaya-nejm-evidence-2022":{"doi":"10.1056/evidoa2100070","openalexId":"W4281645619","cited":1543,"byYear":{"2021":1,"2022":64,"2023":295,"2024":426,"2025":452,"2026":304},"year":2022,"title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma"},"paper-klichinsky-nat-biotechnol":{"doi":"10.1038/s41587-020-0462-y","openalexId":"W2913136103","cited":1503,"byYear":{"2012":1,"2020":70,"2021":179,"2022":209,"2023":245,"2024":305,"2025":266,"2026":228},"year":2020,"title":"Human chimeric antigen receptor macrophages for cancer immunotherapy"},"paper-her2climb-nejm-2020":{"doi":"10.1056/nejmoa1914609","openalexId":"W2995808512","cited":1348,"byYear":{"2020":156,"2021":248,"2022":260,"2023":201,"2024":217,"2025":157,"2026":105},"year":2019,"title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer"},"paper-sankaranarayanan-hpv-screening-nejm-2009":{"doi":"10.1056/nejmoa0808516","openalexId":"W2130297731","cited":1300,"byYear":{"2012":113,"2013":93,"2014":80,"2015":93,"2016":66,"2017":76,"2018":64,"2019":70,"2020":61,"2021":72,"2022":48,"2023":57,"2024":58,"2025":56,"2026":36},"year":2009,"title":"HPV Screening for Cervical Cancer in Rural India"},"paper-telli-hrd-score-platinum-tnbc-ccr-2016":{"doi":"10.1158/1078-0432.ccr-15-2477","openalexId":"W2295085830","cited":1201,"byYear":{"2016":18,"2017":66,"2018":56,"2019":68,"2020":95,"2021":160,"2022":194,"2023":171,"2024":168,"2025":119,"2026":84},"year":2016,"title":"Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer"},"paper-davies-nat-med":{"doi":"10.1038/nm.4292","openalexId":"W2596164112","cited":1162,"byYear":{"2016":1,"2017":33,"2018":83,"2019":93,"2020":126,"2021":159,"2022":159,"2023":199,"2024":133,"2025":108,"2026":67},"year":2017,"title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures"},"paper-murray-brunt-lancet":{"doi":"10.1016/s0140-6736(20)30932-6","openalexId":"W3022548009","cited":1114,"byYear":{"2019":1,"2020":73,"2021":167,"2022":210,"2023":165,"2024":209,"2025":173,"2026":114},"year":2020,"title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial"},"paper-shelley-hwang-cancer-cell-2019":{"doi":"10.1016/j.ccell.2019.02.009","openalexId":"W2931512726","cited":972,"byYear":{"2019":29,"2020":110,"2021":179,"2022":168,"2023":155,"2024":148,"2025":122,"2026":60},"year":2019,"title":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets"},"paper-pd-l1-urothelial-trends-mol-med-2015":{"doi":"10.1016/j.molmed.2014.10.009","openalexId":"W1991235944","cited":861,"byYear":{"2015":25,"2016":41,"2017":45,"2018":67,"2019":75,"2020":73,"2021":107,"2022":110,"2023":113,"2024":97,"2025":69,"2026":38},"year":2014,"title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway"},"paper-ligtenberg-epcam-deletion-msh2-silencing-nat-genet-2009":{"doi":"10.1038/ng.283","openalexId":"W1972254989","cited":833,"byYear":{"2012":49,"2013":70,"2014":58,"2015":46,"2016":58,"2017":51,"2018":55,"2019":45,"2020":62,"2021":41,"2022":36,"2023":52,"2024":39,"2025":34,"2026":17},"year":2008,"title":"Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1"},"paper-clark-syt-ssx-synovial-sarcoma-nat-genet-1994":{"doi":"10.1038/ng0894-502","openalexId":"W2017325023","cited":780,"byYear":{"2012":19,"2013":26,"2014":16,"2015":20,"2016":27,"2017":22,"2018":36,"2019":25,"2020":32,"2021":28,"2022":31,"2023":24,"2024":21,"2025":13,"2026":15},"year":1994,"title":"Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma"},"paper-jacques-grill-acta-neuropathol-2015":{"doi":"10.1007/s00401-015-1478-0","openalexId":"W2101775250","cited":696,"byYear":{"2016":30,"2017":67,"2018":51,"2019":58,"2020":86,"2021":80,"2022":75,"2023":84,"2024":94,"2025":36,"2026":30},"year":2015,"title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes"},"paper-wolff-j-clin-oncol":{"doi":"10.1200/jco.22.02864","openalexId":"W4379600909","cited":683,"byYear":{"2022":1,"2023":42,"2024":139,"2025":261,"2026":240},"year":2023,"title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update"},"paper-mesri-cell-host-microbe":{"doi":"10.1016/j.chom.2014.02.011","openalexId":"W2017517248","cited":663,"byYear":{"2014":16,"2015":29,"2016":39,"2017":45,"2018":60,"2019":65,"2020":59,"2021":88,"2022":67,"2023":67,"2024":56,"2025":40,"2026":31},"year":2014,"title":"Human Viral Oncogenesis: A Cancer Hallmarks Analysis"},"paper-moertel-n-engl-j-med":{"doi":"10.1056/nejm198501173120301","openalexId":"W2332542469","cited":634,"byYear":{"2012":17,"2013":23,"2014":21,"2015":22,"2016":22,"2017":28,"2018":30,"2019":23,"2020":28,"2021":38,"2022":32,"2023":20,"2024":21,"2025":18,"2026":12},"year":1985,"title":"High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer Who Have Had No Prior Chemotherapy"},"paper-moreira-lynch-syndrome-identification-jama-2012":{"doi":"10.1001/jama.2012.13088","openalexId":"W1993051520","cited":571,"byYear":{"2012":2,"2013":37,"2014":45,"2015":32,"2016":33,"2017":26,"2018":41,"2019":50,"2020":54,"2021":62,"2022":49,"2023":43,"2024":45,"2025":32,"2026":16},"year":2012,"title":"Identification of Lynch Syndrome Among Patients With Colorectal Cancer"},"paper-her2climb-brain-lin-jco-2020":{"doi":"10.1200/jco.20.00775","openalexId":"W3030461309","cited":560,"byYear":{"2020":35,"2021":105,"2022":121,"2023":82,"2024":114,"2025":58,"2026":45},"year":2020,"title":"Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial"},"paper-wu-nat-med":{"doi":"10.1038/s41591-021-01312-x","openalexId":"W3143784018","cited":497,"byYear":{"2021":57,"2022":97,"2023":98,"2024":86,"2025":80,"2026":78},"year":2021,"title":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals"},"paper-ibis-i-tamoxifen-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71171-4","openalexId":"W2161387798","cited":467,"byYear":{"2014":1,"2015":36,"2016":44,"2017":41,"2018":43,"2019":37,"2020":44,"2021":48,"2022":38,"2023":47,"2024":36,"2025":35,"2026":16},"year":2014,"title":"Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial"},"paper-shi-lancet-oncol":{"doi":"10.1016/s1470-2045(13)70355-3","openalexId":"W2099180737","cited":426,"byYear":{"2013":1,"2014":43,"2015":47,"2016":48,"2017":34,"2018":36,"2019":34,"2020":48,"2021":45,"2022":28,"2023":15,"2024":21,"2025":20,"2026":6},"year":2013,"title":"Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial"},"paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018":{"doi":"10.1158/1078-0432.ccr-17-3099","openalexId":"W2793938850","cited":378,"byYear":{"2014":1,"2018":20,"2019":48,"2020":56,"2021":76,"2022":52,"2023":37,"2024":37,"2025":25,"2026":26},"year":2018,"title":"Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations"},"paper-bennett-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd005005.pub4","openalexId":"W2165916285","cited":359,"byYear":{"2012":17,"2013":23,"2014":27,"2015":20,"2016":20,"2017":21,"2018":15,"2019":20,"2020":24,"2021":37,"2022":25,"2023":19,"2024":20,"2025":17,"2026":3},"year":2016,"title":"Hyperbaric oxygen therapy for late radiation tissue injury"},"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30070-0","openalexId":"W2592061165","cited":356,"byYear":{"2017":17,"2018":32,"2019":34,"2020":50,"2021":60,"2022":40,"2023":41,"2024":28,"2025":25,"2026":27},"year":2017,"title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial"},"paper-cardillo-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-10-2939","openalexId":"W2099808918","cited":312,"byYear":{"2012":6,"2013":8,"2014":9,"2015":11,"2016":12,"2017":18,"2018":10,"2019":25,"2020":13,"2021":34,"2022":24,"2023":34,"2024":37,"2025":38,"2026":30},"year":2011,"title":"Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys"},"paper-cd19-multiple-myeloma-blood-2020":{"doi":"10.1182/blood.2019004000","openalexId":"W3037830886","cited":309,"byYear":{"2013":1,"2020":6,"2021":38,"2022":46,"2023":69,"2024":54,"2025":43,"2026":51},"year":2020,"title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies"},"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017":{"doi":"10.1200/jco.2016.71.0632","openalexId":"W2590528754","cited":279,"byYear":{"2017":17,"2018":24,"2019":26,"2020":36,"2021":22,"2022":32,"2023":34,"2024":33,"2025":34,"2026":20},"year":2017,"title":"Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum"},"paper-nct04619004-j-clin-oncol-2023":{"doi":"10.1200/jco.23.01476","openalexId":"W4386582468","cited":246,"byYear":{"2023":5,"2024":78,"2025":96,"2026":65},"year":2023,"title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy"},"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017":{"doi":"10.1007/s10555-016-9645-x","openalexId":"W2567683174","cited":217,"byYear":{"2017":4,"2018":10,"2019":15,"2020":45,"2021":19,"2022":16,"2023":25,"2024":31,"2025":36,"2026":16},"year":2016,"title":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?"},"paper-anthony-nichols-nat-genet-2014":{"doi":"10.1038/ng.3096","openalexId":"W2001790878","cited":215,"byYear":{"2015":25,"2016":21,"2017":27,"2018":23,"2019":24,"2020":16,"2021":21,"2022":15,"2023":18,"2024":13,"2025":6,"2026":3},"year":2014,"title":"Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands"},"paper-ezh2-ovarian-mol-cancer-ther-2018":{"doi":"10.1158/1535-7163.mct-17-0437","openalexId":"W2790335078","cited":113,"byYear":{"2018":4,"2019":9,"2020":16,"2021":22,"2022":10,"2023":14,"2024":13,"2025":14,"2026":11},"year":2018,"title":"Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer"},"paper-singhi-alk-rearrangements-pancreatic-jnccn-2017":{"doi":"10.6004/jnccn.2017.0058","openalexId":"W2613359583","cited":106,"byYear":{"2018":8,"2019":5,"2020":10,"2021":20,"2022":20,"2023":18,"2024":10,"2025":10,"2026":5},"year":2017,"title":"Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma"},"paper-mindact-ann-oncol-2014":{"doi":"10.1093/annonc/mdu026","openalexId":"W2132894311","cited":66,"byYear":{"2014":3,"2015":8,"2016":14,"2017":6,"2018":4,"2019":3,"2020":6,"2021":3,"2022":3,"2023":3,"2024":11,"2025":1,"2026":1},"year":2014,"title":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial"},"paper-her2climb-05-j-clin-oncol-2026":{"doi":"10.1200/jco-25-02600","openalexId":"W4417198347","cited":14,"byYear":{"2026":14},"year":2025,"title":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer"},"paper-kassab-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd004845.pub2","openalexId":"W1487842335","cited":152,"byYear":{"2012":11,"2013":13,"2014":13,"2015":7,"2016":10,"2017":9,"2018":8,"2019":10,"2020":5,"2021":16,"2022":6,"2023":4,"2024":5,"2025":3,"2026":1},"year":2009,"title":"Homeopathic medicines for adverse effects of cancer treatments"},"paper-hietanen-rigvir-echovirus-viruses-2022":{"doi":"10.3390/v14030525","openalexId":"W4221087324","cited":19,"byYear":{"2022":1,"2023":3,"2024":8,"2025":5,"2026":2},"year":2022,"title":"Cytolytic Properties and Genome Analysis of Rigvir® Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates"},"paper-nct05435248-j-transl-med-2025":{"doi":"10.1186/s12967-025-06613-0","openalexId":"W4411035626","cited":8,"byYear":{"2025":2,"2026":6},"year":2025,"title":"HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non–small cell lung cancer"},"paper-nct05128487-cell-rep-med-2026":{"doi":"10.1016/j.xcrm.2026.102789","openalexId":"W7160419723","cited":2,"byYear":{"2026":2},"year":2026,"title":"HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results"},"paper-patkar-tata-memorial-gallbladder-cancer-registry-cancer-epidemiol-2025":{"doi":"10.1016/j.canep.2025.102958","openalexId":"W4416257103","cited":1,"byYear":{"2026":1},"year":2025,"title":"Hospital-based gallbladder cancer registry from a high-volume referral cancer centre in India: Insights into epidemiology and roadmap for enhancing cancer care"},"paper-angerilli-her2-ihc-cish-biliary-hum-pathol-2026":{"doi":"10.1016/j.humpath.2026.106234","openalexId":"W7171719480","cited":0,"byYear":{},"year":2026,"title":"HER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: Concordance between immunohistochemistry and chromogenic in situ hybridization in 140 Cases"},"paper-imbrave150-nejm-2020":{"doi":"10.1056/nejmoa1915745","openalexId":"W3025022288","cited":7573,"byYear":{"2014":1,"2016":2,"2019":1,"2020":297,"2021":1051,"2022":1289,"2023":1375,"2024":1352,"2025":1263,"2026":933},"year":2020,"title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma"},"paper-soda-eml4-alk-fusion-nature-2007":{"doi":"10.1038/nature05945","openalexId":"W2055402151","cited":5489,"byYear":{"2012":376,"2013":403,"2014":435,"2015":450,"2016":413,"2017":394,"2018":372,"2019":343,"2020":351,"2021":305,"2022":261,"2023":248,"2024":196,"2025":183,"2026":104},"year":2007,"title":"Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer"},"paper-imwg-criteria-rajkumar-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70442-5","openalexId":"W2144728882","cited":5050,"byYear":{"2013":3,"2014":6,"2015":155,"2016":241,"2017":312,"2018":315,"2019":393,"2020":546,"2021":571,"2022":512,"2023":493,"2024":601,"2025":516,"2026":368},"year":2014,"title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma"},"paper-shankaran-nature":{"doi":"10.1038/35074122","openalexId":"W1642873092","cited":2913,"byYear":{"2012":125,"2013":132,"2014":118,"2015":145,"2016":140,"2017":151,"2018":153,"2019":147,"2020":177,"2021":140,"2022":149,"2023":156,"2024":111,"2025":86,"2026":49},"year":2001,"title":"IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity"},"paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997":{"doi":"10.1056/nejm199704033361402","openalexId":"W1585172067","cited":2531,"byYear":{"2012":104,"2013":80,"2014":98,"2015":67,"2016":65,"2017":70,"2018":64,"2019":94,"2020":85,"2021":87,"2022":91,"2023":80,"2024":59,"2025":44,"2026":27},"year":1997,"title":"Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer"},"paper-markowitz-tgfbr2-inactivation-msi-colon-science-1995":{"doi":"10.1126/science.7761852","openalexId":"W2092513068","cited":2282,"byYear":{"2012":55,"2013":66,"2014":44,"2015":55,"2016":49,"2017":35,"2018":27,"2019":32,"2020":33,"2021":23,"2022":22,"2023":23,"2024":18,"2025":7,"2026":5},"year":1995,"title":"Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability"},"paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998":{"doi":"10.1073/pnas.95.12.6870","openalexId":"W2107972234","cited":1902,"byYear":{"2012":79,"2013":64,"2014":65,"2015":42,"2016":54,"2017":42,"2018":47,"2019":51,"2020":31,"2021":58,"2022":40,"2023":25,"2024":27,"2025":20,"2026":14},"year":1998,"title":"Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma"},"paper-gotoda-endoscopic-resection-criteria-gastric-cancer-2000":{"doi":"10.1007/pl00011720","openalexId":"W2024590196","cited":1805,"byYear":{"2012":108,"2013":103,"2014":118,"2015":127,"2016":120,"2017":108,"2018":101,"2019":91,"2020":112,"2021":82,"2022":64,"2023":66,"2024":39,"2025":43,"2026":28},"year":2000,"title":"Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers"},"paper-visakorpi-androgen-receptor-amplification-nat-genet-1995":{"doi":"10.1038/ng0495-401","openalexId":"W2022635468","cited":1501,"byYear":{"2012":59,"2013":77,"2014":72,"2015":69,"2016":68,"2017":62,"2018":49,"2019":46,"2020":37,"2021":58,"2022":41,"2023":52,"2024":22,"2025":28,"2026":15},"year":1995,"title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer"},"paper-ifm-2009-attal-nejm-2017":{"doi":"10.1056/nejmoa1611750","openalexId":"W2604776612","cited":1268,"byYear":{"2012":1,"2013":1,"2017":58,"2018":110,"2019":121,"2020":196,"2021":178,"2022":139,"2023":151,"2024":118,"2025":120,"2026":69},"year":2017,"title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma"},"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017":{"doi":"10.1038/nature24462","openalexId":"W2767699537","cited":1246,"byYear":{"2017":9,"2018":95,"2019":135,"2020":140,"2021":155,"2022":178,"2023":207,"2024":134,"2025":118,"2026":73},"year":2017,"title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer"},"paper-sikov-calgb-40603-carboplatin-bevacizumab-jco-2015":{"doi":"10.1200/jco.2014.57.0572","openalexId":"W2096745115","cited":1046,"byYear":{"2013":1,"2014":15,"2015":74,"2016":81,"2017":93,"2018":81,"2019":81,"2020":113,"2021":148,"2022":108,"2023":84,"2024":76,"2025":55,"2026":33},"year":2014,"title":"Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)"},"paper-amary-idh-cartilaginous-tumours-j-pathol-2011":{"doi":"10.1002/path.2913","openalexId":"W2011376261","cited":1034,"byYear":{"2012":56,"2013":60,"2014":72,"2015":75,"2016":59,"2017":78,"2018":83,"2019":64,"2020":88,"2021":88,"2022":76,"2023":52,"2024":58,"2025":48,"2026":45},"year":2011,"title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours"},"paper-vuik-early-onset-colorectal-europe-gut-2019":{"doi":"10.1136/gutjnl-2018-317592","openalexId":"W2946089174","cited":928,"byYear":{"2018":1,"2019":28,"2020":81,"2021":126,"2022":162,"2023":167,"2024":138,"2025":148,"2026":76},"year":2019,"title":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years"},"paper-indigo-nejm-2023":{"doi":"10.1056/nejmoa2304194","openalexId":"W4379284101","cited":809,"byYear":{"2015":1,"2022":1,"2023":64,"2024":250,"2025":270,"2026":219},"year":2023,"title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma"},"paper-ielsg32-matrix-induction-ferreri-lancet-haematol-2016":{"doi":"10.1016/s2352-3026(16)00036-3","openalexId":"W2314481096","cited":615,"byYear":{"2016":19,"2017":36,"2018":59,"2019":49,"2020":58,"2021":79,"2022":74,"2023":84,"2024":58,"2025":62,"2026":33},"year":2016,"title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial"},"paper-hodi-imatinib-kit-melanoma-jco-2013":{"doi":"10.1200/jco.2012.47.7836","openalexId":"W2103152130","cited":609,"byYear":{"2013":12,"2014":57,"2015":47,"2016":43,"2017":66,"2018":46,"2019":50,"2020":56,"2021":49,"2022":55,"2023":33,"2024":39,"2025":37,"2026":16},"year":2013,"title":"Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin"},"paper-sinicrope-early-onset-crc-nejm-2022":{"doi":"10.1056/nejmra2200869","openalexId":"W4224217056","cited":547,"byYear":{"2022":32,"2023":116,"2024":160,"2025":142,"2026":97},"year":2022,"title":"Increasing Incidence of Early-Onset Colorectal Cancer"},"paper-imbrave050-lancet-2023":{"doi":"10.1016/s0140-6736(23)01796-8","openalexId":"W4387803249","cited":535,"byYear":{"2023":7,"2024":180,"2025":198,"2026":149},"year":2023,"title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial"},"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019":{"doi":"10.1200/jco.19.01124","openalexId":"W2972751531","cited":498,"byYear":{"2018":1,"2019":9,"2020":43,"2021":77,"2022":70,"2023":102,"2024":81,"2025":62,"2026":53},"year":2019,"title":"Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer"},"paper-archer-1050-os-jco-2018":{"doi":"10.1200/jco.2018.78.7994","openalexId":"W2806325305","cited":443,"byYear":{"2016":1,"2018":28,"2019":83,"2020":79,"2021":79,"2022":69,"2023":37,"2024":34,"2025":22,"2026":11},"year":2018,"title":"Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations"},"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019":{"doi":"10.1016/s0140-6736(18)33137-4","openalexId":"W2913286462","cited":405,"byYear":{"2019":38,"2020":43,"2021":63,"2022":67,"2023":55,"2024":62,"2025":48,"2026":28},"year":2019,"title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials"},"paper-imatinib-dfsp-eortc-swog-rutkowski-jco-2010":{"doi":"10.1200/jco.2009.25.7899","openalexId":"W2148064549","cited":402,"byYear":{"2012":34,"2013":30,"2014":23,"2015":30,"2016":23,"2017":24,"2018":33,"2019":33,"2020":23,"2021":16,"2022":16,"2023":24,"2024":16,"2025":21,"2026":5},"year":2010,"title":"Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials"},"paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017":{"doi":"10.1016/s2352-3026(17)30174-6","openalexId":"W2766491362","cited":391,"byYear":{"2014":1,"2017":2,"2018":19,"2019":39,"2020":43,"2021":57,"2022":54,"2023":62,"2024":39,"2025":44,"2026":29},"year":2017,"title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial"},"paper-florence-duffaud-ann-oncol-2017":{"doi":"10.1093/annonc/mdx484","openalexId":"W2784434802","cited":383,"byYear":{"2018":25,"2019":38,"2020":39,"2021":51,"2022":55,"2023":58,"2024":38,"2025":42,"2026":32},"year":2017,"title":"Improved survival using specialized multidisciplinary board in sarcoma patients"},"paper-mcfarland-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.1213968110","openalexId":"W2059437408","cited":354,"byYear":{"2013":15,"2014":36,"2015":29,"2016":28,"2017":45,"2018":34,"2019":35,"2020":32,"2021":16,"2022":21,"2023":20,"2024":10,"2025":24,"2026":8},"year":2013,"title":"Impact of deleterious passenger mutations on cancer progression"},"paper-mateos-20-2-20-smouldering-bcj-2020":{"doi":"10.1038/s41408-020-00366-3","openalexId":"W3093376706","cited":294,"byYear":{"2020":1,"2021":36,"2022":50,"2023":40,"2024":51,"2025":70,"2026":44},"year":2020,"title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)"},"paper-pawlik-incidental-gallbladder-cancer-residual-disease-jgs-2007":{"doi":"10.1007/s11605-007-0309-6","openalexId":"W1987111930","cited":286,"byYear":{"2012":10,"2013":14,"2014":23,"2015":16,"2016":20,"2017":14,"2018":19,"2019":26,"2020":20,"2021":19,"2022":18,"2023":13,"2024":21,"2025":7,"2026":9},"year":2007,"title":"Incidence of Finding Residual Disease for Incidental Gallbladder Carcinoma: Implications for Re-resection"},"paper-inavo120-n-engl-j-med-2024":{"doi":"10.1056/nejmoa2404625","openalexId":"W4403912600","cited":282,"byYear":{"2024":7,"2025":151,"2026":124},"year":2024,"title":"Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer"},"paper-lenz-cms-calgb-swog-80405-jco-2019":{"doi":"10.1200/jco.18.02258","openalexId":"W2943196840","cited":257,"byYear":{"2018":4,"2019":12,"2020":39,"2021":61,"2022":42,"2023":28,"2024":29,"2025":32,"2026":10},"year":2019,"title":"Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)"},"paper-igcccg-update-gillessen-jco-2021":{"doi":"10.1200/jco.20.03296","openalexId":"W3150204614","cited":254,"byYear":{"2021":12,"2022":44,"2023":53,"2024":53,"2025":49,"2026":42},"year":2021,"title":"Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium"},"paper-anthony-nichols-nat-genet-2017":{"doi":"10.1038/ng.3757","openalexId":"W2571023129","cited":253,"byYear":{"2017":20,"2018":23,"2019":36,"2020":24,"2021":39,"2022":24,"2023":32,"2024":25,"2025":17,"2026":13},"year":2017,"title":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas"},"paper-study-0201-blood-2006":{"doi":"10.1182/blood-2005-10-4073","openalexId":"W2134350774","cited":252,"byYear":{"2012":15,"2013":11,"2014":18,"2015":20,"2016":15,"2017":11,"2018":10,"2019":15,"2020":11,"2021":17,"2022":13,"2023":11,"2024":11,"2025":4,"2026":3},"year":2006,"title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial"},"paper-sankaranarayanan-lancet-oncol":{"doi":"10.1016/s1470-2045(15)00414-3","openalexId":"W2187298330","cited":250,"byYear":{"2014":1,"2015":1,"2016":25,"2017":26,"2018":38,"2019":35,"2020":22,"2021":24,"2022":16,"2023":12,"2024":22,"2025":21,"2026":6},"year":2015,"title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study"},"paper-pfeiffer-embo-mol-med":{"doi":"10.15252/emmm.201809158","openalexId":"W2889863283","cited":215,"byYear":{"2018":3,"2019":11,"2020":15,"2021":32,"2022":26,"2023":20,"2024":25,"2025":36,"2026":47},"year":2018,"title":"In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome"},"paper-ackerman-nat-cancer":{"doi":"10.1038/s43018-020-00136-x","openalexId":"W3111948793","cited":213,"byYear":{"2020":1,"2021":12,"2022":25,"2023":36,"2024":59,"2025":58,"2026":22},"year":2020,"title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity"},"paper-ember-3-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2410858","openalexId":"W4405290807","cited":196,"byYear":{"2025":90,"2026":106},"year":2024,"title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer"},"paper-imwg-plasma-cell-leukaemia-definition-bcj-2021":{"doi":"10.1038/s41408-021-00587-0","openalexId":"W3217094546","cited":186,"byYear":{"2022":24,"2023":37,"2024":43,"2025":52,"2026":28},"year":2021,"title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage"},"paper-chamie-nejm-evid":{"doi":"10.1056/evidoa2200167","openalexId":"W4308713832","cited":177,"byYear":{"2022":1,"2023":14,"2024":38,"2025":71,"2026":53},"year":2022,"title":"IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer"},"paper-rubin-mol-cell":{"doi":"10.1016/j.molcel.2020.10.033","openalexId":"W3103267875","cited":146,"byYear":{"2021":8,"2022":22,"2023":22,"2024":31,"2025":46,"2026":17},"year":2020,"title":"Impact of Lineage Plasticity to and from a Neuroendocrine Phenotype on Progression and Response in Prostate and Lung Cancers"},"paper-imvigor011-nejm-2025":{"doi":"10.1056/nejmoa2511885","openalexId":"W4415351494","cited":145,"byYear":{"2025":12,"2026":133},"year":2025,"title":"ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer"},"paper-imerge-imetelstat-mds-lancet-2024":{"doi":"10.1016/s0140-6736(23)01724-5","openalexId":"W4389229209","cited":144,"byYear":{"2023":1,"2024":40,"2025":67,"2026":35},"year":2023,"title":"Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-royer-plasma-cell-leukaemia-ifm-jco-2016":{"doi":"10.1200/jco.2015.63.1929","openalexId":"W2267013690","cited":0,"byYear":{},"year":2016,"title":"Bortezomib-doxorubicin-cyclophosphamide-dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the IFM"},"paper-cai-j-glob-health":{"doi":"10.7189/jogh.12.11016","openalexId":"W4311715114","cited":61,"byYear":{"2023":19,"2024":19,"2025":14,"2026":9},"year":2022,"title":"Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study"},"paper-wong-ignyte-rp1-nivolumab-jco-2025":{"doi":"10.1200/jco-25-01346","openalexId":"W4412156955","cited":48,"byYear":{"2025":14,"2026":34},"year":2025,"title":"RP1 Combined With Nivolumab in Advanced Anti–PD-1–Failed Melanoma (IGNYTE)"},"paper-ielsg37-pmbcl-martelli-jco-2024":{"doi":"10.1200/jco-24-01373","openalexId":"W4401688491","cited":33,"byYear":{"2024":1,"2025":22,"2026":10},"year":2024,"title":"Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results"},"paper-pyo-incidental-gallbladder-cancer-meta-analysis-jcm-2020":{"doi":"10.3390/jcm9051484","openalexId":"W3024837226","cited":37,"byYear":{"2021":2,"2022":8,"2023":5,"2024":11,"2025":4,"2026":7},"year":2020,"title":"Incidental Carcinoma after Cholecystectomy for Benign Disease of the Gallbladder: A Meta-Analysis"},"paper-nct05732805-eur-j-cancer-2025":{"doi":"10.1016/j.ejca.2025.115674","openalexId":"W4412982006","cited":4,"byYear":{"2026":4},"year":2025,"title":"Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial"},"paper-patil-gallbladder-immune-microenvironment-aimm-2021":{"doi":"10.1097/pai.0000000000000922","openalexId":"W3134538748","cited":5,"byYear":{"2021":1,"2022":2,"2025":1,"2026":1},"year":2021,"title":"Immune Microenvironment in Gallbladder Adenocarcinomas"},"paper-tcga-endometrial-nature-2013":{"doi":"10.1038/nature12113","openalexId":"W1558971561","cited":415,"byYear":{"2012":1,"2013":1,"2014":5,"2015":8,"2016":9,"2017":8,"2018":14,"2019":40,"2020":76,"2021":68,"2022":67,"2023":58,"2024":39,"2025":20},"year":2013,"title":"Integrated genomic characterization of endometrial carcinoma"},"paper-greten-immunity":{"doi":"10.1016/j.immuni.2019.06.025","openalexId":"W2959497269","cited":3893,"byYear":{"2019":16,"2020":168,"2021":417,"2022":684,"2023":734,"2024":813,"2025":649,"2026":411},"year":2019,"title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences"},"paper-taylor-integrative-genomic-profiling-cancer-cell-2010":{"doi":"10.1016/j.ccr.2010.05.026","openalexId":"W2107633226","cited":3848,"byYear":{"2012":189,"2013":268,"2014":298,"2015":296,"2016":283,"2017":276,"2018":308,"2019":283,"2020":283,"2021":251,"2022":238,"2023":265,"2024":209,"2025":143,"2026":87},"year":2010,"title":"Integrative Genomic Profiling of Human Prostate Cancer"},"paper-olive-hedgehog-stroma-gemcitabine-delivery-science-2009":{"doi":"10.1126/science.1171362","openalexId":"W2107441200","cited":3205,"byYear":{"2012":235,"2013":207,"2014":210,"2015":223,"2016":225,"2017":216,"2018":215,"2019":198,"2020":214,"2021":234,"2022":187,"2023":160,"2024":126,"2025":119,"2026":92},"year":2009,"title":"Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer"},"paper-kumar-lancet-oncol":{"doi":"10.1016/s1470-2045(16)30206-6","openalexId":"W2486629951","cited":3112,"byYear":{"2012":1,"2013":2,"2014":2,"2016":17,"2017":138,"2018":165,"2019":210,"2020":328,"2021":360,"2022":333,"2023":393,"2024":457,"2025":408,"2026":288},"year":2016,"title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma"},"paper-icc-2022-arber-blood-2022":{"doi":"10.1182/blood.2022015850","openalexId":"W4283716970","cited":2927,"byYear":{"2022":106,"2023":652,"2024":783,"2025":797,"2026":582},"year":2022,"title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data"},"paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998":{"doi":"10.1200/jco.1998.16.4.1310","openalexId":"W2125919881","cited":2244,"byYear":{"2012":93,"2013":73,"2014":97,"2015":121,"2016":95,"2017":106,"2018":99,"2019":109,"2020":111,"2021":114,"2022":92,"2023":70,"2024":50,"2025":43,"2026":25},"year":1998,"title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099."},"paper-ferrell-j-clin-oncol":{"doi":"10.1200/jco.2016.70.1474","openalexId":"W2549006299","cited":2157,"byYear":{"2014":1,"2015":1,"2016":6,"2017":149,"2018":186,"2019":191,"2020":237,"2021":296,"2022":249,"2023":258,"2024":249,"2025":181,"2026":150},"year":2017,"title":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update"},"paper-pages-immunoscore-international-validation-lancet-2018":{"doi":"10.1016/s0140-6736(18)30789-x","openalexId":"W2802206159","cited":2139,"byYear":{"2015":1,"2017":1,"2018":78,"2019":207,"2020":328,"2021":342,"2022":285,"2023":284,"2024":257,"2025":177,"2026":170},"year":2018,"title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study"},"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017":{"doi":"10.1016/j.ccell.2017.07.007","openalexId":"W2748710555","cited":2124,"byYear":{"2012":1,"2017":18,"2018":125,"2019":194,"2020":303,"2021":320,"2022":272,"2023":263,"2024":240,"2025":231,"2026":155},"year":2017,"title":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma"},"paper-igcccg-classification-jco-1997":{"doi":"10.1200/jco.1997.15.2.594","openalexId":"W44254208","cited":1933,"byYear":{"2012":58,"2013":62,"2014":86,"2015":75,"2016":95,"2017":75,"2018":86,"2019":92,"2020":98,"2021":91,"2022":81,"2023":78,"2024":59,"2025":49,"2026":38},"year":1997,"title":"International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group."},"paper-cancer-genome-atlas-research-nature":{"doi":"10.1038/nature20805","openalexId":"W2570401594","cited":1912,"byYear":{"2017":118,"2018":186,"2019":202,"2020":270,"2021":267,"2022":229,"2023":189,"2024":184,"2025":152,"2026":109},"year":2017,"title":"Integrated genomic characterization of oesophageal carcinoma"},"paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016":{"doi":"10.1056/nejmoa1603144","openalexId":"W2462985846","cited":1707,"byYear":{"2014":1,"2016":35,"2017":123,"2018":145,"2019":162,"2020":190,"2021":224,"2022":210,"2023":174,"2024":178,"2025":151,"2026":110},"year":2016,"title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer"},"paper-ino-vate-inotuzumab-all-nejm-2016":{"doi":"10.1056/nejmoa1509277","openalexId":"W2419639370","cited":1417,"byYear":{"2015":2,"2016":23,"2017":118,"2018":129,"2019":169,"2020":167,"2021":145,"2022":158,"2023":137,"2024":130,"2025":131,"2026":101},"year":2016,"title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia"},"paper-mackay-paediatric-hgg-cancer-cell-2017":{"doi":"10.1016/j.ccell.2017.08.017","openalexId":"W2751187578","cited":1312,"byYear":{"2014":1,"2017":5,"2018":47,"2019":97,"2020":165,"2021":174,"2022":155,"2023":166,"2024":228,"2025":142,"2026":130},"year":2017,"title":"Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma"},"paper-mlecnik-immunoscore-msi-colorectal-immunity-2016":{"doi":"10.1016/j.immuni.2016.02.025","openalexId":"W2299919100","cited":1101,"byYear":{"2014":1,"2015":1,"2016":32,"2017":95,"2018":115,"2019":117,"2020":156,"2021":161,"2022":105,"2023":143,"2024":75,"2025":54,"2026":45},"year":2016,"title":"Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability"},"paper-eortc-22922-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1415369","openalexId":"W1770259999","cited":1033,"byYear":{"2014":1,"2015":40,"2016":127,"2017":142,"2018":107,"2019":121,"2020":115,"2021":95,"2022":94,"2023":68,"2024":55,"2025":33,"2026":32},"year":2015,"title":"Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer"},"paper-schuetz-lancet":{"doi":"10.1016/s0140-6736(18)32776-4","openalexId":"W2942493170","cited":906,"byYear":{"2012":1,"2019":36,"2020":101,"2021":135,"2022":112,"2023":146,"2024":133,"2025":150,"2026":91},"year":2019,"title":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial"},"paper-whel-jama-2007":{"doi":"10.1001/jama.298.3.289","openalexId":"W2109008239","cited":737,"byYear":{"2012":56,"2013":57,"2014":40,"2015":44,"2016":43,"2017":39,"2018":29,"2019":34,"2020":41,"2021":26,"2022":32,"2023":31,"2024":24,"2025":19,"2026":20},"year":2007,"title":"Influence of a Diet Very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for Breast Cancer"},"paper-couch-tnbc-germline-17-genes-jco-2015":{"doi":"10.1200/jco.2014.57.1414","openalexId":"W2100989310","cited":702,"byYear":{"2014":1,"2015":47,"2016":67,"2017":77,"2018":72,"2019":76,"2020":71,"2021":80,"2022":56,"2023":42,"2024":58,"2025":31,"2026":24},"year":2014,"title":"Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer"},"paper-interfant-99-lancet-2007":{"doi":"10.1016/s0140-6736(07)61126-x","openalexId":"W2164959344","cited":661,"byYear":{"2012":37,"2013":32,"2014":37,"2015":31,"2016":35,"2017":32,"2018":28,"2019":39,"2020":50,"2021":51,"2022":37,"2023":35,"2024":27,"2025":18,"2026":19},"year":2007,"title":"A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial"},"paper-zhang-nat-commun":{"doi":"10.1038/s41467-017-01968-5","openalexId":"W2770572337","cited":617,"byYear":{"2017":4,"2018":38,"2019":55,"2020":103,"2021":82,"2022":85,"2023":78,"2024":62,"2025":56,"2026":54},"year":2017,"title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer"},"paper-pace-b-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(19)30569-8","openalexId":"W2973514824","cited":555,"byYear":{"2016":1,"2019":6,"2020":75,"2021":99,"2022":98,"2023":89,"2024":80,"2025":60,"2026":45},"year":2019,"title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial"},"paper-kyoto-2024-evidence-based-guidelines-ipmn-pancreatology-2024":{"doi":"10.1016/j.pan.2023.12.009","openalexId":"W4390350622","cited":493,"byYear":{"2015":1,"2024":92,"2025":201,"2026":199},"year":2023,"title":"International Evidence-Based Kyoto Guidelines for the Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas"},"paper-dawood-inflammatory-breast-consensus-ann-oncol-2011":{"doi":"10.1093/annonc/mdq345","openalexId":"W2113334910","cited":489,"byYear":{"2012":38,"2013":31,"2014":37,"2015":43,"2016":37,"2017":43,"2018":40,"2019":30,"2020":38,"2021":29,"2022":34,"2023":20,"2024":17,"2025":21,"2026":14},"year":2010,"title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment"},"paper-raajit-rampal-blood-2014":{"doi":"10.1182/blood-2014-02-554634","openalexId":"W2063756127","cited":443,"byYear":{"2014":18,"2015":37,"2016":49,"2017":38,"2018":26,"2019":33,"2020":39,"2021":57,"2022":36,"2023":39,"2024":25,"2025":28,"2026":18},"year":2014,"title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis"},"paper-lyman-j-clin-oncol":{"doi":"10.1200/jco.2018.79.2721","openalexId":"W2808500840","cited":435,"byYear":{"2017":1,"2018":13,"2019":28,"2020":55,"2021":67,"2022":51,"2023":87,"2024":55,"2025":37,"2026":41},"year":2018,"title":"Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline"},"paper-mao-j-clin-oncol":{"doi":"10.1200/jco.22.01357","openalexId":"W4296460105","cited":372,"byYear":{"2022":9,"2023":68,"2024":93,"2025":98,"2026":103},"year":2022,"title":"Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology–ASCO Guideline"},"paper-brentuximab-vedotin-hodgkin-lymphoma-blood-2018":{"doi":"10.1182/blood-2017-10-811224","openalexId":"W2772084440","cited":324,"byYear":{"2017":6,"2018":48,"2019":50,"2020":56,"2021":61,"2022":38,"2023":26,"2024":16,"2025":11,"2026":9},"year":2017,"title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma"},"paper-pace-b-lancet-oncol-2022-update":{"doi":"10.1016/s1470-2045(22)00517-4","openalexId":"W4295838570","cited":318,"byYear":{"2022":5,"2023":84,"2024":99,"2025":85,"2026":45},"year":2022,"title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial"},"paper-carlson-j-clin-oncol":{"doi":"10.1200/jco.23.00857","openalexId":"W4385829606","cited":309,"byYear":{"2023":4,"2024":63,"2025":110,"2026":132},"year":2023,"title":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline"},"paper-ians-anal-cancer-screening-guidelines-ijc-2024":{"doi":"10.1002/ijc.34850","openalexId":"W4391445467","cited":308,"byYear":{"2024":82,"2025":139,"2026":87},"year":2024,"title":"International Anal Neoplasia Society's consensus guidelines for anal cancer screening"},"paper-interfant-06-pieters-jco-2019":{"doi":"10.1200/jco.19.00261","openalexId":"W2957551926","cited":305,"byYear":{"2019":4,"2020":32,"2021":55,"2022":49,"2023":52,"2024":45,"2025":41,"2026":27},"year":2019,"title":"Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study"},"paper-eortc-22922-lancet-oncol-2020-update":{"doi":"10.1016/s1470-2045(20)30472-1","openalexId":"W3097739674","cited":302,"byYear":{"2020":1,"2021":47,"2022":61,"2023":60,"2024":48,"2025":49,"2026":34},"year":2020,"title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial"},"paper-sharpe-lancet":{"doi":"10.1016/s0140-6736(14)61231-9","openalexId":"W2125875374","cited":276,"byYear":{"2012":1,"2013":1,"2014":7,"2015":29,"2016":31,"2017":35,"2018":20,"2019":22,"2020":21,"2021":19,"2022":18,"2023":22,"2024":23,"2025":15,"2026":12},"year":2014,"title":"Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial"},"paper-franklin-nat-rev-cancer":{"doi":"10.1038/s41568-023-00579-1","openalexId":"W4380357753","cited":219,"byYear":{"2023":13,"2024":80,"2025":86,"2026":40},"year":2023,"title":"Insights into recent findings and clinical application of YAP and TAZ in cancer"},"paper-innovatv-301-tisotumab-nejm-2024":{"doi":"10.1056/nejmoa2313811","openalexId":"W4400270342","cited":195,"byYear":{"2024":29,"2025":79,"2026":87},"year":2024,"title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer"},"paper-amit-induction-chemotherapy-response-snuc-jco-2019":{"doi":"10.1200/jco.18.00353","openalexId":"W2907165378","cited":175,"byYear":{"2019":8,"2020":22,"2021":35,"2022":22,"2023":31,"2024":24,"2025":15,"2026":18},"year":2019,"title":"Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma"},"paper-interlace-lancet-2024":{"doi":"10.1016/s0140-6736(24)01438-7","openalexId":"W4403384496","cited":174,"byYear":{"2024":5,"2025":91,"2026":78},"year":2024,"title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial"},"paper-interaact-carboplatin-paclitaxel-advanced-anal-cancer-rao-jco-2020":{"doi":"10.1200/jco.19.03266","openalexId":"W3034884769","cited":155,"byYear":{"2020":6,"2021":33,"2022":33,"2023":23,"2024":22,"2025":19,"2026":18},"year":2020,"title":"International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct"},"paper-zheng-nigerian-inherited-breast-cancer-jco-2018":{"doi":"10.1200/jco.2018.78.3977","openalexId":"W2888483008","cited":133,"byYear":{"2018":2,"2019":17,"2020":16,"2021":23,"2022":21,"2023":19,"2024":14,"2025":11,"2026":10},"year":2018,"title":"Inherited Breast Cancer in Nigerian Women"},"paper-seligmann-j-clin-oncol":{"doi":"10.1200/jco.21.01435","openalexId":"W3200898477","cited":117,"byYear":{"2021":1,"2022":25,"2023":35,"2024":16,"2025":22,"2026":18},"year":2021,"title":"Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring"},"paper-nepal-gallbladder-microenvironment-subtypes-j-hepatol-2021":{"doi":"10.1016/j.jhep.2020.11.033","openalexId":"W3108066728","cited":89,"byYear":{"2021":6,"2022":15,"2023":8,"2024":23,"2025":21,"2026":16},"year":2020,"title":"Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes"},"paper-froeling-pstt-ett-intensified-therapy-bjc-2019":{"doi":"10.1038/s41416-019-0402-0","openalexId":"W2916250198","cited":81,"byYear":{"2019":4,"2020":8,"2021":10,"2022":9,"2023":14,"2024":14,"2025":14,"2026":8},"year":2019,"title":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours"},"paper-nct04606446-nat-med-2024":{"doi":"10.1038/s41591-024-03060-0","openalexId":"W4399255326","cited":61,"byYear":{"2024":10,"2025":29,"2026":22},"year":2024,"title":"Inhibition of lysine acetyltransferase KAT6 in ER+HER2− metastatic breast cancer: a phase 1 trial"},"paper-gemstone-302-nat-cancer-2023-update":{"doi":"10.1038/s43018-023-00578-z","openalexId":"W4380714829","cited":35,"byYear":{"2024":12,"2025":18,"2026":5},"year":2023,"title":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC"},"paper-splash-front-oncol-2024":{"doi":"10.3389/fonc.2024.1483953","openalexId":"W4406132320","cited":21,"byYear":{"2025":4,"2026":17},"year":2025,"title":"Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial"},"paper-pandey-gallbladder-elf3-nat-commun-2020":{"doi":"10.1038/s41467-020-17880-4","openalexId":"W3080607404","cited":68,"byYear":{"2020":2,"2021":13,"2022":14,"2023":11,"2024":14,"2025":8,"2026":6},"year":2020,"title":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate"},"paper-tcga-ovarian-nature-2011":{"doi":"10.1038/nature10166","openalexId":"W2216554257","cited":12,"byYear":{"2012":1,"2021":1,"2022":1,"2023":1,"2026":8},"year":2011,"title":"Integrated genomic analyses of ovarian carcinoma"},"paper-jemal-global-cancer-statistics-2011-cacancer":{"doi":"10.3322/caac.20107","openalexId":"W2106787323","cited":55013,"byYear":{"2012":3940,"2013":5245,"2014":5978,"2015":6168,"2016":5167,"2017":4541,"2018":4044,"2019":3632,"2020":3080,"2021":2353,"2022":1127,"2023":793,"2024":564,"2025":321,"2026":93},"year":2011,"title":"Global cancer statistics"},"paper-jemal-cancer-statistics-2010-cacancer-2010":{"doi":"10.3322/caac.20073","openalexId":"W2158734599","cited":12620,"byYear":{"2012":2612,"2013":1694,"2014":1233,"2015":935,"2016":708,"2017":544,"2018":452,"2019":436,"2020":358,"2021":301,"2022":185,"2023":139,"2024":120,"2025":64,"2026":16},"year":2010,"title":"Cancer Statistics, 2010"},"paper-kalluri-weinberg-emt-basics-jci-2009":{"doi":"10.1172/jci39104","openalexId":"W2154589460","cited":10307,"byYear":{"2012":434,"2013":488,"2014":592,"2015":679,"2016":712,"2017":833,"2018":768,"2019":850,"2020":771,"2021":816,"2022":747,"2023":711,"2024":595,"2025":483,"2026":270},"year":2009,"title":"The basics of epithelial-mesenchymal transition"},"paper-jemal-cancer-statistics-2008-cacancer-2008":{"doi":"10.3322/ca.2007.0010","openalexId":"W2043103956","cited":10203,"byYear":{"2012":758,"2013":696,"2014":508,"2015":485,"2016":376,"2017":295,"2018":273,"2019":245,"2020":184,"2021":142,"2022":114,"2023":83,"2024":76,"2025":49,"2026":13},"year":2008,"title":"Cancer Statistics, 2008"},"paper-jemal-cancer-statistics-2009-cacancer-2009":{"doi":"10.3322/caac.20006","openalexId":"W2101995865","cited":9724,"byYear":{"2012":1176,"2013":846,"2014":696,"2015":523,"2016":411,"2017":355,"2018":229,"2019":199,"2020":181,"2021":149,"2022":108,"2023":92,"2024":78,"2025":50,"2026":13},"year":2009,"title":"Cancer Statistics, 2009"},"paper-jemal-cancer-statistics-2007-cacancer-2007":{"doi":"10.3322/canjclin.57.1.43","openalexId":"W1965734230","cited":7474,"byYear":{"2012":420,"2013":330,"2014":332,"2015":221,"2016":196,"2017":181,"2018":118,"2019":101,"2020":146,"2021":126,"2022":95,"2023":113,"2024":76,"2025":34,"2026":13},"year":2007,"title":"Cancer Statistics, 2007"},"paper-jaiswal-chip-nejm-2014":{"doi":"10.1056/nejmoa1408617","openalexId":"W2149858388","cited":4922,"byYear":{"2012":3,"2013":1,"2014":6,"2015":151,"2016":241,"2017":302,"2018":364,"2019":393,"2020":474,"2021":540,"2022":556,"2023":547,"2024":517,"2025":448,"2026":368},"year":2014,"title":"Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes"},"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019":{"doi":"10.1056/nejmoa1804980","openalexId":"W2903062212","cited":4165,"byYear":{"2012":2,"2013":1,"2015":1,"2018":3,"2019":219,"2020":516,"2021":649,"2022":699,"2023":611,"2024":620,"2025":504,"2026":327},"year":2018,"title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma"},"paper-karapetis-kras-cetuximab-colorectal-nejm-2008":{"doi":"10.1056/nejmoa0804385","openalexId":"W2155311724","cited":3629,"byYear":{"2012":324,"2013":307,"2014":321,"2015":256,"2016":222,"2017":206,"2018":167,"2019":174,"2020":170,"2021":160,"2022":117,"2023":94,"2024":98,"2025":70,"2026":57},"year":2008,"title":"K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer"},"paper-iris-imatinib-nejm-2003":{"doi":"10.1056/nejmoa022457","openalexId":"W2028959752","cited":3598,"byYear":{"2012":220,"2013":195,"2014":149,"2015":151,"2016":149,"2017":147,"2018":114,"2019":132,"2020":109,"2021":112,"2022":104,"2023":101,"2024":74,"2025":76,"2026":52},"year":2003,"title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia"},"paper-iwai-pdl1-tumour-escape-pnas-2002":{"doi":"10.1073/pnas.192461099","openalexId":"W2063264144","cited":3265,"byYear":{"2012":69,"2013":97,"2014":82,"2015":185,"2016":187,"2017":203,"2018":222,"2019":265,"2020":282,"2021":286,"2022":286,"2023":267,"2024":246,"2025":171,"2026":104},"year":2002,"title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade"},"paper-katherine-nejm-2019":{"doi":"10.1056/nejmoa1814017","openalexId":"W2902218997","cited":2689,"byYear":{"2017":1,"2018":1,"2019":161,"2020":327,"2021":413,"2022":429,"2023":410,"2024":397,"2025":320,"2026":222},"year":2018,"title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer"},"paper-javelin-bladder-100-nejm-2020":{"doi":"10.1056/nejmoa2002788","openalexId":"W3087464965","cited":1527,"byYear":{"2020":23,"2021":234,"2022":307,"2023":291,"2024":292,"2025":250,"2026":125},"year":2020,"title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma"},"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023":{"doi":"10.1007/s10120-022-01331-8","openalexId":"W4308373104","cited":1306,"byYear":{"2020":1,"2021":15,"2022":20,"2023":173,"2024":370,"2025":434,"2026":292},"year":2022,"title":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)"},"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017":{"doi":"10.1016/j.ccell.2017.05.005","openalexId":"W2626440326","cited":1295,"byYear":{"2013":1,"2015":1,"2017":24,"2018":105,"2019":113,"2020":159,"2021":182,"2022":155,"2023":163,"2024":140,"2025":156,"2026":89},"year":2017,"title":"Intertumoral Heterogeneity within Medulloblastoma Subgroups"},"paper-ipss-m-bernard-nejm-evidence-2022":{"doi":"10.1056/evidoa2200008","openalexId":"W4281727476","cited":865,"byYear":{"2022":78,"2023":227,"2024":203,"2025":218,"2026":136},"year":2022,"title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes"},"paper-kadish-olfactory-neuroblastoma-staging-cancer-1976":{"doi":"10.1002/1097-0142(197603)37:3<1571::aid-cncr2820370347>3.0.co;2-l","openalexId":"W2003728267","cited":838,"byYear":{"2012":45,"2013":18,"2014":29,"2015":36,"2016":41,"2017":33,"2018":26,"2019":24,"2020":45,"2021":33,"2022":26,"2023":36,"2024":22,"2025":14,"2026":5},"year":1976,"title":"Olfactory neuroblastoma—A clinical analysis of 17 cases"},"paper-senft-lancet-oncol":{"doi":"10.1016/s1470-2045(11)70196-6","openalexId":"W2127383724","cited":827,"byYear":{"2012":29,"2013":37,"2014":51,"2015":70,"2016":65,"2017":74,"2018":54,"2019":71,"2020":71,"2021":74,"2022":68,"2023":48,"2024":41,"2025":36,"2026":34},"year":2011,"title":"Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial"},"paper-kelly-russell-oncolytic-history-moltherapy-2007":{"doi":"10.1038/sj.mt.6300108","openalexId":"W2063512646","cited":776,"byYear":{"2012":32,"2013":34,"2014":39,"2015":39,"2016":38,"2017":44,"2018":26,"2019":41,"2020":70,"2021":52,"2022":52,"2023":59,"2024":75,"2025":46,"2026":32},"year":2007,"title":"History of Oncolytic Viruses: Genesis to Genetic Engineering"},"paper-karmma-3-ide-cel-nejm-2023":{"doi":"10.1056/nejmoa2213614","openalexId":"W4319812103","cited":776,"byYear":{"2013":1,"2023":102,"2024":249,"2025":236,"2026":184},"year":2023,"title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma"},"paper-romero-nat-med":{"doi":"10.1038/nm.4407","openalexId":"W2764232556","cited":690,"byYear":{"2017":5,"2018":47,"2019":74,"2020":94,"2021":81,"2022":103,"2023":81,"2024":83,"2025":69,"2026":52},"year":2017,"title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis"},"paper-isg-sts-1001-gronchi-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30334-0","openalexId":"W2613892444","cited":499,"byYear":{"2016":2,"2017":16,"2018":67,"2019":67,"2020":71,"2021":62,"2022":62,"2023":42,"2024":37,"2025":49,"2026":22},"year":2017,"title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial"},"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30450-3","openalexId":"W2743639018","cited":481,"byYear":{"2016":1,"2017":10,"2018":31,"2019":69,"2020":70,"2021":82,"2022":71,"2023":67,"2024":34,"2025":31,"2026":15},"year":2017,"title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial"},"paper-invictus-ripretinib-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30168-6","openalexId":"W3033611734","cited":430,"byYear":{"2020":21,"2021":64,"2022":75,"2023":86,"2024":70,"2025":67,"2026":45},"year":2020,"title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial"},"paper-jupiter-02-toripalimab-chemotherapy-npc-nat-med-2021":{"doi":"10.1038/s41591-021-01444-0","openalexId":"W3190270536","cited":417,"byYear":{"2021":9,"2022":70,"2023":122,"2024":95,"2025":84,"2026":36},"year":2021,"title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial"},"paper-ipatential150-ipatasertib-abiraterone-pten-lancet-2021":{"doi":"10.1016/s0140-6736(21)00580-8","openalexId":"W3180644743","cited":340,"byYear":{"2021":16,"2022":60,"2023":88,"2024":69,"2025":69,"2026":37},"year":2021,"title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial"},"paper-jcog0912-katai-lancet-gastroenterol-hepatol-2020":{"doi":"10.1016/s2468-1253(19)30332-2","openalexId":"W2990486250","cited":334,"byYear":{"2019":2,"2020":22,"2021":59,"2022":61,"2023":53,"2024":57,"2025":45,"2026":34},"year":2019,"title":"Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial"},"paper-raajit-rampal-cancer-discov-2015":{"doi":"10.1158/2159-8290.cd-14-0736","openalexId":"W2143668961","cited":323,"byYear":{"2015":16,"2016":22,"2017":34,"2018":18,"2019":32,"2020":33,"2021":42,"2022":30,"2023":28,"2024":28,"2025":20,"2026":19},"year":2015,"title":"JAK–STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response"},"paper-adsay-icpn-gallbladder-ajsp-2012":{"doi":"10.1097/pas.0b013e318262787c","openalexId":"W2079912108","cited":266,"byYear":{"2012":3,"2013":2,"2014":11,"2015":12,"2016":9,"2017":11,"2018":15,"2019":15,"2020":21,"2021":24,"2022":26,"2023":36,"2024":35,"2025":22,"2026":21},"year":2012,"title":"Intracholecystic Papillary-Tubular Neoplasms (ICPN) of the Gallbladder (Neoplastic Polyps, Adenomas, and Papillary Neoplasms That Are ≥1.0 cm)"},"paper-partridge-n-engl-j-med":{"doi":"10.1056/nejmoa2212856","openalexId":"W4367833987","cited":228,"byYear":{"2023":39,"2024":78,"2025":74,"2026":36},"year":2023,"title":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer"},"paper-orecchia-lancet-oncol":{"doi":"10.1016/s1470-2045(21)00080-2","openalexId":"W3155789907","cited":211,"byYear":{"2021":24,"2022":38,"2023":53,"2024":41,"2025":34,"2026":20},"year":2021,"title":"Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial"},"paper-harmoni-a-jama-2024":{"doi":"10.1001/jama.2024.10613","openalexId":"W4399201775","cited":198,"byYear":{"2024":19,"2025":92,"2026":87},"year":2024,"title":"Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant"},"paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019":{"doi":"10.1158/1078-0432.ccr-19-0191","openalexId":"W2944179533","cited":161,"byYear":{"2019":3,"2020":18,"2021":42,"2022":32,"2023":23,"2024":20,"2025":19,"2026":3},"year":2019,"title":"NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma"},"paper-felsenstein-ipmn-cooccurring-cancer-relatedness-gut-2018":{"doi":"10.1136/gutjnl-2017-315062","openalexId":"W2792209856","cited":143,"byYear":{"2018":9,"2019":18,"2020":19,"2021":21,"2022":17,"2023":19,"2024":15,"2025":15,"2026":9},"year":2018,"title":"IPMNs with co-occurring invasive cancers: neighbours but not always relatives"},"paper-isaacsson-velho-intraductal-germline-dna-repair-prostate-2018":{"doi":"10.1002/pros.23484","openalexId":"W2787971554","cited":141,"byYear":{"2018":7,"2019":14,"2020":26,"2021":20,"2022":32,"2023":14,"2024":15,"2025":8,"2026":5},"year":2018,"title":"Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer"},"paper-tang-ivermectin-potential-anticancer-pharmacol-res-2021":{"doi":"10.1016/j.phrs.2020.105207","openalexId":"W3089240778","cited":128,"byYear":{"2021":17,"2022":21,"2023":22,"2024":23,"2025":23,"2026":22},"year":2020,"title":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug"},"paper-intrigue-ripretinib-vs-sunitinib-jco-2022":{"doi":"10.1200/jco.22.00294","openalexId":"W4292565458","cited":121,"byYear":{"2022":8,"2023":24,"2024":29,"2025":39,"2026":20},"year":2022,"title":"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial"},"paper-riley-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd011552.pub2","openalexId":"W1823070336","cited":115,"byYear":{"2012":1,"2016":7,"2017":6,"2018":7,"2019":10,"2020":17,"2021":18,"2022":11,"2023":18,"2024":9,"2025":9,"2026":2},"year":2015,"title":"Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy"},"paper-intuitt-nf2-brigatinib-plotkin-nejm-2024":{"doi":"10.1056/nejmoa2400985","openalexId":"W4399899070","cited":68,"byYear":{"2024":7,"2025":32,"2026":29},"year":2024,"title":"Brigatinib in NF2 -Related Schwannomatosis with Progressive Tumors"},"paper-smith-nejm-evid":{"doi":"10.1056/evidoa2200333","openalexId":"W4367180315","cited":57,"byYear":{"2022":1,"2023":2,"2024":17,"2025":20,"2026":17},"year":2023,"title":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery"},"paper-nct05840016-lancet-2025":{"doi":"10.1016/s0140-6736(25)01848-3","openalexId":"W4415340551","cited":43,"byYear":{"2025":3,"2026":40},"year":2025,"title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial"},"paper-nct03897881-j-clin-oncol-2026-update":{"doi":"10.1200/jco-26-00835","openalexId":"W7163002264","cited":12,"byYear":{"2026":12},"year":2026,"title":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study"},"paper-draganov-ivermectin-cold-tumours-npj-breast-cancer-2021":{"doi":"10.1038/s41523-021-00229-5","openalexId":"W3133489659","cited":48,"byYear":{"2021":4,"2022":4,"2023":11,"2024":11,"2025":10,"2026":8},"year":2021,"title":"Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer"},"paper-nct05840016-lancet-2026-update":{"doi":"10.1016/s0140-6736(26)00966-9","openalexId":"W7162938233","cited":8,"byYear":{"2026":8},"year":2026,"title":"Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China"},"paper-patel-ivermectin-cancer-curr-oncol-rep-2025":{"doi":"10.1007/s11912-025-01704-z","openalexId":"W4412671221","cited":7,"byYear":{"2025":2,"2026":5},"year":2025,"title":"Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential?"},"paper-rockwell-ivermectin-benzimidazole-prescribing-jama-netw-open-2026":{"doi":"10.1001/jamanetworkopen.2026.16780","openalexId":"W7160965219","cited":3,"byYear":{"2026":3},"year":2026,"title":"Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement"},"paper-yilmaz-ivermectin-toxicity-j-appl-toxicol-2026":{"doi":"10.1002/jat.70166","openalexId":"W7137106648","cited":2,"byYear":{"2026":2},"year":2026,"title":"Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management"},"paper-mujumdar-ivermectin-gynaecological-cancer-2025":{"doi":"10.1016/j.gore.2025.101803","openalexId":"W4412435826","cited":1,"byYear":{"2025":1},"year":2025,"title":"Ivermectin and Gynecologic Cancer: What are the data?"},"paper-straughn-ivermectin-hope-versus-hype-2025":{"doi":"10.1016/j.gore.2025.101920","openalexId":"W4412980879","cited":0,"byYear":{},"year":2025,"title":"Ivermectin treatment for gynecologic cancers—Hope versus hype"},"paper-nct06396065-lancet-oncol-2026":{"doi":"10.1016/s1470-2045(26)00282-2","openalexId":"W7204086740","cited":0,"byYear":{},"year":2026,"title":"Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial"},"paper-keynote-024-nejm-2016":{"doi":"10.1056/nejmoa1606774","openalexId":"W2527905628","cited":10324,"byYear":{"2013":2,"2014":2,"2015":2,"2016":46,"2017":725,"2018":1136,"2019":1167,"2020":1358,"2021":1367,"2022":1149,"2023":1058,"2024":1000,"2025":759,"2026":532},"year":2016,"title":"Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer"},"paper-lamouille-emt-molecular-mechanisms-nrmcb-2014":{"doi":"10.1038/nrm3758","openalexId":"W1964847767","cited":8357,"byYear":{"2013":1,"2014":113,"2015":335,"2016":552,"2017":692,"2018":732,"2019":774,"2020":948,"2021":952,"2022":872,"2023":748,"2024":781,"2025":520,"2026":332},"year":2014,"title":"Molecular mechanisms of epithelial–mesenchymal transition"},"paper-keynote-189-nejm-2018":{"doi":"10.1056/nejmoa1801005","openalexId":"W2796582438","cited":6779,"byYear":{"2013":1,"2015":1,"2016":1,"2017":2,"2018":287,"2019":684,"2020":989,"2021":1093,"2022":923,"2023":852,"2024":853,"2025":651,"2026":429},"year":2018,"title":"Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer"},"paper-keynote-010-lancet-2016":{"doi":"10.1016/s0140-6736(15)01281-7","openalexId":"W2198093519","cited":6598,"byYear":{"2013":1,"2014":4,"2015":5,"2016":281,"2017":615,"2018":821,"2019":857,"2020":946,"2021":839,"2022":649,"2023":554,"2024":546,"2025":312,"2026":156},"year":2015,"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial"},"paper-keynote-001-pembrolizumab-nsclc-nejm-2015":{"doi":"10.1056/nejmoa1501824","openalexId":"W1982488143","cited":6318,"byYear":{"2013":1,"2014":3,"2015":170,"2016":606,"2017":684,"2018":663,"2019":664,"2020":739,"2021":714,"2022":575,"2023":527,"2024":428,"2025":347,"2026":189},"year":2015,"title":"Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer"},"paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015":{"doi":"10.1056/nejmoa1503093","openalexId":"W2152897456","cited":5993,"byYear":{"2013":2,"2014":5,"2015":188,"2016":628,"2017":758,"2018":687,"2019":587,"2020":682,"2021":592,"2022":493,"2023":456,"2024":393,"2025":301,"2026":208},"year":2015,"title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma"},"paper-keynote-426-nejm-2019":{"doi":"10.1056/nejmoa1816714","openalexId":"W2913745075","cited":3500,"byYear":{"2018":1,"2019":222,"2020":543,"2021":612,"2022":604,"2023":451,"2024":494,"2025":330,"2026":239},"year":2019,"title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma"},"paper-keynote-048-lancet-2019":{"doi":"10.1016/s0140-6736(19)32591-7","openalexId":"W2986633517","cited":3354,"byYear":{"2013":1,"2019":5,"2020":279,"2021":476,"2022":542,"2023":542,"2024":572,"2025":558,"2026":373},"year":2019,"title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study"},"paper-keynote-177-nejm-2020":{"doi":"10.1056/nejmoa2017699","openalexId":"W3110528877","cited":3149,"byYear":{"2012":1,"2020":4,"2021":380,"2022":582,"2023":619,"2024":568,"2025":538,"2026":452},"year":2020,"title":"Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer"},"paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020":{"doi":"10.1200/jco.19.02105","openalexId":"W2984359187","cited":3086,"byYear":{"2013":1,"2014":2,"2017":1,"2019":6,"2020":213,"2021":499,"2022":563,"2023":569,"2024":482,"2025":444,"2026":303},"year":2019,"title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study"},"paper-heinrich-kit-mutation-imatinib-response-jco-2003":{"doi":"10.1200/jco.2003.04.190","openalexId":"W2150501295","cited":2313,"byYear":{"2012":136,"2013":130,"2014":102,"2015":104,"2016":83,"2017":81,"2018":74,"2019":88,"2020":70,"2021":82,"2022":52,"2023":48,"2024":45,"2025":34,"2026":32},"year":2003,"title":"Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor"},"paper-keynote-054-eggermont-nejm-2018":{"doi":"10.1056/nejmoa1802357","openalexId":"W2797309423","cited":1909,"byYear":{"2017":1,"2018":87,"2019":249,"2020":308,"2021":312,"2022":240,"2023":205,"2024":209,"2025":172,"2026":120},"year":2018,"title":"Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma"},"paper-lacc-nejm-2018":{"doi":"10.1056/nejmoa1806395","openalexId":"W2898881288","cited":1907,"byYear":{"2012":1,"2013":1,"2015":1,"2018":10,"2019":203,"2020":303,"2021":296,"2022":293,"2023":229,"2024":261,"2025":203,"2026":100},"year":2018,"title":"Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer"},"paper-keynote-590-lancet-2021":{"doi":"10.1016/s0140-6736(21)01234-4","openalexId":"W3195935456","cited":1685,"byYear":{"2018":1,"2021":17,"2022":264,"2023":323,"2024":448,"2025":374,"2026":258},"year":2021,"title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study"},"paper-faubert-cell":{"doi":"10.1016/j.cell.2017.09.019","openalexId":"W2763979809","cited":1374,"byYear":{"2017":9,"2018":77,"2019":150,"2020":175,"2021":199,"2022":171,"2023":166,"2024":148,"2025":168,"2026":109},"year":2017,"title":"Lactate Metabolism in Human Lung Tumors"},"paper-ahn-n-engl-j-med":{"doi":"10.1056/nejmp1409841","openalexId":"W2312782750","cited":1255,"byYear":{"2013":1,"2014":3,"2015":76,"2016":85,"2017":124,"2018":122,"2019":123,"2020":151,"2021":122,"2022":133,"2023":98,"2024":87,"2025":74,"2026":53},"year":2014,"title":"Korea's Thyroid-Cancer “Epidemic” — Screening and Overdiagnosis"},"paper-keynote-522-nejm-2022":{"doi":"10.1056/nejmoa2112651","openalexId":"W4210957314","cited":1233,"byYear":{"2022":157,"2023":268,"2024":316,"2025":270,"2026":222},"year":2022,"title":"Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer"},"paper-keynote-355-nejm-2022":{"doi":"10.1056/nejmoa2202809","openalexId":"W4285992810","cited":1201,"byYear":{"2022":30,"2023":216,"2024":335,"2025":333,"2026":286},"year":2022,"title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer"},"paper-keynote-062-shitara-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2020.3370","openalexId":"W3082736986","cited":1172,"byYear":{"2019":2,"2020":16,"2021":121,"2022":264,"2023":206,"2024":253,"2025":194,"2026":116},"year":2020,"title":"Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer"},"paper-keynote-966-lancet-2023":{"doi":"10.1016/s0140-6736(23)00727-4","openalexId":"W4365998338","cited":1158,"byYear":{"2020":1,"2023":95,"2024":323,"2025":421,"2026":317},"year":2023,"title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-lap07-chemoradiotherapy-locally-advanced-pancreatic-jama-2016":{"doi":"10.1001/jama.2016.4324","openalexId":"W2346921980","cited":1108,"byYear":{"2015":3,"2016":27,"2017":94,"2018":113,"2019":100,"2020":97,"2021":137,"2022":127,"2023":113,"2024":123,"2025":96,"2026":72},"year":2016,"title":"Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib"},"paper-keynote-826-nejm-2021":{"doi":"10.1056/nejmoa2112435","openalexId":"W3200231835","cited":1066,"byYear":{"2020":1,"2021":10,"2022":159,"2023":230,"2024":270,"2025":222,"2026":172},"year":2021,"title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer"},"paper-keynote-775-nejm-2022":{"doi":"10.1056/nejmoa2108330","openalexId":"W4205306227","cited":941,"byYear":{"2022":120,"2023":227,"2024":236,"2025":214,"2026":144},"year":2022,"title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer"},"paper-keynote-942-lancet-2024":{"doi":"10.1016/s0140-6736(23)02268-7","openalexId":"W4391067309","cited":876,"byYear":{"2024":169,"2025":366,"2026":341},"year":2024,"title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study"},"paper-keynote-564-nejm-2021":{"doi":"10.1056/nejmoa2106391","openalexId":"W3196207248","cited":796,"byYear":{"2021":26,"2022":200,"2023":175,"2024":152,"2025":136,"2026":105},"year":2021,"title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma"},"paper-antonarakis-keynote-199-pembrolizumab-jco-2020":{"doi":"10.1200/jco.19.01638","openalexId":"W2990771207","cited":745,"byYear":{"2015":1,"2017":1,"2018":1,"2019":1,"2020":83,"2021":124,"2022":117,"2023":123,"2024":113,"2025":99,"2026":80},"year":2019,"title":"Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study"},"paper-keynote-859-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00515-6","openalexId":"W7212039369","cited":30,"byYear":{"2026":30},"year":2023,"title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial"},"paper-pik3ca-colorectal-lancet-oncol-2011":{"doi":"10.1016/s1470-2045(10)70209-6","openalexId":"W2131371081","cited":614,"byYear":{"2012":45,"2013":49,"2014":62,"2015":60,"2016":45,"2017":44,"2018":48,"2019":39,"2020":48,"2021":42,"2022":31,"2023":27,"2024":37,"2025":12,"2026":15},"year":2010,"title":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer"},"paper-klimstra-acinar-cell-carcinoma-pancreas-28-cases-ajsp-1992":{"doi":"10.1097/00000478-199209000-00001","openalexId":"W2019678947","cited":583,"byYear":{"2012":25,"2013":21,"2014":21,"2015":29,"2016":28,"2017":23,"2018":16,"2019":18,"2020":24,"2021":23,"2022":17,"2023":18,"2024":9,"2025":10,"2026":8},"year":1992,"title":"Acinar Cell Carcinoma of the Pancreas"},"paper-keynote-057-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00147-9","openalexId":"W3164781831","cited":566,"byYear":{"2020":1,"2021":31,"2022":103,"2023":102,"2024":129,"2025":125,"2026":74},"year":2021,"title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study"},"paper-wells-cell":{"doi":"10.1016/j.cell.2020.09.015","openalexId":"W3091991776","cited":562,"byYear":{"2012":1,"2019":1,"2020":8,"2021":80,"2022":94,"2023":103,"2024":109,"2025":97,"2026":69},"year":2020,"title":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction"},"paper-keynote-811-janjigian-lancet-2023":{"doi":"10.1016/s0140-6736(23)02033-0","openalexId":"W4387812259","cited":535,"byYear":{"2023":8,"2024":153,"2025":204,"2026":170},"year":2023,"title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial"},"paper-krystal-1-crc-yaeger-nejm-2023":{"doi":"10.1056/nejmoa2212419","openalexId":"W4312094576","cited":528,"byYear":{"2023":90,"2024":174,"2025":159,"2026":104},"year":2022,"title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C"},"paper-klass-01-kim-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2018.6727","openalexId":"W2913826755","cited":520,"byYear":{"2019":28,"2020":53,"2021":95,"2022":99,"2023":74,"2024":83,"2025":49,"2026":39},"year":2019,"title":"Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer"},"paper-keynote-716-lancet-2022":{"doi":"10.1016/s0140-6736(22)00562-1","openalexId":"W4220789323","cited":503,"byYear":{"2022":60,"2023":136,"2024":137,"2025":102,"2026":68},"year":2022,"title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial"},"paper-keynote-a18-pfs-lancet-2024":{"doi":"10.1016/s0140-6736(24)00317-9","openalexId":"W4393965986","cited":400,"byYear":{"2024":100,"2025":180,"2026":120},"year":2024,"title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial"},"paper-keynote-689-nejm-2025":{"doi":"10.1056/nejmoa2415434","openalexId":"W4411407753","cited":392,"byYear":{"2025":97,"2026":295},"year":2025,"title":"Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer"},"paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023":{"doi":"10.1200/jco.23.00434","openalexId":"W4367041654","cited":308,"byYear":{"2023":20,"2024":98,"2025":115,"2026":74},"year":2023,"title":"Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation"},"paper-keynote-629-pembrolizumab-cscc-grob-jco-2020":{"doi":"10.1200/jco.19.03054","openalexId":"W3043252982","cited":304,"byYear":{"2020":5,"2021":55,"2022":54,"2023":51,"2024":47,"2025":50,"2026":40},"year":2020,"title":"Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)"},"paper-keynote-204-pembrolizumab-vs-brentuximab-rr-hodgkin-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00005-x","openalexId":"W3137610925","cited":270,"byYear":{"2021":28,"2022":51,"2023":66,"2024":46,"2025":45,"2026":33},"year":2021,"title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study"},"paper-klimstra-pancreatoblastoma-clinicopathologic-study-ajsp-1995":{"doi":"10.1097/00000478-199512000-00005","openalexId":"W2008589319","cited":267,"byYear":{"2012":18,"2013":12,"2014":11,"2015":12,"2016":8,"2017":12,"2018":7,"2019":7,"2020":12,"2021":5,"2022":13,"2023":8,"2024":8,"2025":4,"2026":5},"year":1995,"title":"Pancreatoblastoma A Clinicopathologic Study and Review of the Literature"},"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019":{"doi":"10.1200/jco.19.01389","openalexId":"W2979952645","cited":266,"byYear":{"2019":2,"2020":46,"2021":61,"2022":38,"2023":52,"2024":24,"2025":30,"2026":12},"year":2019,"title":"Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma"},"paper-bournet-kras-g12d-prognosis-pancreatic-ctg-2016":{"doi":"10.1038/ctg.2016.18","openalexId":"W2316733897","cited":212,"byYear":{"2016":3,"2017":15,"2018":9,"2019":19,"2020":26,"2021":30,"2022":31,"2023":19,"2024":24,"2025":28,"2026":8},"year":2016,"title":"KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma"},"paper-keynote-a18-os-lancet-2024":{"doi":"10.1016/s0140-6736(24)01808-7","openalexId":"W4402535093","cited":205,"byYear":{"2024":9,"2025":99,"2026":97},"year":2024,"title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-la-rosa-acinar-cell-carcinoma-62-cases-ajsp-2012":{"doi":"10.1097/pas.0b013e318263209d","openalexId":"W2315136264","cited":197,"byYear":{"2012":1,"2013":8,"2014":15,"2015":14,"2016":12,"2017":16,"2018":15,"2019":12,"2020":15,"2021":19,"2022":18,"2023":13,"2024":12,"2025":18,"2026":8},"year":2012,"title":"Clinicopathologic Study of 62 Acinar Cell Carcinomas of the Pancreas"},"paper-montoya-science":{"doi":"10.1126/science.adi5798","openalexId":"W4391428485","cited":168,"byYear":{"2024":49,"2025":75,"2026":44},"year":2024,"title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127"},"paper-keynote-483-lancet-2023":{"doi":"10.1016/s0140-6736(23)01613-6","openalexId":"W4388278632","cited":107,"byYear":{"2023":4,"2024":18,"2025":50,"2026":35},"year":2023,"title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial"},"paper-schirripa-kras-g12c-metastatic-colorectal-clin-colorectal-cancer-2020":{"doi":"10.1016/j.clcc.2020.04.009","openalexId":"W3025145964","cited":69,"byYear":{"2020":1,"2021":10,"2022":11,"2023":22,"2024":13,"2025":10,"2026":2},"year":2020,"title":"KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population"},"paper-milazzo-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd005476.pub4","openalexId":"W2108029687","cited":77,"byYear":{"2012":2,"2013":1,"2014":3,"2015":5,"2016":5,"2017":5,"2019":8,"2020":8,"2021":9,"2022":8,"2023":4,"2024":6,"2025":3},"year":2015,"title":"Laetrile treatment for cancer"},"paper-le-mmr-deficiency-pd1-nejm-2015":{"doi":"10.1056/nejmoa1500596","openalexId":"W1940241680","cited":9601,"byYear":{"2013":1,"2014":5,"2015":167,"2016":672,"2017":881,"2018":942,"2019":921,"2020":1169,"2021":1190,"2022":1018,"2023":916,"2024":731,"2025":582,"2026":395},"year":2015,"title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency"},"paper-lemmon-schlessinger-rtk-signalling-cell-2010":{"doi":"10.1016/j.cell.2010.06.011","openalexId":"W2028415754","cited":8024,"byYear":{"2012":366,"2013":362,"2014":388,"2015":407,"2016":378,"2017":383,"2018":381,"2019":443,"2020":428,"2021":524,"2022":425,"2023":412,"2024":384,"2025":290,"2026":224},"year":2010,"title":"Cell Signaling by Receptor Tyrosine Kinases"},"paper-levine-p53-gatekeeper-cell-1997":{"doi":"10.1016/s0092-8674(00)81871-1","openalexId":"W1991494214","cited":7769,"byYear":{"2012":267,"2013":248,"2014":228,"2015":172,"2016":183,"2017":168,"2018":150,"2019":174,"2020":172,"2021":142,"2022":128,"2023":144,"2024":110,"2025":96,"2026":69},"year":1997,"title":"p53, the Cellular Gatekeeper for Growth and Division"},"paper-mazzaferro-milan-criteria-nejm-1996":{"doi":"10.1056/nejm199603143341104","openalexId":"W2315027248","cited":7225,"byYear":{"2012":316,"2013":351,"2014":373,"2015":351,"2016":330,"2017":310,"2018":319,"2019":296,"2020":347,"2021":347,"2022":302,"2023":316,"2024":310,"2025":211,"2026":154},"year":1996,"title":"Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis"},"paper-le-mmr-deficiency-science-2017":{"doi":"10.1126/science.aan6733","openalexId":"W2622499649","cited":6825,"byYear":{"2013":1,"2015":3,"2017":129,"2018":607,"2019":747,"2020":934,"2021":970,"2022":946,"2023":820,"2024":704,"2025":536,"2026":419},"year":2017,"title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade"},"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017":{"doi":"10.1158/0008-5472.can-17-0307","openalexId":"W2765224588","cited":6624,"byYear":{"2018":18,"2019":106,"2020":640,"2021":1319,"2022":1459,"2023":1217,"2024":1120,"2025":535,"2026":207},"year":2017,"title":"TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells"},"paper-li-timer2-nar-2020":{"doi":"10.1093/nar/gkaa407","openalexId":"W3027286012","cited":5799,"byYear":{"2019":1,"2020":39,"2021":627,"2022":1282,"2023":1216,"2024":1317,"2025":910,"2026":405},"year":2020,"title":"TIMER2.0 for analysis of tumor-infiltrating immune cells"},"paper-leach-allison-ctla4-blockade-science-1996":{"doi":"10.1126/science.271.5256.1734","openalexId":"W2094366129","cited":4012,"byYear":{"2012":87,"2013":111,"2014":90,"2015":187,"2016":203,"2017":214,"2018":243,"2019":322,"2020":345,"2021":334,"2022":266,"2023":282,"2024":265,"2025":212,"2026":101},"year":1996,"title":"Enhancement of Antitumor Immunity by CTLA-4 Blockade"},"paper-drilon-larotrectinib-nejm-2018":{"doi":"10.1056/nejmoa1714448","openalexId":"W2790254562","cited":2833,"byYear":{"2017":3,"2018":116,"2019":294,"2020":412,"2021":450,"2022":412,"2023":314,"2024":293,"2025":290,"2026":240},"year":2018,"title":"Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children"},"paper-latitude-nejm-2017":{"doi":"10.1056/nejmoa1704174","openalexId":"W2620798309","cited":2316,"byYear":{"2014":1,"2015":1,"2017":95,"2018":261,"2019":263,"2020":256,"2021":282,"2022":247,"2023":247,"2024":237,"2025":221,"2026":197},"year":2017,"title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer"},"paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990":{"doi":"10.1056/nejm199002083220602","openalexId":"W2313857605","cited":2269,"byYear":{"2012":65,"2013":67,"2014":66,"2015":53,"2016":62,"2017":39,"2018":46,"2019":42,"2020":55,"2021":41,"2022":47,"2023":32,"2024":31,"2025":30,"2026":19},"year":1990,"title":"Levamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma"},"paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007":{"doi":"10.1056/nejmoa070594","openalexId":"W1992538067","cited":1460,"byYear":{"2012":127,"2013":136,"2014":91,"2015":85,"2016":97,"2017":87,"2018":69,"2019":55,"2020":59,"2021":46,"2022":51,"2023":56,"2024":26,"2025":14,"2026":8},"year":2007,"title":"Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma"},"paper-esmo-localised-colon-cancer-guideline-ann-oncol-2020":{"doi":"10.1016/j.annonc.2020.06.022","openalexId":"W4211121451","cited":1404,"byYear":{"2020":17,"2021":122,"2022":221,"2023":243,"2024":314,"2025":288,"2026":197},"year":2020,"title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-logsdon-nat-rev-genet":{"doi":"10.1038/s41576-020-0236-x","openalexId":"W3033870872","cited":1361,"byYear":{"2017":1,"2020":36,"2021":154,"2022":211,"2023":217,"2024":293,"2025":264,"2026":182},"year":2020,"title":"Long-read human genome sequencing and its applications"},"paper-rtog-91-11-long-term-forastiere-jco-2013":{"doi":"10.1200/jco.2012.43.6097","openalexId":"W2140753782","cited":1304,"byYear":{"2012":1,"2013":44,"2014":75,"2015":98,"2016":126,"2017":114,"2018":89,"2019":107,"2020":115,"2021":114,"2022":97,"2023":97,"2024":89,"2025":84,"2026":44},"year":2012,"title":"Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer"},"paper-klotz-active-surveillance-jco-2015":{"doi":"10.1200/jco.2014.55.1192","openalexId":"W2106869018","cited":1231,"byYear":{"2012":1,"2013":4,"2014":2,"2015":96,"2016":144,"2017":176,"2018":117,"2019":106,"2020":119,"2021":121,"2022":90,"2023":76,"2024":74,"2025":65,"2026":39},"year":2014,"title":"Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer"},"paper-calgb-140503-n-engl-j-med-2023":{"doi":"10.1056/nejmoa2212083","openalexId":"W4319456746","cited":1108,"byYear":{"2023":182,"2024":351,"2025":334,"2026":241},"year":2023,"title":"Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer"},"paper-libretto-001-selpercatinib-nsclc-nejm-2020":{"doi":"10.1056/nejmoa2005653","openalexId":"W3081278682","cited":869,"byYear":{"2020":30,"2021":152,"2022":195,"2023":161,"2024":170,"2025":105,"2026":54},"year":2020,"title":"Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer"},"paper-draisma-lead-time-overdiagnosis-psa-jnci-2009":{"doi":"10.1093/jnci/djp001","openalexId":"W2100142491","cited":801,"byYear":{"2012":74,"2013":65,"2014":60,"2015":70,"2016":43,"2017":52,"2018":54,"2019":41,"2020":46,"2021":47,"2022":21,"2023":29,"2024":18,"2025":30,"2026":20},"year":2009,"title":"Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and Context"},"paper-symmans-rcb-long-term-prognosis-subtype-jco-2017":{"doi":"10.1200/jco.2015.63.1010","openalexId":"W2585697071","cited":745,"byYear":{"2016":3,"2017":26,"2018":39,"2019":63,"2020":80,"2021":113,"2022":92,"2023":90,"2024":99,"2025":79,"2026":59},"year":2017,"title":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype"},"paper-hao-nat-methods":{"doi":"10.1038/s41592-024-02305-7","openalexId":"W4399387478","cited":561,"byYear":{"2023":2,"2024":73,"2025":223,"2026":262},"year":2024,"title":"Large-scale foundation model on single-cell transcriptomics"},"paper-saper-jama":{"doi":"10.1001/jama.300.8.915","openalexId":"W2172021285","cited":531,"byYear":{"2012":29,"2013":33,"2014":36,"2015":38,"2016":34,"2017":33,"2018":30,"2019":25,"2020":29,"2021":26,"2022":33,"2023":22,"2024":17,"2025":28,"2026":24},"year":2008,"title":"Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet"},"paper-nsabp-b39-lancet-2019":{"doi":"10.1016/s0140-6736(19)32514-0","openalexId":"W2993667428","cited":488,"byYear":{"2019":1,"2020":62,"2021":100,"2022":73,"2023":86,"2024":75,"2025":57,"2026":30},"year":2019,"title":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial"},"paper-lch-iii-therapy-prolongation-multisystem-lch-blood-2013":{"doi":"10.1182/blood-2012-09-455774","openalexId":"W2009347177","cited":458,"byYear":{"2013":8,"2014":26,"2015":30,"2016":32,"2017":33,"2018":31,"2019":30,"2020":39,"2021":42,"2022":46,"2023":46,"2024":42,"2025":28,"2026":21},"year":2013,"title":"Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis"},"paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017":{"doi":"10.1038/ng.3764","openalexId":"W2576896693","cited":434,"byYear":{"2017":37,"2018":63,"2019":37,"2020":59,"2021":60,"2022":43,"2023":40,"2024":39,"2025":37,"2026":17},"year":2017,"title":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer"},"paper-erivance-bmc-cancer-2017-update":{"doi":"10.1186/s12885-017-3286-5","openalexId":"W2615693675","cited":415,"byYear":{"2014":3,"2015":8,"2016":1,"2017":13,"2018":33,"2019":55,"2020":49,"2021":54,"2022":56,"2023":50,"2024":49,"2025":30,"2026":11},"year":2017,"title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study"},"paper-opra-j-clin-oncol-2024":{"doi":"10.1200/jco.23.01208","openalexId":"W4387951183","cited":382,"byYear":{"2022":1,"2023":2,"2024":88,"2025":141,"2026":150},"year":2023,"title":"Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial"},"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017":{"doi":"10.1016/s0140-6736(17)30396-3","openalexId":"W2590454024","cited":376,"byYear":{"2017":19,"2018":44,"2019":38,"2020":58,"2021":40,"2022":33,"2023":46,"2024":52,"2025":35,"2026":9},"year":2017,"title":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial"},"paper-brown-nat-med":{"doi":"10.1038/s41591-024-02875-1","openalexId":"W4392560879","cited":343,"byYear":{"2023":1,"2024":73,"2025":134,"2026":134},"year":2024,"title":"Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial"},"paper-checkmate-204-lancet-oncol-2021-update":{"doi":"10.1016/s1470-2045(21)00545-3","openalexId":"W3214532628","cited":342,"byYear":{"2022":51,"2023":70,"2024":111,"2025":76,"2026":34},"year":2021,"title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study"},"paper-leap-012-lancet-2025":{"doi":"10.1016/s0140-6736(24)02575-3","openalexId":"W4406160646","cited":321,"byYear":{"2025":147,"2026":174},"year":2025,"title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study"},"paper-vaidya-bmj":{"doi":"10.1136/bmj.m2836","openalexId":"W3067502370","cited":298,"byYear":{"2012":1,"2020":5,"2021":56,"2022":65,"2023":61,"2024":45,"2025":43,"2026":20},"year":2020,"title":"Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial"},"paper-libretto-431-nejm-2023":{"doi":"10.1056/nejmoa2309457","openalexId":"W4387844786","cited":234,"byYear":{"2023":8,"2024":83,"2025":85,"2026":58},"year":2023,"title":"First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC"},"paper-geyer-brightness-4-year-follow-up-ann-oncol-2022":{"doi":"10.1016/j.annonc.2022.01.009","openalexId":"W4210452542","cited":228,"byYear":{"2022":44,"2023":57,"2024":55,"2025":46,"2026":26},"year":2022,"title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial"},"paper-nifty-liposomal-irinotecan-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00486-1","openalexId":"W3206691421","cited":223,"byYear":{"2021":4,"2022":44,"2023":58,"2024":58,"2025":39,"2026":19},"year":2021,"title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study"},"paper-fahrmann-ca19-9-lead-time-gastroenterology-2021":{"doi":"10.1053/j.gastro.2020.11.052","openalexId":"W3110895646","cited":211,"byYear":{"2021":12,"2022":32,"2023":38,"2024":44,"2025":53,"2026":32},"year":2020,"title":"Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection"},"paper-libretto-531-nejm-2023":{"doi":"10.1056/nejmoa2309719","openalexId":"W4387844848","cited":208,"byYear":{"2023":6,"2024":67,"2025":73,"2026":62},"year":2023,"title":"Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer"},"paper-bolt-j-eur-acad-dermatol-venereol-2018-update":{"doi":"10.1111/jdv.14542","openalexId":"W2747660904","cited":194,"byYear":{"2017":2,"2018":16,"2019":27,"2020":25,"2021":38,"2022":33,"2023":16,"2024":19,"2025":12,"2026":3},"year":2017,"title":"Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study"},"paper-ferreri-leukemia":{"doi":"10.1038/s41375-022-01582-5","openalexId":"W4280648573","cited":173,"byYear":{"2022":11,"2023":39,"2024":45,"2025":47,"2026":31},"year":2022,"title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial"},"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022":{"doi":"10.1016/s1470-2045(22)00380-1","openalexId":"W4285023195","cited":136,"byYear":{"2022":7,"2023":22,"2024":43,"2025":34,"2026":30},"year":2022,"title":"Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial"},"paper-convert-int-j-radiat-oncol-biol-phys-2024-update":{"doi":"10.1016/j.ijrobp.2024.02.063","openalexId":"W4393037634","cited":34,"byYear":{"2024":6,"2025":11,"2026":17},"year":2024,"title":"Long-Term Outcomes After Concurrent Once- or Twice-Daily Chemoradiation in Limited-Stage Small Cell Lung Cancer: A Brief Report From the CONVERT Trial"},"paper-eichenauer-nlphl-ghsg-hd7-hd15-long-term-jco-2020":{"doi":"10.1200/jco.19.00986","openalexId":"W2980810865","cited":64,"byYear":{"2020":9,"2021":14,"2022":9,"2023":13,"2024":2,"2025":11,"2026":6},"year":2019,"title":"Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group"},"paper-glaser-br-j-dermatol":{"doi":"10.1111/bjd.13443","openalexId":"W2076832634","cited":50,"byYear":{"2015":2,"2016":2,"2017":2,"2018":4,"2019":4,"2020":4,"2021":8,"2022":6,"2023":5,"2024":6,"2025":4,"2026":2},"year":2014,"title":"Long‐term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy‐induced eyelash hypotrichosis: a randomized controlled trial"},"paper-rennert-neurosurgery":{"doi":"10.1093/neuros/nyz141","openalexId":"W2944579145","cited":44,"byYear":{"2019":2,"2020":10,"2021":9,"2022":8,"2023":6,"2024":4,"2025":2,"2026":3},"year":2019,"title":"Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): Procedural Safety and Hospitalization"},"paper-nordicc-lancet-2026-update":{"doi":"10.1016/s0140-6736(26)00508-8","openalexId":"W7160247416","cited":8,"byYear":{"2026":8},"year":2026,"title":"Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial"},"paper-protect-bju-int-2026-update":{"doi":"10.1111/bju.70261","openalexId":"W7141884464","cited":4,"byYear":{"2026":4},"year":2026,"title":"Long‐term outcomes of cribriform‐positive and cribriform‐negative prostate cancer treated with radical prostatectomy in the ProtecT trial"},"paper-nct04270591-transl-lung-cancer-res-2025-update":{"doi":"10.21037/tlcr-2025-638","openalexId":"W4415544549","cited":3,"byYear":{"2026":3},"year":2025,"title":"Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer"},"paper-nct04395677-j-clin-oncol-2026-update":{"doi":"10.1200/jco-26-00434","openalexId":"W7155038059","cited":0,"byYear":{},"year":2026,"title":"Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1 + Non–Small Cell Lung Cancer: Results From the Phase II TRUST-I Study"},"paper-ballman-j-clin-oncol":{"doi":"10.1200/jco-26-00444","openalexId":"W7160962457","cited":0,"byYear":{},"year":2026,"title":"Lessons From GBM AGILE's Regorafenib Experience in Newly Diagnosed and Recurrent Glioblastoma"},"paper-saperstein-ivermectin-neurotoxicity-breast-cancer-2026":{"doi":"10.1080/00325481.2026.2672183","openalexId":"W7162087671","cited":0,"byYear":{},"year":2026,"title":"Life-threatening neurotoxicity following off-label ivermectin use in metastatic breast cancer: a case report"},"paper-mani-emt-stem-cell-properties-cell-2008":{"doi":"10.1016/j.cell.2008.03.027","openalexId":"W2014691022","cited":8838,"byYear":{"2012":597,"2013":655,"2014":680,"2015":689,"2016":631,"2017":640,"2018":562,"2019":529,"2020":576,"2021":592,"2022":471,"2023":395,"2024":284,"2025":253,"2026":122},"year":2008,"title":"The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells"},"paper-maude-ctl019-all-nejm-2014":{"doi":"10.1056/nejmoa1407222","openalexId":"W2118796952","cited":5498,"byYear":{"2012":4,"2013":3,"2014":24,"2015":262,"2016":385,"2017":543,"2018":503,"2019":544,"2020":693,"2021":575,"2022":507,"2023":526,"2024":394,"2025":320,"2026":205},"year":2014,"title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia"},"paper-levental-cell":{"doi":"10.1016/j.cell.2009.10.027","openalexId":"W2100303404","cited":4176,"byYear":{"2012":192,"2013":239,"2014":247,"2015":217,"2016":261,"2017":271,"2018":274,"2019":276,"2020":348,"2021":356,"2022":300,"2023":288,"2024":236,"2025":238,"2026":200},"year":2009,"title":"Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling"},"paper-lace-adjuvant-cisplatin-pooled-analysis-jco-2008":{"doi":"10.1200/jco.2007.13.9030","openalexId":"W2104504726","cited":2707,"byYear":{"2012":103,"2013":138,"2014":101,"2015":131,"2016":129,"2017":124,"2018":149,"2019":108,"2020":190,"2021":223,"2022":244,"2023":275,"2024":228,"2025":160,"2026":110},"year":2008,"title":"Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group"},"paper-denardo-nat-rev-immunol":{"doi":"10.1038/s41577-019-0127-6","openalexId":"W2914311347","cited":2685,"byYear":{"2019":51,"2020":201,"2021":323,"2022":456,"2023":443,"2024":497,"2025":405,"2026":309},"year":2019,"title":"Macrophages as regulators of tumour immunity and immunotherapy"},"paper-stephens-cell":{"doi":"10.1016/j.cell.2010.11.055","openalexId":"W2109948920","cited":2503,"byYear":{"2012":169,"2013":190,"2014":198,"2015":185,"2016":189,"2017":155,"2018":173,"2019":149,"2020":178,"2021":192,"2022":134,"2023":134,"2024":153,"2025":123,"2026":81},"year":2011,"title":"Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development"},"paper-martincorena-somatic-mutations-normal-skin-science-2015":{"doi":"10.1126/science.aaa6806","openalexId":"W1956871134","cited":1886,"byYear":{"2014":2,"2015":34,"2016":122,"2017":156,"2018":149,"2019":195,"2020":222,"2021":218,"2022":204,"2023":176,"2024":166,"2025":143,"2026":94},"year":2015,"title":"High burden and pervasive positive selection of somatic mutations in normal human skin"},"paper-masaoka-thymoma-clinical-staging-cancer-1981":{"doi":"10.1002/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r","openalexId":"W2083719902","cited":1725,"byYear":{"2012":72,"2013":56,"2014":70,"2015":65,"2016":67,"2017":69,"2018":55,"2019":51,"2020":63,"2021":57,"2022":58,"2023":44,"2024":28,"2025":32,"2026":19},"year":1981,"title":"Follow-up study of thymomas with special reference to their clinical stages"},"paper-elad-cancer":{"doi":"10.1002/cncr.33100","openalexId":"W2158334747","cited":1343,"byYear":{"2014":16,"2015":46,"2016":54,"2017":81,"2018":51,"2019":83,"2020":93,"2021":141,"2022":126,"2023":146,"2024":175,"2025":166,"2026":164},"year":2020,"title":"MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy"},"paper-hughes-j-clin-oncol":{"doi":"10.1200/jco.2012.45.2615","openalexId":"W2122428334","cited":1319,"byYear":{"2012":17,"2013":30,"2014":49,"2015":80,"2016":68,"2017":85,"2018":81,"2019":93,"2020":147,"2021":115,"2022":119,"2023":126,"2024":125,"2025":110,"2026":64},"year":2013,"title":"Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343"},"paper-haanen-ann-oncol":{"doi":"10.1016/j.annonc.2022.10.001","openalexId":"W4306692674","cited":1295,"byYear":{"2015":1,"2022":2,"2023":191,"2024":318,"2025":404,"2026":375},"year":2022,"title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-majestec-1-teclistamab-nejm-2022":{"doi":"10.1056/nejmoa2203478","openalexId":"W4282033105","cited":1253,"byYear":{"2013":1,"2022":39,"2023":236,"2024":330,"2025":344,"2026":300},"year":2022,"title":"Teclistamab in Relapsed or Refractory Multiple Myeloma"},"paper-hughes-n-engl-j-med":{"doi":"10.1056/nejmoa040587","openalexId":"W1982853521","cited":1084,"byYear":{"2012":79,"2013":82,"2014":40,"2015":53,"2016":41,"2017":53,"2018":38,"2019":33,"2020":52,"2021":50,"2022":49,"2023":33,"2024":43,"2025":32,"2026":21},"year":2004,"title":"Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer"},"paper-martuza-engineered-hsv-glioma-science-1991":{"doi":"10.1126/science.1851332","openalexId":"W2073134590","cited":1062,"byYear":{"2012":28,"2013":28,"2014":20,"2015":21,"2016":29,"2017":34,"2018":35,"2019":24,"2020":39,"2021":48,"2022":44,"2023":53,"2024":31,"2025":41,"2026":28},"year":1991,"title":"Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant"},"paper-woodcock-n-engl-j-med":{"doi":"10.1056/nejmra1510062","openalexId":"W2726405642","cited":1043,"byYear":{"2012":1,"2017":11,"2018":69,"2019":124,"2020":116,"2021":147,"2022":121,"2023":113,"2024":124,"2025":105,"2026":111},"year":2017,"title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both"},"paper-shelley-hwang-cancer-cell-2014":{"doi":"10.1016/j.ccell.2014.09.006","openalexId":"W2142530756","cited":1032,"byYear":{"2013":1,"2014":1,"2015":52,"2016":50,"2017":54,"2018":71,"2019":79,"2020":112,"2021":121,"2022":124,"2023":117,"2024":111,"2025":87,"2026":52},"year":2014,"title":"Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells"},"paper-maia-daratumumab-rd-nejm-2019":{"doi":"10.1056/nejmoa1817249","openalexId":"W2947874495","cited":1026,"byYear":{"2012":1,"2018":1,"2019":40,"2020":195,"2021":209,"2022":146,"2023":131,"2024":110,"2025":110,"2026":79},"year":2019,"title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma"},"paper-van-klaveren-n-engl-j-med":{"doi":"10.1056/nejmoa0906085","openalexId":"W2147757711","cited":826,"byYear":{"2012":83,"2013":81,"2014":87,"2015":72,"2016":54,"2017":44,"2018":52,"2019":45,"2020":54,"2021":38,"2022":34,"2023":25,"2024":24,"2025":21,"2026":11},"year":2009,"title":"Management of Lung Nodules Detected by Volume CT Scanning"},"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023":{"doi":"10.1038/s41586-023-05874-3","openalexId":"W4362606390","cited":811,"byYear":{"2023":101,"2024":261,"2025":267,"2026":181},"year":2023,"title":"Lung adenocarcinoma promotion by air pollutants"},"paper-mavoric-mogamulizumab-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30379-6","openalexId":"W2885239461","cited":673,"byYear":{"2018":4,"2019":64,"2020":84,"2021":99,"2022":78,"2023":86,"2024":85,"2025":115,"2026":57},"year":2018,"title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial"},"paper-caps-consortium-surveillance-recommendations-gut-2020":{"doi":"10.1136/gutjnl-2019-319352","openalexId":"W2982364478","cited":659,"byYear":{"2018":1,"2019":1,"2020":46,"2021":109,"2022":112,"2023":101,"2024":113,"2025":101,"2026":73},"year":2019,"title":"Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium"},"paper-roeland-j-clin-oncol":{"doi":"10.1200/jco.20.00611","openalexId":"W3028453792","cited":645,"byYear":{"2020":23,"2021":79,"2022":107,"2023":97,"2024":141,"2025":102,"2026":96},"year":2020,"title":"Management of Cancer Cachexia: ASCO Guideline"},"paper-magnetismm-3-elranatamab-natmed-2023":{"doi":"10.1038/s41591-023-02528-9","openalexId":"W4385839624","cited":644,"byYear":{"2023":29,"2024":184,"2025":243,"2026":188},"year":2023,"title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results"},"paper-antoine-italiano-nat-cancer-2021":{"doi":"10.1038/s43018-021-00232-6","openalexId":"W3187890850","cited":640,"byYear":{"2021":12,"2022":50,"2023":103,"2024":171,"2025":161,"2026":143},"year":2021,"title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression"},"paper-paice-j-clin-oncol":{"doi":"10.1200/jco.2016.68.5206","openalexId":"W2491579167","cited":608,"byYear":{"2017":35,"2018":53,"2019":68,"2020":63,"2021":74,"2022":79,"2023":62,"2024":59,"2025":62,"2026":52},"year":2016,"title":"Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline"},"paper-masai-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00298-x","openalexId":"W4385448527","cited":576,"byYear":{"2022":1,"2023":32,"2024":169,"2025":207,"2026":167},"year":2023,"title":"Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study"},"paper-amer-zeidan-n-engl-j-med-2020":{"doi":"10.1056/nejmoa1908892","openalexId":"W2998901800","cited":555,"byYear":{"2019":1,"2020":73,"2021":112,"2022":76,"2023":91,"2024":77,"2025":77,"2026":46},"year":2020,"title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes"},"paper-mariposa-nejm-2024":{"doi":"10.1056/nejmoa2403614","openalexId":"W4400029774","cited":454,"byYear":{"2023":1,"2024":39,"2025":236,"2026":178},"year":2024,"title":"Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC"},"paper-centore-trends-genet":{"doi":"10.1016/j.tig.2020.07.011","openalexId":"W3082857338","cited":406,"byYear":{"2020":4,"2021":44,"2022":41,"2023":85,"2024":112,"2025":77,"2026":43},"year":2020,"title":"Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies"},"paper-esmo-marginal-zone-lymphoma-zucca-ann-oncol-2020":{"doi":"10.1016/j.annonc.2019.10.010","openalexId":"W2999740565","cited":353,"byYear":{"2020":23,"2021":51,"2022":55,"2023":70,"2024":62,"2025":52,"2026":36},"year":2020,"title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-asco-hereditary-breast-cancer-guideline-jco-2020":{"doi":"10.1200/jco.20.00299","openalexId":"W3014383023","cited":341,"byYear":{"2020":19,"2021":74,"2022":52,"2023":51,"2024":55,"2025":53,"2026":35},"year":2020,"title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline"},"paper-andricovich-kdm6a-squamous-pancreatic-cancer-cell-2018":{"doi":"10.1016/j.ccell.2018.02.003","openalexId":"W2791796258","cited":334,"byYear":{"2018":17,"2019":32,"2020":42,"2021":55,"2022":41,"2023":47,"2024":33,"2025":42,"2026":24},"year":2018,"title":"Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors"},"paper-kishan-jama-oncol":{"doi":"10.1001/jamaoncol.2022.6558","openalexId":"W4315706058","cited":327,"byYear":{"2023":65,"2024":87,"2025":110,"2026":65},"year":2023,"title":"Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer"},"paper-matterhorn-nejm-2025":{"doi":"10.1056/nejmoa2503701","openalexId":"W4410927244","cited":323,"byYear":{"2025":84,"2026":239},"year":2025,"title":"Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer"},"paper-kutner-ann-intern-med":{"doi":"10.7326/0003-4819-149-6-200809160-00003","openalexId":"W2161500580","cited":265,"byYear":{"2012":30,"2013":18,"2014":14,"2015":15,"2016":11,"2017":22,"2018":14,"2019":12,"2020":14,"2021":11,"2022":11,"2023":18,"2024":7,"2025":6,"2026":11},"year":2008,"title":"Massage Therapy versus Simple Touch to Improve Pain and Mood in Patients with Advanced Cancer"},"paper-hassett-j-clin-oncol":{"doi":"10.1200/jco.19.03120","openalexId":"W3006424097","cited":263,"byYear":{"2020":14,"2021":34,"2022":39,"2023":55,"2024":44,"2025":44,"2026":33},"year":2020,"title":"Management of Male Breast Cancer: ASCO Guideline"},"paper-pant-nat-med":{"doi":"10.1038/s41591-023-02760-3","openalexId":"W4390707107","cited":260,"byYear":{"2024":61,"2025":114,"2026":85},"year":2024,"title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial"},"paper-herbst-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-13-3473","openalexId":"W2105805568","cited":244,"byYear":{"2015":21,"2016":24,"2017":30,"2018":32,"2019":34,"2020":25,"2021":25,"2022":13,"2023":11,"2024":12,"2025":7,"2026":10},"year":2015,"title":"Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400"},"paper-patil-low-dose-nivolumab-jco-2023":{"doi":"10.1200/jco.22.01015","openalexId":"W4306921237","cited":218,"byYear":{"2022":6,"2023":51,"2024":63,"2025":55,"2026":43},"year":2022,"title":"Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study"},"paper-bohlius-j-clin-oncol":{"doi":"10.1200/jco.18.02142","openalexId":"W4253850874","cited":162,"byYear":{"2019":4,"2020":22,"2021":26,"2022":19,"2023":16,"2024":25,"2025":20,"2026":30},"year":2019,"title":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update"},"paper-gallbladder-polyp-joint-guideline-eur-radiol-2022":{"doi":"10.1007/s00330-021-08384-w","openalexId":"W4200618142","cited":139,"byYear":{"2022":16,"2023":17,"2024":32,"2025":46,"2026":27},"year":2021,"title":"Management and follow-up of gallbladder polyps: updated joint guidelines between the ESGAR, EAES, EFISDS and ESGE"},"paper-mars-2-lancet-respir-med-2024":{"doi":"10.1016/s2213-2600(24)00119-x","openalexId":"W4396829550","cited":128,"byYear":{"2024":34,"2025":56,"2026":38},"year":2024,"title":"Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial"},"paper-shin-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd009873.pub3","openalexId":"W1480403177","cited":117,"byYear":{"2012":1,"2014":1,"2017":7,"2018":11,"2019":17,"2020":27,"2021":11,"2022":10,"2023":6,"2024":12,"2025":7,"2026":5},"year":2016,"title":"Massage with or without aromatherapy for symptom relief in people with cancer"},"paper-patil-lancet-glob-health":{"doi":"10.1016/s2214-109x(20)30275-8","openalexId":"W3065773319","cited":105,"byYear":{"2020":4,"2021":20,"2022":17,"2023":23,"2024":18,"2025":16,"2026":7},"year":2020,"title":"Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial"},"paper-magnolia-zanubrutinib-mzl-ccr-2021":{"doi":"10.1158/1078-0432.ccr-21-1704","openalexId":"W3200817711","cited":85,"byYear":{"2022":16,"2023":25,"2024":16,"2025":13,"2026":14},"year":2021,"title":"The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma"},"paper-alascca-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2504650","openalexId":"W4414274506","cited":83,"byYear":{"2025":18,"2026":65},"year":2025,"title":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer"},"paper-lutetium-177-dotatate-neuroendocrine-pract-radiat-oncol-2022":{"doi":"10.1016/j.prro.2022.02.002","openalexId":"W4282972785","cited":42,"byYear":{"2022":1,"2023":9,"2024":17,"2025":10,"2026":5},"year":2022,"title":"Lutetium-177 DOTATATE: A Practical Review"},"paper-matrix-ielsg43-asct-consolidation-pcnsl-illerhaus-lancet-2026":{"doi":"10.1016/s0140-6736(26)00917-7","openalexId":"W7170094642","cited":3,"byYear":{"2026":3},"year":2026,"title":"High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial"},"paper-kozono-j-thorac-oncol":{"doi":"10.1016/j.jtho.2024.07.024","openalexId":"W4401328311","cited":5,"byYear":{"2024":2,"2025":3},"year":2024,"title":"Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400)"},"paper-mcclements-capbil-incidental-gallbladder-cancer-bjs-2026":{"doi":"10.1093/bjs/znag050","openalexId":"W7155104666","cited":0,"byYear":{},"year":2026,"title":"Management of incidental gallbladder cancer in the nationwide CAPBIL study"},"paper-calin-nat-rev-cancer":{"doi":"10.1038/nrc1997","openalexId":"W2002995168","cited":7668,"byYear":{"2012":504,"2013":554,"2014":585,"2015":703,"2016":569,"2017":604,"2018":525,"2019":486,"2020":456,"2021":361,"2022":279,"2023":221,"2024":199,"2025":169,"2026":100},"year":2006,"title":"MicroRNA signatures in human cancers"},"paper-wherry-nat-rev-immunol":{"doi":"10.1038/nri3862","openalexId":"W1910012553","cited":4768,"byYear":{"2014":1,"2015":12,"2016":129,"2017":230,"2018":310,"2019":394,"2020":474,"2021":572,"2022":556,"2023":526,"2024":562,"2025":506,"2026":492},"year":2015,"title":"Molecular and cellular insights into T cell exhaustion"},"paper-engelman-met-amplification-gefitinib-resistance-science-2007":{"doi":"10.1126/science.1141478","openalexId":"W1998971866","cited":4502,"byYear":{"2012":346,"2013":367,"2014":347,"2015":373,"2016":290,"2017":290,"2018":269,"2019":217,"2020":187,"2021":197,"2022":159,"2023":137,"2024":128,"2025":107,"2026":81},"year":2007,"title":"MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling"},"paper-chang-cell":{"doi":"10.1016/j.cell.2015.08.016","openalexId":"W2100039832","cited":3410,"byYear":{"2013":1,"2015":12,"2016":110,"2017":178,"2018":200,"2019":253,"2020":346,"2021":405,"2022":449,"2023":378,"2024":363,"2025":348,"2026":366},"year":2015,"title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression"},"paper-minnesota-fobt-nejm-1993":{"doi":"10.1056/nejm199305133281901","openalexId":"W2046686567","cited":3263,"byYear":{"2012":126,"2013":120,"2014":116,"2015":115,"2016":87,"2017":90,"2018":74,"2019":74,"2020":68,"2021":71,"2022":63,"2023":55,"2024":58,"2025":38,"2026":23},"year":1993,"title":"Reducing Mortality from Colorectal Cancer by Screening for Fecal Occult Blood"},"paper-spranger-nature":{"doi":"10.1038/nature14404","openalexId":"W1498931318","cited":2910,"byYear":{"2015":31,"2016":150,"2017":216,"2018":202,"2019":250,"2020":346,"2021":407,"2022":343,"2023":286,"2024":241,"2025":234,"2026":201},"year":2015,"title":"Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity"},"paper-catalona-psa-screening-test-nejm-1991":{"doi":"10.1056/nejm199104253241702","openalexId":"W2335679869","cited":2399,"byYear":{"2012":84,"2013":74,"2014":81,"2015":65,"2016":67,"2017":59,"2018":45,"2019":59,"2020":53,"2021":60,"2022":41,"2023":55,"2024":43,"2025":50,"2026":27},"year":1991,"title":"Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer"},"paper-ajcc-8-melanoma-gershenwald-ca-2017":{"doi":"10.3322/caac.21409","openalexId":"W2762347490","cited":2327,"byYear":{"2014":1,"2017":12,"2018":189,"2019":258,"2020":368,"2021":343,"2022":329,"2023":272,"2024":249,"2025":200,"2026":97},"year":2017,"title":"Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual"},"paper-chen-androgen-receptor-overexpression-antiandrogen-resistance-nat-med-2004":{"doi":"10.1038/nm972","openalexId":"W2003955264","cited":2292,"byYear":{"2012":156,"2013":153,"2014":128,"2015":119,"2016":104,"2017":110,"2018":101,"2019":87,"2020":73,"2021":89,"2022":61,"2023":74,"2024":41,"2025":38,"2026":17},"year":2003,"title":"Molecular determinants of resistance to antiandrogen therapy"},"paper-massague-nature":{"doi":"10.1038/nature17038","openalexId":"W2266814182","cited":2126,"byYear":{"2015":1,"2016":52,"2017":123,"2018":173,"2019":206,"2020":236,"2021":272,"2022":266,"2023":249,"2024":257,"2025":164,"2026":125},"year":2016,"title":"Metastatic colonization by circulating tumour cells"},"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023":{"doi":"10.1016/j.annonc.2022.10.003","openalexId":"W4307401860","cited":1802,"byYear":{"2012":1,"2022":8,"2023":262,"2024":538,"2025":558,"2026":433},"year":2022,"title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-symmans-j-clin-oncol":{"doi":"10.1200/jco.2007.10.6823","openalexId":"W2096145980","cited":1704,"byYear":{"2012":52,"2013":69,"2014":55,"2015":82,"2016":99,"2017":87,"2018":79,"2019":101,"2020":112,"2021":141,"2022":147,"2023":150,"2024":141,"2025":131,"2026":96},"year":2007,"title":"Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy"},"paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018":{"doi":"10.1200/jco.2017.75.3384","openalexId":"W2783897381","cited":1436,"byYear":{"2017":2,"2018":97,"2019":180,"2020":264,"2021":256,"2022":198,"2023":184,"2024":136,"2025":77,"2026":42},"year":2018,"title":"Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing"},"paper-knowles-nat-rev-cancer":{"doi":"10.1038/nrc3817","openalexId":"W2035297454","cited":1296,"byYear":{"2012":1,"2014":2,"2015":50,"2016":94,"2017":107,"2018":95,"2019":105,"2020":152,"2021":154,"2022":140,"2023":119,"2024":138,"2025":80,"2026":56},"year":2014,"title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity"},"paper-pajtler-cancer-cell":{"doi":"10.1016/j.ccell.2015.04.002","openalexId":"W1949037014","cited":1265,"byYear":{"2014":2,"2015":22,"2016":67,"2017":98,"2018":105,"2019":121,"2020":130,"2021":184,"2022":130,"2023":114,"2024":117,"2025":95,"2026":71},"year":2015,"title":"Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups"},"paper-sosa-nat-rev-cancer":{"doi":"10.1038/nrc3793","openalexId":"W2006986876","cited":1149,"byYear":{"2014":4,"2015":56,"2016":84,"2017":79,"2018":117,"2019":107,"2020":114,"2021":126,"2022":107,"2023":115,"2024":84,"2025":87,"2026":67},"year":2014,"title":"Mechanisms of disseminated cancer cell dormancy: an awakening field"},"paper-ren-nat-rev-cancer":{"doi":"10.1038/nrc1567","openalexId":"W2012828386","cited":1079,"byYear":{"2012":56,"2013":59,"2014":38,"2015":47,"2016":44,"2017":48,"2018":48,"2019":58,"2020":47,"2021":74,"2022":77,"2023":42,"2024":34,"2025":29,"2026":20},"year":2005,"title":"Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia"},"paper-beltran-nepc-aurka-mycn-cancer-discov-2011":{"doi":"10.1158/2159-8290.cd-11-0130","openalexId":"W2130955565","cited":1044,"byYear":{"2012":14,"2013":34,"2014":63,"2015":42,"2016":55,"2017":68,"2018":94,"2019":76,"2020":74,"2021":88,"2022":98,"2023":98,"2024":111,"2025":83,"2026":42},"year":2011,"title":"Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets"},"paper-gerstberger-cell":{"doi":"10.1016/j.cell.2023.03.003","openalexId":"W4365449901","cited":929,"byYear":{"2023":56,"2024":268,"2025":354,"2026":251},"year":2023,"title":"Metastasis"},"paper-portec-3-molecular-leon-castillo-jco-2020":{"doi":"10.1200/jco.20.00549","openalexId":"W3047152751","cited":873,"byYear":{"2012":1,"2020":14,"2021":87,"2022":139,"2023":159,"2024":178,"2025":170,"2026":125},"year":2020,"title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy"},"paper-ivey-npm1-mrd-nejm-2016":{"doi":"10.1056/nejmoa1507471","openalexId":"W2276580523","cited":862,"byYear":{"2016":66,"2017":81,"2018":88,"2019":106,"2020":82,"2021":115,"2022":67,"2023":79,"2024":72,"2025":64,"2026":42},"year":2016,"title":"Assessment of Minimal Residual Disease in Standard-Risk AML"},"paper-frampton-met-exon-14-cancer-discov-2015":{"doi":"10.1158/2159-8290.cd-15-0285","openalexId":"W2160212814","cited":814,"byYear":{"2013":2,"2014":1,"2015":13,"2016":65,"2017":86,"2018":72,"2019":71,"2020":96,"2021":100,"2022":76,"2023":88,"2024":71,"2025":48,"2026":23},"year":2015,"title":"Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors"},"paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014":{"doi":"10.1158/1078-0432.ccr-14-0332","openalexId":"W2159064822","cited":773,"byYear":{"2014":2,"2015":18,"2016":30,"2017":37,"2018":50,"2019":74,"2020":84,"2021":101,"2022":90,"2023":102,"2024":88,"2025":60,"2026":34},"year":2014,"title":"Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies"},"paper-awad-met-exon-14-mutations-lung-jco-2016":{"doi":"10.1200/jco.2015.63.4600","openalexId":"W2230948985","cited":708,"byYear":{"2014":1,"2016":46,"2017":72,"2018":51,"2019":59,"2020":77,"2021":92,"2022":79,"2023":80,"2024":76,"2025":44,"2026":30},"year":2016,"title":"MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression"},"paper-annema-jama":{"doi":"10.1001/jama.2010.1705","openalexId":"W2063592828","cited":639,"byYear":{"2012":64,"2013":66,"2014":52,"2015":59,"2016":41,"2017":34,"2018":36,"2019":27,"2020":45,"2021":48,"2022":24,"2023":24,"2024":23,"2025":30,"2026":16},"year":2010,"title":"Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer"},"paper-mntx-302-thomas-nejm-2008":{"doi":"10.1056/nejmoa0707377","openalexId":"W2164341191","cited":597,"byYear":{"2012":53,"2013":39,"2014":29,"2015":45,"2016":19,"2017":23,"2018":42,"2019":16,"2020":20,"2021":17,"2022":18,"2023":13,"2024":7,"2025":10,"2026":4},"year":2008,"title":"Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness"},"paper-mesothelin-mesothelioma-cancer-discov-2016":{"doi":"10.1158/2159-8290.cd-15-0583","openalexId":"W1926256541","cited":506,"byYear":{"2016":18,"2017":42,"2018":43,"2019":40,"2020":67,"2021":73,"2022":48,"2023":61,"2024":45,"2025":48,"2026":20},"year":2015,"title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors"},"paper-mirasol-nejm-2023":{"doi":"10.1056/nejmoa2309169","openalexId":"W4389376362","cited":483,"byYear":{"2021":1,"2023":1,"2024":83,"2025":202,"2026":196},"year":2023,"title":"Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer"},"paper-andrea-decensi-cancer-prev-res-phila-2014":{"doi":"10.1158/1940-6207.capr-13-0424","openalexId":"W1976655891","cited":470,"byYear":{"2014":10,"2015":28,"2016":43,"2017":41,"2018":43,"2019":44,"2020":40,"2021":44,"2022":47,"2023":40,"2024":43,"2025":29,"2026":17},"year":2014,"title":"Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders"},"paper-mesothelin-mesothelioma-clin-cancer-res-2004":{"doi":"10.1158/1078-0432.ccr-03-0801","openalexId":"W1995837838","cited":444,"byYear":{"2012":32,"2013":25,"2014":22,"2015":19,"2016":14,"2017":19,"2018":20,"2019":18,"2020":16,"2021":12,"2022":15,"2023":10,"2024":12,"2025":21,"2026":11},"year":2004,"title":"Mesothelin"},"paper-bielack-j-clin-oncol":{"doi":"10.1200/jco.2014.60.0734","openalexId":"W2095599995","cited":431,"byYear":{"2014":5,"2015":14,"2016":42,"2017":38,"2018":19,"2019":36,"2020":65,"2021":50,"2022":35,"2023":39,"2024":39,"2025":33,"2026":16},"year":2015,"title":"Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial"},"paper-sharma-endpac-model-new-onset-diabetes-gastroenterology-2018":{"doi":"10.1053/j.gastro.2018.05.023","openalexId":"W2803190522","cited":394,"byYear":{"2018":5,"2019":20,"2020":36,"2021":51,"2022":55,"2023":62,"2024":59,"2025":58,"2026":48},"year":2018,"title":"Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes"},"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017":{"doi":"10.1200/jco.2016.71.9807","openalexId":"W2589836162","cited":360,"byYear":{"2017":27,"2018":38,"2019":43,"2020":65,"2021":45,"2022":33,"2023":22,"2024":33,"2025":26,"2026":28},"year":2017,"title":"Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology"},"paper-gebhart-ann-oncol":{"doi":"10.1093/annonc/mdv577","openalexId":"W2198899045","cited":358,"byYear":{"2016":22,"2017":33,"2018":37,"2019":31,"2020":45,"2021":40,"2022":34,"2023":36,"2024":39,"2025":22,"2026":19},"year":2015,"title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial"},"paper-cillessen-psychooncology":{"doi":"10.1002/pon.5214","openalexId":"W2970124303","cited":333,"byYear":{"2019":3,"2020":29,"2021":38,"2022":52,"2023":66,"2024":59,"2025":48,"2026":36},"year":2019,"title":"Mindfulness‐based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta‐analysis of randomized controlled trials"},"paper-mesothelin-mesothelioma-j-clin-oncol-2016":{"doi":"10.1200/jco.2016.68.3672","openalexId":"W2531335004","cited":329,"byYear":{"2016":2,"2017":22,"2018":39,"2019":35,"2020":41,"2021":36,"2022":43,"2023":36,"2024":26,"2025":32,"2026":17},"year":2016,"title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?"},"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020":{"doi":"10.1200/jco.20.01364","openalexId":"W3047482470","cited":306,"byYear":{"2020":4,"2021":56,"2022":47,"2023":52,"2024":54,"2025":51,"2026":42},"year":2020,"title":"Metastatic Pancreatic Cancer: ASCO Guideline Update"},"paper-flaherty-j-clin-oncol":{"doi":"10.1200/jco.19.03010","openalexId":"W3092241364","cited":303,"byYear":{"2020":3,"2021":43,"2022":57,"2023":71,"2024":56,"2025":41,"2026":32},"year":2020,"title":"Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)"},"paper-horneber-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd003297.pub2","openalexId":"W1825673949","cited":229,"byYear":{"2012":11,"2013":13,"2014":19,"2015":10,"2016":11,"2017":23,"2018":13,"2019":14,"2020":15,"2021":12,"2022":10,"2023":14,"2024":9,"2025":5,"2026":1},"year":2008,"title":"Mistletoe therapy in oncology"},"paper-philip-kras-wild-type-pancreatic-ccr-2022":{"doi":"10.1158/1078-0432.ccr-21-3581","openalexId":"W4220775305","cited":187,"byYear":{"2022":8,"2023":42,"2024":53,"2025":56,"2026":28},"year":2022,"title":"Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma"},"paper-seely-integr-cancer-ther":{"doi":"10.1177/1534735411425484","openalexId":"W2170181695","cited":175,"byYear":{"2012":8,"2013":10,"2014":6,"2015":11,"2016":5,"2017":17,"2018":13,"2019":16,"2020":17,"2021":19,"2022":12,"2023":10,"2024":12,"2025":7,"2026":12},"year":2011,"title":"Melatonin as Adjuvant Cancer Care With and Without Chemotherapy"},"paper-authors-nat-methods-2021":{"doi":"10.1038/s41592-020-01042-x","openalexId":"W4233578221","cited":170,"byYear":{"2021":23,"2022":34,"2023":35,"2024":35,"2025":30,"2026":13},"year":2021,"title":"Method of the Year 2020: spatially resolved transcriptomics"},"paper-nct03907852-nat-med-2023":{"doi":"10.1038/s41591-023-02452-y","openalexId":"W4385302690","cited":112,"byYear":{"2023":8,"2024":29,"2025":45,"2026":30},"year":2023,"title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results"},"paper-authors-nat-methods":{"doi":"10.1038/nmeth.2329","openalexId":"W4235124130","cited":111,"byYear":{"2013":3,"2014":14,"2015":13,"2016":9,"2017":13,"2018":8,"2019":8,"2020":10,"2021":10,"2022":3,"2023":5,"2024":9,"2025":5,"2026":1},"year":2012,"title":"Method of the Year 2012"},"paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019":{"doi":"10.1038/s41416-018-0199-2","openalexId":"W2898899606","cited":110,"byYear":{"2019":10,"2020":10,"2021":11,"2022":22,"2023":17,"2024":20,"2025":14,"2026":5},"year":2018,"title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma"},"paper-tjulandin-prolgolimab-miraculum-ejc-2021":{"doi":"10.1016/j.ejca.2021.02.030","openalexId":"W3153241053","cited":66,"byYear":{"2021":3,"2022":10,"2023":19,"2024":18,"2025":12,"2026":4},"year":2021,"title":"Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice"},"paper-ren-tnbc-mmr-msi-440-front-oncol-2021":{"doi":"10.3389/fonc.2021.570623","openalexId":"W3135356275","cited":50,"byYear":{"2021":7,"2022":16,"2023":9,"2024":8,"2025":8,"2026":2},"year":2021,"title":"Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients"},"paper-kurata-japanese-tnbc-msi-breast-cancer-2020":{"doi":"10.1007/s12282-019-01043-5","openalexId":"W2998347368","cited":26,"byYear":{"2020":3,"2021":6,"2022":3,"2023":4,"2024":4,"2025":2,"2026":4},"year":2020,"title":"Microsatellite instability in Japanese female patients with triple-negative breast cancer"},"paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026":{"doi":"10.1158/1078-0432.ccr-26-0428","openalexId":"W7166189255","cited":2,"byYear":{"2026":2},"year":2026,"title":"Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer"},"paper-cheng-melanoma-ctdna-antiparasitic-front-oncol-2026":{"doi":"10.3389/fonc.2026.1907192","openalexId":"W7204867729","cited":0,"byYear":{},"year":2026,"title":"Case Report: Metastatic melanoma with initial ctdna decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?"},"paper-perou-molecular-portraits-breast-tumours-nature-2000":{"doi":"10.1038/35021093","openalexId":"W2097255042","cited":16575,"byYear":{"2012":763,"2013":883,"2014":849,"2015":875,"2016":841,"2017":825,"2018":733,"2019":794,"2020":934,"2021":894,"2022":905,"2023":836,"2024":701,"2025":522,"2026":379},"year":2000,"title":"Molecular portraits of human breast tumours"},"paper-knudson-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.68.4.820","openalexId":"W2077858999","cited":7709,"byYear":{"2012":242,"2013":213,"2014":237,"2015":222,"2016":212,"2017":216,"2018":208,"2019":199,"2020":264,"2021":271,"2022":218,"2023":254,"2024":205,"2025":192,"2026":113},"year":1971,"title":"Mutation and Cancer: Statistical Study of Retinoblastoma"},"paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013":{"doi":"10.1056/nejmoa1304369","openalexId":"W2165480504","cited":6845,"byYear":{"2012":1,"2013":15,"2014":267,"2015":423,"2016":423,"2017":512,"2018":550,"2019":542,"2020":664,"2021":709,"2022":637,"2023":640,"2024":583,"2025":501,"2026":363},"year":2013,"title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine"},"paper-zaretsky-n-engl-j-med":{"doi":"10.1056/nejmoa1604958","openalexId":"W2465860350","cited":3304,"byYear":{"2012":1,"2016":46,"2017":326,"2018":338,"2019":310,"2020":390,"2021":431,"2022":371,"2023":325,"2024":277,"2025":250,"2026":235},"year":2016,"title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma"},"paper-almoguera-kras-codon-12-pancreatic-cell-1988":{"doi":"10.1016/0092-8674(88)90571-5","openalexId":"W2164034599","cited":2124,"byYear":{"2012":81,"2013":87,"2014":77,"2015":84,"2016":78,"2017":69,"2018":37,"2019":60,"2020":47,"2021":45,"2022":39,"2023":33,"2024":24,"2025":15,"2026":11},"year":1988,"title":"Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes"},"paper-taylor-medulloblastoma-consensus-acta-neuropathol-2012":{"doi":"10.1007/s00401-011-0922-z","openalexId":"W2127643721","cited":1998,"byYear":{"2012":57,"2013":96,"2014":121,"2015":133,"2016":127,"2017":150,"2018":163,"2019":162,"2020":162,"2021":161,"2022":154,"2023":162,"2024":149,"2025":124,"2026":62},"year":2011,"title":"Molecular subgroups of medulloblastoma: the current consensus"},"paper-imperiale-multitarget-stool-dna-screening-nejm-2014":{"doi":"10.1056/nejmoa1311194","openalexId":"W2099828433","cited":1928,"byYear":{"2014":71,"2015":132,"2016":132,"2017":155,"2018":120,"2019":161,"2020":144,"2021":190,"2022":182,"2023":148,"2024":197,"2025":184,"2026":100},"year":2014,"title":"Multitarget Stool DNA Testing for Colorectal-Cancer Screening"},"paper-hanna-bmj":{"doi":"10.1136/bmj.m4087","openalexId":"W3095689420","cited":1757,"byYear":{"2012":1,"2020":8,"2021":291,"2022":370,"2023":261,"2024":335,"2025":298,"2026":190},"year":2020,"title":"Mortality due to cancer treatment delay: systematic review and meta-analysis"},"paper-nct02107703-j-clin-oncol-2017":{"doi":"10.1200/jco.2017.73.7585","openalexId":"W2620993107","cited":1708,"byYear":{"2016":3,"2017":58,"2018":157,"2019":150,"2020":202,"2021":221,"2022":182,"2023":194,"2024":203,"2025":211,"2026":123},"year":2017,"title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy"},"paper-kras-nsclc-j-clin-oncol-2005":{"doi":"10.1200/jco.2005.02.857","openalexId":"W2142850084","cited":1485,"byYear":{"2012":109,"2013":118,"2014":92,"2015":88,"2016":69,"2017":52,"2018":41,"2019":26,"2020":41,"2021":45,"2022":33,"2023":34,"2024":7,"2025":11,"2026":5},"year":2005,"title":"Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib"},"paper-mslt-ii-faries-nejm-2017":{"doi":"10.1056/nejmoa1613210","openalexId":"W2624147378","cited":1415,"byYear":{"2017":54,"2018":169,"2019":193,"2020":192,"2021":192,"2022":154,"2023":135,"2024":119,"2025":117,"2026":82},"year":2017,"title":"Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma"},"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019":{"doi":"10.1038/s41568-019-0133-9","openalexId":"W2928432651","cited":1339,"byYear":{"2019":26,"2020":116,"2021":170,"2022":248,"2023":209,"2024":225,"2025":201,"2026":140},"year":2019,"title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data"},"paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995":{"doi":"10.1056/nejm199505253322101","openalexId":"W2340799873","cited":1261,"byYear":{"2012":40,"2013":65,"2014":58,"2015":47,"2016":46,"2017":38,"2018":35,"2019":34,"2020":17,"2021":31,"2022":31,"2023":36,"2024":18,"2025":12,"2026":8},"year":1995,"title":"Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer"},"paper-napoli-1-nanoliposomal-irinotecan-lancet-2016":{"doi":"10.1016/s0140-6736(15)00986-1","openalexId":"W2187917981","cited":1241,"byYear":{"2014":1,"2015":7,"2016":53,"2017":101,"2018":99,"2019":116,"2020":121,"2021":156,"2022":120,"2023":121,"2024":137,"2025":124,"2026":84},"year":2015,"title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial"},"paper-n107c-brown-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30441-2","openalexId":"W2726463501","cited":1218,"byYear":{"2017":28,"2018":104,"2019":118,"2020":154,"2021":145,"2022":180,"2023":152,"2024":135,"2025":124,"2026":74},"year":2017,"title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial"},"paper-gainor-alk-resistance-mutations-cancer-discov-2016":{"doi":"10.1158/2159-8290.cd-16-0596","openalexId":"W2482427906","cited":1174,"byYear":{"2014":1,"2016":17,"2017":104,"2018":129,"2019":127,"2020":170,"2021":145,"2022":141,"2023":116,"2024":96,"2025":73,"2026":53},"year":2016,"title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer"},"paper-garcia-murillas-ctdna-mutation-tracking-stm-2015":{"doi":"10.1126/scitranslmed.aab0021","openalexId":"W2104641188","cited":1170,"byYear":{"2012":1,"2014":2,"2015":15,"2016":79,"2017":124,"2018":136,"2019":131,"2020":121,"2021":119,"2022":114,"2023":104,"2024":93,"2025":78,"2026":53},"year":2015,"title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer"},"paper-alexandrov-tobacco-smoking-mutational-signatures-science-2016":{"doi":"10.1126/science.aag0299","openalexId":"W2547187744","cited":1144,"byYear":{"2013":1,"2016":4,"2017":95,"2018":99,"2019":127,"2020":165,"2021":160,"2022":120,"2023":110,"2024":111,"2025":90,"2026":61},"year":2016,"title":"Mutational signatures associated with tobacco smoking in human cancer"},"paper-monarche-jco-2020":{"doi":"10.1200/jco.20.02514","openalexId":"W3087501542","cited":1034,"byYear":{"2020":14,"2021":114,"2022":159,"2023":199,"2024":186,"2025":219,"2026":139},"year":2020,"title":"Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)"},"paper-murano-venetoclax-rituximab-nejm-2018":{"doi":"10.1056/nejmoa1713976","openalexId":"W2792666902","cited":937,"byYear":{"2013":1,"2017":1,"2018":53,"2019":133,"2020":133,"2021":145,"2022":124,"2023":111,"2024":104,"2025":78,"2026":53},"year":2018,"title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia"},"paper-shah-foxl2-granulosa-nejm-2009":{"doi":"10.1056/nejmoa0902542","openalexId":"W2066801022","cited":782,"byYear":{"2012":56,"2013":51,"2014":56,"2015":44,"2016":48,"2017":39,"2018":41,"2019":35,"2020":41,"2021":53,"2022":60,"2023":41,"2024":40,"2025":38,"2026":23},"year":2009,"title":"Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary"},"paper-sicklick-nat-med":{"doi":"10.1038/s41591-019-0407-5","openalexId":"W2938206352","cited":738,"byYear":{"2019":34,"2020":96,"2021":116,"2022":116,"2023":139,"2024":92,"2025":91,"2026":54},"year":2019,"title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study"},"paper-monumental-1-talquetamab-nejm-2022":{"doi":"10.1056/nejmoa2204591","openalexId":"W4312072518","cited":726,"byYear":{"2013":1,"2022":1,"2023":118,"2024":201,"2025":229,"2026":173},"year":2022,"title":"Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma"},"paper-act-in-sarc-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(19)30326-2","openalexId":"W2961319233","cited":540,"byYear":{"2019":12,"2020":59,"2021":68,"2022":79,"2023":74,"2024":75,"2025":95,"2026":78},"year":2019,"title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial"},"paper-nadina-nejm-2024":{"doi":"10.1056/nejmoa2402604","openalexId":"W4399274678","cited":538,"byYear":{"2024":68,"2025":267,"2026":203},"year":2024,"title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma"},"paper-myxofibrosarcoma-mentzel-ajsp-1996":{"doi":"10.1097/00000478-199604000-00001","openalexId":"W1975796636","cited":530,"byYear":{"2012":30,"2013":24,"2014":28,"2015":12,"2016":31,"2017":23,"2018":17,"2019":19,"2020":29,"2021":24,"2022":20,"2023":22,"2024":13,"2025":15,"2026":12},"year":1996,"title":"Myxofibrosarcoma"},"paper-napoli-3-lancet-2023":{"doi":"10.1016/s0140-6736(23)01366-1","openalexId":"W4386614978","cited":511,"byYear":{"2023":27,"2024":139,"2025":185,"2026":160},"year":2023,"title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial"},"paper-labrecque-mcrpc-phenotypes-jci-2019":{"doi":"10.1172/jci128212","openalexId":"W2965156742","cited":496,"byYear":{"2019":2,"2020":35,"2021":78,"2022":58,"2023":76,"2024":100,"2025":82,"2026":64},"year":2019,"title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer"},"paper-taylor-bmj":{"doi":"10.1136/bmj.c951","openalexId":"W2023152838","cited":478,"byYear":{"2012":23,"2013":30,"2014":29,"2015":24,"2016":19,"2017":29,"2018":32,"2019":42,"2020":49,"2021":38,"2022":29,"2023":30,"2024":23,"2025":28,"2026":26},"year":2010,"title":"Multidisciplinary team working in cancer: what is the evidence?"},"paper-nadofaragene-firadenovec-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(20)30540-4","openalexId":"W3108799736","cited":478,"byYear":{"2020":4,"2021":50,"2022":49,"2023":78,"2024":101,"2025":109,"2026":87},"year":2020,"title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial"},"paper-jean-pascal-machiels-ann-oncol-2021":{"doi":"10.1016/j.annonc.2020.12.007","openalexId":"W3115988948","cited":459,"byYear":{"2021":19,"2022":56,"2023":98,"2024":102,"2025":114,"2026":67},"year":2020,"title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†"},"paper-mrc-te19-carboplatin-seminoma-oliver-lancet-2005":{"doi":"10.1016/s0140-6736(05)66984-x","openalexId":"W2140944538","cited":448,"byYear":{"2012":22,"2013":18,"2014":21,"2015":30,"2016":23,"2017":15,"2018":17,"2019":22,"2020":10,"2021":14,"2022":14,"2023":11,"2024":12,"2025":5,"2026":5},"year":2005,"title":"Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial"},"paper-horiuchi-myc-tnbc-cdk-synthetic-lethal-jem-2012":{"doi":"10.1084/jem.20111512","openalexId":"W2118528246","cited":398,"byYear":{"2012":4,"2013":17,"2014":26,"2015":28,"2016":26,"2017":35,"2018":28,"2019":26,"2020":38,"2021":52,"2022":25,"2023":35,"2024":19,"2025":25,"2026":14},"year":2012,"title":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition"},"paper-natalee-nejm-2024":{"doi":"10.1056/nejmoa2305488","openalexId":"W4392977246","cited":398,"byYear":{"2023":2,"2024":78,"2025":196,"2026":122},"year":2024,"title":"Ribociclib plus Endocrine Therapy in Early Breast Cancer"},"paper-hu-nat-genet":{"doi":"10.1038/s41588-020-0628-z","openalexId":"W3024627825","cited":388,"byYear":{"2020":26,"2021":71,"2022":65,"2023":65,"2024":62,"2025":53,"2026":46},"year":2020,"title":"Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases"},"paper-childers-j-clin-oncol":{"doi":"10.1200/jco.2017.73.6314","openalexId":"W2745994405","cited":358,"byYear":{"2018":33,"2019":61,"2020":41,"2021":48,"2022":40,"2023":41,"2024":47,"2025":27,"2026":20},"year":2017,"title":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer"},"paper-navigator-avapritinib-heinrich-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30269-2","openalexId":"W3037595396","cited":320,"byYear":{"2020":18,"2021":66,"2022":60,"2023":50,"2024":38,"2025":53,"2026":34},"year":2020,"title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial"},"paper-lehmann-tnbc-subtype-multiomics-nat-commun-2021":{"doi":"10.1038/s41467-021-26502-6","openalexId":"W3208558332","cited":286,"byYear":{"2022":29,"2023":74,"2024":61,"2025":71,"2026":51},"year":2021,"title":"Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes"},"paper-bradt-cochrane-database-syst-rev-2021":{"doi":"10.1002/14651858.cd006911.pub4","openalexId":"W3206014549","cited":239,"byYear":{"2017":1,"2021":2,"2022":19,"2023":38,"2024":60,"2025":76,"2026":43},"year":2021,"title":"Music interventions for improving psychological and physical outcomes in people with cancer"},"paper-morice-mucinous-ovarian-carcinoma-nejm-2019":{"doi":"10.1056/nejmra1813254","openalexId":"W2924865772","cited":231,"byYear":{"2019":8,"2020":26,"2021":27,"2022":43,"2023":43,"2024":31,"2025":27,"2026":24},"year":2019,"title":"Mucinous Ovarian Carcinoma"},"paper-morpho-gilteritinib-levis-jco-2024":{"doi":"10.1200/jco.23.02474","openalexId":"W4392691406","cited":222,"byYear":{"2016":1,"2024":52,"2025":91,"2026":78},"year":2024,"title":"Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3"},"paper-engstrom-cancer-discov":{"doi":"10.1158/2159-8290.cd-23-0669","openalexId":"W4385650986","cited":221,"byYear":{"2023":4,"2024":45,"2025":101,"2026":71},"year":2023,"title":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer"},"paper-momentum-momelotinib-lancet-2023":{"doi":"10.1016/s0140-6736(22)02036-0","openalexId":"W4318159227","cited":201,"byYear":{"2023":42,"2024":66,"2025":51,"2026":42},"year":2023,"title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study"},"paper-garralda-nat-med":{"doi":"10.1038/s41591-024-02805-1","openalexId":"W4391576268","cited":196,"byYear":{"2024":43,"2025":85,"2026":68},"year":2024,"title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial"},"paper-weinberg-biliary-profiling-jgo-2019":{"doi":"10.21037/jgo.2018.08.18","openalexId":"W2894518105","cited":189,"byYear":{"2017":1,"2019":2,"2020":12,"2021":38,"2022":30,"2023":36,"2024":34,"2025":20,"2026":16},"year":2019,"title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets"},"paper-amer-zeidan-j-clin-oncol-2021":{"doi":"10.1200/jco.20.01632","openalexId":"W3095552675","cited":180,"byYear":{"2019":1,"2020":7,"2021":38,"2022":47,"2023":31,"2024":25,"2025":21,"2026":9},"year":2020,"title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia"},"paper-wagner-j-immunother-cancer":{"doi":"10.1136/jitc-2021-002990","openalexId":"W3099993684","cited":169,"byYear":{"2021":10,"2022":22,"2023":28,"2024":42,"2025":41,"2026":26},"year":2021,"title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)"},"paper-guedes-msh2-loss-primary-prostate-ccr-2017":{"doi":"10.1158/1078-0432.ccr-17-0955","openalexId":"W2743298940","cited":159,"byYear":{"2017":3,"2018":16,"2019":24,"2020":24,"2021":16,"2022":27,"2023":16,"2024":13,"2025":10,"2026":10},"year":2017,"title":"MSH2 Loss in Primary Prostate Cancer"},"paper-naliricc-lancet-gastroenterol-hepatol-2024":{"doi":"10.1016/s2468-1253(24)00119-5","openalexId":"W4399655685","cited":54,"byYear":{"2024":4,"2025":31,"2026":19},"year":2024,"title":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial"},"paper-pramesh-bull-world-health-organ":{"doi":"10.2471/blt.24.292230","openalexId":"W4410267874","cited":2,"byYear":{"2026":2},"year":2025,"title":"National Cancer Grid initiative for electronic medical records, India"},"paper-braf-melanoma-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1412082","openalexId":"W2128035403","cited":5455,"byYear":{"2012":2,"2013":2,"2014":13,"2015":366,"2016":599,"2017":706,"2018":639,"2019":576,"2020":600,"2021":515,"2022":426,"2023":331,"2024":306,"2025":228,"2026":135},"year":2014,"title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation"},"paper-nelson-nejm-2020":{"doi":"10.1056/nejmoa1911793","openalexId":"W3003415550","cited":3680,"byYear":{"2012":1,"2020":282,"2021":502,"2022":548,"2023":613,"2024":611,"2025":635,"2026":481},"year":2020,"title":"Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial"},"paper-netter-1-nejm-2017":{"doi":"10.1056/nejmoa1607427","openalexId":"W2573369749","cited":3314,"byYear":{"2012":1,"2014":1,"2016":1,"2017":144,"2018":254,"2019":276,"2020":357,"2021":431,"2022":368,"2023":357,"2024":410,"2025":374,"2026":329},"year":2017,"title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors"},"paper-checkmate-227-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1801946","openalexId":"W2797675588","cited":3190,"byYear":{"2015":1,"2016":1,"2018":250,"2019":546,"2020":576,"2021":542,"2022":449,"2023":307,"2024":241,"2025":182,"2026":92},"year":2018,"title":"Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden"},"paper-keunchil-park-n-engl-j-med-2019":{"doi":"10.1056/nejmoa1910231","openalexId":"W2976744492","cited":2909,"byYear":{"2013":1,"2015":1,"2019":18,"2020":373,"2021":597,"2022":527,"2023":470,"2024":435,"2025":316,"2026":164},"year":2019,"title":"Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer"},"paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30422-9","openalexId":"W2739132742","cited":2894,"byYear":{"2012":1,"2013":1,"2014":1,"2015":1,"2017":31,"2018":223,"2019":289,"2020":375,"2021":455,"2022":381,"2023":403,"2024":321,"2025":245,"2026":162},"year":2017,"title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study"},"paper-niraparib-ovarian-n-engl-j-med-2016":{"doi":"10.1056/nejmoa1611310","openalexId":"W2528228811","cited":2502,"byYear":{"2015":1,"2016":19,"2017":168,"2018":225,"2019":281,"2020":315,"2021":324,"2022":342,"2023":282,"2024":230,"2025":201,"2026":112},"year":2016,"title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer"},"paper-ncic-sr2-preoperative-vs-postoperative-radiotherapy-osullivan-lancet-2002":{"doi":"10.1016/s0140-6736(02)09292-9","openalexId":"W2153477869","cited":1616,"byYear":{"2012":49,"2013":52,"2014":72,"2015":75,"2016":76,"2017":77,"2018":92,"2019":72,"2020":118,"2021":98,"2022":117,"2023":90,"2024":96,"2025":88,"2026":59},"year":2002,"title":"Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial"},"paper-albrengues-science":{"doi":"10.1126/science.aao4227","openalexId":"W2894451493","cited":1511,"byYear":{"2017":1,"2018":10,"2019":105,"2020":174,"2021":230,"2022":192,"2023":210,"2024":225,"2025":207,"2026":156},"year":2018,"title":"Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice"},"paper-niche-2-nat-med-2020":{"doi":"10.1038/s41591-020-0805-8","openalexId":"W3015035400","cited":1442,"byYear":{"2014":1,"2015":2,"2020":81,"2021":172,"2022":219,"2023":296,"2024":284,"2025":242,"2026":141},"year":2020,"title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers"},"paper-conroy-prodige-23-neoadjuvant-folfirinox-rectal-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00079-6","openalexId":"W3154995350","cited":1367,"byYear":{"2012":1,"2021":66,"2022":196,"2023":253,"2024":295,"2025":307,"2026":244},"year":2021,"title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial"},"paper-impassion031-lancet-2020":{"doi":"10.1016/s0140-6736(20)31953-x","openalexId":"W3087393791","cited":1101,"byYear":{"2020":17,"2021":182,"2022":241,"2023":208,"2024":199,"2025":154,"2026":99},"year":2020,"title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial"},"paper-asco-neoadjuvant-therapy-breast-guideline-jco-2021":{"doi":"10.1200/jco.20.03399","openalexId":"W3122861570","cited":1060,"byYear":{"2021":61,"2022":132,"2023":214,"2024":229,"2025":263,"2026":161},"year":2021,"title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline"},"paper-geparsixto-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70160-3","openalexId":"W2086064725","cited":1048,"byYear":{"2013":2,"2014":26,"2015":71,"2016":84,"2017":89,"2018":89,"2019":68,"2020":117,"2021":118,"2022":107,"2023":86,"2024":82,"2025":62,"2026":42},"year":2014,"title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial"},"paper-jacques-grill-cell-2016":{"doi":"10.1016/j.cell.2016.01.015","openalexId":"W2286322195","cited":1027,"byYear":{"2013":1,"2014":2,"2015":2,"2016":32,"2017":75,"2018":101,"2019":96,"2020":131,"2021":128,"2022":98,"2023":105,"2024":122,"2025":90,"2026":38},"year":2016,"title":"New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs"},"paper-brentuximab-vedotin-hodgkin-lymphoma-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(16)30167-x","openalexId":"W2504623699","cited":931,"byYear":{"2015":1,"2016":15,"2017":131,"2018":181,"2019":113,"2020":136,"2021":116,"2022":90,"2023":60,"2024":42,"2025":31,"2026":13},"year":2016,"title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial"},"paper-swog-s1801-n-engl-j-med-2023":{"doi":"10.1056/nejmoa2211437","openalexId":"W4322718735","cited":899,"byYear":{"2023":125,"2024":280,"2025":301,"2026":191},"year":2023,"title":"Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma"},"paper-dangelo-mucosal-melanoma-pooled-jco-2017":{"doi":"10.1200/jco.2016.67.9258","openalexId":"W2553340100","cited":666,"byYear":{"2016":1,"2017":37,"2018":39,"2019":60,"2020":95,"2021":81,"2022":90,"2023":71,"2024":83,"2025":62,"2026":47},"year":2017,"title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis"},"paper-issels-lancet-oncol":{"doi":"10.1016/s1470-2045(10)70071-1","openalexId":"W2128668604","cited":665,"byYear":{"2012":41,"2013":39,"2014":46,"2015":55,"2016":56,"2017":52,"2018":47,"2019":41,"2020":59,"2021":42,"2022":40,"2023":29,"2024":22,"2025":31,"2026":17},"year":2010,"title":"Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study"},"paper-nala-j-clin-oncol-2020":{"doi":"10.1200/jco.20.00147","openalexId":"W3043096450","cited":617,"byYear":{"2019":1,"2020":26,"2021":110,"2022":131,"2023":122,"2024":109,"2025":79,"2026":38},"year":2020,"title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial"},"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019":{"doi":"10.1158/1078-0432.ccr-19-0624","openalexId":"W2939485990","cited":614,"byYear":{"2012":1,"2019":22,"2020":104,"2021":108,"2022":102,"2023":105,"2024":77,"2025":62,"2026":33},"year":2019,"title":"Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer"},"paper-kristine-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(17)30716-7","openalexId":"W2768649895","cited":548,"byYear":{"2016":4,"2017":1,"2018":23,"2019":50,"2020":61,"2021":70,"2022":68,"2023":73,"2024":83,"2025":60,"2026":54},"year":2017,"title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial"},"paper-dizman-nat-med":{"doi":"10.1038/s41591-022-01694-6","openalexId":"W4214706689","cited":511,"byYear":{"2022":55,"2023":119,"2024":124,"2025":115,"2026":97},"year":2022,"title":"Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial"},"paper-niche-2-nejm-2024":{"doi":"10.1056/nejmoa2400634","openalexId":"W4399369796","cited":474,"byYear":{"2024":61,"2025":207,"2026":206},"year":2024,"title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer"},"paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30104-3","openalexId":"W2589072142","cited":408,"byYear":{"2014":1,"2017":21,"2018":48,"2019":42,"2020":55,"2021":65,"2022":49,"2023":41,"2024":29,"2025":26,"2026":29},"year":2017,"title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study"},"paper-niagara-nejm-2024":{"doi":"10.1056/nejmoa2408154","openalexId":"W4402552345","cited":403,"byYear":{"2024":14,"2025":192,"2026":197},"year":2024,"title":"Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer"},"paper-pagliaro-neoadjuvant-tip-penile-cancer-jco-2010":{"doi":"10.1200/jco.2010.29.5477","openalexId":"W2101270203","cited":401,"byYear":{"2012":13,"2013":21,"2014":25,"2015":25,"2016":28,"2017":26,"2018":17,"2019":19,"2020":34,"2021":29,"2022":29,"2023":30,"2024":25,"2025":35,"2026":21},"year":2010,"title":"Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study"},"paper-netter-2-lancet-2024":{"doi":"10.1016/s0140-6736(24)00701-3","openalexId":"W4399369977","cited":376,"byYear":{"2024":44,"2025":187,"2026":145},"year":2024,"title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study"},"paper-magnitude-j-clin-oncol-2023":{"doi":"10.1200/jco.22.01649","openalexId":"W4360608257","cited":349,"byYear":{"2023":52,"2024":123,"2025":109,"2026":65},"year":2023,"title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer"},"paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022":{"doi":"10.1056/nejmoa2209813","openalexId":"W4295271013","cited":335,"byYear":{"2022":13,"2023":79,"2024":90,"2025":94,"2026":59},"year":2022,"title":"Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma"},"paper-gounder-n-engl-j-med":{"doi":"10.1056/nejmoa2210140","openalexId":"W4323532421","cited":271,"byYear":{"2023":31,"2024":87,"2025":73,"2026":80},"year":2023,"title":"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors"},"paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024":{"doi":"10.1056/nejmoa2402141","openalexId":"W4404784379","cited":271,"byYear":{"2024":2,"2025":131,"2026":138},"year":2024,"title":"Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer"},"paper-blue-c-n-engl-j-med-2024":{"doi":"10.1056/nejmoa2310336","openalexId":"W4392744299","cited":241,"byYear":{"2024":52,"2025":96,"2026":93},"year":2024,"title":"Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening"},"paper-nct03916627-lancet-gastroenterol-hepatol-2022":{"doi":"10.1016/s2468-1253(21)00385-x","openalexId":"W4206656883","cited":235,"byYear":{"2021":1,"2022":21,"2023":48,"2024":67,"2025":65,"2026":33},"year":2022,"title":"Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial"},"paper-nhs-galleri-design-cancers-2022":{"doi":"10.3390/cancers14194818","openalexId":"W4303613649","cited":190,"byYear":{"2022":3,"2023":32,"2024":58,"2025":51,"2026":46},"year":2022,"title":"Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial"},"paper-azad-j-clin-oncol":{"doi":"10.1200/jco.19.00818","openalexId":"W2991389580","cited":171,"byYear":{"2019":1,"2020":14,"2021":33,"2022":35,"2023":46,"2024":20,"2025":15,"2026":7},"year":2019,"title":"Nivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study"},"paper-lung-map-s1400i-jama-oncol-2021":{"doi":"10.1001/jamaoncol.2021.2209","openalexId":"W3181034934","cited":107,"byYear":{"2021":1,"2022":24,"2023":26,"2024":34,"2025":12,"2026":10},"year":2021,"title":"Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer"},"paper-gain-trial-protocol-bmc-cancer-2020":{"doi":"10.1186/s12885-020-6610-4","openalexId":"W3008446067","cited":89,"byYear":{"2020":3,"2021":16,"2022":11,"2023":14,"2024":20,"2025":16,"2026":9},"year":2020,"title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) – a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)– the AIO/ CALGP/ ACO- GAIN-trial –"},"paper-trastuzumab-deruxtecan-breast-hr-positive-ann-oncol-2026":{"doi":"10.1016/j.annonc.2025.10.019","openalexId":"W4415390112","cited":83,"byYear":{"2025":6,"2026":77},"year":2025,"title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial"},"paper-nct04497844-nat-med-2025":{"doi":"10.1038/s41591-025-03961-8","openalexId":"W4414886615","cited":67,"byYear":{"2025":6,"2026":61},"year":2025,"title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial"},"paper-qin-j-clin-oncol":{"doi":"10.1200/jco.22.02630","openalexId":"W4386279361","cited":61,"byYear":{"2024":9,"2025":36,"2026":16},"year":2023,"title":"Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer"},"paper-preopanc-2-neoadjuvant-folfirinox-vs-chemoradiotherapy-lancet-oncol-2025":{"doi":"10.1016/s1470-2045(25)00363-8","openalexId":"W4414104868","cited":52,"byYear":{"2025":10,"2026":42},"year":2025,"title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial"},"paper-nct05890742-cancer-cell-2025":{"doi":"10.1016/j.ccell.2025.09.004","openalexId":"W4414803284","cited":24,"byYear":{"2025":5,"2026":19},"year":2025,"title":"Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study"},"paper-nct04969887-jama-oncol-2025":{"doi":"10.1001/jamaoncol.2025.1916","openalexId":"W4412003129","cited":23,"byYear":{"2025":4,"2026":19},"year":2025,"title":"Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers"},"paper-nct02938299-ann-oncol-2025":{"doi":"10.1016/j.annonc.2025.06.014","openalexId":"W4412076546","cited":17,"byYear":{"2025":3,"2026":14},"year":2025,"title":"Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma"},"paper-nci9673-part-b-nivolumab-ipilimumab-anal-cancer-morris-jco-2026":{"doi":"10.1200/jco-25-00929","openalexId":"W7118592224","cited":7,"byYear":{"2026":7},"year":2026,"title":"NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal"},"paper-akgor-vaccines-basel":{"doi":"10.3390/vaccines14020140","openalexId":"W7126033493","cited":4,"byYear":{"2026":4},"year":2026,"title":"New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review"},"paper-varshney-neoadjuvant-incidental-gallbladder-cancer-systematic-review-ahbps-2025":{"doi":"10.14701/ahbps.24-223","openalexId":"W4408283841","cited":5,"byYear":{"2025":2,"2026":3},"year":2025,"title":"Neoadjuvant treatment for incidental gallbladder cancer: A systematic review"},"paper-nct02938299-j-clin-oncol-2026-update":{"doi":"10.1200/jco-26-00852","openalexId":"W7202195333","cited":0,"byYear":{},"year":2026,"title":"Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial"},"paper-nct06747338-jama-oncol-2026":{"doi":"10.1001/jamaoncol.2026.3329","openalexId":"W7207532079","cited":0,"byYear":{},"year":2026,"title":"Neoadjuvant Anbenitamab and HB1801 in ERBB2 -Positive Breast Cancer"},"paper-warburg-science":{"doi":"10.1126/science.123.3191.309","openalexId":"W2072451938","cited":13542,"byYear":{"2012":543,"2013":603,"2014":655,"2015":746,"2016":696,"2017":721,"2018":715,"2019":779,"2020":912,"2021":974,"2022":888,"2023":795,"2024":786,"2025":668,"2026":389},"year":1956,"title":"On the Origin of Cancer Cells"},"paper-nlst-nejm-2011":{"doi":"10.1056/nejmoa1102873","openalexId":"W130099911","cited":11273,"byYear":{"2012":376,"2013":496,"2014":528,"2015":607,"2016":595,"2017":593,"2018":726,"2019":768,"2020":934,"2021":981,"2022":957,"2023":1001,"2024":1013,"2025":884,"2026":659},"year":2011,"title":"Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening"},"paper-jain-science":{"doi":"10.1126/science.1104819","openalexId":"W2006202974","cited":5543,"byYear":{"2012":348,"2013":359,"2014":304,"2015":292,"2016":253,"2017":236,"2018":221,"2019":245,"2020":252,"2021":288,"2022":241,"2023":223,"2024":221,"2025":212,"2026":211},"year":2005,"title":"Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy"},"paper-olympiad-nejm-2017":{"doi":"10.1056/nejmoa1706450","openalexId":"W2621271973","cited":3336,"byYear":{"2013":1,"2016":3,"2017":54,"2018":224,"2019":323,"2020":402,"2021":468,"2022":428,"2023":451,"2024":386,"2025":332,"2026":255},"year":2017,"title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation"},"paper-chakravarty-jco-precis-oncol":{"doi":"10.1200/po.17.00011","openalexId":"W2614443510","cited":2775,"byYear":{"2017":19,"2018":114,"2019":184,"2020":288,"2021":377,"2022":376,"2023":422,"2024":456,"2025":357,"2026":178},"year":2017,"title":"OncoKB: A Precision Oncology Knowledge Base"},"paper-andtbacka-optim-talimogene-jco-2015":{"doi":"10.1200/jco.2014.58.3377","openalexId":"W2109274792","cited":2672,"byYear":{"2013":2,"2014":1,"2015":59,"2016":193,"2017":253,"2018":247,"2019":257,"2020":286,"2021":271,"2022":230,"2023":250,"2024":232,"2025":214,"2026":172},"year":2015,"title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma"},"paper-habr-gama-nonoperative-stage-0-rectal-ann-surg-2004":{"doi":"10.1097/01.sla.0000141194.27992.32","openalexId":"W2159919969","cited":1923,"byYear":{"2012":74,"2013":82,"2014":81,"2015":85,"2016":97,"2017":101,"2018":110,"2019":111,"2020":131,"2021":151,"2022":156,"2023":146,"2024":146,"2025":114,"2026":99},"year":2004,"title":"Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy"},"paper-chang-nat-rev-mol-cell-biol":{"doi":"10.1038/nrm.2017.48","openalexId":"W2614952490","cited":1846,"byYear":{"2013":1,"2014":1,"2016":2,"2017":28,"2018":77,"2019":159,"2020":215,"2021":282,"2022":247,"2023":257,"2024":208,"2025":216,"2026":152},"year":2017,"title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair"},"paper-mcculloch-lancet":{"doi":"10.1016/s0140-6736(09)61116-8","openalexId":"W1976576973","cited":1823,"byYear":{"2012":72,"2013":83,"2014":86,"2015":93,"2016":119,"2017":135,"2018":125,"2019":127,"2020":144,"2021":146,"2022":144,"2023":133,"2024":108,"2025":116,"2026":109},"year":2009,"title":"No surgical innovation without evaluation: the IDEAL recommendations"},"paper-olympia-nejm-2021":{"doi":"10.1056/nejmoa2105215","openalexId":"W3165576985","cited":1748,"byYear":{"2021":89,"2022":330,"2023":377,"2024":383,"2025":340,"2026":226},"year":2021,"title":"Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer"},"paper-atkin-once-only-flexible-sigmoidoscopy-lancet-2010":{"doi":"10.1016/s0140-6736(10)60551-x","openalexId":"W2146233513","cited":1633,"byYear":{"2012":198,"2013":162,"2014":178,"2015":141,"2016":111,"2017":114,"2018":79,"2019":97,"2020":78,"2021":55,"2022":44,"2023":39,"2024":61,"2025":42,"2026":17},"year":2010,"title":"Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial"},"paper-rtog-1016-lancet-2019":{"doi":"10.1016/s0140-6736(18)32779-x","openalexId":"W2901263658","cited":1318,"byYear":{"2018":5,"2019":130,"2020":200,"2021":231,"2022":211,"2023":148,"2024":143,"2025":164,"2026":81},"year":2018,"title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial"},"paper-morvan-nat-rev-cancer":{"doi":"10.1038/nrc.2015.5","openalexId":"W2221432805","cited":1183,"byYear":{"2015":1,"2016":22,"2017":78,"2018":97,"2019":121,"2020":148,"2021":175,"2022":144,"2023":135,"2024":121,"2025":92,"2026":49},"year":2015,"title":"NK cells and cancer: you can teach innate cells new tricks"},"paper-mintz-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.72.9.3585","openalexId":"W1968807484","cited":1181,"byYear":{"2012":40,"2013":45,"2014":30,"2015":25,"2016":26,"2017":30,"2018":19,"2019":29,"2020":25,"2021":23,"2022":20,"2023":16,"2024":26,"2025":14,"2026":4},"year":1975,"title":"Normal genetically mosaic mice produced from malignant teratocarcinoma cells."},"paper-tiriac-cancer-discov":{"doi":"10.1158/2159-8290.cd-18-0349","openalexId":"W2807088563","cited":1141,"byYear":{"2018":16,"2019":86,"2020":135,"2021":177,"2022":160,"2023":139,"2024":170,"2025":139,"2026":116},"year":2018,"title":"Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer"},"paper-noa-08-temozolomide-vs-radiotherapy-elderly-wick-lancet-oncol-2012":{"doi":"10.1016/s1470-2045(12)70164-x","openalexId":"W2154526619","cited":1138,"byYear":{"2012":35,"2013":87,"2014":107,"2015":100,"2016":90,"2017":97,"2018":84,"2019":76,"2020":108,"2021":79,"2022":72,"2023":57,"2024":61,"2025":48,"2026":33},"year":2012,"title":"Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial"},"paper-tallman-atra-apl-nejm-1997":{"doi":"10.1056/nejm199710093371501","openalexId":"W2334200141","cited":1099,"byYear":{"2012":37,"2013":38,"2014":55,"2015":36,"2016":33,"2017":34,"2018":27,"2019":21,"2020":21,"2021":21,"2022":19,"2023":18,"2024":21,"2025":14,"2026":8},"year":1997,"title":"All-trans-Retinoic Acid in Acute Promyelocytic Leukemia"},"paper-nordic-nec-sorbye-ann-oncol-2013":{"doi":"10.1093/annonc/mds276","openalexId":"W2161676563","cited":1040,"byYear":{"2012":4,"2013":15,"2014":34,"2015":56,"2016":63,"2017":75,"2018":95,"2019":83,"2020":115,"2021":119,"2022":98,"2023":91,"2024":67,"2025":76,"2026":45},"year":2012,"title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study"},"paper-garcia-aguilar-opra-organ-preservation-jco-2022":{"doi":"10.1200/jco.22.00032","openalexId":"W4225137108","cited":989,"byYear":{"2017":1,"2022":62,"2023":228,"2024":251,"2025":243,"2026":201},"year":2022,"title":"Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy"},"paper-kuznetsov-bull-math-biol":{"doi":"10.1007/bf02460644","openalexId":"W1979575182","cited":942,"byYear":{"2012":34,"2013":42,"2014":42,"2015":50,"2016":41,"2017":42,"2018":47,"2019":72,"2020":76,"2021":63,"2022":33,"2023":57,"2024":65,"2025":74,"2026":60},"year":1994,"title":"Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis"},"paper-nrg-cc001-brown-jco-2020":{"doi":"10.1200/jco.19.02767","openalexId":"W3005704292","cited":861,"byYear":{"2020":81,"2021":149,"2022":145,"2023":134,"2024":133,"2025":127,"2026":90},"year":2020,"title":"Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001"},"paper-nordicc-nejm-2022":{"doi":"10.1056/nejmoa2208375","openalexId":"W4303940405","cited":823,"byYear":{"2012":1,"2022":10,"2023":184,"2024":255,"2025":228,"2026":144},"year":2022,"title":"Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death"},"paper-olympiad-ann-oncol-2019-update":{"doi":"10.1093/annonc/mdz012","openalexId":"W2913584903","cited":787,"byYear":{"2019":33,"2020":84,"2021":118,"2022":140,"2023":149,"2024":110,"2025":84,"2026":68},"year":2019,"title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer"},"paper-nrg-gy018-nejm-2023":{"doi":"10.1056/nejmoa2302312","openalexId":"W4360992337","cited":767,"byYear":{"2023":87,"2024":245,"2025":274,"2026":161},"year":2023,"title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer"},"paper-robin-jones-lancet-2016":{"doi":"10.1016/s0140-6736(16)30587-6","openalexId":"W2413552560","cited":595,"byYear":{"2016":17,"2017":97,"2018":114,"2019":93,"2020":85,"2021":44,"2022":43,"2023":34,"2024":33,"2025":25,"2026":9},"year":2016,"title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial"},"paper-jak2-myeloproliferative-neoplasms-leukemia-2010":{"doi":"10.1038/leu.2010.69","openalexId":"W2028803880","cited":531,"byYear":{"2012":65,"2013":48,"2014":53,"2015":47,"2016":30,"2017":42,"2018":25,"2019":21,"2020":18,"2021":24,"2022":11,"2023":16,"2024":8,"2025":9,"2026":8},"year":2010,"title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1"},"paper-sedrak-ca-cancer-j-clin":{"doi":"10.3322/caac.21638","openalexId":"W3091199432","cited":493,"byYear":{"2021":43,"2022":104,"2023":112,"2024":120,"2025":71,"2026":43},"year":2020,"title":"Older adult participation in cancer clinical trials: A systematic review of barriers and interventions"},"paper-dalla-torre-nat-methods":{"doi":"10.1038/s41592-024-02523-z","openalexId":"W4404821554","cited":492,"byYear":{"2023":1,"2024":20,"2025":197,"2026":274},"year":2024,"title":"Nucleotide Transformer: building and evaluating robust foundation models for human genomics"},"paper-nct02734004-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30324-7","openalexId":"W3047848114","cited":481,"byYear":{"2020":12,"2021":80,"2022":87,"2023":101,"2024":73,"2025":84,"2026":44},"year":2020,"title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study"},"paper-navari-n-engl-j-med":{"doi":"10.1056/nejmoa1515725","openalexId":"W2460792208","cited":455,"byYear":{"2016":9,"2017":52,"2018":54,"2019":34,"2020":53,"2021":39,"2022":37,"2023":43,"2024":60,"2025":47,"2026":25},"year":2016,"title":"Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting"},"paper-dangelo-ny-eso-1-tcr-synovial-sarcoma-cancer-discov-2018":{"doi":"10.1158/2159-8290.cd-17-1417","openalexId":"W2807603420","cited":443,"byYear":{"2017":1,"2018":10,"2019":41,"2020":59,"2021":65,"2022":70,"2023":73,"2024":52,"2025":44,"2026":27},"year":2018,"title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma"},"paper-oreilly-gemcitabine-cisplatin-veliparib-gbrca-palb2-pancreatic-jco-2020":{"doi":"10.1200/jco.19.02931","openalexId":"W3001713806","cited":412,"byYear":{"2019":1,"2020":41,"2021":85,"2022":74,"2023":68,"2024":56,"2025":54,"2026":33},"year":2020,"title":"Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation"},"paper-esmo-non-epithelial-ovarian-ray-coquard-ann-oncol-2018":{"doi":"10.1093/annonc/mdy001","openalexId":"W4248292785","cited":381,"byYear":{"2015":1,"2016":2,"2017":1,"2018":6,"2019":19,"2020":43,"2021":39,"2022":49,"2023":58,"2024":57,"2025":59,"2026":44},"year":2018,"title":"Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-egfr-glioblastoma-sci-signal-2009":{"doi":"10.1126/scisignal.287re6","openalexId":"W2136734008","cited":370,"byYear":{"2012":27,"2013":29,"2014":32,"2015":21,"2016":17,"2017":28,"2018":23,"2019":28,"2020":24,"2021":22,"2022":17,"2023":24,"2024":21,"2025":14,"2026":6},"year":2009,"title":"Oncogenic EGFR Signaling Networks in Glioma"},"paper-jones-non-v600-braf-colorectal-jco-2017":{"doi":"10.1200/jco.2016.71.4394","openalexId":"W2613375073","cited":359,"byYear":{"2017":11,"2018":37,"2019":50,"2020":37,"2021":47,"2022":40,"2023":51,"2024":59,"2025":20,"2026":7},"year":2017,"title":"Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer"},"paper-lu-laura-osimertinib-stage-iii-nejm-2024":{"doi":"10.1056/nejmoa2402614","openalexId":"W4399274593","cited":344,"byYear":{"2024":58,"2025":160,"2026":126},"year":2024,"title":"Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC"},"paper-propel-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00382-0","openalexId":"W4386631299","cited":320,"byYear":{"2023":11,"2024":112,"2025":124,"2026":73},"year":2023,"title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial"},"paper-scher-nuclear-arv7-taxane-vs-arsi-jama-oncol-2018":{"doi":"10.1001/jamaoncol.2018.1621","openalexId":"W2811305164","cited":244,"byYear":{"2015":1,"2018":6,"2019":48,"2020":54,"2021":38,"2022":32,"2023":24,"2024":21,"2025":12,"2026":8},"year":2018,"title":"Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer"},"paper-norpact-1-neoadjuvant-folfirinox-labori-lancet-gastroenterol-hepatol-2024":{"doi":"10.1016/s2468-1253(23)00405-3","openalexId":"W4390870665","cited":227,"byYear":{"2023":4,"2024":60,"2025":101,"2026":62},"year":2024,"title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial"},"paper-wang-adjuvant-chemoradiotherapy-nomogram-gallbladder-cancer-jco-2011":{"doi":"10.1200/jco.2010.33.8020","openalexId":"W2152111392","cited":222,"byYear":{"2012":5,"2013":4,"2014":11,"2015":19,"2016":12,"2017":21,"2018":26,"2019":15,"2020":23,"2021":27,"2022":17,"2023":15,"2024":14,"2025":9,"2026":2},"year":2011,"title":"Nomogram for Predicting the Benefit of Adjuvant Chemoradiotherapy for Resected Gallbladder Cancer"},"paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025":{"doi":"10.1056/nejmoa2404512","openalexId":"W4409852706","cited":216,"byYear":{"2025":66,"2026":150},"year":2025,"title":"Nonoperative Management of Mismatch Repair–Deficient Tumors"},"paper-kelly-jama-oncol":{"doi":"10.1001/jamaoncol.2019.6152","openalexId":"W3001836957","cited":215,"byYear":{"2020":19,"2021":31,"2022":47,"2023":30,"2024":35,"2025":32,"2026":21},"year":2020,"title":"Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab"},"paper-stopsack-mcspc-genomic-alterations-outcomes-ccr-2020":{"doi":"10.1158/1078-0432.ccr-20-0168","openalexId":"W3014088197","cited":187,"byYear":{"2020":12,"2021":30,"2022":36,"2023":30,"2024":31,"2025":34,"2026":14},"year":2020,"title":"Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer"},"paper-lumina-n-engl-j-med-2023":{"doi":"10.1056/nejmoa2302344","openalexId":"W4385855809","cited":177,"byYear":{"2023":18,"2024":76,"2025":53,"2026":30},"year":2023,"title":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer"},"paper-navigate-j-clin-invest-2021":{"doi":"10.1172/jci144847","openalexId":"W3178521081","cited":142,"byYear":{"2021":3,"2022":28,"2023":32,"2024":25,"2025":34,"2026":20},"year":2021,"title":"NTRK and RET fusion–directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake"},"paper-arrillaga-romany-j-clin-oncol":{"doi":"10.1200/jco.23.01134","openalexId":"W4391694006","cited":115,"byYear":{"2020":1,"2023":1,"2024":22,"2025":40,"2026":51},"year":2024,"title":"ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma"},"paper-ring-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-23-1696","openalexId":"W4387157290","cited":40,"byYear":{"2024":9,"2025":18,"2026":13},"year":2023,"title":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)"},"paper-nct06106308-j-clin-oncol-2025":{"doi":"10.1200/jco-24-01266","openalexId":"W4403915006","cited":27,"byYear":{"2024":2,"2025":14,"2026":11},"year":2024,"title":"Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial"},"paper-kim-t1b-gallbladder-cancer-international-jhbps-2018":{"doi":"10.1002/jhbp.593","openalexId":"W2903826947","cited":54,"byYear":{"2019":4,"2020":9,"2021":9,"2022":11,"2023":8,"2024":5,"2025":7,"2026":1},"year":2018,"title":"Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study"},"paper-nct03944772-jco-precis-oncol-2025":{"doi":"10.1200/po-24-00818","openalexId":"W4411017098","cited":11,"byYear":{"2025":5,"2026":6},"year":2025,"title":"ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib"},"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006":{"doi":"10.1056/nejmoa061884","openalexId":"W2145835533","cited":5795,"byYear":{"2012":514,"2013":459,"2014":401,"2015":388,"2016":320,"2017":280,"2018":256,"2019":227,"2020":184,"2021":188,"2022":177,"2023":147,"2024":124,"2025":71,"2026":40},"year":2006,"title":"Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer"},"paper-pacific-nejm-2017":{"doi":"10.1056/nejmoa1709937","openalexId":"W2753065806","cited":4663,"byYear":{"2013":1,"2014":1,"2017":47,"2018":454,"2019":467,"2020":581,"2021":643,"2022":568,"2023":555,"2024":541,"2025":468,"2026":333},"year":2017,"title":"Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer"},"paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004":{"doi":"10.1056/nejmoa032709","openalexId":"W2171232394","cited":3706,"byYear":{"2012":199,"2013":196,"2014":185,"2015":187,"2016":168,"2017":169,"2018":161,"2019":199,"2020":202,"2021":172,"2022":170,"2023":138,"2024":126,"2025":108,"2026":97},"year":2004,"title":"Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer"},"paper-osimertinib-nsclc-n-engl-j-med-2017":{"doi":"10.1056/nejmoa1612674","openalexId":"W2560717039","cited":3400,"byYear":{"2015":2,"2016":2,"2017":269,"2018":391,"2019":366,"2020":408,"2021":448,"2022":419,"2023":326,"2024":309,"2025":278,"2026":175},"year":2016,"title":"Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer"},"paper-paloma-2-n-engl-j-med-2016":{"doi":"10.1056/nejmoa1607303","openalexId":"W2552099557","cited":3066,"byYear":{"2013":1,"2015":1,"2016":9,"2017":158,"2018":284,"2019":263,"2020":311,"2021":380,"2022":329,"2023":358,"2024":381,"2025":341,"2026":243},"year":2016,"title":"Palbociclib and Letrozole in Advanced Breast Cancer"},"paper-osimertinib-nsclc-n-engl-j-med-2020":{"doi":"10.1056/nejmoa1913662","openalexId":"W2990041408","cited":2944,"byYear":{"2019":1,"2020":287,"2021":452,"2022":486,"2023":434,"2024":499,"2025":469,"2026":311},"year":2019,"title":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC"},"paper-pacific-n-engl-j-med-2018-update":{"doi":"10.1056/nejmoa1809697","openalexId":"W2893824814","cited":2858,"byYear":{"2013":1,"2018":27,"2019":337,"2020":542,"2021":514,"2022":416,"2023":376,"2024":271,"2025":229,"2026":140},"year":2018,"title":"Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC"},"paper-ostrem-kras-g12c-nature-2013":{"doi":"10.1038/nature12796","openalexId":"W2128339707","cited":2599,"byYear":{"2013":2,"2014":85,"2015":109,"2016":133,"2017":121,"2018":125,"2019":140,"2020":196,"2021":243,"2022":303,"2023":286,"2024":321,"2025":285,"2026":245},"year":2013,"title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions"},"paper-hidalgo-pancreatic-cancer-review-nejm-2010":{"doi":"10.1056/nejmra0901557","openalexId":"W4244578979","cited":2596,"byYear":{"2012":143,"2013":186,"2014":245,"2015":226,"2016":221,"2017":227,"2018":197,"2019":195,"2020":212,"2021":165,"2022":149,"2023":112,"2024":81,"2025":67,"2026":49},"year":2010,"title":"Pancreatic Cancer"},"paper-cristescu-science":{"doi":"10.1126/science.aar3593","openalexId":"W2897815318","cited":2413,"byYear":{"2012":1,"2017":1,"2018":14,"2019":189,"2020":315,"2021":393,"2022":441,"2023":367,"2024":310,"2025":220,"2026":159},"year":2018,"title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy"},"paper-kleeff-nat-rev-dis-primers":{"doi":"10.1038/nrdp.2016.22","openalexId":"W4211181525","cited":1948,"byYear":{"2012":1,"2014":1,"2016":16,"2017":58,"2018":99,"2019":154,"2020":232,"2021":303,"2022":253,"2023":227,"2024":231,"2025":232,"2026":140},"year":2016,"title":"Pancreatic cancer"},"paper-welch-j-natl-cancer-inst":{"doi":"10.1093/jnci/djq099","openalexId":"W2168133848","cited":1608,"byYear":{"2012":126,"2013":124,"2014":118,"2015":113,"2016":114,"2017":127,"2018":120,"2019":121,"2020":94,"2021":86,"2022":84,"2023":77,"2024":72,"2025":66,"2026":56},"year":2010,"title":"Overdiagnosis in Cancer"},"paper-nccn-pancreatic-adenocarcinoma-v2-2021-jnccn-2021":{"doi":"10.6004/jnccn.2021.0017","openalexId":"W3153075376","cited":1345,"byYear":{"2016":1,"2017":1,"2019":2,"2020":4,"2021":95,"2022":238,"2023":306,"2024":259,"2025":267,"2026":171},"year":2021,"title":"Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology"},"paper-phillips-jama-oncol":{"doi":"10.1001/jamaoncol.2020.0147","openalexId":"W3013251573","cited":1182,"byYear":{"2020":80,"2021":203,"2022":215,"2023":192,"2024":208,"2025":161,"2026":121},"year":2020,"title":"Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer"},"paper-pace-ponatinib-nejm-2013":{"doi":"10.1056/nejmoa1306494","openalexId":"W2147109509","cited":1147,"byYear":{"2012":2,"2013":6,"2014":91,"2015":113,"2016":123,"2017":104,"2018":89,"2019":83,"2020":80,"2021":103,"2022":95,"2023":77,"2024":80,"2025":55,"2026":38},"year":2013,"title":"A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias"},"paper-loeb-overdiagnosis-overtreatment-prostate-eur-urol-2014":{"doi":"10.1016/j.eururo.2013.12.062","openalexId":"W1989403098","cited":983,"byYear":{"2014":23,"2015":74,"2016":77,"2017":72,"2018":97,"2019":75,"2020":82,"2021":98,"2022":94,"2023":54,"2024":94,"2025":80,"2026":62},"year":2014,"title":"Overdiagnosis and Overtreatment of Prostate Cancer"},"paper-imcgp100-202-n-engl-j-med-2021":{"doi":"10.1056/nejmoa2103485","openalexId":"W3200574709","cited":917,"byYear":{"2021":15,"2022":152,"2023":207,"2024":225,"2025":186,"2026":131},"year":2021,"title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma"},"paper-monaleesa-2-n-engl-j-med-2022-update":{"doi":"10.1056/nejmoa2114663","openalexId":"W4220709633","cited":776,"byYear":{"2022":33,"2023":149,"2024":210,"2025":226,"2026":158},"year":2022,"title":"Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer"},"paper-menon-lancet":{"doi":"10.1016/s0140-6736(21)00731-5","openalexId":"W3162975920","cited":741,"byYear":{"2021":32,"2022":131,"2023":155,"2024":172,"2025":150,"2026":101},"year":2021,"title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial"},"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023":{"doi":"10.1056/nejmoa2306434","openalexId":"W4388484248","cited":733,"byYear":{"2023":5,"2024":175,"2025":318,"2026":234},"year":2023,"title":"Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC"},"paper-columbus-lancet-oncol-2018-update":{"doi":"10.1016/s1470-2045(18)30497-2","openalexId":"W2891205725","cited":589,"byYear":{"2012":1,"2018":8,"2019":77,"2020":132,"2021":87,"2022":93,"2023":76,"2024":57,"2025":41,"2026":17},"year":2018,"title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial"},"paper-pishvaian-lancet-oncol":{"doi":"10.1016/s1470-2045(20)30074-7","openalexId":"W3009738007","cited":560,"byYear":{"2019":2,"2020":29,"2021":119,"2022":105,"2023":92,"2024":90,"2025":81,"2026":41},"year":2020,"title":"Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial"},"paper-keynote-522-n-engl-j-med-2024-update":{"doi":"10.1056/nejmoa2409932","openalexId":"W4402551965","cited":553,"byYear":{"2024":19,"2025":239,"2026":295},"year":2024,"title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer"},"paper-tropics-02-lancet-2023":{"doi":"10.1016/s0140-6736(23)01245-x","openalexId":"W4386102828","cited":478,"byYear":{"2021":1,"2023":16,"2024":139,"2025":185,"2026":137},"year":2023,"title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial"},"paper-olympia-overall-survival-ann-oncol-2022":{"doi":"10.1016/j.annonc.2022.09.159","openalexId":"W4304084160","cited":477,"byYear":{"2022":3,"2023":116,"2024":134,"2025":132,"2026":92},"year":2022,"title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer"},"paper-lutz-pract-radiat-oncol":{"doi":"10.1016/j.prro.2016.08.001","openalexId":"W2479968209","cited":472,"byYear":{"2014":1,"2016":1,"2017":16,"2018":48,"2019":41,"2020":50,"2021":66,"2022":75,"2023":53,"2024":55,"2025":41,"2026":24},"year":2016,"title":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline"},"paper-paloma-2-breast-cancer-res-treat-2019-update":{"doi":"10.1007/s10549-018-05125-4","openalexId":"W2908699784","cited":450,"byYear":{"2019":21,"2020":52,"2021":68,"2022":60,"2023":70,"2024":74,"2025":68,"2026":36},"year":2019,"title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up"},"paper-golan-brca-pancreatic-platinum-survival-bjc-2014":{"doi":"10.1038/bjc.2014.418","openalexId":"W2015943054","cited":447,"byYear":{"2015":20,"2016":17,"2017":31,"2018":34,"2019":44,"2020":57,"2021":64,"2022":59,"2023":45,"2024":31,"2025":26,"2026":19},"year":2014,"title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers"},"paper-maniakas-neoadjuvant-braf-atc-jama-oncol-2020":{"doi":"10.1001/jamaoncol.2020.3362","openalexId":"W3047570563","cited":398,"byYear":{"2013":1,"2020":3,"2021":54,"2022":56,"2023":76,"2024":82,"2025":82,"2026":42},"year":2020,"title":"Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019"},"paper-sanders-j-clin-oncol":{"doi":"10.1200/jco.24.00542","openalexId":"W4396939189","cited":356,"byYear":{"2024":28,"2025":149,"2026":179},"year":2024,"title":"Palliative Care for Patients With Cancer: ASCO Guideline Update"},"paper-penelope-b-j-clin-oncol-2021":{"doi":"10.1200/jco.20.03639","openalexId":"W3148345241","cited":331,"byYear":{"2021":25,"2022":56,"2023":73,"2024":78,"2025":68,"2026":29},"year":2021,"title":"Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial"},"paper-nct02486718-ann-oncol-2023-update":{"doi":"10.1016/j.annonc.2023.07.001","openalexId":"W4384564675","cited":265,"byYear":{"2023":11,"2024":90,"2025":117,"2026":47},"year":2023,"title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial"},"paper-pallas-penelope-b-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(20)30642-2","openalexId":"W3120241209","cited":262,"byYear":{"2021":51,"2022":67,"2023":59,"2024":30,"2025":39,"2026":14},"year":2021,"title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study"},"paper-checkmate-816-n-engl-j-med-2025-update":{"doi":"10.1056/nejmoa2502931","openalexId":"W4410943999","cited":240,"byYear":{"2025":52,"2026":188},"year":2025,"title":"Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer"},"paper-therap-lancet-oncol-2024-update":{"doi":"10.1016/s1470-2045(23)00529-6","openalexId":"W4389210100","cited":226,"byYear":{"2024":55,"2025":105,"2026":66},"year":2023,"title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial"},"paper-outback-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00147-x","openalexId":"W4366085279","cited":204,"byYear":{"2023":19,"2024":68,"2025":78,"2026":39},"year":2023,"title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial"},"paper-relativity-047-nejm-evid-2023-update":{"doi":"10.1056/evidoa2200239","openalexId":"W4353060526","cited":129,"byYear":{"2023":10,"2024":50,"2025":54,"2026":15},"year":2023,"title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma"},"paper-imspire150-lancet-oncol-2023-update":{"doi":"10.1016/s1470-2045(22)00687-8","openalexId":"W4310554573","cited":112,"byYear":{"2023":22,"2024":40,"2025":22,"2026":28},"year":2022,"title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study"},"paper-inavo120-n-engl-j-med-2025-update":{"doi":"10.1056/nejmoa2501796","openalexId":"W4410919646","cited":102,"byYear":{"2025":28,"2026":74},"year":2025,"title":"Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer"},"paper-szpakowski-gallbladder-polyps-20-year-cohort-jama-netw-open-2020":{"doi":"10.1001/jamanetworkopen.2020.5143","openalexId":"W3024080414","cited":93,"byYear":{"2020":3,"2021":9,"2022":10,"2023":15,"2024":19,"2025":24,"2026":11},"year":2020,"title":"Outcomes of Gallbladder Polyps and Their Association With Gallbladder Cancer in a 20-Year Cohort"},"paper-ahn-jco-precis-oncol":{"doi":"10.1200/po.20.00037","openalexId":"W3037624356","cited":70,"byYear":{"2020":2,"2021":10,"2022":15,"2023":22,"2024":11,"2025":7,"2026":3},"year":2020,"title":"Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study"},"paper-monarche-ann-oncol-2026-update":{"doi":"10.1016/j.annonc.2025.10.005","openalexId":"W4415280900","cited":63,"byYear":{"2025":2,"2026":61},"year":2025,"title":"Overall survival with abemaciclib in early breast cancer"},"paper-patina-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2511218","openalexId":"W7125981927","cited":38,"byYear":{"2026":38},"year":2026,"title":"Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer"},"paper-cd47-pancreatic-pharmacol-res-2022":{"doi":"10.1016/j.phrs.2022.106264","openalexId":"W4280614947","cited":36,"byYear":{"2023":21,"2024":8,"2025":5,"2026":2},"year":2022,"title":"Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade"},"paper-nct03706690-j-hematol-oncol-2025":{"doi":"10.1186/s13045-025-01768-1","openalexId":"W4417097041","cited":11,"byYear":{"2026":11},"year":2025,"title":"PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy"},"paper-nct04956640-nat-commun-2026":{"doi":"10.1038/s41467-026-69943-7","openalexId":"W7135017986","cited":9,"byYear":{"2026":9},"year":2026,"title":"Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study"},"paper-kothari-paget-disease-nipple-multifocal-cancer-2002":{"doi":"10.1002/cncr.10638","openalexId":"W2094967414","cited":170,"byYear":{"2012":9,"2013":11,"2014":6,"2015":10,"2016":6,"2017":7,"2018":6,"2019":7,"2020":11,"2021":6,"2022":7,"2023":10,"2024":7,"2025":8,"2026":3},"year":2002,"title":"Paget disease of the nipple"},"paper-jimenez-gaona-ivermectin-loja-ecuador-2023":{"doi":"10.3390/nursrep13010030","openalexId":"W4321596241","cited":8,"byYear":{"2023":1,"2024":2,"2025":3,"2026":2},"year":2023,"title":"Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador"},"paper-paganetti-proton-rbe-ijrobp-2014":{"doi":"10.1016/j.ijrobp.2014.07.001","openalexId":"W2157434743","cited":12,"byYear":{"2015":1,"2016":1,"2018":1,"2019":2,"2020":3,"2021":2,"2023":1,"2024":1},"year":2014,"title":"Topical Agents for Radiation Dermatitis in Breast Cancer: 50 Shades of Red or Same Old, Same Old?"},"paper-worthington-precede-early-detection-biomarkers-ijc-2026":{"doi":"10.1002/ijc.70592","openalexId":"W7164902970","cited":0,"byYear":{},"year":2026,"title":"Pancreatic Cancer Early Detection Biomarkers for High‐Risk Individuals: Insights From the PRECEDE Consortium"},"paper-parkin-global-cancer-statistics-2002-cacancer-2005":{"doi":"10.3322/canjclin.55.2.74","openalexId":"W2020830322","cited":18399,"byYear":{"2012":1581,"2013":1534,"2014":1308,"2015":1116,"2016":924,"2017":794,"2018":725,"2019":562,"2020":655,"2021":497,"2022":330,"2023":262,"2024":181,"2025":107,"2026":41},"year":2005,"title":"Global Cancer Statistics, 2002"},"paper-pardoll-immune-checkpoint-blockade-nrc-2012":{"doi":"10.1038/nrc3239","openalexId":"W2066671159","cited":14085,"byYear":{"2012":39,"2013":240,"2014":337,"2015":644,"2016":896,"2017":1143,"2018":1207,"2019":1261,"2020":1463,"2021":1528,"2022":1350,"2023":1257,"2024":1219,"2025":909,"2026":573},"year":2012,"title":"The blockade of immune checkpoints in cancer immunotherapy"},"paper-cortazar-ctneobc-pcr-pooled-analysis-lancet-2014":{"doi":"10.1016/s0140-6736(13)62422-8","openalexId":"W2075894019","cited":4876,"byYear":{"2014":91,"2015":194,"2016":233,"2017":264,"2018":286,"2019":312,"2020":457,"2021":548,"2022":498,"2023":505,"2024":578,"2025":516,"2026":379},"year":2014,"title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis"},"paper-keynote-407-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1810865","openalexId":"W2892640821","cited":3714,"byYear":{"2013":1,"2016":1,"2017":1,"2018":16,"2019":364,"2020":617,"2021":643,"2022":578,"2023":455,"2024":504,"2025":330,"2026":195},"year":2018,"title":"Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer"},"paper-pembrolizumab-urothelial-n-engl-j-med-2017":{"doi":"10.1056/nejmoa1613683","openalexId":"W2588916311","cited":3467,"byYear":{"2013":1,"2015":1,"2016":1,"2017":163,"2018":352,"2019":394,"2020":502,"2021":478,"2022":437,"2023":378,"2024":365,"2025":240,"2026":149},"year":2017,"title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma"},"paper-keynote-042-lancet-2019":{"doi":"10.1016/s0140-6736(18)32409-7","openalexId":"W2925446385","cited":3391,"byYear":{"2012":2,"2016":2,"2018":1,"2019":150,"2020":523,"2021":603,"2022":536,"2023":544,"2024":500,"2025":349,"2026":178},"year":2019,"title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial"},"paper-keynote-522-n-engl-j-med-2020":{"doi":"10.1056/nejmoa1910549","openalexId":"W3006930853","cited":3314,"byYear":{"2012":1,"2013":1,"2019":1,"2020":155,"2021":401,"2022":532,"2023":536,"2024":584,"2025":586,"2026":513},"year":2020,"title":"Pembrolizumab for Early Triple-Negative Breast Cancer"},"paper-lord-science":{"doi":"10.1126/science.aam7344","openalexId":"W2597062310","cited":2995,"byYear":{"2015":2,"2016":1,"2017":56,"2018":171,"2019":234,"2020":321,"2021":407,"2022":384,"2023":403,"2024":352,"2025":375,"2026":287},"year":2017,"title":"PARP inhibitors: Synthetic lethality in the clinic"},"paper-pd-l1-urothelial-mol-cancer-ther-2015":{"doi":"10.1158/1535-7163.mct-14-0983","openalexId":"W2136859769","cited":2381,"byYear":{"2015":27,"2016":110,"2017":157,"2018":189,"2019":206,"2020":302,"2021":335,"2022":293,"2023":288,"2024":242,"2025":157,"2026":69},"year":2015,"title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy"},"paper-heinrich-pdgfra-gist-science-2003":{"doi":"10.1126/science.1079666","openalexId":"W2140626630","cited":2309,"byYear":{"2012":121,"2013":123,"2014":98,"2015":88,"2016":79,"2017":99,"2018":80,"2019":77,"2020":84,"2021":91,"2022":79,"2023":66,"2024":53,"2025":52,"2026":34},"year":2003,"title":"PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors"},"paper-douillard-prime-panitumumab-ras-nejm-2013":{"doi":"10.1056/nejmoa1305275","openalexId":"W2085633477","cited":2286,"byYear":{"2012":2,"2013":15,"2014":239,"2015":289,"2016":251,"2017":226,"2018":182,"2019":178,"2020":163,"2021":207,"2022":129,"2023":117,"2024":122,"2025":99,"2026":58},"year":2013,"title":"Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer"},"paper-biankin-pancreatic-exomes-axon-guidance-nature-2012":{"doi":"10.1038/nature11547","openalexId":"W2161884651","cited":2133,"byYear":{"2012":1,"2013":113,"2014":158,"2015":178,"2016":192,"2017":191,"2018":165,"2019":167,"2020":175,"2021":203,"2022":202,"2023":135,"2024":97,"2025":99,"2026":53},"year":2012,"title":"Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes"},"paper-paola-1-nejm-2019":{"doi":"10.1056/nejmoa1911361","openalexId":"W2994977341","cited":2116,"byYear":{"2019":1,"2020":181,"2021":322,"2022":376,"2023":396,"2024":346,"2025":278,"2026":210},"year":2019,"title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer"},"paper-keynote-355-lancet-2020":{"doi":"10.1016/s0140-6736(20)32531-9","openalexId":"W3109853980","cited":1856,"byYear":{"2020":17,"2021":262,"2022":414,"2023":380,"2024":337,"2025":264,"2026":181},"year":2020,"title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial"},"paper-jean-pascal-machiels-lancet-2019":{"doi":"10.1016/s0140-6736(18)31999-8","openalexId":"W2903493423","cited":1731,"byYear":{"2013":1,"2018":2,"2019":134,"2020":244,"2021":260,"2022":261,"2023":228,"2024":261,"2025":220,"2026":116},"year":2018,"title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study"},"paper-empower-cscc-1-cemiplimab-migden-nejm-2018":{"doi":"10.1056/nejmoa1805131","openalexId":"W2805968856","cited":1434,"byYear":{"2013":1,"2014":1,"2018":22,"2019":170,"2020":228,"2021":233,"2022":190,"2023":179,"2024":154,"2025":148,"2026":98},"year":2018,"title":"PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma"},"paper-hirsch-j-thorac-oncol":{"doi":"10.1016/j.jtho.2016.11.2228","openalexId":"W2557730509","cited":1278,"byYear":{"2016":2,"2017":160,"2018":217,"2019":185,"2020":185,"2021":157,"2022":113,"2023":91,"2024":68,"2025":49,"2026":46},"year":2016,"title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project"},"paper-keynote-017-n-engl-j-med-2016":{"doi":"10.1056/nejmoa1603702","openalexId":"W2339890238","cited":1266,"byYear":{"2015":3,"2016":41,"2017":175,"2018":188,"2019":173,"2020":170,"2021":145,"2022":105,"2023":85,"2024":77,"2025":68,"2026":30},"year":2016,"title":"PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma"},"paper-hruban-panin-nomenclature-ajsp-2001":{"doi":"10.1097/00000478-200105000-00003","openalexId":"W1964064067","cited":1122,"byYear":{"2012":62,"2013":40,"2014":48,"2015":54,"2016":51,"2017":45,"2018":44,"2019":24,"2020":32,"2021":43,"2022":30,"2023":38,"2024":20,"2025":16,"2026":15},"year":2001,"title":"Pancreatic Intraepithelial Neoplasia"},"paper-gay-sclc-subtypes-inflamed-cancer-cell-2021":{"doi":"10.1016/j.ccell.2020.12.014","openalexId":"W3124749091","cited":991,"byYear":{"2020":1,"2021":92,"2022":157,"2023":166,"2024":219,"2025":211,"2026":142},"year":2021,"title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities"},"paper-keynote-177-lancet-oncol-2022-update":{"doi":"10.1016/s1470-2045(22)00197-8","openalexId":"W4223510971","cited":961,"byYear":{"2019":1,"2020":20,"2021":17,"2022":71,"2023":197,"2024":235,"2025":247,"2026":171},"year":2022,"title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study"},"paper-blueprint-phase-2-pd-l1-assays-jto-2018":{"doi":"10.1016/j.jtho.2018.05.013","openalexId":"W2804957255","cited":823,"byYear":{"2018":30,"2019":103,"2020":132,"2021":188,"2022":121,"2023":75,"2024":87,"2025":53,"2026":32},"year":2018,"title":"PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project"},"paper-pd-l1-urothelial-onco-targets-ther-2016":{"doi":"10.2147/ott.s105862","openalexId":"W2509486054","cited":808,"byYear":{"2014":1,"2016":2,"2017":58,"2018":86,"2019":72,"2020":93,"2021":93,"2022":94,"2023":93,"2024":100,"2025":79,"2026":37},"year":2016,"title":"PD-L1 expression in human cancers and its association with clinical outcomes"},"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017":{"doi":"10.1200/jco.2016.70.1524","openalexId":"W2602907503","cited":668,"byYear":{"2013":1,"2017":31,"2018":89,"2019":87,"2020":97,"2021":88,"2022":91,"2023":52,"2024":57,"2025":48,"2026":26},"year":2017,"title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study"},"paper-coles-lancet":{"doi":"10.1016/s0140-6736(17)31145-5","openalexId":"W2740659413","cited":620,"byYear":{"2017":10,"2018":41,"2019":63,"2020":83,"2021":81,"2022":82,"2023":71,"2024":84,"2025":68,"2026":34},"year":2017,"title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial"},"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023":{"doi":"10.1016/j.annonc.2023.08.009","openalexId":"W4386529421","cited":596,"byYear":{"2023":5,"2024":131,"2025":244,"2026":216},"year":2023,"title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-keynote-407-j-clin-oncol-2023-update":{"doi":"10.1200/jco.22.01990","openalexId":"W4319068412","cited":564,"byYear":{"2021":1,"2022":1,"2023":68,"2024":154,"2025":192,"2026":148},"year":2023,"title":"Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study"},"paper-antoine-italiano-j-clin-oncol-2022":{"doi":"10.1200/jco.21.01874","openalexId":"W4206041598","cited":523,"byYear":{"2020":1,"2022":60,"2023":138,"2024":122,"2025":125,"2026":77},"year":2022,"title":"Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study"},"paper-keynote-158-ann-oncol-2022-update":{"doi":"10.1016/j.annonc.2022.05.519","openalexId":"W4281630256","cited":473,"byYear":{"2014":1,"2020":2,"2021":4,"2022":9,"2023":81,"2024":151,"2025":140,"2026":85},"year":2022,"title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study"},"paper-paskett-ca-cancer-j-clin":{"doi":"10.3322/caac.20111","openalexId":"W1963893873","cited":465,"byYear":{"2012":20,"2013":36,"2014":35,"2015":43,"2016":45,"2017":36,"2018":39,"2019":40,"2020":28,"2021":37,"2022":43,"2023":23,"2024":17,"2025":15,"2026":6},"year":2011,"title":"Patient navigation: An update on the state of the science"},"paper-giaccone-pembrolizumab-thymic-carcinoma-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30062-7","openalexId":"W2784751095","cited":411,"byYear":{"2018":24,"2019":42,"2020":48,"2021":61,"2022":59,"2023":56,"2024":42,"2025":45,"2026":33},"year":2018,"title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study"},"paper-cooper-chem-soc-rev":{"doi":"10.1039/d0cs00556h","openalexId":"W3113803919","cited":408,"byYear":{"2021":23,"2022":65,"2023":81,"2024":95,"2025":87,"2026":57},"year":2020,"title":"Peptides as a platform for targeted therapeutics for cancer: peptide–drug conjugates (PDCs)"},"paper-pathfinder-lancet-2023":{"doi":"10.1016/s0140-6736(23)01700-2","openalexId":"W4387381160","cited":399,"byYear":{"2023":6,"2024":116,"2025":147,"2026":130},"year":2023,"title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study"},"paper-amant-n-engl-j-med":{"doi":"10.1056/nejmoa1508913","openalexId":"W2248489854","cited":373,"byYear":{"2013":1,"2015":5,"2016":33,"2017":25,"2018":38,"2019":43,"2020":39,"2021":41,"2022":31,"2023":31,"2024":37,"2025":32,"2026":15},"year":2015,"title":"Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy"},"paper-nct02332668-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(19)30671-0","openalexId":"W2992921938","cited":358,"byYear":{"2018":1,"2019":5,"2020":32,"2021":61,"2022":49,"2023":59,"2024":51,"2025":58,"2026":42},"year":2019,"title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial"},"paper-tetzlaff-ann-oncol":{"doi":"10.1093/annonc/mdy226","openalexId":"W2810879984","cited":288,"byYear":{"2018":4,"2019":17,"2020":25,"2021":24,"2022":35,"2023":32,"2024":44,"2025":56,"2026":50},"year":2018,"title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma"},"paper-papmet-pal-lancet-2021":{"doi":"10.1016/s0140-6736(21)00152-5","openalexId":"W3129780093","cited":288,"byYear":{"2021":35,"2022":47,"2023":66,"2024":55,"2025":58,"2026":26},"year":2021,"title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial"},"paper-paradigm-jama-2023":{"doi":"10.1001/jama.2023.4428","openalexId":"W4366236521","cited":281,"byYear":{"2023":25,"2024":96,"2025":92,"2026":68},"year":2023,"title":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer"},"paper-omori-ipmn-progression-pathways-gastroenterology-2019":{"doi":"10.1053/j.gastro.2018.10.029","openalexId":"W2895902053","cited":187,"byYear":{"2019":22,"2020":26,"2021":29,"2022":29,"2023":30,"2024":16,"2025":17,"2026":18},"year":2018,"title":"Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features"},"paper-tabrizian-am-j-transplant":{"doi":"10.1111/ajt.16448","openalexId":"W3111770708","cited":158,"byYear":{"2021":9,"2022":28,"2023":31,"2024":56,"2025":24,"2026":10},"year":2020,"title":"PD-1 inhibitor as bridge therapy to liver transplantation?"},"paper-pathfinder-avapritinib-advanced-systemic-mastocytosis-nat-med-2021":{"doi":"10.1038/s41591-021-01539-8","openalexId":"W4200407033","cited":151,"byYear":{"2021":2,"2022":37,"2023":42,"2024":23,"2025":28,"2026":19},"year":2021,"title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial"},"paper-keynote-716-lancet-oncol-2022-update":{"doi":"10.1016/s1470-2045(22)00559-9","openalexId":"W4306649419","cited":150,"byYear":{"2022":4,"2023":50,"2024":50,"2025":32,"2026":14},"year":2022,"title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial"},"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021":{"doi":"10.1093/jnci/djab108","openalexId":"W3170352885","cited":148,"byYear":{"2021":19,"2022":37,"2023":31,"2024":28,"2025":22,"2026":11},"year":2021,"title":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab -Paclitaxel–Treated Advanced Triple-Negative Breast Cancer"},"paper-nct03725059-nat-med-2025":{"doi":"10.1038/s41591-024-03415-7","openalexId":"W4406679883","cited":138,"byYear":{"2025":67,"2026":71},"year":2025,"title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial"},"paper-blay-lancet-oncol":{"doi":"10.1016/s1470-2045(23)00282-6","openalexId":"W4383498522","cited":96,"byYear":{"2023":8,"2024":28,"2025":32,"2026":28},"year":2023,"title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial"},"paper-nct02861573-eur-urol-2022":{"doi":"10.1016/j.eururo.2022.02.023","openalexId":"W4223609500","cited":84,"byYear":{"2022":6,"2023":24,"2024":23,"2025":20,"2026":11},"year":2022,"title":"Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study"},"paper-partiqol-astro-2024":{"doi":"10.1016/j.ijrobp.2024.08.012","openalexId":"W4402910389","cited":30,"byYear":{"2024":1,"2025":13,"2026":16},"year":2024,"title":"Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer"},"paper-nct04821622-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2604126","openalexId":"W7162853803","cited":9,"byYear":{"2026":9},"year":2026,"title":"PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer"},"paper-bien-pediatr-blood-cancer":{"doi":"10.1002/pbc.29112","openalexId":"W3133637808","cited":27,"byYear":{"2021":1,"2022":4,"2023":4,"2024":10,"2025":6,"2026":2},"year":2021,"title":"Pancreatoblastoma in children: EXPeRT/PARTNER diagnostic and therapeutic recommendations"},"paper-nct06099782-jco-oncol-pract-2026":{"doi":"10.1200/op-25-01248","openalexId":"W7163393619","cited":0,"byYear":{},"year":2026,"title":"Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study"},"paper-scagliotti-cisplatin-pemetrexed-histology-jco-2008":{"doi":"10.1200/jco.2007.15.0375","openalexId":"W2099725888","cited":3235,"byYear":{"2012":266,"2013":296,"2014":269,"2015":245,"2016":203,"2017":218,"2018":199,"2019":160,"2020":168,"2021":150,"2022":92,"2023":70,"2024":90,"2025":39,"2026":38},"year":2008,"title":"Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer"},"paper-vogelzang-pemetrexed-mesothelioma-jco-2003":{"doi":"10.1200/jco.2003.11.136","openalexId":"W2102627969","cited":3091,"byYear":{"2012":173,"2013":131,"2014":159,"2015":144,"2016":145,"2017":146,"2018":157,"2019":138,"2020":157,"2021":192,"2022":168,"2023":139,"2024":87,"2025":91,"2026":45},"year":2003,"title":"Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma"},"paper-cleopatra-n-engl-j-med-2012":{"doi":"10.1056/nejmoa1113216","openalexId":"W2166199281","cited":2565,"byYear":{"2012":157,"2013":285,"2014":256,"2015":229,"2016":182,"2017":196,"2018":154,"2019":155,"2020":161,"2021":177,"2022":143,"2023":134,"2024":140,"2025":113,"2026":74},"year":2011,"title":"Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer"},"paper-royal-ipilimumab-pancreatic-j-immunother-2010":{"doi":"10.1097/cji.0b013e3181eec14c","openalexId":"W2044363258","cited":1278,"byYear":{"2012":16,"2013":29,"2014":38,"2015":43,"2016":78,"2017":85,"2018":89,"2019":99,"2020":128,"2021":140,"2022":135,"2023":118,"2024":117,"2025":89,"2026":61},"year":2010,"title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma"},"paper-keynote-671-n-engl-j-med-2023":{"doi":"10.1056/nejmoa2302983","openalexId":"W4379209546","cited":1152,"byYear":{"2023":102,"2024":373,"2025":392,"2026":285},"year":2023,"title":"Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer"},"paper-cleopatra-lancet-oncol-2013-update":{"doi":"10.1016/s1470-2045(13)70130-x","openalexId":"W2120661754","cited":1012,"byYear":{"2013":43,"2014":116,"2015":102,"2016":87,"2017":83,"2018":85,"2019":71,"2020":91,"2021":88,"2022":65,"2023":79,"2024":38,"2025":31,"2026":29},"year":2013,"title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study"},"paper-attard-abiraterone-phase-1-cyp17-jco-2008":{"doi":"10.1200/jco.2007.15.9749","openalexId":"W2170544517","cited":903,"byYear":{"2012":96,"2013":89,"2014":83,"2015":42,"2016":56,"2017":32,"2018":49,"2019":40,"2020":34,"2021":35,"2022":18,"2023":31,"2024":18,"2025":20,"2026":11},"year":2008,"title":"Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven"},"paper-heymach-aegean-perioperative-durvalumab-nejm-2023":{"doi":"10.1056/nejmoa2304875","openalexId":"W4387879971","cited":786,"byYear":{"2023":4,"2024":250,"2025":286,"2026":246},"year":2023,"title":"Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer"},"paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013":{"doi":"10.1158/1078-0432.ccr-12-3327","openalexId":"W2098804778","cited":756,"byYear":{"2013":4,"2014":29,"2015":38,"2016":73,"2017":77,"2018":72,"2019":61,"2020":68,"2021":78,"2022":92,"2023":61,"2024":37,"2025":43,"2026":23},"year":2013,"title":"Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer"},"paper-cd19-all-leukemia-j-clin-oncol-2014":{"doi":"10.1200/jco.2014.56.3247","openalexId":"W1967512987","cited":666,"byYear":{"2014":3,"2015":74,"2016":80,"2017":83,"2018":57,"2019":72,"2020":58,"2021":65,"2022":48,"2023":40,"2024":34,"2025":37,"2026":12},"year":2014,"title":"Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia"},"paper-perseus-dara-vrd-transplant-nejm-2024":{"doi":"10.1056/nejmoa2312054","openalexId":"W4389606680","cited":586,"byYear":{"2023":3,"2024":150,"2025":253,"2026":179},"year":2023,"title":"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma"},"paper-mypathway-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(18)30904-5","openalexId":"W2921113926","cited":580,"byYear":{"2013":1,"2019":23,"2020":64,"2021":90,"2022":100,"2023":95,"2024":92,"2025":70,"2026":44},"year":2019,"title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study"},"paper-lim-neuro-oncol":{"doi":"10.1093/neuonc/noac116","openalexId":"W4225630787","cited":541,"byYear":{"2022":23,"2023":111,"2024":159,"2025":140,"2026":105},"year":2022,"title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter"},"paper-nct04025879-n-engl-j-med-2024":{"doi":"10.1056/nejmoa2311926","openalexId":"W4396915845","cited":521,"byYear":{"2023":1,"2024":69,"2025":258,"2026":193},"year":2024,"title":"Perioperative Nivolumab in Resectable Lung Cancer"},"paper-tap-lancet":{"doi":"10.1016/s0140-6736(19)30764-0","openalexId":"W2951817901","cited":497,"byYear":{"2018":2,"2019":6,"2020":59,"2021":76,"2022":78,"2023":60,"2024":82,"2025":82,"2026":52},"year":2019,"title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial"},"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023":{"doi":"10.1056/nejmoa2215530","openalexId":"W4382363420","cited":486,"byYear":{"2023":53,"2024":171,"2025":157,"2026":105},"year":2023,"title":"Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer"},"paper-javle-mypathway-her2-biliary-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00336-3","openalexId":"W3193026281","cited":427,"byYear":{"2021":11,"2022":75,"2023":89,"2024":100,"2025":102,"2026":50},"year":2021,"title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study"},"paper-patel-jama-surg":{"doi":"10.1001/jamasurg.2018.1153","openalexId":"W2804198114","cited":395,"byYear":{"2018":11,"2019":37,"2020":57,"2021":56,"2022":46,"2023":67,"2024":41,"2025":40,"2026":38},"year":2018,"title":"Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules"},"paper-viardot-blood":{"doi":"10.1182/blood-2015-06-651380","openalexId":"W2236959863","cited":378,"byYear":{"2015":2,"2016":10,"2017":31,"2018":34,"2019":39,"2020":45,"2021":58,"2022":45,"2023":30,"2024":37,"2025":27,"2026":19},"year":2016,"title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma"},"paper-ishigami-j-clin-oncol":{"doi":"10.1200/jco.2018.77.8613","openalexId":"W2801279586","cited":368,"byYear":{"2018":10,"2019":25,"2020":52,"2021":55,"2022":47,"2023":44,"2024":53,"2025":52,"2026":28},"year":2018,"title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial"},"paper-defibrotide-2005-01-blood-2016":{"doi":"10.1182/blood-2015-10-676924","openalexId":"W2295805773","cited":336,"byYear":{"2016":17,"2017":37,"2018":28,"2019":33,"2020":35,"2021":37,"2022":34,"2023":38,"2024":28,"2025":28,"2026":16},"year":2016,"title":"Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure"},"paper-shen-cell":{"doi":"10.1016/j.cell.2020.10.027","openalexId":"W3099461365","cited":324,"byYear":{"2020":2,"2021":39,"2022":51,"2023":64,"2024":63,"2025":60,"2026":45},"year":2020,"title":"Persistent Cancer Cells: The Deadly Survivors"},"paper-mirvetuximab-soravtansine-ovarian-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.02.017","openalexId":"W3135098376","cited":304,"byYear":{"2021":14,"2022":29,"2023":68,"2024":74,"2025":77,"2026":42},"year":2021,"title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I"},"paper-crane-smad4-progression-pattern-locally-advanced-jco-2011":{"doi":"10.1200/jco.2010.33.8038","openalexId":"W2153539090","cited":287,"byYear":{"2012":31,"2013":29,"2014":43,"2015":21,"2016":24,"2017":30,"2018":19,"2019":16,"2020":12,"2021":10,"2022":13,"2023":11,"2024":10,"2025":8,"2026":1},"year":2011,"title":"Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression"},"paper-cd30-hodgkin-lymphoma-j-clin-oncol-2015":{"doi":"10.1200/jco.2014.60.3969","openalexId":"W2119799189","cited":283,"byYear":{"2012":1,"2014":1,"2015":8,"2016":24,"2017":44,"2018":28,"2019":34,"2020":26,"2021":32,"2022":21,"2023":20,"2024":17,"2025":20,"2026":7},"year":2015,"title":"Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project"},"paper-van-as-n-engl-j-med":{"doi":"10.1056/nejmoa2403365","openalexId":"W4403463061","cited":272,"byYear":{"2024":3,"2025":145,"2026":124},"year":2024,"title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer"},"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019":{"doi":"10.1200/jco.18.00545","openalexId":"W2901312960","cited":269,"byYear":{"2019":10,"2020":33,"2021":35,"2022":40,"2023":43,"2024":42,"2025":44,"2026":22},"year":2018,"title":"Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma"},"paper-overman-capox-small-bowel-adenocarcinoma-jco-2009":{"doi":"10.1200/jco.2008.19.7145","openalexId":"W2129754451","cited":257,"byYear":{"2012":14,"2013":16,"2014":13,"2015":16,"2016":17,"2017":15,"2018":18,"2019":19,"2020":12,"2021":13,"2022":17,"2023":18,"2024":16,"2025":11,"2026":9},"year":2009,"title":"Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater"},"paper-reiss-rucaparib-maintenance-brca-palb2-pancreatic-jco-2021":{"doi":"10.1200/jco.21.00003","openalexId":"W3162325855","cited":256,"byYear":{"2020":4,"2021":19,"2022":46,"2023":63,"2024":46,"2025":47,"2026":31},"year":2021,"title":"Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1 , BRCA2 , or PALB2"},"paper-reckamp-j-clin-oncol":{"doi":"10.1200/jco.22.00912","openalexId":"W4281721227","cited":250,"byYear":{"2022":18,"2023":59,"2024":87,"2025":57,"2026":29},"year":2022,"title":"Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A"},"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019":{"doi":"10.1200/jco.18.01859","openalexId":"W2291746651","cited":248,"byYear":{"2015":1,"2016":3,"2017":3,"2018":2,"2019":9,"2020":24,"2021":37,"2022":35,"2023":39,"2024":34,"2025":37,"2026":23},"year":2019,"title":"Phase II Study of Lenvatinib in Patients With Progressive, Recurrent or Metastatic Adenoid Cystic Carcinoma"},"paper-gpc3-hcc-oncoimmunology-2016":{"doi":"10.1080/2162402x.2015.1129483","openalexId":"W2413809012","cited":179,"byYear":{"2016":4,"2017":18,"2018":14,"2019":26,"2020":20,"2021":19,"2022":14,"2023":18,"2024":16,"2025":23,"2026":7},"year":2016,"title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients"},"paper-wang-notch-pest-mutations-tnbc-ccr-2015":{"doi":"10.1158/1078-0432.ccr-14-1348","openalexId":"W1984365236","cited":155,"byYear":{"2015":10,"2016":11,"2017":13,"2018":17,"2019":11,"2020":16,"2021":19,"2022":15,"2023":9,"2024":14,"2025":12,"2026":8},"year":2015,"title":"PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor"},"paper-nct04379635-lancet-respir-med-2025":{"doi":"10.1016/s2213-2600(24)00269-8","openalexId":"W4404581119","cited":133,"byYear":{"2024":2,"2025":67,"2026":64},"year":2024,"title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial"},"paper-pharos-encorafenib-binimetinib-riely-jco-2023":{"doi":"10.1200/jco.23.00774","openalexId":"W4379278616","cited":126,"byYear":{"2023":4,"2024":48,"2025":43,"2026":30},"year":2023,"title":"Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer"},"paper-reidy-lagunes-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-19-1026","openalexId":"W2969596297","cited":111,"byYear":{"2019":2,"2020":11,"2021":14,"2022":23,"2023":18,"2024":17,"2025":13,"2026":13},"year":2019,"title":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan"},"paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023":{"doi":"10.1200/jco.22.00690","openalexId":"W4307027657","cited":78,"byYear":{"2022":1,"2023":12,"2024":29,"2025":22,"2026":14},"year":2022,"title":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor–T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1)"},"paper-eckstein-j-clin-oncol":{"doi":"10.1200/jco.21.02840","openalexId":"W4221097460","cited":68,"byYear":{"2022":5,"2023":23,"2024":21,"2025":11,"2026":8},"year":2022,"title":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial"},"paper-gupta-jco-precis-oncol":{"doi":"10.1200/po.22.00306","openalexId":"W4307883113","cited":63,"byYear":{"2023":12,"2024":23,"2025":21,"2026":7},"year":2022,"title":"Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer WithERBB2Amplification orERBB2/3Mutations: Results From the TAPUR Study"},"paper-luca-gianni-cancer-med-2023":{"doi":"10.1002/cam4.5893","openalexId":"W4367367218","cited":56,"byYear":{"2023":5,"2024":29,"2025":11,"2026":11},"year":2023,"title":"Phase II study ( KAMELEON ) of single‐agent T‐DM1 in patients with HER2 ‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma"},"paper-nct05061550-nat-med-2025":{"doi":"10.1038/s41591-025-03746-z","openalexId":"W4410915155","cited":41,"byYear":{"2025":10,"2026":31},"year":2025,"title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial"},"paper-impassion031-nat-med-2025-update":{"doi":"10.1038/s41591-025-03725-4","openalexId":"W4411037230","cited":38,"byYear":{"2025":8,"2026":30},"year":2025,"title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial"},"paper-nct03767244-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2603878","openalexId":"W7162949605","cited":25,"byYear":{"2026":25},"year":2026,"title":"Perioperative Apalutamide in High-Risk Localized Prostate Cancer"},"paper-nct04585750-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2508820","openalexId":"W7131429230","cited":24,"byYear":{"2026":24},"year":2026,"title":"Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C–Mutated Tumors"},"paper-nct03974022-j-clin-oncol-2025":{"doi":"10.1200/jco-25-00788","openalexId":"W4414082275","cited":22,"byYear":{"2025":3,"2026":19},"year":2025,"title":"Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)"},"paper-nct04379635-ann-oncol-2026-update":{"doi":"10.1016/j.annonc.2025.11.017","openalexId":"W4416918324","cited":14,"byYear":{"2026":14},"year":2025,"title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial"},"paper-chen-exp-hematol-oncol":{"doi":"10.1186/s40164-025-00710-y","openalexId":"W4414674414","cited":4,"byYear":{"2026":4},"year":2025,"title":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma"},"paper-cd47-colorectal-cancer-res-commun-2025":{"doi":"10.1158/2767-9764.crc-25-0332","openalexId":"W4415740353","cited":4,"byYear":{"2025":1,"2026":3},"year":2025,"title":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer"},"paper-nct05877430-j-immunother-cancer-2026":{"doi":"10.1136/jitc-2025-014702","openalexId":"W7161286259","cited":1,"byYear":{"2026":1},"year":2026,"title":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma"},"paper-nhs-galleri-performance-nat-med-2026":{"doi":"10.1038/s41591-026-04652-8","openalexId":"W7214040585","cited":1,"byYear":{"2026":1},"year":2026,"title":"Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial"},"paper-agostinis-ca-cancer-j-clin":{"doi":"10.3322/caac.20114","openalexId":"W2151734986","cited":5185,"byYear":{"2012":114,"2013":141,"2014":206,"2015":256,"2016":293,"2017":323,"2018":355,"2019":448,"2020":516,"2021":548,"2022":502,"2023":467,"2024":504,"2025":370,"2026":123},"year":2011,"title":"Photodynamic therapy of cancer: An update"},"paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001":{"doi":"10.1056/nejmoa010580","openalexId":"W2132565869","cited":4236,"byYear":{"2012":189,"2013":193,"2014":207,"2015":205,"2016":168,"2017":154,"2018":152,"2019":168,"2020":196,"2021":171,"2022":178,"2023":183,"2024":112,"2025":120,"2026":57},"year":2001,"title":"Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer"},"paper-precision-mri-targeted-biopsy-nejm-2018":{"doi":"10.1056/nejmoa1801993","openalexId":"W2793905111","cited":3109,"byYear":{"2018":192,"2019":337,"2020":397,"2021":431,"2022":381,"2023":364,"2024":383,"2025":359,"2026":254},"year":2018,"title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis"},"paper-andriole-plco-prostate-screening-nejm-2009":{"doi":"10.1056/nejmoa0810696","openalexId":"W2132528779","cited":2929,"byYear":{"2012":361,"2013":254,"2014":226,"2015":199,"2016":168,"2017":142,"2018":122,"2019":96,"2020":101,"2021":88,"2022":80,"2023":65,"2024":61,"2025":44,"2026":32},"year":2009,"title":"Mortality Results from a Randomized Prostate-Cancer Screening Trial"},"paper-endocrine-society-pheochromocytoma-paraganglioma-guideline-jcem-2014":{"doi":"10.1210/jc.2014-1498","openalexId":"W2135003179","cited":2840,"byYear":{"2014":23,"2015":121,"2016":139,"2017":181,"2018":217,"2019":250,"2020":299,"2021":322,"2022":304,"2023":271,"2024":256,"2025":252,"2026":186},"year":2014,"title":"Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline"},"paper-overgaard-n-engl-j-med":{"doi":"10.1056/nejm199710023371401","openalexId":"W2332829713","cited":2584,"byYear":{"2012":113,"2013":104,"2014":94,"2015":90,"2016":91,"2017":98,"2018":60,"2019":61,"2020":64,"2021":74,"2022":54,"2023":60,"2024":38,"2025":35,"2026":22},"year":1997,"title":"Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy"},"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019":{"doi":"10.1056/nejmoa1903387","openalexId":"W2947826965","cited":2331,"byYear":{"2012":1,"2014":1,"2019":68,"2020":310,"2021":454,"2022":415,"2023":325,"2024":304,"2025":265,"2026":182},"year":2019,"title":"Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer"},"paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017":{"doi":"10.1038/nature22364","openalexId":"W2608738563","cited":1978,"byYear":{"2016":1,"2017":67,"2018":158,"2019":176,"2020":218,"2021":275,"2022":268,"2023":259,"2024":206,"2025":201,"2026":146},"year":2017,"title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution"},"paper-peinado-nat-rev-cancer":{"doi":"10.1038/nrc.2017.6","openalexId":"W2596133050","cited":1941,"byYear":{"2012":1,"2017":49,"2018":112,"2019":186,"2020":202,"2021":263,"2022":273,"2023":277,"2024":242,"2025":189,"2026":145},"year":2017,"title":"Pre-metastatic niches: organ-specific homes for metastases"},"paper-sebag-montefiore-cr07-preoperative-radiotherapy-lancet-2009":{"doi":"10.1016/s0140-6736(09)60484-0","openalexId":"W2142818315","cited":1517,"byYear":{"2012":97,"2013":101,"2014":114,"2015":109,"2016":92,"2017":81,"2018":96,"2019":103,"2020":106,"2021":100,"2022":77,"2023":87,"2024":76,"2025":47,"2026":33},"year":2009,"title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial"},"paper-mohile-j-clin-oncol":{"doi":"10.1200/jco.2018.78.8687","openalexId":"W2804780558","cited":1490,"byYear":{"2018":26,"2019":126,"2020":154,"2021":224,"2022":252,"2023":214,"2024":183,"2025":140,"2026":167},"year":2018,"title":"Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology"},"paper-mavaddat-am-j-hum-genet":{"doi":"10.1016/j.ajhg.2018.11.002","openalexId":"W2901952863","cited":1215,"byYear":{"2019":85,"2020":141,"2021":200,"2022":169,"2023":181,"2024":195,"2025":145,"2026":96},"year":2018,"title":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes"},"paper-portec-2-lancet-2010":{"doi":"10.1016/s0140-6736(09)62163-2","openalexId":"W2114222627","cited":1155,"byYear":{"2012":89,"2013":45,"2014":78,"2015":90,"2016":82,"2017":68,"2018":71,"2019":94,"2020":74,"2021":70,"2022":82,"2023":86,"2024":58,"2025":40,"2026":42},"year":2010,"title":"Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial"},"paper-preopanc-preoperative-chemoradiotherapy-jco-2020":{"doi":"10.1200/jco.19.02274","openalexId":"W3008190574","cited":1104,"byYear":{"2013":2,"2018":1,"2019":4,"2020":103,"2021":211,"2022":231,"2023":179,"2024":169,"2025":112,"2026":86},"year":2020,"title":"Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial"},"paper-polarix-polatuzumab-rchp-nejm-2022":{"doi":"10.1056/nejmoa2115304","openalexId":"W4200197309","cited":926,"byYear":{"2020":1,"2022":84,"2023":164,"2024":205,"2025":259,"2026":213},"year":2021,"title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma"},"paper-nia-science":{"doi":"10.1126/science.aaz0868","openalexId":"W3097206347","cited":883,"byYear":{"2012":1,"2020":6,"2021":80,"2022":145,"2023":143,"2024":165,"2025":189,"2026":154},"year":2020,"title":"Physical traits of cancer"},"paper-preopanc-neoadjuvant-chemoradiotherapy-long-term-jco-2022":{"doi":"10.1200/jco.21.02233","openalexId":"W4210426142","cited":759,"byYear":{"2022":80,"2023":174,"2024":197,"2025":176,"2026":132},"year":2022,"title":"Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial"},"paper-lee-prc2-mpnst-nat-genet-2014":{"doi":"10.1038/ng.3095","openalexId":"W2070604281","cited":653,"byYear":{"2012":1,"2013":1,"2014":1,"2015":20,"2016":49,"2017":50,"2018":49,"2019":45,"2020":87,"2021":68,"2022":57,"2023":64,"2024":76,"2025":46,"2026":34},"year":2014,"title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors"},"paper-portec-3-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30079-2","openalexId":"W2787725515","cited":643,"byYear":{"2018":29,"2019":87,"2020":79,"2021":76,"2022":99,"2023":77,"2024":73,"2025":65,"2026":53},"year":2018,"title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial"},"paper-wilt-pivot-prostatectomy-observation-nejm-2017":{"doi":"10.1056/nejmoa1615869","openalexId":"W2735211627","cited":626,"byYear":{"2012":1,"2016":1,"2017":31,"2018":89,"2019":84,"2020":88,"2021":90,"2022":52,"2023":66,"2024":56,"2025":37,"2026":30},"year":2017,"title":"Follow-up of Prostatectomy versus Observation for Early Prostate Cancer"},"paper-predimed-breast-jama-im-2015":{"doi":"10.1001/jamainternmed.2015.4838","openalexId":"W2155215362","cited":534,"byYear":{"2015":6,"2016":31,"2017":43,"2018":60,"2019":45,"2020":56,"2021":75,"2022":53,"2023":55,"2024":43,"2025":35,"2026":30},"year":2015,"title":"Mediterranean Diet and Invasive Breast Cancer Risk Among Women at High Cardiovascular Risk in the PREDIMED Trial"},"paper-tan-phyllodes-consensus-histopathology-2016":{"doi":"10.1111/his.12876","openalexId":"W2191690617","cited":513,"byYear":{"2012":1,"2014":1,"2015":1,"2016":20,"2017":44,"2018":30,"2019":44,"2020":55,"2021":73,"2022":54,"2023":51,"2024":42,"2025":58,"2026":38},"year":2015,"title":"Phyllodes tumours of the breast: a consensus review"},"paper-ghaffarizadeh-plos-comput-biol":{"doi":"10.1371/journal.pcbi.1005991","openalexId":"W2949797623","cited":506,"byYear":{"2012":1,"2017":1,"2018":16,"2019":38,"2020":43,"2021":60,"2022":84,"2023":69,"2024":75,"2025":62,"2026":57},"year":2018,"title":"PhysiCell: An open source physics-based cell simulator for 3-D multicellular systems"},"paper-aparicio-aggressive-variant-ccr-2013":{"doi":"10.1158/1078-0432.ccr-12-3791","openalexId":"W2106315111","cited":485,"byYear":{"2012":1,"2013":5,"2014":32,"2015":27,"2016":26,"2017":27,"2018":38,"2019":27,"2020":44,"2021":46,"2022":43,"2023":46,"2024":53,"2025":35,"2026":34},"year":2013,"title":"Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer"},"paper-foxtrot-preoperative-chemotherapy-colon-jco-2023":{"doi":"10.1200/jco.22.00046","openalexId":"W4317473373","cited":482,"byYear":{"2022":2,"2023":69,"2024":156,"2025":143,"2026":112},"year":2023,"title":"Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial"},"paper-chera-j-clin-oncol":{"doi":"10.1200/jco.19.02444","openalexId":"W3004553637","cited":417,"byYear":{"2019":4,"2020":38,"2021":47,"2022":77,"2023":65,"2024":58,"2025":82,"2026":46},"year":2020,"title":"Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer"},"paper-prasad-surrogate-endpoints-jama-im-2015":{"doi":"10.1001/jamainternmed.2015.2829","openalexId":"W1570249624","cited":407,"byYear":{"2013":1,"2015":7,"2016":24,"2017":32,"2018":38,"2019":41,"2020":28,"2021":38,"2022":39,"2023":43,"2024":50,"2025":33,"2026":32},"year":2015,"title":"The Strength of Association Between Surrogate End Points and Survival in Oncology"},"paper-van-den-heuvel-eibrink-nat-rev-urol":{"doi":"10.1038/nrurol.2017.163","openalexId":"W2765282913","cited":395,"byYear":{"2018":18,"2019":20,"2020":41,"2021":50,"2022":74,"2023":65,"2024":41,"2025":44,"2026":38},"year":2017,"title":"Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol"},"paper-roohani-nat-biotechnol":{"doi":"10.1038/s41587-023-01905-6","openalexId":"W4385955324","cited":358,"byYear":{"2023":10,"2024":92,"2025":125,"2026":131},"year":2023,"title":"Predicting transcriptional outcomes of novel multigene perturbations with GEARS"},"paper-gabai-kapara-population-brca-screening-pnas-2014":{"doi":"10.1073/pnas.1415979111","openalexId":"W2080103464","cited":350,"byYear":{"2014":6,"2015":17,"2016":37,"2017":39,"2018":32,"2019":47,"2020":49,"2021":17,"2022":34,"2023":20,"2024":31,"2025":11,"2026":10},"year":2014,"title":"Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2"},"paper-groarke-ponsegromab-cancer-cachexia-nejm-2024":{"doi":"10.1056/nejmoa2409515","openalexId":"W4402540592","cited":309,"byYear":{"2024":16,"2025":146,"2026":147},"year":2024,"title":"Ponsegromab for the Treatment of Cancer Cachexia"},"paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017":{"doi":"10.1158/1078-0432.ccr-16-0806","openalexId":"W2566484518","cited":280,"byYear":{"2014":1,"2017":15,"2018":36,"2019":35,"2020":48,"2021":30,"2022":34,"2023":24,"2024":22,"2025":19,"2026":15},"year":2016,"title":"Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker"},"paper-powell-esmo-open":{"doi":"10.1016/j.esmoop.2022.100554","openalexId":"W4291396228","cited":262,"byYear":{"2022":11,"2023":55,"2024":57,"2025":65,"2026":74},"year":2022,"title":"Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies"},"paper-burden-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd008879.pub2","openalexId":"W4365787129","cited":260,"byYear":{"2013":8,"2014":11,"2015":21,"2016":19,"2017":15,"2018":21,"2019":29,"2020":20,"2021":33,"2022":24,"2023":25,"2024":16,"2025":10,"2026":4},"year":2012,"title":"Pre-operative Nutrition Support in Patients Undergoing Gastrointestinal Surgery."},"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022":{"doi":"10.1200/jco.21.01604","openalexId":"W4285386328","cited":243,"byYear":{"2022":9,"2023":50,"2024":62,"2025":67,"2026":55},"year":2022,"title":"Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer"},"paper-linder-nat-genet":{"doi":"10.1038/s41588-024-02053-6","openalexId":"W4406178430","cited":217,"byYear":{"2024":5,"2025":92,"2026":120},"year":2025,"title":"Predicting RNA-seq coverage from DNA sequence as a unifying model of gene regulation"},"paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019":{"doi":"10.1200/jco.19.00946","openalexId":"W2953173394","cited":211,"byYear":{"2019":8,"2020":28,"2021":40,"2022":35,"2023":33,"2024":26,"2025":27,"2026":14},"year":2019,"title":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update"},"paper-roa-gallbladder-preneoplastic-lesions-jso-2006":{"doi":"10.1002/jso.20527","openalexId":"W2111902674","cited":199,"byYear":{"2012":8,"2013":8,"2014":13,"2015":12,"2016":15,"2017":8,"2018":8,"2019":12,"2020":6,"2021":17,"2022":11,"2023":8,"2024":2,"2025":9,"2026":9},"year":2006,"title":"Preneoplastic lesions in gallbladder cancer"},"paper-burd-nat-med":{"doi":"10.1038/s41591-020-1089-8","openalexId":"W3094566369","cited":197,"byYear":{"2019":1,"2020":1,"2021":30,"2022":40,"2023":40,"2024":27,"2025":42,"2026":15},"year":2020,"title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial"},"paper-sheikh-ann-intern-med":{"doi":"10.7326/m21-0252","openalexId":"W3185826980","cited":129,"byYear":{"2021":4,"2022":30,"2023":25,"2024":29,"2025":26,"2026":15},"year":2021,"title":"Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality"},"paper-makohon-moore-precursor-cells-ductal-system-nature-2018":{"doi":"10.1038/s41586-018-0481-8","openalexId":"W2888908131","cited":127,"byYear":{"2018":3,"2019":20,"2020":22,"2021":15,"2022":13,"2023":18,"2024":15,"2025":8,"2026":11},"year":2018,"title":"Precancerous neoplastic cells can move through the pancreatic ductal system"},"paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019":{"doi":"10.1007/s00464-018-6444-1","openalexId":"W2890665624","cited":91,"byYear":{"2019":6,"2020":9,"2021":18,"2022":14,"2023":7,"2024":13,"2025":18,"2026":4},"year":2018,"title":"Polyp size of 1 cm is insufficient to discriminate neoplastic and non-neoplastic gallbladder polyps"},"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023":{"doi":"10.1056/evidoa2200339","openalexId":"W4377694353","cited":80,"byYear":{"2023":10,"2024":16,"2025":35,"2026":19},"year":2023,"title":"Avapritinib versus Placebo in Indolent Systemic Mastocytosis"},"paper-abou-alfa-phocus-pexa-vec-liver-cancer-2024":{"doi":"10.1159/000533650","openalexId":"W4390015099","cited":53,"byYear":{"2024":6,"2025":27,"2026":20},"year":2023,"title":"PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma"},"paper-pod1um-303-retifanlimab-anal-cancer-rao-lancet-2025":{"doi":"10.1016/s0140-6736(25)00631-2","openalexId":"W4411228025","cited":42,"byYear":{"2025":11,"2026":31},"year":2025,"title":"Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial"},"paper-nct05101096-int-j-clin-oncol-2024":{"doi":"10.1007/s10147-024-02589-x","openalexId":"W4402692718","cited":16,"byYear":{"2024":1,"2025":5,"2026":10},"year":2024,"title":"Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors"},"paper-roa-dysplasia-to-carcinoma-interval-gastroenterology-1996":{"doi":"10.1053/gast.1996.v111.pm8698204","openalexId":"W2035733003","cited":136,"byYear":{"2012":9,"2013":8,"2014":4,"2015":8,"2016":7,"2017":5,"2018":3,"2019":1,"2020":7,"2021":6,"2022":4,"2023":8,"2024":2,"2025":5,"2026":2},"year":1996,"title":"Preneoplastic lesions and gallbladder cancer: An estimate of the period required for progression"},"paper-hesseling-pediatr-blood-cancer":{"doi":"10.1002/pbc.24407","openalexId":"W2146788190","cited":70,"byYear":{"2013":8,"2014":4,"2015":11,"2016":6,"2017":7,"2018":1,"2019":8,"2020":9,"2021":2,"2022":1,"2023":2,"2024":6,"2025":2,"2026":1},"year":2012,"title":"Practical recommendations for the management of children with Endemic Burkitt Lymphoma (BL) in a resource limited setting"},"paper-luca-gianni-j-natl-cancer-inst-2022":{"doi":"10.1093/jnci/djac126","openalexId":"W4283817644","cited":31,"byYear":{"2022":2,"2023":8,"2024":5,"2025":13,"2026":3},"year":2022,"title":"Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab"},"paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025":{"doi":"10.1016/j.modpat.2025.100824","openalexId":"W4411399519","cited":7,"byYear":{"2025":2,"2026":5},"year":2025,"title":"Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance"},"paper-ahmed-promis-multiparametric-mri-lancet-2017":{"doi":"10.1016/s0140-6736(16)32401-1","openalexId":"W2577453388","cited":3325,"byYear":{"2013":1,"2015":3,"2017":173,"2018":322,"2019":334,"2020":394,"2021":413,"2022":363,"2023":353,"2024":386,"2025":327,"2026":243},"year":2017,"title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study"},"paper-prado-lancet-oncol":{"doi":"10.1016/s1470-2045(08)70153-0","openalexId":"W2127424726","cited":3290,"byYear":{"2012":55,"2013":58,"2014":104,"2015":142,"2016":146,"2017":160,"2018":239,"2019":252,"2020":332,"2021":353,"2022":306,"2023":284,"2024":297,"2025":256,"2026":223},"year":2008,"title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study"},"paper-beer-prevail-enzalutamide-nejm-2014":{"doi":"10.1056/nejmoa1405095","openalexId":"W2166918329","cited":3078,"byYear":{"2013":3,"2014":71,"2015":245,"2016":294,"2017":285,"2018":274,"2019":290,"2020":321,"2021":300,"2022":259,"2023":227,"2024":231,"2025":163,"2026":102},"year":2014,"title":"Enzalutamide in Metastatic Prostate Cancer before Chemotherapy"},"paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018":{"doi":"10.1056/nejmoa1809775","openalexId":"W2903623792","cited":2934,"byYear":{"2013":2,"2018":1,"2019":204,"2020":389,"2021":531,"2022":459,"2023":477,"2024":357,"2025":321,"2026":189},"year":2018,"title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer"},"paper-promid-rinke-jco-2009":{"doi":"10.1200/jco.2009.22.8510","openalexId":"W2137142564","cited":2526,"byYear":{"2012":156,"2013":147,"2014":157,"2015":164,"2016":178,"2017":175,"2018":155,"2019":161,"2020":169,"2021":175,"2022":149,"2023":144,"2024":124,"2025":104,"2026":74},"year":2009,"title":"Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group"},"paper-profound-nejm-2020":{"doi":"10.1056/nejmoa1911440","openalexId":"W3020771563","cited":2329,"byYear":{"2014":1,"2020":128,"2021":399,"2022":420,"2023":401,"2024":399,"2025":343,"2026":233},"year":2020,"title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer"},"paper-prima-niraparib-nejm-2019":{"doi":"10.1056/nejmoa1910962","openalexId":"W2975141952","cited":2324,"byYear":{"2013":1,"2019":13,"2020":254,"2021":344,"2022":395,"2023":420,"2024":386,"2025":303,"2026":204},"year":2019,"title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer"},"paper-heng-j-clin-oncol":{"doi":"10.1200/jco.2008.21.4809","openalexId":"W2099752220","cited":2165,"byYear":{"2012":72,"2013":119,"2014":107,"2015":131,"2016":144,"2017":148,"2018":154,"2019":155,"2020":189,"2021":186,"2022":180,"2023":154,"2024":134,"2025":98,"2026":78},"year":2009,"title":"Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study"},"paper-propsma-hofman-lancet-2020":{"doi":"10.1016/s0140-6736(20)30314-7","openalexId":"W3012827461","cited":2059,"byYear":{"2012":1,"2013":1,"2019":1,"2020":128,"2021":303,"2022":342,"2023":333,"2024":330,"2025":362,"2026":253},"year":2020,"title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study"},"paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999":{"doi":"10.1056/nejm199908123410703","openalexId":"W2339444986","cited":1727,"byYear":{"2012":78,"2013":72,"2014":58,"2015":67,"2016":74,"2017":81,"2018":85,"2019":67,"2020":82,"2021":95,"2022":71,"2023":67,"2024":50,"2025":54,"2026":44},"year":1999,"title":"Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission"},"paper-islami-ca-cancer-j-clin":{"doi":"10.3322/caac.21440","openalexId":"W2768132193","cited":1654,"byYear":{"2017":1,"2018":61,"2019":113,"2020":183,"2021":237,"2022":229,"2023":343,"2024":244,"2025":184,"2026":50},"year":2017,"title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States"},"paper-brca-risk-reducing-surgery-jama-2010":{"doi":"10.1001/jama.2010.1237","openalexId":"W2117576401","cited":1507,"byYear":{"2012":80,"2013":81,"2014":103,"2015":91,"2016":116,"2017":126,"2018":102,"2019":120,"2020":111,"2021":95,"2022":63,"2023":98,"2024":92,"2025":68,"2026":62},"year":2010,"title":"Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality"},"paper-kras-colorectal-j-clin-oncol-2010":{"doi":"10.1200/jco.2009.23.3452","openalexId":"W2144026118","cited":1168,"byYear":{"2012":96,"2013":97,"2014":96,"2015":92,"2016":81,"2017":83,"2018":60,"2019":79,"2020":90,"2021":58,"2022":45,"2023":51,"2024":52,"2025":29,"2026":16},"year":2009,"title":"Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial"},"paper-slotman-n-engl-j-med":{"doi":"10.1056/nejmoa071780","openalexId":"W2138683149","cited":1141,"byYear":{"2012":68,"2013":60,"2014":58,"2015":62,"2016":63,"2017":81,"2018":68,"2019":64,"2020":62,"2021":79,"2022":55,"2023":65,"2024":42,"2025":64,"2026":31},"year":2007,"title":"Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer"},"paper-prosper-nejm-2018":{"doi":"10.1056/nejmoa1800536","openalexId":"W2810806599","cited":1061,"byYear":{"2014":1,"2017":2,"2018":42,"2019":159,"2020":191,"2021":200,"2022":118,"2023":120,"2024":98,"2025":79,"2026":47},"year":2018,"title":"Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer"},"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017":{"doi":"10.1093/annonc/mdx175","openalexId":"W2605964154","cited":849,"byYear":{"2017":31,"2018":85,"2019":121,"2020":130,"2021":119,"2022":104,"2023":88,"2024":74,"2025":51,"2026":45},"year":2017,"title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials"},"paper-impassion131-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.05.801","openalexId":"W3175173749","cited":756,"byYear":{"2020":5,"2021":62,"2022":183,"2023":163,"2024":143,"2025":110,"2026":90},"year":2021,"title":"Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer"},"paper-kanda-panin-1-somatic-mutations-gastroenterology-2012":{"doi":"10.1053/j.gastro.2011.12.042","openalexId":"W2081681778","cited":740,"byYear":{"2012":25,"2013":40,"2014":39,"2015":42,"2016":50,"2017":67,"2018":61,"2019":41,"2020":49,"2021":77,"2022":50,"2023":57,"2024":48,"2025":53,"2026":40},"year":2012,"title":"Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia"},"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017":{"doi":"10.1001/jamaoncol.2016.3797","openalexId":"W2531319683","cited":729,"byYear":{"2016":3,"2017":95,"2018":103,"2019":97,"2020":86,"2021":92,"2022":70,"2023":51,"2024":80,"2025":35,"2026":16},"year":2016,"title":"Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer"},"paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2018.5801","openalexId":"W2908503672","cited":685,"byYear":{"2017":1,"2018":4,"2019":52,"2020":101,"2021":104,"2022":103,"2023":100,"2024":100,"2025":70,"2026":49},"year":2018,"title":"Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade"},"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017":{"doi":"10.1158/2159-8290.cd-16-1337","openalexId":"W2603411876","cited":672,"byYear":{"2014":1,"2017":12,"2018":56,"2019":67,"2020":85,"2021":108,"2022":98,"2023":107,"2024":69,"2025":40,"2026":26},"year":2017,"title":"Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies"},"paper-bonvalot-retroperitoneal-sarcoma-compartmental-jco-2009":{"doi":"10.1200/jco.2008.18.0802","openalexId":"W2098225751","cited":651,"byYear":{"2012":25,"2013":23,"2014":28,"2015":33,"2016":38,"2017":39,"2018":56,"2019":39,"2020":52,"2021":46,"2022":57,"2023":50,"2024":38,"2025":43,"2026":21},"year":2008,"title":"Primary Retroperitoneal Sarcomas: A Multivariate Analysis of Surgical Factors Associated With Local Control"},"paper-epstein-neuroendocrine-prostate-morphologic-classification-ajsp-2014":{"doi":"10.1097/pas.0000000000000208","openalexId":"W2039511031","cited":592,"byYear":{"2012":1,"2014":14,"2015":25,"2016":46,"2017":41,"2018":57,"2019":36,"2020":54,"2021":64,"2022":81,"2023":66,"2024":48,"2025":38,"2026":18},"year":2014,"title":"Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation"},"paper-takahashi-lancet-oncol":{"doi":"10.1016/s1470-2045(17)30230-9","openalexId":"W2598659203","cited":554,"byYear":{"2017":33,"2018":59,"2019":53,"2020":61,"2021":73,"2022":67,"2023":66,"2024":46,"2025":54,"2026":39},"year":2017,"title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial"},"paper-win-cancer-epidemiol-biomarkers-prev":{"doi":"10.1158/1055-9965.epi-16-0693","openalexId":"W2545241042","cited":544,"byYear":{"2013":1,"2017":10,"2018":31,"2019":36,"2020":51,"2021":68,"2022":70,"2023":87,"2024":65,"2025":79,"2026":45},"year":2016,"title":"Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer"},"paper-chari-pancreatic-cancer-following-diabetes-gastroenterology-2005":{"doi":"10.1016/j.gastro.2005.05.007","openalexId":"W4229835970","cited":541,"byYear":{"2012":17,"2013":24,"2014":27,"2015":25,"2016":22,"2017":29,"2018":33,"2019":30,"2020":36,"2021":37,"2022":38,"2023":33,"2024":33,"2025":32,"2026":25},"year":2005,"title":"Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study"},"paper-prospect-nejm-2023":{"doi":"10.1056/nejmoa2303269","openalexId":"W4379284138","cited":493,"byYear":{"2023":67,"2024":154,"2025":151,"2026":120},"year":2023,"title":"Preoperative Treatment of Locally Advanced Rectal Cancer"},"paper-nagata-int-j-radiat-oncol-biol-phys":{"doi":"10.1016/j.ijrobp.2015.07.2278","openalexId":"W2101859975","cited":454,"byYear":{"2012":3,"2014":8,"2015":6,"2016":31,"2017":60,"2018":58,"2019":40,"2020":55,"2021":40,"2022":35,"2023":41,"2024":31,"2025":29,"2026":15},"year":2015,"title":"Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403"},"paper-karschnia-neuro-oncol":{"doi":"10.1093/neuonc/noac193","openalexId":"W4290930135","cited":387,"byYear":{"2022":3,"2023":42,"2024":121,"2025":118,"2026":102},"year":2022,"title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group"},"paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019":{"doi":"10.1001/jamaoncol.2018.6760","openalexId":"W2912387879","cited":373,"byYear":{"2017":1,"2019":21,"2020":35,"2021":65,"2022":73,"2023":60,"2024":54,"2025":39,"2026":25},"year":2019,"title":"Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines"},"paper-prophecy-arv7-validation-jco-2019":{"doi":"10.1200/jco.18.01731","openalexId":"W2921497169","cited":371,"byYear":{"2017":1,"2019":47,"2020":69,"2021":58,"2022":63,"2023":39,"2024":37,"2025":35,"2026":21},"year":2019,"title":"Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study"},"paper-barroso-sousa-breast-tmb-prevalence-ann-oncol-2020":{"doi":"10.1016/j.annonc.2019.11.010","openalexId":"W3000078203","cited":363,"byYear":{"2020":37,"2021":50,"2022":77,"2023":70,"2024":58,"2025":48,"2026":22},"year":2020,"title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer"},"paper-church-pole-endometrial-jnci-2015":{"doi":"10.1093/jnci/dju402","openalexId":"W2110037976","cited":344,"byYear":{"2014":1,"2015":19,"2016":34,"2017":29,"2018":25,"2019":32,"2020":25,"2021":31,"2022":42,"2023":33,"2024":36,"2025":20,"2026":16},"year":2014,"title":"Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer"},"paper-alyami-lancet-oncol":{"doi":"10.1016/s1470-2045(19)30318-3","openalexId":"W2954661925","cited":336,"byYear":{"2019":5,"2020":49,"2021":76,"2022":50,"2023":40,"2024":42,"2025":43,"2026":29},"year":2019,"title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications"},"paper-park-tils-untreated-early-tnbc-ann-oncol-2019":{"doi":"10.1093/annonc/mdz395","openalexId":"W2979547848","cited":273,"byYear":{"2019":3,"2020":35,"2021":33,"2022":45,"2023":42,"2024":77,"2025":22,"2026":16},"year":2019,"title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy"},"paper-yang-j-oncol-pract":{"doi":"10.1200/jop.2013.001319","openalexId":"W2151887932","cited":254,"byYear":{"2013":1,"2014":9,"2015":23,"2016":15,"2017":20,"2018":23,"2019":17,"2020":21,"2021":25,"2022":24,"2023":23,"2024":20,"2025":20,"2026":13},"year":2014,"title":"Projected Supply of and Demand for Oncologists and Radiation Oncologists Through 2025: An Aging, Better-Insured Population Will Result in Shortage"},"paper-schmid-placental-site-trophoblastic-tumour-outcomes-lancet-2009":{"doi":"10.1016/s0140-6736(09)60618-8","openalexId":"W2136501226","cited":249,"byYear":{"2012":12,"2013":11,"2014":14,"2015":16,"2016":21,"2017":13,"2018":13,"2019":20,"2020":17,"2021":22,"2022":14,"2023":12,"2024":15,"2025":15,"2026":9},"year":2009,"title":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study"},"paper-barth-phyllodes-adjuvant-radiotherapy-ann-surg-oncol-2009":{"doi":"10.1245/s10434-009-0489-2","openalexId":"W2108075673","cited":239,"byYear":{"2012":4,"2013":12,"2014":10,"2015":17,"2016":21,"2017":17,"2018":18,"2019":18,"2020":19,"2021":18,"2022":11,"2023":14,"2024":22,"2025":22,"2026":8},"year":2009,"title":"A Prospective, Multi-Institutional Study of Adjuvant Radiotherapy After Resection of Malignant Phyllodes Tumors"},"paper-vokinger-lancet-oncol":{"doi":"10.1016/s1470-2045(20)30139-x","openalexId":"W3021316203","cited":238,"byYear":{"2015":1,"2016":1,"2017":1,"2018":1,"2019":1,"2020":19,"2021":31,"2022":52,"2023":47,"2024":29,"2025":29,"2026":25},"year":2020,"title":"Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis"},"paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018":{"doi":"10.1093/jnci/djy024","openalexId":"W2792327545","cited":226,"byYear":{"2018":8,"2019":22,"2020":34,"2021":38,"2022":50,"2023":28,"2024":22,"2025":18,"2026":6},"year":2018,"title":"Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms"},"paper-autio-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-19-1457","openalexId":"W2979540828","cited":186,"byYear":{"2019":2,"2020":15,"2021":35,"2022":28,"2023":27,"2024":30,"2025":29,"2026":20},"year":2019,"title":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology"},"paper-marinac-jama-oncol":{"doi":"10.1001/jamaoncol.2016.0164","openalexId":"W2325958252","cited":185,"byYear":{"2016":2,"2017":5,"2018":11,"2019":13,"2020":13,"2021":19,"2022":32,"2023":33,"2024":25,"2025":17,"2026":13},"year":2016,"title":"Prolonged Nightly Fasting and Breast Cancer Prognosis"},"paper-szmulewitz-j-clin-oncol":{"doi":"10.1200/jco.2017.76.4381","openalexId":"W2795001216","cited":182,"byYear":{"2017":1,"2018":15,"2019":25,"2020":31,"2021":24,"2022":23,"2023":22,"2024":14,"2025":21,"2026":5},"year":2018,"title":"Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer"},"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019":{"doi":"10.1200/po.18.00283","openalexId":"W2944320012","cited":165,"byYear":{"2017":1,"2019":4,"2020":27,"2021":27,"2022":26,"2023":28,"2024":24,"2025":21,"2026":7},"year":2019,"title":"Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors"},"paper-wei-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd008831.pub3","openalexId":"W2888923564","cited":109,"byYear":{"2018":4,"2019":8,"2020":23,"2021":15,"2022":10,"2023":12,"2024":19,"2025":16,"2026":2},"year":2018,"title":"Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer"},"paper-cavallone-tnbc-ctdna-neoadjuvant-sci-rep-2020":{"doi":"10.1038/s41598-020-71236-y","openalexId":"W3083427612","cited":97,"byYear":{"2021":13,"2022":13,"2023":15,"2024":19,"2025":26,"2026":11},"year":2020,"title":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer"},"paper-nct05663866-j-thorac-oncol-2025":{"doi":"10.1016/j.jtho.2025.01.018","openalexId":"W4406787921","cited":38,"byYear":{"2025":17,"2026":21},"year":2025,"title":"Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Report"},"paper-checkmate-915-j-immunother-cancer-2025":{"doi":"10.1136/jitc-2025-012034","openalexId":"W4412199902","cited":13,"byYear":{"2025":1,"2026":12},"year":2025,"title":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915"},"paper-albrecht-pdl1-western-gallbladder-cancers-2021":{"doi":"10.3390/cancers13071682","openalexId":"W3142881787","cited":34,"byYear":{"2021":2,"2022":14,"2023":4,"2024":5,"2025":7,"2026":2},"year":2021,"title":"Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer"},"paper-kang-t2-gallbladder-cancer-location-meta-analysis-jcm-2021":{"doi":"10.3390/jcm10153317","openalexId":"W3186912494","cited":12,"byYear":{"2022":1,"2023":1,"2024":5,"2025":4,"2026":1},"year":2021,"title":"Prognostic Significance of Tumor Location in T2 Gallbladder Cancer: A Systematic Review and Meta-Analysis"},"paper-quail-joyce-microenvironment-metastasis-natmed-2013":{"doi":"10.1038/nm.3394","openalexId":"W2033278321","cited":8318,"byYear":{"2012":2,"2013":4,"2014":110,"2015":287,"2016":375,"2017":472,"2018":560,"2019":630,"2020":794,"2021":976,"2022":1084,"2023":923,"2024":942,"2025":709,"2026":445},"year":2013,"title":"Microenvironmental regulation of tumor progression and metastasis"},"paper-rahib-projecting-cancer-deaths-2030-cancerres-2014":{"doi":"10.1158/0008-5472.can-14-0155","openalexId":"W1968812902","cited":7382,"byYear":{"2013":2,"2014":39,"2015":186,"2016":340,"2017":422,"2018":569,"2019":724,"2020":931,"2021":965,"2022":866,"2023":841,"2024":691,"2025":513,"2026":281},"year":2014,"title":"Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States"},"paper-bonner-cetuximab-radiotherapy-nejm-2006":{"doi":"10.1056/nejmoa053422","openalexId":"W2155384808","cited":5136,"byYear":{"2012":341,"2013":310,"2014":297,"2015":256,"2016":320,"2017":267,"2018":222,"2019":228,"2020":232,"2021":212,"2022":196,"2023":164,"2024":144,"2025":140,"2026":72},"year":2006,"title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck"},"paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006":{"doi":"10.1001/jama.295.21.2492","openalexId":"W2161426850","cited":3865,"byYear":{"2012":249,"2013":275,"2014":287,"2015":241,"2016":237,"2017":228,"2018":186,"2019":197,"2020":225,"2021":208,"2022":177,"2023":157,"2024":111,"2025":98,"2026":60},"year":2006,"title":"Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study"},"paper-bekes-nat-rev-drug-discov":{"doi":"10.1038/s41573-021-00371-6","openalexId":"W4205379795","cited":3309,"byYear":{"2014":1,"2022":264,"2023":580,"2024":817,"2025":942,"2026":705},"year":2022,"title":"PROTAC targeted protein degraders: the past is prologue"},"paper-radiant-3-everolimus-pnet-yao-nejm-2011":{"doi":"10.1056/nejmoa1009290","openalexId":"W2115686439","cited":2883,"byYear":{"2012":250,"2013":270,"2014":251,"2015":255,"2016":220,"2017":226,"2018":196,"2019":156,"2020":181,"2021":162,"2022":168,"2023":129,"2024":115,"2025":116,"2026":64},"year":2011,"title":"Everolimus for Advanced Pancreatic Neuroendocrine Tumors"},"paper-hardcastle-nottingham-faecal-occult-blood-lancet-1996":{"doi":"10.1016/s0140-6736(96)03386-7","openalexId":"W2118835794","cited":2814,"byYear":{"2012":133,"2013":138,"2014":97,"2015":123,"2016":91,"2017":86,"2018":70,"2019":61,"2020":60,"2021":58,"2022":40,"2023":46,"2024":45,"2025":23,"2026":17},"year":1996,"title":"Randomised controlled trial of faecal-occult-blood screening for colorectal cancer"},"paper-protect-nejm-2016":{"doi":"10.1056/nejmoa1606220","openalexId":"W2523396458","cited":2675,"byYear":{"2012":1,"2015":1,"2016":41,"2017":302,"2018":310,"2019":387,"2020":361,"2021":359,"2022":300,"2023":236,"2024":173,"2025":127,"2026":72},"year":2016,"title":"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer"},"paper-kronborg-funen-faecal-occult-blood-lancet-1996":{"doi":"10.1016/s0140-6736(96)03430-7","openalexId":"W2145602937","cited":2512,"byYear":{"2012":121,"2013":121,"2014":90,"2015":104,"2016":79,"2017":80,"2018":60,"2019":55,"2020":58,"2021":39,"2022":32,"2023":26,"2024":24,"2025":21,"2026":19},"year":1996,"title":"Randomised study of screening for colorectal cancer with faecal-occult-blood test"},"paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014":{"doi":"10.1016/s1470-2045(14)70420-6","openalexId":"W2111237964","cited":2508,"byYear":{"2012":1,"2014":18,"2015":125,"2016":201,"2017":227,"2018":248,"2019":205,"2020":266,"2021":248,"2022":219,"2023":226,"2024":253,"2025":170,"2026":96},"year":2014,"title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial"},"paper-stamey-psa-serum-marker-nejm-1987":{"doi":"10.1056/nejm198710083171501","openalexId":"W2330292521","cited":2498,"byYear":{"2012":98,"2013":72,"2014":76,"2015":49,"2016":48,"2017":56,"2018":51,"2019":43,"2020":61,"2021":46,"2022":43,"2023":52,"2024":50,"2025":47,"2026":20},"year":1987,"title":"Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate"},"paper-verwaal-cytoreduction-hipec-peritoneal-colorectal-jco-2003":{"doi":"10.1200/jco.2003.04.187","openalexId":"W2004554342","cited":2051,"byYear":{"2012":92,"2013":105,"2014":91,"2015":89,"2016":125,"2017":106,"2018":114,"2019":147,"2020":129,"2021":127,"2022":108,"2023":99,"2024":99,"2025":74,"2026":59},"year":2003,"title":"Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer"},"paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010":{"doi":"10.1056/nejmoa0907667","openalexId":"W2151255896","cited":2028,"byYear":{"2012":120,"2013":120,"2014":148,"2015":121,"2016":116,"2017":136,"2018":133,"2019":140,"2020":151,"2021":173,"2022":128,"2023":123,"2024":114,"2025":110,"2026":75},"year":2010,"title":"Quality Indicators for Colonoscopy and the Risk of Interval Cancer"},"paper-kastenhuber-cell":{"doi":"10.1016/j.cell.2017.08.028","openalexId":"W2752942423","cited":1982,"byYear":{"2016":1,"2017":15,"2018":122,"2019":180,"2020":260,"2021":262,"2022":266,"2023":280,"2024":232,"2025":227,"2026":135},"year":2017,"title":"Putting p53 in Context"},"paper-baca-punctuated-evolution-chromoplexy-cell-2013":{"doi":"10.1016/j.cell.2013.03.021","openalexId":"W2011957420","cited":1377,"byYear":{"2012":1,"2013":36,"2014":114,"2015":129,"2016":101,"2017":121,"2018":118,"2019":123,"2020":123,"2021":128,"2022":88,"2023":103,"2024":82,"2025":75,"2026":30},"year":2013,"title":"Punctuated Evolution of Prostate Cancer Genomes"},"paper-radiant-4-everolimus-lancet-2016":{"doi":"10.1016/s0140-6736(15)00817-x","openalexId":"W2209368665","cited":1296,"byYear":{"2012":1,"2014":2,"2015":2,"2016":80,"2017":139,"2018":134,"2019":107,"2020":140,"2021":138,"2022":139,"2023":115,"2024":113,"2025":113,"2026":66},"year":2015,"title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study"},"paper-parker-lancet":{"doi":"10.1016/s0140-6736(18)32486-3","openalexId":"W2897236707","cited":1289,"byYear":{"2017":1,"2018":13,"2019":146,"2020":223,"2021":195,"2022":190,"2023":151,"2024":157,"2025":136,"2026":72},"year":2018,"title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial"},"paper-bentzen-int-j-radiat-oncol-biol-phys":{"doi":"10.1016/j.ijrobp.2009.09.040","openalexId":"W2029328961","cited":1271,"byYear":{"2012":43,"2013":66,"2014":63,"2015":55,"2016":65,"2017":58,"2018":71,"2019":106,"2020":103,"2021":112,"2022":105,"2023":95,"2024":111,"2025":89,"2026":87},"year":2010,"title":"Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues"},"paper-protect-15-year-nejm-2023":{"doi":"10.1056/nejmoa2214122","openalexId":"W4323928271","cited":820,"byYear":{"2023":107,"2024":273,"2025":248,"2026":192},"year":2023,"title":"Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer"},"paper-psogi-pseudomyxoma-appendiceal-classification-am-j-surg-pathol-2016":{"doi":"10.1097/pas.0000000000000535","openalexId":"W1789059098","cited":810,"byYear":{"2013":1,"2014":1,"2015":1,"2016":20,"2017":41,"2018":47,"2019":69,"2020":84,"2021":99,"2022":80,"2023":93,"2024":116,"2025":85,"2026":70},"year":2015,"title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia"},"paper-quartz-lancet-2016":{"doi":"10.1016/s0140-6736(16)30825-x","openalexId":"W2510132475","cited":732,"byYear":{"2015":1,"2016":8,"2017":70,"2018":81,"2019":83,"2020":104,"2021":88,"2022":76,"2023":81,"2024":65,"2025":47,"2026":25},"year":2016,"title":"Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial"},"paper-rtog-9601-n-engl-j-med-2017":{"doi":"10.1056/nejmoa1607529","openalexId":"W2585109238","cited":678,"byYear":{"2017":68,"2018":78,"2019":86,"2020":82,"2021":85,"2022":63,"2023":59,"2024":67,"2025":56,"2026":32},"year":2017,"title":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer"},"paper-nct02411448-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(19)30634-5","openalexId":"W2978677918","cited":620,"byYear":{"2016":1,"2019":2,"2020":83,"2021":130,"2022":124,"2023":98,"2024":81,"2025":65,"2026":34},"year":2019,"title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-mascia-jama-oncol":{"doi":"10.1001/jamaoncol.2022.5843","openalexId":"W4307116049","cited":584,"byYear":{"2022":1,"2023":310,"2024":77,"2025":116,"2026":80},"year":2022,"title":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases"},"paper-iozzo-j-cell-mol-med":{"doi":"10.1111/j.1582-4934.2010.01236.x","openalexId":"W2055475863","cited":580,"byYear":{"2012":25,"2013":45,"2014":44,"2015":36,"2016":41,"2017":29,"2018":39,"2019":38,"2020":56,"2021":45,"2022":55,"2023":35,"2024":29,"2025":30,"2026":23},"year":2010,"title":"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis"},"paper-welch-albertsen-psa-era-diagnosis-treatment-jnci-2009":{"doi":"10.1093/jnci/djp278","openalexId":"W2150679001","cited":576,"byYear":{"2012":56,"2013":62,"2014":49,"2015":43,"2016":45,"2017":32,"2018":41,"2019":26,"2020":24,"2021":20,"2022":23,"2023":18,"2024":9,"2025":17,"2026":10},"year":2009,"title":"Prostate Cancer Diagnosis and Treatment After the Introduction of Prostate-Specific Antigen Screening: 1986-2005"},"paper-omuro-neuro-oncol":{"doi":"10.1093/neuonc/noac099","openalexId":"W4223897107","cited":525,"byYear":{"2022":20,"2023":100,"2024":156,"2025":143,"2026":103},"year":2022,"title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial"},"paper-halo-301-pegvorhyaluronidase-jco-2020":{"doi":"10.1200/jco.20.00590","openalexId":"W3044807317","cited":484,"byYear":{"2020":18,"2021":83,"2022":87,"2023":70,"2024":70,"2025":69,"2026":86},"year":2020,"title":"Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma"},"paper-anthony-nichols-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(19)30410-3","openalexId":"W2967453129","cited":478,"byYear":{"2019":6,"2020":76,"2021":88,"2022":89,"2023":75,"2024":57,"2025":53,"2026":33},"year":2019,"title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial"},"paper-quazar-aml-001-wei-nejm-2020":{"doi":"10.1056/nejmoa2004444","openalexId":"W3114952208","cited":445,"byYear":{"2014":1,"2021":83,"2022":97,"2023":91,"2024":68,"2025":59,"2026":44},"year":2020,"title":"Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission"},"paper-radicals-rt-lancet-2020":{"doi":"10.1016/s0140-6736(20)31553-1","openalexId":"W3088359655","cited":421,"byYear":{"2020":13,"2021":70,"2022":84,"2023":68,"2024":78,"2025":68,"2026":40},"year":2020,"title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial"},"paper-quantum-first-quizartinib-lancet-2023":{"doi":"10.1016/s0140-6736(23)00464-6","openalexId":"W4366977509","cited":419,"byYear":{"2023":38,"2024":139,"2025":127,"2026":115},"year":2023,"title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-goteborg-2-n-engl-j-med-2022":{"doi":"10.1056/nejmoa2209454","openalexId":"W4311843617","cited":386,"byYear":{"2021":1,"2022":2,"2023":90,"2024":118,"2025":95,"2026":79},"year":2022,"title":"Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only"},"paper-ross-bmj":{"doi":"10.1136/bmj.d7292","openalexId":"W2050560655","cited":380,"byYear":{"2012":21,"2013":38,"2014":43,"2015":40,"2016":28,"2017":29,"2018":32,"2019":29,"2020":33,"2021":20,"2022":24,"2023":12,"2024":15,"2025":9,"2026":7},"year":2012,"title":"Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis"},"paper-murthy-j-clin-oncol":{"doi":"10.1200/jco.20.03282","openalexId":"W3125743225","cited":346,"byYear":{"2021":41,"2022":64,"2023":73,"2024":64,"2025":62,"2026":42},"year":2021,"title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial"},"paper-pembrolizumab-glioblastoma-clin-cancer-res-2021":{"doi":"10.1158/1078-0432.ccr-20-2500","openalexId":"W3099035428","cited":270,"byYear":{"2021":22,"2022":41,"2023":63,"2024":65,"2025":44,"2026":35},"year":2020,"title":"Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma"},"paper-grever-j-clin-oncol":{"doi":"10.1200/jco.1995.13.4.974","openalexId":"W1910475489","cited":269,"byYear":{"2012":9,"2013":5,"2014":11,"2015":14,"2016":5,"2017":11,"2018":7,"2019":8,"2020":12,"2021":9,"2022":14,"2023":6,"2024":3,"2025":2,"2026":1},"year":1995,"title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study."},"paper-ferraldeschi-pten-protein-loss-abiraterone-eur-urol-2015":{"doi":"10.1016/j.eururo.2014.10.027","openalexId":"W2000060994","cited":265,"byYear":{"2012":1,"2014":1,"2015":15,"2016":22,"2017":36,"2018":23,"2019":18,"2020":25,"2021":35,"2022":15,"2023":19,"2024":21,"2025":23,"2026":11},"year":2014,"title":"PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate"},"paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-1467","openalexId":"W2991084017","cited":254,"byYear":{"2019":1,"2020":17,"2021":36,"2022":53,"2023":34,"2024":41,"2025":39,"2026":33},"year":2019,"title":"Purity Independent Subtyping of Tumors (PurIST), A Clinically Robust, Single-sample Classifier for Tumor Subtyping in Pancreatic Cancer"},"paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017":{"doi":"10.1200/jco.2016.69.3564","openalexId":"W2578876390","cited":227,"byYear":{"2017":12,"2018":15,"2019":18,"2020":29,"2021":47,"2022":26,"2023":28,"2024":23,"2025":17,"2026":9},"year":2017,"title":"Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial"},"paper-elkins-j-clin-oncol":{"doi":"10.1200/jco.2008.16.6389","openalexId":"W2112732719","cited":220,"byYear":{"2012":19,"2013":11,"2014":17,"2015":8,"2016":13,"2017":24,"2018":9,"2019":6,"2020":10,"2021":16,"2022":7,"2023":12,"2024":7,"2025":11,"2026":8},"year":2008,"title":"Randomized Trial of a Hypnosis Intervention for Treatment of Hot Flashes Among Breast Cancer Survivors"},"paper-esteva-npj-digit-med":{"doi":"10.1038/s41746-022-00613-w","openalexId":"W4282942659","cited":215,"byYear":{"2022":4,"2023":27,"2024":43,"2025":88,"2026":53},"year":2022,"title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials"},"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019":{"doi":"10.1200/jco.18.00771","openalexId":"W2911210943","cited":175,"byYear":{"2019":8,"2020":27,"2021":22,"2022":29,"2023":27,"2024":27,"2025":22,"2026":13},"year":2019,"title":"Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site"},"paper-carboplatin-glioblastoma-neuro-oncol-2015":{"doi":"10.1093/neuonc/nov104","openalexId":"W1933614403","cited":162,"byYear":{"2013":1,"2014":1,"2015":3,"2016":8,"2017":15,"2018":13,"2019":16,"2020":17,"2021":25,"2022":8,"2023":21,"2024":16,"2025":9,"2026":9},"year":2015,"title":"Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma"},"paper-stampede-plos-med-2022-update":{"doi":"10.1371/journal.pmed.1003998","openalexId":"W4281639779","cited":125,"byYear":{"2022":4,"2023":27,"2024":36,"2025":42,"2026":16},"year":2022,"title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial"},"paper-martin-jama":{"doi":"10.1001/jama.2024.4011","openalexId":"W4394012749","cited":112,"byYear":{"2024":30,"2025":40,"2026":42},"year":2024,"title":"Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality"},"paper-ligibel-npj-breast-cancer":{"doi":"10.1038/s41523-017-0040-8","openalexId":"W2753529942","cited":108,"byYear":{"2016":2,"2017":1,"2018":12,"2019":12,"2020":18,"2021":16,"2022":18,"2023":14,"2024":8,"2025":5,"2026":2},"year":2017,"title":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design"},"paper-sandhya-j-clin-oncol":{"doi":"10.1200/jco.22.01997","openalexId":"W4361250463","cited":106,"byYear":{"2023":13,"2024":35,"2025":33,"2026":25},"year":2023,"title":"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer"},"paper-ramp-201-avutometinib-defactinib-lgsoc-jco-2025":{"doi":"10.1200/jco-25-00112","openalexId":"W4412352341","cited":52,"byYear":{"2025":9,"2026":43},"year":2025,"title":"Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201"},"paper-pugh-self-experimentation-publication-jme-2026":{"doi":"10.1136/jme-2025-110730","openalexId":"W4414112230","cited":2,"byYear":{"2026":2},"year":2025,"title":"Self-censorship: should scientific journals decline to publish self-experimentation?"},"paper-cheson-j-clin-oncol":{"doi":"10.1200/jco.2013.54.8800","openalexId":"W2119147717","cited":5738,"byYear":{"2012":4,"2013":2,"2014":23,"2015":169,"2016":245,"2017":288,"2018":318,"2019":380,"2020":538,"2021":642,"2022":643,"2023":692,"2024":646,"2025":635,"2026":487},"year":2014,"title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"},"paper-reflect-lenvatinib-lancet-2018":{"doi":"10.1016/s0140-6736(18)30207-1","openalexId":"W2787358630","cited":5593,"byYear":{"2013":2,"2014":2,"2015":1,"2016":1,"2017":1,"2018":136,"2019":396,"2020":650,"2021":833,"2022":798,"2023":882,"2024":822,"2025":678,"2026":379},"year":2018,"title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial"},"paper-sorlie-repeated-observation-subtypes-brca1-basal-pnas-2003":{"doi":"10.1073/pnas.0932692100","openalexId":"W2157840751","cited":5482,"byYear":{"2012":335,"2013":315,"2014":279,"2015":291,"2016":264,"2017":284,"2018":220,"2019":222,"2020":196,"2021":203,"2022":170,"2023":205,"2024":112,"2025":69,"2026":31},"year":2003,"title":"Repeated observation of breast tumor subtypes in independent gene expression data sets"},"paper-tomlins-tmprss2-ets-fusion-science-2005":{"doi":"10.1126/science.1117679","openalexId":"W2121158863","cited":3901,"byYear":{"2012":280,"2013":309,"2014":270,"2015":244,"2016":207,"2017":223,"2018":181,"2019":174,"2020":200,"2021":171,"2022":155,"2023":113,"2024":90,"2025":102,"2026":68},"year":2005,"title":"Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer"},"paper-grothey-correct-regorafenib-lancet-2013":{"doi":"10.1016/s0140-6736(12)61900-x","openalexId":"W2147834058","cited":2934,"byYear":{"2012":7,"2013":122,"2014":204,"2015":234,"2016":197,"2017":222,"2018":195,"2019":244,"2020":223,"2021":215,"2022":221,"2023":220,"2024":286,"2025":211,"2026":122},"year":2012,"title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial"},"paper-hsieh-nat-rev-dis-primers":{"doi":"10.1038/nrdp.2017.9","openalexId":"W2726542547","cited":2861,"byYear":{"2015":1,"2016":2,"2017":57,"2018":93,"2019":160,"2020":270,"2021":429,"2022":437,"2023":406,"2024":402,"2025":365,"2026":236},"year":2017,"title":"Renal cell carcinoma"},"paper-ratify-midostaurin-nejm-2017":{"doi":"10.1056/nejmoa1614359","openalexId":"W2715749014","cited":2270,"byYear":{"2014":1,"2016":2,"2017":65,"2018":170,"2019":245,"2020":291,"2021":327,"2022":288,"2023":269,"2024":233,"2025":218,"2026":160},"year":2017,"title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation"},"paper-wotherspoon-h-pylori-malt-lancet-1993":{"doi":"10.1016/0140-6736(93)91409-f","openalexId":"W2038426029","cited":2137,"byYear":{"2012":69,"2013":64,"2014":50,"2015":42,"2016":51,"2017":44,"2018":27,"2019":35,"2020":29,"2021":32,"2022":28,"2023":30,"2024":31,"2025":20,"2026":8},"year":1993,"title":"Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori"},"paper-esmo-rectal-cancer-guideline-ann-oncol-2017":{"doi":"10.1093/annonc/mdx224","openalexId":"W4244315786","cited":2100,"byYear":{"2016":1,"2017":5,"2018":84,"2019":160,"2020":222,"2021":277,"2022":309,"2023":301,"2024":318,"2025":286,"2026":130},"year":2017,"title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-relativity-047-nejm-2022":{"doi":"10.1056/nejmoa2109970","openalexId":"W4206239577","cited":1897,"byYear":{"2022":276,"2023":418,"2024":493,"2025":401,"2026":309},"year":2022,"title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma"},"paper-brown-n-engl-j-med":{"doi":"10.1056/nejmoa1610497","openalexId":"W2567424265","cited":1881,"byYear":{"2013":1,"2016":2,"2017":107,"2018":166,"2019":169,"2020":211,"2021":232,"2022":235,"2023":236,"2024":209,"2025":177,"2026":132},"year":2016,"title":"Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy"},"paper-citron-j-clin-oncol":{"doi":"10.1200/jco.2003.09.081","openalexId":"W2101760255","cited":1576,"byYear":{"2012":72,"2013":63,"2014":55,"2015":68,"2016":45,"2017":56,"2018":46,"2019":43,"2020":52,"2021":48,"2022":51,"2023":39,"2024":37,"2025":36,"2026":15},"year":2003,"title":"Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741"},"paper-lehmann-tnbctype-4-refinement-plos-one-2016":{"doi":"10.1371/journal.pone.0157368","openalexId":"W2430731787","cited":1471,"byYear":{"2014":1,"2016":9,"2017":62,"2018":97,"2019":115,"2020":169,"2021":198,"2022":206,"2023":177,"2024":153,"2025":176,"2026":107},"year":2016,"title":"Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection"},"paper-mayer-recourse-tas-102-nejm-2015":{"doi":"10.1056/nejmoa1414325","openalexId":"W242040007","cited":1457,"byYear":{"2015":27,"2016":79,"2017":116,"2018":115,"2019":116,"2020":155,"2021":143,"2022":154,"2023":148,"2024":178,"2025":139,"2026":83},"year":2015,"title":"Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer"},"paper-ma-20-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1415340","openalexId":"W993406450","cited":1326,"byYear":{"2014":1,"2015":43,"2016":138,"2017":153,"2018":111,"2019":130,"2020":126,"2021":142,"2022":133,"2023":115,"2024":86,"2025":79,"2026":64},"year":2015,"title":"Regional Nodal Irradiation in Early-Stage Breast Cancer"},"paper-badalian-very-braf-mutations-lch-blood-2010":{"doi":"10.1182/blood-2010-04-279083","openalexId":"W2048765718","cited":1259,"byYear":{"2012":48,"2013":51,"2014":78,"2015":89,"2016":89,"2017":90,"2018":94,"2019":77,"2020":98,"2021":108,"2022":99,"2023":81,"2024":99,"2025":76,"2026":42},"year":2010,"title":"Recurrent BRAF mutations in Langerhans cell histiocytosis"},"paper-carver-pi3k-ar-reciprocal-feedback-prostate-cancer-cell-2011":{"doi":"10.1016/j.ccr.2011.04.008","openalexId":"W2073100248","cited":1213,"byYear":{"2012":71,"2013":113,"2014":121,"2015":97,"2016":78,"2017":94,"2018":69,"2019":69,"2020":86,"2021":103,"2022":78,"2023":76,"2024":49,"2025":46,"2026":36},"year":2011,"title":"Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer"},"paper-ku-rb1-trp53-lineage-plasticity-science-2017":{"doi":"10.1126/science.aah4199","openalexId":"W2571250257","cited":1146,"byYear":{"2016":1,"2017":45,"2018":119,"2019":103,"2020":108,"2021":140,"2022":125,"2023":152,"2024":142,"2025":124,"2026":87},"year":2017,"title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance"},"paper-seshagiri-rspo-fusions-colon-nature-2012":{"doi":"10.1038/nature11282","openalexId":"W2083457841","cited":992,"byYear":{"2012":13,"2013":70,"2014":78,"2015":87,"2016":94,"2017":95,"2018":89,"2019":88,"2020":88,"2021":67,"2022":63,"2023":61,"2024":50,"2025":27,"2026":21},"year":2012,"title":"Recurrent R-spondin fusions in colon cancer"},"paper-smith-j-clin-oncol":{"doi":"10.1200/jco.2015.62.3488","openalexId":"W2110645520","cited":927,"byYear":{"2015":12,"2016":63,"2017":88,"2018":73,"2019":86,"2020":106,"2021":98,"2022":95,"2023":92,"2024":87,"2025":75,"2026":50},"year":2015,"title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update"},"paper-paganetti-phys-med-biol":{"doi":"10.1088/0031-9155/59/22/r419","openalexId":"W2083770395","cited":919,"byYear":{"2015":27,"2016":46,"2017":69,"2018":89,"2019":102,"2020":121,"2021":96,"2022":73,"2023":93,"2024":89,"2025":74,"2026":40},"year":2014,"title":"Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer"},"paper-gatta-eur-j-cancer":{"doi":"10.1016/j.ejca.2011.08.008","openalexId":"W2126438085","cited":819,"byYear":{"2012":22,"2013":22,"2014":28,"2015":38,"2016":47,"2017":45,"2018":54,"2019":51,"2020":76,"2021":72,"2022":76,"2023":65,"2024":85,"2025":77,"2026":56},"year":2011,"title":"Rare cancers are not so rare: The rare cancer burden in Europe"},"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016":{"doi":"10.1056/nejmoa1510093","openalexId":"W2469052042","cited":817,"byYear":{"2014":3,"2016":19,"2017":81,"2018":87,"2019":81,"2020":102,"2021":102,"2022":94,"2023":75,"2024":69,"2025":52,"2026":49},"year":2016,"title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma"},"paper-persson-myb-nfib-pnas-2009":{"doi":"10.1073/pnas.0909114106","openalexId":"W1974202442","cited":793,"byYear":{"2012":39,"2013":48,"2014":38,"2015":61,"2016":57,"2017":70,"2018":57,"2019":52,"2020":47,"2021":53,"2022":49,"2023":55,"2024":39,"2025":37,"2026":18},"year":2009,"title":"Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck"},"paper-wu-gnas-ipmn-sci-transl-med-2011":{"doi":"10.1126/scitranslmed.3002543","openalexId":"W1975940378","cited":786,"byYear":{"2012":36,"2013":67,"2014":88,"2015":81,"2016":61,"2017":68,"2018":67,"2019":63,"2020":63,"2021":46,"2022":39,"2023":38,"2024":24,"2025":26,"2026":13},"year":2011,"title":"Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development"},"paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015":{"doi":"10.1056/nejmoa1408648","openalexId":"W2039888190","cited":761,"byYear":{"2014":4,"2015":39,"2016":70,"2017":90,"2018":74,"2019":50,"2020":89,"2021":86,"2022":85,"2023":58,"2024":46,"2025":30,"2026":34},"year":2015,"title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma"},"paper-armstrong-n-engl-j-med":{"doi":"10.1056/nejmoa1510795","openalexId":"W2323716083","cited":584,"byYear":{"2016":36,"2017":49,"2018":54,"2019":72,"2020":69,"2021":68,"2022":57,"2023":58,"2024":44,"2025":48,"2026":27},"year":2016,"title":"Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer"},"paper-andrew-lassman-j-clin-oncol-2023":{"doi":"10.1200/jco.23.01059","openalexId":"W7211988651","cited":26,"byYear":{"2026":26},"year":2023,"title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults"},"paper-shaw-alk-l1198f-resensitisation-nejm-2016":{"doi":"10.1056/nejmoa1508887","openalexId":"W2205667543","cited":491,"byYear":{"2014":1,"2016":63,"2017":73,"2018":80,"2019":42,"2020":43,"2021":56,"2022":44,"2023":34,"2024":26,"2025":18,"2026":11},"year":2015,"title":"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F"},"paper-carson-jama":{"doi":"10.1001/jama.2023.12914","openalexId":"W4387563884","cited":429,"byYear":{"2023":9,"2024":109,"2025":176,"2026":135},"year":2023,"title":"Red Blood Cell Transfusion"},"paper-reproducibility-project-cancer-biology-elife-2021":{"doi":"10.7554/elife.71601","openalexId":"W4200247206","cited":393,"byYear":{"2021":8,"2022":73,"2023":117,"2024":69,"2025":74,"2026":51},"year":2021,"title":"Investigating the replicability of preclinical cancer biology"},"paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018":{"doi":"10.1158/2159-8290.cd-18-0275","openalexId":"W2808191072","cited":374,"byYear":{"2018":10,"2019":34,"2020":55,"2021":71,"2022":60,"2023":49,"2024":40,"2025":38,"2026":15},"year":2018,"title":"Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine"},"paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018":{"doi":"10.1056/nejmoa1805104","openalexId":"W2891543930","cited":372,"byYear":{"2018":5,"2019":51,"2020":58,"2021":63,"2022":52,"2023":36,"2024":38,"2025":53,"2026":15},"year":2018,"title":"Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma"},"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019":{"doi":"10.1053/j.gastro.2019.02.037","openalexId":"W2919944461","cited":351,"byYear":{"2019":9,"2020":43,"2021":64,"2022":57,"2023":57,"2024":50,"2025":43,"2026":26},"year":2019,"title":"Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers"},"paper-chesney-j-clin-oncol":{"doi":"10.1200/jco.22.00343","openalexId":"W4292851027","cited":321,"byYear":{"2022":3,"2023":52,"2024":82,"2025":90,"2026":94},"year":2022,"title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma"},"paper-andrea-decensi-diabetologia-2017":{"doi":"10.1007/s00125-017-4372-6","openalexId":"W2742254242","cited":300,"byYear":{"2017":8,"2018":29,"2019":27,"2020":39,"2021":46,"2022":62,"2023":24,"2024":28,"2025":20,"2026":17},"year":2017,"title":"Repurposing metformin for the prevention of cancer and cancer recurrence"},"paper-sonabend-lancet-oncol":{"doi":"10.1016/s1470-2045(23)00112-2","openalexId":"W4367673693","cited":257,"byYear":{"2023":20,"2024":85,"2025":82,"2026":69},"year":2023,"title":"Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial"},"paper-remora-lenvatinib-thymic-carcinoma-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30162-5","openalexId":"W3034160707","cited":216,"byYear":{"2020":7,"2021":18,"2022":51,"2023":52,"2024":42,"2025":30,"2026":16},"year":2020,"title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial"},"paper-downing-n-engl-j-med":{"doi":"10.1056/nejmsa1200223","openalexId":"W2010240859","cited":175,"byYear":{"2012":6,"2013":19,"2014":11,"2015":20,"2016":19,"2017":17,"2018":16,"2019":13,"2020":12,"2021":6,"2022":6,"2023":12,"2024":3,"2025":12,"2026":3},"year":2012,"title":"Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies"},"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017":{"doi":"10.1038/modpathol.2016.239","openalexId":"W2578205502","cited":122,"byYear":{"2016":1,"2017":5,"2018":12,"2019":15,"2020":9,"2021":25,"2022":19,"2023":12,"2024":12,"2025":4,"2026":8},"year":2017,"title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma"},"paper-ying-cancer-med":{"doi":"10.1002/cam4.3686","openalexId":"W3116504222","cited":107,"byYear":{"2021":3,"2022":19,"2023":29,"2024":21,"2025":22,"2026":12},"year":2020,"title":"Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China"},"paper-de-savornin-lohman-re-resection-incidental-gallbladder-cancer-aso-2020":{"doi":"10.1245/s10434-019-08074-4","openalexId":"W2985357104","cited":67,"byYear":{"2019":1,"2020":4,"2021":12,"2022":10,"2023":10,"2024":18,"2025":5,"2026":6},"year":2019,"title":"Re-resection in Incidental Gallbladder Cancer: Survival and the Incidence of Residual Disease"},"paper-narayan-gallbladder-regional-mutations-cancer-2019":{"doi":"10.1002/cncr.31850","openalexId":"W2900839004","cited":59,"byYear":{"2019":5,"2020":6,"2021":12,"2022":19,"2023":4,"2024":6,"2025":3,"2026":4},"year":2018,"title":"Regional differences in gallbladder cancer pathogenesis: Insights from a multi‐institutional comparison of tumor mutations"},"paper-alchemist-jama-oncol-2022":{"doi":"10.1001/jamaoncol.2022.0039","openalexId":"W4220833278","cited":57,"byYear":{"2022":8,"2023":19,"2024":16,"2025":6,"2026":8},"year":2022,"title":"Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216)"},"paper-gonda-precede-consortium-recommendations-gastroenterology-2021":{"doi":"10.1053/j.gastro.2021.08.036","openalexId":"W3195864307","cited":45,"byYear":{"2022":5,"2023":13,"2024":7,"2025":12,"2026":8},"year":2021,"title":"Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Consortium"},"paper-nct02411448-j-thorac-oncol-2025-update":{"doi":"10.1016/j.jtho.2024.11.032","openalexId":"W4404884940","cited":20,"byYear":{"2025":12,"2026":8},"year":2024,"title":"RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC"},"paper-pembrolizumab-glioblastoma-clin-cancer-res-2025":{"doi":"10.1158/1078-0432.ccr-24-1629","openalexId":"W4404165254","cited":12,"byYear":{"2025":4,"2026":8},"year":2024,"title":"Re-Irradiation Plus Pembrolizumab: A Phase II Study for Patients with Recurrent Glioblastoma"},"paper-gpc3-gastric-pathol-res-pract-2026":{"doi":"10.1016/j.prp.2026.156477","openalexId":"W7154949773","cited":0,"byYear":{},"year":2026,"title":"Research progress of GPC3 and gastric cancer: Clinicopathologic characteristics and application prospects"},"paper-hulscher-ivermectin-mebendazole-cohort-anticancer-res-2026":{"doi":"10.21873/anticanres.18194","openalexId":"W7162545043","cited":0,"byYear":{},"year":2026,"title":"Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort"},"paper-reya-cancer-stem-cells-nature-2001":{"doi":"10.1038/35102167","openalexId":"W2102085111","cited":9805,"byYear":{"2012":647,"2013":646,"2014":627,"2015":644,"2016":544,"2017":549,"2018":442,"2019":465,"2020":441,"2021":432,"2022":347,"2023":358,"2024":280,"2025":180,"2026":83},"year":2001,"title":"Stem cells, cancer, and cancer stem cells"},"paper-rizvi-mutational-landscape-pd1-science-2015":{"doi":"10.1126/science.aaa1348","openalexId":"W2049553585","cited":8069,"byYear":{"2014":1,"2015":216,"2016":618,"2017":768,"2018":893,"2019":898,"2020":1006,"2021":991,"2022":887,"2023":631,"2024":515,"2025":393,"2026":233},"year":2015,"title":"Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer"},"paper-ribas-wolchok-checkpoint-blockade-science-2018":{"doi":"10.1126/science.aar4060","openalexId":"W2791483720","cited":6986,"byYear":{"2016":1,"2018":166,"2019":582,"2020":821,"2021":974,"2022":1017,"2023":966,"2024":986,"2025":830,"2026":640},"year":2018,"title":"Cancer immunotherapy using checkpoint blockade"},"paper-cooper-rtog-9501-nejm-2004":{"doi":"10.1056/nejmoa032646","openalexId":"W2145078756","cited":3297,"byYear":{"2012":148,"2013":135,"2014":159,"2015":168,"2016":166,"2017":192,"2018":152,"2019":182,"2020":199,"2021":205,"2022":169,"2023":163,"2024":150,"2025":169,"2026":100},"year":2004,"title":"Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck"},"paper-rtog-91-11-forastiere-nejm-2003":{"doi":"10.1056/nejmoa031317","openalexId":"W2100961085","cited":3193,"byYear":{"2012":167,"2013":204,"2014":174,"2015":172,"2016":187,"2017":166,"2018":142,"2019":163,"2020":151,"2021":126,"2022":119,"2023":128,"2024":137,"2025":102,"2026":49},"year":2003,"title":"Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer"},"paper-liedtke-neoadjuvant-response-survival-tnbc-jco-2008":{"doi":"10.1200/jco.2007.14.4147","openalexId":"W2118605519","cited":2955,"byYear":{"2012":124,"2013":147,"2014":157,"2015":167,"2016":150,"2017":193,"2018":181,"2019":183,"2020":257,"2021":255,"2022":223,"2023":210,"2024":156,"2025":129,"2026":87},"year":2008,"title":"Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer"},"paper-ata-medullary-thyroid-guideline-wells-thyroid-2015":{"doi":"10.1089/thy.2014.0335","openalexId":"W1594241115","cited":2459,"byYear":{"2012":1,"2013":3,"2014":1,"2015":56,"2016":161,"2017":163,"2018":193,"2019":180,"2020":242,"2021":284,"2022":263,"2023":257,"2024":242,"2025":228,"2026":167},"year":2015,"title":"Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma"},"paper-r-iss-palumbo-jco-2015":{"doi":"10.1200/jco.2015.61.2267","openalexId":"W2128192762","cited":2254,"byYear":{"2015":11,"2016":87,"2017":140,"2018":131,"2019":185,"2020":253,"2021":265,"2022":285,"2023":248,"2024":235,"2025":253,"2026":152},"year":2015,"title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group"},"paper-monaleesa-2-n-engl-j-med-2016":{"doi":"10.1056/nejmoa1609709","openalexId":"W2528767298","cited":2069,"byYear":{"2013":1,"2015":1,"2016":17,"2017":168,"2018":237,"2019":178,"2020":208,"2021":255,"2022":191,"2023":222,"2024":228,"2025":216,"2026":144},"year":2016,"title":"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer"},"paper-robey-nat-rev-cancer":{"doi":"10.1038/s41568-018-0005-8","openalexId":"W2796552195","cited":1898,"byYear":{"2018":39,"2019":142,"2020":261,"2021":280,"2022":260,"2023":262,"2024":252,"2025":225,"2026":173},"year":2018,"title":"Revisiting the role of ABC transporters in multidrug-resistant cancer"},"paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017":{"doi":"10.1016/j.pan.2017.07.007","openalexId":"W2736069212","cited":1819,"byYear":{"2012":1,"2015":1,"2017":5,"2018":115,"2019":184,"2020":213,"2021":246,"2022":252,"2023":257,"2024":219,"2025":169,"2026":147},"year":2017,"title":"Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas"},"paper-emile-revised-classification-of-histiocytoses-blood-2016":{"doi":"10.1182/blood-2016-01-690636","openalexId":"W2295097092","cited":1604,"byYear":{"2013":1,"2014":1,"2015":2,"2016":21,"2017":100,"2018":129,"2019":130,"2020":167,"2021":186,"2022":195,"2023":180,"2024":197,"2025":177,"2026":106},"year":2016,"title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages"},"paper-bergethon-ros1-rearrangements-lung-jco-2012":{"doi":"10.1200/jco.2011.35.6345","openalexId":"W2130488043","cited":1569,"byYear":{"2012":75,"2013":144,"2014":165,"2015":149,"2016":127,"2017":108,"2018":134,"2019":115,"2020":134,"2021":101,"2022":96,"2023":77,"2024":62,"2025":46,"2026":31},"year":2012,"title":"ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers"},"paper-weaver-j-cell-biol":{"doi":"10.1083/jcb.137.1.231","openalexId":"W1541555963","cited":1497,"byYear":{"2012":88,"2013":63,"2014":64,"2015":58,"2016":63,"2017":64,"2018":64,"2019":53,"2020":54,"2021":49,"2022":40,"2023":52,"2024":19,"2025":30,"2026":19},"year":1997,"title":"Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies"},"paper-russell-peng-bell-oncolytic-virotherapy-natbiotech-2012":{"doi":"10.1038/nbt.2287","openalexId":"W4211238487","cited":1439,"byYear":{"2012":7,"2013":99,"2014":110,"2015":129,"2016":99,"2017":115,"2018":104,"2019":86,"2020":121,"2021":105,"2022":102,"2023":111,"2024":96,"2025":79,"2026":75},"year":2012,"title":"Oncolytic virotherapy"},"paper-olsen-mycosis-fungoides-staging-blood-2007":{"doi":"10.1182/blood-2007-03-055749","openalexId":"W2100103468","cited":1435,"byYear":{"2012":80,"2013":71,"2014":95,"2015":90,"2016":86,"2017":83,"2018":91,"2019":96,"2020":77,"2021":90,"2022":81,"2023":77,"2024":84,"2025":60,"2026":53},"year":2007,"title":"Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)"},"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023":{"doi":"10.1038/s41586-023-06063-y","openalexId":"W4376133743","cited":1411,"byYear":{"2012":1,"2022":1,"2023":146,"2024":396,"2025":491,"2026":376},"year":2023,"title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer"},"paper-rtog-9402-cairncross-jco-2013":{"doi":"10.1200/jco.2012.43.2674","openalexId":"W2147013683","cited":1174,"byYear":{"2012":11,"2013":63,"2014":84,"2015":120,"2016":97,"2017":102,"2018":103,"2019":118,"2020":92,"2021":79,"2022":86,"2023":69,"2024":78,"2025":46,"2026":21},"year":2012,"title":"Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402"},"paper-rtog-9802-buckner-nejm-2016":{"doi":"10.1056/nejmoa1500925","openalexId":"W2313086999","cited":1072,"byYear":{"2015":1,"2016":43,"2017":106,"2018":124,"2019":132,"2020":128,"2021":103,"2022":104,"2023":91,"2024":98,"2025":78,"2026":60},"year":2016,"title":"Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma"},"paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019":{"doi":"10.1056/nejmoa1814213","openalexId":"W2917403028","cited":878,"byYear":{"2019":33,"2020":93,"2021":167,"2022":170,"2023":128,"2024":113,"2025":105,"2026":67},"year":2019,"title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer"},"paper-ruby-nejm-2023":{"doi":"10.1056/nejmoa2216334","openalexId":"W4360991857","cited":873,"byYear":{"2021":1,"2023":117,"2024":283,"2025":295,"2026":177},"year":2023,"title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer"},"paper-rtog-9408-short-term-adt-jones-nejm-2011":{"doi":"10.1056/nejmoa1012348","openalexId":"W2108864389","cited":704,"byYear":{"2012":51,"2013":58,"2014":58,"2015":69,"2016":59,"2017":48,"2018":58,"2019":37,"2020":58,"2021":40,"2022":40,"2023":39,"2024":32,"2025":17,"2026":15},"year":2011,"title":"Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer"},"paper-bradley-nat-rev-cancer":{"doi":"10.1038/s41568-022-00541-7","openalexId":"W4315475728","cited":607,"byYear":{"2022":2,"2023":52,"2024":194,"2025":211,"2026":148},"year":2023,"title":"RNA splicing dysregulation and the hallmarks of cancer"},"paper-jak2-polycythaemia-vera-nat-rev-cancer-2007":{"doi":"10.1038/nrc2210","openalexId":"W2054753195","cited":592,"byYear":{"2012":38,"2013":45,"2014":37,"2015":39,"2016":25,"2017":26,"2018":15,"2019":28,"2020":26,"2021":26,"2022":24,"2023":18,"2024":23,"2025":18,"2026":12},"year":2007,"title":"Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders"},"paper-rohaas-til-vs-ipilimumab-nejm-2022":{"doi":"10.1056/nejmoa2210233","openalexId":"W4311584464","cited":578,"byYear":{"2022":6,"2023":95,"2024":164,"2025":189,"2026":124},"year":2022,"title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma"},"paper-yau-rcb-pooled-analysis-5161-lancet-oncol-2022":{"doi":"10.1016/s1470-2045(21)00589-1","openalexId":"W4200028620","cited":469,"byYear":{"2022":53,"2023":72,"2024":135,"2025":123,"2026":86},"year":2021,"title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients"},"paper-canto-caps-long-term-surveillance-gastroenterology-2018":{"doi":"10.1053/j.gastro.2018.05.035","openalexId":"W2803439891","cited":418,"byYear":{"2018":10,"2019":41,"2020":49,"2021":57,"2022":73,"2023":65,"2024":58,"2025":33,"2026":32},"year":2018,"title":"Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance"},"paper-monje-cell":{"doi":"10.1016/j.cell.2020.03.034","openalexId":"W3017089772","cited":386,"byYear":{"2020":15,"2021":44,"2022":78,"2023":59,"2024":54,"2025":72,"2026":64},"year":2020,"title":"Roadmap for the Emerging Field of Cancer Neuroscience"},"paper-gisslinger-lancet-haematol":{"doi":"10.1016/s2352-3026(19)30236-4","openalexId":"W3003423609","cited":366,"byYear":{"2013":1,"2016":1,"2018":1,"2020":42,"2021":62,"2022":55,"2023":51,"2024":49,"2025":65,"2026":38},"year":2020,"title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study"},"paper-minard-colin-n-engl-j-med":{"doi":"10.1056/nejmoa1915315","openalexId":"W3031891765","cited":324,"byYear":{"2020":12,"2021":42,"2022":44,"2023":63,"2024":68,"2025":61,"2026":34},"year":2020,"title":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children"},"paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025":{"doi":"10.1038/s41586-024-08508-4","openalexId":"W4407722177","cited":312,"byYear":{"2024":1,"2025":127,"2026":184},"year":2025,"title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer"},"paper-russell-mv-nis-myeloma-mayo-2014":{"doi":"10.1016/j.mayocp.2014.04.003","openalexId":"W2012611138","cited":275,"byYear":{"2013":2,"2014":19,"2015":43,"2016":24,"2017":38,"2018":28,"2019":18,"2020":30,"2021":23,"2022":11,"2023":14,"2024":8,"2025":6,"2026":10},"year":2014,"title":"Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy"},"paper-sparano-blood":{"doi":"10.1182/blood-2009-08-231613","openalexId":"W2079598348","cited":258,"byYear":{"2012":29,"2013":24,"2014":22,"2015":14,"2016":16,"2017":16,"2018":17,"2019":12,"2020":24,"2021":20,"2022":9,"2023":12,"2024":10,"2025":9,"2026":2},"year":2009,"title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma"},"paper-lichtman-j-pain-symptom-manage":{"doi":"10.1016/j.jpainsymman.2017.09.001","openalexId":"W2756282134","cited":237,"byYear":{"2018":16,"2019":21,"2020":32,"2021":39,"2022":46,"2023":29,"2024":29,"2025":16,"2026":9},"year":2017,"title":"Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain"},"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023":{"doi":"10.1016/j.annonc.2022.11.005","openalexId":"W4309773737","cited":206,"byYear":{"2022":3,"2023":29,"2024":56,"2025":71,"2026":47},"year":2022,"title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer"},"paper-teply-restore-bipolar-androgen-therapy-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(17)30906-3","openalexId":"W2772636479","cited":200,"byYear":{"2017":1,"2018":19,"2019":24,"2020":31,"2021":33,"2022":26,"2023":24,"2024":17,"2025":15,"2026":9},"year":2017,"title":"Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study"},"paper-van-poznak-j-clin-oncol":{"doi":"10.1200/jco.2017.75.4614","openalexId":"W2765774285","cited":183,"byYear":{"2016":1,"2018":15,"2019":22,"2020":32,"2021":24,"2022":25,"2023":20,"2024":12,"2025":18,"2026":14},"year":2017,"title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update"},"paper-frazier-j-clin-oncol":{"doi":"10.1200/jco.2014.58.3369","openalexId":"W2101983821","cited":170,"byYear":{"2015":5,"2016":15,"2017":11,"2018":15,"2019":13,"2020":14,"2021":21,"2022":14,"2023":17,"2024":15,"2025":15,"2026":15},"year":2014,"title":"Revised Risk Classification for Pediatric Extracranial Germ Cell Tumors Based on 25 Years of Clinical Trial Data From the United Kingdom and United States"},"paper-harrison-j-clin-oncol":{"doi":"10.1200/jco.22.01935","openalexId":"W4367596117","cited":162,"byYear":{"2023":17,"2024":53,"2025":53,"2026":39},"year":2023,"title":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial"},"paper-rolapitant-study-3-schwartzberg-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(15)00034-0","openalexId":"W2108765055","cited":154,"byYear":{"2015":8,"2016":24,"2017":31,"2018":21,"2019":9,"2020":13,"2021":9,"2022":5,"2023":13,"2024":12,"2025":2,"2026":5},"year":2015,"title":"Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial"},"paper-ascent-03-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2511734","openalexId":"W4415507659","cited":89,"byYear":{"2025":6,"2026":83},"year":2025,"title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer"},"paper-zeidan-lancet-haematol":{"doi":"10.1016/s2352-3026(23)00333-2","openalexId":"W4389327718","cited":77,"byYear":{"2023":1,"2024":23,"2025":27,"2026":25},"year":2023,"title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial"},"paper-ascent-04-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2508959","openalexId":"W7125394157","cited":70,"byYear":{"2026":70},"year":2026,"title":"Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer"},"paper-rosella-relacorilant-lancet-2025":{"doi":"10.1016/s0140-6736(25)01040-2","openalexId":"W4410954797","cited":60,"byYear":{"2025":18,"2026":42},"year":2025,"title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial"},"paper-trastuzumab-deruxtecan-tnbc-esmo-open-2021":{"doi":"10.1016/j.esmoop.2021.100204","openalexId":"W3176491405","cited":54,"byYear":{"2021":2,"2022":7,"2023":21,"2024":11,"2025":8,"2026":5},"year":2021,"title":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape"},"paper-wisdom-trial-jama-2026":{"doi":"10.1001/jama.2025.24784","openalexId":"W4417304321","cited":49,"byYear":{"2025":1,"2026":48},"year":2025,"title":"Risk-Based vs Annual Breast Cancer Screening"},"paper-nct04152499-j-hematol-oncol-2025":{"doi":"10.1186/s13045-025-01705-2","openalexId":"W4411099473","cited":27,"byYear":{"2025":5,"2026":22},"year":2025,"title":"Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies"},"paper-natalee-jama-oncol-2025-update":{"doi":"10.1001/jamaoncol.2025.3700","openalexId":"W4414508430","cited":27,"byYear":{"2025":3,"2026":24},"year":2025,"title":"Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer"},"paper-patil-mebendazole-glioma-phase-1-cancer-med-2020":{"doi":"10.1002/cam4.3094","openalexId":"W3024790653","cited":24,"byYear":{"2020":3,"2021":7,"2022":3,"2023":3,"2024":5,"2025":1,"2026":2},"year":2020,"title":"Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma"},"paper-makis-fenbendazole-case-series-retracted-2025":{"doi":"10.1159/000546362","openalexId":"W4410772980","cited":1,"byYear":{"2025":1},"year":2025,"title":"Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients"},"paper-sharp-sorafenib-nejm-2008":{"doi":"10.1056/nejmoa0708857","openalexId":"W1971837077","cited":13134,"byYear":{"2012":622,"2013":686,"2014":750,"2015":719,"2016":700,"2017":804,"2018":732,"2019":810,"2020":979,"2021":1120,"2022":1034,"2023":893,"2024":786,"2025":623,"2026":350},"year":2008,"title":"Sorafenib in Advanced Hepatocellular Carcinoma"},"paper-siegel-cancer-statistics-2012-cacancer-2012":{"doi":"10.3322/caac.20138","openalexId":"W2165948908","cited":10717,"byYear":{"2012":1179,"2013":2833,"2014":2040,"2015":1324,"2016":811,"2017":654,"2018":477,"2019":375,"2020":299,"2021":261,"2022":172,"2023":123,"2024":87,"2025":42,"2026":16},"year":2012,"title":"Cancer statistics, 2012"},"paper-brahmer-anti-pd-l1-phase-1-nejm-2012":{"doi":"10.1056/nejmoa1200694","openalexId":"W2101653483","cited":8109,"byYear":{"2012":107,"2013":493,"2014":574,"2015":759,"2016":723,"2017":733,"2018":594,"2019":638,"2020":716,"2021":633,"2022":593,"2023":573,"2024":469,"2025":316,"2026":161},"year":2012,"title":"Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer"},"paper-sato-lgr5-organoids-nature-2009":{"doi":"10.1038/nature07935","openalexId":"W1965157206","cited":7392,"byYear":{"2012":159,"2013":201,"2014":220,"2015":259,"2016":340,"2017":401,"2018":461,"2019":448,"2020":681,"2021":711,"2022":666,"2023":704,"2024":715,"2025":674,"2026":490},"year":2009,"title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche"},"paper-schreiber-cancer-immunoediting-science-2011":{"doi":"10.1126/science.1203486","openalexId":"W2004630197","cited":6592,"byYear":{"2012":222,"2013":315,"2014":273,"2015":368,"2016":424,"2017":432,"2018":410,"2019":497,"2020":590,"2021":649,"2022":587,"2023":586,"2024":498,"2025":374,"2026":294},"year":2011,"title":"Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion"},"paper-sauer-preoperative-chemoradiotherapy-rectal-nejm-2004":{"doi":"10.1056/nejmoa040694","openalexId":"W2125452425","cited":6114,"byYear":{"2012":345,"2013":333,"2014":341,"2015":347,"2016":291,"2017":300,"2018":305,"2019":327,"2020":335,"2021":329,"2022":320,"2023":305,"2024":243,"2025":206,"2026":151},"year":2004,"title":"Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer"},"paper-filippakopoulos-nature":{"doi":"10.1038/nature09504","openalexId":"W2041535798","cited":4363,"byYear":{"2012":117,"2013":177,"2014":245,"2015":278,"2016":334,"2017":308,"2018":316,"2019":335,"2020":364,"2021":346,"2022":331,"2023":342,"2024":317,"2025":304,"2026":177},"year":2010,"title":"Selective inhibition of BET bromodomains"},"paper-lincoff-n-engl-j-med":{"doi":"10.1056/nejmoa2307563","openalexId":"W4388592674","cited":3071,"byYear":{"2023":26,"2024":805,"2025":1117,"2026":1120},"year":2023,"title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes"},"paper-ma-nat-commun":{"doi":"10.1038/s41467-024-44824-z","openalexId":"W4391109864","cited":2893,"byYear":{"2023":44,"2024":620,"2025":1237,"2026":992},"year":2024,"title":"Segment anything in medical images"},"paper-select-lenvatinib-nejm-2015":{"doi":"10.1056/nejmoa1406470","openalexId":"W1967792499","cited":2109,"byYear":{"2013":1,"2014":1,"2015":92,"2016":121,"2017":154,"2018":162,"2019":196,"2020":187,"2021":228,"2022":257,"2023":196,"2024":190,"2025":193,"2026":123},"year":2015,"title":"Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer"},"paper-uspstf-lung-cancer-screening-jama-2021":{"doi":"10.1001/jama.2021.1117","openalexId":"W3134934271","cited":1829,"byYear":{"2014":1,"2018":1,"2019":4,"2020":24,"2021":136,"2022":296,"2023":362,"2024":352,"2025":378,"2026":273},"year":2021,"title":"Screening for Lung Cancer"},"paper-bahadoer-rapido-short-course-radiotherapy-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(20)30555-6","openalexId":"W3111308000","cited":1723,"byYear":{"2012":1,"2017":1,"2020":6,"2021":154,"2022":273,"2023":334,"2024":350,"2025":344,"2026":255},"year":2020,"title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial"},"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017":{"doi":"10.1016/s1470-2045(17)30624-1","openalexId":"W2762797139","cited":1480,"byYear":{"2016":1,"2017":8,"2018":73,"2019":108,"2020":176,"2021":200,"2022":189,"2023":203,"2024":183,"2025":212,"2026":125},"year":2017,"title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial"},"paper-blinatumomab-all-leukemia-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71170-2","openalexId":"W2107925822","cited":1280,"byYear":{"2012":1,"2013":1,"2014":1,"2015":89,"2016":143,"2017":164,"2018":97,"2019":120,"2020":120,"2021":117,"2022":96,"2023":107,"2024":93,"2025":76,"2026":51},"year":2014,"title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study"},"paper-cui-nat-methods":{"doi":"10.1038/s41592-024-02201-0","openalexId":"W4392168151","cited":1264,"byYear":{"2014":1,"2023":14,"2024":216,"2025":492,"2026":540},"year":2024,"title":"scGPT: toward building a foundation model for single-cell multi-omics using generative AI"},"paper-perry-n-engl-j-med":{"doi":"10.1056/nejmoa1611977","openalexId":"W2599750069","cited":1212,"byYear":{"2016":3,"2017":55,"2018":94,"2019":97,"2020":179,"2021":153,"2022":154,"2023":126,"2024":158,"2025":110,"2026":79},"year":2017,"title":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma"},"paper-bellera-ann-oncol":{"doi":"10.1093/annonc/mdr587","openalexId":"W2160293835","cited":1134,"byYear":{"2012":18,"2013":26,"2014":29,"2015":43,"2016":48,"2017":52,"2018":60,"2019":59,"2020":73,"2021":97,"2022":115,"2023":145,"2024":134,"2025":111,"2026":120},"year":2012,"title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool"},"paper-hpv-self-sampling-bmj-2018":{"doi":"10.1136/bmj.k4823","openalexId":"W2902810541","cited":907,"byYear":{"2019":42,"2020":97,"2021":106,"2022":130,"2023":145,"2024":155,"2025":142,"2026":89},"year":2018,"title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses"},"paper-schmitt-nat-rev-clin-oncol":{"doi":"10.1038/s41571-022-00668-4","openalexId":"W4293747103","cited":791,"byYear":{"2015":1,"2020":1,"2022":8,"2023":111,"2024":265,"2025":277,"2026":128},"year":2022,"title":"Senescence and cancer — role and therapeutic opportunities"},"paper-abc-06-folfox-second-line-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00027-9","openalexId":"W3144916167","cited":787,"byYear":{"2021":70,"2022":156,"2023":164,"2024":159,"2025":146,"2026":89},"year":2021,"title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial"},"paper-plco-chest-radiograph-lung-cancer-mortality-jama-2011":{"doi":"10.1001/jama.2011.1591","openalexId":"W2018404797","cited":664,"byYear":{"2012":52,"2013":69,"2014":59,"2015":68,"2016":29,"2017":45,"2018":43,"2019":31,"2020":44,"2021":36,"2022":47,"2023":41,"2024":47,"2025":22,"2026":23},"year":2011,"title":"Screening by Chest Radiograph and Lung Cancer Mortality"},"paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023":{"doi":"10.1038/s41571-022-00719-w","openalexId":"W4315646654","cited":585,"byYear":{"2022":1,"2023":58,"2024":177,"2025":203,"2026":146},"year":2023,"title":"Therapy with oncolytic viruses: progress and challenges"},"paper-koelsche-nat-commun":{"doi":"10.1038/s41467-020-20603-4","openalexId":"W3122927608","cited":560,"byYear":{"2021":53,"2022":109,"2023":83,"2024":134,"2025":117,"2026":61},"year":2021,"title":"Sarcoma classification by DNA methylation profiling"},"paper-baine-sclc-subtype-immunohistochemistry-jto-2020":{"doi":"10.1016/j.jtho.2020.09.009","openalexId":"W3090613431","cited":533,"byYear":{"2020":5,"2021":44,"2022":88,"2023":94,"2024":110,"2025":113,"2026":76},"year":2020,"title":"SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization"},"paper-checkmate-358-j-clin-oncol-2019":{"doi":"10.1200/jco.19.00739","openalexId":"W2972117663","cited":443,"byYear":{"2013":1,"2019":2,"2020":40,"2021":73,"2022":82,"2023":80,"2024":69,"2025":69,"2026":27},"year":2019,"title":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial"},"paper-sempet-de-santis-jco-2004":{"doi":"10.1200/jco.2004.07.188","openalexId":"W2151775324","cited":426,"byYear":{"2012":24,"2013":19,"2014":26,"2015":22,"2016":15,"2017":11,"2018":28,"2019":19,"2020":18,"2021":9,"2022":25,"2023":9,"2024":13,"2025":11,"2026":5},"year":2004,"title":"2- 18 fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial"},"paper-trappe-lancet-oncol":{"doi":"10.1016/s1470-2045(11)70300-x","openalexId":"W2170308172","cited":390,"byYear":{"2012":17,"2013":33,"2014":25,"2015":27,"2016":28,"2017":31,"2018":27,"2019":26,"2020":29,"2021":37,"2022":24,"2023":27,"2024":23,"2025":16,"2026":13},"year":2011,"title":"Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial"},"paper-idbaih-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-18-3643","openalexId":"W2925110565","cited":364,"byYear":{"2019":20,"2020":44,"2021":54,"2022":60,"2023":58,"2024":47,"2025":53,"2026":27},"year":2019,"title":"Safety and Feasibility of Repeated and Transient Blood–Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma"},"paper-nct01933932-jama-2017":{"doi":"10.1001/jama.2017.3438","openalexId":"W2613467753","cited":342,"byYear":{"2017":16,"2018":50,"2019":39,"2020":59,"2021":58,"2022":43,"2023":21,"2024":29,"2025":16,"2026":10},"year":2017,"title":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS -Mutant Advanced Non–Small Cell Lung Cancer"},"paper-widdison-j-med-chem":{"doi":"10.1021/jm060319f","openalexId":"W2004783782","cited":313,"byYear":{"2012":20,"2013":19,"2014":18,"2015":23,"2016":17,"2017":23,"2018":17,"2019":16,"2020":17,"2021":21,"2022":11,"2023":18,"2024":14,"2025":8,"2026":5},"year":2006,"title":"Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer"},"paper-lewis-science":{"doi":"10.1126/science.adv9817","openalexId":"W4412165572","cited":289,"byYear":{"2025":66,"2026":223},"year":2025,"title":"Scalable emulation of protein equilibrium ensembles with generative deep learning"},"paper-shape-nejm-2024":{"doi":"10.1056/nejmoa2308900","openalexId":"W4392229557","cited":280,"byYear":{"2024":79,"2025":126,"2026":75},"year":2024,"title":"Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer"},"paper-scanu-salmonella-gallbladder-transformation-cell-host-microbe-2015":{"doi":"10.1016/j.chom.2015.05.002","openalexId":"W2134550810","cited":272,"byYear":{"2015":5,"2016":12,"2017":20,"2018":20,"2019":12,"2020":29,"2021":45,"2022":29,"2023":31,"2024":34,"2025":22,"2026":12},"year":2015,"title":"Salmonella Manipulation of Host Signaling Pathways Provokes Cellular Transformation Associated with Gallbladder Carcinoma"},"paper-scalp-trial-jama-2017":{"doi":"10.1001/jama.2016.20939","openalexId":"W2588306525","cited":235,"byYear":{"2017":16,"2018":24,"2019":26,"2020":37,"2021":26,"2022":16,"2023":17,"2024":29,"2025":19,"2026":22},"year":2017,"title":"Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer"},"paper-van-herpen-esmo-open":{"doi":"10.1016/j.esmoop.2022.100602","openalexId":"W4308157823","cited":210,"byYear":{"2023":26,"2024":59,"2025":66,"2026":57},"year":2022,"title":"Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up"},"paper-cd19-dlbcl-clin-cancer-res-2011":{"doi":"10.1158/1078-0432.ccr-11-0485","openalexId":"W2169000897","cited":170,"byYear":{"2012":22,"2013":21,"2014":18,"2015":20,"2016":12,"2017":9,"2018":12,"2019":13,"2020":12,"2021":6,"2022":5,"2023":6,"2024":2,"2025":6},"year":2011,"title":"SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies"},"paper-masai-lancet-digit-health-2025":{"doi":"10.1016/s2589-7500(24)00267-x","openalexId":"W4407091026","cited":161,"byYear":{"2020":1,"2025":65,"2026":95},"year":2025,"title":"Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study"},"paper-koshiol-salmonella-typhi-gallbladder-cancer-cancer-med-2016":{"doi":"10.1002/cam4.915","openalexId":"W2530968656","cited":156,"byYear":{"2017":4,"2018":7,"2019":8,"2020":22,"2021":21,"2022":13,"2023":23,"2024":20,"2025":24,"2026":13},"year":2016,"title":"Salmonella entericaserovar Typhi and gallbladder cancer: a case–control study and meta‐analysis"},"paper-nct05870319-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2512071","openalexId":"W4415334747","cited":72,"byYear":{"2025":5,"2026":67},"year":2025,"title":"Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC"},"paper-nct05347134-nat-med-2025":{"doi":"10.1038/s41591-025-03630-w","openalexId":"W4409370679","cited":63,"byYear":{"2025":24,"2026":39},"year":2025,"title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial"},"paper-soho-01-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2511065","openalexId":"W4415295860","cited":63,"byYear":{"2025":5,"2026":58},"year":2025,"title":"Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer"},"paper-nct03778229-ann-oncol-2025":{"doi":"10.1016/j.annonc.2025.04.003","openalexId":"W4410958726","cited":56,"byYear":{"2025":14,"2026":42},"year":2025,"title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study"},"paper-nct06448312-lancet-2026":{"doi":"10.1016/s0140-6736(26)00968-2","openalexId":"W7162754680","cited":9,"byYear":{"2026":9},"year":2026,"title":"Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial"},"paper-karius-radiother-oncol":{"doi":"10.1016/j.radonc.2023.109590","openalexId":"W4322487924","cited":10,"byYear":{"2023":1,"2024":4,"2025":1,"2026":4},"year":2023,"title":"Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy"},"paper-thakurdesai-fenbendazole-liver-injury-2024":{"doi":"10.14309/crj.0000000000001354","openalexId":"W4396576756","cited":9,"byYear":{"2024":1,"2025":4,"2026":4},"year":2024,"title":"Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole"},"paper-nct04819100-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2602628","openalexId":"W7162956606","cited":8,"byYear":{"2026":8},"year":2026,"title":"Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer"},"paper-transcend-miller-nejm-2026":{"doi":"10.1056/nejmoa2512275","openalexId":"W7167674005","cited":8,"byYear":{"2026":8},"year":2026,"title":"Setmelanotide for the Treatment of Acquired Hypothalamic Obesity"},"paper-lutetium-177-vipivotide-tetrax-prostate-oncol-ther-2025":{"doi":"10.1007/s40487-025-00377-9","openalexId":"W4414929926","cited":1,"byYear":{"2026":1},"year":2025,"title":"Sequencing of Radium-223 and Lutetium-177 Vipivotide Tetraxetan: Maximizing the Benefit of Systemic Targeted Radiation Therapy in Metastatic Castration-Resistant Prostate Cancer"},"paper-sherr-roberts-cdk-inhibitors-genesdev-1999":{"doi":"10.1101/gad.13.12.1501","openalexId":"W2121619780","cited":6156,"byYear":{"2012":256,"2013":230,"2014":205,"2015":206,"2016":154,"2017":162,"2018":147,"2019":145,"2020":158,"2021":157,"2022":139,"2023":127,"2024":101,"2025":99,"2026":62},"year":1999,"title":"CDK inhibitors: positive and negative regulators of G1-phase progression"},"paper-nct03330847-clin-cancer-res-2026":{"doi":"10.1158/1078-0432.ccr-26-1066","openalexId":"W7213916673","cited":0,"byYear":{},"year":2026,"title":"Safety and Efficacy of Ceralasertib plus Olaparib for Advanced/Metastatic Triple-Negative Breast Cancer in Three Molecular Strata: The Phase II VIOLETTE Study"},"paper-siegel-cancer-statistics-2019-cacancer-2019":{"doi":"10.3322/caac.21551","openalexId":"W2911188335","cited":21056,"byYear":{"2012":1,"2013":1,"2015":1,"2016":1,"2017":7,"2018":5,"2019":2375,"2020":6466,"2021":5022,"2022":2906,"2023":1961,"2024":1454,"2025":659,"2026":178},"year":2019,"title":"Cancer statistics, 2019"},"paper-siegel-cancer-statistics-2022-cacancer-2022":{"doi":"10.3322/caac.21708","openalexId":"W4206841660","cited":18373,"byYear":{"2016":1,"2020":1,"2021":5,"2022":3397,"2023":7042,"2024":5243,"2025":2090,"2026":574},"year":2022,"title":"Cancer statistics, 2022"},"paper-siegel-cancer-statistics-2021-cacancer-2021":{"doi":"10.3322/caac.21654","openalexId":"W3119005666","cited":17457,"byYear":{"2012":1,"2014":1,"2018":4,"2019":1,"2020":6,"2021":2810,"2022":6101,"2023":4240,"2024":2841,"2025":1172,"2026":270},"year":2021,"title":"Cancer Statistics, 2021"},"paper-siegel-cancer-statistics-2018-cacancer-2018":{"doi":"10.3322/caac.21442","openalexId":"W2781525129","cited":17066,"byYear":{"2012":1,"2013":2,"2014":1,"2015":1,"2017":7,"2018":2275,"2019":4820,"2020":3496,"2021":2306,"2022":1510,"2023":1005,"2024":947,"2025":532,"2026":143},"year":2018,"title":"Cancer statistics, 2018"},"paper-siegel-cancer-statistics-2023-cacancer-2023":{"doi":"10.3322/caac.21763","openalexId":"W4315754639","cited":17061,"byYear":{"2014":1,"2017":2,"2020":2,"2021":2,"2022":9,"2023":3569,"2024":8282,"2025":4062,"2026":1126},"year":2023,"title":"Cancer statistics, 2023"},"paper-siegel-cancer-statistics-2016-cacancer-2016":{"doi":"10.3322/caac.21332","openalexId":"W2235523093","cited":16201,"byYear":{"2012":1,"2013":3,"2014":28,"2015":38,"2016":1696,"2017":4328,"2018":3126,"2019":2013,"2020":1636,"2021":1259,"2022":821,"2023":591,"2024":381,"2025":216,"2026":45},"year":2016,"title":"Cancer statistics, 2016"},"paper-siegel-cancer-statistics-2017-cacancer-2017":{"doi":"10.3322/caac.21387","openalexId":"W2570618306","cited":15019,"byYear":{"2013":3,"2015":3,"2016":2,"2017":1841,"2018":4338,"2019":3283,"2020":2141,"2021":1276,"2022":890,"2023":533,"2024":453,"2025":180,"2026":49},"year":2017,"title":"Cancer statistics, 2017"},"paper-siegel-cancer-statistics-2015-cacancer-2015":{"doi":"10.3322/caac.21254","openalexId":"W2170552969","cited":11939,"byYear":{"2012":1,"2013":2,"2014":7,"2015":1449,"2016":3302,"2017":2369,"2018":1361,"2019":1024,"2020":778,"2021":596,"2022":434,"2023":278,"2024":194,"2025":103,"2026":25},"year":2015,"title":"Cancer statistics, 2015"},"paper-siegel-cancer-statistics-2013-cacancer-2013":{"doi":"10.3322/caac.21166","openalexId":"W2161817637","cited":11921,"byYear":{"2012":16,"2013":1228,"2014":3157,"2015":2147,"2016":1359,"2017":1052,"2018":755,"2019":615,"2020":445,"2021":347,"2022":240,"2023":193,"2024":222,"2025":97,"2026":18},"year":2013,"title":"Cancer statistics, 2013"},"paper-slamon-her2-amplification-science-1987":{"doi":"10.1126/science.3798106","openalexId":"W2141393790","cited":11835,"byYear":{"2012":461,"2013":545,"2014":484,"2015":434,"2016":414,"2017":395,"2018":348,"2019":326,"2020":342,"2021":354,"2022":310,"2023":340,"2024":323,"2025":229,"2026":178},"year":1987,"title":"Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene"},"paper-slamon-trastuzumab-nejm-2001":{"doi":"10.1056/nejm200103153441101","openalexId":"W2318605753","cited":11621,"byYear":{"2012":563,"2013":602,"2014":592,"2015":566,"2016":539,"2017":492,"2018":470,"2019":437,"2020":452,"2021":405,"2022":422,"2023":452,"2024":412,"2025":292,"2026":208},"year":2001,"title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2"},"paper-siegel-cancer-statistics-2014-cacancer-2014":{"doi":"10.3322/caac.21208","openalexId":"W2169961966","cited":11587,"byYear":{"2012":4,"2013":4,"2014":1378,"2015":3282,"2016":2077,"2017":1285,"2018":906,"2019":684,"2020":571,"2021":400,"2022":336,"2023":264,"2024":233,"2025":106,"2026":27},"year":2014,"title":"Cancer statistics, 2014"},"paper-siegel-cancer-statistics-2024-cacancer-2024":{"doi":"10.3322/caac.21820","openalexId":"W4390946922","cited":9543,"byYear":{"2021":3,"2022":1,"2023":3,"2024":2887,"2025":5094,"2026":1552},"year":2024,"title":"Cancer statistics, 2024"},"paper-singh-brain-tumour-initiating-cells-nature-2004":{"doi":"10.1038/nature03128","openalexId":"W2001544973","cited":7490,"byYear":{"2012":519,"2013":519,"2014":435,"2015":441,"2016":411,"2017":392,"2018":312,"2019":330,"2020":343,"2021":335,"2022":296,"2023":267,"2024":200,"2025":173,"2026":108},"year":2004,"title":"Identification of human brain tumour initiating cells"},"paper-slamon-her2-breast-ovarian-science-1989":{"doi":"10.1126/science.2470152","openalexId":"W2095156669","cited":6868,"byYear":{"2012":236,"2013":247,"2014":208,"2015":220,"2016":160,"2017":164,"2018":142,"2019":111,"2020":148,"2021":171,"2022":129,"2023":153,"2024":121,"2025":75,"2026":49},"year":1989,"title":"Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer"},"paper-kantoff-n-engl-j-med":{"doi":"10.1056/nejmoa1001294","openalexId":"W2103959341","cited":5590,"byYear":{"2012":439,"2013":491,"2014":502,"2015":451,"2016":371,"2017":354,"2018":321,"2019":299,"2020":310,"2021":340,"2022":320,"2023":289,"2024":274,"2025":253,"2026":167},"year":2010,"title":"Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer"},"paper-solo-1-nejm-2018":{"doi":"10.1056/nejmoa1810858","openalexId":"W2897430921","cited":2936,"byYear":{"2013":1,"2017":1,"2018":16,"2019":229,"2020":419,"2021":458,"2022":429,"2023":432,"2024":378,"2025":323,"2026":242},"year":2018,"title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer"},"paper-solar-1-alpelisib-nejm-2019":{"doi":"10.1056/nejmoa1813904","openalexId":"W2945564879","cited":2667,"byYear":{"2019":85,"2020":357,"2021":460,"2022":388,"2023":346,"2024":399,"2025":360,"2026":266},"year":2019,"title":"Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer"},"paper-kras-nsclc-n-engl-j-med-2021":{"doi":"10.1056/nejmoa2103695","openalexId":"W3172081492","cited":1879,"byYear":{"2021":90,"2022":330,"2023":406,"2024":438,"2025":346,"2026":268},"year":2021,"title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation"},"paper-robin-jones-ann-oncol-2018":{"doi":"10.1093/annonc/mdy096","openalexId":"W772589830","cited":1635,"byYear":{"2012":2,"2013":24,"2014":50,"2015":48,"2016":76,"2017":79,"2018":109,"2019":130,"2020":224,"2021":228,"2022":182,"2023":184,"2024":171,"2025":84,"2026":37},"year":2018,"title":"Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-rudin-nat-rev-dis-primers":{"doi":"10.1038/s41572-020-00235-0","openalexId":"W3121328438","cited":1632,"byYear":{"2021":66,"2022":216,"2023":328,"2024":379,"2025":394,"2026":245},"year":2021,"title":"Small-cell lung cancer"},"paper-curtin-kit-melanoma-jco-2006":{"doi":"10.1200/jco.2006.06.2984","openalexId":"W2156266404","cited":1619,"byYear":{"2012":126,"2013":131,"2014":123,"2015":102,"2016":102,"2017":85,"2018":73,"2019":80,"2020":90,"2021":68,"2022":62,"2023":42,"2024":44,"2025":37,"2026":19},"year":2006,"title":"Somatic Activation of KIT in Distinct Subtypes of Melanoma"},"paper-peto-smoking-cessation-lung-cancer-uk-bmj-2000":{"doi":"10.1136/bmj.321.7257.323","openalexId":"W2077030176","cited":1416,"byYear":{"2012":78,"2013":66,"2014":62,"2015":67,"2016":43,"2017":58,"2018":50,"2019":33,"2020":37,"2021":50,"2022":36,"2023":48,"2024":33,"2025":32,"2026":17},"year":2000,"title":"Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies"},"paper-spartan-nejm-2018":{"doi":"10.1056/nejmoa1715546","openalexId":"W2792086148","cited":1361,"byYear":{"2014":1,"2017":2,"2018":99,"2019":180,"2020":200,"2021":208,"2022":183,"2023":141,"2024":149,"2025":118,"2026":73},"year":2018,"title":"Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer"},"paper-trojani-int-j-cancer":{"doi":"10.1002/ijc.2910330108","openalexId":"W1983206829","cited":1329,"byYear":{"2012":44,"2013":54,"2014":48,"2015":40,"2016":46,"2017":46,"2018":44,"2019":58,"2020":64,"2021":63,"2022":98,"2023":82,"2024":67,"2025":52,"2026":32},"year":1984,"title":"Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system"},"paper-martincorena-science":{"doi":"10.1126/science.aau3879","openalexId":"W2897064819","cited":1197,"byYear":{"2017":1,"2018":12,"2019":143,"2020":181,"2021":188,"2022":183,"2023":164,"2024":122,"2025":113,"2026":89},"year":2018,"title":"Somatic mutant clones colonize the human esophagus with age"},"paper-ren-lancet-oncol":{"doi":"10.1016/s1470-2045(21)00252-7","openalexId":"W3166753505","cited":1151,"byYear":{"2021":22,"2022":180,"2023":265,"2024":296,"2025":243,"2026":143},"year":2021,"title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study"},"paper-mu-sox2-lineage-plasticity-science-2017":{"doi":"10.1126/science.aah4307","openalexId":"W2567986926","cited":1094,"byYear":{"2017":53,"2018":116,"2019":104,"2020":115,"2021":128,"2022":131,"2023":113,"2024":133,"2025":123,"2026":77},"year":2017,"title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer"},"paper-esmo-sts-guideline-gronchi-ann-oncol-2021":{"doi":"10.1016/j.annonc.2021.07.006","openalexId":"W4211038654","cited":1063,"byYear":{"2021":17,"2022":161,"2023":207,"2024":216,"2025":259,"2026":199},"year":2021,"title":"Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆"},"paper-caldecott-nat-rev-genet":{"doi":"10.1038/nrg2380","openalexId":"W1912177776","cited":1050,"byYear":{"2012":59,"2013":58,"2014":73,"2015":59,"2016":58,"2017":70,"2018":50,"2019":72,"2020":75,"2021":82,"2022":75,"2023":55,"2024":67,"2025":57,"2026":29},"year":2008,"title":"Single-strand break repair and genetic disease"},"paper-hayes-science":{"doi":"10.1126/science.ads0018","openalexId":"W4406440058","cited":762,"byYear":{"2020":1,"2024":10,"2025":342,"2026":409},"year":2025,"title":"Simulating 500 million years of evolution with a language model"},"paper-lin-tnbc-cns-metastases-dfci-cancer-2008":{"doi":"10.1002/cncr.23930","openalexId":"W2035570331","cited":745,"byYear":{"2012":35,"2013":37,"2014":30,"2015":49,"2016":35,"2017":44,"2018":32,"2019":37,"2020":49,"2021":55,"2022":61,"2023":72,"2024":56,"2025":46,"2026":28},"year":2008,"title":"Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer"},"paper-shattuck-n-engl-j-med":{"doi":"10.1056/nejmoa031237","openalexId":"W2115054276","cited":600,"byYear":{"2012":29,"2013":30,"2014":34,"2015":26,"2016":30,"2017":27,"2018":25,"2019":17,"2020":24,"2021":23,"2022":23,"2023":19,"2024":16,"2025":15,"2026":12},"year":2003,"title":"Somatic and Germ-Line Mutations of the HRPT2 Gene in Sporadic Parathyroid Carcinoma"},"paper-raajit-rampal-nature-2020":{"doi":"10.1038/s41586-020-2864-x","openalexId":"W3094802395","cited":552,"byYear":{"2020":8,"2021":91,"2022":130,"2023":91,"2024":110,"2025":72,"2026":49},"year":2020,"title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies"},"paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019":{"doi":"10.1172/jci96313","openalexId":"W2914282788","cited":451,"byYear":{"2019":12,"2020":38,"2021":65,"2022":87,"2023":67,"2024":65,"2025":56,"2026":60},"year":2019,"title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers"},"paper-grunwald-subtme-pancreatic-cell-2021":{"doi":"10.1016/j.cell.2021.09.022","openalexId":"W3206996158","cited":444,"byYear":{"2021":5,"2022":66,"2023":104,"2024":104,"2025":101,"2026":63},"year":2021,"title":"Spatially confined sub-tumor microenvironments in pancreatic cancer"},"paper-xu-jama":{"doi":"10.1001/jama.2023.19918","openalexId":"W4389326921","cited":407,"byYear":{"2021":1,"2024":87,"2025":181,"2026":138},"year":2023,"title":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer"},"paper-treon-blood":{"doi":"10.1182/blood-2014-01-550905","openalexId":"W2042887247","cited":390,"byYear":{"2013":1,"2014":16,"2015":25,"2016":42,"2017":49,"2018":40,"2019":37,"2020":30,"2021":33,"2022":36,"2023":25,"2024":24,"2025":20,"2026":10},"year":2014,"title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia"},"paper-morrow-j-clin-oncol":{"doi":"10.1200/jco.2016.68.3573","openalexId":"W2514536911","cited":388,"byYear":{"2014":1,"2015":1,"2016":10,"2017":38,"2018":35,"2019":51,"2020":48,"2021":40,"2022":33,"2023":31,"2024":33,"2025":36,"2026":29},"year":2016,"title":"Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ"},"paper-brock-n-engl-j-med":{"doi":"10.1056/nejmoa1801109","openalexId":"W2809505594","cited":384,"byYear":{"2017":1,"2018":11,"2019":38,"2020":41,"2021":42,"2022":30,"2023":58,"2024":68,"2025":53,"2026":41},"year":2018,"title":"Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss"},"paper-siop-cns-gct-96-calaminus-neuro-oncology-2013":{"doi":"10.1093/neuonc/not019","openalexId":"W2128316091","cited":378,"byYear":{"2012":1,"2013":6,"2014":19,"2015":21,"2016":13,"2017":26,"2018":24,"2019":40,"2020":36,"2021":41,"2022":38,"2023":39,"2024":28,"2025":26,"2026":17},"year":2013,"title":"SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease"},"paper-siopel-4-dose-dense-cisplatin-high-risk-hepatoblastoma-zsiros-lancet-oncol-2013":{"doi":"10.1016/s1470-2045(13)70272-9","openalexId":"W1964189436","cited":349,"byYear":{"2013":7,"2014":6,"2015":9,"2016":24,"2017":21,"2018":26,"2019":32,"2020":34,"2021":41,"2022":32,"2023":30,"2024":29,"2025":30,"2026":23},"year":2013,"title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study"},"paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009":{"doi":"10.1056/nejmoa0810613","openalexId":"W2016158954","cited":326,"byYear":{"2012":30,"2013":21,"2014":15,"2015":14,"2016":18,"2017":13,"2018":21,"2019":12,"2020":24,"2021":27,"2022":20,"2023":14,"2024":23,"2025":20,"2026":10},"year":2009,"title":"Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma"},"paper-domingo-somatic-pole-proofreading-colorectal-lancet-gastro-2016":{"doi":"10.1016/s2468-1253(16)30014-0","openalexId":"W2488353409","cited":313,"byYear":{"2016":4,"2017":17,"2018":26,"2019":39,"2020":33,"2021":41,"2022":38,"2023":36,"2024":40,"2025":26,"2026":13},"year":2016,"title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study"},"paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013":{"doi":"10.1371/journal.pmed.1001376","openalexId":"W2147340827","cited":225,"byYear":{"2013":3,"2014":12,"2015":22,"2016":12,"2017":11,"2018":15,"2019":20,"2020":20,"2021":20,"2022":14,"2023":22,"2024":19,"2025":20,"2026":15},"year":2013,"title":"Socioeconomic Inequalities in Lung Cancer Treatment: Systematic Review and Meta-Analysis"},"paper-nechuta-am-j-clin-nutr":{"doi":"10.3945/ajcn.112.035972","openalexId":"W2118917928","cited":205,"byYear":{"2012":2,"2013":18,"2014":16,"2015":10,"2016":18,"2017":15,"2018":13,"2019":7,"2020":15,"2021":13,"2022":40,"2023":7,"2024":10,"2025":16,"2026":5},"year":2012,"title":"Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women"},"paper-badwe-progesterone-jco-2011":{"doi":"10.1200/jco.2010.33.0738","openalexId":"W2152752482","cited":89,"byYear":{"2012":5,"2013":2,"2014":4,"2015":6,"2016":17,"2017":7,"2018":10,"2019":2,"2020":7,"2021":8,"2022":6,"2023":8,"2024":4,"2025":1},"year":2011,"title":"Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial"},"paper-english-cancer":{"doi":"10.1002/cncr.29062","openalexId":"W1579568789","cited":22,"byYear":{"2015":4,"2016":5,"2017":2,"2018":1,"2019":1,"2020":2,"2021":1,"2022":1,"2023":1,"2024":2,"2025":2},"year":2014,"title":"Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo"},"paper-peters-j-clin-oncol":{"doi":"10.1200/jco-25-02777","openalexId":"W7171355843","cited":2,"byYear":{"2026":2},"year":2026,"title":"SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer"},"paper-nct04665856-j-thorac-oncol-2026":{"doi":"10.1016/j.jtho.2026.103713","openalexId":"W7150965506","cited":0,"byYear":{},"year":2026,"title":"SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China"},"paper-sung-globocan-2020-cacancer-2021":{"doi":"10.3322/caac.21660","openalexId":"W3128646645","cited":114778,"byYear":{"2012":4,"2013":3,"2014":3,"2016":2,"2017":2,"2018":8,"2019":11,"2020":28,"2021":6915,"2022":22881,"2023":29457,"2024":32430,"2025":17192,"2026":5704},"year":2021,"title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries"},"paper-stupp-temozolomide-nejm-2005":{"doi":"10.1056/nejmoa043330","openalexId":"W2096287682","cited":22144,"byYear":{"2012":871,"2013":898,"2014":1016,"2015":1108,"2016":1066,"2017":1155,"2018":1171,"2019":1285,"2020":1506,"2021":1690,"2022":1597,"2023":1595,"2024":1589,"2025":1400,"2026":1100},"year":2005,"title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma"},"paper-parker-j-clin-oncol":{"doi":"10.1200/jco.2008.18.1370","openalexId":"W2132619562","cited":4982,"byYear":{"2012":161,"2013":233,"2014":273,"2015":301,"2016":325,"2017":271,"2018":297,"2019":345,"2020":371,"2021":447,"2022":359,"2023":427,"2024":401,"2025":273,"2026":189},"year":2009,"title":"Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes"},"paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015":{"doi":"10.1016/j.cell.2015.05.001","openalexId":"W1578291413","cited":3731,"byYear":{"2014":4,"2015":64,"2016":263,"2017":357,"2018":367,"2019":349,"2020":402,"2021":409,"2022":375,"2023":386,"2024":331,"2025":258,"2026":159},"year":2015,"title":"Integrative Clinical Genomics of Advanced Prostate Cancer"},"paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004":{"doi":"10.1056/nejmoa041318","openalexId":"W2080439368","cited":3703,"byYear":{"2012":236,"2013":245,"2014":214,"2015":210,"2016":198,"2017":176,"2018":166,"2019":124,"2020":122,"2021":139,"2022":123,"2023":85,"2024":92,"2025":56,"2026":26},"year":2004,"title":"Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer"},"paper-swog-8710-neoadjuvant-mvac-nejm-2003":{"doi":"10.1056/nejmoa022148","openalexId":"W1975918912","cited":2688,"byYear":{"2012":108,"2013":129,"2014":151,"2015":143,"2016":129,"2017":145,"2018":168,"2019":155,"2020":181,"2021":193,"2022":166,"2023":153,"2024":144,"2025":126,"2026":95},"year":2003,"title":"Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer"},"paper-demetri-sunitinib-gist-lancet-2006":{"doi":"10.1016/s0140-6736(06)69446-4","openalexId":"W2139511378","cited":2626,"byYear":{"2012":193,"2013":163,"2014":161,"2015":142,"2016":131,"2017":117,"2018":112,"2019":109,"2020":107,"2021":104,"2022":115,"2023":104,"2024":102,"2025":64,"2026":47},"year":2006,"title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial"},"paper-raymond-sunitinib-pnet-nejm-2011":{"doi":"10.1056/nejmoa1003825","openalexId":"W2158474413","cited":2568,"byYear":{"2012":221,"2013":206,"2014":234,"2015":203,"2016":177,"2017":193,"2018":178,"2019":165,"2020":148,"2021":172,"2022":153,"2023":127,"2024":105,"2025":117,"2026":57},"year":2011,"title":"Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors"},"paper-rhim-stroma-restrains-pancreatic-cancer-cell-2014":{"doi":"10.1016/j.ccr.2014.04.021","openalexId":"W1996912024","cited":2104,"byYear":{"2014":44,"2015":120,"2016":178,"2017":159,"2018":164,"2019":165,"2020":211,"2021":230,"2022":231,"2023":178,"2024":156,"2025":135,"2026":132},"year":2014,"title":"Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma"},"paper-li-j-mol-diagn":{"doi":"10.1016/j.jmoldx.2016.10.002","openalexId":"W2566723262","cited":2101,"byYear":{"2012":1,"2017":53,"2018":101,"2019":172,"2020":189,"2021":257,"2022":276,"2023":242,"2024":309,"2025":279,"2026":221},"year":2016,"title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer"},"paper-collisson-pancreatic-subtypes-nat-med-2011":{"doi":"10.1038/nm.2344","openalexId":"W2154790710","cited":2066,"byYear":{"2012":39,"2013":46,"2014":44,"2015":64,"2016":88,"2017":112,"2018":121,"2019":158,"2020":207,"2021":233,"2022":245,"2023":219,"2024":185,"2025":158,"2026":128},"year":2011,"title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy"},"paper-rtog-0617-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71207-0","openalexId":"W1968899146","cited":2050,"byYear":{"2012":1,"2014":4,"2015":93,"2016":163,"2017":198,"2018":213,"2019":214,"2020":251,"2021":209,"2022":167,"2023":155,"2024":166,"2025":122,"2026":90},"year":2015,"title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study"},"paper-sabr-comet-lancet-2019":{"doi":"10.1016/s0140-6736(18)32487-5","openalexId":"W2939770857","cited":1899,"byYear":{"2016":1,"2017":1,"2018":1,"2019":110,"2020":378,"2021":335,"2022":326,"2023":240,"2024":216,"2025":170,"2026":116},"year":2019,"title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial"},"paper-stampede-abiraterone-nejm-2017":{"doi":"10.1056/nejmoa1702900","openalexId":"W2620746860","cited":1809,"byYear":{"2015":1,"2016":1,"2017":95,"2018":240,"2019":234,"2020":226,"2021":221,"2022":193,"2023":176,"2024":164,"2025":162,"2026":92},"year":2017,"title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy"},"paper-kras-nsclc-cancer-discov-2018":{"doi":"10.1158/2159-8290.cd-18-0099","openalexId":"W2804812017","cited":1677,"byYear":{"2018":27,"2019":108,"2020":246,"2021":270,"2022":230,"2023":221,"2024":224,"2025":190,"2026":160},"year":2018,"title":"STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma"},"paper-hpv-vaccine-sweden-nejm-2020":{"doi":"10.1056/nejmoa1917338","openalexId":"W3090300247","cited":1520,"byYear":{"2020":13,"2021":270,"2022":256,"2023":278,"2024":254,"2025":263,"2026":181},"year":2020,"title":"HPV Vaccination and the Risk of Invasive Cervical Cancer"},"paper-palma-j-clin-oncol":{"doi":"10.1200/jco.20.00818","openalexId":"W3032651552","cited":1299,"byYear":{"2020":47,"2021":168,"2022":247,"2023":233,"2024":222,"2025":239,"2026":143},"year":2020,"title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial"},"paper-storm-adjuvant-sorafenib-bruix-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(15)00198-9","openalexId":"W2115991409","cited":1132,"byYear":{"2014":1,"2015":17,"2016":68,"2017":106,"2018":98,"2019":97,"2020":123,"2021":112,"2022":109,"2023":119,"2024":120,"2025":99,"2026":59},"year":2015,"title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial"},"paper-calon-stromal-gene-expression-poor-prognosis-colorectal-nat-genet-2015":{"doi":"10.1038/ng.3225","openalexId":"W2085963386","cited":1119,"byYear":{"2014":1,"2015":40,"2016":88,"2017":108,"2018":84,"2019":108,"2020":115,"2021":178,"2022":122,"2023":102,"2024":81,"2025":53,"2026":39},"year":2015,"title":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer"},"paper-ssg-xviii-adjuvant-imatinib-joensuu-jama-2012":{"doi":"10.1001/jama.2012.347","openalexId":"W1970687736","cited":984,"byYear":{"2012":48,"2013":91,"2014":112,"2015":96,"2016":72,"2017":79,"2018":75,"2019":69,"2020":60,"2021":55,"2022":58,"2023":46,"2024":42,"2025":44,"2026":28},"year":2012,"title":"One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor"},"paper-jean-pascal-machiels-ann-oncol-2020":{"doi":"10.1016/j.annonc.2020.07.011","openalexId":"W3200779885","cited":929,"byYear":{"2020":1,"2021":66,"2022":132,"2023":168,"2024":203,"2025":196,"2026":160},"year":2020,"title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-spotlight-lancet-2023":{"doi":"10.1016/s0140-6736(23)00620-7","openalexId":"W4365813058","cited":828,"byYear":{"2023":71,"2024":235,"2025":257,"2026":265},"year":2023,"title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial"},"paper-stojdl-vsv-interferon-defect-natmed-2000":{"doi":"10.1038/77558","openalexId":"W1542691850","cited":819,"byYear":{"2012":34,"2013":49,"2014":33,"2015":27,"2016":31,"2017":30,"2018":37,"2019":28,"2020":31,"2021":37,"2022":30,"2023":32,"2024":25,"2025":22,"2026":10},"year":2000,"title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus"},"paper-kumar-interindividual-genomic-diversity-metastatic-prostate-nat-med-2016":{"doi":"10.1038/nm.4053","openalexId":"W2292362441","cited":778,"byYear":{"2014":1,"2016":28,"2017":66,"2018":92,"2019":95,"2020":93,"2021":86,"2022":82,"2023":84,"2024":62,"2025":66,"2026":23},"year":2016,"title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer"},"paper-barretina-nat-genet":{"doi":"10.1038/ng.619","openalexId":"W2086797990","cited":741,"byYear":{"2012":29,"2013":59,"2014":71,"2015":57,"2016":34,"2017":53,"2018":47,"2019":58,"2020":53,"2021":59,"2022":42,"2023":49,"2024":26,"2025":21,"2026":27},"year":2010,"title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy"},"paper-isella-stromal-contribution-colorectal-transcriptome-nat-genet-2015":{"doi":"10.1038/ng.3224","openalexId":"W2033751993","cited":678,"byYear":{"2014":1,"2015":35,"2016":64,"2017":78,"2018":62,"2019":62,"2020":67,"2021":70,"2022":59,"2023":62,"2024":63,"2025":35,"2026":20},"year":2015,"title":"Stromal contribution to the colorectal cancer transcriptome"},"paper-peter-thuss-patience-eur-j-cancer-2011":{"doi":"10.1016/j.ejca.2011.06.002","openalexId":"W2104631255","cited":618,"byYear":{"2012":30,"2013":43,"2014":45,"2015":58,"2016":53,"2017":52,"2018":62,"2019":35,"2020":46,"2021":43,"2022":40,"2023":36,"2024":30,"2025":21,"2026":11},"year":2011,"title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)"},"paper-chisel-lancet-oncol-2019":{"doi":"10.1016/s1470-2045(18)30896-9","openalexId":"W2911260009","cited":600,"byYear":{"2019":48,"2020":84,"2021":84,"2022":91,"2023":96,"2024":98,"2025":66,"2026":33},"year":2019,"title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial"},"paper-puleo-pancreatic-tumour-microenvironment-subtypes-gastroenterology-2018":{"doi":"10.1053/j.gastro.2018.08.033","openalexId":"W2889433609","cited":599,"byYear":{"2018":4,"2019":33,"2020":76,"2021":111,"2022":83,"2023":102,"2024":78,"2025":67,"2026":44},"year":2018,"title":"Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features"},"paper-obenauf-trends-cancer":{"doi":"10.1016/j.trecan.2015.07.009","openalexId":"W2145990138","cited":598,"byYear":{"2016":16,"2017":28,"2018":35,"2019":65,"2020":71,"2021":72,"2022":91,"2023":69,"2024":69,"2025":50,"2026":31},"year":2015,"title":"Surviving at a Distance: Organ-Specific Metastasis"},"paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013":{"doi":"10.1056/nejmoa1212299","openalexId":"W2081084828","cited":583,"byYear":{"2013":34,"2014":54,"2015":68,"2016":56,"2017":49,"2018":43,"2019":36,"2020":40,"2021":45,"2022":35,"2023":23,"2024":43,"2025":34,"2026":21},"year":2013,"title":"Intermittent versus Continuous Androgen Deprivation in Prostate Cancer"},"paper-bill-axelson-spcg-4-29-year-nejm-2018":{"doi":"10.1056/nejmoa1807801","openalexId":"W2905295080","cited":505,"byYear":{"2018":1,"2019":55,"2020":91,"2021":91,"2022":57,"2023":65,"2024":68,"2025":49,"2026":24},"year":2018,"title":"Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up"},"paper-strass-lancet-oncol-2020":{"doi":"10.1016/s1470-2045(20)30446-0","openalexId":"W3086258129","cited":499,"byYear":{"2020":19,"2021":71,"2022":88,"2023":94,"2024":77,"2025":90,"2026":54},"year":2020,"title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial"},"paper-zhukova-tp53-medulloblastoma-jco-2013":{"doi":"10.1200/jco.2012.48.5052","openalexId":"W2129331946","cited":492,"byYear":{"2012":1,"2013":4,"2014":29,"2015":30,"2016":33,"2017":35,"2018":46,"2019":44,"2020":48,"2021":55,"2022":40,"2023":30,"2024":36,"2025":39,"2026":18},"year":2013,"title":"Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma"},"paper-swog-s0809-adjuvant-chemoradiation-jco-2015":{"doi":"10.1200/jco.2014.60.2219","openalexId":"W2124474327","cited":420,"byYear":{"2012":1,"2013":1,"2015":6,"2016":22,"2017":32,"2018":28,"2019":37,"2020":53,"2021":50,"2022":39,"2023":45,"2024":38,"2025":41,"2026":25},"year":2015,"title":"SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma"},"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016":{"doi":"10.1016/s1470-2045(15)00489-1","openalexId":"W2210989209","cited":408,"byYear":{"2015":3,"2016":39,"2017":67,"2018":66,"2019":66,"2020":43,"2021":30,"2022":33,"2023":19,"2024":17,"2025":16,"2026":8},"year":2015,"title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data"},"paper-stampede-abiraterone-high-risk-attard-lancet-2022":{"doi":"10.1016/s0140-6736(21)02437-5","openalexId":"W4200383319","cited":388,"byYear":{"2022":65,"2023":95,"2024":83,"2025":83,"2026":62},"year":2021,"title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol"},"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018":{"doi":"10.1093/annonc/mdy460","openalexId":"W2895846919","cited":310,"byYear":{"2018":1,"2019":26,"2020":40,"2021":62,"2022":58,"2023":35,"2024":53,"2025":17,"2026":17},"year":2018,"title":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto"},"paper-spearhead-1-lancet-2024":{"doi":"10.1016/s0140-6736(24)00319-2","openalexId":"W4393238683","cited":294,"byYear":{"2014":1,"2024":39,"2025":152,"2026":102},"year":2024,"title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial"},"paper-hur-sugar-sweetened-beverages-early-onset-colorectal-gut-2021":{"doi":"10.1136/gutjnl-2020-323450","openalexId":"W3159187004","cited":247,"byYear":{"2021":8,"2022":44,"2023":72,"2024":39,"2025":51,"2026":33},"year":2021,"title":"Sugar-sweetened beverage intake in adulthood and adolescence and risk of early-onset colorectal cancer among women"},"paper-gemstone-302-lancet-oncol-2022":{"doi":"10.1016/s1470-2045(21)00650-1","openalexId":"W4205569586","cited":237,"byYear":{"2022":33,"2023":60,"2024":58,"2025":55,"2026":31},"year":2022,"title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial"},"paper-lee-t2-gallbladder-cancer-surgical-strategy-aso-2015":{"doi":"10.1245/s10434-014-4300-7","openalexId":"W2056099284","cited":88,"byYear":{"2013":1,"2016":1,"2017":3,"2018":8,"2019":6,"2020":13,"2021":17,"2022":8,"2023":10,"2024":10,"2025":7,"2026":2},"year":2014,"title":"Surgical Strategy for T2 Gallbladder Cancer According to Tumor Location"},"paper-nct05712902-lancet-respir-med-2024":{"doi":"10.1016/s2213-2600(23)00379-x","openalexId":"W4389606425","cited":70,"byYear":{"2023":2,"2024":18,"2025":34,"2026":16},"year":2023,"title":"Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial"},"paper-topham-subtype-discordant-pancreatic-ccr-2021":{"doi":"10.1158/1078-0432.ccr-20-2831","openalexId":"W3091923748","cited":62,"byYear":{"2021":5,"2022":8,"2023":16,"2024":19,"2025":9,"2026":5},"year":2020,"title":"Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics"},"paper-sunrise-1-jco-2025":{"doi":"10.1200/jco-25-01651","openalexId":"W4412744020","cited":45,"byYear":{"2025":5,"2026":40},"year":2025,"title":"TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study"},"paper-nct05722015-ann-oncol-2025":{"doi":"10.1016/j.annonc.2025.03.012","openalexId":"W4408967923","cited":39,"byYear":{"2025":8,"2026":31},"year":2025,"title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial"},"paper-bakker-n-engl-j-med":{"doi":"10.1056/nejmoa1903986","openalexId":"W2991330623","cited":721,"byYear":{"2019":2,"2020":82,"2021":100,"2022":117,"2023":126,"2024":137,"2025":80,"2026":74},"year":2019,"title":"Supplemental MRI Screening for Women with Extremely Dense Breast Tissue"},"paper-mcclements-capbil-surgical-outcomes-gallbladder-cancer-hpb-2026":{"doi":"10.1016/j.hpb.2026.06.009","openalexId":"W7165581396","cited":0,"byYear":{},"year":2026,"title":"Surgical outcomes in gallbladder cancer: evidence from the UK nationwide CAPBIL study"},"paper-olympia-6-year-update-ann-oncol-2026":{"doi":"10.1016/j.annonc.2026.08.002","openalexId":"W7204088122","cited":0,"byYear":{},"year":2026,"title":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial"},"paper-nct05168566-j-thorac-oncol-2026":{"doi":"10.1016/j.jtho.2026.104165","openalexId":"W7204093332","cited":0,"byYear":{},"year":2026,"title":"Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial"},"paper-who-2021-cns-louis-neuro-oncology-2021":{"doi":"10.1093/neuonc/noab106","openalexId":"W3174246647","cited":12654,"byYear":{"2012":1,"2013":5,"2014":2,"2015":5,"2016":2,"2017":5,"2020":2,"2021":271,"2022":1834,"2023":2633,"2024":3096,"2025":2673,"2026":2083},"year":2021,"title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary"},"paper-temel-early-palliative-care-nejm-2010":{"doi":"10.1056/nejmoa1000678","openalexId":"W2147016542","cited":7563,"byYear":{"2012":357,"2013":404,"2014":452,"2015":477,"2016":530,"2017":599,"2018":542,"2019":527,"2020":546,"2021":544,"2022":520,"2023":470,"2024":486,"2025":417,"2026":344},"year":2010,"title":"Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer"},"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004":{"doi":"10.1056/nejmoa040720","openalexId":"W2120292596","cited":5780,"byYear":{"2012":394,"2013":370,"2014":343,"2015":336,"2016":322,"2017":279,"2018":279,"2019":242,"2020":280,"2021":275,"2022":243,"2023":175,"2024":198,"2025":134,"2026":89},"year":2004,"title":"Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer"},"paper-mariathasan-nature":{"doi":"10.1038/nature25501","openalexId":"W2785803176","cited":5741,"byYear":{"2012":1,"2017":1,"2018":142,"2019":285,"2020":488,"2021":740,"2022":1066,"2023":932,"2024":921,"2025":600,"2026":562},"year":2018,"title":"TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells"},"paper-who-2019-digestive-system-tumours-nagtegaal-histopathology-2020":{"doi":"10.1111/his.13975","openalexId":"W2969542839","cited":4276,"byYear":{"2012":8,"2013":5,"2014":13,"2015":12,"2016":8,"2017":12,"2018":12,"2019":24,"2020":263,"2021":534,"2022":631,"2023":792,"2024":746,"2025":708,"2026":486},"year":2019,"title":"The 2019 WHO classification of tumours of the digestive system"},"paper-paszek-cancer-cell":{"doi":"10.1016/j.ccr.2005.08.010","openalexId":"W2099052265","cited":4014,"byYear":{"2012":183,"2013":237,"2014":223,"2015":245,"2016":235,"2017":261,"2018":267,"2019":227,"2020":288,"2021":246,"2022":208,"2023":181,"2024":160,"2025":178,"2026":125},"year":2005,"title":"Tensional homeostasis and the malignant phenotype"},"paper-tcga-molecular-taxonomy-primary-prostate-cell-2015":{"doi":"10.1016/j.cell.2015.10.025","openalexId":"W2161112598","cited":3306,"byYear":{"2014":1,"2015":5,"2016":144,"2017":272,"2018":354,"2019":328,"2020":398,"2021":395,"2022":356,"2023":368,"2024":323,"2025":207,"2026":153},"year":2015,"title":"The Molecular Taxonomy of Primary Prostate Cancer"},"paper-tcga-pancancer-atlas-cell-2018":{"doi":"10.1016/j.cell.2018.03.022","openalexId":"W2796153844","cited":2787,"byYear":{"2013":1,"2018":70,"2019":197,"2020":371,"2021":433,"2022":406,"2023":390,"2024":365,"2025":306,"2026":245},"year":2018,"title":"Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer"},"paper-tailorx-nejm-2018":{"doi":"10.1056/nejmoa1804710","openalexId":"W2805734855","cited":2449,"byYear":{"2013":1,"2018":103,"2019":299,"2020":307,"2021":378,"2022":293,"2023":327,"2024":278,"2025":269,"2026":183},"year":2018,"title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer"},"paper-embraca-n-engl-j-med-2018":{"doi":"10.1056/nejmoa1802905","openalexId":"W2886477543","cited":2206,"byYear":{"2016":1,"2017":1,"2018":20,"2019":197,"2020":284,"2021":324,"2022":360,"2023":330,"2024":268,"2025":241,"2026":173},"year":2018,"title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation"},"paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013":{"doi":"10.1073/pnas.1320318110","openalexId":"W2086834665","cited":2126,"byYear":{"2014":30,"2015":63,"2016":95,"2017":121,"2018":126,"2019":153,"2020":207,"2021":250,"2022":228,"2023":224,"2024":255,"2025":159,"2026":213},"year":2013,"title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer"},"paper-tauriello-tgfbeta-immune-evasion-colorectal-nature-2018":{"doi":"10.1038/nature25492","openalexId":"W2788975052","cited":1893,"byYear":{"2018":95,"2019":176,"2020":263,"2021":317,"2022":311,"2023":215,"2024":167,"2025":187,"2026":162},"year":2018,"title":"TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis"},"paper-steeg-nat-rev-cancer":{"doi":"10.1038/nrc.2016.25","openalexId":"W4211214747","cited":1397,"byYear":{"2016":25,"2017":119,"2018":119,"2019":129,"2020":217,"2021":176,"2022":168,"2023":139,"2024":162,"2025":98,"2026":44},"year":2016,"title":"Targeting metastasis"},"paper-roberts-ph-like-all-nejm-2014":{"doi":"10.1056/nejmoa1403088","openalexId":"W2148202982","cited":1396,"byYear":{"2012":4,"2014":18,"2015":105,"2016":132,"2017":143,"2018":129,"2019":122,"2020":141,"2021":151,"2022":116,"2023":121,"2024":97,"2025":72,"2026":43},"year":2014,"title":"Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia"},"paper-malmstrom-lancet-oncol":{"doi":"10.1016/s1470-2045(12)70265-6","openalexId":"W2107731988","cited":1296,"byYear":{"2012":19,"2013":78,"2014":98,"2015":101,"2016":86,"2017":121,"2018":94,"2019":89,"2020":125,"2021":120,"2022":102,"2023":93,"2024":74,"2025":52,"2026":38},"year":2012,"title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial"},"paper-shay-nat-rev-genet":{"doi":"10.1038/s41576-019-0099-1","openalexId":"W2914968800","cited":955,"byYear":{"2018":1,"2019":35,"2020":101,"2021":134,"2022":140,"2023":183,"2024":154,"2025":122,"2026":84},"year":2019,"title":"Telomeres and telomerase: three decades of progress"},"paper-blinatumomab-all-leukemia-j-clin-oncol-2011":{"doi":"10.1200/jco.2010.32.7270","openalexId":"W2118241155","cited":921,"byYear":{"2012":92,"2013":80,"2014":81,"2015":97,"2016":89,"2017":88,"2018":52,"2019":62,"2020":43,"2021":49,"2022":35,"2023":34,"2024":37,"2025":30,"2026":23},"year":2011,"title":"Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival"},"paper-goonetilleke-ca19-9-systematic-review-ejso-2007":{"doi":"10.1016/j.ejso.2006.10.004","openalexId":"W2121289368","cited":887,"byYear":{"2012":40,"2013":63,"2014":44,"2015":45,"2016":53,"2017":57,"2018":60,"2019":66,"2020":58,"2021":55,"2022":78,"2023":46,"2024":62,"2025":41,"2026":27},"year":2006,"title":"Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer"},"paper-gordan-j-clin-oncol":{"doi":"10.1200/jco.20.02672","openalexId":"W3100629716","cited":617,"byYear":{"2020":2,"2021":75,"2022":167,"2023":147,"2024":143,"2025":57,"2026":25},"year":2020,"title":"Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline"},"paper-talapro-2-lancet-2023":{"doi":"10.1016/s0140-6736(23)01055-3","openalexId":"W4379285544","cited":536,"byYear":{"2023":56,"2024":194,"2025":187,"2026":99},"year":2023,"title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial"},"paper-hainsworth-j-clin-oncol":{"doi":"10.1200/jco.2017.75.3780","openalexId":"W2783112448","cited":510,"byYear":{"2014":1,"2016":2,"2017":9,"2018":45,"2019":64,"2020":61,"2021":78,"2022":68,"2023":69,"2024":50,"2025":39,"2026":23},"year":2018,"title":"Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study"},"paper-di-maio-j-clin-oncol":{"doi":"10.1200/jco.2014.57.9334","openalexId":"W2156635540","cited":508,"byYear":{"2015":22,"2016":38,"2017":39,"2018":41,"2019":43,"2020":51,"2021":54,"2022":51,"2023":45,"2024":57,"2025":39,"2026":26},"year":2015,"title":"Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials"},"paper-baumert-lancet-oncol":{"doi":"10.1016/s1470-2045(16)30313-8","openalexId":"W7212046136","cited":5,"byYear":{"2018":1,"2020":1,"2021":1,"2026":2},"year":2016,"title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study"},"paper-pemmaraju-n-engl-j-med":{"doi":"10.1056/nejmoa1815105","openalexId":"W2940782615","cited":438,"byYear":{"2019":27,"2020":59,"2021":70,"2022":59,"2023":68,"2024":58,"2025":53,"2026":43},"year":2019,"title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm"},"paper-gounder-lancet-oncol":{"doi":"10.1016/s1470-2045(20)30451-4","openalexId":"W3092409743","cited":433,"byYear":{"2019":1,"2020":5,"2021":52,"2022":74,"2023":69,"2024":99,"2025":76,"2026":57},"year":2020,"title":"Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study"},"paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019":{"doi":"10.1053/j.gastro.2019.06.041","openalexId":"W2958334035","cited":411,"byYear":{"2013":1,"2019":1,"2020":37,"2021":78,"2022":56,"2023":63,"2024":72,"2025":58,"2026":45},"year":2019,"title":"Terminology, Molecular Features, Epidemiology, and Management of Serrated Colorectal Neoplasia"},"paper-zadik-support-care-cancer":{"doi":"10.1007/s00520-019-04890-2","openalexId":"W2957712509","cited":373,"byYear":{"2019":7,"2020":63,"2021":64,"2022":55,"2023":59,"2024":55,"2025":43,"2026":26},"year":2019,"title":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines"},"paper-laurie-licitra-salivary-systemic-jco-2006":{"doi":"10.1200/jco.2005.05.3025","openalexId":"W1993487250","cited":301,"byYear":{"2012":20,"2013":19,"2014":19,"2015":21,"2016":14,"2017":14,"2018":9,"2019":21,"2020":12,"2021":15,"2022":14,"2023":14,"2024":7,"2025":10,"2026":11},"year":2006,"title":"Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers"},"paper-mikhael-j-clin-oncol":{"doi":"10.1200/jco.22.01345","openalexId":"W4315749947","cited":285,"byYear":{"2022":1,"2023":39,"2024":73,"2025":92,"2026":80},"year":2023,"title":"Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography"},"paper-tarlatamab-sclc-n-engl-j-med-2025":{"doi":"10.1056/nejmoa2502099","openalexId":"W4410961676","cited":273,"byYear":{"2025":75,"2026":198},"year":2025,"title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy"},"paper-swog-s1826-nivolumab-avd-nejm-2024":{"doi":"10.1056/nejmoa2405888","openalexId":"W4403462752","cited":249,"byYear":{"2020":1,"2024":9,"2025":121,"2026":118},"year":2024,"title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma"},"paper-ashkenazi-j-clin-invest":{"doi":"10.1172/jci80420","openalexId":"W2092524729","cited":243,"byYear":{"2015":10,"2016":30,"2017":25,"2018":21,"2019":26,"2020":34,"2021":29,"2022":17,"2023":19,"2024":13,"2025":10,"2026":9},"year":2015,"title":"Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions"},"paper-irwin-j-clin-oncol":{"doi":"10.1200/jco.2016.71.0285","openalexId":"W2613454393","cited":207,"byYear":{"2017":5,"2018":11,"2019":17,"2020":23,"2021":30,"2022":22,"2023":26,"2024":25,"2025":27,"2026":20},"year":2017,"title":"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferiority Trial"},"paper-luminosity-j-clin-oncol-2024":{"doi":"10.1200/jco.24.00720","openalexId":"W4399395212","cited":172,"byYear":{"2023":10,"2024":12,"2025":65,"2026":85},"year":2024,"title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial"},"paper-nagaraja-eslick-typhi-carrier-gallbladder-cancer-meta-analysis-apt-2014":{"doi":"10.1111/apt.12655","openalexId":"W1972866964","cited":162,"byYear":{"2014":3,"2015":2,"2016":12,"2017":8,"2018":9,"2019":12,"2020":18,"2021":24,"2022":17,"2023":15,"2024":13,"2025":14,"2026":14},"year":2014,"title":"Systematic review with meta‐analysis: the relationship between chronic S almonella typhi carrier status and gall‐bladder cancer"},"paper-tebentafusp-melanoma-cancers-basel-2019":{"doi":"10.3390/cancers11070971","openalexId":"W2957721117","cited":155,"byYear":{"2019":3,"2020":16,"2021":25,"2022":22,"2023":32,"2024":27,"2025":20,"2026":10},"year":2019,"title":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma"},"paper-zon-jco-oncol-pract":{"doi":"10.1200/op.21.00438","openalexId":"W3185703835","cited":152,"byYear":{"2021":3,"2022":37,"2023":33,"2024":36,"2025":23,"2026":20},"year":2021,"title":"Telehealth in Oncology: ASCO Standards and Practice Recommendations"},"paper-soreide-incidental-gallbladder-cancer-review-bjs-2019":{"doi":"10.1002/bjs.11035","openalexId":"W2905704347","cited":149,"byYear":{"2019":12,"2020":21,"2021":17,"2022":21,"2023":23,"2024":28,"2025":18,"2026":9},"year":2018,"title":"Systematic review of management of incidental gallbladder cancer after cholecystectomy"},"paper-nct02864992-jama-oncol-2023-update":{"doi":"10.1001/jamaoncol.2023.1962","openalexId":"W4379278548","cited":113,"byYear":{"2023":8,"2024":32,"2025":38,"2026":34},"year":2023,"title":"Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer"},"paper-greer-jama":{"doi":"10.1001/jama.2024.13964","openalexId":"W4402455522","cited":108,"byYear":{"2024":7,"2025":41,"2026":60},"year":2024,"title":"Telehealth vs In-Person Early Palliative Care for Patients With Advanced Lung Cancer"},"paper-lineweaver-bioessays":{"doi":"10.1002/bies.201400070","openalexId":"W2162907510","cited":94,"byYear":{"2014":1,"2015":3,"2016":5,"2017":8,"2018":6,"2019":5,"2020":8,"2021":17,"2022":9,"2023":8,"2024":19,"2025":4,"2026":1},"year":2014,"title":"Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model"},"paper-lung-map-j-thorac-oncol-2019":{"doi":"10.1016/j.jtho.2019.06.027","openalexId":"W2957919816","cited":78,"byYear":{"2018":2,"2019":2,"2020":13,"2021":17,"2022":17,"2023":8,"2024":12,"2025":3,"2026":4},"year":2019,"title":"SWOG S1400C (NCT02154490)—A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration–Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy)"},"paper-talapro-2-lancet-2025-update":{"doi":"10.1016/s0140-6736(25)00684-1","openalexId":"W4412522153","cited":51,"byYear":{"2025":13,"2026":38},"year":2025,"title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial"},"paper-st-gallen-2025-consensus-ann-oncol-2025":{"doi":"10.1016/j.annonc.2025.09.007","openalexId":"W4415000885","cited":39,"byYear":{"2025":2,"2026":37},"year":2025,"title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer"},"paper-jain-talicabtagene-lancet-haem-2025":{"doi":"10.1016/s2352-3026(24)00377-6","openalexId":"W4408392398","cited":17,"byYear":{"2025":6,"2026":11},"year":2025,"title":"Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study"},"paper-ezh2-sarcoma-biochem-pharmacol-2023":{"doi":"10.1016/j.bcp.2023.115727","openalexId":"W4385494385","cited":27,"byYear":{"2023":1,"2024":7,"2025":11,"2026":8},"year":2023,"title":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors"},"paper-nct03436485-nejm-evid-2024":{"doi":"10.1056/evidoa2300171","openalexId":"W4390227891","cited":26,"byYear":{"2023":2,"2024":9,"2025":11,"2026":4},"year":2023,"title":"Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer"},"paper-ishiguro-dichloroacetate-ivermectin-cureus-2022":{"doi":"10.7759/cureus.21884","openalexId":"W4210673961","cited":11,"byYear":{"2022":2,"2023":5,"2024":2,"2025":1,"2026":1},"year":2022,"title":"Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin"},"paper-luminosity-jto-clin-res-rep-2026-update":{"doi":"10.1016/j.jtocrr.2026.100988","openalexId":"W7136469112","cited":2,"byYear":{"2026":2},"year":2026,"title":"Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial"},"paper-hallmarks-of-cancer-cell-2000":{"doi":"10.1016/s0092-8674(00)81683-9","openalexId":"W2034269086","cited":28976,"byYear":{"2012":1475,"2013":1394,"2014":1399,"2015":1343,"2016":1194,"2017":1161,"2018":1093,"2019":1137,"2020":1240,"2021":1297,"2022":1180,"2023":1035,"2024":966,"2025":826,"2026":398},"year":2000,"title":"The Hallmarks of Cancer"},"paper-nowell-science":{"doi":"10.1126/science.959840","openalexId":"W1967304777","cited":6646,"byYear":{"2012":201,"2013":228,"2014":246,"2015":262,"2016":273,"2017":347,"2018":322,"2019":280,"2020":313,"2021":299,"2022":229,"2023":218,"2024":196,"2025":165,"2026":111},"year":1976,"title":"The Clonal Evolution of Tumor Cell Populations"},"paper-pavlova-cell-metab":{"doi":"10.1016/j.cmet.2015.12.006","openalexId":"W2234115940","cited":6225,"byYear":{"2012":1,"2016":105,"2017":258,"2018":355,"2019":486,"2020":647,"2021":925,"2022":890,"2023":747,"2024":751,"2025":562,"2026":497},"year":2016,"title":"The Emerging Hallmarks of Cancer Metabolism"},"paper-cms-guinney-nat-med-2015":{"doi":"10.1038/nm.3967","openalexId":"W1934094702","cited":5428,"byYear":{"2013":1,"2014":2,"2015":10,"2016":155,"2017":306,"2018":391,"2019":448,"2020":583,"2021":675,"2022":682,"2023":628,"2024":582,"2025":525,"2026":427},"year":2015,"title":"The consensus molecular subtypes of colorectal cancer"},"paper-paget-cancer-metastasis-rev":{"doi":"10.1016/s0140-6736(00)49915-0","openalexId":"W1985727076","cited":5202,"byYear":{"2012":206,"2013":202,"2014":191,"2015":199,"2016":201,"2017":239,"2018":241,"2019":259,"2020":302,"2021":329,"2022":302,"2023":282,"2024":240,"2025":176,"2026":66},"year":1889,"title":"THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST."},"paper-herbst-nature":{"doi":"10.1038/nature25183","openalexId":"W2784371446","cited":5130,"byYear":{"2014":1,"2018":53,"2019":204,"2020":518,"2021":755,"2022":869,"2023":777,"2024":808,"2025":709,"2026":434},"year":2018,"title":"The biology and management of non-small cell lung cancer"},"paper-kalluri-nat-rev-cancer":{"doi":"10.1038/nrc.2016.73","openalexId":"W2512899508","cited":4492,"byYear":{"2016":4,"2017":145,"2018":276,"2019":364,"2020":491,"2021":622,"2022":563,"2023":605,"2024":541,"2025":461,"2026":416},"year":2016,"title":"The biology and function of fibroblasts in cancer"},"paper-de-visser-cancer-cell":{"doi":"10.1016/j.ccell.2023.02.016","openalexId":"W4324046169","cited":4034,"byYear":{"2016":1,"2022":2,"2023":210,"2024":1033,"2025":1647,"2026":1141},"year":2023,"title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth"},"paper-stratton-nature":{"doi":"10.1038/nature07943","openalexId":"W2059300459","cited":3581,"byYear":{"2012":200,"2013":229,"2014":196,"2015":204,"2016":249,"2017":245,"2018":234,"2019":234,"2020":232,"2021":264,"2022":240,"2023":188,"2024":218,"2025":182,"2026":82},"year":2009,"title":"The cancer genome"},"paper-morris-j-r-soc-med":{"doi":"10.1258/jrsm.2011.110180","openalexId":"W2142149055","cited":3466,"byYear":{"2012":7,"2013":16,"2014":39,"2015":74,"2016":109,"2017":143,"2018":185,"2019":229,"2020":343,"2021":368,"2022":318,"2023":505,"2024":509,"2025":406,"2026":211},"year":2011,"title":"The answer is 17 years, what is the question: understanding time lags in translational research"},"paper-rieke-npj-digit-med":{"doi":"10.1038/s41746-020-00323-1","openalexId":"W3012501605","cited":3084,"byYear":{"2012":1,"2020":9,"2021":115,"2022":306,"2023":418,"2024":521,"2025":765,"2026":947},"year":2020,"title":"The future of digital health with federated learning"},"paper-heald-mesorectum-rectal-cancer-surgery-br-j-surg-1982":{"doi":"10.1002/bjs.1800691019","openalexId":"W2009781085","cited":2960,"byYear":{"2012":77,"2013":94,"2014":118,"2015":110,"2016":132,"2017":125,"2018":156,"2019":141,"2020":163,"2021":168,"2022":162,"2023":148,"2024":113,"2025":98,"2026":81},"year":1982,"title":"The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?"},"paper-hu-signal-transduct-target-ther":{"doi":"10.1038/s41392-021-00791-1","openalexId":"W3216146155","cited":2641,"byYear":{"2019":1,"2020":1,"2021":1,"2022":143,"2023":462,"2024":735,"2025":777,"2026":520},"year":2021,"title":"The JAK/STAT signaling pathway: from bench to clinic"},"paper-protac-concept-sakamoto-pnas-2001":{"doi":"10.1073/pnas.141230798","openalexId":"W2151683271","cited":2576,"byYear":{"2012":10,"2013":9,"2014":13,"2015":15,"2016":27,"2017":47,"2018":80,"2019":117,"2020":202,"2021":232,"2022":300,"2023":323,"2024":388,"2025":421,"2026":292},"year":2001,"title":"Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation"},"paper-keall-med-phys":{"doi":"10.1118/1.2349696","openalexId":"W2127480863","cited":2330,"byYear":{"2012":110,"2013":123,"2014":151,"2015":145,"2016":128,"2017":148,"2018":141,"2019":123,"2020":139,"2021":128,"2022":146,"2023":115,"2024":124,"2025":136,"2026":89},"year":2006,"title":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76a)"},"paper-shah-tnbc-clonal-evolution-nature-2012":{"doi":"10.1038/nature10933","openalexId":"W2063382533","cited":2043,"byYear":{"2012":78,"2013":203,"2014":205,"2015":199,"2016":180,"2017":175,"2018":137,"2019":126,"2020":137,"2021":126,"2022":142,"2023":153,"2024":80,"2025":61,"2026":39},"year":2012,"title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers"},"paper-nelson-j-med-chem":{"doi":"10.1021/acs.jmedchem.6b00975","openalexId":"W2579340176","cited":1958,"byYear":{"2016":1,"2017":76,"2018":158,"2019":184,"2020":213,"2021":260,"2022":245,"2023":242,"2024":208,"2025":212,"2026":158},"year":2017,"title":"The Essential Medicinal Chemistry of Curcumin"},"paper-inrg-cohn-jco-2009":{"doi":"10.1200/jco.2008.16.6785","openalexId":"W2152420890","cited":1939,"byYear":{"2012":79,"2013":81,"2014":82,"2015":90,"2016":95,"2017":98,"2018":107,"2019":133,"2020":167,"2021":181,"2022":172,"2023":174,"2024":123,"2025":105,"2026":94},"year":2008,"title":"The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report"},"paper-palbociclib-breast-hr-positive-lancet-oncol-2015":{"doi":"10.1016/s1470-2045(14)71159-3","openalexId":"W2144790402","cited":1935,"byYear":{"2012":1,"2014":2,"2015":130,"2016":205,"2017":220,"2018":242,"2019":175,"2020":190,"2021":172,"2022":131,"2023":140,"2024":149,"2025":121,"2026":54},"year":2014,"title":"The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study"},"paper-feinberg-nat-rev-genet-2006":{"doi":"10.1038/nrg1748","openalexId":"W2036986058","cited":1873,"byYear":{"2012":144,"2013":135,"2014":114,"2015":78,"2016":105,"2017":75,"2018":67,"2019":74,"2020":61,"2021":80,"2022":55,"2023":64,"2024":58,"2025":30,"2026":20},"year":2005,"title":"The epigenetic progenitor origin of human cancer"},"paper-arvanitis-nat-rev-cancer":{"doi":"10.1038/s41568-019-0205-x","openalexId":"W2979984433","cited":1824,"byYear":{"2014":1,"2019":6,"2020":96,"2021":246,"2022":273,"2023":305,"2024":295,"2025":335,"2026":264},"year":2019,"title":"The blood–brain barrier and blood–tumour barrier in brain tumours and metastases"},"paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012":{"doi":"10.1038/nature11219","openalexId":"W2116731538","cited":1762,"byYear":{"2012":36,"2013":141,"2014":170,"2015":186,"2016":188,"2017":168,"2018":142,"2019":160,"2020":110,"2021":115,"2022":118,"2023":81,"2024":68,"2025":46,"2026":27},"year":2012,"title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers"},"paper-burnet-prog-exp-tumor-res":{"doi":"10.1159/000386035","openalexId":"W1483194800","cited":1659,"byYear":{"2012":46,"2013":52,"2014":59,"2015":46,"2016":52,"2017":59,"2018":61,"2019":58,"2020":72,"2021":63,"2022":53,"2023":45,"2024":35,"2025":30,"2026":14},"year":2015,"title":"The Concept of Immunological Surveillance"},"paper-withers-acta-oncol":{"doi":"10.3109/02841868809090333","openalexId":"W2105150213","cited":1607,"byYear":{"2012":36,"2013":35,"2014":28,"2015":42,"2016":33,"2017":44,"2018":40,"2019":33,"2020":33,"2021":25,"2022":35,"2023":35,"2024":21,"2025":24,"2026":21},"year":1988,"title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy"},"paper-armitage-br-j-cancer":{"doi":"10.1038/bjc.1954.1","openalexId":"W4248142848","cited":1574,"byYear":{"2012":31,"2013":33,"2014":56,"2015":52,"2016":58,"2017":45,"2018":63,"2019":46,"2020":57,"2021":46,"2022":49,"2023":56,"2024":55,"2025":54,"2026":27},"year":1954,"title":"The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis"},"paper-independent-uk-panel-on-breast-cancer-lancet":{"doi":"10.1016/s0140-6736(12)61611-0","openalexId":"W250128136","cited":1510,"byYear":{"2012":4,"2013":124,"2014":141,"2015":156,"2016":115,"2017":112,"2018":133,"2019":93,"2020":103,"2021":124,"2022":106,"2023":87,"2024":73,"2025":85,"2026":49},"year":2012,"title":"The benefits and harms of breast cancer screening: an independent review"},"paper-pavlova-cell-metab-2022":{"doi":"10.1016/j.cmet.2022.01.007","openalexId":"W4220798004","cited":1472,"byYear":{"2022":90,"2023":261,"2024":447,"2025":398,"2026":276},"year":2022,"title":"The hallmarks of cancer metabolism: Still emerging"},"paper-gundem-evolutionary-history-lethal-metastatic-prostate-nature-2015":{"doi":"10.1038/nature14347","openalexId":"W2050146329","cited":1467,"byYear":{"2015":40,"2016":152,"2017":166,"2018":158,"2019":156,"2020":157,"2021":147,"2022":154,"2023":122,"2024":105,"2025":70,"2026":37},"year":2015,"title":"The evolutionary history of lethal metastatic prostate cancer"},"paper-prior-cancer-res":{"doi":"10.1158/0008-5472.can-19-3682","openalexId":"W3013377779","cited":1166,"byYear":{"2016":1,"2020":27,"2021":128,"2022":163,"2023":202,"2024":256,"2025":227,"2026":161},"year":2020,"title":"The Frequency of Ras Mutations in Cancer"},"paper-zafar-oncologist":{"doi":"10.1634/theoncologist.2012-0279","openalexId":"W2099354636","cited":1144,"byYear":{"2013":12,"2014":39,"2015":49,"2016":64,"2017":67,"2018":74,"2019":122,"2020":91,"2021":120,"2022":120,"2023":103,"2024":107,"2025":96,"2026":78},"year":2013,"title":"The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience"},"paper-freedman-plos-biol":{"doi":"10.1371/journal.pbio.1002165","openalexId":"W585341442","cited":1099,"byYear":{"2013":1,"2015":50,"2016":104,"2017":98,"2018":112,"2019":121,"2020":156,"2021":99,"2022":98,"2023":99,"2024":71,"2025":48,"2026":42},"year":2015,"title":"The Economics of Reproducibility in Preclinical Research"},"paper-nct02107703-jama-oncol-2020-update":{"doi":"10.1001/jamaoncol.2019.4782","openalexId":"W2976415870","cited":1015,"byYear":{"2019":10,"2020":130,"2021":175,"2022":132,"2023":149,"2024":170,"2025":157,"2026":91},"year":2019,"title":"The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2"},"paper-armenia-long-tail-oncogenic-drivers-prostate-nat-genet-2018":{"doi":"10.1038/s41588-018-0078-z","openalexId":"W2789900707","cited":921,"byYear":{"2018":49,"2019":103,"2020":132,"2021":141,"2022":133,"2023":112,"2024":115,"2025":85,"2026":51},"year":2018,"title":"The long tail of oncogenic drivers in prostate cancer"},"paper-bolouri-paediatric-aml-genomics-nat-med-2018":{"doi":"10.1038/nm.4439","openalexId":"W2773514102","cited":903,"byYear":{"2016":1,"2017":1,"2018":32,"2019":74,"2020":80,"2021":127,"2022":130,"2023":153,"2024":127,"2025":114,"2026":63},"year":2017,"title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions"},"paper-goodwin-n-engl-j-med":{"doi":"10.1056/nejmoa011871","openalexId":"W2023305103","cited":896,"byYear":{"2012":53,"2013":48,"2014":39,"2015":35,"2016":31,"2017":32,"2018":25,"2019":20,"2020":22,"2021":23,"2022":25,"2023":17,"2024":16,"2025":6,"2026":7},"year":2001,"title":"The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer"},"paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019":{"doi":"10.1038/s41586-019-1672-7","openalexId":"W2981552021","cited":798,"byYear":{"2018":1,"2019":17,"2020":105,"2021":133,"2022":148,"2023":124,"2024":99,"2025":98,"2026":73},"year":2019,"title":"The landscape of somatic mutation in normal colorectal epithelial cells"},"paper-ladanyi-aspl-tfe3-oncogene-2001":{"doi":"10.1038/sj.onc.1204074","openalexId":"W2146355396","cited":629,"byYear":{"2012":25,"2013":29,"2014":33,"2015":23,"2016":32,"2017":34,"2018":30,"2019":25,"2020":30,"2021":27,"2022":25,"2023":27,"2024":33,"2025":17,"2026":13},"year":2001,"title":"The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25"},"paper-phan-nat-rev-cancer":{"doi":"10.1038/s41568-020-0263-0","openalexId":"W3031826692","cited":593,"byYear":{"2020":8,"2021":69,"2022":102,"2023":117,"2024":119,"2025":100,"2026":78},"year":2020,"title":"The dormant cancer cell life cycle"},"paper-jan-burger-blood-2009":{"doi":"10.1182/blood-2009-06-225326","openalexId":"W2154992334","cited":583,"byYear":{"2012":59,"2013":77,"2014":47,"2015":62,"2016":43,"2017":22,"2018":26,"2019":21,"2020":27,"2021":29,"2022":15,"2023":13,"2024":10,"2025":12,"2026":8},"year":2009,"title":"The microenvironment in mature B-cell malignancies: a target for new treatment strategies"},"paper-prasad-nat-rev-clin-oncol":{"doi":"10.1038/nrclinonc.2017.31","openalexId":"W2600333833","cited":451,"byYear":{"2016":1,"2017":18,"2018":35,"2019":33,"2020":69,"2021":56,"2022":53,"2023":57,"2024":59,"2025":35,"2026":35},"year":2017,"title":"The high price of anticancer drugs: origins, implications, barriers, solutions"},"paper-ali-thyroid":{"doi":"10.1089/thy.2023.0141","openalexId":"W4383710624","cited":368,"byYear":{"2023":29,"2024":142,"2025":105,"2026":91},"year":2023,"title":"The 2023 Bethesda System for Reporting Thyroid Cytopathology"},"paper-who-2021-thymus-mediastinum-classification-marx-jto-2022":{"doi":"10.1016/j.jtho.2021.10.010","openalexId":"W3209749406","cited":358,"byYear":{"2013":1,"2022":45,"2023":72,"2024":89,"2025":86,"2026":64},"year":2021,"title":"The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?"},"paper-schoenfeld-smarca4-alterations-lung-ccr-2020":{"doi":"10.1158/1078-0432.ccr-20-1825","openalexId":"W3044448118","cited":303,"byYear":{"2020":3,"2021":37,"2022":37,"2023":59,"2024":47,"2025":71,"2026":49},"year":2020,"title":"The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer"},"paper-herschkowitz-rb1-loss-basal-like-bcr-2008":{"doi":"10.1186/bcr2142","openalexId":"W2141223216","cited":267,"byYear":{"2012":17,"2013":28,"2014":17,"2015":5,"2016":11,"2017":15,"2018":23,"2019":12,"2020":9,"2021":28,"2022":10,"2023":12,"2024":12,"2025":8,"2026":3},"year":2008,"title":"The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas"},"paper-cd19-dlbcl-cytotherapy-2020":{"doi":"10.1016/j.jcyt.2019.12.004","openalexId":"W3004183788","cited":158,"byYear":{"2020":12,"2021":16,"2022":25,"2023":25,"2024":29,"2025":29,"2026":22},"year":2020,"title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19"},"paper-chicago-consensus-appendiceal-neoplasms-cancer-2020":{"doi":"10.1002/cncr.32881","openalexId":"W4252877098","cited":110,"byYear":{"2020":10,"2021":6,"2022":14,"2023":19,"2024":18,"2025":27,"2026":16},"year":2020,"title":"The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms"},"paper-zhang-bmj-glob-health":{"doi":"10.1136/bmjgh-2021-006196","openalexId":"W3181146697","cited":78,"byYear":{"2021":1,"2022":11,"2023":16,"2024":18,"2025":18,"2026":14},"year":2021,"title":"The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China"},"paper-martinez-cibrian-br-j-haematol":{"doi":"10.1111/bjh.19170","openalexId":"W4388034178","cited":24,"byYear":{"2024":7,"2025":8,"2026":9},"year":2023,"title":"The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel ( ARI ‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma"},"paper-ranganathan-lancet-oncol":{"doi":"10.1016/s1470-2045(21)00077-2","openalexId":"W3176933341","cited":45,"byYear":{"2021":3,"2022":10,"2023":13,"2024":9,"2025":5,"2026":5},"year":2021,"title":"The International Collaboration for Research methods Development in Oncology (CReDO) workshops: shaping the future of global oncology research"},"paper-hudson-phillips-expanded-germline-testing-clin-breast-cancer-2026":{"doi":"10.1016/j.clbc.2026.07.031","openalexId":"W7172213632","cited":0,"byYear":{},"year":2026,"title":"The Impact of Expanded Access to Germline High Penetrance Genetic Testing for Women With a New Diagnosis of Invasive Breast Cancer or High-Grade DCIS"},"paper-therasse-recist-jnci-2000":{"doi":"10.1093/jnci/92.3.205","openalexId":"W2139248078","cited":15763,"byYear":{"2012":1223,"2013":1189,"2014":1056,"2015":883,"2016":715,"2017":626,"2018":453,"2019":409,"2020":391,"2021":402,"2022":316,"2023":267,"2024":191,"2025":149,"2026":75},"year":2000,"title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors"},"paper-thiery-emt-tumour-progression-nrc-2002":{"doi":"10.1038/nrc822","openalexId":"W2076583198","cited":6753,"byYear":{"2012":431,"2013":391,"2014":439,"2015":411,"2016":430,"2017":450,"2018":371,"2019":341,"2020":300,"2021":328,"2022":271,"2023":217,"2024":224,"2025":100,"2026":60},"year":2002,"title":"Epithelial–mesenchymal transitions in tumour progression"},"paper-thorsson-immune-landscape-of-cancer-immunity-2018":{"doi":"10.1016/j.immuni.2018.03.023","openalexId":"W2796207838","cited":6336,"byYear":{"2017":2,"2018":106,"2019":302,"2020":597,"2021":1042,"2022":1239,"2023":1045,"2024":991,"2025":625,"2026":385},"year":2018,"title":"The Immune Landscape of Cancer"},"paper-fidler-nat-rev-cancer":{"doi":"10.1038/nrc1098","openalexId":"W1520425169","cited":4744,"byYear":{"2012":249,"2013":284,"2014":285,"2015":260,"2016":298,"2017":289,"2018":253,"2019":278,"2020":256,"2021":286,"2022":221,"2023":220,"2024":184,"2025":141,"2026":89},"year":2003,"title":"The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited"},"paper-alexandrov-nature":{"doi":"10.1038/s41586-020-1943-3","openalexId":"W3004480399","cited":3860,"byYear":{"2014":1,"2018":4,"2019":16,"2020":316,"2021":582,"2022":632,"2023":753,"2024":642,"2025":537,"2026":377},"year":2020,"title":"The repertoire of mutational signatures in human cancer"},"paper-grasso-mutational-landscape-lethal-crpc-nature-2012":{"doi":"10.1038/nature11125","openalexId":"W2051025382","cited":2622,"byYear":{"2012":34,"2013":170,"2014":177,"2015":214,"2016":194,"2017":197,"2018":212,"2019":198,"2020":258,"2021":209,"2022":186,"2023":200,"2024":162,"2025":132,"2026":69},"year":2012,"title":"The mutational landscape of lethal castration-resistant prostate cancer"},"paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997":{"doi":"10.1056/nejm199705153362001","openalexId":"W2328105863","cited":2295,"byYear":{"2012":78,"2013":80,"2014":76,"2015":56,"2016":57,"2017":52,"2018":35,"2019":47,"2020":41,"2021":38,"2022":41,"2023":32,"2024":18,"2025":17,"2026":13},"year":1997,"title":"The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi Jews"},"paper-musacchio-nat-rev-mol-cell-biol":{"doi":"10.1038/nrm2163","openalexId":"W2048938594","cited":2259,"byYear":{"2012":207,"2013":147,"2014":137,"2015":131,"2016":107,"2017":102,"2018":80,"2019":92,"2020":98,"2021":86,"2022":100,"2023":75,"2024":70,"2025":67,"2026":46},"year":2007,"title":"The spindle-assembly checkpoint in space and time"},"paper-rohrig-nat-rev-cancer":{"doi":"10.1038/nrc.2016.89","openalexId":"W2523687917","cited":1725,"byYear":{"2015":1,"2016":7,"2017":60,"2018":91,"2019":97,"2020":169,"2021":215,"2022":262,"2023":214,"2024":259,"2025":213,"2026":136},"year":2016,"title":"The multifaceted roles of fatty acid synthesis in cancer"},"paper-haviland-lancet-oncol":{"doi":"10.1016/s1470-2045(13)70386-3","openalexId":"W2096499183","cited":1483,"byYear":{"2013":6,"2014":62,"2015":94,"2016":109,"2017":104,"2018":99,"2019":100,"2020":168,"2021":149,"2022":155,"2023":123,"2024":125,"2025":117,"2026":66},"year":2013,"title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials"},"paper-cabanillas-lancet":{"doi":"10.1016/s0140-6736(16)30172-6","openalexId":"W4211213741","cited":1469,"byYear":{"2014":1,"2016":6,"2017":37,"2018":64,"2019":81,"2020":154,"2021":204,"2022":236,"2023":253,"2024":223,"2025":131,"2026":76},"year":2016,"title":"Thyroid cancer"},"paper-ho-pancreatic-tumour-microenvironment-review-nrco-2020":{"doi":"10.1038/s41571-020-0363-5","openalexId":"W3023998523","cited":1357,"byYear":{"2020":22,"2021":143,"2022":214,"2023":241,"2024":305,"2025":256,"2026":176},"year":2020,"title":"The tumour microenvironment in pancreatic cancer — clinical challenges and opportunities"},"paper-wynder-graham-tobacco-bronchiogenic-carcinoma-jama-1950":{"doi":"10.1001/jama.1950.02910390001001","openalexId":"W134923470","cited":1038,"byYear":{"2012":37,"2013":36,"2014":30,"2015":21,"2016":19,"2017":27,"2018":16,"2019":13,"2020":27,"2021":14,"2022":14,"2023":14,"2024":12,"2025":21,"2026":14},"year":1950,"title":"TOBACCO SMOKING AS A POSSIBLE ETIOLOGIC FACTOR IN BRONCHIOGENIC CARCINOMA"},"paper-dhanasekaran-nat-rev-clin-oncol":{"doi":"10.1038/s41571-021-00549-2","openalexId":"W3196329163","cited":1026,"byYear":{"2021":6,"2022":69,"2023":158,"2024":305,"2025":301,"2026":187},"year":2021,"title":"The MYC oncogene — the grand orchestrator of cancer growth and immune evasion"},"paper-langley-int-j-cancer":{"doi":"10.1002/ijc.26031","openalexId":"W2132966617","cited":977,"byYear":{"2012":48,"2013":58,"2014":53,"2015":48,"2016":45,"2017":75,"2018":69,"2019":53,"2020":74,"2021":108,"2022":76,"2023":91,"2024":79,"2025":58,"2026":26},"year":2011,"title":"The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organs"},"paper-doll-hill-mortality-of-doctors-smoking-bmj-1954":{"doi":"10.1136/bmj.1.4877.1451","openalexId":"W2004634778","cited":928,"byYear":{"2012":39,"2013":48,"2014":44,"2015":28,"2016":41,"2017":23,"2018":25,"2019":68,"2020":30,"2021":34,"2022":28,"2023":24,"2024":23,"2025":15,"2026":12},"year":1954,"title":"The Mortality of Doctors in Relation to Their Smoking Habits"},"paper-tcga-chromophobe-davis-cancer-cell-2014":{"doi":"10.1016/j.ccr.2014.07.014","openalexId":"W2010991736","cited":872,"byYear":{"2012":2,"2013":1,"2014":10,"2015":53,"2016":77,"2017":94,"2018":78,"2019":90,"2020":88,"2021":88,"2022":74,"2023":66,"2024":50,"2025":59,"2026":39},"year":2014,"title":"The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma"},"paper-bakhoum-cell":{"doi":"10.1016/j.cell.2018.08.027","openalexId":"W2891405227","cited":778,"byYear":{"2018":8,"2019":50,"2020":71,"2021":88,"2022":105,"2023":132,"2024":137,"2025":110,"2026":77},"year":2018,"title":"The Multifaceted Role of Chromosomal Instability in Cancer and Its Microenvironment"},"paper-aster-annu-rev-pathol":{"doi":"10.1146/annurev-pathol-052016-100127","openalexId":"W2419558864","cited":754,"byYear":{"2016":1,"2017":18,"2018":43,"2019":50,"2020":95,"2021":122,"2022":110,"2023":124,"2024":94,"2025":63,"2026":34},"year":2016,"title":"The Varied Roles of Notch in Cancer"},"paper-jan-burger-blood-2015":{"doi":"10.1182/blood-2014-10-606038","openalexId":"W1986924929","cited":664,"byYear":{"2014":2,"2015":56,"2016":114,"2017":143,"2018":69,"2019":73,"2020":58,"2021":51,"2022":22,"2023":39,"2024":18,"2025":11,"2026":6},"year":2015,"title":"Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib"},"paper-yoshida-nature":{"doi":"10.1038/s41586-020-1961-1","openalexId":"W3003949123","cited":579,"byYear":{"2019":1,"2020":68,"2021":112,"2022":104,"2023":102,"2024":65,"2025":80,"2026":47},"year":2020,"title":"Tobacco smoking and somatic mutations in human bronchial epithelium"},"paper-tonon-crtc1-maml2-nat-genet-2003":{"doi":"10.1038/ng1083","openalexId":"W2060525726","cited":571,"byYear":{"2012":20,"2013":23,"2014":28,"2015":38,"2016":32,"2017":35,"2018":20,"2019":32,"2020":40,"2021":35,"2022":29,"2023":26,"2024":25,"2025":17,"2026":8},"year":2003,"title":"t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway"},"paper-esmo-thymic-epithelial-tumours-guideline-ann-oncol-2015":{"doi":"10.1093/annonc/mdv277","openalexId":"W1767875808","cited":517,"byYear":{"2015":1,"2016":14,"2017":26,"2018":32,"2019":45,"2020":54,"2021":70,"2022":63,"2023":49,"2024":70,"2025":54,"2026":37},"year":2015,"title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"},"paper-bettington-serrated-pathway-colorectal-histopathology-2013":{"doi":"10.1111/his.12055","openalexId":"W1990204500","cited":513,"byYear":{"2013":13,"2014":44,"2015":42,"2016":50,"2017":39,"2018":40,"2019":40,"2020":51,"2021":46,"2022":45,"2023":33,"2024":25,"2025":24,"2026":20},"year":2012,"title":"The serrated pathway to colorectal carcinoma: current concepts and challenges"},"paper-cho-lancet-oncol":{"doi":"10.1016/s1470-2045(22)00226-1","openalexId":"W4280554695","cited":463,"byYear":{"2022":38,"2023":107,"2024":111,"2025":124,"2026":83},"year":2022,"title":"Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study"},"paper-maffini-j-cell-sci":{"doi":"10.1242/jcs.01000","openalexId":"W2096127904","cited":422,"byYear":{"2012":26,"2013":22,"2014":19,"2015":13,"2016":16,"2017":18,"2018":11,"2019":5,"2020":15,"2021":16,"2022":20,"2023":21,"2024":15,"2025":15,"2026":1},"year":2004,"title":"The stroma as a crucial target in rat mammary gland carcinogenesis"},"paper-pik3ca-colorectal-acta-oncol-2014":{"doi":"10.3109/0284186x.2014.895036","openalexId":"W2003157997","cited":399,"byYear":{"2014":10,"2015":34,"2016":40,"2017":40,"2018":37,"2019":43,"2020":39,"2021":24,"2022":29,"2023":28,"2024":43,"2025":18,"2026":14},"year":2014,"title":"The predictive value ofKRAS, NRAS, BRAF, PIK3CAand PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis"},"paper-soto-bioessays":{"doi":"10.1002/bies.201100025","openalexId":"W2147656978","cited":354,"byYear":{"2012":26,"2013":24,"2014":26,"2015":20,"2016":17,"2017":23,"2018":23,"2019":31,"2020":19,"2021":27,"2022":23,"2023":23,"2024":31,"2025":26,"2026":6},"year":2011,"title":"The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory"},"paper-shen-j-clin-oncol":{"doi":"10.1200/jco.21.01926","openalexId":"W4224213460","cited":324,"byYear":{"2021":3,"2022":27,"2023":68,"2024":81,"2025":105,"2026":40},"year":2022,"title":"Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study"},"paper-pettersson-tmprss2-erg-outcome-meta-analysis-cebp-2012":{"doi":"10.1158/1055-9965.epi-12-0042","openalexId":"W2116353323","cited":317,"byYear":{"2012":3,"2013":24,"2014":26,"2015":39,"2016":31,"2017":41,"2018":25,"2019":17,"2020":27,"2021":20,"2022":17,"2023":13,"2024":14,"2025":14,"2026":6},"year":2012,"title":"The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis"},"paper-imcgp100-202-n-engl-j-med-2023-update":{"doi":"10.1056/nejmoa2304753","openalexId":"W4387845260","cited":289,"byYear":{"2023":8,"2024":67,"2025":131,"2026":83},"year":2023,"title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma"},"paper-fabbri-nat-rev-cancer":{"doi":"10.1038/s41568-021-00380-y","openalexId":"W3188249441","cited":288,"byYear":{"2021":4,"2022":37,"2023":58,"2024":89,"2025":65,"2026":35},"year":2021,"title":"The plasticity of mRNA translation during cancer progression and therapy resistance"},"paper-dbouk-caps5-stage-survival-jco-2022":{"doi":"10.1200/jco.22.00298","openalexId":"W4282963663","cited":249,"byYear":{"2022":13,"2023":50,"2024":76,"2025":64,"2026":46},"year":2022,"title":"The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival"},"paper-sonnenschein-semin-cancer-biol":{"doi":"10.1016/j.semcancer.2008.03.012","openalexId":"W2058078233","cited":221,"byYear":{"2012":11,"2013":14,"2014":11,"2015":11,"2016":14,"2017":17,"2018":12,"2019":13,"2020":13,"2021":17,"2022":6,"2023":10,"2024":9,"2025":4,"2026":2},"year":2008,"title":"Theories of carcinogenesis: An emerging perspective"},"paper-o-dwyer-nat-med":{"doi":"10.1038/s41591-023-02379-4","openalexId":"W4380786209","cited":203,"byYear":{"2023":9,"2024":75,"2025":57,"2026":62},"year":2023,"title":"The NCI-MATCH trial: lessons for precision oncology"},"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019":{"doi":"10.1038/s41467-019-11862-x","openalexId":"W2970379806","cited":194,"byYear":{"2019":2,"2020":24,"2021":30,"2022":19,"2023":37,"2024":33,"2025":33,"2026":15},"year":2019,"title":"The molecular origin and taxonomy of mucinous ovarian carcinoma"},"paper-kilburn-nat-med":{"doi":"10.1038/s41591-023-02668-y","openalexId":"W7212021366","cited":14,"byYear":{"2025":1,"2026":13},"year":2024,"title":"The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial"},"paper-keynote-017-j-immunother-cancer-2021-update":{"doi":"10.1136/jitc-2021-002478","openalexId":"W3154020616","cited":144,"byYear":{"2021":6,"2022":26,"2023":29,"2024":36,"2025":35,"2026":11},"year":2021,"title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma"},"paper-middleton-nature":{"doi":"10.1038/s41586-020-2481-8","openalexId":"W3043661890","cited":143,"byYear":{"2020":10,"2021":33,"2022":31,"2023":26,"2024":22,"2025":14,"2026":7},"year":2020,"title":"The National Lung Matrix Trial of personalized therapy in lung cancer"},"paper-elmasry-gallbladder-polyp-malignancy-systematic-review-int-j-surg-2016":{"doi":"10.1016/j.ijsu.2016.07.061","openalexId":"W2502726562","cited":130,"byYear":{"2017":5,"2018":12,"2019":19,"2020":12,"2021":19,"2022":13,"2023":11,"2024":16,"2025":18,"2026":5},"year":2016,"title":"The risk of malignancy in ultrasound detected gallbladder polyps: A systematic review"},"paper-pramesh-indian-j-med-paediatr-oncol":{"doi":"10.4103/0971-5851.142040","openalexId":"W1984545104","cited":92,"byYear":{"2014":1,"2015":8,"2016":1,"2017":2,"2018":7,"2019":9,"2020":7,"2021":7,"2022":13,"2023":7,"2024":8,"2025":15,"2026":7},"year":2014,"title":"The National Cancer Grid of India"},"paper-villarreal-garza-mexican-tnbc-brca-bcrt-2015":{"doi":"10.1007/s10549-015-3312-8","openalexId":"W1975803034","cited":89,"byYear":{"2015":5,"2016":6,"2017":8,"2018":10,"2019":16,"2020":7,"2021":10,"2022":7,"2023":4,"2024":4,"2025":5,"2026":7},"year":2015,"title":"The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer"},"paper-tracc-clin-cancer-res-2024":{"doi":"10.1158/1078-0432.ccr-24-0226","openalexId":"W4399569781","cited":38,"byYear":{"2024":3,"2025":18,"2026":17},"year":2024,"title":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study"},"paper-cldn18-gastric-front-oncol-2020":{"doi":"10.3389/fonc.2020.01214","openalexId":"W3081634347","cited":45,"byYear":{"2021":4,"2022":8,"2023":11,"2024":9,"2025":8,"2026":5},"year":2020,"title":"The Significance of the CLDN18-ARHGAP Fusion Gene in Gastric Cancer: A Systematic Review and Meta-Analysis"},"paper-halassy-self-experiment-ovt-vaccines-2024":{"doi":"10.3390/vaccines12090958","openalexId":"W4401883103","cited":21,"byYear":{"2024":2,"2025":13,"2026":6},"year":2024,"title":"An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer"},"paper-browne-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-24-0651","openalexId":"W4415664944","cited":7,"byYear":{"2024":1,"2026":6},"year":2025,"title":"The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial"},"paper-erices-chilean-gallbladder-landscape-front-oncol-2025":{"doi":"10.3389/fonc.2025.1658528","openalexId":"W4414771294","cited":3,"byYear":{"2025":1,"2026":2},"year":2025,"title":"The mutational landscape and actionable targets of gallbladder cancer: an ancestry-informed and comparative analysis of a Chilean population"},"paper-gilene-ivermectin-toxicity-paediatric-oncology-2025":{"doi":"10.1002/pbc.31876","openalexId":"W4411615876","cited":2,"byYear":{"2025":1,"2026":1},"year":2025,"title":"The Threat of Medical Misinformation: A Case of Ivermectin Toxicity in a Pediatric Oncology Patient"},"paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026":{"doi":"10.1016/j.hpb.2025.12.017","openalexId":"W4417067451","cited":1,"byYear":{"2026":1},"year":2025,"title":"Timing of revision surgery for incidental gallbladder cancer: a systematic review and individual patient data meta-analysis"},"paper-torre-global-cancer-statistics-2012-cacancer-2015":{"doi":"10.3322/caac.21262","openalexId":"W2917837889","cited":27467,"byYear":{"2012":16,"2013":14,"2014":14,"2015":751,"2016":2928,"2017":4243,"2018":4800,"2019":4230,"2020":3452,"2021":2741,"2022":1662,"2023":1163,"2024":840,"2025":437,"2026":101},"year":2015,"title":"Global cancer statistics, 2012"},"paper-topalian-anti-pd1-nejm-2012":{"doi":"10.1056/nejmoa1200690","openalexId":"W2160834915","cited":12860,"byYear":{"2012":140,"2013":629,"2014":814,"2015":1063,"2016":1203,"2017":1245,"2018":1080,"2019":1071,"2020":1211,"2021":994,"2022":881,"2023":860,"2024":702,"2025":565,"2026":372},"year":2012,"title":"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer"},"paper-toga-trastuzumab-gastric-lancet-2010":{"doi":"10.1016/s0140-6736(10)61121-x","openalexId":"W2100439220","cited":7407,"byYear":{"2012":293,"2013":404,"2014":508,"2015":486,"2016":475,"2017":527,"2018":484,"2019":480,"2020":515,"2021":535,"2022":548,"2023":532,"2024":569,"2025":442,"2026":302},"year":2010,"title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial"},"paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005":{"doi":"10.1056/nejmoa052122","openalexId":"W2146384083","cited":5394,"byYear":{"2012":302,"2013":340,"2014":320,"2015":319,"2016":267,"2017":226,"2018":218,"2019":202,"2020":222,"2021":167,"2022":190,"2023":138,"2024":122,"2025":98,"2026":51},"year":2005,"title":"Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer"},"paper-hera-b31-n9831-n-engl-j-med-2005":{"doi":"10.1056/nejmoa052306","openalexId":"W2149908785","cited":5132,"byYear":{"2012":266,"2013":325,"2014":269,"2015":311,"2016":225,"2017":243,"2018":199,"2019":178,"2020":209,"2021":188,"2022":219,"2023":161,"2024":142,"2025":112,"2026":69},"year":2005,"title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer"},"paper-tracerx-100-nejm-2017":{"doi":"10.1056/nejmoa1616288","openalexId":"W2609243345","cited":2504,"byYear":{"2016":1,"2017":89,"2018":236,"2019":288,"2020":360,"2021":356,"2022":341,"2023":269,"2024":234,"2025":179,"2026":145},"year":2017,"title":"Tracking the Evolution of Non–Small-Cell Lung Cancer"},"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015":{"doi":"10.1056/nejmoa1506859","openalexId":"W2235405584","cited":2224,"byYear":{"2014":3,"2015":10,"2016":181,"2017":246,"2018":259,"2019":251,"2020":300,"2021":238,"2022":200,"2023":185,"2024":151,"2025":115,"2026":80},"year":2015,"title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer"},"paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020":{"doi":"10.1056/nejmoa1914510","openalexId":"W2996630100","cited":2030,"byYear":{"2016":1,"2020":175,"2021":316,"2022":359,"2023":375,"2024":325,"2025":266,"2026":209},"year":2019,"title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer"},"paper-chen-nat-med":{"doi":"10.1038/s41591-024-02857-3","openalexId":"W4392947521","cited":1479,"byYear":{"2023":5,"2024":167,"2025":629,"2026":678},"year":2024,"title":"Towards a general-purpose foundation model for computational pathology"},"paper-bradner-cell":{"doi":"10.1016/j.cell.2016.12.013","openalexId":"W2586373162","cited":1285,"byYear":{"2017":26,"2018":69,"2019":113,"2020":150,"2021":190,"2022":167,"2023":172,"2024":163,"2025":142,"2026":92},"year":2017,"title":"Transcriptional Addiction in Cancer"},"paper-topaz-1-nejm-evidence-2022":{"doi":"10.1056/evidoa2200015","openalexId":"W4281630496","cited":1215,"byYear":{"2020":1,"2022":43,"2023":229,"2024":337,"2025":344,"2026":259},"year":2022,"title":"Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer"},"paper-theodoris-nature":{"doi":"10.1038/s41586-023-06139-9","openalexId":"W4378838672","cited":1207,"byYear":{"2021":1,"2023":58,"2024":292,"2025":428,"2026":428},"year":2023,"title":"Transfer learning enables predictions in network biology"},"paper-miften-med-phys":{"doi":"10.1002/mp.12810","openalexId":"W2791042095","cited":1109,"byYear":{"2018":17,"2019":62,"2020":94,"2021":116,"2022":159,"2023":152,"2024":163,"2025":210,"2026":136},"year":2018,"title":"Tolerance limits and methodologies for IMRT measurement‐based verification QA : Recommendations of AAPM Task Group No. 218"},"paper-trabectedin-vs-dacarbazine-demetri-jco-2016":{"doi":"10.1200/jco.2015.62.4734","openalexId":"W1955072209","cited":847,"byYear":{"2013":1,"2014":1,"2015":5,"2016":60,"2017":91,"2018":80,"2019":79,"2020":88,"2021":85,"2022":111,"2023":92,"2024":61,"2025":56,"2026":36},"year":2015,"title":"Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial"},"paper-transform-liso-cel-lancet-2022":{"doi":"10.1016/s0140-6736(22)00662-6","openalexId":"W4283023614","cited":803,"byYear":{"2013":1,"2022":44,"2023":213,"2024":230,"2025":201,"2026":114},"year":2022,"title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial"},"paper-chan-seng-yue-pancreatic-transcription-phenotypes-nat-genet-2020":{"doi":"10.1038/s41588-019-0566-9","openalexId":"W2999027176","cited":719,"byYear":{"2020":56,"2021":118,"2022":97,"2023":115,"2024":133,"2025":112,"2026":87},"year":2020,"title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution"},"paper-butler-nature":{"doi":"10.1038/453840a","openalexId":"W2075432689","cited":718,"byYear":{"2012":36,"2013":41,"2014":29,"2015":32,"2016":42,"2017":45,"2018":41,"2019":48,"2020":49,"2021":67,"2022":60,"2023":36,"2024":37,"2025":45,"2026":27},"year":2008,"title":"Translational research: Crossing the valley of death"},"paper-destiny-breast03-lancet-2023-update":{"doi":"10.1016/s0140-6736(22)02420-5","openalexId":"W4311116389","cited":685,"byYear":{"2022":4,"2023":124,"2024":227,"2025":209,"2026":121},"year":2022,"title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial"},"paper-wang-cancer-cell":{"doi":"10.1016/j.ccell.2022.02.007","openalexId":"W4214915284","cited":593,"byYear":{"2022":68,"2023":153,"2024":153,"2025":134,"2026":85},"year":2022,"title":"Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial"},"paper-todo-g47delta-glioblastoma-natmed-2022":{"doi":"10.1038/s41591-022-01897-x","openalexId":"W4286492761","cited":537,"byYear":{"2022":19,"2023":122,"2024":133,"2025":157,"2026":105},"year":2022,"title":"Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial"},"paper-murphy-jama-oncol":{"doi":"10.1001/jamaoncol.2019.0892","openalexId":"W2947955936","cited":528,"byYear":{"2019":17,"2020":77,"2021":106,"2022":92,"2023":61,"2024":66,"2025":60,"2026":48},"year":2019,"title":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer"},"paper-conti-trans-ancestry-gwas-prostate-nat-genet-2021":{"doi":"10.1038/s41588-020-00748-0","openalexId":"W3115151307","cited":510,"byYear":{"2020":1,"2021":61,"2022":109,"2023":115,"2024":113,"2025":64,"2026":46},"year":2021,"title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction"},"paper-train-2-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(18)30570-9","openalexId":"W2899659781","cited":469,"byYear":{"2018":1,"2019":13,"2020":31,"2021":65,"2022":68,"2023":69,"2024":87,"2025":72,"2026":62},"year":2018,"title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial"},"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00086-3","openalexId":"W3159805754","cited":426,"byYear":{"2021":20,"2022":103,"2023":112,"2024":84,"2025":61,"2026":45},"year":2021,"title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial"},"paper-tracerx-evolution-nature-2023":{"doi":"10.1038/s41586-023-05783-5","openalexId":"W4365137743","cited":340,"byYear":{"2023":60,"2024":113,"2025":97,"2026":70},"year":2023,"title":"The evolution of lung cancer and impact of subclonal selection in TRACERx"},"paper-contopoulos-ioannidis-am-j-med":{"doi":"10.1016/s0002-9343(03)00013-5","openalexId":"W1994880204","cited":324,"byYear":{"2012":12,"2013":16,"2014":14,"2015":17,"2016":20,"2017":13,"2018":17,"2019":21,"2020":30,"2021":16,"2022":12,"2023":14,"2024":5,"2025":11,"2026":6},"year":2003,"title":"Translation of highly promising basic science research into clinical applications"},"paper-yala-sci-transl-med":{"doi":"10.1126/scitranslmed.aba4373","openalexId":"W3124938033","cited":287,"byYear":{"2021":15,"2022":37,"2023":47,"2024":60,"2025":72,"2026":56},"year":2021,"title":"Toward robust mammography-based models for breast cancer risk"},"paper-mai-jama":{"doi":"10.1001/jama.2023.20181","openalexId":"W4389082473","cited":275,"byYear":{"2023":1,"2024":64,"2025":116,"2026":94},"year":2023,"title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma"},"paper-tpextreme-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(20)30755-5","openalexId":"W3134959030","cited":239,"byYear":{"2021":17,"2022":35,"2023":45,"2024":56,"2025":54,"2026":32},"year":2021,"title":"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial"},"paper-destiny-breast12-nat-med-2024":{"doi":"10.1038/s41591-024-03261-7","openalexId":"W4402514945","cited":218,"byYear":{"2022":1,"2023":1,"2024":13,"2025":111,"2026":92},"year":2024,"title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial"},"paper-kelley-j-cell-biol":{"doi":"10.1083/jcb.201311112","openalexId":"W2130606966","cited":200,"byYear":{"2012":1,"2014":9,"2015":16,"2016":21,"2017":16,"2018":11,"2019":27,"2020":24,"2021":14,"2022":13,"2023":16,"2024":13,"2025":13,"2026":5},"year":2014,"title":"Traversing the basement membrane in vivo: A diversity of strategies"},"paper-study-201-jama-dermatol-2013":{"doi":"10.1001/2013.jamadermatol.541","openalexId":"W2076908917","cited":190,"byYear":{"2012":2,"2013":2,"2014":11,"2015":6,"2016":6,"2017":6,"2018":7,"2019":8,"2020":23,"2021":35,"2022":24,"2023":17,"2024":17,"2025":11,"2026":12},"year":2012,"title":"Topical Chemotherapy in Cutaneous T-cell Lymphoma"},"paper-chernet-dis-model-mech":{"doi":"10.1242/dmm.010835","openalexId":"W2100967971","cited":154,"byYear":{"2013":5,"2014":12,"2015":15,"2016":12,"2017":12,"2018":16,"2019":11,"2020":14,"2021":11,"2022":12,"2023":10,"2024":8,"2025":7,"2026":9},"year":2013,"title":"Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model"},"paper-hernandez-jama-oncol":{"doi":"10.1001/jamaoncol.2018.0977","openalexId":"W2800595080","cited":151,"byYear":{"2018":9,"2019":14,"2020":16,"2021":19,"2022":18,"2023":19,"2024":22,"2025":22,"2026":12},"year":2018,"title":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy"},"paper-destiny-crc02-lancet-oncol-2024":{"doi":"10.1016/s1470-2045(24)00380-2","openalexId":"W4401322169","cited":150,"byYear":{"2024":8,"2025":69,"2026":73},"year":2024,"title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial"},"paper-cloughesy-toca5-glioma-jamaoncol-2020":{"doi":"10.1001/jamaoncol.2020.3161","openalexId":"W3096229634","cited":146,"byYear":{"2020":3,"2021":27,"2022":28,"2023":24,"2024":28,"2025":18,"2026":17},"year":2020,"title":"Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma"},"paper-denmeade-transformer-bipolar-androgen-therapy-jco-2021":{"doi":"10.1200/jco.20.02759","openalexId":"W3133300324","cited":144,"byYear":{"2017":1,"2021":13,"2022":29,"2023":25,"2024":36,"2025":25,"2026":15},"year":2021,"title":"TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer"},"paper-rozhok-proc-natl-acad-sci-u-s-a":{"doi":"10.1073/pnas.1501713112","openalexId":"W1705514413","cited":129,"byYear":{"2015":4,"2016":18,"2017":19,"2018":13,"2019":13,"2020":14,"2021":11,"2022":6,"2023":8,"2024":9,"2025":6,"2026":8},"year":2015,"title":"Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations"},"paper-nct04639219-lancet-oncol-2024":{"doi":"10.1016/s1470-2045(24)00140-2","openalexId":"W4396626913","cited":120,"byYear":{"2024":11,"2025":63,"2026":46},"year":2024,"title":"Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study"},"paper-destiny-breast09-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2508668","openalexId":"W4415677336","cited":76,"byYear":{"2025":6,"2026":70},"year":2025,"title":"Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer"},"paper-luca-gianni-j-clin-oncol-2022":{"doi":"10.1200/jco.21.00896","openalexId":"W4200063289","cited":66,"byYear":{"2020":1,"2022":11,"2023":20,"2024":14,"2025":15,"2026":5},"year":2021,"title":"Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study"},"paper-ohba-herb-trastuzumab-deruxtecan-biliary-jco-2024":{"doi":"10.1200/jco.23.02010","openalexId":"W4401325998","cited":63,"byYear":{"2024":4,"2025":31,"2026":28},"year":2024,"title":"Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial"},"paper-destiny-breast05-n-engl-j-med-2026":{"doi":"10.1056/nejmoa2514661","openalexId":"W4417208811","cited":63,"byYear":{"2026":63},"year":2025,"title":"Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer"},"paper-langley-lancet":{"doi":"10.1016/s0140-6736(21)00100-8","openalexId":"W3127030943","cited":51,"byYear":{"2021":5,"2022":10,"2023":5,"2024":13,"2025":7,"2026":11},"year":2021,"title":"Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme"},"paper-destiny-breast04-nat-med-2025-update":{"doi":"10.1038/s41591-025-03981-4","openalexId":"W4414930698","cited":39,"byYear":{"2025":3,"2026":36},"year":2025,"title":"Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial"},"paper-nct05081609-j-immunother-cancer-2022":{"doi":"10.1136/jitc-2022-004991","openalexId":"W4285005811","cited":41,"byYear":{"2022":2,"2023":10,"2024":11,"2025":11,"2026":7},"year":2022,"title":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer"},"paper-zhu-clin-transl-sci":{"doi":"10.1111/cts.70082","openalexId":"W4405182250","cited":4,"byYear":{"2025":2,"2026":2},"year":2024,"title":"Translational findings support regimen selection for first‐in‐human study of ubamatamab ( MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer"},"paper-nct05246514-clin-lung-cancer-2026":{"doi":"10.1016/j.cllc.2026.06.003","openalexId":"W7164368651","cited":0,"byYear":{},"year":2026,"title":"Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non–Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial"},"paper-horizon-breast01-lancet-oncol-2026":{"doi":"10.1016/s1470-2045(26)00193-2","openalexId":"W7166869441","cited":0,"byYear":{},"year":2026,"title":"Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial"},"paper-nct06968585-j-clin-oncol-2026":{"doi":"10.1200/jco-26-00602","openalexId":"W7212223268","cited":0,"byYear":{},"year":2026,"title":"Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial"},"paper-vander-heiden-science":{"doi":"10.1126/science.1160809","openalexId":"W2097259163","cited":16543,"byYear":{"2012":536,"2013":662,"2014":727,"2015":823,"2016":918,"2017":1038,"2018":1036,"2019":1080,"2020":1353,"2021":1530,"2022":1418,"2023":1231,"2024":1329,"2025":1233,"2026":862},"year":2009,"title":"Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation"},"paper-tumeh-pd1-adaptive-immune-resistance-nature-2014":{"doi":"10.1038/nature13954","openalexId":"W2039123767","cited":6787,"byYear":{"2012":1,"2013":2,"2014":12,"2015":302,"2016":487,"2017":567,"2018":595,"2019":627,"2020":830,"2021":815,"2022":735,"2023":628,"2024":540,"2025":396,"2026":236},"year":2014,"title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance"},"paper-dent-tnbc-clinical-features-recurrence-ccr-2007":{"doi":"10.1158/1078-0432.ccr-06-3045","openalexId":"W2170602872","cited":5233,"byYear":{"2012":172,"2013":180,"2014":246,"2015":267,"2016":258,"2017":277,"2018":301,"2019":359,"2020":424,"2021":485,"2022":453,"2023":446,"2024":375,"2025":320,"2026":218},"year":2007,"title":"Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence"},"paper-dvorak-n-engl-j-med":{"doi":"10.1056/nejm198612253152606","openalexId":"W2314203153","cited":4427,"byYear":{"2012":178,"2013":195,"2014":175,"2015":202,"2016":179,"2017":203,"2018":167,"2019":188,"2020":189,"2021":238,"2022":214,"2023":163,"2024":144,"2025":104,"2026":92},"year":1986,"title":"Tumors: Wounds That Do Not Heal"},"paper-bergers-nat-rev-cancer":{"doi":"10.1038/nrc1093","openalexId":"W2804842145","cited":3566,"byYear":{"2012":197,"2013":220,"2014":228,"2015":174,"2016":148,"2017":171,"2018":162,"2019":159,"2020":150,"2021":163,"2022":150,"2023":123,"2024":132,"2025":80,"2026":47},"year":2003,"title":"Tumorigenesis and the angiogenic switch"},"paper-de-bono-tropic-cabazitaxel-lancet-2010":{"doi":"10.1016/s0140-6736(10)61389-x","openalexId":"W2123526148","cited":3329,"byYear":{"2012":242,"2013":276,"2014":287,"2015":269,"2016":260,"2017":244,"2018":244,"2019":226,"2020":211,"2021":209,"2022":184,"2023":180,"2024":125,"2025":108,"2026":75},"year":2010,"title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial"},"paper-shailender-bhatia-cell-2017":{"doi":"10.1016/j.cell.2017.09.028","openalexId":"W2761575992","cited":2641,"byYear":{"2013":1,"2017":10,"2018":109,"2019":177,"2020":252,"2021":373,"2022":378,"2023":437,"2024":452,"2025":270,"2026":178},"year":2017,"title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab"},"paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018":{"doi":"10.1016/s1470-2045(17)30904-x","openalexId":"W2771978163","cited":2217,"byYear":{"2015":1,"2017":1,"2018":50,"2019":144,"2020":251,"2021":303,"2022":303,"2023":340,"2024":348,"2025":292,"2026":180},"year":2017,"title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy"},"paper-hutchins-n-engl-j-med":{"doi":"10.1056/nejm199912303412706","openalexId":"W2331849216","cited":2204,"byYear":{"2012":119,"2013":96,"2014":106,"2015":98,"2016":102,"2017":97,"2018":94,"2019":97,"2020":92,"2021":91,"2022":78,"2023":62,"2024":62,"2025":50,"2026":21},"year":1999,"title":"Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials"},"paper-scher-j-clin-oncol":{"doi":"10.1200/jco.2015.64.2702","openalexId":"W2278392405","cited":1673,"byYear":{"2016":41,"2017":97,"2018":105,"2019":124,"2020":163,"2021":192,"2022":166,"2023":215,"2024":213,"2025":182,"2026":172},"year":2016,"title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3"},"paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999":{"doi":"10.1056/nejm199901283400403","openalexId":"W2323020638","cited":1516,"byYear":{"2012":62,"2013":63,"2014":47,"2015":50,"2016":56,"2017":76,"2018":65,"2019":48,"2020":63,"2021":76,"2022":45,"2023":49,"2024":33,"2025":53,"2026":38},"year":1999,"title":"Twice-Daily Compared with Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently with Cisplatin and Etoposide"},"paper-whipple-carcinoma-ampulla-of-vater-ann-surg-1935":{"doi":"10.1097/00000658-193510000-00023","openalexId":"W2044347879","cited":1366,"byYear":{"2012":32,"2013":43,"2014":36,"2015":54,"2016":35,"2017":48,"2018":26,"2019":39,"2020":28,"2021":44,"2022":42,"2023":32,"2024":34,"2025":29,"2026":16},"year":1935,"title":"TEEATMENT OF CARCINOMA OF THE AMPULLA OF VATER"},"paper-williams-bep-vs-pvb-nejm-1987":{"doi":"10.1056/nejm198706043162302","openalexId":"W2323139555","cited":1181,"byYear":{"2012":23,"2013":28,"2014":37,"2015":33,"2016":26,"2017":23,"2018":26,"2019":23,"2020":29,"2021":20,"2022":16,"2023":18,"2024":16,"2025":15,"2026":7},"year":1987,"title":"Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide"},"paper-bourhis-radiother-oncol":{"doi":"10.1016/j.radonc.2019.06.019","openalexId":"W2958174590","cited":968,"byYear":{"2019":7,"2020":74,"2021":92,"2022":110,"2023":364,"2024":119,"2025":122,"2026":80},"year":2019,"title":"Treatment of a first patient with FLASH-radiotherapy"},"paper-loi-tils-pooled-early-tnbc-jco-2019":{"doi":"10.1200/jco.18.01010","openalexId":"W2909799373","cited":933,"byYear":{"2019":44,"2020":103,"2021":144,"2022":138,"2023":149,"2024":143,"2025":114,"2026":93},"year":2019,"title":"Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers"},"paper-widmark-lancet":{"doi":"10.1016/s0140-6736(19)31131-6","openalexId":"W2952903287","cited":901,"byYear":{"2018":1,"2019":26,"2020":134,"2021":134,"2022":128,"2023":132,"2024":141,"2025":126,"2026":77},"year":2019,"title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial"},"paper-lane-bmj":{"doi":"10.1136/bmj-2023-077310","openalexId":"W4392600894","cited":856,"byYear":{"2022":1,"2024":162,"2025":378,"2026":315},"year":2024,"title":"Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses"},"paper-andrew-lassman-j-clin-oncol-2022":{"doi":"10.1200/jco.21.02314","openalexId":"W4200190043","cited":849,"byYear":{"2022":76,"2023":186,"2024":224,"2025":219,"2026":138},"year":2021,"title":"Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline"},"paper-abida-triton2-rucaparib-brca-jco-2020":{"doi":"10.1200/jco.20.01035","openalexId":"W3049351332","cited":704,"byYear":{"2020":13,"2021":131,"2022":159,"2023":152,"2024":118,"2025":79,"2026":48},"year":2020,"title":"Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration"},"paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023":{"doi":"10.1056/nejmoa2214963","openalexId":"W4367835002","cited":466,"byYear":{"2023":38,"2024":168,"2025":148,"2026":111},"year":2023,"title":"Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer"},"paper-fizazi-triton3-rucaparib-nejm-2023":{"doi":"10.1056/nejmoa2214676","openalexId":"W4321079951","cited":450,"byYear":{"2023":86,"2024":146,"2025":135,"2026":83},"year":2023,"title":"Rucaparib or Physician’s Choice in Metastatic Prostate Cancer"},"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022":{"doi":"10.1038/s41591-022-01935-8","openalexId":"W4290673816","cited":404,"byYear":{"2022":23,"2023":107,"2024":147,"2025":87,"2026":40},"year":2022,"title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial"},"paper-ucart19-allogeneic-car-t-lancet-2020":{"doi":"10.1016/s0140-6736(20)32334-5","openalexId":"W3113171896","cited":376,"byYear":{"2013":1,"2021":49,"2022":77,"2023":76,"2024":82,"2025":53,"2026":38},"year":2020,"title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies"},"paper-stutman-science":{"doi":"10.1126/science.183.4124.534","openalexId":"W2036999053","cited":349,"byYear":{"2012":11,"2013":17,"2014":16,"2015":10,"2016":14,"2017":15,"2018":17,"2019":16,"2020":6,"2021":10,"2022":5,"2023":11,"2024":4,"2025":3,"2026":1},"year":1974,"title":"Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice"},"paper-shimelis-tnbc-risk-genes-jnci-2018":{"doi":"10.1093/jnci/djy106","openalexId":"W2885684012","cited":328,"byYear":{"2018":2,"2019":55,"2020":53,"2021":46,"2022":53,"2023":28,"2024":52,"2025":23,"2026":16},"year":2018,"title":"Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing"},"paper-korolev-nat-rev-cancer":{"doi":"10.1038/nrc3712","openalexId":"W2007614382","cited":313,"byYear":{"2014":5,"2015":25,"2016":30,"2017":35,"2018":21,"2019":36,"2020":35,"2021":28,"2022":24,"2023":26,"2024":17,"2025":22,"2026":9},"year":2014,"title":"Turning ecology and evolution against cancer"},"paper-metter-jama-netw-open":{"doi":"10.1001/jamanetworkopen.2019.4337","openalexId":"W2947825023","cited":306,"byYear":{"2019":7,"2020":52,"2021":50,"2022":50,"2023":42,"2024":43,"2025":42,"2026":20},"year":2019,"title":"Trends in the US and Canadian Pathologist Workforces From 2007 to 2017"},"paper-nct02716116-jama-oncol-2021":{"doi":"10.1001/jamaoncol.2021.4761","openalexId":"W3206796634","cited":292,"byYear":{"2021":7,"2022":77,"2023":91,"2024":56,"2025":46,"2026":14},"year":2021,"title":"Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer"},"paper-jiang-lancet-oncol":{"doi":"10.1016/s1470-2045(19)30164-0","openalexId":"W2940712523","cited":275,"byYear":{"2019":7,"2020":37,"2021":38,"2022":47,"2023":39,"2024":57,"2025":36,"2026":14},"year":2019,"title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023":{"doi":"10.1016/s1470-2045(23)00150-x","openalexId":"W4367670315","cited":259,"byYear":{"2023":24,"2024":105,"2025":75,"2026":55},"year":2023,"title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study"},"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017":{"doi":"10.1038/bcj.2017.85","openalexId":"W2752993654","cited":248,"byYear":{"2018":7,"2019":20,"2020":31,"2021":35,"2022":35,"2023":37,"2024":38,"2025":26,"2026":18},"year":2017,"title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions"},"paper-st-gallen-2023-consensus-ann-oncol-2023":{"doi":"10.1016/j.annonc.2023.08.017","openalexId":"W4386485122","cited":243,"byYear":{"2023":5,"2024":80,"2025":96,"2026":62},"year":2023,"title":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023"},"paper-shindoh-t2-gallbladder-cancer-tumour-location-ann-surg-2015":{"doi":"10.1097/sla.0000000000000728","openalexId":"W2050646684","cited":239,"byYear":{"2013":1,"2014":2,"2015":10,"2016":3,"2017":10,"2018":20,"2019":27,"2020":29,"2021":32,"2022":21,"2023":22,"2024":28,"2025":19,"2026":11},"year":2014,"title":"Tumor Location Is a Strong Predictor of Tumor Progression and Survival in T2 Gallbladder Cancer"},"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024":{"doi":"10.1001/jama.2024.3056","openalexId":"W4393410416","cited":239,"byYear":{"2024":48,"2025":99,"2026":92},"year":2024,"title":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer"},"paper-trident-1-repotrectinib-nejm-2024":{"doi":"10.1056/nejmoa2302299","openalexId":"W4390690905","cited":236,"byYear":{"2023":1,"2024":56,"2025":92,"2026":87},"year":2024,"title":"Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer"},"paper-tropion-breast01-jco-2024":{"doi":"10.1200/jco.24.00920","openalexId":"W4402472398","cited":189,"byYear":{"2024":2,"2025":82,"2026":105},"year":2024,"title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01"},"paper-barroso-sousa-tmb-pten-ici-mtnbc-ccr-2020":{"doi":"10.1158/1078-0432.ccr-19-3507","openalexId":"W3004453915","cited":188,"byYear":{"2020":21,"2021":56,"2022":38,"2023":28,"2024":21,"2025":19,"2026":5},"year":2020,"title":"Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer"},"paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024":{"doi":"10.1016/s0140-6736(24)00184-3","openalexId":"W4396571240","cited":152,"byYear":{"2024":27,"2025":70,"2026":55},"year":2024,"title":"Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network"},"paper-dix-j-clin-oncol-2018":{"doi":"10.1200/jco.2017.77.1931","openalexId":"W2802241849","cited":140,"byYear":{"2015":2,"2016":1,"2018":5,"2019":8,"2020":12,"2021":20,"2022":24,"2023":21,"2024":12,"2025":20,"2026":14},"year":2018,"title":"Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children’s Oncology Group AREN0533 Study"},"paper-trophimmun-avelumab-chemoresistant-gtn-you-jco-2020":{"doi":"10.1200/jco.20.00803","openalexId":"W3044901904","cited":112,"byYear":{"2020":5,"2021":20,"2022":21,"2023":20,"2024":14,"2025":18,"2026":14},"year":2020,"title":"Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial"},"paper-nct04579380-j-clin-oncol-2023":{"doi":"10.1200/jco.23.00606","openalexId":"W4387040106","cited":109,"byYear":{"2023":1,"2024":38,"2025":45,"2026":25},"year":2023,"title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study"},"paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019":{"doi":"10.1093/annonc/mdz385","openalexId":"W2979453163","cited":103,"byYear":{"2019":1,"2020":17,"2021":23,"2022":17,"2023":19,"2024":11,"2025":9,"2026":6},"year":2019,"title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion"},"paper-panova-3-ttfields-locally-advanced-pancreatic-jco-2025":{"doi":"10.1200/jco-25-00746","openalexId":"W4410919644","cited":47,"byYear":{"2025":13,"2026":34},"year":2025,"title":"Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study"},"paper-mountaineer-nat-commun-2026-update":{"doi":"10.1038/s41467-025-67824-z","openalexId":"W7122905459","cited":12,"byYear":{"2026":12},"year":2026,"title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis"},"paper-rueth-inflammatory-breast-trimodality-jco-2014":{"doi":"10.1200/jco.2014.55.1978","openalexId":"W2129679725","cited":147,"byYear":{"2012":1,"2015":12,"2016":12,"2017":12,"2018":11,"2019":14,"2020":13,"2021":16,"2022":12,"2023":13,"2024":12,"2025":13,"2026":6},"year":2014,"title":"Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database"},"paper-zhou-clin-cancer-res":{"doi":"10.1158/1078-0432.ccr-23-0983","openalexId":"W4389882185","cited":14,"byYear":{"2024":3,"2025":7,"2026":4},"year":2023,"title":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial"},"paper-her2climb-02-ann-oncol-2026":{"doi":"10.1016/j.annonc.2025.11.005","openalexId":"W4416410316","cited":8,"byYear":{"2026":8},"year":2025,"title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02"},"paper-hammel-j-clin-oncol":{"doi":"10.1200/jco-25-00872","openalexId":"W4415889326","cited":3,"byYear":{"2025":1,"2026":2},"year":2025,"title":"TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma"},"paper-khan-t2-gallbladder-cancer-liver-resection-meta-analysis-updates-surg-2021":{"doi":"10.1007/s13304-021-01150-z","openalexId":"W3196042623","cited":4,"byYear":{"2024":2,"2025":2},"year":2021,"title":"Tumor location and concurrent liver resection, impact survival in T2 gallbladder cancer: a meta-analysis of the literature"},"paper-tropion-breast01-china-cohort-esmo-open-2026":{"doi":"10.1016/j.esmoop.2026.108538","openalexId":"W7212308210","cited":0,"byYear":{},"year":2026,"title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort"},"paper-veber-oral-bioavailability-jmedchem-2002":{"doi":"10.1021/jm020017n","openalexId":"W2105649494","cited":8420,"byYear":{"2012":151,"2013":170,"2014":196,"2015":181,"2016":237,"2017":265,"2018":358,"2019":411,"2020":571,"2021":729,"2022":867,"2023":874,"2024":912,"2025":911,"2026":746},"year":2002,"title":"Molecular Properties That Influence the Oral Bioavailability of Drug Candidates"},"paper-vogelstein-surfing-p53-network-nature-2000":{"doi":"10.1038/35042675","openalexId":"W1650797637","cited":6641,"byYear":{"2012":330,"2013":330,"2014":329,"2015":289,"2016":246,"2017":236,"2018":222,"2019":225,"2020":230,"2021":228,"2022":208,"2023":153,"2024":144,"2025":94,"2026":59},"year":2000,"title":"Surfing the p53 network"},"paper-who-2022-myeloid-khoury-leukemia-2022":{"doi":"10.1038/s41375-022-01613-1","openalexId":"W4283271244","cited":4237,"byYear":{"2012":1,"2013":1,"2014":1,"2019":1,"2022":193,"2023":964,"2024":1156,"2025":1138,"2026":773},"year":2022,"title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms"},"paper-who-2022-lymphoid-alaggio-leukemia-2022":{"doi":"10.1038/s41375-022-01620-2","openalexId":"W4283381496","cited":4037,"byYear":{"2022":148,"2023":884,"2024":1106,"2025":1079,"2026":810},"year":2022,"title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms"},"paper-kaplan-nature":{"doi":"10.1038/nature04186","openalexId":"W2146530991","cited":3293,"byYear":{"2012":197,"2013":191,"2014":161,"2015":163,"2016":170,"2017":159,"2018":158,"2019":164,"2020":189,"2021":178,"2022":175,"2023":174,"2024":112,"2025":125,"2026":77},"year":2005,"title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche"},"paper-viale-a-venetoclax-azacitidine-nejm-2020":{"doi":"10.1056/nejmoa2012971","openalexId":"W3048827006","cited":2945,"byYear":{"2014":1,"2019":2,"2020":69,"2021":368,"2022":464,"2023":542,"2024":545,"2025":541,"2026":403},"year":2020,"title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia"},"paper-vision-nejm-2021":{"doi":"10.1056/nejmoa2107322","openalexId":"W3176208875","cited":2851,"byYear":{"2012":1,"2014":1,"2021":109,"2022":390,"2023":518,"2024":594,"2025":621,"2026":616},"year":2021,"title":"Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer"},"paper-moyer-uspstf-prostate-screening-ann-intern-med-2012":{"doi":"10.7326/0003-4819-157-2-201207170-00459","openalexId":"W2134793522","cited":2542,"byYear":{"2012":106,"2013":206,"2014":245,"2015":278,"2016":256,"2017":245,"2018":196,"2019":147,"2020":153,"2021":145,"2022":129,"2023":91,"2024":92,"2025":61,"2026":28},"year":2012,"title":"Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement"},"paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015":{"doi":"10.1038/ng.3398","openalexId":"W1497915798","cited":2318,"byYear":{"2015":9,"2016":66,"2017":97,"2018":128,"2019":180,"2020":240,"2021":331,"2022":277,"2023":276,"2024":261,"2025":249,"2026":198},"year":2015,"title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma"},"paper-liu-n-engl-j-med":{"doi":"10.1056/nejmoa1910607","openalexId":"W3004611567","cited":2229,"byYear":{"2012":1,"2017":1,"2020":212,"2021":384,"2022":363,"2023":330,"2024":344,"2025":336,"2026":254},"year":2020,"title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors"},"paper-uspstf-crc-screening-45-jama-2021":{"doi":"10.1001/jama.2021.6238","openalexId":"W4231576061","cited":2063,"byYear":{"2020":1,"2021":83,"2022":304,"2023":355,"2024":492,"2025":468,"2026":360},"year":2021,"title":"Screening for Colorectal Cancer"},"paper-braf-thyroid-n-engl-j-med-2015":{"doi":"10.1056/nejmoa1502309","openalexId":"W1846586690","cited":1783,"byYear":{"2014":2,"2015":30,"2016":170,"2017":243,"2018":193,"2019":192,"2020":214,"2021":194,"2022":144,"2023":128,"2024":119,"2025":101,"2026":48},"year":2015,"title":"Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations"},"paper-kris-lung-cancer-mutation-consortium-jama-2014":{"doi":"10.1001/jama.2014.3741","openalexId":"W2065477010","cited":1766,"byYear":{"2013":2,"2014":37,"2015":147,"2016":175,"2017":160,"2018":190,"2019":138,"2020":180,"2021":181,"2022":179,"2023":119,"2024":103,"2025":101,"2026":51},"year":2014,"title":"Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs"},"paper-atezolizumab-hcc-j-hepatol-2022":{"doi":"10.1016/j.jhep.2021.11.030","openalexId":"W4200388794","cited":1754,"byYear":{"2014":1,"2022":157,"2023":404,"2024":440,"2025":432,"2026":317},"year":2021,"title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma"},"paper-martincorena-cell":{"doi":"10.1016/j.cell.2017.09.042","openalexId":"W2611387862","cited":1710,"byYear":{"2017":12,"2018":120,"2019":175,"2020":206,"2021":214,"2022":233,"2023":251,"2024":226,"2025":175,"2026":96},"year":2017,"title":"Universal Patterns of Selection in Cancer and Somatic Tissues"},"paper-manson-n-engl-j-med":{"doi":"10.1056/nejmoa1809944","openalexId":"W2899572198","cited":1644,"byYear":{"2013":1,"2017":2,"2018":15,"2019":223,"2020":259,"2021":224,"2022":252,"2023":230,"2024":176,"2025":151,"2026":109},"year":2018,"title":"Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease"},"paper-howlader-us-incidence-breast-subtypes-jnci-2014":{"doi":"10.1093/jnci/dju055","openalexId":"W2159427817","cited":1553,"byYear":{"2013":1,"2014":11,"2015":44,"2016":69,"2017":81,"2018":88,"2019":117,"2020":149,"2021":166,"2022":152,"2023":181,"2024":177,"2025":173,"2026":138},"year":2014,"title":"US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status"},"paper-uspstf-prostate-screening-jama-2018":{"doi":"10.1001/jama.2018.3710","openalexId":"W2966258052","cited":1463,"byYear":{"2013":1,"2016":7,"2017":18,"2018":58,"2019":133,"2020":172,"2021":179,"2022":189,"2023":202,"2024":202,"2025":187,"2026":114},"year":2018,"title":"Screening for Prostate Cancer"},"paper-vision-tepotinib-paik-nejm-2020":{"doi":"10.1056/nejmoa2004407","openalexId":"W3031018272","cited":892,"byYear":{"2020":35,"2021":133,"2022":183,"2023":158,"2024":165,"2025":128,"2026":86},"year":2020,"title":"Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations"},"paper-alex-ann-oncol-2020-update":{"doi":"10.1016/j.annonc.2020.04.478","openalexId":"W3022131485","cited":711,"byYear":{"2019":1,"2020":11,"2021":81,"2022":137,"2023":116,"2024":172,"2025":124,"2026":66},"year":2020,"title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study"},"paper-ramsey-health-aff-millwood":{"doi":"10.1377/hlthaff.2012.1263","openalexId":"W2071663583","cited":698,"byYear":{"2013":10,"2014":37,"2015":39,"2016":64,"2017":62,"2018":64,"2019":75,"2020":59,"2021":68,"2022":64,"2023":55,"2024":31,"2025":45,"2026":24},"year":2013,"title":"Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis"},"paper-schnipper-j-clin-oncol":{"doi":"10.1200/jco.2016.68.2518","openalexId":"W2413636075","cited":665,"byYear":{"2016":24,"2017":101,"2018":68,"2019":89,"2020":73,"2021":86,"2022":48,"2023":65,"2024":50,"2025":37,"2026":24},"year":2016,"title":"Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received"},"paper-lindeman-lung-molecular-testing-guideline-jto-2018":{"doi":"10.1016/j.jtho.2017.12.001","openalexId":"W2784623697","cited":653,"byYear":{"2017":1,"2018":53,"2019":97,"2020":154,"2021":94,"2022":82,"2023":45,"2024":54,"2025":33,"2026":40},"year":2018,"title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors"},"paper-unger-trial-participation-barriers-jnci-2019":{"doi":"10.1093/jnci/djy221","openalexId":"W2915663023","cited":585,"byYear":{"2019":17,"2020":46,"2021":73,"2022":82,"2023":82,"2024":114,"2025":92,"2026":78},"year":2018,"title":"Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation"},"paper-schmitz-n-engl-j-med":{"doi":"10.1056/nejmoa0810118","openalexId":"W2149447033","cited":584,"byYear":{"2012":56,"2013":33,"2014":48,"2015":33,"2016":41,"2017":40,"2018":35,"2019":17,"2020":36,"2021":38,"2022":27,"2023":16,"2024":23,"2025":23,"2026":22},"year":2009,"title":"Weight Lifting in Women with Breast-Cancer–Related Lymphedema"},"paper-tarpswg-retroperitoneal-sarcoma-gronchi-ann-surg-2016":{"doi":"10.1097/sla.0000000000001447","openalexId":"W2323526189","cited":563,"byYear":{"2016":15,"2017":43,"2018":52,"2019":38,"2020":61,"2021":55,"2022":83,"2023":62,"2024":44,"2025":66,"2026":39},"year":2016,"title":"Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS)"},"paper-robinson-vismodegib-shh-medulloblastoma-jco-2015":{"doi":"10.1200/jco.2014.60.1591","openalexId":"W2111433192","cited":472,"byYear":{"2015":6,"2016":37,"2017":46,"2018":57,"2019":52,"2020":48,"2021":57,"2022":44,"2023":38,"2024":43,"2025":28,"2026":16},"year":2015,"title":"Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032"},"paper-ve-basket-vemurafenib-erdheim-chester-lch-jama-oncol-2018":{"doi":"10.1001/jamaoncol.2017.5029","openalexId":"W2770975168","cited":419,"byYear":{"2018":32,"2019":43,"2020":63,"2021":49,"2022":46,"2023":49,"2024":59,"2025":50,"2026":25},"year":2017,"title":"Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis"},"paper-gehl-acta-oncol":{"doi":"10.1080/0284186x.2018.1454602","openalexId":"W2793453599","cited":414,"byYear":{"2013":1,"2018":14,"2019":43,"2020":56,"2021":59,"2022":59,"2023":48,"2024":44,"2025":55,"2026":34},"year":2018,"title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases"},"paper-johnston-nature":{"doi":"10.1038/s41586-019-1674-5","openalexId":"W2981635494","cited":409,"byYear":{"2019":2,"2020":33,"2021":59,"2022":63,"2023":57,"2024":82,"2025":71,"2026":42},"year":2019,"title":"VISTA is an acidic pH-selective ligand for PSGL-1"},"paper-bareche-tnbc-multiomic-heterogeneity-ann-oncol-2018":{"doi":"10.1093/annonc/mdy024","openalexId":"W2794018125","cited":394,"byYear":{"2018":16,"2019":20,"2020":48,"2021":66,"2022":49,"2023":57,"2024":50,"2025":48,"2026":39},"year":2018,"title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis"},"paper-key-j-clin-oncol":{"doi":"10.1200/jco.23.00294","openalexId":"W4366446437","cited":357,"byYear":{"2023":20,"2024":109,"2025":116,"2026":110},"year":2023,"title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update"},"paper-carlson-link-vestibular-schwannomas-nejm-2021":{"doi":"10.1056/nejmra2020394","openalexId":"W4205574973","cited":345,"byYear":{"2021":8,"2022":32,"2023":64,"2024":77,"2025":86,"2026":77},"year":2021,"title":"Vestibular Schwannomas"},"paper-johnson-alternative-medicine-jnci-2018":{"doi":"10.1093/jnci/djx145","openalexId":"W2743558319","cited":338,"byYear":{"2017":9,"2018":31,"2019":36,"2020":38,"2021":34,"2022":43,"2023":42,"2024":36,"2025":39,"2026":29},"year":2017,"title":"Use of Alternative Medicine for Cancer and Its Impact on Survival"},"paper-javelin-merkel-200-j-immunother-cancer-2018-update":{"doi":"10.1186/s40425-017-0310-x","openalexId":"W2783234388","cited":335,"byYear":{"2017":2,"2018":27,"2019":70,"2020":69,"2021":62,"2022":21,"2023":29,"2024":25,"2025":15,"2026":12},"year":2018,"title":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial"},"paper-rothwell-nat-med":{"doi":"10.1038/s41591-019-0380-z","openalexId":"W2938864889","cited":308,"byYear":{"2012":1,"2019":25,"2020":52,"2021":49,"2022":48,"2023":54,"2024":37,"2025":36,"2026":6},"year":2019,"title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study"},"paper-basu-single-dose-hpv-lancet-oncol-2021":{"doi":"10.1016/s1470-2045(21)00453-8","openalexId":"W3204615344","cited":271,"byYear":{"2021":9,"2022":41,"2023":47,"2024":75,"2025":64,"2026":35},"year":2021,"title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study"},"paper-bisogno-lancet-oncol":{"doi":"10.1016/s1470-2045(19)30617-5","openalexId":"W2975416164","cited":254,"byYear":{"2019":5,"2020":34,"2021":31,"2022":51,"2023":47,"2024":30,"2025":28,"2026":26},"year":2019,"title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial"},"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019":{"doi":"10.1200/jco.19.00456","openalexId":"W2972707815","cited":233,"byYear":{"2012":1,"2019":1,"2020":26,"2021":39,"2022":32,"2023":45,"2024":35,"2025":28,"2026":23},"year":2019,"title":"Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study"},"paper-lazebnik-nat-rev-cancer":{"doi":"10.1038/nrc2827","openalexId":"W2056383219","cited":229,"byYear":{"2012":20,"2013":14,"2014":11,"2015":10,"2016":11,"2017":22,"2018":10,"2019":20,"2020":16,"2021":18,"2022":14,"2023":13,"2024":18,"2025":9,"2026":4},"year":2010,"title":"What are the hallmarks of cancer?"},"paper-andrea-decensi-j-clin-oncol-2019":{"doi":"10.1200/jco.19.01472","openalexId":"W2971583637","cited":222,"byYear":{"2019":1,"2020":27,"2021":34,"2022":18,"2023":44,"2024":39,"2025":26,"2026":31},"year":2019,"title":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update"},"paper-bareche-tnbc-microenvironment-jnci-2020":{"doi":"10.1093/jnci/djz208","openalexId":"W2982501627","cited":213,"byYear":{"2019":1,"2020":11,"2021":29,"2022":36,"2023":46,"2024":39,"2025":33,"2026":17},"year":2019,"title":"Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach"},"paper-scott-tnbc-disparities-uscs-cancer-2019":{"doi":"10.1002/cncr.32207","openalexId":"W2959687156","cited":173,"byYear":{"2019":4,"2020":17,"2021":30,"2022":30,"2023":49,"2024":16,"2025":16,"2026":11},"year":2019,"title":"Update on triple‐negative breast cancer disparities for the United States: A population‐based study from the United States Cancer Statistics database, 2010 through 2014"},"paper-chalasani-clin-gastroenterol-hepatol":{"doi":"10.1016/j.cgh.2021.08.010","openalexId":"W3188377701","cited":160,"byYear":{"2021":2,"2022":17,"2023":44,"2024":45,"2025":30,"2026":22},"year":2021,"title":"Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma"},"paper-chernet-oncotarget":{"doi":"10.18632/oncotarget.8036","openalexId":"W2299444549","cited":107,"byYear":{"2016":1,"2017":14,"2018":9,"2019":15,"2020":8,"2021":11,"2022":9,"2023":9,"2024":14,"2025":11,"2026":6},"year":2016,"title":"Use of genetically encoded, light-gated ion translocators to control tumorigenesis"},"paper-gelderblom-lancet":{"doi":"10.1016/s0140-6736(24)00885-7","openalexId":"W4399300859","cited":80,"byYear":{"2024":8,"2025":38,"2026":34},"year":2024,"title":"Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial"},"paper-asco-pembrolizumab-early-tnbc-rapid-update-jco-2022":{"doi":"10.1200/jco.22.00503","openalexId":"W4223904426","cited":59,"byYear":{"2022":6,"2023":12,"2024":16,"2025":12,"2026":13},"year":2022,"title":"Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update"},"paper-giannis-ajcc8-gallbladder-staging-validation-cancers-2021":{"doi":"10.3390/cancers13030547","openalexId":"W3126365363","cited":57,"byYear":{"2021":2,"2022":10,"2023":14,"2024":6,"2025":15,"2026":9},"year":2021,"title":"Validation of the 8th Edition American Joint Commission on Cancer (AJCC) Gallbladder Cancer Staging System: Prognostic Discrimination and Identification of Key Predictive Factors"},"paper-esmo-mbc-living-guideline-update-ann-oncol-2025":{"doi":"10.1016/j.annonc.2025.07.017","openalexId":"W4413190431","cited":28,"byYear":{"2025":2,"2026":26},"year":2025,"title":"Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline"},"paper-pharos-j-thorac-oncol-2025":{"doi":"10.1016/j.jtho.2025.05.023","openalexId":"W4411023368","cited":16,"byYear":{"2025":4,"2026":12},"year":2025,"title":"Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report"},"paper-yarden-sliwkowski-erbb-network-nrmcb-2001":{"doi":"10.1038/35052073","openalexId":"W1964321121","cited":7046,"byYear":{"2012":377,"2013":413,"2014":320,"2015":319,"2016":278,"2017":257,"2018":263,"2019":218,"2020":243,"2021":275,"2022":265,"2023":279,"2024":243,"2025":182,"2026":180},"year":2001,"title":"Untangling the ErbB signalling network"},"paper-zuma-1-axi-cel-nejm-2017":{"doi":"10.1056/nejmoa1707447","openalexId":"W2773804840","cited":6109,"byYear":{"2012":2,"2013":2,"2016":2,"2017":4,"2018":264,"2019":483,"2020":715,"2021":859,"2022":899,"2023":801,"2024":804,"2025":735,"2026":520},"year":2017,"title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma"},"paper-kras-colorectal-j-clin-oncol-2008":{"doi":"10.1200/jco.2007.14.7116","openalexId":"W2106789440","cited":3216,"byYear":{"2012":287,"2013":253,"2014":279,"2015":252,"2016":179,"2017":163,"2018":132,"2019":135,"2020":112,"2021":125,"2022":117,"2023":76,"2024":62,"2025":47,"2026":26},"year":2008,"title":"Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer"},"paper-waddell-whole-genomes-pancreatic-nature-2015":{"doi":"10.1038/nature14169","openalexId":"W1987313243","cited":2732,"byYear":{"2012":1,"2014":1,"2015":97,"2016":229,"2017":245,"2018":268,"2019":261,"2020":304,"2021":311,"2022":266,"2023":250,"2024":210,"2025":173,"2026":106},"year":2015,"title":"Whole genomes redefine the mutational landscape of pancreatic cancer"},"paper-zuma-2-brexu-cel-mantle-cell-nejm-2020":{"doi":"10.1056/nejmoa1914347","openalexId":"W3014583893","cited":1877,"byYear":{"2012":1,"2020":82,"2021":328,"2022":370,"2023":331,"2024":331,"2025":247,"2026":181},"year":2020,"title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma"},"paper-zuma-7-axi-cel-second-line-nejm-2022":{"doi":"10.1056/nejmoa2116133","openalexId":"W4200201081","cited":1613,"byYear":{"2013":1,"2021":1,"2022":215,"2023":355,"2024":411,"2025":385,"2026":243},"year":2021,"title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma"},"paper-zeta-vandetanib-mtc-wells-jco-2012":{"doi":"10.1200/jco.2011.35.5040","openalexId":"W2119501407","cited":1569,"byYear":{"2012":86,"2013":118,"2014":128,"2015":125,"2016":117,"2017":102,"2018":88,"2019":91,"2020":105,"2021":115,"2022":128,"2023":101,"2024":86,"2025":82,"2026":59},"year":2011,"title":"Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial"},"paper-hayward-melanoma-whole-genome-nature-2017":{"doi":"10.1038/nature22071","openalexId":"W2611187032","cited":1554,"byYear":{"2012":1,"2014":1,"2017":41,"2018":121,"2019":166,"2020":205,"2021":188,"2022":173,"2023":217,"2024":191,"2025":129,"2026":117},"year":2017,"title":"Whole-genome landscapes of major melanoma subtypes"},"paper-bissell-nat-med":{"doi":"10.1038/nm.2328","openalexId":"W2007040134","cited":1543,"byYear":{"2012":107,"2013":105,"2014":124,"2015":97,"2016":134,"2017":117,"2018":125,"2019":114,"2020":127,"2021":109,"2022":113,"2023":78,"2024":64,"2025":64,"2026":31},"year":2011,"title":"Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression"},"paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015":{"doi":"10.1038/ncomms7744","openalexId":"W2067826589","cited":1167,"byYear":{"2014":2,"2015":20,"2016":77,"2017":115,"2018":124,"2019":114,"2020":141,"2021":150,"2022":145,"2023":99,"2024":63,"2025":89,"2026":27},"year":2015,"title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets"},"paper-who-2022-gu-moch-eur-urol-2022":{"doi":"10.1016/j.eururo.2022.06.016","openalexId":"W7212055315","cited":16,"byYear":{"2026":16},"year":2022,"title":"The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours"},"paper-wu-pancreatic-cyst-exomes-rnf43-pnas-2011":{"doi":"10.1073/pnas.1118046108","openalexId":"W2062696188","cited":649,"byYear":{"2012":29,"2013":51,"2014":66,"2015":52,"2016":51,"2017":64,"2018":57,"2019":51,"2020":36,"2021":52,"2022":43,"2023":40,"2024":23,"2025":19,"2026":14},"year":2011,"title":"Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways"},"paper-zanubrutinib-cll-n-engl-j-med-2023":{"doi":"10.1056/nejmoa2211582","openalexId":"W4311293040","cited":493,"byYear":{"2022":1,"2023":104,"2024":137,"2025":147,"2026":103},"year":2022,"title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia"},"paper-chan-nature":{"doi":"10.1038/s41586-019-1102-x","openalexId":"W2905437169","cited":490,"byYear":{"2012":1,"2019":23,"2020":50,"2021":84,"2022":61,"2023":37,"2024":98,"2025":79,"2026":56},"year":2019,"title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers"},"paper-li-gallbladder-exome-erbb-nat-genet-2014":{"doi":"10.1038/ng.3030","openalexId":"W2073597876","cited":481,"byYear":{"2014":1,"2015":31,"2016":36,"2017":27,"2018":35,"2019":41,"2020":50,"2021":65,"2022":71,"2023":37,"2024":49,"2025":19,"2026":15},"year":2014,"title":"Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway"},"paper-cramer-cochrane-database-syst-rev":{"doi":"10.1002/14651858.cd010802.pub2","openalexId":"W2566963236","cited":446,"byYear":{"2015":3,"2016":1,"2017":12,"2018":22,"2019":49,"2020":42,"2021":57,"2022":59,"2023":74,"2024":59,"2025":44,"2026":24},"year":2017,"title":"Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer"},"paper-roberts-familial-pancreatic-whole-genome-cancer-discov-2016":{"doi":"10.1158/2159-8290.cd-15-0402","openalexId":"W2232697670","cited":372,"byYear":{"2016":18,"2017":32,"2018":35,"2019":45,"2020":40,"2021":59,"2022":30,"2023":35,"2024":48,"2025":18,"2026":12},"year":2015,"title":"Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer"},"paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019":{"doi":"10.1038/s41591-019-0582-4","openalexId":"W2976898289","cited":329,"byYear":{"2019":1,"2020":46,"2021":65,"2022":61,"2023":45,"2024":53,"2025":34,"2026":24},"year":2019,"title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study"},"paper-barton-j-natl-cancer-inst":{"doi":"10.1093/jnci/djt181","openalexId":"W2111361718","cited":300,"byYear":{"2013":8,"2014":27,"2015":29,"2016":19,"2017":23,"2018":28,"2019":27,"2020":23,"2021":25,"2022":21,"2023":26,"2024":20,"2025":14,"2026":8},"year":2013,"title":"Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2"},"paper-zanubrutinib-cll-lancet-oncol-2022":{"doi":"10.1016/s1470-2045(22)00293-5","openalexId":"W4284883545","cited":294,"byYear":{"2022":8,"2023":68,"2024":86,"2025":80,"2026":51},"year":2022,"title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial"},"paper-harding-lancet-oncol":{"doi":"10.1016/s1470-2045(23)00242-5","openalexId":"W4379114671","cited":285,"byYear":{"2023":15,"2024":80,"2025":101,"2026":88},"year":2023,"title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study"},"paper-wisnoski-acinar-cell-carcinoma-672-patients-seer-surgery-2008":{"doi":"10.1016/j.surg.2008.03.006","openalexId":"W2073181413","cited":209,"byYear":{"2012":12,"2013":11,"2014":11,"2015":13,"2016":14,"2017":12,"2018":11,"2019":9,"2020":13,"2021":17,"2022":18,"2023":15,"2024":12,"2025":4,"2026":10},"year":2008,"title":"672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma"},"paper-ren-chinese-prostate-whole-genome-eur-urol-2018":{"doi":"10.1016/j.eururo.2017.08.027","openalexId":"W2754374178","cited":206,"byYear":{"2017":3,"2018":14,"2019":26,"2020":21,"2021":22,"2022":29,"2023":33,"2024":23,"2025":20,"2026":15},"year":2017,"title":"Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression"},"paper-zanubrutinib-cll-lancet-haematol-2021":{"doi":"10.1016/s2352-3026(21)00307-0","openalexId":"W3216472165","cited":112,"byYear":{"2021":1,"2022":20,"2023":27,"2024":29,"2025":25,"2026":10},"year":2021,"title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial"},"paper-cowan-lancet-oncol":{"doi":"10.1016/s1470-2045(23)00246-2","openalexId":"W4382934836","cited":108,"byYear":{"2023":11,"2024":33,"2025":38,"2026":26},"year":2023,"title":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial"},"paper-zebra-pembrolizumab-small-bowel-adenocarcinoma-ccr-2021":{"doi":"10.1158/1078-0432.ccr-21-0159","openalexId":"W3155675611","cited":64,"byYear":{"2021":4,"2022":11,"2023":17,"2024":12,"2025":12,"2026":8},"year":2021,"title":"ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma"},"paper-nct05425940-lancet-2025":{"doi":"10.1016/s0140-6736(25)02025-2","openalexId":"W4415363450","cited":33,"byYear":{"2025":1,"2026":32},"year":2025,"title":"Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial"},"paper-nct04036682-j-clin-oncol-2025":{"doi":"10.1200/jco-25-00763","openalexId":"W4410927214","cited":17,"byYear":{"2025":4,"2026":13},"year":2025,"title":"Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab"},"paper-dhillon-mol-diagn-ther":{"doi":"10.1007/s40291-024-00723-z","openalexId":"W4399783546","cited":3,"byYear":{"2024":1,"2025":1,"2026":1},"year":2024,"title":"Zevorcabtagene Autoleucel: First Approval"}},"missing":["paper-ezzo-cochrane-database-syst-rev","paper-adaura-8-year-os-jto-2026","paper-nct05415072-nat-med-2026","paper-tamrakar-cancer","paper-daraxonrasib-pancreatic-cureus-2026","paper-aranote-eur-urol-2026","paper-nct04854668-signal-transduct-target-ther-2026","paper-flaura2-long-term-safety-lung-cancer-2026","paper-conroy-nhs-r208-mainstream-testing-audit-breast-j-2026","paper-kapoor-jco-glob-oncol","paper-krystal-12-plain-language-summary-future-oncol-2026","paper-malla-ctdna-resected-biliary-tract-cancer-esmo-gi-onc-2026","paper-nct06612151-n-engl-j-med-2026","paper-pantziarka-ecancermedicalscience"]}